0000950170-24-12410310-Q UNIVERSAL HEALTH SERVICES INC 20241108202411081615281615281615281

gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000352915us-gaap:ParentMember2023-06-300000352915us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-09-300000352915uhs:AssetPurchaseAndSaleAgreementMemberuhs:AcuteCareHospitalServicesMemberuhs:UniversalHealthRealtyIncomeTrustMemberuhs:AikenSouthCarolinaMemberuhs:AikenReg01-012021-12-310000352915uhs:BehavioralHealthCareFacilityMemberuhs:OutsideOwnersMemberstpr:MO2024-09-300000352915us-gaap:FairValueMeasurementsRecurringMember2024-09-300000352915us-gaap:NoncontrollingInterestMember2022-12-310000352915uhs:OtherRelatedPartyTransactionsMemberuhs:UniversalHealthRealtyIncomeTrustMember2024-09-30000035291529152024-01-010000352915us-gaap:ProfessionalMalpracticeLiabilityMembersrt:MaximumMembersrt:SubsidiariesMember2021-12-310000352915srt:MinimumMembersrt:ChiefExecutiveOfficerMember2024-01-012024-09-300000352915us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000352915uhs:ManagedCareMember2024-01-012024-09-300000352915us-gaap:FairValueInputsLevel2Memberuhs:AccruedLiabilitiesOtherMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMember2024-09-300000352915us-gaap:NoncontrollingInterestMember2023-09-300000352915uhs:AcuteCareHospitalServicesMemberuhs:MedicareMember2023-07-012023-09-300000352915us-gaap:CommonStockMemberus-gaap:CommonClassBMember2024-01-012024-09-300000352915us-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000352915us-gaap:CommonStockMemberus-gaap:CommonClassBMember2023-09-300000352915uhs:OtherNonPatientRevenueMemberuhs:BehavioralHealthServicesMember2024-01-012024-09-300000352915us-gaap:GeneralLiabilityMembersrt:MaximumMembersrt:SubsidiariesMember2023-12-310000352915us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300000352915us-gaap:GeneralLiabilityMembersrt:MaximumMembersrt:SubsidiariesMember2016-12-310000352915uhs:BehavioralHealthCareFacilityMemberuhs:OutsideOwnersMemberstpr:OH2024-09-300000352915stpr:TXsrt:MaximumMemberus-gaap:FloodMember2024-09-300000352915uhs:AcuteCareHospitalServicesMemberuhs:ManagedMedicareMember2024-01-012024-09-30000035291529152023-06-300000352915uhs:AcuteCareHospitalServicesMemberuhs:UKRevenueMember2024-07-012024-09-300000352915uhs:WindStormsMembersrt:MaximumMember2024-09-300000352915us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-12-310000352915uhs:AcuteCareHospitalServicesMemberuhs:ManagedMedicaidMember2024-01-012024-09-300000352915uhs:UniversalHealthRealtyIncomeTrustMember2023-12-310000352915uhs:NewSeniorSecuredCreditFacilityMember2024-09-300000352915uhs:FourPointSixTwoFivePercentSeniorSecuredNotesDueTwoThousandTwentyNineMemberuhs:NewSeniorSecuredCreditFacilityMember2024-09-26000035291529152023-09-300000352915uhs:OtherPatientRevenueAndAdjustmentsNetMemberuhs:BehavioralHealthServicesMember2024-07-012024-09-300000352915us-gaap:RetainedEarningsUnappropriatedMember2024-01-012024-09-300000352915uhs:FivePointZeroFiveZeroPercentSeniorSecuredNotesDueTwoThousandThirtyFourMemberuhs:NewSeniorSecuredCreditFacilityMember2024-09-26000035291529152023-09-300000352915uhs:GroupNineMemberuhs:TrancheATermLoanMember2024-01-012024-09-300000352915us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000352915uhs:BehavioralHealthCareFacilityMemberuhs:UniversalHealthRealtyIncomeTrustMember2023-01-012023-09-30000035291529152023-12-310000352915uhs:DepartmentOfHumanServicesMember2024-01-012024-09-300000352915us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000352915uhs:OtherPatientRevenueAndAdjustmentsNetMemberuhs:BehavioralHealthServicesMember2023-07-012023-09-300000352915uhs:AcuteCareHospitalServicesMemberuhs:MedicareMember2024-01-012024-09-300000352915uhs:UKRevenueMember2024-07-012024-09-300000352915us-gaap:CommonClassBMember2024-10-310000352915uhs:TwoThousandTwentyStockIncentivePlanMember2024-01-012024-09-300000352915us-gaap:GeneralLiabilityMemberuhs:ThePavilionBehavioralHealthSystemMember2024-09-300000352915uhs:AcuteCareHospitalServicesMemberuhs:OtherPatientRevenueAndAdjustmentsNetMember2023-07-012023-09-300000352915uhs:AssetPurchaseAndSaleAgreementMemberuhs:BehavioralHealthCareFacilityMemberuhs:UniversalHealthRealtyIncomeTrustMemberuhs:AikenSouthCarolinaMemberuhs:AikenP01-012021-12-310000352915us-gaap:LetterOfCreditMemberuhs:AmendedRevolvingCreditFacilityMember2024-09-300000352915uhs:UniversalHealthRealtyIncomeTrustMember2024-09-300000352915srt:MinimumMemberuhs:CanyonCreekBehavioralHealthMember2024-01-012024-09-300000352915uhs:UniversalHealthRealtyIncomeTrustMemberus-gaap:InvestmentAdviceMember2023-01-012023-09-300000352915uhs:MedicareMemberuhs:BehavioralHealthServicesMember2024-07-012024-09-300000352915uhs:MedicareMember2024-07-012024-09-300000352915uhs:BehavioralHealthServicesMembercountry:GB2023-09-300000352915us-gaap:RetainedEarningsAppropriatedMember2024-07-012024-09-300000352915uhs:OtherNonPatientRevenueMemberus-gaap:AllOtherSegmentsMember2023-01-012023-09-300000352915uhs:ManagedCareMember2023-07-012023-09-300000352915us-gaap:RetainedEarningsAppropriatedMember2023-01-012023-09-300000352915uhs:FivePointZeroFiveZeroPercentSeniorSecuredNotesDueTwoThousandThirtyFourMember2024-09-260000352915us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300000352915uhs:AcuteCareHospitalServicesMemberuhs:MedicaidMember2023-01-012023-09-300000352915uhs:CliveBehavioralHealthHospitalMember2024-01-012024-09-300000352915uhs:WellingtonRegionalMedicalCenterMember2024-01-012024-09-300000352915us-gaap:GeneralLiabilityMembersrt:MaximumMembersrt:SubsidiariesMember2017-12-310000352915uhs:CommonClassDMemberus-gaap:CommonStockMember2023-12-310000352915uhs:ManagedMedicaidMember2023-01-012023-09-300000352915uhs:McAllenMedicalCenterMember2024-01-012024-09-300000352915uhs:AnotherTwoHospitalFacilitiesMember2024-01-012024-09-300000352915uhs:GeneralAndProfessionalLiabilityMember2023-12-310000352915us-gaap:RetainedEarningsAppropriatedMember2024-01-012024-09-300000352915uhs:CommonClassDMemberus-gaap:CommonStockMember2024-06-300000352915us-gaap:GeneralLiabilityMembersrt:MaximumMembersrt:SubsidiariesMember2021-12-310000352915uhs:AcuteCareHospitalServicesMemberuhs:UKRevenueMember2024-01-012024-09-300000352915uhs:RedeemableInterestMember2023-07-012023-09-300000352915uhs:RedeemableInterestMember2024-07-012024-09-300000352915uhs:DepartmentOfHumanServicesMember2014-01-012014-12-310000352915us-gaap:EarthquakeMembersrt:MaximumMemberuhs:FaultyZonesOfUSMember2024-09-300000352915uhs:BehavioralHealthServicesMembercountry:GB2024-07-012024-09-300000352915uhs:CompensatoryDamagesMemberuhs:CumberlandHospitalForChildrenAndAdolescentsMember2024-09-272024-09-270000352915uhs:FirstThreeRenewalOptionsMembersrt:MinimumMemberuhs:TwoFreeStandingEmergencyDepartmentsMember2024-01-012024-09-300000352915us-gaap:GeneralLiabilityMembersrt:MaximumMembersrt:SubsidiariesMember2019-12-310000352915us-gaap:RetainedEarningsAppropriatedMember2023-06-300000352915uhs:MedicaidMember2024-01-012024-09-300000352915us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000352915srt:ScenarioForecastMembersrt:ChiefExecutiveOfficerMember2024-01-012024-12-310000352915us-gaap:CommonClassCMemberus-gaap:CommonStockMember2023-09-300000352915us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000352915uhs:BehavioralHealthServicesMembercountry:GB2024-09-300000352915uhs:ManagedMedicaidMember2024-01-012024-09-300000352915uhs:TrancheATermLoanMembersrt:MaximumMember2024-09-260000352915uhs:GeneralAndProfessionalLiabilityInsurancePoliciesMember2023-07-012023-09-300000352915uhs:BehavioralHealthServicesMemberuhs:UKRevenueMember2024-01-012024-09-300000352915uhs:UniversalHealthRealtyIncomeTrustMember2022-01-012022-12-310000352915uhs:AcuteCareHospitalServicesMemberuhs:OtherPatientRevenueAndAdjustmentsNetMember2024-07-012024-09-300000352915uhs:GeneralAndProfessionalLiabilityInsurancePoliciesMember2024-01-012024-09-300000352915us-gaap:ProfessionalMalpracticeLiabilityMembersrt:MaximumMembersrt:SubsidiariesMember2018-12-310000352915us-gaap:AllOtherSegmentsMember2024-01-012024-09-300000352915uhs:FirstThreeRenewalOptionsMemberuhs:TwoFreeStandingEmergencyDepartmentsMember2024-01-012024-09-300000352915uhs:AcuteCareHospitalServicesMemberuhs:ManagedCareMember2024-01-012024-09-300000352915uhs:MedicaidMember2024-07-012024-09-300000352915srt:MaximumMember2024-01-012024-09-300000352915uhs:MedicaidMemberuhs:BehavioralHealthServicesMember2024-07-012024-09-300000352915uhs:CygnetHealthCareLimitedMemberus-gaap:ProfessionalMalpracticeLiabilityMembersrt:SubsidiariesMember2024-09-300000352915us-gaap:RetainedEarningsAppropriatedMember2024-09-300000352915srt:MaximumMember2024-09-300000352915us-gaap:RestrictedStockMemberuhs:TwoThousandTwentyStockIncentivePlanMember2024-01-012024-09-300000352915uhs:OtherPatientRevenueAndAdjustmentsNetMember2024-01-012024-09-300000352915uhs:RedeemableInterestMember2024-06-300000352915uhs:AikenRegionalMedicalCenterAuroraPavilionBehavioralHealthServicesMembersrt:MaximumMember2024-01-012024-09-300000352915srt:ChiefExecutiveOfficerMemberuhs:TrustOwnedByChiefExecutiveOfficerMember2024-01-012024-09-300000352915uhs:TrancheATermLoanMember2024-09-300000352915uhs:AcuteCareHospitalServicesMemberuhs:MedicaidMember2024-07-012024-09-300000352915us-gaap:ProfessionalMalpracticeLiabilityMembersrt:MaximumMembersrt:SubsidiariesMember2023-12-310000352915uhs:CumberlandHospitalForChildrenAndAdolescentsMembersrt:MaximumMemberuhs:PunitiveDamagesMember2024-09-272024-09-270000352915us-gaap:OtherNoncurrentAssetsMemberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000352915us-gaap:CommonStockMemberus-gaap:CommonClassAMember2024-06-300000352915srt:ChiefExecutiveOfficerMember2024-01-012024-09-30000035291529152024-01-012024-09-300000352915uhs:ABRBasedLoansMember2024-09-300000352915uhs:TwoPointSixFivePercentSeniorSecuredNotesDueTwoThousandThirtyMemberuhs:NewSeniorSecuredCreditFacilityMember2024-01-012024-09-300000352915uhs:UKRevenueMember2023-07-012023-09-300000352915us-gaap:RestrictedStockMemberuhs:GroupPurchasingOrganizationAgreementMemberuhs:PremierIncMember2013-10-012013-12-310000352915uhs:RestrictedStockAwardsRestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember2023-01-012023-09-300000352915us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:ForeignExchangeContractMember2024-01-012024-09-300000352915us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300000352915uhs:TwoPointSixFivePercentSeniorSecuredNotesDueTwoThousandThirtyMemberuhs:NewSeniorSecuredCreditFacilityMember2020-09-210000352915uhs:BehavioralHealthServicesMember2023-09-300000352915uhs:CommonClassDMemberus-gaap:CommonStockMember2023-09-300000352915uhs:OtherNonPatientRevenueMember2024-01-012024-09-300000352915uhs:GeneralAndProfessionalLiabilityInsurancePoliciesMembersrt:MaximumMembersrt:SubsidiariesMember2023-12-310000352915uhs:DepartmentOfHumanServicesMember2015-01-012015-12-310000352915us-gaap:CommonStockMemberus-gaap:CommonClassBMember2024-09-300000352915us-gaap:CommonStockMemberus-gaap:CommonClassBMember2023-06-300000352915uhs:CanyonCreekBehavioralHealthMember2024-01-012024-09-300000352915us-gaap:EmployeeStockOptionMember2023-07-012023-09-300000352915uhs:CliveBehavioralHealthHospitalMembersrt:MaximumMember2024-01-012024-09-300000352915us-gaap:ForeignExchangeForwardMember2024-01-012024-09-300000352915uhs:ManagedCareMember2024-07-012024-09-300000352915us-gaap:ParentMember2023-09-300000352915uhs:AcuteCareHospitalServicesMemberuhs:ManagedMedicaidMember2024-07-012024-09-300000352915uhs:BehavioralHealthCareFacilityMemberstpr:PAuhs:OutsideOwnersMember2024-09-300000352915us-gaap:AllOtherSegmentsMember2023-09-300000352915us-gaap:NoncontrollingInterestMember2023-12-310000352915stpr:NVuhs:OutsideOwnersMemberuhs:AcuteCareFacilityMember2024-09-300000352915uhs:ManagedMedicaidMember2024-07-012024-09-300000352915uhs:NewSeniorSecuredCreditFacilityMemberuhs:OnePointSixFivePercentSeniorSecuredNotesDueTwoThousandTwentySixMember2021-08-240000352915uhs:ManagedCareMemberuhs:BehavioralHealthServicesMember2024-07-012024-09-300000352915us-gaap:RetainedEarningsAppropriatedMember2024-06-300000352915uhs:MedicareMemberuhs:BehavioralHealthServicesMember2023-07-012023-09-300000352915srt:ChiefExecutiveOfficerMember2023-01-012023-12-310000352915uhs:UniversalHealthRealtyIncomeTrustMemberus-gaap:InvestmentAdviceMember2023-07-012023-09-300000352915uhs:AcuteCareHospitalServicesMemberuhs:MedicaidMember2023-07-012023-09-300000352915uhs:CumberlandHospitalForChildrenAndAdolescentsMemberuhs:CompensatoryDamagesTrebledAndPunitiveDamagesMember2024-09-272024-09-270000352915us-gaap:OtherNoncurrentAssetsMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000352915uhs:AcuteCareHospitalServicesMemberuhs:UKRevenueMember2023-07-012023-09-300000352915uhs:FourPointSixTwoFivePercentSeniorSecuredNotesDueTwoThousandTwentyNineMemberuhs:NewSeniorSecuredCreditFacilityMember2024-01-012024-09-300000352915uhs:OutsideOwnersMemberuhs:BehavioralHealthCareFacilityOneMemberstpr:MI2024-09-300000352915uhs:RedeemableInterestMember2023-01-012023-09-300000352915uhs:PremierIncMemberus-gaap:OtherOperatingIncomeExpenseMember2024-01-012024-09-300000352915srt:MinimumMemberuhs:UniversalHealthRealtyIncomeTrustMemberuhs:LimitedLiabilityCompaniesMember2024-09-300000352915uhs:CommonClassDMemberus-gaap:CommonStockMember2023-06-300000352915us-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000352915us-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMemberuhs:DeferredCompensationAssetsMember2023-12-310000352915uhs:BehavioralHealthServicesMemberuhs:ManagedMedicareMember2024-07-012024-09-300000352915uhs:CanyonCreekBehavioralHealthMember2024-01-012024-01-010000352915uhs:OtherNonPatientRevenueMember2023-01-012023-09-300000352915us-gaap:ProfessionalMalpracticeLiabilityMembersrt:MaximumMembersrt:SubsidiariesMember2019-12-310000352915srt:MaximumMemberuhs:CanyonCreekBehavioralHealthMember2024-01-012024-09-300000352915uhs:UniversalHealthRealtyIncomeTrustMember2021-01-012021-12-310000352915us-gaap:RetainedEarningsUnappropriatedMember2023-12-310000352915uhs:ThePavilionBehavioralHealthSystemMemberuhs:PunitiveDamagesMember2024-03-282024-03-280000352915us-gaap:RestrictedStockMemberuhs:GroupPurchasingOrganizationAgreementMemberuhs:PremierIncMember2023-01-012023-12-310000352915uhs:ManagedCareMemberuhs:BehavioralHealthServicesMember2023-07-012023-09-300000352915us-gaap:CommonClassCMemberus-gaap:CommonStockMember2023-12-310000352915uhs:AmendedRevolvingCreditFacilityMember2024-01-012024-09-300000352915us-gaap:FairValueInputsLevel2Memberuhs:AccruedLiabilitiesOtherMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMember2023-12-310000352915uhs:UniversalHealthRealtyIncomeTrustMember2023-01-012023-03-310000352915uhs:CommonClassDMemberus-gaap:CommonStockMember2022-12-310000352915us-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2023-12-310000352915uhs:OtherNonPatientRevenueMemberus-gaap:AllOtherSegmentsMember2023-07-012023-09-300000352915us-gaap:EarthquakeMemberuhs:CaliforniaNewMadridSeismicZonePacificNorthwestSeismicZoneAlaskaAndCertainCountiesInNevadaMember2024-09-300000352915uhs:OtherNonPatientRevenueMember2023-07-012023-09-300000352915uhs:RedeemableInterestMember2022-12-310000352915us-gaap:RetainedEarningsAppropriatedMember2023-07-012023-09-300000352915uhs:BehavioralHealthServicesMember2023-01-012023-09-300000352915us-gaap:NoncontrollingInterestMember2024-07-012024-09-300000352915us-gaap:NoncontrollingInterestMember2023-07-012023-09-300000352915uhs:BehavioralHealthServicesMember2023-07-012023-09-300000352915uhs:AcuteCareHospitalServicesMemberuhs:ManagedCareMember2024-07-012024-09-30000035291529152023-07-012023-09-

300000352915uhs:OneHospitalFacilityMember2024-01-012024-09-300000352915us-gaap:AllOtherSegmentsMember2023-07-012023-09-300000352915srt:MaximumMemberuhs:WellingtonRegionalMedicalCenterMember2024-01-012024-09-300000352915uhs:OtherPatientRevenueAndAdjustmentsNetMember2023-01-012023-09-300000352915us-gaap:RestrictedStockMemberuhs:GroupPurchasingOrganizationAgreementMemberuhs:PremierIncMember2024-01-012024-09-300000352915us-gaap:ProfessionalMalpracticeLiabilityMembersrt:MaximumMembersrt:SubsidiariesMember2022-12-310000352915us-gaap:ProfessionalMalpracticeLiabilityMembersrt:MaximumMembersrt:SubsidiariesMember2017-12-310000352915uhs:UniversalHealthRealtyIncomeTrustMemberus-gaap:InvestmentAdviceMember2024-01-012024-09-300000352915us-gaap:NoncontrollingInterestMember2024-06-300000352915uhs:CommonClassDMemberus-gaap:CommonStockMember2024-09-300000352915us-gaap:DebtMember2024-09-300000352915uhs:BehavioralHealthCareFacilityMemberuhs:UniversalHealthRealtyIncomeTrustMember2024-01-012024-09-300000352915us-gaap:CommonClassCMemberus-gaap:CommonStockMember2023-06-300000352915uhs:AmendedRevolvingCreditFacilityMember2024-09-262024-09-260000352915us-gaap:RetainedEarningsUnappropriatedMember2023-06-300000352915uhs:MedicareMemberuhs:BehavioralHealthServicesMember2023-01-012023-09-300000352915us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300000352915us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:NetInvestmentHedgingMemberus-gaap:ForeignExchangeContractMember2023-01-012023-09-300000352915us-gaap:ProfessionalMalpracticeLiabilityMembersrt:MaximumMembersrt:SubsidiariesMember2020-12-310000352915uhs:FirstThreeRenewalOptionsMemberuhs:TwoFreeStandingEmergencyDepartmentsMembersrt:MaximumMember2024-01-012024-09-300000352915uhs:GeneralAndProfessionalLiabilityInsurancePoliciesMembersrt:MaximumMembersrt:SubsidiariesMember2021-12-310000352915uhs:OtherPatientRevenueAndAdjustmentsNetMember2023-07-012023-09-300000352915srt:MinimumMember2024-09-300000352915uhs:TermLoanAFacilityMemberuhs:OneMonthSOFRRatePlusIndexBasedLoansMembersrt:MaximumMember2024-09-300000352915uhs:PerformanceBasedRestrictedStockUnitsMemberuhs:TwoThousandTwentyStockIncentivePlanMember2024-01-012024-09-300000352915uhs:AcuteCareHospitalServicesMemberuhs:MedicareMember2024-07-012024-09-300000352915uhs:BehavioralHealthCareFacilityMemberuhs:OutsideOwnersMembercountry:AZ2024-09-300000352915uhs:UniversalHealthRealtyIncomeTrustMemberus-gaap:InvestmentAdviceMember2024-07-012024-09-300000352915uhs:DeferredCompensationLiabilityMemberus-gaap:FairValueInputsLevel1Memberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000352915us-gaap:NoncontrollingInterestMember2024-09-300000352915uhs:DepartmentOfHumanServicesMember2022-01-012022-12-310000352915uhs:UniversalHealthRealtyIncomeTrustMember2023-01-012023-12-310000352915uhs:OtherStatesMemberus-gaap:EarthquakeMembersrt:MaximumMember2024-09-300000352915uhs:MedicaidMemberuhs:BehavioralHealthServicesMember2023-07-012023-09-300000352915uhs:AcuteCareHospitalServicesMemberuhs:ManagedMedicaidMember2023-07-012023-09-3000003529152023-01-012023-09-300000352915us-gaap:RetainedEarningsUnappropriatedMember2023-01-012023-09-300000352915uhs:AcuteCareHospitalServicesMemberuhs:OtherPatientRevenueAndAdjustmentsNetMember2023-01-012023-09-300000352915uhs:BehavioralHealthServicesMemberuhs:ManagedMedicaidMember2024-01-012024-09-300000352915us-gaap:OtherNoncurrentAssetsMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000352915us-gaap:FairValueMeasurementsRecurringMember2023-12-310000352915uhs:BehavioralHealthServicesMemberuhs:ManagedMedicareMember2023-07-012023-09-300000352915uhs:AcuteCareHospitalServicesMemberuhs:ManagedCareMember2023-01-012023-09-300000352915us-gaap:ParentMember2023-07-012023-09-300000352915uhs:UKRevenueMember2023-01-012023-09-300000352915uhs:AcuteCareHospitalServicesMemberuhs:ManagedCareMember2023-07-012023-09-300000352915us-gaap:CommonClassCMemberus-gaap:CommonStockMember2024-09-300000352915us-gaap:RevolvingCreditFacilityMember2024-01-012024-09-300000352915us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000352915us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300000352915uhs:AcuteCareHospitalServicesMemberuhs:ManagedMedicareMember2023-07-012023-09-300000352915uhs:NewSeniorSecuredCreditFacilityMemberuhs:OnePointSixFivePercentSeniorSecuredNotesDueTwoThousandTwentySixMember2024-01-012024-09-300000352915us-gaap:GeneralLiabilityMembersrt:MaximumMembersrt:SubsidiariesMember2024-09-300000352915us-gaap:ProfessionalMalpracticeLiabilityMembersrt:MaximumMembersrt:SubsidiariesMember2016-12-310000352915uhs:RedeemableInterestMember2023-09-300000352915us-gaap:GeneralLiabilityMembersrt:MaximumMembersrt:SubsidiariesMember2020-12-310000352915us-gaap:NoncontrollingInterestMember2023-06-300000352915uhs:UniversalHealthRealtyIncomeTrustMember2023-07-012023-09-300000352915us-gaap:RevolvingCreditFacilityMember2024-09-300000352915us-gaap:ParentMember2023-12-310000352915uhs:UnvestedStockOptionMember2024-09-300000352915us-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:EquitySecuritiesMember2024-09-300000352915us-gaap:EmployeeStockOptionMember2024-07-012024-09-300000352915uhs:PremierIncMemberus-gaap:OtherOperatingIncomeExpenseMember2023-01-012023-09-300000352915uhs:PremierIncMemberus-gaap:OtherOperatingIncomeExpenseMember2023-07-012023-09-300000352915uhs:BehavioralHealthServicesMemberuhs:ManagedMedicareMember2023-01-012023-09-300000352915uhs:FourPointSixTwoFivePercentSeniorSecuredNotesDueTwoThousandTwentyNineMember2024-09-260000352915uhs:CumberlandHospitalForChildrenAndAdolescentsMember2024-09-272024-09-270000352915uhs:TrancheATermLoanMember2024-01-012024-09-300000352915us-gaap:OtherNoncurrentAssetsMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000352915us-gaap:EarthquakeMemberuhs:CaliforniaNewMadridSeismicZonePacificNorthwestSeismicZoneAlaskaAndCertainCountiesInNevadaMembersrt:MaximumMember2024-09-300000352915uhs:AcuteCareHospitalServicesMember2023-01-012023-09-300000352915us-gaap:ProfessionalMalpracticeLiabilityMemberuhs:ThePavilionBehavioralHealthSystemMember2024-09-300000352915uhs:TwoFreeStandingEmergencyDepartmentsMembersrt:MaximumMember2024-10-012024-10-310000352915uhs:ManagedCareMemberuhs:BehavioralHealthServicesMember2024-01-012024-09-300000352915us-gaap:CommonStockMemberus-gaap:CommonClassBMember2023-07-012023-09-300000352915uhs:McAllenMedicalCenterMembersrt:MaximumMember2024-01-012024-09-300000352915uhs:AccruedLiabilitiesOtherMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMember2023-12-310000352915uhs:GeneralAndProfessionalLiabilityInsurancePoliciesMember2023-01-012023-09-300000352915uhs:TwoHospitalFacilitiesMember2024-01-012024-09-300000352915uhs:TwoFreeStandingEmergencyDepartmentsMember2024-10-012024-10-31uhs:Hospitaliso4217:USDxbrli:sharesxbrli:purexbrli:sharesuhs:Plaintiffsuhs:Facilityuhs:Bediso4217:GBPuhs:SquareFootiso4217:USDuhs:RenewalOption Â UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Â FORM 10-Q Â (MARK ONE) â˜’ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR â˜ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-10765 Â UNIVERSAL HEALTH SERVICES, INC. (Exact name of registrant as specified in its charter) Â Delaware Â 23-2077891 (State or other jurisdiction ofincorporation or organization) Â (I.R.S. EmployerIdentification No.) UNIVERSAL CORPORATE CENTER 367 SOUTH GULPH ROAD KING OF PRUSSIA, Pennsylvania 19406 (Address of principal executive offices) (Zip Code) Registrantâ€™s telephone number, including area code (610) 768-3300 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Class B Common Stock, $0.01 par value UHS New York Stock Exchange Â Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes â˜’ No â˜ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes â˜’ No â˜ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act. Large accelerated filer â˜’ Accelerated filer â˜ Â Â Â Â Â Non-accelerated filer â˜ Smaller reporting company â˜ Â Â Emerging growth company â˜ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. â˜ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes â˜ No â˜’ Indicate the number of shares outstanding of each of the issuerâ€™s classes of common stock, as of the latest practicable date. Common shares outstanding, as of October 31, 2024: Class A Â 6,576,475 Class B Â 58,714,711 Class C Â 661,688 Class D Â 12,774 Â Â Â UNIVERSAL HEALTH SERVICES, INC. INDEX PAGE NO. PART I. FINANCIAL INFORMATION Item 1. Financial Statements (unaudited) Condensed Consolidated Statements of Income â€“ Three and Nine Months Ended September 30, 2024 and 2023 3 Â Condensed Consolidated Statements of Comprehensive Income â€“ Three and Nine Months Ended September 30, 2024 and 2023 4 Â Condensed Consolidated Balance Sheets â€“ September 30, 2024 and December 31, 2023 5 Â Condensed Consolidated Statements of Changes in Equity â€“ Three and Nine Months Ended September 30, 2024 and 2023 Â 6 Â Â Â Condensed Consolidated Statements of Cash Flows - Nine Months Ended September 30, 2024 and 2023 8 Â Notes to Condensed Consolidated Financial Statements 9 Â Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations 27 Â Item 3. Quantitative and Qualitative Disclosures About Market Risk 63 Â Item 4. Controls and Procedures 63 Â PART II. Other Information Â Â Item 1. Legal Proceedings 64 Â Item 1A. Risk Factors 64 Â Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 65 Â Â Â Item 5. Other Information 66 Â Â Â Item 6. Exhibits 67 Â Signatures 68 This Quarterly Report on Form 10-Q is for the quarter ended September 30, 2024. This Report modifies and supersedes documents filed prior to this Report. Information that we file with the Securities and Exchange Commission (the â€œSECâ€) in the future will automatically update and supersede information contained in this Report. In this Quarterly Report, â€œwe,â€ â€œus,â€ â€œourâ€ â€œUHSâ€ and the â€œCompanyâ€ refer to Universal Health Services, Inc. and its subsidiaries. UHS is a registered trademark of UHS of Delaware, Inc., the management company for, and a wholly-owned subsidiary of Universal Health Services, Inc. Universal Health Services, Inc. is a holding company and operates through its subsidiaries including its management company, UHS of Delaware, Inc. All healthcare and management operations are conducted by subsidiaries of Universal Health Services, Inc. To the extent any reference to â€œUHSâ€ or â€œUHS facilitiesâ€ in this report including letters, narratives or other forms contained herein relates to our healthcare or management operations it is referring to Universal Health Services, Inc.â€™s subsidiaries including UHS of Delaware, Inc. Further, the terms â€œwe,â€ â€œus,â€ â€œourâ€ or the â€œCompanyâ€ in such context similarly refer to the operations of Universal Health Services Inc.â€™s subsidiaries including UHS of Delaware, Inc. Any reference to employees or employment contained herein refers to employment with or employees of the subsidiaries of Universal Health Services, Inc. including UHS of Delaware, Inc. 2 Â PART I. FINANCIAL INFORMATION UNIVERSAL HEALTH SERVICES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME (amounts in thousands, except per share amounts) (unaudited) Â Three months endedSeptember 30, Â Â Nine months endedSeptember 30, Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Net revenues $ 3,963,027 Â Â $ 3,562,774 Â Â $ 11,714,213 Â Â $ 10,578,430 Â Operating charges: Â Â Â Â Â Â Â Â Â Â Â Salaries, wages and benefits Â 1,912,308 Â Â Â 1,784,870 Â Â Â 5,611,304 Â Â Â 5,308,476 Â Other operating expenses Â 1,090,197 Â Â Â 941,219 Â Â Â 3,165,483 Â Â Â 2,758,484 Â Supplies expense Â 390,250 Â Â Â 378,667 Â Â Â 1,181,886 Â Â Â 1,138,950 Â Depreciation and amortization Â 149,567 Â Â Â 137,195 Â Â Â 438,050 Â Â Â 422,560 Â Lease and rental expense Â 36,540 Â Â Â 35,466 Â Â Â 108,165 Â Â Â 105,775 Â Â Â 3,578,862 Â Â Â 3,277,417 Â Â Â 10,504,888 Â Â Â 9,734,245 Â Income from operations Â 384,165 Â Â Â 285,357 Â Â Â 1,209,325 Â Â Â 844,185 Â Interest expense, net Â 44,660 Â Â Â 53,378 Â Â Â 146,385 Â Â Â 153,085 Â Other (income) expense, net Â (2,028) Â Â 11,472 Â Â Â 3,315 Â Â Â 31,797 Â Income before income taxes Â 341,533 Â Â Â 220,507 Â Â Â 1,059,625 Â Â Â 659,303 Â Provision for income taxes Â 75,623 Â Â Â 52,499 Â Â Â 233,563 Â Â Â 159,618 Â Net income Â 265,910 Â Â Â 168,008 Â Â Â 826,062 Â Â Â 499,685 Â Less: Net income (loss) attributable to noncontrolling interests Â 7,196 Â Â Â 1,019 Â Â Â 16,362 Â Â Â (1,732) Net income attributable to UHS $ 258,714 Â Â $ 166,989 Â Â $ 809,700 Â Â $ 501,417 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Basic earnings per share attributable to UHS $ 3.89 Â Â $ 2.42 Â Â $ 12.11 Â Â $ 7.18 Â Diluted earnings per share attributable to UHS $ 3.80 Â Â $ 2.40 Â Â $ 11.88 Â Â $ 7.09 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Weighted average number of common shares - basic Â 66,537 Â Â Â 68,867 Â Â Â 66,873 Â Â Â 69,825 Â Add: Other share equivalents Â 1,571 Â Â Â 757 Â Â Â 1,297 Â Â Â 825 Â Weighted average number of common shares and Â Â Â equivalents - diluted Â 68,108 Â Â Â 69,624 Â Â Â 68,170 Â Â Â 70,650 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â The accompanying notes are an integral part of these condensed consolidated financial statements. Â 3 Â UNIVERSAL HEALTH SERVICES, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (amounts in thousands, unaudited) Â Â Three months endedSeptember 30, Â Â Nine months endedSeptember 30, Â Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Net income Â $ 265,910 Â Â $ 168,008 Â Â $ 826,062 Â Â $ 499,685 Â Other comprehensive income (loss): Â Â Â Â Â Â Â Â Â Â Â Foreign currency translation adjustment Â Â 29,221 Â Â Â (24,631) Â Â 29,155 Â Â Â (703) Other Â Â - Â Â Â - Â Â Â 17 Â Â Â - Â Other comprehensive income (loss) before tax Â Â 29,221 Â Â Â Â (24,631) Â Â 29,172 Â Â Â Â (703) Income tax expense (benefit) related to items of otherÂ Â Â comprehensive income (loss) Â Â (140) Â Â (926) Â Â 288 Â Â Â (95) Total other comprehensive (loss) income, net of tax Â Â 29,361 Â Â Â Â (23,705) Â Â 28,884 Â Â Â (608) Comprehensive income Â Â 295,271 Â Â Â 144,303 Â Â Â 854,946 Â Â Â 499,077 Â Less: Comprehensive income (loss) attributable to noncontrollingÂ Â Â interests Â Â 7,196 Â Â Â 1,019 Â Â Â 16,362 Â Â Â (1,732) Comprehensive income attributable to UHS Â $ 288,075 Â Â $ 143,284 Â Â $ 838,584 Â Â $ 500,809 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â

Â Â Issued/(converted) Â Â â€” Â Â Â â€” Â Â Â 3 Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 3,634 Â Â Â â€” Â Â Â 3,637 Â Â Â â€” Â Â Â 3,637 Â Repurchased, including excise tax Â Â â€” Â Â Â â€” Â Â Â (8) Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (184,131) Â Â â€” Â Â Â (184,139) Â Â â€” Â Â Â (184,139) Restricted share-based compensation expense Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 12,867 Â Â Â â€” Â Â Â 12,867 Â Â Â â€” Â Â Â 12,867 Â Dividends paid and accrued Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (13,472) Â Â â€” Â Â Â â€” Â Â Â (13,472) Â Â â€” Â Â Â (13,472) Stock option expense Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 13,356 Â Â Â â€” Â Â Â 13,356 Â Â Â â€” Â Â Â 13,356 Â Distributions to noncontrolling interests Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â (702) Â Â (702) Sale of ownership interests to minority members Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â â€” Â Â Â 3,668 Â Â Â 3,668 Â Comprehensive income: Â Â Â

the leases at the lease terms described above and below by providing notice to the Trust at least 90 days prior to the termination of the then current term. We also have the right to purchase the respective leased hospitals at their appraised fair market value upon any of the following: (i) at the end of the lease terms or any renewal terms; (ii) upon one monthâ€™s notice should a change of control of the Trust occur, or; (iii) within the time period as specified in the lease in the event that we provide notice to the Trust of our intent to offer a substitution property/properties in exchange for one (or more) of the hospital properties leased from the Trust should we be unable to reach an agreement with the Trust on the properties to be substituted. In addition, we have rights of first refusal to: (i) purchase the respective leased facilities during and for a specified period after the lease terms at the same price, terms and conditions of any third-party offer, or; (ii) renew the lease on the respective leased facility at the end of, and for a specified period after, the lease term at the same terms and conditions pursuant to any third-party offer.In addition, we are the managing, majority member in a joint venture with an unrelated third-party that operates Clive Behavioral Health, a 100-bed behavioral health care facility located in Clive, Iowa. The real property of this facility, which was completed and opened in late 2020, is also leased from the Trust (annual rental of approximately $2.8 million and $2.7 million during 2024 and 2023, respectively) pursuant to the lease terms as provided in the table below. In connection with the lease on this facility, the joint venture has the right to purchase the leased facility from the Trust at its appraised fair market value upon either of the following: (i) by providing notice at least 270 days prior to the end of the lease terms or any renewal terms, or; (ii) upon 30 days' notice anytime within 12 months of a change of control of the Trust (UHS also has this right should the joint venture decline to exercise its purchase right). Additionally, the joint venture has rights of first offer to purchase the facility prior to any third-party sale.The table below provides certain details for each of the hospitals leased from the Trust as of September 30, 2024:Â Hospital Name Â AnnualMinimumRent Â Â End of Lease Term Â RenewalTerm(years) Â Â McAllen Medical Center Â $ 5,485,000 Â Â December, 2026 Â Â 5 Â (a) Wellington Regional Medical Center Â $ 6,639,000 Â Â December, 2026 Â Â 5 Â (b) Aiken Regional Medical Center/Aurora Pavilion Behavioral Health Services Â $ 4,072,000 Â Â December, 2033 Â Â 35 Â (c) Canyon Creek Behavioral Health Â $ 1,841,000 Â Â December, 2033 Â Â 35 Â (c) Clive Behavioral Health Hospital Â $ 2,775,000 Â Â December, 2040 Â Â 50 Â (d) Â (a)We have one 5-year renewal option at existing lease rates (through 2031).(b)We have one 5-year renewal option at fair market value lease rates (through 2031). On each January 1st through 2026, the annual rent will increase by 2.5% on a cumulative and compounded basis.(c)We have seven 5-year renewal options at fair market value lease rates (2034 through 2068). On each January 1st through 2033, the annual rent will increase by 2.25% on a cumulative and compounded basis. (d)This facility is operated by a joint venture in which we are the managing, majority member and an unrelated third-party holds a minority ownership interest. The joint venture has three, 10-year renewal options at computed lease rates as stipulated in the lease (2041 through 2070) and two additional, 10-year renewal options at fair market value lease rates (2071 through 2090). In each January through 2040 (and potentially through 2070 if three, 10-year renewal options are exercised), the annual rental will increase by 2.75% on a cumulative and compounded basis.In addition, certain of our subsidiaries are tenants in several medical office buildings (â€œMOBsâ€) and two free-standing emergency departments ("FED") owned by the Trust or by limited liability companies in which the Trust holds 95% to 100% of the ownership 10 Â interest. In connection with these two FEDs, in October, 2024, our subsidiaries exercised their 5-year renewal options on the facilities which are located in Weslaco and Mission, Texas. Each renewal option covers the period of February 1, 2025 through January 31, 2030 (the current lease terms were scheduled to expire on January 31, 2025; with aggregate annual lease rates of approximately $979,000). Pursuant to terms of the leases, and consistent with the terms of the leases currently in effect for each property, the lease rates are scheduled to increase 2% per year through the end of the renewed lease terms. Our subsidiaries have five, 5-year renewal options remaining on each of these FEDs, with the first three renewal options (covering the years 2030 through 2044) providing for 2% annual increases to the lease rates, and the remaining two, 5-year renewal options (covering the years 2045 through 2054) providing for lease rates at the then fair market value. These leases are cross-defaulted with one another and our subsidiaries have the option to purchase the leased properties upon the expiration of each five-year extended term at the fair market value at that time. During the third quarter of 2023, the Trust acquired the McAllen Doctor's Center, a 79,500 rentable square feet medical office building located in McAllen, Texas. A master lease was executed between a wholly-owned subsidiary of ours and the Trust, pursuant to the terms of which our subsidiary will master lease 100% of the rentable square feet of the MOB at an initial minimum rent of $624,000 annually. The master lease commenced during August, 2023 and is scheduled to expire in twelve years.During the first quarter of 2023, the Trust substantially completed construction on a new 86,000 rentable square feet multi-tenant MOB that is located on the campus of Northern Nevada Sierra Medical Center in Reno, Nevada. Northern Nevada Sierra Medical Center, a 170-bed newly constructed acute care hospital owned and operated by a wholly-owned subsidiary of ours, was completed and opened in April, 2022. In connection with this MOB, a ground lease and a master flex lease was executed between a wholly-owned subsidiary of ours and the Trust, pursuant to the terms of which our subsidiary will master lease approximately 68% of the rentable square feet of the MOB at an initial minimum rent of $1.3 million annually plus a pro-rata share of the common area maintenance expenses. The master flex lease could be reduced during the term if certain conditions are met. The ground lease and master flex lease each commenced during the first quarter of 2023.Other Related Party Transactions:In December, 2010, our Board of Directors approved the Companyâ€™s entering into supplemental life insurance plans and agreements on the lives of Alan B. Miller (our Executive Chairman of the Board) and his wife. As a result of these agreements, as amended in October, 2016, based on actuarial tables and other assumptions, during the life expectancies of the insureds, we would pay approximately $28 million in premiums, and certain trusts owned by our Executive Chairman of the Board, would pay approximately $9 million in premiums. Based on the projected premiums mentioned above, and assuming the policies remain in effect until the death of the insureds, we will be entitled to receive death benefit proceeds of no less than approximately $37 million representing the $28 million of aggregate premiums paid by us as well as the $9 million of aggregate premiums paid by the trusts. In connection with these policies, we will pay or have paid approximately $1.0 million, net, in premium payments during 2024 and 2023.In August, 2015, Marc D. Miller, our President and Chief Executive Officer and member of our Board of Directors, was appointed to the Board of Directors of Premier, Inc. (â€œPremierâ€), a healthcare performance improvement alliance. During 2013, we entered into a new group purchasing organization agreement (â€œGPOâ€) with Premier. In conjunction with the GPO agreement, we acquired a minority interest in Premier for a nominal amount. During the fourth quarter of 2013, in connection with the completion of an initial public offering of the stock of Premier, we received cash proceeds for the sale of a portion of our ownership interest in the GPO. Also in connection with this GPO agreement, we received shares of restricted stock of Premier which vested ratably over a seven-year period (2014 through 2020), contingent upon our continued participation and minority ownership interest in the GPO. During the third quarter of 2020, we entered into an agreement with Premier pursuant to the terms of which, among other things, our ownership interest in Premier was converted into shares of Class A Common Stock of Premier. We have elected to retain a portion of the previously vested shares of Premier, the market value of which is included in other assets on our condensed consolidated balance sheets. Based upon the closing price of Premierâ€™s stock on each respective date, the market value of our shares of Premier was approximately $45 million and $50 million as of September 30, 2024 and December 31, 2023, respectively. Any change in market value of our Premier shares since December 31, 2023 was recorded as an unrealized gain/loss in â€œOther (income) expense, netâ€ in our condensed consolidated statements of income for the three and nine-month period ended September 30, 2024. Additionally, we received cash dividends from Premier amounting to approximately $470,000 for each of the three-month periods ended September 30, 2024 and 2023, and approximately $1.4 million for each of the nine-month periods ended September 30, 2024 and 2023. The dividends are included in â€œOther (income) expense, netâ€ in our condensed consolidated statements of income. A member of our Board of Directors, Executive Committee and Finance Committee is a partner in Norton Rose Fulbright US LLP, a law firm engaged by us for a variety of legal services. The Board member and his law firm also provide personal legal services to our Executive Chairman and he acts as trustee of certain trusts for the benefit of our Executive Chairman and his family. (3) Other Noncurrent liabilities and Redeemable/Noncontrolling InterestsOther noncurrent liabilities include the long-term portion of our professional and general liability, workersâ€™ compensation reserves, pension and deferred compensation liabilities, and liabilities incurred in connection with split-dollar life insurance agreements on the lives of our chief executive officer and his wife. 11 Â As of September 30, 2024, outside owners held noncontrolling, minority ownership interests of: (i) approximately 7% in an acute care facility located in Texas; (ii) 49%, 20%, 30%, 20%, 25%, and 48% in six behavioral health care facilities located in Arizona, Pennsylvania, Ohio, Washington, Missouri, and Iowa, respectively, (iii) 26% and 49% in two behavioral health care facilities located in Michigan (one currently under construction with an expected opening in the second quarter of 2025) and; (iv) approximately 5% in an acute care facility and 49% in a surgery center, located in Nevada. The noncontrolling interest and redeemable noncontrolling interest balances of $75 million and $6 million, respectively, as of September 30, 2024, consist primarily of the third-party ownership interests in these hospitals.In connection with the two behavioral health care facilities located in Pennsylvania and Ohio, the minority ownership interests of which are reflected as redeemable noncontrolling interests on our consolidated balance sheets, the outside owners have â€œput optionsâ€ to put their entire ownership interest to us at any time. If exercised, the put option requires us to purchase the minority memberâ€™s interest at fair market value. Accordingly, the amounts recorded as redeemable noncontrolling interests on our consolidated balance sheets reflect the estimated fair market value of these ownership interests. (4) TreasuryIn September, 2024, we completed the following financing transactions:â€¢The public offering of $500 million of aggregate principal amount of 4.625% senior secured notes due on October 15, 2029 ("2029 Notes");â€¢The public offering of $500 million of aggregate principal amount of 5.050% senior secured notes due on October 15, 2034 ("2034 Notes");â€¢Amended our credit agreement to:oExtend the maturity date to September, 2029 (from August, 2026 previously);oIncrease the revolving credit facility to $1.3 billion (from $1.2 billion previously), and;oreduce the outstanding borrowings pursuant to the tranche term loan A facility by approximately $1.0 billion, to $1.2 billion, utilizing the proceeds generated from the issuance of the above-mentioned 2029 Notes and 2034 Notes.On September 26, 2024, we entered into a tenth amendment ("Tenth Amendment") to our credit agreement ("Credit Agreement"), dated as of November 15, 2010, as amended and restated at various times from March, 2011 to June, 2022, among UHS, as borrower, the several banks and other financial institutions or entities from time to time parties thereto, as lenders, and JPMorgan Chase Bank, N.A., as administrative agent. The Tenth Amendment provided for: (i) an extension of the maturity date to September 26, 2029; (ii) a new revolving credit facility of up to $1.3 billion (which as of September 30, 2024, had $1.01 billion of aggregate available borrowing capacity, net of $288 million of outstanding borrowings and $3 million of letters of credit), and; (iii) a new replacement tranche A term loan facility ("Tranche A Term Loan") of up to $1.2 billion (which had $1.2 billion of outstanding borrowings as of September 30, 2024).Pursuant to the terms of the Tenth Amendment, the Tranche A Term Loan provides for installment payments of $7.5 million per quarter commencing on December 31, 2024 through September 30, 2026, and $15.0 million per quarter commencing on December 31, 2026 through June 30, 2029. The unpaid principal balance at June 30, 2029 (scheduled to be $975.0 million) is payable on the September 26, 2029 scheduled maturity date of the Credit Agreement.Revolving credit and Tranche A Term Loan borrowings under the Credit Agreement bear interest at our election at either (1) the ABR rate which is defined as the rate per annum equal to the greatest of (a) the lenderâ€™s prime rate, (b) the weighted average of the federal funds rate, plus 0.5% and (c) one month term SOFR rate plus 1%, in each case, plus an applicable margin based upon our consolidated leverage ratio at the end of each quarter ranging from 0.25% to 0.625%, or (2) the one, three or six month term SOFR rate plus 0.1% (at our election), plus an applicable margin based upon our consolidated leverage ratio at the end of each quarter ranging from 1.25% to 1.625%. As of September 30, 2024, the applicable margins were 0.375% for ABR-based loans and 1.375% for SOFR-based loans under the revolving credit and term loan A facilities. The revolving credit facility includes a $125 million sub-limit for letters of credit. The Credit Agreement is secured by certain assets of the Company and our material subsidiaries (which generally excludes asset classes such as substantially all of the patient-related accounts receivable of our acute care hospitals, if sold to a receivables facility pursuant to the Credit Agreement, and certain real estate assets and assets held in joint-ventures with third parties) and is guaranteed by our material subsidiaries.The Credit Agreement includes a material adverse change clause that must be represented at each draw. The Credit Agreement also contains covenants that include a limitation on sales of assets, mergers, change of ownership, liens, indebtedness, transactions with affiliates, dividends and stock repurchases; and requires compliance with financial covenants including maximum leverage. We were in compliance with all required covenants as of September 30, 2024 pursuant to the terms of the Credit Agreement, as amended on September 26, 2024, and as of December 31, 2023 pursuant to the terms of the previous credit agreement. 12 Â As mentioned above, on September 26, 2024, we completed the public offering of: (i) $500,000,000 aggregate principal amount of the 4.625%, 2029 Notes, and; (ii) $500,000,000 aggregate principal amount of the 5.050%, 2034 Notes (and together with the 2029 Notes, the "2029 and 2034 Notes"), each guaranteed on a senior secured basis by all of our existing and future direct and indirect subsidiaries that guarantee our senior secured credit facility or our other first lien obligations or any junior lien obligations (the â€œSubsidiary Guarantorsâ€). The 2029 and 2034 Notes have been registered under the Securities Act of 1933, as amended (the â€œSecurities Actâ€), pursuant to the Issuerâ€™s and the Subsidiary Guarantorsâ€™ registration statement on Form S-3 (File No. 333-282135), including the prospectus dated September 16, 2024, and a related prospectus supplement dated September 17, 2024, as filed with the Securities and Exchange Commission on September 19, 2024.As of September 30, 2024, including the above-mentioned newly issued Notes, we had combined aggregate principal of $3.0 billion from the following senior secured notes:â€¢$700 million aggregate principal amount of 1.65% senior secured notes due in September, 2026 ("2026 Notes") which were issued on August 24, 2021. Interest on the 2026 Notes is payable on March 1st and September 1st until the maturity date of September 1, 2026.â€¢$500 million of aggregate principal amount of 4.625% senior secured notes due in October, 2029 ("2029 Notes") which were issued on September 26, 2024. Interest on the 2029 Notes is payable on April 15th and October 15th, commencing April 15, 2025 until the maturity date of October 15, 2029.â€¢$800 million aggregate principal amount of 2.65% senior secured notes due in October, 2030 ("2030 Notes") which were issued on September 21, 2020. Interest on the 2030 Notes is payable on April 15th and October 15th, until the maturity date of October 15, 2030.â€¢$500 million of aggregate principal amount of 2.65% senior secured notes due in January, 2032 ("2032 Notes") which were issued on August 24, 2021. Interest on the 2032 Notes is payable on January 15th and July 15th until the maturity date of January 15, 2032.â€¢$500 million of aggregate principal amount of 5.050% senior secured notes due in October, 2034 ("2034 Notes") which were issued on September 26, 2024. Interest on the 2034 Notes is payable on April 15th and October 15th, commencing on April 15, 2025 until the maturity date of October 15, 2034.The 2026 Notes, 2030 Notes and 2032 Notes (collectively the "2026, 2030 and 2032 Notes") were initially issued only to qualified institutional buyers under Rule 144A and to non-U.S. persons outside the United States in reliance on Regulation S under the Securities Act. In December, 2022, we completed a registered exchange offer in which virtually all previously outstanding 2026, 2030 and 2032 Notes were exchanged for identical 2026, 2030 and 2032 Notes that were registered under the Securities Act, and thereby became freely transferable (subject to certain restrictions applicable to affiliates and broker dealers). 2026, 2030 and 2032 Notes originally issued under Rule 144A or Regulation S that were not exchanged remain outstanding and may not be offered or sold in the United States absent registration under the Securities Act or an applicable exemption from registration requirements thereunder.The 2026, 2030 and 2032 Notes, and the 2029 and 2034 Notes (collectively "All the Notes") are guaranteed (the â€œGuaranteesâ€) on a senior secured basis by our Subsidiary Guarantors that guarantee our Credit Agreement, or other first lien obligations or any junior lien obligations. All the Notes and the Guarantees are secured by first-priority liens, subject to permitted liens, on certain of the Companyâ€™s and the Subsidiary Guarantorsâ€™ assets now owned or acquired in the future by the Company or the Subsidiary Guarantors (other than real property, accounts receivable sold pursuant to a Company-related receivables facility (as defined in the Indenture pursuant to which All The Notes were issued (the â€œIndenturesâ€), and certain other excluded assets). The Companyâ€™s obligations with respect to All the Notes, the obligations of the Subsidiary Guarantors under the Guarantees, and the performance of all of the Companyâ€™s and the Subsidiary Guarantorsâ€™ other obligations under the Indentures, are secured equally and ratably with the Companyâ€™s and the Subsidiary Guarantorsâ€™ obligations under the Credit Agreement. However, the liens on the collateral securing All the Notes and the Guarantees will be released if: (i) All the Notes have investment grade ratings; (ii) no default has occurred and is continuing, and; (iii) the liens on the collateral securing all first lien obligations (including the Credit Agreement and All the Notes) and any junior lien obligations are released or the collateral under the Credit Agreement, any other first lien obligations and any junior lien obligations is released or no longer required to be pledged. The liens on any collateral securing All the Notes and the Guarantees will also be released if the liens on that collateral securing the Credit Agreement, other first lien obligations and any junior lien obligations are released.As discussed in Note 2 to the Condensed Consolidated Financial Statements-Relationship with Universal Health Realty Income Trust and Other Related Party Transactions, on December 31, 2021, we (through wholly-owned subsidiaries of ours) entered into an asset purchase and sale agreement with Universal Health Realty Income Trust (the â€œTrustâ€). Pursuant to the terms of the agreement, which was amended during the first quarter of 2022, we, among other things, transferred to the Trust, the real estate assets of Aiken Regional Medical Center (â€œAikenâ€) and Canyon Creek Behavioral Health (â€œCanyon Creekâ€). In connection with this transaction, Aiken and Canyon Creek (as lessees), entered into a master lease and individual property leases, as amended, (with the Trust as lessor), for initial lease terms on each property of approximately twelve years, ending on December 31, 2033.

As a result of our purchase option within 13 Â the Aiken and Canyon Creek lease agreements, this asset purchase and sale transaction is accounted for as a failed sale leaseback in accordance with U.S. GAAP and we have accounted for the transaction as a financing arrangement. Our lease payments payable to the Trust are recorded to interest expense and as a reduction of the outstanding financial liability, and the amount allocated to interest expense is determined based upon our incremental borrowing rate and the outstanding financial liability. In connection with this transaction, our consolidated balance sheets at September 30, 2024 and December 31, 2023 reflect financial liabilities, which are included in debt, of approximately $75 million and $77 million, respectively.At September 30, 2024, the carrying value and fair value of our debt were approximately $4.7 billion and $4.4 billion, respectively. At December 31, 2023, the carrying value and fair value of our debt were approximately $4.9 billion and $4.6 billion, respectively. The fair value of our debt was computed based upon quotes received from financial institutions. We consider these to be â€œlevel 2â€ in the fair value hierarchy as outlined in the authoritative guidance for disclosures in connection with debt instruments.The aggregate scheduled maturities of our $4.7 billion total debt outstanding as of September 30, 2024 (before $21 million of unamortized financing costs), are as follows: (i) $38 million due during the next 12 months; (ii) $738 million due during months 13 to 24; (iii) $69 million due during months 25 to 36; (iv) $70 million due during months 37 to 48; (v) $1.3 billion due during months 49 to 60, and; (vi) $2.4 billion due in greater than 60 months.Foreign Currency Forward Exchange Contracts:We use forward exchange contracts to hedge our net investment in foreign operations against movements in exchange rates. The effective portion of the unrealized gains or losses on these contracts is recorded in foreign currency translation adjustment within accumulated other comprehensive income and remains there until either the sale or liquidation of the subsidiary. In connection with these forward exchange contracts, we recorded net cash outflows of $36 million during the nine-month period ended September 30, 2024 and net cash outflows of $8 million during the nine-month period ended September 30, 2023.Derivatives Hedging Relationships:The following table presents the effects of our foreign currency forward exchange contracts on our results of operations for the three and nine-month periods ended September 30, 2024 and 2023 (in thousands): Â Gain/(Loss) recognized in AOCI Â Â Three months ended Â Â Nine months ended Â Â September 30, Â Â September 30, Â Â September 30, Â Â September 30, Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Net Investment Hedge relationships Â Â Â Â Â Â Â Â Â Â Â Â Foreign currency forward exchange contracts $ (43,490) Â $ 19,619 Â Â $ (35,289) Â $ (10,781) No other gains or losses were recognized in income related to derivatives in Subtopic 815-20.Cash, Cash Equivalents and Restricted Cash:Cash, cash equivalents, and restricted cash as reported in the condensed consolidated statements of cash flows are presented separately on our condensed consolidated balance sheets as follows (in thousands): Â September 30, Â Â September 30, Â Â December 31, Â Â 2024 Â Â 2023 Â Â 2023 Â Cash and cash equivalents $ 106,077 Â $ 80,768 Â $ 119,439 Â Restricted cashÂ (a) Â 98,520 Â Â 99,871 Â Â 95,031 Â Total cash, cash equivalents and restricted cash $ 204,597 Â Â $ 180,639 Â Â $ 214,470 Â (a) Restricted cash is included in other noncurrent assets on the accompanying condensed consolidated balance sheets. (5) Fair Value MeasurementFair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels:â€¢Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.â€¢Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These included quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.â€¢Level 3: Unobservable inputs that reflect the reporting entityâ€™s own assumptions. 14 Â The following tables present the assets and liabilities recorded at fair value on a recurring basis: Â Balance at Â Balance Sheet Basis of Fair Value Measurement Â (in thousands) September 30, 2024 Â Location Level 1 Â Level 2 Â Level 3 Â Assets: Â Â Â Â Â Â Â Â Money market mutual funds $ 115,205 Â Other noncurrent assets $ 115,205 Â Â Â Â Â Certificates of deposit Â 2,201 Â Other noncurrent assets Â Â Â 2,201 Â Â Â Equity securities Â 44,654 Â Other noncurrent assets Â 44,654 Â Â Â Â Â Deferred compensation assets Â 49,270 Â Other noncurrent assets Â 49,270 Â Â Â Â Â Â $ 211,330 Â Â $ 209,129 Â $ 2,201 Â Â - Â Liabilities: Â Â Â Â Â Â Â Â Â Foreign currency forward exchange contracts $ 1,533 Â Accounts payable and other liabilities Â Â $ 1,533 Â Â Â Deferred compensation liability Â 49,270 Â Other noncurrent liabilities Â 49,270 Â Â Â Â Â Â $ 50,803 Â Â $ 49,270 Â $ 1,533 Â Â - Â Â Â Â Â Â Â Â Â Â Â Â Balance at Â Balance Sheet Basis of Fair Value Measurement Â (in thousands) December 31, 2023 Â Location Level 1 Â Level 2 Â Level 3 Â Assets: Â Â Â Â Â Â Â Â Â Money market mutual funds $ 111,129 Â Other noncurrent assets $ 111,129 Â Â Â Â Â Certificates of deposit Â 2,300 Â Other noncurrent assets Â Â Â 2,300 Â Â Â Equity securities Â 49,923 Â Other noncurrent assets Â 49,923 Â Â Â Â Â Deferred compensation assets Â 43,060 Â Other noncurrent assets Â 43,060 Â Â Â Â Â Â $ 206,412 Â Â $ 204,112 Â $ 2,300 Â Â - Â Liabilities: Â Â Â Â Â Â Â Â Â Foreign currency forward exchange contracts $ 1,911 Â Accounts payable and other liabilities Â Â $ 1,911 Â Â Â Deferred compensation liability Â 43,060 Â Other noncurrent liabilities Â 43,060 Â Â Â Â Â Â $ 44,971 Â Â $ 43,060 Â $ 1,911 Â Â - Â The fair value of our money market mutual funds, certificates of deposit and equity securities with a readily determinable fair value are computed based upon quoted market prices in an active market. The fair value of deferred compensation assets and the offsetting liability are computed based on market prices in an active market held in a rabbi trust. The fair value of our foreign currency exchange contracts is determined using quoted forward exchange rates and spot rates at the reporting date. (6) Commitments and ContingenciesProfessional and General Liability, Workersâ€™ Compensation Liability The vast majority of our subsidiaries are self-insured for professional and general liability exposure up to: (i) $20 million for professional liability and $3 million for general liability per occurrence in 2024, 2023, 2022 and 2021; (ii) $10 million and $3 million per occurrence, respectively, in 2020; (iii) $5 million and $3 million per occurrence, respectively, during 2019, 2018 and 2017, and; (iv) $10 million and $3 million per occurrence, respectively, prior to 2017.These subsidiaries are provided with several excess policies through commercial insurance carriers which provide for coverage in excess of the applicable per occurrence and aggregate self-insured retention or underlying policy limits up to approximately $175 million in 2024; $165 million in 2023; $162 million in 2022; $155 million in 2021 and $250 million during each of 2014 through 2020. In addition, from time to time based upon marketplace conditions, we may elect to purchase additional commercial coverage for certain of our facilities or businesses. Our behavioral health care facilities located in the U.K. have policies through a commercial insurance carrier located in the U.K. that provides for Â£18.5 million of professional liability coverage, and Â£25 million of general liability coverage. The commercial insurance limits indicated above for each policy year may have been reduced due to payment of covered claims or suits, subject to the policy terms and conditions.As of September 30, 2024, the total net accrual for our self-insured professional and general liability claims was $480 million, of which $70 million was included in current liabilities. As of December 31, 2023, the total net accrual for our self-insured professional and general liability claims was $431 million, of which $70 million was included in current liabilities.As a result of unfavorable trends experienced during the past several years, included in our results of operations were increases to our reserves for self-insured professional and general liability claims amounting to approximately $30 million and $44 million during the three and nine-month periods ended September 30, 2024, respectively, and $5 million and $25 million during the three and nine-month periods ended September 30, 2023. Our estimated liability for self-insured professional and general liability claims is based on a number of factors including, among other things, the number of asserted claims and reported incidents, estimates of losses for these 15 Â claims based on recent and historical settlement amounts, estimates of incurred but not reported claims based on historical experience, and estimates of amounts recoverable under our commercial insurance policies. While we continuously monitor these factors, our ultimate liability for professional and general liability claims could change materially from our current estimates due to inherent uncertainties involved in making this estimate. Given our significant self-insured exposure for professional and general liability claims, there can be no assurance that a sharp increase in the number and/or severity of claims asserted against us will not have a material adverse effect on our future results of operations.As of September 30, 2024, the total accrual for our workersâ€™ compensation liability claims was $136 million, $58 million of which was included in current liabilities. As of December 31, 2023, the total accrual for our workersâ€™ compensation liability claims was $130 million, $55 million of which was included in current liabilities. As a result of favorable trends experienced in prior years, included in our results of operations during the nine-month period ended September 30, 2023, was a pre-tax decrease to our reserves for self-insured workers' compensation liability claims of approximately $10 million (recorded during the second quarter of 2023).Although we are unable to predict whether or not our future financial statements will require updates to estimates for our prior year reserves for self-insured general and professional and workersâ€™ compensation claims, given the relatively unpredictable nature of these potential liabilities and the factors impacting these reserves, as discussed above, it is reasonably likely that our future financial results may include material adjustments to prior period reserves.As disclosed below in Legal Proceedings:â€¢On March 28, 2024, a jury returned a verdict for compensatory damages of $60 million and punitive damages of $475 million and a related judgment was entered against The Pavilion Behavioral Health System (the â€œPavilionâ€), an indirect subsidiary of the Company. In an order dated October 10, 2024, the trial court ordered a remittitur of punitive damages from $475 million to $120 million. The court denied the Pavilionâ€™s request for reduction of compensatory damages. The Pavilion intends to appeal the remaining judgment.â€¢Cumberland Hospital for Children and Adolescents (â€œCumberlandâ€), an indirect subsidiary of the Company, is a defendant in multi-plaintiff lawsuits filed in the Circuit Court for Richmond, Virginia (the â€œCumberland Litigationâ€), relating to allegations of inappropriate sexual contact during medical examinations by Dr. Daniel Davidow, an independent contractor and the former medical director for Cumberland. The Company and UHS of Delaware, Inc., our administrative services subsidiary (â€œUHS Delawareâ€), were also named as co-defendants in the Cumberland Litigation. Plaintiffs have asserted claims of negligence, assault and battery (against Dr. Davidow), false imprisonment, violations of the Virginia Consumer Protection Act (â€œVCPAâ€), and vicarious liability for Dr. Davidowâ€™s conduct against Cumberland, the Company, and UHS Delaware. The Company and UHS Delaware were dismissed from the action during the trial, which occurred in September, 2024. On September 27, 2024, a jury entered a verdict finding Dr. Davidow and Cumberland liable and awarded these three plaintiffs combined compensatory damages of $60 million for all liability theories, an additional combined $180 million in trebled damages for violation of the VCPA, and an additional combined $120 million in punitive damages. Cumberland is evaluating all legal options and intends to challenge this verdict, including the amounts awarded in the verdict, in post-trial proceedings and on appeal. Based upon Virginia law, we expect that the punitive damage amount should be reduced to a combined maximum of $1.05 million as a matter of law. There are approximately 40 additional plaintiffs making similar allegations with claims pending in the Cumberland Litigation.We are uncertain as to the ultimate financial exposure related to the above-mentioned Cumberland and Pavilion matters and we can make no assurances regarding their outcomes, or the amounts of damages that may be held recoverable after post-judgment proceedings and appeals. While Cumberland and Pavilion have professional liability insurance to cover a portion of these amounts, the resolution of these matters may have a material adverse effect on the Company. Without reduction for any potential amounts related to the above-mentioned Cumberland and Pavilion matters, the Company and its subsidiaries have aggregate insurance coverage of approximately $221 million remaining under commercial policies for matters applicable to the 2020 policy year (in excess of the applicable self-insured retention amounts of $10 million per occurrence for professional liability claims and $3 million per occurrence for general liability claims).In the event the resolution of the Cumberland and/or Pavilion matters exhausts all or a significant portion of the remaining commercial insurance coverage available to the Company and its subsidiaries for claims that occurred in 2020 (the applicable year for the Pavilion matter and substantially all of the Cumberland matters, as discussed above), or it requires the posting of large bonds or other collateral during appeal processes, our future results of operations and capital resources could be materially adversely impacted.Property InsuranceWe have commercial property insurance policies for our properties, covering the period of June 1, 2024 to June 1, 2025, providing property and business interruption coverage for losses in excess of $15 million per occurrence or per location (as applicable based upon the event) up to a $1 billion annual policy limitation for certain catastrophic events or perils. These commercial policies provide for coverage of up to $250 million of annual aggregate coverage for losses resulting from windstorm damage. Losses resulting from named windstorms are subject to deductibles between 3% and 5% of the total insurable value of the property. In addition, we have 16 Â commercial property insurance policies covering catastrophic losses resulting from earthquake and flood damage, each subject to aggregated loss limits (as opposed to per occurrence losses). Commercially insured earthquake coverage for our facilities is subject to various deductibles and limitations including: (i) $100 million limitation for our facilities located in California, New Madrid Seismic Zone, Pacific Northwest Seismic Zone, Alaska and certain counties in Nevada; (ii) $100 million limitation for our facilities located in fault zones within the United States; (iii) $40 million limitation for our facilities located in Puerto Rico, and; (iv) $250 million limitation for many of our facilities located in other states. Our commercially insured flood coverage has a limit of $100 million annually. There is also a $10 million sublimit for one of our facilities located in Houston, Texas, and a $1 million sublimit for our facilities located in Puerto Rico. In addition, subject to the underlying policies' deductible provisions, our facilities located in California, New Madrid Seismic Zone, Pacific Northwest Seismic Zone, Alaska and certain counties in Nevada, have $50 million of excess commercial property insurance coverage for earthquake losses in excess of $100 million. Property insurance for our behavioral health facilities located in the U.K. are provided on an all risk basis up to a Â£1.5 billion policy limit, with coverage caps per location, that includes coverage for real and personal property as well as business interruption losses.These commercial policies are subject to a deductible of: (i) $5 million per location for damage resulting from earthquake, wind, hail and flood, and; (ii) $5 million per occurrence for all other events. For per location or per occurrence losses in excess of the applicable deductible, we are self-insured, through our wholly-owned captive insurance company, for up to $10 million of annual aggregate losses. Should the $10 million self-insured annual aggregate limitation be exhausted during the policy year, we have commercial insurance coverage for the next $30 million of annual aggregate losses in excess of the applicable deductible. In the event the $30 million of commercial coverage is also exhausted, we are self-insured for all per location or per occurrence losses up to $25 million, including the $5 million deductible.Commitment to Develop, Lease and Operate an Acute Care Hospital in Washington, D.C.During 2020, we entered into various agreements with the District of Columbia (the â€œDistrictâ€) related to the development, leasing and operation of an acute care hospital and certain other facilities/structures on land owned by the District (â€œDistrict Facilitiesâ€). The agreements contemplate that we will serve as manager for development and construction of the District Facilities on behalf of the District, with a projected aggregate cost of approximately $439 million, approximately $295 million of which was incurred as of September 30, 2024, which will be entirely funded by the District. Construction of the District Facilities is expected to be completed in the Spring of 2025.Upon completion of the District Facilities, we will lease the District Facilities for a nominal rental amount for a period of 75 years and are obligated to operate the District Facilities during the lease term. We have certain lease termination rights in connection with the District Facilities beginning on the tenth anniversary of the lease commencement date for various and decreasing amounts as provided for in the agreements. Additionally, any time after the 10th anniversary of the lease term, we have a right to purchase the District Facilities for a price equal to the greater of fair market value of the District Facilities or the amount necessary to defease the bonds issued by the District to fund the construction of the District Facilities. The lease agreement also entitles the District to participation rent should certain specified earnings before interest, taxes, depreciation and amortization thresholds be achieved by the acute care hospital.Additionally, we have committed to expend no less than $75 million (approximately $12 million of which has been incurred as of September 30, 2024), over a projected 12-year period, in healthcare infrastructure including expenditures related to the District Facilities as well as other healthcare related expenditures in certain specified areas of Washington, D.C. Pursuant to the agreements, the District is entitled to certain termination fees and other amounts as specified in the agreements in the event we, within certain specified periods of time, cease to operate the acute care hospital or there is a transfer of control of us or our subsidiary operating the hospital.Legal ProceedingsWe operate in a highly regulated and litigious industry which subjects us to various claims and lawsuits in the ordinary course of business as well as regulatory proceedings and government investigations. These claims or suits include claims for damages for personal injuries, medical malpractice, commercial/contractual disputes, wrongful restriction of, or interference with, physiciansâ€™ staff privileges, and employment related claims. In addition, health care companies are subject to investigations and/or actions by various state and federal governmental agencies or those bringing claims on their behalf. Government action has increased with respect to investigations and/or allegations against healthcare providers concerning possible violations of fraud and abuse and false claims statutes as well as compliance with clinical and operational regulations. Currently, and from time to time, we and some of our facilities are subjected to inquiries in the form of subpoenas, Civil Investigative Demands, audits and other document requests from various federal and state agencies. These inquiries can lead to notices and/or actions including repayment obligations from state and federal government agencies associated with potential non-compliance with laws and regulations. Further, the federal False Claims Act allows private individuals to bring lawsuits (qui tam actions) against healthcare providers that submit claims for payments to the government. Various states have also adopted similar statutes. When such a claim is filed, the government will investigate the matter and decide if they are going to intervene in the pending case. These qui tam lawsuits are placed under seal by the court to comply with the False Claims Actâ€™s requirements. If the government chooses not to intervene, the private individual(s) can proceed independently on behalf 17 Â of the government. Health care providers that are found to violate the False Claims Act may be subject to substantial monetary fines/penalties as well as face potential exclusion from participating in

government health care programs or be required to comply with Corporate Integrity Agreements as a condition of a settlement of a False Claims Act matter. In September 2014, the Criminal Division of the Department of Justice (â€œDOJâ€) announced that all qui tam cases will be shared with their Division to determine if a parallel criminal investigation should be opened. The DOJ has also announced an intention to pursue civil and criminal actions against individuals within a company as well as the corporate entity or entities. In addition, health care facilities are subject to monitoring by state and federal surveyors to ensure compliance with program Conditions of Participation. In the event a facility is found to be out of compliance with a Condition of Participation and unable to remedy the alleged deficiency(s), the facility faces termination from the Medicare and Medicaid programs or compliance with a System Improvement Agreement to remedy deficiencies and ensure compliance.The laws and regulations governing the healthcare industry are complex covering, among other things, government healthcare participation requirements, licensure, certification and accreditation, privacy of patient information, reimbursement for patient services as well as fraud and abuse compliance. These laws and regulations are constantly evolving and expanding. Further, the original Patient Protection and Affordable Care Act, as amended by the Health and Education Reconciliation Act, has added additional obligations on healthcare providers to report and refund overpayments by government healthcare programs and authorizes the suspension of Medicare and Medicaid payments â€œpending an investigation of a credible allegation of fraud.â€ We monitor our business and have developed an ethics and compliance program with respect to these complex laws, rules and regulations. Although we believe our policies, procedures and practices comply with government regulations, there is no assurance that we will not be faced with the sanctions referenced above which include fines, penalties and/or substantial damages, repayment obligations, payment suspensions, licensure revocation, and expulsion from government healthcare programs. Even if we were to ultimately prevail in any action brought against us or our facilities or in responding to any inquiry, such action or inquiry could have a material adverse effect on us.Certain legal matters are described below:Knight v. Miller, et. al.In July 2021, a shareholder derivative lawsuit was filed by plaintiff, Robin Knight, in the Chancery Court in Delaware against the members of the Board of Directors of the Company as well as certain officers (C.A. No.: 2021-0581-SG). The Company was named as a nominal defendant. The lawsuit alleged that in March 2020 stock options were awarded with exercise prices that did not reflect the Companyâ€™s fundamentals and business prospects, and in anticipation of future market rebound resulting in excessive gains. The lawsuit made claims of breaches of fiduciary duties, waste of corporate assets, and unjust enrichment. The lawsuit sought monetary damages allegedly incurred by the Company, disgorgement of the March 2020 stock awards as well as any proceeds derived therefrom and unspecified equitable relief. Defendants denied the allegations. We filed a motion to dismiss the complaint and the court granted part and denied part of our motion. During the third quarter of 2022, we reached a preliminary settlement, which would not have had a material impact on our consolidated financial statements. The settlement required court approval which the court declined to provide. Our Board of Directors authorized the formation of a Special Litigation Committee ("SLC") to review the matter and determine whether it was in the best interests of the Company to pursue this claim. The court stayed the litigation while the SLC conducted their review. According to the SLCâ€™s status letter to the Court of Chancery, dated April 15, 2024, after a thorough examination of documentary evidence, interviews with relevant persons, and a review of the applicable law, the SLC determined that the claims asserted in the shareholder derivative lawsuit did not have merit and that pursuing them would not be in the interest of the Company. The SLC further advised the court that the SLC concluded that the claims should be dismissed. The parties jointly filed a stipulation with the court requesting dismissal of the case. After a preliminary hearing on the matter, the court requested a revised stipulation be filed which was prepared and filed with the court. During the third quarter of 2024, the court entered the stipulation dismissing the case and the matter has been concluded.Disproportionate Share Hospital Payment Matter:In late September, 2015, many hospitals in Pennsylvania, including certain of our behavioral health care hospitals located in the state, received letters from the Pennsylvania Department of Human Services (the â€œDepartmentâ€) demanding repayment of allegedly excess Medicaid Disproportionate Share Hospital payments (â€œDSHâ€), primarily consisting of managed care payments characterized as DSH payments, for the federal fiscal year (â€œFFYâ€) 2011 amounting to approximately $4 million in the aggregate. Since that time, certain of our behavioral health care hospitals in Pennsylvania have received similar requests for repayment for alleged DSH overpayments for FFYs 2012 through 2015. For FFY 2012, the claimed overpayment amounts to approximately $4 million. For FY 2013, FY 2014 and FY 2015 the initial claimed overpayments and attempted recoupment by the Department were approximately $7 million, $8 million and $7 million, respectively. The Department has agreed to a change in methodology which, upon confirmation of the underlying data being accepted by the Department, could reduce the initial claimed overpayments for FY 2013, FY 2014 and FY 2015 to approximately $2 million, $2 million and $3 million, respectively. We filed administrative appeals for all of our facilities contesting the recoupment efforts for FFYs 2011 through 2015 as we believe the Departmentâ€™s calculation methodology is inaccurate and conflicts with applicable federal and state laws and regulations. The Department agreed to postpone the recoupment of the stateâ€™s share for FFY 2011 to 2013 until all hospital appeals are resolved but recouped the federal share. For FFY 2014 and FFY 2015, the Department initiated the recoupment of the alleged overpayments (both federal and state shares). Starting in FY 2016, the first full 18 Â fiscal year after the January 1, 2015 effective date of Medicaid expansion in Pennsylvania, the Department no longer characterized managed care payments received by the hospitals as DSH payments. While the administrative appeals on the disputed DSH payments remain pending, we have been in continued settlement discussions with the Department. As a part of these discussions, we have presented certain calculation errors that we believe, if corrected, could materially reduce the alleged overpayments. We have recently reached a settlement in principle with the Department that will result in a partial repayment to us of amounts previously recouped. The parties are in the process of drafting a definitive settlement agreement codifying our agreement to conclude this matter. In the event that we are unable to complete the settlement agreement, we will continue with our administrative appeals. We can provide no assurance that we will ultimately be successful in our legal and administrative appeals related to the Departmentâ€™s repayment demands in the event the pending settlement is not finalized and we are unable to assess liability or damages with certainty at this time. If our legal and administrative appeals are unsuccessful, our future consolidated results of operations and financial condition could be adversely impacted by these repayments.Rachel Capriglione, as natural mother and Next Friend of A.T., a minor, Plaintiff, v. The Pavilion Foundation d/b/a The Pavilion Behavioral Health SystemAs previously reported on Form 8-K, as filed on April 1, 2024, the Pavilion Behavioral Health System (the â€œPavilionâ€), an indirect subsidiary of the Company, is the sole defendant in a lawsuit filed in Champaign County, Illinois, relating to the sexual assault of one minor patient by another minor patient in 2020. Plaintiff asserted claims of negligence and misrepresentation. The Pavilion denied any liability.The case went to trial in March of 2024. On March 28, 2024, a jury rejected the misrepresentation claim, returned a verdict for ordinary negligence, and awarded compensatory damages of $60 million and punitive damages of $475 million. Based on a search of verdicts in comparable cases, the magnitude of this verdict was unexpected and is unprecedented for a single-plaintiff injury case of this type in Champaign County, Illinois. The Pavilion filed post-trial motions, among other items, contesting the excessiveness of the damage awards.As previously reported on Form 8-K, as filed on October 11, 2024, in an order dated October 10, 2024, the trial court ordered a remittitur of punitive damages from $475 million to $120 million. The court denied the Pavilionâ€™s request for reduction of compensatory damages. Pursuant to Illinois law and procedure, plaintiff had 21 days from the date of the order to either accept the remittitur of the punitive damages or refuse the remittitur, which would have resulted in further legal proceedings. Plaintiff accepted the remittitur by the trial court while reserving all rights to appeal the remittitur. The Pavilion intends to appeal the remaining judgment. Although we can make no assurances regarding the ultimate outcome of this matter, or what damages will ultimately be awarded, its final resolution could have a material adverse effect on the Company K.E.E., et al., Plaintiffs v. Cumberland Hospital, LLC d/b/a Cumberland Hospital for Children and Adolescents, et al. (and related lawsuits)Cumberland Hospital for Children and Adolescents (â€œCumberlandâ€), an indirect subsidiary of the Company, is a defendant in multi-plaintiff lawsuits filed in the Circuit Court for Richmond, Virginia (the â€œCumberland Litigationâ€), relating to allegations of inappropriate sexual contact during medical examinations by Dr. Daniel Davidow, an independent contractor and the former medical director for Cumberland. The Company and UHS of Delaware, Inc., our administrative services subsidiary (â€œUHS Delawareâ€), were also named as co-defendants in the Cumberland Litigation. Plaintiffs have asserted claims of negligence, assault and battery (against Dr. Davidow), false imprisonment, violations of the Virginia Consumer Protection Act (â€œVCPAâ€), and vicarious liability for Dr. Davidowâ€™s conduct against Cumberland, the Company, and UHS Delaware. All defendants have denied liability.The claims asserted by three of the plaintiffs in the Cumberland Litigation were consolidated for trial in September of 2024. The Company and UHS Delaware were dismissed from the action during trial. As previously reported on Form 8-K, as filed on September 30, 2024, on September 27, 2024, a jury entered a verdict finding Dr. Davidow and Cumberland liable and awarded these three plaintiffs combined compensatory damages of $60 million for all liability theories, an additional combined $180 million in trebled damages for violation of the VCPA, and an additional combined $120 million in punitive damages. Cumberland is evaluating all legal options and intends to challenge this verdict, including the amounts awarded in the verdict, in post-trial proceedings and on appeal. Based upon Virginia law, we expect that the punitive damage amount should be reduced to a combined maximum of $1.05 million as a matter of law.There are approximately 40 additional plaintiffs making similar allegations with claims pending in the Cumberland Litigation.Although we can make no assurances regarding the ultimate outcomes of the various claims made in connection with the Cumberland Litigation, or what damages will ultimately be awarded, the final resolution of these matters could have a material adverse effect on the Company Other Matters:Various other suits, claims and investigations, including government subpoenas, arising against, or issued to, us are pending and additional such matters may arise in the future. Management will consider additional disclosure from time to time to the extent it 19 Â believes such matters may be or become material. The outcome of any current or future litigation or governmental or internal investigations, including the matters described above, cannot be accurately predicted, nor can we predict any resulting penalties, fines or other sanctions that may be imposed at the discretion of federal or state regulatory authorities. We record accruals for such contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. No estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made at this time regarding the matters described above or that are otherwise pending because the inherently unpredictable nature of legal proceedings may be exacerbated by various factors, including, but not limited to: (i) the damages sought in the proceedings are unsubstantiated or indeterminate; (ii) discovery is not complete; (iii) the matter is in its early stages; (iv) the matters present legal uncertainties; (v) there are significant facts in dispute; (vi) there are a large number of parties, or; (vii) there is a wide range of potential outcomes. It is possible that the outcome of these matters could have a material adverse impact on our future results of operations, financial position, cash flows and, potentially, our reputation. (7) Segment ReportingOur reportable operating segments consist of acute care hospital services and behavioral health care services. The â€œOtherâ€ segment column below includes centralized services including, but not limited to, information technology, purchasing, reimbursement, accounting and finance, taxation, legal, advertising and design and construction. The chief operating decision making group for our acute care services and behavioral health care services is comprised of our Chief Executive Officer and the Presidents of each operating segment. The Presidents for each operating segment also manage the profitability of each respective segmentâ€™s various facilities. The operating segments are managed separately because each operating segment represents a business unit that offers different types of healthcare services or operates in different healthcare environments. The accounting policies of the operating segments are the same as those described in the summary of significant accounting policies included in our Annual Report on Form 10-K for the year ended December 31, 2023. The corporate overhead allocations, as reflected below, are utilized for internal reporting purposes and are comprised of each periodâ€™s projected corporate-level operating expenses (excluding interest expense). The overhead expenses are captured and allocated directly to each segment, to the extent possible, based upon each segmentâ€™s respective percentage of total operating expenses. 20 Â Â Â Â Three months ended September 30, 2024 Â Â Â Acute CareHospitalServices Â Â BehavioralHealthServices (a) Â Â Other Â Â TotalConsolidated Â Â Â (Dollar amounts in thousands) Â Gross inpatient revenues Â $ 12,277,563 Â Â $ 2,835,301 Â Â Â Â Â $ 15,112,864 Â Gross outpatient revenues Â $ 8,573,270 Â Â $ 268,182 Â Â Â Â Â $ 8,841,452 Â Total net revenues Â $ 2,245,517 Â Â $ 1,714,914 Â Â $ 2,596 Â Â $ 3,963,027 Â Income/(loss) before allocation of corporate overhead andÂ Â Â income taxes Â $ 199,316 Â Â $ 318,864 Â Â $ (176,647) Â $ 341,533 Â Allocation of corporate overhead Â $ (64,883) Â $ (46,898) Â $ 111,781 Â Â $ 0 Â Income/(loss) after allocation of corporate overhead andÂ Â Â before income taxes Â $ 134,433 Â Â $ 271,966 Â Â $ (64,866) Â $ 341,533 Â Total assets as of September 30, 2024 Â $ 6,481,922 Â Â $ 7,631,827 Â Â $ 240,099 Â Â $ 14,353,848 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Nine months ended September 30, 2024 Â Â Â Acute CareHospitalServices Â Â BehavioralHealthServices (a) Â Â Other Â Â TotalConsolidated Â Â Â (Dollar amounts in thousands) Â Gross inpatient revenues Â $ 37,522,395 Â Â $ 8,375,470 Â Â Â Â Â $ 45,897,865 Â Gross outpatient revenues Â $ 25,553,451 Â Â $ 833,260 Â Â Â Â Â $ 26,386,711 Â Total net revenues Â $ 6,604,007 Â Â $ 5,102,290 Â Â $ 7,916 Â Â $ 11,714,213 Â Income/(loss) before allocation of corporate overhead andÂ Â Â income taxes Â $ 616,503 Â Â $ 999,282 Â Â $ (556,160) Â $ 1,059,625 Â Allocation of corporate overhead Â $ (194,616) Â $ (140,808) Â $ 335,424 Â Â $ 0 Â Income/(loss) after allocation of corporate overhead andÂ Â Â before income taxes Â $ 421,887 Â Â $ 858,474 Â Â $ (220,736) Â $ 1,059,625 Â Total assets as of September 30, 2024 Â $ 6,481,922 Â Â $ 7,631,827 Â Â $ 240,099 Â Â $ 14,353,848 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Three months ended September 30, 2023 Â Â Â Acute CareHospitalServices Â Â BehavioralHealthServices (a) Â Â Other Â Â TotalConsolidated Â Â Â (Dollar amounts in thousands) Â Gross inpatient revenues Â $ 10,916,060 Â Â $ 2,703,478 Â Â Â Â Â $ 13,619,538 Â Gross outpatient revenues Â $ 7,480,353 Â Â $ 259,060 Â Â Â Â Â $ 7,739,413 Â Total net revenues Â $ 2,017,288 Â Â $ 1,542,695 Â Â $ 2,791 Â Â $ 3,562,774 Â Income/(loss) before allocation of corporate overhead andÂ Â Â income taxes Â $ 132,406 Â Â $ 262,168 Â Â $ (174,067) Â $ 220,507 Â Allocation of corporate overhead Â $ (66,355) Â $ (46,677) Â $ 113,032 Â Â $ 0 Â Income/(loss) after allocation of corporate overhead andÂ Â Â before income taxes Â $ 66,051 Â Â $ 215,491 Â Â $ (61,035) Â $ 220,507 Â Total assets as of September 30, 2023 Â $ 6,252,434 Â Â $ 7,372,995 Â Â $ 248,041 Â Â $ 13,873,470 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Nine months ended September 30, 2023 Â Â Â Acute CareHospitalServices Â Â BehavioralHealthServices (a) Â Â Other Â Â TotalConsolidated Â Â Â (Dollar amounts in thousands) Â Gross inpatient revenues Â $ 33,278,396 Â Â $ 8,001,838 Â Â Â Â Â $ 41,280,234 Â Gross outpatient revenues Â $ 22,292,249 Â Â $ 812,467 Â Â Â Â Â $ 23,104,716 Â Total net revenues Â $ 5,993,899 Â Â $ 4,575,378 Â Â $ 9,153 Â Â $ 10,578,430 Â Income/(loss) before allocation of corporate overhead andÂ Â Â income taxes Â $ 396,229 Â Â $ 792,217 Â Â $ (529,143) Â $ 659,303 Â Allocation of corporate overhead Â $ (199,943) Â $ (139,998) Â $ 339,941 Â Â $ 0 Â Income/(loss) after allocation of corporate overhead andÂ Â Â before income taxes Â $ 196,286 Â Â $ 652,219 Â Â $ (189,202) Â $ 659,303 Â Total assets as of September 30, 2023 Â $ 6,252,434 Â Â $ 7,372,995 Â Â $ 248,041 Â Â $ 13,873,470 Â (a)Includes net revenues generated from our behavioral health care facilities located in the U.K. amounting to approximately $230 million and $203 million for the three-month periods ended September 30, 2024 and 2023, respectively, and approximately $651 million and $561 million for the nine-month periods ended September 30, 2024 and 2023, respectively. Total assets at our U.K. behavioral health care facilities were approximately $1.442 billion and $1.260 billion as of September 30, 2024 and 2023, respectively. 21 Â Â (8) Earnings Per Share Data and Stock Based CompensationBasic earnings per share are based on the weighted average number of common shares outstanding during the period. Diluted earnings per share are based on the weighted average number of common shares outstanding during the period adjusted to give effect to common stock equivalents.The following table sets forth the computation of basic and diluted earnings per share for the periods indicated (in thousands, except per share data): Â Â Three months endedSeptember 30, Â Â Nine months endedSeptember 30, Â Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Basic and Diluted: Â Â Â Â Â Â Â Â Â Â Â Â Net income attributable to UHS Â $ 258,714 Â Â $ 166,989 Â Â $ 809,700 Â Â $ 501,417 Â Less: Net income attributable to unvested restricted shareÂ Â Â grants Â Â - Â Â Â (52) Â Â (50) Â Â (242) Net income attributable to UHS â€“ basic and diluted Â $ 258,714 Â Â $ 166,937 Â Â $ 809,650 Â Â $ 501,175 Â Â Â Â Â Â Â Â Â Â Â Â Weighted average number of common shares - basic Â Â 66,537 Â Â Â 68,867 Â Â Â 66,873 Â Â Â 69,825 Â Net effect of dilutive stock options and grants based on theÂ Â Â treasury stock method Â Â 1,571 Â Â Â 757 Â Â Â 1,297 Â Â Â 825 Â Weighted average number of common shares andÂ Â Â equivalents - diluted Â Â 68,108 Â Â Â 69,624 Â Â Â 68,170 Â Â Â 70,650 Â Earnings per basic share attributable to UHS: Â $ 3.89 Â Â $ 2.42 Â Â $ 12.11 Â Â $ 7.18 Â Earnings per diluted share attributable to UHS: Â $ 3.80 Â Â $ 2.40 Â Â $ 11.88 Â Â $ 7.09 Â The â€œNet effect of dilutive stock options and grants based on the treasury stock methodâ€, for all periods presented above, excludes certain outstanding stock options applicable to each period since the effect would have been anti-dilutive. There were no excluded weighted-average stock options for the three-months ended September 30, 2024 and 799,000 for the nine-months ended September 30, 2024. The excluded weighted-average stock options totaled 5.0 million for the three months ended September 30, 2023 and 5.1 million for the nine months ended September 30, 2023. All classes of our common stock have the same dividend rights.Stock-Based Compensation: During the three-month periods ended September 30, 2024 and 2023, pre-tax compensation costs of $13.4 million and $16.2 million, respectively, was recognized related to outstanding stock options. During the nine-month periods ended September 30, 2024 and 2023, pre-tax compensation costs of $41.0 million and $48.3 million, respectively, was recognized related to outstanding stock options. In addition, during the three-month periods ended September

30, 2024 and 2023, pre-tax compensation cost of approximately $12.9 million and $6.1 million, respectively, was recognized related to restricted stock awards, restricted stock units and performance based restricted stock units. During the nine-month periods ended September 30, 2024 and 2023, pre-tax compensation costs of approximately $30.7 million and $16.4 million, respectively, was recognized related to restricted stock awards, restricted stock units and performance based restricted stock units. As of September 30, 2024 there was approximately $177.9 million of unrecognized compensation cost related to unvested options, restricted stock awards, restricted stock units and performance based restricted stock units which is expected to be recognized over the remaining weighted average vesting period of 2.5 years. There were 3,000 stock options granted during the first nine months of 2024 under the 2020 Stock Incentive Plan with a weighted-average grant date fair value of $44.58 per option. There were an aggregate of 501,290 restricted units, net of cancellations, granted during the first nine months of 2024 under the 2020 Stock Incentive Plan, including 63,362 performance based restricted stock units, with a weighted-average grant date fair value of $181.05 per share.The expense associated with stock-based compensation arrangements is a non-cash charge. In the condensed consolidated statements of cash flows, stock-based compensation expense is an adjustment to reconcile net income to cash provided by operating activities and aggregated to $72.7 million and $65.7 million during the nine-month periods ended September 30, 2024 and 2023, respectively. 22 Â (9) Dispositions and acquisitionsNine-month period ended September 30, 2024:Acquisitions:During the first nine months of 2024, there were no acquisitions.Divestitures:During the first nine months of 2024, we received $30 million from the sales of assets and businesses.Nine-month period ended September 30, 2023:Acquisitions:During the first nine months of 2023, we spent $4 million on the acquisition of businesses and property.Divestitures:During the first nine months of 2023, we received $24 million from the sales of assets and businesses. (10) DividendsWe declared and paid dividends of $13.3 million, or $.20 per share, during the third quarter of 2024 and $13.8 million, or $.20 per share, during the third quarter of 2023. We declared and paid dividends of $40.3 million, or $.60 per share, during the nine-month period ended September 30, 2024 and $42.2 million, or $.60 per share, during the nine-month period ended September 30, 2023. Included in the amounts above were dividend equivalents applicable to unvested restricted stock units which were accrued during 2024 and 2023 and will be, or were, paid upon vesting of the restricted stock unit. (11) Income TaxesOur effective income tax rates were 22.1% and 23.8% during the three-month periods ended September 30, 2024 and 2023, respectively, and 22.0% and 24.2% during the nine-month periods ended September 30, 2024, and 2023, respectively. The decrease in the effective tax rates during the three and nine-month period ended September 30, 2024, as compared to the comparable periods of 2023, was primarily due to favorable changes of $4 million and $16 million, respectively, in the net tax benefit recognized from employee share-based payments, net of the impact of executive compensation limitations pursuant to IRC section 162(m). As of January 1, 2024, our unrecognized tax benefits were approximately $2 million. The amount, if recognized, that would favorably affect the effective tax rate is approximately $2 million. During the nine months ended September 30, 2024, changes to the estimated liabilities for uncertain tax positions (including accrued interest) relating to tax positions taken during prior and current periods did not have a material impact on our financial statements.We recognize accrued interest and penalties associated with uncertain tax positions as part of the tax provision. As of September 30, 2024, we have less than $1 million of accrued interest and penalties. The U.S. federal statute of limitations remains open for 2020 and subsequent years. Foreign and U.S. state and local jurisdictions have statutes of limitations generally ranging from 3 to 4 years. The statute of limitations on certain jurisdictions could expire within the next twelve months. It is reasonably possible that the amount of uncertain tax benefits will change during the next 12 months, however, it is anticipated that any such change, if it were to occur, would not have a material impact on our results of operations.We operate in multiple jurisdictions with varying tax laws. We are subject to audits by any of these taxing authorities. We believe that adequate accruals have been provided for federal, foreign and state taxes. Â 23 Â (12) RevenueWe recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. Our estimate for amounts not expected to be collected based on historical experience will continue to be recognized as a reduction to net revenue. However, subsequent changes in estimate of collectability due to a change in the financial status of a payer, for example a bankruptcy, will be recognized as bad debt expense in operating charges.The performance obligation is separately identifiable from other promises in the customer contract. As the performance obligations are met (i.e. room, board, ancillary services, level of care), revenue is recognized based upon allocated transaction price. The transaction price is allocated to separate performance obligations based upon the relative standalone selling price. In instances where we determine there are multiple performance obligations across multiple months, the transaction price will be allocated by applying an estimated implicit and explicit rate to gross charges based on the separate performance obligations.In assessing collectability, we have elected the portfolio approach. This portfolio approach is being used as we have large volume of similar contracts with similar classes of customers. We reasonably expect that the effect of applying a portfolio approach to a group of contracts would not differ materially from considering each contract separately. Managementâ€™s judgment to group the contracts by portfolio is based on the payment behavior expected in each portfolio category. As a result, aggregating all of the contracts (which are at the patient level) by the particular payer or group of payers, will result in the recognition of the same amount of revenue as applying the analysis at the individual patient level.We group our revenues into categories based on payment behaviors. Each component has its own reimbursement structure which allows us to disaggregate the revenue into categories that share the nature and timing of payments. The other patient revenue consists primarily of self-pay, government-funded non-Medicaid, and other.The following table disaggregates our revenue by major source for the three and nine-month periods ended September 30, 2024 and 2023 (in thousands):Â 24 Â Â For the three months ended September 30, 2024 Â Â Acute Care Â Â Behavioral Health Â Â Other Â Â Total Â Medicare $ 322,466 Â Â 14 % Â $ 81,148 Â Â 5 % Â Â Â Â Â $ 403,614 Â Â 10 % Managed Medicare Â 361,804 Â Â 16 % Â Â 107,910 Â Â 6 % Â Â Â Â Â Â 469,714 Â Â 12 % Medicaid Â 296,966 Â Â 13 % Â Â 262,393 Â Â 15 % Â Â Â Â Â Â 559,359 Â Â 14 % Managed Medicaid Â 154,762 Â Â 7 % Â Â 422,563 Â Â 25 % Â Â Â Â Â Â 577,325 Â Â 15 % Managed Care (HMO and PPOs) Â 725,014 Â Â 32 % Â Â 401,004 Â Â 23 % Â Â Â Â Â Â 1,126,018 Â Â 28 % UK Revenue Â 0 Â Â 0 % Â Â 230,153 Â Â 13 % Â Â Â Â Â Â 230,153 Â Â 6 % Other patient revenue and adjustments, net Â 117,679 Â Â 5 % Â Â 155,332 Â Â 9 % Â Â Â Â Â Â 273,011 Â Â 7 % Other non-patient revenue Â 266,826 Â Â 12 % Â Â 54,411 Â Â 3 % Â Â 2,596 Â Â Â Â 323,833 Â Â 8 % Total Net Revenue $ 2,245,517 Â Â 100 % Â $ 1,714,914 Â Â 100 % Â $ 2,596 Â Â Â Â 3,963,027 Â Â 100 % Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â For the nine months ended September 30, 2024 Â Â Acute Care Â Â Behavioral Health Â Â Other Â Â Total Â Medicare $ 1,009,630 Â Â 15 % Â $ 234,295 Â Â 5 % Â Â Â Â Â $ 1,243,925 Â Â 11 % Managed Medicare Â 1,104,493 Â Â 17 % Â Â 307,388 Â Â 6 % Â Â Â Â Â Â 1,411,881 Â Â 12 % Medicaid Â 771,298 Â Â 12 % Â Â 804,254 Â Â 16 % Â Â Â Â Â Â 1,575,552 Â Â 13 % Managed Medicaid Â 466,881 Â Â 7 % Â Â 1,262,108 Â Â 25 % Â Â Â Â Â Â 1,728,989 Â Â 15 % Managed Care (HMO and PPOs) Â 2,129,117 Â Â 32 % Â Â 1,227,056 Â Â 24 % Â Â Â Â Â Â 3,356,173 Â Â 29 % UK Revenue Â 0 Â Â 0 % Â Â 650,655 Â Â 13 % Â Â Â Â Â Â 650,655 Â Â 6 % Other patient revenue and adjustments, net Â 375,161 Â Â 6 % Â Â 449,609 Â Â 9 % Â Â Â Â Â Â 824,770 Â Â 7 % Other non-patient revenue Â 747,427 Â Â 11 % Â Â 166,925 Â Â 3 % Â Â 7,916 Â Â Â Â 922,268 Â Â 8 % Total Net Revenue $ 6,604,007 Â Â 100 % Â $ 5,102,290 Â Â 100 % Â $ 7,916 Â Â Â Â $ 11,714,213 Â Â 100 % Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â For the three months ended September 30, 2023 Â Â Acute Care Â Â Behavioral Health Â Â Other Â Â Total Â Medicare $ 298,121 Â Â 15 % Â $ 81,689 Â Â 5 % Â Â Â Â Â $ 379,810 Â Â 11 % Managed Medicare Â 324,486 Â Â 16 % Â Â 95,094 Â Â 6 % Â Â Â Â Â Â 419,580 Â Â 12 % Medicaid Â 201,148 Â Â 10 % Â Â 204,154 Â Â 13 % Â Â Â Â Â Â 405,302 Â Â 11 % Managed Medicaid Â 181,051 Â Â 9 % Â Â 387,975 Â Â 25 % Â Â Â Â Â Â 569,026 Â Â 16 % Managed Care (HMO and PPOs) Â 651,816 Â Â 32 % Â Â 383,146 Â Â 25 % Â Â Â Â Â Â 1,034,962 Â Â 29 % UK Revenue Â 0 Â Â 0 % Â Â 202,994 Â Â 13 % Â Â Â Â Â Â 202,994 Â Â 6 % Other patient revenue and adjustments, net Â 108,676 Â Â 5 % Â Â 129,492 Â Â 8 % Â Â Â Â Â Â 238,168 Â Â 7 % Other non-patient revenue Â 251,990 Â Â 12 % Â Â 58,151 Â Â 4 % Â Â 2,791 Â Â Â Â 312,932 Â Â 9 % Total Net Revenue $ 2,017,288 Â Â 100 % Â $ 1,542,695 Â Â 100 % Â $ 2,791 Â Â $ 3,562,774 Â Â 100 % Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â For the nine months ended September 30, 2023 Â Â Acute Care Â Â Behavioral Health Â Â Other Â Â Total Â Medicare $ 961,640 Â Â 16 % Â $ 233,930 Â Â 5 % Â Â Â Â Â $ 1,195,570 Â Â 11 % Managed Medicare Â 1,013,493 Â Â 17 % Â Â 255,782 Â Â 6 % Â Â Â Â Â Â 1,269,275 Â Â 12 % Medicaid Â 445,678 Â Â 7 % Â Â 625,956 Â Â 14 % Â Â Â Â Â Â 1,071,634 Â Â 10 % Managed Medicaid Â 545,173 Â Â 9 % Â Â 1,184,315 Â Â 26 % Â Â Â Â Â Â 1,729,488 Â Â 16 % Managed Care (HMO and PPOs) Â 2,009,110 Â Â 34 % Â Â 1,160,820 Â Â 25 % Â Â Â Â Â Â 3,169,930 Â Â 30 % UK Revenue Â 0 Â Â 0 % Â Â 560,897 Â Â 12 % Â Â Â Â Â Â 560,897 Â Â 5 % Other patient revenue and adjustments, net Â 303,923 Â Â 5 % Â Â 387,327 Â Â 8 % Â Â Â Â Â Â 691,250 Â Â 7 % Other non-patient revenue Â 714,882 Â Â 12 % Â Â 166,351 Â Â 4 % Â Â 9,153 Â Â Â Â 890,386 Â Â 8 % Total Net Revenue $ 5,993,899 Â Â 100 % Â $ 4,575,378 Â Â 100 % Â $ 9,153 Â Â $ 10,578,430 Â Â 100 % Â 25 Â (13) Lease AccountingOur operating leases are primarily for real estate, including certain acute care facilities, off-campus outpatient facilities, medical office buildings, and corporate and other administrative offices. Our real estate lease agreements typically have initial terms of five to ten years. These real estate leases may include one or more options to renew, with renewals that can extend the lease term from five to ten years. The exercise of lease renewal options is at our sole discretion. When determining the lease term, we included options to extend or terminate the lease when it is reasonably certain that we will exercise that option.Five of our hospital facilities are held under operating leases with Universal Health Realty Income Trust with two leases expiring in 2026, two expiring in 2033 and one expiring in 2040 (for additional disclosure, see Note 2 to the Consolidated Financial Statements-Relationship with Universal Health Realty Income Trust and Other Related Party Transactions). We are also the lessee of the real property of certain facilities from unrelated third parties.Supplemental cash flow information related to leases for the nine-month period ended September 30, 2024 and 2023 are as follows (in thousands): Â Nine months endedSeptember 30, Â Â 2024 Â Â 2023 Â Â Â Â Â Â Cash paid for amounts included in the measurement of lease liabilities: Â Â Â Â Operating cash flows from operating leases $ 99,526 Â Â $ 96,922 Â Operating cash flows from finance leases $ 2,756 Â Â $ 2,890 Â Financing cash flows from finance leases $ 3,167 Â Â $ 2,910 Â Â Â Â Â Â Â Right-of-use assets obtained in exchange for lease obligations: Â Â Â Â Â Operating leases $ 50,696 Â Â $ 50,940 Â Finance leases $ 8,441 Â Â $ 452 Â Â Â (14) Recent Accounting StandardsÂ In November 2024, the FASB issued ASU 2024-03, â€œIncome Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (subtopic 220-40)". ASU 2024-03 requires disclosures, in the notes to financial statements, of specified information about certain costs and expenses. This ASU is effective for fiscal years beginning after December 15, 2026, with early adoption permitted. We are currently evaluating the impact this new standard will have on the related disclosures in the consolidated financial statements.In November 2023, the FASB issued ASU 2023-07, â€œImprovements to Reportable Segment Disclosures (Topic 280)â€. ASU 2023-07 modifies reportable segment disclosure requirements, primarily through enhanced disclosures about segment expenses categorized as significant or regularly provided to the Chief Operating Decision Maker (CODM). In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, and contain other disclosure requirements. The purpose of the amendments is to enable investors to better understand an entityâ€™s overall performance and assess potential future cash flows. This ASU is effective for annual periods beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the impact this new standard will have on the related disclosures in the consolidated financial statements, but do not believe there will be a material impact.In December 2023, the FASB issued ASU 2023-09, â€œImprovements to Income Tax Disclosures (Topic 740)â€. ASU 2023-09 requires enhanced disclosures on income taxes paid, adds disaggregation of continuing operations before income taxes between foreign and domestic earnings and defines specific categories for the reconciliation of jurisdictional tax rate to effective tax rate. This ASU is effective for fiscal years beginning after December 15, 2024, and can be applied on a prospective basis. We are currently evaluating the impact this new standard will have on the related disclosures in the consolidated financial statements.From time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by the Company as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. The Company has assessed the recently issued guidance that is not yet effective and believes the new guidance will not have a material impact on our results of operations, cash flows or financial position. 26 Â Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations Overview As of September 30, 2024, we owned and/or operated 361 inpatient facilities and 49 outpatient and other facilities, including the following, located in 39 states, Washington, D.C., the United Kingdom and Puerto Rico: Acute care facilities located in the U.S.: â€¢27 inpatient acute care hospitals; â€¢28 free-standing emergency departments, and; â€¢10 outpatient centers & 1 surgical hospital. Behavioral health care facilities (334 inpatient facilities and 10 outpatient facilities): Located in the U.S.: â€¢184 inpatient behavioral health care facilities, and; â€¢8 outpatient behavioral health care facilities. Located in the U.K.: â€¢147 inpatient behavioral health care facilities, and; â€¢2 outpatient behavioral health care facilities. Located in Puerto Rico: â€¢3 inpatient behavioral health care facilities. Net revenues from our acute care hospitals, outpatient facilities and commercial health insurer accounted for 57% of our consolidated net revenues during each of the three-month periods ended September 30, 2024 and 2023, and 56% and 57% during the nine-month periods ended September 30, 2024 and 2023, respectively. Net revenues from our behavioral health care facilities and commercial health insurer accounted for 43% of our consolidated net revenues during each of the three-month periods ended September 30, 2024 and 2023, and 44% and 43% during nine-month periods ended September 30, 2024 and 2023, respectively. Our behavioral health care facilities located in the U.K. generated net revenues of approximately $230 million and $203 million during the three-month periods ended September 30, 2024 and 2023, respectively, and $651 million and $561 million during the nine-month periods ended September 30, 2024 and 2023, respectively. Total assets at our U.K. behavioral health care facilities were approximately $1.442 billion as of September 30, 2024 and $1.327 billion as of December 31, 2023. Services provided by our hospitals include general and specialty surgery, internal medicine, obstetrics, emergency room care, radiology, oncology, diagnostic care, coronary care, pediatric services, pharmacy services and/or behavioral health services. We provide capital resources as well as a variety of management services to our facilities, including central purchasing, information services, finance and control systems, facilities planning, physician recruitment services, administrative personnel management, marketing and public relations. Forward-Looking Statements and Risk Factors You should carefully review the information contained in this Quarterly Report and should particularly consider any risk factors that we set forth in our Annual Report on Form 10-K for the year ended December 31, 2023, this Quarterly Report and in other reports or documents that we file from time to time with the Securities and Exchange Commission (the â€œSECâ€). In this Quarterly Report, we state our beliefs of future events and of our future financial performance. This Quarterly Report contains â€œforward-looking statementsâ€ that reflect our current estimates, expectations and projections about our future results, performance, prospects and opportunities. Forward-looking statements include, among other things, the information concerning our possible future results of operations, business and growth strategies, financing plans, expectations that regulatory developments or other matters will or will not have a material adverse effect on our business or financial condition, our competitive position and the effects of competition, the projected growth of the industry in which we operate, and the benefits and synergies to be obtained from our completed and any future acquisitions, and statements of our goals and objectives, and other similar expressions concerning matters that are not historical facts. Words such as â€œmay,â€ â€œwill,â€ â€œshould,â€ â€œcould,â€ â€œwould,â€ â€œpredicts,â€ â€œpotential,â€ â€œcontinue,â€ â€œexpects,â€ â€œanticipates,â€ â€œfuture,â€ â€œintends,â€ â€œplans,â€ â€œbelieves,â€ â€œestimates,â€ â€œappears,â€ â€œprojectsâ€ and similar expressions, as well as statements in future tense, identify forward-looking statements. In evaluating those statements, you should specifically consider various factors, including the risks related to healthcare industry trends and those set forth herein in Item 1A. Risk Factors and Item 7. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations-Forward Looking Statements and Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2023 and in Item 2. Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations-Forward Looking Statements and Risk Factors, as included herein. Those factors may cause our actual results to differ materially from any of our forward-looking statements. 27 Â Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by which, such performance or results will be achieved. Forward-looking information is based on information available at the time and/or our good faith belief with respect to future events, and is subject to risks and uncertainties that are difficult to predict and many of which are outside of our control. Many factors, including those set forth herein in Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2023, and other important factors disclosed in this Quarterly Report, and from time to time in our other filings with the SEC, could cause actual performance or results to differ materially from those expressed in the statements. Such factors include, among other things, the following: â€¢the healthcare industry is labor intensive and salaries, wages and benefits are subject to inflationary pressures, as are supplies expense and other operating expenses. In the past, staffing shortages have, at times, required us to hire expensive temporary personnel and/or enhance wages and benefits to recruit and retain nurses and other clinical staff and support personnel. At certain facilities, particularly within our behavioral health care segment, there have been occasions when we were unable to fill all vacant positions and, consequently, we were required to limit patient volumes. We have also experienced general inflationary cost increases related to certain of our other operating expenses.

Many of these factors, which had a material unfavorable impact on our results of operations in prior years, have moderated more recently. However, we cannot predict future inflationary increases, which if significant, could have a material unfavorable impact on our future results of operations. We have experienced inflationary pressures, primarily in personnel costs, although those pressures have moderated more recently. The extent of any future impacts from inflation on our business and our results of operations will be dependent upon how long the elevated inflation levels persist and the extent to which the rate of inflation further increases, if at all, neither of which we are able to predict. If elevated levels of inflation were to persist or if the rate of inflation were to accelerate, our expenses could increase faster than anticipated and we may utilize our capital resources sooner than expected. Further, given the complexities of the reimbursement landscape in which we operate, our ability to pass on increased costs associated with providing healthcare to Medicare and Medicaid patients is limited due to various federal, state and local laws, which in certain circumstances, limit our ability to increase prices; â€¢in our acute care segment, we have experienced a significant increase in hospital based physician related expenses, especially in the areas of emergency room care and anesthesiology. We have implemented various initiatives to mitigate the increased expense, to the degree possible, which has moderated the rate of increase. However, significant increases in these physician related expenses could have a material unfavorable impact on our future results of operations; â€¢the increase in interest rates during the past few years has increased our interest expense significantly increasing our expenses and reducing our free cash flow and our ability to access the capital markets on favorable terms. As such, the effects of increased borrowing rates have adversely impacted our results of operations, financial condition and cash flows. We cannot predict future changes to interest rates, however, significant increases in our borrowing rates could have a material unfavorable impact on our future results of operations; â€¢President Biden signed into law fiscal year 2025 appropriations to federal agencies for continuing projects and activities through December 20, 2024. We cannot predict whether or not there will be future legislation averting a federal government shutdown, however, our operating cash flows and results of operations could be materially unfavorably impacted by a federal government shutdown; â€¢on December 29, 2022, the Consolidated Appropriations Act, 2023, was signed into law phasing out the enhanced federal medical assistance percentage rate that states received during the COVID-19 public health emergency and fully eliminated the increase on December 31, 2023. States were also permitted to begin Medicaid eligibility redeterminations on March 31, 2023, which has resulted in a decrease in Medicaid enrollment; â€¢our ability to comply with the existing laws and government regulations, and/or changes in laws and government regulations; â€¢an increasing number of legislative initiatives have been passed into law that may result in major changes in the health care delivery system on a national or state level. For example, Congress has reduced to $0 the penalty for failing to maintain health coverage that was part of the original Patient Protection and Affordable Care Act, as amended by the Health and Education Reconciliation Act (collectively, the "Legislation") as part of the Tax Cuts and Jobs Act. To date, the Biden administration has issued executive orders implementing a special enrollment period permitting individuals to enroll in health plans outside of the annual open enrollment period and reexamining policies that may undermine the Legislation or the Medicaid program. The Inflation Reduction Act of 2022 (â€œIRAâ€) was passed on August 16, 2022, which among other things, allows for the Centers for Medicare and Medicaid Services ("CMS") to negotiate prices for certain single-source drugs reimbursed under Medicare Part B and Part D. The American Rescue Plan Actâ€™s expansion of subsidies to purchase coverage through a Legislation exchange, which the IRA continued through 2025, is anticipated to increase exchange enrollment. However, if the subsidies are not extended beyond 2025, exchange enrollment may be adversely impacted; 28 Â â€¢there have been numerous political and legal efforts to expand, repeal, replace or modify the Legislation, since its enactment, some of which have been successful, in part, in modifying the Legislation, as well as court challenges to the constitutionality of the Legislation. The U.S. Supreme Court held in California v. Texas that the plaintiffs lacked standing to challenge the Legislationâ€™s requirement to obtain minimum essential health insurance coverage, or the individual mandate. The Court dismissed the case without specifically ruling on the constitutionality of the Legislation. As a result, the Legislation will continue to remain law, in its entirety, likely for the foreseeable future. On September 7, 2022, the Legislation faced its most recent challenge when a Texas Federal District Court judge, in the case of Braidwood Management v. Becerra, ruled that a requirement that certain health plans cover services without cost sharing violates the Appointments Clause of the U.S. Constitution and that the coverage of certain HIV prevention medication violates the Religious Freedom Restoration Act. The decision was appealed to the U.S. Court of Appeals for the Fifth Circuit, which on June 21, 2024, affirmed the District Courtâ€™s ruling regarding preventive services recommended by United States Preventive Services Task Force being unconstitutional. However, the Fifth Circuit overturned the nationwide injunction imposed by the District Court, preserving access to the majority of preventive services in dispute for now. On September 19, 2024, the U.S. Government filed a Petition for Writ of Certiorari, seeking review by the U.S. Supreme Court. The outcome and impacts of this litigation cannot be predicted. Any future efforts to challenge, replace or replace the Legislation or expand or substantially amend its provision is unknown. See below in Sources of Revenues and Health Care Reform for additional disclosure; â€¢as part of the Consolidated Appropriations Act of 2021 (the "CAA"), Congress passed legislation aimed at preventing or limiting patient balance billing in certain circumstances. The CAA addresses surprise medical bills stemming from emergency services, out-of-network ancillary providers at in-network facilities, and air ambulance carriers. The CAA prohibits surprise billing when out-of-network emergency services or out-of-network services at an in-network facility are provided, unless informed consent is received. In these circumstances providers are prohibited from billing the patient for any amounts that exceed in-network cost-sharing requirements. HHS, the Department of Labor and the Department of the Treasury have issued rules to implement the legislation. The rules have limited the ability of our hospital-based physicians to receive payments for services at usually higher out-of-network rates in certain circumstances, and, as a result, have caused us to increase subsidies to these physicians or to replace their services at a higher cost level; â€¢in June 2024, the U.S. Supreme Court issued its decision in Loper Bright Enters. v. Raimondo and Relentless, Inc. v. Department of Commerce, which modified the regulatory interpretation standard established 40 years ago by Chevron v. National Resources Defense Council. Chevron doctrine generally required courts to defer to federal agencies in their interpretation of federal statutes when a statute was silent or ambiguous with respect to a specific issue. In Loper Bright, the Supreme Court held that courts are no longer required to grant such deference, though they may consider an agencyâ€™s statutory interpretation. As it is highly regulated, the health care industry could be significantly impacted by the Loper Bright decision, particularly in the areas of Medicare reimbursement, decision making by the Food & Drug Administration and health care fraud and abuse compliance, where parties may no longer be able to rely on federal agenciesâ€™ policies, rules and guidance; â€¢possible unfavorable changes in the levels and terms of reimbursement for our charges by third party payers or government based payers, including Medicare or Medicaid in the United States, and government based payers in the United Kingdom; â€¢our ability to enter into managed care provider agreements on acceptable terms and the ability of our competitors to do the same; â€¢the outcome of known and unknown litigation, government investigations, inquiries, false claims act allegations, and liabilities and other claims asserted against us and other matters, and the effects of adverse publicity relating to such matters, including, but not limited to, the jury verdicts returned against The Pavilion Behavioral Health System (the "Pavilion") and Cumberland Hospital for Children and Adolescents ("Cumberland"), two of our indirect subsidiaries, as disclosed in Note 6 to the Condensed Consolidated Financial Statements - Commitments and Contingencies, Legal Proceedings. We are uncertain as to the ultimate financial exposure related to the Pavilion and Cumberland matters (which relate to occurrences in 2020) and we can make no assurances regarding timing or substance of their outcome, or the amount of damages that may be ultimately held recoverable after post-judgment proceedings and appeals. As of September 30, 2024, without reduction for any potential amounts related to the Pavilion and Cumberland matters, the Company and its subsidiaries have aggregate insurance coverage of approximately $221 million remaining under commercial policies for matters applicable to the 2020 policy year (in excess of the applicable self-insured retention amounts of $10 million per occurrence for professional liability claims and $3 million per occurrence for general liability claims). In the event the resolution of the Pavilion and Cumberland matters exhausts all or a significant portion of the remaining commercial insurance coverage available to the Company and its subsidiaries related to other matters that occurred in 2020, or the Pavilion and Cumberland matters cause the posting of large bonds or other collateral during the appeal processes, our future results of operations and capital resources could be materially adversely impacted; 29 Â â€¢competition from other healthcare providers (including physician owned facilities) in certain markets; â€¢technological and pharmaceutical improvements that increase the cost of providing, or reduce the demand for healthcare; â€¢our ability to attract and retain qualified personnel, nurses, physicians and other healthcare professionals and the impact on our labor and related expenses resulting from a shortage of nurses, physicians and other healthcare professionals; â€¢demographic changes; â€¢there is a heightened risk of future cybersecurity threats, including ransomware attacks targeting healthcare providers. If successful, future cyberattacks could have a material adverse effect on our business. Any costs that we incur as a result of a data security incident or breach, including costs to update our security protocols to mitigate such an incident or breach could be significant. Any breach or failure in our operational security systems, or any third-party security systems that we rely on, can result in loss of data or an unauthorized disclosure of or access to sensitive or confidential member or protected personal or health information and could result in violations of applicable privacy and other laws, significant penalties or fines, litigation, loss of customers, significant damage to our reputation and business, and other liability or losses. We may also incur additional costs related to cybersecurity risk management and remediation. There can be no assurance that we or our service providers, if applicable, will not suffer losses relating to cyber-attacks or other information security breaches in the future or that our insurance coverage will be adequate to cover all the costs resulting from such events; â€¢the availability of suitable acquisition and divestiture opportunities and our ability to successfully integrate and improve our acquisitions since failure to achieve expected acquisition benefits from certain of our prior or future acquisitions could result in impairment charges for goodwill and purchased intangibles; â€¢the impact of severe weather conditions, including the effects of hurricanes and climate change; â€¢our business, results of operations, financial condition, or stock price may be adversely affected if we are not able to achieve our environmental, social and governance (â€œESGâ€) goals or comply with emerging ESG regulations, or otherwise meet the expectations of our stakeholders with respect to ESG matters; â€¢as discussed below in Sources of Revenue, we receive revenues from various state and county-based programs, including Medicaid in all the states in which we operate. We receive annual Medicaid revenues of approximately $100 million, or greater, from each of Texas, Nevada, California, Illinois, Pennsylvania, Washington, D.C., Kentucky, Massachusetts, Virginia, Mississippi and Florida,. We also receive Medicaid DSH payments in certain states including, most significantly, Texas. We are therefore particularly sensitive to potential reductions in Medicaid and other state-based revenue programs as well as regulatory, economic, environmental and competitive changes in those states; â€¢our ability to continue to obtain capital on acceptable terms, including borrowed funds, to fund the future growth of our business; â€¢our inpatient acute care and behavioral health care facilities may experience decreasing admission and length of stay trends; â€¢our financial statements reflect large amounts due from various commercial and private payers and there can be no assurance that failure of the payers to remit amounts due to us will not have a material adverse effect on our future results of operations; â€¢the Budget Control Act of 2011 (the â€œ2011 Actâ€) imposed annual spending limits for most federal agencies and programs aimed at reducing budget deficits by $917 billion between 2012 and 2021, according to a report released by the Congressional Budget Office. Among its other provisions, the law established a bipartisan Congressional committee, known as the Joint Select Committee on Deficit Reduction (the â€œJoint Committeeâ€), which was tasked with making recommendations aimed at reducing future federal budget deficits by an additional $1.5 trillion over 10 years. The Joint Committee was unable to reach an agreement by the November 23, 2011 deadline and, as a result, across-the-board cuts to discretionary, national defense and Medicare spending were implemented on March 1, 2013 resulting in Medicare payment reductions of up to 2% per fiscal year with a uniform percentage reduction across all Medicare programs. Current legislation has extended these reductions through 2032. We cannot predict whether Congress will restructure the implemented Medicare payment reductions or what other federal budget deficit reduction initiatives may be proposed by Congress going forward; â€¢uninsured and self-pay patients treated at our acute care facilities unfavorably impact our ability to satisfactorily and timely collect our self-pay patient accounts; â€¢changes in our business strategies or development plans; 30 Â â€¢we have exposure to fluctuations in foreign currency exchange rates, primarily the pound sterling. We have international subsidiaries that operate in the United Kingdom. We routinely hedge our exposures to foreign currencies with certain financial institutions in an effort to minimize the impact of certain currency exchange rate fluctuations, but these hedges may be inadequate to protect us from currency exchange rate fluctuations. To the extent that these hedges are inadequate, our reported financial results or the way we conduct our business could be adversely affected. Furthermore, if a financial counterparty to our hedges experiences financial difficulties or is otherwise unable to honor the terms of the foreign currency hedge, we may experience material financial losses; â€¢the impact of a shift of care from inpatient to lower cost outpatient settings and controls designed to reduce inpatient services on our revenue, and; â€¢other factors referenced herein or in our other filings with the Securities and Exchange Commission. Given these uncertainties, risks and assumptions, as outlined above, you are cautioned not to place undue reliance on such forward-looking statements. Our actual results and financial condition could differ materially from those expressed in, or implied by, the forward-looking statements. Forward-looking statements speak only as of the date the statements are made. We assume no obligation to publicly update any forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting forward-looking information, except as may be required by law. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by this cautionary statement. Critical Accounting Policies and Estimates There have been no significant changes to our critical accounting policies or estimates from those disclosed in our 2023 Annual Report on Form 10-K. Recent Accounting Standards: For a summary of accounting standards, please see Note 14 to the Condensed Consolidated Financial Statements, as included herein. Results of Operations Clinical Staffing, Physician Related Expenses and Effects of Inflation: The healthcare industry is labor intensive and salaries, wages and benefits are subject to inflationary pressures, as are supplies expense and other operating expenses. In the past, staffing shortages have, at times, required us to hire expensive temporary personnel and/or enhance wages and benefits to recruit and retain nurses and other clinical staff and support personnel. At certain facilities, particularly within our behavioral health care segment, there have been occasions when we were unable to fill all vacant positions and, consequently, we were required to limit patient volumes. We have also experienced general inflationary cost increases related to certain of our other operating expenses. Many of these factors, which had a material unfavorable impact on our results of operations in prior years, have moderated more recently. However, we cannot predict future inflationary increases, which if significant, could have a material unfavorable impact on our future results of operations. We have experienced inflationary pressures, primarily in personnel costs, although those pressures have moderated more recently. The extent of any future impacts from inflation on our business and our results of operations will be dependent upon how long the elevated inflation levels persist and the extent to which the rate of inflation further increases, if at all, neither of which we are able to predict. If elevated levels of inflation were to persist or if the rate of inflation were to accelerate, our expenses could increase faster than anticipated and we may utilize our capital resources sooner than expected. Further, given the complexities of the reimbursement landscape in which we operate, our ability to pass on increased costs associated with providing healthcare to Medicare and Medicaid patients is limited due to various federal, state and local laws, which in certain circumstances, limit our ability to increase prices. In our acute care segment, we have experienced a significant increase in hospital-based physician related expenses, especially in the areas of emergency room care and anesthesiology. We have implemented various initiatives to mitigate the increased expense, to the degree possible, which has moderated the rate of increase. However, significant increases in these physician related expenses could have a material unfavorable impact on our future results of operations. Although our ability to pass on increased costs associated with providing healthcare to Medicare and Medicaid patients is limited, as discussed above, we have been requesting and negotiating increased rates from commercial insurers to defray our increased cost of providing patient care. In addition, we have implemented various productivity enhancement programs and cost reduction initiatives including, but not limited to, the following: team-based patient care initiatives designed to optimize the level of patient care services provided by our licensed nurses/clinicians; efforts to reduce utilization of, and rates paid for, premium pay labor; consolidation of medical supply vendors to increase purchasing discounts; review and reduction of clinical variation in connection with the utilization of medical supplies, and; various other efforts to increase productivity and/or reduce costs including investments in new information technology applications. 31 Â Financial results for the three-month periods ended September 30, 2024 and 2023: The following table summarizes our results of operations and is used in the discussion below for the three-month periods ended September 30, 2024 and 2023 (dollar amounts in thousands): Â Â Three months endedSeptember 30, 2024 Â Â Three months endedSeptember 30, 2023 Â Â Â Amount Â Â Â % of NetRevenues Â Â Amount Â Â Â % of NetRevenues Â Net revenues Â $ 3,963,027 Â Â Â 100.0 % Â $ 3,562,774 Â Â Â Â 100.0 % Operating charges: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Salaries, wages and benefits Â Â 1,912,308 Â Â Â 48.3 % Â Â 1,784,870 Â Â Â 50.1 % Other operating expenses Â Â 1,090,197 Â Â Â 27.5 % Â Â 941,219 Â Â Â Â 26.4 % Supplies expense Â Â 390,250 Â Â Â 9.8 % Â Â 378,667 Â Â Â 10.6 % Depreciation and amortization Â Â 149,567 Â Â Â 3.8 % Â Â 137,195 Â Â Â 3.9 % Lease and rental expense Â Â 36,540 Â Â Â 0.9 % Â Â 35,466 Â Â Â 1.0 % Subtotal-operating expenses Â Â 3,578,862 Â Â Â 90.3 % Â Â 3,277,417 Â Â Â 92.0 % Income from operations Â Â 384,165 Â Â Â 9.7 % Â Â 285,357 Â Â Â 8.0 % Interest expense, net Â Â 44,660 Â Â Â 1.1 % Â Â 53,378 Â Â Â 1.5 %

Other (income) expense, net Â Â (2,028) Â Â (0.1)% Â Â 11,472 Â Â Â 0.3 % Income before income taxes Â Â 341,533 Â Â Â 8.6 % Â Â 220,507 Â Â Â 6.2 % Provision for income taxes Â Â 75,623 Â Â Â 1.9 % Â Â 52,499 Â Â Â 1.5 % Net income Â Â 265,910 Â Â Â 6.7 % Â Â 168,008 Â Â Â 4.7 % Less: Income (loss) attributable to noncontrolling interests Â Â 7,196 Â Â Â 0.2 % Â Â 1,019 Â Â Â 0.0 % Net income attributable to UHS Â $ 258,714 Â Â Â 6.5 % Â $ 166,989 Â Â Â 4.7 % Net revenues increased by 11.2%, or $400 million, to $3.963 billion during the three-month period ended September 30, 2024, as compared to $3.563 billion during the third quarter of 2023. The net increase was primarily attributable to: (i) a $340 million, or 9.8%, increase in net revenues generated from our acute care hospital services and behavioral health services operated during both periods (which we refer to as â€œSame Facilityâ€), and; (ii) an other combined net increase of $60 million due to an increase in provider tax assessments (which increased net revenues and other operating expenses but had no impact on income before income taxes). Income before income taxes (before income attributable to noncontrolling interests) increased by $121 million, or 55%, to $342 million during the three-month period ended September 30, 2024 as compared to $221 million during the third quarter of 2023. The net increase was due to: â€¢an increase of $67 million at our acute care facilities, as discussed below in Acute Care Hospital Services; â€¢an increase of $57 million at our behavioral health care facilities, as discussed below in Behavioral Health Care Services, and; â€¢$3 million of other combined net decreases. Net income attributable to UHS increased by $92 million, or 55%, to $259 million during the three-month period ended September 30, 2024, as compared to $167 million during the third quarter of 2023. This increase was attributable to: â€¢a $121 million increase in income before income taxes, as discussed above; â€¢a decrease of $6 million due to an unfavorable change in income/loss attributable to noncontrolling interests, and; â€¢a decrease of $23 million resulting from an increase in the provision for income taxes resulting primarily from: (i) the increase in the provision for income taxes resulting from the $115 million increase in pre-tax income, partially offset by; (ii) a $4 million decrease in the provision for income taxes during the third quarter of 2024 from the net tax benefit recorded pursuant to ASU 2016-09, Compensation-Stock Compensation: Improvements to Employee Share-Based Payment Accounting ("ASU 2016-09"), net of the impact of executive compensation limitations pursuant to IRC section 162(m). 32 Â Financial results for the nine-month periods ended September 30, 2024 and 2023: The following table summarizes our results of operations and is used in the discussion below for the nine-month periods ended September 30, 2024 and 2023 (dollar amounts in thousands): Â Â Nine months endedSeptember 30, 2024 Â Â Nine months endedSeptember 30, 2023 Â Â Â Amount Â Â % of NetRevenues Â Â Amount Â Â % of NetRevenues Â Net revenues Â $ 11,714,213 Â Â Â 100.0 % Â $ 10,578,430 Â Â Â 100.0 % Operating charges: Â Â Â Â Â Â Â Â Â Â Â Â Â Â Salaries, wages and benefits Â Â 5,611,304 Â Â Â 47.9 % Â Â 5,308,476 Â Â Â 50.2 % Other operating expenses Â Â 3,165,483 Â Â Â 27.0 % Â Â 2,758,484 Â Â Â 26.1 % Supplies expense Â Â 1,181,886 Â Â Â 10.1 % Â Â 1,138,950 Â Â Â 10.8 % Depreciation and amortization Â Â 438,050 Â Â Â 3.7 % Â Â 422,560 Â Â Â 4.0 % Lease and rental expense Â Â 108,165 Â Â Â 0.9 % Â Â 105,775 Â Â Â 1.0 % Subtotal-operating expenses Â Â 10,504,888 Â Â Â 89.7 % Â Â 9,734,245 Â Â Â 92.0 % Income from operations Â Â 1,209,325 Â Â Â 10.3 % Â Â 844,185 Â Â Â 8.0 % Interest expense, net Â Â 146,385 Â Â Â 1.2 % Â Â 153,085 Â Â Â 1.4 % Other (income) expense, net Â Â 3,315 Â Â Â 0.0 % Â Â 31,797 Â Â Â 0.3 % Income before income taxes Â Â 1,059,625 Â Â Â 9.0 % Â Â 659,303 Â Â Â 6.2 % Provision for income taxes Â Â 233,563 Â Â Â 2.0 % Â Â 159,618 Â Â Â 1.5 % Net income Â Â 826,062 Â Â Â 7.1 % Â Â 499,685 Â Â Â 4.7 % Less: Income (loss) attributable to noncontrolling interests Â Â 16,362 Â Â Â 0.1 % Â Â (1,732) Â Â (0.0)% Net income attributable to UHS Â $ 809,700 Â Â Â 6.9 % Â $ 501,417 Â Â Â 4.7 % Net revenues increased by 10.7%, or $1.136 billion, to $11.714 billion during the nine-month period ended September 30, 2024, as compared to $10.578 billion during the first nine months of 2023. The net increase was primarily attributable to: (i) a $975 million, or 9.4%, increase in net revenues generated from our acute care hospital services and behavioral health services, on a same facility basis, and; (ii) an other combined net increase of $182 million, consisting primarily of a $174 million increase in provider tax assessments (which increased net revenues and other operating expenses but had no impact on income before income taxes), partially offset by a $21 million decrease in net revenues generated at Desert Springs Hospital Medical Center ("Desert Springs") located in Las Vegas, Nevada, which discontinued all inpatient operations during the first quarter of 2023. Income before income taxes (before income attributable to noncontrolling interests) increased by $400 million, or 61%, to $1.060 billion during the nine-month period ended September 30, 2024 as compared to $659 million during the first nine months of 2023. The net increase was due to: â€¢an increase of $220 million at our acute care facilities, as discussed below in Acute Care Hospital Services; â€¢an increase of $207 million at our behavioral health care facilities, as discussed below in Behavioral Health Care Services, and; â€¢$27 million of other combined net decreases. Net income attributable to UHS increased by $308 million, or 62%, to $810 million during the nine-month period ended September 30, 2024, as compared to $501 million during the first nine months 2023. This increase was attributable to: â€¢a $400 million increase in income before income taxes, as discussed above; â€¢a decrease of $18 million due to an unfavorable change in income/loss attributable to noncontrolling interests, and; â€¢a decrease of $74 million resulting from an increase in the provision for income taxes resulting primarily from: (i) the increase in the provision for income taxes resulting from the $382 million increase in pre-tax income, partially offset by; (ii) a $18 million decrease in the provision for income taxes during the first nine months of 2024, as compared to the comparable period of 2023, from the net tax benefit recorded pursuant to ASU 2016-09, net of the impact of executive compensation limitations pursuant to IRC section 162(m). Adjustments to self-insured professional and general liability reserves: Our estimated liability for self-insured professional and general liability claims is based on a number of factors including, among other things, the number of asserted claims and reported incidents, estimates of losses for these claims based on recent and historical settlement amounts, estimates of incurred but not reported claims based on historical experience, and estimates of amounts recoverable under our commercial insurance policies. 33 Â As a result of unfavorable trends experienced during the past several years, included in our results of operations were increases to our reserves for self-insured professional and general liability claims amounting to approximately $30 million and $44 million during the three and nine-month periods ended September 30, 2024, respectively. Approximately $23 million and $33 million of the increase is included in our same facility basis acute care hospital services' results during the three and nine-month periods ended September 30, 2024, respectively, and approximately $7 million and $11 million is included in our same facility basis behavioral health services' results during the three and nine-month periods ended September 30, 2024, respectively. Our results of operations for the comparable periods of 2023 included increases to our reserves for self-insured professional and general liability claims amounting to approximately $5 million and $25 million during the three and nine-month periods ended September 30, 2023, respectively. Approximately $4 million and $18 million of the increase is included in our same facility basis acute care hospital services' results during the three and nine-month periods ended September 30, 2023, respectively, and approximately $1 million and $7 million is included in our same facility basis behavioral health services' results during the three and nine-month periods ended September 30, 2023, respectively. Acute Care Hospital Services The following table sets forth certain operating statistics for our acute care hospital services for the three and nine-month periods ended September 30, 2024 and 2023. Â Same Facility Basis Â Â All Â Â Same Facility Basis Â Â All Â Â Three Months Ended Â Â Three Months Ended Â Â Nine Months Ended Â Â Nine Months Ended Â Â September 30, Â Â September 30, Â Â September 30, Â Â September 30, Â Â September 30, Â Â September 30, Â Â September 30, Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Average licensed beds Â 6,657 Â Â Â 6,667 Â Â Â 6,657 Â Â Â 6,667 Â Â Â 6,657 Â Â Â 6,634 Â Â Â 6,657 Â Â Â 6,697 Â Average available beds Â 6,485 Â Â Â 6,495 Â Â Â 6,485 Â Â Â 6,495 Â Â Â 6,485 Â Â Â 6,462 Â Â Â 6,485 Â Â Â 6,525 Â Patient days Â 393,521 Â Â Â 384,348 Â Â Â 393,521 Â Â Â 384,348 Â Â Â 1,199,271 Â Â Â 1,166,693 Â Â Â 1,199,271 Â Â Â 1,172,957 Â Average daily census Â 4,277.4 Â Â Â 4,177.7 Â Â Â 4,277.4 Â Â Â 4,177.7 Â Â Â 4,376.9 Â Â Â 4,273.6 Â Â Â 4,376.9 Â Â Â 4,296.5 Â Occupancy-licensed beds Â 64.3 % Â Â 62.7 % Â Â 64.3 % Â Â 62.7 % Â Â 65.7 % Â Â 64.4 % Â Â 65.7 % Â Â 64.2 % Occupancy-available beds Â 66.0 % Â Â 64.3 % Â Â 66.0 % Â Â 64.3 % Â Â 67.5 % Â Â 66.1 % Â Â 67.5 % Â Â 65.8 % Admissions Â 81,731 Â Â Â 80,074 Â Â Â 81,731 Â Â Â 80,074 Â Â Â 247,170 Â Â Â 238,237 Â Â Â 247,170 Â Â Â 239,300 Â Length of stay Â 4.8 Â Â Â 4.8 Â Â Â 4.8 Â Â Â 4.8 Â Â Â 4.9 Â Â Â 4.9 Â Â Â 4.9 Â Â Â 4.9 Â Acute Care Hospital Services-Same Facility Basis We believe that providing our results on a â€œSame Facilityâ€ basis (which is a non-GAAP measure), which includes the operating results for facilities and businesses operated in both the current year and prior year periods, is helpful to our investors as a measure of our operating performance. Our Same Facility results also neutralize (if applicable) the effect of items that are non-operational in nature including items such as, but not limited to, gains/losses on sales of assets and businesses, impacts of settlements, legal judgments and lawsuits, impairments of long-lived and intangible assets and other amounts that may be reflected in the current or prior year financial statements that relate to prior periods. Our Same Facility basis results reflected on the table below also exclude from net revenues and other operating expenses, provider tax assessments incurred in each period as discussed below Sources of Revenue-Summary of Various State Medicaid Supplemental Payment Programs. However, these provider tax assessments are included in net revenues and other operating expenses as reflected in the table below under All Acute Care Hospital Services. The provider tax assessments had no impact on the income before income taxes as reflected on the tables below since the amounts offset between net revenues and other operating expenses. To obtain a complete understanding of our financial performance, the Same Facility results should be examined in connection with our net income as determined in accordance with U.S. GAAP and as presented in the condensed consolidated financial statements and notes thereto as contained in this Quarterly Report on Form 10-Q. The following table summarizes the results of operations for our acute care facilities on a Same Facility basis and is used in the discussion below for the three and nine-month periods ended September 30, 2024 and 2023 (dollar amounts in thousands): 34 Â Â Â Three months ended Â Â Three months ended Â Â Nine months ended Â Â Nine months ended Â Â Â September 30, 2024 Â Â September 30, 2023 Â Â September 30, 2024 Â Â September 30, 2023 Â Â Â Amount Â Â % of NetRevenues Â Â Amount Â Â % of NetRevenues Â Â Amount Â Â % of NetRevenues Â Â Amount Â Â % of NetRevenues Â Net revenues Â $ 2,147,732 Â Â Â 100.0 % Â $ 1,965,985 Â Â Â 100.0 % Â $ 6,355,078 Â Â Â 100.0 % Â $ 5,858,015 Â Â Â 100.0 % Operating charges: Â Salaries, wages and benefits Â Â 893,436 Â Â Â 41.6 % Â Â 854,284 Â Â Â 43.5 % Â Â 2,609,544 Â Â Â 41.1 % Â Â 2,517,163 Â Â Â 43.0 % Other operating expenses Â Â 598,840 Â Â Â 27.9 % Â Â 543,584 Â Â Â 27.6 % Â Â 1,754,999 Â Â Â 27.6 % Â Â 1,604,084 Â Â Â 27.4 % Supplies expense Â Â 332,799 Â Â Â 15.5 % Â Â 323,580 Â Â Â 16.5 % Â Â 1,011,602 Â Â Â 15.9 % Â Â 976,712 Â Â Â 16.7 % Depreciation and amortization Â Â 93,752 Â Â Â 4.4 % Â Â 86,437 Â Â Â 4.4 % Â Â 278,062 Â Â Â 4.4 % Â Â 273,646 Â Â Â 4.7 % Lease and rental expense Â Â 24,202 Â Â Â 1.1 % Â Â 24,443 Â Â Â 1.2 % Â Â 72,308 Â Â Â 1.1 % Â Â 72,459 Â Â Â 1.2 % Subtotal-operating expenses Â Â 1,943,029 Â Â Â 90.5 % Â Â 1,832,328 Â Â Â 93.2 % Â Â 5,726,515 Â Â Â 90.1 % Â Â 5,444,064 Â Â Â 92.9 % Income from operations Â Â 204,703 Â Â Â 9.5 % Â Â 133,657 Â Â Â 6.8 % Â Â 628,563 Â Â Â 9.9 % Â Â 413,951 Â Â Â 7.1 % Interest expense, net Â Â 1,077 Â Â Â 0.1 % Â Â (778) Â Â (0.0)% Â Â 3,363 Â Â Â 0.1 % Â Â (1,858) Â Â (0.0)% Other (income) expense, net Â Â (590) Â Â (0.0)% Â Â (490) Â Â (0.0)% Â Â (1,348) Â Â (0.0)% Â Â 5,723 Â Â Â 0.1 % Income before income taxes Â $ 204,216 Â Â Â 9.5 % Â $ 134,925 Â Â Â 6.9 % Â $ 626,548 Â Â Â 9.9 % Â $ 410,086 Â Â Â 7.0 % Three-month periods ended September 30, 2024 and 2023: During the three-month period ended September 30, 2024, as compared to the comparable prior year quarter, net revenues from our acute care hospital services, on a Same Facility basis, increased by $182 million or 9.2%. Income before income taxes (and before income attributable to noncontrolling interests) increased by $69 million, or 51%, amounting to $204 million, or 9.5% of net revenues during the third quarter of 2024, as compared to $135 million, or 6.9% of net revenues during the third quarter of 2023. Included in our Same Facility basis' net revenues and income before income taxes, during the third quarter of 2024, was approximately $40 million of net reimbursements (net of related provider taxes) recorded in connection with the Nevada state directed payment program which was approved by the Centers for Medicare and Medicaid Services in December, 2023. Please see additional disclosure below in Sources of Revenue-Nevada State Directed Payment Program ("SDP"). During the three-month period ended September 30, 2024, net revenue per adjusted admission increased by 7.0% while net revenue per adjusted patient day increased 6.5%, as compared to the comparable quarter of 2023. During the three-month period ended September 30, 2024, as compared to the comparable prior year quarter, inpatient admissions to our acute care hospitals increased by 2.1% while adjusted admissions (adjusted for outpatient activity) increased by 1.5%. Patient days at these facilities increased by 2.4% and adjusted patient days increased by 2.0% during the three-month period ended September 30, 2024, as compared to the comparable prior year quarter. The average length of inpatient stay at these facilities was 4.8 days during each of the three-month periods ended September 30, 2024 and 2023. The occupancy rate, based on the average available beds at these facilities, was 66% and 64% during the three-month periods ended September 30, 2024 and 2023, respectively. On a Same Facility basis, during the three-month period ended September 30, 2024, as compared to the comparable quarter of 2023, salaries, wages and benefits expense increased by $39 million, or 4.6%. Although our acute care facilities experienced an increase in patient volumes during the third quarter of 2024, as compared to the comparable quarter of 2023, the related incremental staffing cost increase was partially offset by the following: (i) a reduction in premium pay (overtime paid to employees and external temporary resources' expense) which decreased by approximately $8 million, or 12%, during the third quarter of 2024, as compared to the comparable quarter of 2023, and; (ii) a restructuring, that occurred in early 2024, at certain of our acute care hospitals that reduced the number of employees in positions that were not directly related to the delivery of patient care. As a percentage of net revenues, salaries, wages and benefits expense decreased to 41.6% during the third quarter of 2024 as compared to 43.5% during the third quarter of 2023. Other operating expenses increased by $55 million, or 10.2%, during the third quarter of 2024, as compared to the comparable quarter of 2023. Operating expenses incurred by our commercial health insurer, consisting primarily of medical costs, increased by $19 million during the third quarter of 2024, as compared to the comparable quarter of 2023. In addition, as discussed above in Results of Operations-Adjustments to self-insured professional and general liability reserves, included in the other operating expenses of our acute care hospital services during the third quarter of 2024, as compared to the comparable quarter of 2023, was a $19 million increase in the adjustments made to our self-insured professional and general liability reserves. Excluding these expense items from each period, other operating expenses increased by $17 million, or 4.0%. As a percentage of net revenues, other operating expenses increased to 27.9% during the third quarter of 2024, as compared to 27.6% during the comparable quarter of 2023. Supplies expense increased by $9 million, or 2.8%, during the third quarter of 2024, as compared to the third quarter of 2023. As a percentage of net revenues, supplies expense decreased to 15.5% during the three-month period ended September 30, 2024, as compared to 16.5% during the third quarter of 2023. Nine-month periods ended September 30, 2024 and 2023: During the nine-month period ended September 30, 2024, as compared to the comparable prior year period, net revenues from our acute care hospital services, on a Same Facility basis, increased by $497 million or 8.5%. Income before income taxes (and before 35 Â income attributable to noncontrolling interests) increased by $216 million, or 53%, amounting to $627 million, or 9.9% of net revenues during the first nine months of 2024, as compared to $410 million, or 7.0% of net revenues during the comparable period of 2023. Included in our Same Facility basis' net revenues and income before income taxes, during the first nine months of 2024, was approximately $117 million of net reimbursements (net of related provider taxes) recorded in connection with the Nevada state directed payment program which was approved by the Centers for Medicare and Medicaid Services in December, 2023. Please see additional disclosure below in Sources of Revenue-Nevada State Directed Payment Program ("SDP"). During the nine-month period ended September 30, 2024, net revenue per adjusted admission increased by 5.0% while net revenue per adjusted patient day increased by 5.8%, as compared to the comparable period of 2023. During the nine-month period ended September 30, 2024, as compared to the comparable prior year period, inpatient admissions to our acute care hospitals increased by 3.7% while adjusted admissions increased by 3.1%. Patient days and adjusted patient days at these facilities increased by 2.8% and 2.3%, respectively, during the nine-month period ended September 30, 2024, as compared to the comparable prior year period. The average length of inpatient stay at these facilities was 4.9 days during each of the nine-month periods ended September 30, 2024 and 2023. The occupancy rate, based on the average available beds at these facilities, was 68% and 66% during the nine-month periods ended September 30, 2024 and 2023, respectively. On a Same Facility basis during the nine-month period ended September 30, 2024, as compared to the comparable period of 2023, salaries, wages and benefits expense increased by $92 million, or 3.7%. Although our acute care facilities experienced an increase in patient volumes during the first nine months of 2024, as compared to the comparable period of 2023, the related incremental staffing cost increase was offset by the following: (i) a reduction in premium pay (overtime paid to employees and external temporary resources' expense) which decreased by approximately $40 million during the first nine months of 2024, as compared to the comparable period of 2023, and; (ii) a restructuring, that occurred in early 2024, at certain of our acute care hospitals that reduced the number of employees in positions that were not directly related to the delivery of patient care. As a percentage of net revenues, salaries, wages and benefits expense decreased to 41.1% during the first nine months of 2024 as compared to 43.0% during the comparable period of 2023. Other operating expenses increased by $151 million, or 9.4%, during the first nine months of 2024, as compared to the comparable period of 2023. Operating expenses incurred by our commercial health insurer, consisting primarily of medical costs, increased by $34 million during the first nine months of 2024, as compared to the comparable period of 2023. In addition, as discussed above in Results of Operations-Adjustments to self-insured professional and general liability reserves, included in the other operating expenses of our acute care hospital services

during the first nine months of 2024, as compared to the comparable period of 2023, was a $15 million increase in the adjustments made to our self-insured professional and general liability reserves. Excluding these expense items from each period, other operating expenses increased by $101 million, or 8.1%. Contributing to the increase during the first nine months of 2024, as compared to the comparable period of 2023, was a $37 million, or 8.6%, increase in physician-related expenses, as well as the expenses incurred in connection with the increase in patient volumes. As a percentage of net revenues, other operating expenses increased to 27.6% during the first nine months of 2024, as compared to 27.4% during the comparable period of 2023. Supplies expense increased by $35 million, or 3.6%, during the first nine months of 2024, as compared to the comparable period of 2023. As a percentage of net revenues, supplies expense decreased to 15.9% during the nine-month period ended September 30, 2024, as compared to 16.7% during the comparable period of 2023. All Acute Care Hospital Services The following table summarizes the results of operations for all our acute care operations during the three and nine-month periods ended September 30, 2024 and 2023. These amounts include: (i) our acute care results on a Same Facility basis, as indicated above; (ii) the impact of provider tax assessments which increased net revenues and other operating expenses but had no impact on income before income taxes, and; (iii) certain other amounts including, if applicable, the results of recently acquired/opened facilities and businesses as well as the operating results for Desert Springs which discontinued all inpatient operations during the first quarter of 2023. Dollar amounts below are reflected in thousands. 36 Â Â Â Three months endedSeptember 30, 2024 Â Â Three months endedSeptember 30, 2023 Â Â Nine months endedSeptember 30, 2024 Â Â Nine months endedSeptember 30, 2023 Â Â Â Amount Â Â % of NetRevenues Â Â Amount Â Â % of NetRevenues Â Â Amount Â Â % of NetRevenues Â Â Amount Â Â % of NetRevenues Â Net revenues Â $ 2,245,517 Â Â Â 100.0 % Â $ 2,017,288 Â Â Â 100.0 % Â $ 6,604,007 Â Â Â 100.0 % Â $ 5,993,899 Â Â Â 100.0 % Operating charges: Â Â Â

(iii) certain other amounts including the results of facilities acquired or opened during the past year. Dollar amounts below are reflected in thousands. Â Â Â Three months endedSeptember 30, 2024 Â Â Three months endedSeptember 30, 2023 Â Â Nine months endedSeptember 30, 2024 Â Â Nine months endedSeptember 30, 2023 Â Â Â Amount Â Â % of NetRevenues Â Â Amount Â Â % of NetRevenues Â Â Amount Â Â % of NetRevenues Â Â Amount Â Â % of NetRevenues Â Net revenues Â $ 1,714,914 Â Â Â 100.0 % Â $ 1,542,695 Â Â Â 100.0 % Â $ 5,102,290 Â Â Â 100.0 % Â $ 4,575,378 Â Â Â 100.0 % Operating charges: Â Â Â

overall increase in IPPS payments is approximately 4.6.%. Including DSH payments, an increase to the Medicare Outlier threshold and certain other adjustments, we estimate our overall increase from the final IPPS 2023 rule (covering the period of October 1, 2022 through September 30, 2023) will approximate 4.4%. This projected impact from the IPPS 2023 final rule includes an increase of approximately 0.5% to partially restore cuts made as a result of the American Taxpayer Relief Act of 2012, as required by the 21st Century Cures Act, but excludes the impact of the sequestration reductions related to the 2011 Act, Bipartisan Budget Act of 2015, and Bipartisan Budget Act of 2018. In June, 2019, the Supreme Court of the United States issued a decision favorable to hospitals impacting prior year Medicare DSH payments (Azar v. Allina Health Services, No. 17-1484 (U.S. Jun. 3, 2019)). In Allina, the hospitals challenged the Medicare DSH adjustments for federal fiscal year 2012, specifically challenging CMSâ€™s decision to include inpatient hospital days attributable to Medicare Part C enrollee patients in the numerator and denominator of the Medicare/SSI fraction used to calculate a hospitalâ€™s DSH payments. This ruling addresses CMSâ€™s attempts to impose the policy espoused in its vacated 2004 rulemaking to a fiscal year in the 2004â€“2013 time period without using notice-and-comment rulemaking. This decision should require CMS to recalculate hospitalsâ€™ DSH Medicare/SSI fractions, with Medicare Part C days excluded, for at least federal fiscal year 2012, but likely federal fiscal years 2005 through 2013. In August, 2020, CMS issued a rule that proposed to retroactively negate the effects of the aforementioned Supreme Court decision, which rule has yet to be finalized. Although we can provide no assurance that we will ultimately receive additional funds, we estimate that the favorable impact of this court ruling on certain prior year hospital Medicare DSH payments could range between $18 million to $28 million in the aggregate. The 2011 Act included the imposition of annual spending limits for most federal agencies and programs aimed at reducing budget deficits by $917 billion between 2012 and 2021, according to a report released by the Congressional Budget Office. Among its other provisions, the law established a bipartisan Congressional committee, known as the Joint Committee, which was responsible for developing recommendations aimed at reducing future federal budget deficits by an additional $1.5 trillion over 10 years. The Joint Committee was unable to reach an agreement by the November 23, 2011 deadline and, as a result, across-the-board cuts to discretionary, national defense and Medicare spending were implemented on March 1, 2013 resulting in Medicare payment reductions of up to 2% per fiscal year. Subsequent legislation has extended this sequestration through 2032. The CARES Act, as amended, temporarily suspended or limited the application of this sequestration from May 1, 2020 through June 30, 2022, with a return to the full 2% Medicare payment reduction thereafter. Inpatient services furnished by psychiatric hospitals under the Medicare program are paid under a Psychiatric Prospective Payment System (â€œPsych PPSâ€). Medicare payments to psychiatric hospitals are based on a prospective per diem rate with adjustments to account for certain facility and patient characteristics. The Psych PPS also contains provisions for outlier payments and an adjustment to a psychiatric hospitalâ€™s base payment if it maintains a full-service emergency department. In July, 2024, CMS published its Psych PPS final rule for the federal fiscal year 2025. Under this final rule, payments to our behavioral health care hospitals and units from the market basket update are estimated to increase by 2.8% compared to federal fiscal year 2024. This amount includes the effect of the 3.3% net market basket update which reflects the offset of a 0.5% productivity adjustment. When all of the final patient level adjustments described below as well as proposed wage index values are considered, we estimate that Psych PPS payments will increase by 2.1% in FFY 2025. In addition to the market basket update noted above, CMS will make the following changes: â€¢Revisions to the methodology for determining the payment rates under the Inpatient Psychiatric Facility ("IPF") PPS for psychiatric hospitals and psychiatric units based on a review of the data and information collected in prior years in accordance with section 1886(s)(5)(A) of the Social Security Act, as added by the Consolidated Appropriations Act of 2023 ("CAA of 2023"). CMS finalized revisions to the IPF patient-level adjustment factors. The patient-level adjustments include Medicare Severity Diagnosis Related Groups (MSâ€“DRGs) assignment of the patientâ€™s principal diagnosis, selected comorbidities, patient age, and the variable per diem adjustments, and; â€¢Implement these revisions in a budget-neutral manner (that is, estimated payments to IPFs for FFY 2025 would be the same with or without the final revisions). â€¢Clarified the criteria regarding all-inclusive cost reporting. This clarification will require our behavioral health care hospitals, which are currently utilizing an all-inclusive charging practice, to modify both their billing practices and information technology applications to ensure compliance with future regulations. 44 Â This final rule also includes two requests for information on future revisions to the IPF PPS facility-level adjustment factors and development of the new standardized IPF Patient Assessment Instrument, required by the CAA of 2023, which IPFs participating in the IPF Quality Reporting Program will be required to report for Rate Year 2028. In July, 2023, CMS published its Psych PPS final rule for the federal fiscal year 2024. Under this final rule, payments to our behavioral health care hospitals and units are estimated to increase by 3.3% compared to federal fiscal year 2023. This amount includes the effect of the 3.5% net market basket update which reflects the offset of a 0.2% productivity adjustment. In July, 2022, CMS published its Psych PPS final rule for the federal fiscal year 2023. Under this final rule, payments to our behavioral health care hospitals and units are estimated to increase by 3.8% compared to federal fiscal year 2022. This amount includes the effect of the 4.1% net market basket update which reflects the offset of a 0.3% productivity adjustment. On November 2, 2023, in light of the Supreme Courtâ€™s decision in American Hospital Association v. Becerra (142 S. Ct. 1896 (2022)) and the district courtâ€™s remand to the agency, CMS issued a final rule outlining the remedy for the 340B-acquired drug payment policy for calendar years 2018-2022. CMS published the final rule to remedy the payment rates the Court held were invalid aspects of their past policy and will affect nearly all hospitals paid under the OPPS. As part of the final remedy, CMS will make an adjustment to the update factor to maintain budget neutrality as required by statute. CMS finalized the 340B policy for calendar year 2018 in 2017 in a budget neutral manner that included increasing payments for non-drug items and services; this payment increase was in effect from calendar years 2018 through 2022. CMS estimates that hospitals were paid $7.8 billion more for non-drug items and services during this time period than they would have been paid in the absence of the 340B payment policy. Because CMS is now making additional payments to affected 340B covered entity hospitals to pay them what they would have been paid had the 340B policy never been implemented, CMS will make a corresponding offset to maintain budget neutrality as if the 340B payment policy had never been in effect. To carry out this required $7.8 billion budget neutrality adjustment, CMS will reduce future non-drug item and service payments by adjusting the OPPS conversion factor by minus 0.5% starting in calendar year 2026 and continuing for 16 years. The impact of this 0.5% reduction on our 2026 results of operations is approximately $4 million. In November, 2024, CMS issued its OPPS final rule for 2025. The hospital market basket increase is 3.4% and the productivity adjustment reduction is 0.5% for a net market basket increase of 2.9%. When other statutorily required adjustments and hospital patient service mix are considered, including a 14.2% increase to the partial hospitalization rate, we estimate that our overall Medicare OPPS update for 2025 will aggregate to a net increase of 3.6%. In November, 2023, CMS issued its OPPS final rule for 2024. The hospital market basket increase is 3.3% and the productivity adjustment reduction is 0.2% for a net market basket increase of 3.1%. When other statutorily required adjustments and hospital patient service mix are considered, we estimate that our overall Medicare OPPS update for 2024 will aggregate to a net increase of 9.7%. This percentage reflects the impact resulting from rural floor changes to the Medicare wage index adjustment factor where certain states, such as California and Nevada, will materially benefit from this change. In November, 2022, CMS issued its OPPS final rule for 2023. The hospital market basket increase is 4.1% and the productivity adjustment reduction is -0.3% for a net market basket increase of 3.8%. The final rule provides that in light of the Supreme Court decision in American Hospital Association v. Becerra, CMS is applying the default rate, generally average sales price plus 6%, to 340B acquired drugs and biologicals for 2023. During the 2018-2022 time period, we recorded an aggregate of approximately $45 million to $50 million of Medicare revenues related to the prior 340B payment policy. When other statutorily required adjustments and hospital patient service mix are considered, as well as impact of the aforementioned 340B Program policy change, our overall Medicare OPPS update for 2023 aggregated to a net increase of approximately 0.9% which includes a 0.3% increase to behavioral health division partial hospitalization rates. On November 2, 2021, CMS issued its OPPS final rule for 2022. The hospital market basket increase is 2.7% and the productivity adjustment reduction is -0.7% for a net market basket increase of 2.0%. When other statutorily required adjustments and hospital patient service mix are considered, our overall Medicare OPPS update for 2022 aggregated to a net increase of approximately 2.4% which includes a 3.0% increase to behavioral health division partial hospitalization rates. In November, 2019, CMS finalized its Hospital Price Transparency rule that implements certain requirements under the June 24, 2019 Presidential Executive Order related to Improving Price and Quality Transparency in American Healthcare to Put Patients First. Under this final rule, effective January 1, 2021, CMS will require: hospitals to make public: (1) their standard changes (both gross charges and payer-specific negotiated charges) for all items and services online in a machine-readable format, and; (2) standard charge data for a limited set of â€œshoppable servicesâ€ the hospital provides in a form and manner that is more consumer friendly. On November 2, 2021, CMS released a final rule increasing the monetary penalty that CMS can impose on hospitals that fail to comply with the price transparency requirements. We believe that our hospitals are in full compliance with the applicable federal regulations. In November, 2023, CMS finalized multiple provisions, effective as of January 1, 2024, focused on increasing hospital price transparency and compliance enforcement including but not limited to: (1) standard charges data would be posted online using a CMS template, instead of using the hospitalâ€™s own form/format; (2) all standard charge information would be encoded with a specified set of data elements (e.g., hospital name; license number; payer/plan name; description of service; billing codes, among others); (3) other technical changes related to increasing consumersâ€™ automated accessibility to hospital standard charges, and; (4) 45 Â certifications regarding accuracy of standard charge data and related compliance warning notices from CMS and requiring accessibility to health system leadership regarding transparency noncompliance. In September, 2024, the Departments of Labor, Health and Human Services and the Treasury published final rules that: â€¢Mandate that insurers analyze the outcomes of their coverage to ensure there's equivalent access to mental health care, including provider networks, prior authorization rates and payment for out-of-network providers, and take action to get in compliance; â€¢Establish when health plans canâ€™t use prior authorization or other tactics to make it more difficult to access mental health and substance use treatment; â€¢Require additional insurers to comply with the 2008 Mental Health Parity and Addiction Equity Act. While these rules will likely improve patient access to inpatient and outpatient mental health services, we are unable to estimate the related potential impact on our results of operations. Medicaid: Medicaid is a joint federal-state funded health care benefit program that is administered by the states to provide benefits to qualifying individuals. Most state Medicaid payments are made under a PPS-like system, or under programs that negotiate payment levels with individual hospitals. Amounts received under the Medicaid program are generally significantly less than a hospitalâ€™s customary charges for services provided. In addition to revenues received pursuant to the Medicare program, we receive a large portion of our revenues either directly from Medicaid programs or from managed care companies managing Medicaid. All of our acute care hospitals and most of our behavioral health centers are certified as providers of Medicaid services by the appropriate governmental authorities. We receive revenues from various state and county-based programs, including Medicaid in all the states in which we operate. We receive annual Medicaid revenues of approximately $100 million, or greater, from each of Texas, Nevada, California, Illinois, Pennsylvania, Washington, D.C., Kentucky, Massachusetts, Virginia, Mississippi and Florida. We also receive Medicaid disproportionate share hospital payments in certain states including, most significantly, Texas. We are therefore particularly sensitive to potential reductions in Medicaid and other state-based revenue programs as well as regulatory, economic, environmental and competitive changes in those states. We can provide no assurance that reductions to revenues earned pursuant to these programs, particularly in the above-mentioned states, will not have a material adverse effect on our future results of operations. The Legislation substantially increases the federally and state-funded Medicaid insurance program, and authorizes states to establish federally subsidized non-Medicaid health plans for low-income residents not eligible for Medicaid starting in 2014. However, the Supreme Court has struck down portions of the Legislation requiring states to expand their Medicaid programs in exchange for increased federal funding. Accordingly, many states in which we operate have not expanded Medicaid coverage to individuals at 133% of the federal poverty level. Facilities in states not opting to expand Medicaid coverage under the Legislation may be additionally penalized by corresponding reductions to Medicaid disproportionate share hospital payments beginning in fiscal year 2024, as discussed below. We can provide no assurance that further reductions to Medicaid revenues, particularly in the above-mentioned states, will not have a material adverse effect on our future results of operations. Summary of Various State Medicaid Supplemental Payment Programs: The following table summarizes the revenues, taxes imposed by states in the form of a licensing fee, assessment or other mandatory payment ("Provider Taxes") and net benefit related to each of the below-mentioned Medicaid supplemental programs for three and nine-month periods ended September 30, 2024 and 2023. The Provider Taxes are recorded in other operating expenses on the condensed consolidated statements of income as included herein. 46 Â Â (amounts in millions) Â Â Â Â Three Months Ended Â Â Nine Months Ended Â Â Projected Â Â September 30, Â September 30, Â Â September 30, Â September 30, Â Full Year 2024 Â Â 2024 Â 2023 Â Â 2024 Â 2023 Â Texas Supplemental Payment Programs: Â Â Â Â Â Â Â Â Â Â Â Â Revenues $ 352 Â Â $ 124 Â $ 87 Â Â $ 243 Â $ 175 Â Provider Taxes Â (138) Â Â (47) Â (30) Â Â (96) Â (62) Net benefit $ 214 Â Â $ 77 Â Â $ 147 Â $ 113 Â Â Â Â Â Â Â Â Â Â Â Â Nevada SDP: Â Â Â Â Â Â Â Â Â Â Â Â Revenues $ 272 Â Â $ 70 Â $ 0 Â Â $ 203 Â $ 0 Â Provider Taxes Â (109) Â Â (28) Â 0 Â Â Â (82) Â 0 Â Net benefit $ 163 Â Â $ 42 Â $ 0 Â Â $ 121 Â $ 0 Â Â Â Â Â Â Â Â Â Â Â Â Various Other State Programs: Â Â Â Â Â Â Â Â Â Â Â Â Revenues $ 811 Â Â $ 177 Â $ 121 Â Â $ 568 Â $ 376 Â Provider Taxes Â (275) Â Â (63) Â (46) Â Â (189) Â (129) Net benefit $ 536 Â Â $ 114 Â $ 75 Â Â $ 379 Â $ 247 Â Â Â Â Â Â Â Â Â Â Â Â Subtotal-Provider Tax Programs: Â Â Â Â Â Â Â Â Â Â Â Â Revenues $ 1,435 Â Â $ 371 Â $ 208 Â Â $ 1,014 Â $ 551 Â Provider Taxes Â (522) Â Â (138) Â (76) Â Â (367) Â (191) Aggregate net benefit from Provider Tax Programs $ 913 Â Â $ 233 Â $ 132 Â Â $ 647 Â $ 360 Â Â Â Â Â Â Â Â Â Â Â Â Texas DSH and Nevada SPA Programs: Â Â Â Â Â Â Â Â Â Â Â Â Revenues $ 53 Â Â $ 18 Â $ 18 Â Â $ 41 Â $ 60 Â Provider Taxes Â 0 Â Â Â 0 Â Â 0 Â Â Â 0 Â Â 0 Â Net benefit $ 53 Â Â $ 18 Â $ 18 Â Â $ 41 Â $ 60 Â Â Â Â Â Â Â Â Â Â Â Â Total Supplemental Medicaid Programs: Â Â Â Â Â Â Â Â Â Â Â Â Revenues $ 1,488 Â Â $ 389 Â $ 226 Â Â $ 1,055 Â $ 611 Â Â Provider Taxes Â (522) Â Â (138) Â (76) Â Â (367) Â (191) Aggregate net benefit from all Supplemental Programs $ 966 Â Â $ 251 Â $ 150 Â Â $ 688 Â $ 420 Â Texas Supplemental Payment Programs: Certain of our acute care hospitals located in various counties of Texas participate in Medicaid supplemental payment Section 1115 Waiver indigent care programs. The 1115 Waiver has been approved by CMS through September 30, 2030. These hospitals also have affiliation agreements with third-party hospitals to provide free hospital and physician care to qualifying indigent residents of these counties. Our hospitals receive both supplemental payments from the Medicaid program and indigent care payments from third-party, affiliated hospitals. The supplemental payments are contingent on the county or hospital district making an Inter-Governmental Transfer (â€œIGTâ€) to the state Medicaid program while the indigent care payment is contingent on a transfer of funds from the applicable affiliated hospitals. However, the county or hospital district is prohibited from entering into an agreement to condition any IGT on the amount of any private hospitalâ€™s indigent care obligation. CHIRP (including QIF) On August 1, 2022, CMS approved the Comprehensive Hospital Increase Reimbursement Program ("CHIRP"), with a pool of $5.2 billion, for the rate period effective September 1, 2022 to August 31, 2023. On July 31, 2023, CMS approved the CHIRP program, with a pool of $6.5 billion, for the rate period of September 1, 2023 to August 31, 2024. On September 13, 2024, CMS approved the CHIRP program with a pool of $6.5 billion for the rate period September 1, 2024 to August 31, 2025 (with an amended CMS approval on October 1, 2024). 47 Â On January 26, 2024, the Texas Health and Human Services Commission ("THHSC") issued a final rule that will modify the CHIRP payments beginning with the State Fiscal Year (SFY) 2025 rate period to promote the advancement of the quality goals and strategies the program is designed to advance. The final modifications include: â€¢Creation of a new pay-for-performance incentive payment through a third component in CHIRP, the Alternate Participating Hospital Reimbursement for Improving Quality Award ("APHRIQA"). For state fiscal years beginning with SFY 2025, behavioral health hospitals and rural hospitals will not be included in the pay-for-performance program. â€¢The funds for payment of the APHRIQA component will be transitioned from the existing uniform rate increase components of the Uniform Hospital Rate Increase Percentage and the Average Commercial Incentive Award and will be paid using a scorecard that directs managed care organizations to pay providers for performance achievements on quality outcome measures. Payments will be distributed under APHRIQA on a semi-annual basis that aligns with the measurement period determined for quality metrics reporting. CHIRP payment levels could be reduced materially if our hospitals are not able meet the required APHRIQA pay-for-performance metrics. Certain of our acute care hospitals located in Texas recorded an aggregate of $33 million in Quality Incentive Fund (â€œQIFâ€) revenues during 2023. Included in our results of operations in connection with this program was approximately $36 million during the three and nine-month periods ended September 30, 2024 and $25 million during the three-month and nine-month periods ended September 30, 2023. This revenue was earned pursuant to contract terms with various Medicaid managed care plans which requires the annual payout of QIF funds when a managed care service delivery areaâ€™s actual claims-based CHIRP payments are less than targeted CHIRP payments for a specific rate year. We estimate that our hospitals will be entitled to approximately $55 million of aggregate QIF revenue during the year ended December 31, 2024. UC Included in these provider tax programs are reimbursements received in connection with the Texas Uncompensated Care program ("UC"). The size and distribution of the UC pool are determined based on charity care costs reported to THHSC in accordance with Medicare cost report Worksheet S-10 principles. HARP On September 24, 2021, THHSC finalized New Fee-for-Service Supplemental Payment Program:

Hospital Augmented Reimbursement Program (â€œHARPâ€) to be effective October 1, 2021. The HARP program continues the financial transition for providers who have historically participated in the Delivery System Reform Incentive Payment program described below. The program, which was approved by CMS on August 15, 2023, will provide additional funding to hospitals to help offset the cost hospitals incur while providing Medicaid services. HARP is technically a Medicaid Upper Payment Limit as payment under this program is based on a reasonable estimate of the amount that would be paid for the services under Medicare payment principles but is referred to as HARP by THHSC. In connection with this program, included in our results of operations was approximately $7 million and $13 million during the three-month periods ended September 30, 2024 and 2023, respectively, and approximately $21 million and $13 million during the nine-month periods ended September 30, 2024 and 2023, respectively. We expect our net reimbursements pursuant to HARP to approximate $42 million during the year ended December 31, 2024. Nevada State Directed Payment Program ("SDP"): As previously reported, in February, 2023, the Nevada Division of Health Care Financing and Policy (â€œDHCFPâ€) outlined a new provider fee on private hospitals located in Nevada that would effectively capture new Medicaid federal share for certain categories of services eligible for the new payment program. In late December, 2023, CMS approved the Medicaid managed care component of the Nevada SDP program, with an effective date of January 1, 2024. Payments made pursuant to this component of the Nevada SDP program, which requires annual approval by CMS, are subject to reconciliation by DHCFP based on actual Medicaid managed care utilization during 2024. There can be no assurance that the Medicaid managed care component of the Nevada SDP will continue for any period after December 31, 2024, or that it will not be modified. There was no impact from this program included in our results of operations during the three and nine-month periods ended September 30, 2023. Our results of operations for the three and nine-month periods ended September 30, 2024 included approximately $42 million and $121 million, respectively, recorded in connection with this program. Including the impact of the Medicaid fee for service upper payment limit component of the Nevada SDP program (estimated net reimbursements of $23 million attributable to our Nevada facilities during the year ended December 31, 2024), which was approved by CMS in November and December of 2023, after consideration of an updated payment model published by the DHCFP for rate year 48 Â 2025 (July 1, 2024 to June 30, 2025), we estimate that our aggregate net reimbursements pursuant to both components of the Nevada SDP program (net of related provider taxes) will approximate $163 million during the year ended December 31, 2024. In September, 2024, DHCFP published a technical bulletin (24-001) which announced the provider assessment rates for SFY 2025. Pending CMS approval, the increased assessment rate will be used to fund an increase to the SDP pool size. If approved, the funding increase to the existing Nevada program, with estimated annual net incremental benefit of approximately $56 million, would be effective July 1, 2024. Various Other State Programs: We receive substantial reimbursement from multiple states in connection with various supplemental Medicaid payment programs. The states include, but are not limited to, the state programs listed below from which we receive significant reimbursements. Kentucky Hospital Rate Increase Program (â€œHRIPâ€) In early 2021, CMS approved the Kentucky Medicaid Managed Care Hospital Rate Increase Program. In connection with this program, included in our results of operations was approximately $19 million and $15 million during the three-month periods ended September 30, 2024 and 2023, respectively, and approximately $61 million and $57 million during the nine-month periods ended September 30, 2024 and 2023, respectively. In January, 2024, CMS approved the program for the period of January 1, 2024 through December 31, 2024 at rates comparable to the prior year. We estimate that our net reimbursements pursuant to HRIP will approximate $80 million during the year ended December 31, 2024. California Supplemental Payments In California, the state continues to operate Medicaid supplemental payment programs consisting of three components: Fee For Service Payment, Managed Care-Pass-Through Payment and Managed Care-Directed Payment. The non-federal share for these programs are financed by a statewide provider tax. The Directed Payment method will be based on actual concurrent hospital Medicaid managed care in-network patient volume whereas the other programs are based on prior year Medicaid utilization. The CMS program approval status is outlined in the table below. California Hospital Fee Program CMS Approval Status: Hospital Fee Program Component CMS Methodology Approval CMS Rate Setting Approval Status Status Fee For Service Payment Approved through December 31, 2024 Approved through December 31, 2024; Paid through March 31, 2024Â Managed Care-Pass-Through Payment Approved through December 31, 2024 Approved through December 31, 2022 and paid through December 31, 2023Â Managed Care-Directed Payment Approved through December 31, 2024 Approved through December 31, 2022 and paid through December 31, 2023Â In connection with this program, included in our results of operations was approximately $8 million and $10 million during the three-month period ended September 30, 2024 and 2023, respectively, and approximately $34 million and $33 million during the nine-month periods ended September 30, 2024 and 2023, respectively. We estimate that our net reimbursements pursuant to this program will approximate $47 million during the year ended December 31, 2024. On April 25, 2024, the Office of Health Care Affordability board approved a five-year statewide health care spending growth target for 2025 through 2029 as follows 3.5%, 3.5%, 3.2%, 3.2% and 3.0%. The FY 2025 target is non-enforceable. We are unable to predict the financial impact from this spending target on our hospitals operating in California. Mississippi Hospital Access Program In September, 2023, subject to CMS approval, Mississippi announced a $689 million, two-part Medicaid payment proposal, effective retroactively to July 1, 2023, that would be funded by annual hospital assessments to the state's Medicaid program. These hospital assessments are calculated using a formula provided under state law. The first part of the proposal, known as the Mississippi Hospital Access Program (â€œMHAPâ€), would provide direct payments for hospitals that serve patients in the state's Medicaid managed care delivery system. Hospitals would be reimbursed near the average commercial rate, which is the upper limit ("UPL") for Medicaid managed care reimbursements. The second part of the proposal would supplement Medicaid payment rates for hospitals providing 49 Â inpatient and outpatient services up to Medicaid's regulated UPL. In December, 2023, CMS approved the MHAP program component. The UPL component was approved in April, 2024. In connection with this program, included in our results of operations was approximately $11 million and $3 million recorded during the three-month periods ended September 30, 2024 and 2023, respectively, and approximately $38 million and $13 million recorded during the nine-month periods ended September 30, 2024 and 2023, respectively. We estimate that our net reimbursements pursuant to these supplemental payment programs will approximate $49 million during the year ended December 31, 2024. Florida Medicaid Managed Care Directed Payment Program (â€œDPPâ€) The Florida DPP provides for an additional payment for Medicaid managed care contracted services. Although the impact of this program did not have a significant impact on our results of operations during the three and nine-month periods ended September 30, 2024 or 2023, we estimate that our net reimbursements pursuant to this DPP will approximate $43 million during the year ended December 31, 2024 (substantially all of which we anticipate recording during the fourth quarter of 2024). For the year ended December 31, 2023, our results of operations included approximately $43 million recorded in connection with this program (substantially all of which was recorded during the fourth quarter of 2023). Illinois Medicaid Supplemental Payment Programs The Illinois Medicaid Supplemental Payment Programs are comprised of three components: (1) Medicaid managed care directed payment program; (2) Medicaid managed care pass-through program, and; (3) Medicaid fee for service supplemental payment program. These programs require various related legislative and regulatory approvals each year. In connection with this program, included in our results of operations was approximately $9 million and $8 million recorded during the three-month periods ended September 30, 2024 and 2023, respectively, and approximately $28 million and $29 million recorded during the nine-month periods ended September 30, 2024 and 2023, respectively. We estimate that our net reimbursements pursuant to these supplemental payment programs will approximate $38 million during the year ended December 31, 2024. Indiana Medicaid Managed Care DPP The Indiana DPP provides for an additional payment for Medicaid managed care contracted services. In connection with this program, included in our results of operations was approximately $8 million recorded during each of the three-month periods ended September 30, 2024 and 2023, and approximately $24 million recorded during each of the nine-month periods ended September 30, 2024 and 2023. We estimate that our net reimbursements pursuant to this program will approximate $32 million during the year ended December 31, 2024. Oklahoma (Transition to Managed Care and Implementation of a Medicaid Managed Care DPP) The current Oklahoma Medicaid supplemental payment program in effect, prior to the planned implementation of the new DPP in 2024, is the Supplemental Hospital Offset Payment Program (â€œSHOPPâ€). The SHOPP component will remain in place for certain categories of Medicaid patients that will continue to be enrolled in the traditional Medicaid Fee for Service program. In May, 2022, Oklahoma enacted legislation that directs the Oklahoma Health Care Authority ("OHCA") to: (i) transition its Medicaid program from a fee for service payment model to a managed care payment model by no later than October 1, 2023, and: (ii) concurrently implement a Medicaid managed care DPP using a managed care gap of 90% of average commercial rates. In December, 2022, the OHCA delayed the implementation date of the Medicaid managed care change and related DPP until April 1, 2024. In September, 2023, CMS approved the DPP program effective as of April 1, 2024. In connection with this program, included in our results of operations was approximately $6 million and $5 million recorded during the three-month periods ended September 30, 2024 and 2023, respectively, and approximately $14 million and $10 million recorded during the nine-month periods ended September 30, 2024 and 2023, respectively. We estimate that our net reimbursements pursuant to these two supplemental payment programs (i.e. SHOPP and DPP) will approximate $20 million during the year ended December 31, 2024. South Carolina Health Access, Workforce and Quality (â€œHAWQâ€) Program In September 2023, CMS approved the South Carolina HAWQ Program retroactive to July 1, 2023 and subsequently approved by CMS in July, 2024 for the period of July 1, 2024 to June 30, 2025. This program is Medicaid managed care directed payment program that provides for a rate enhancement to Medicaid managed care encounters. In connection with this program, included in our results of operations was approximately $9 million and $6 million recorded during the three-month periods ended September 30, 2024 and 2023, respectively, and approximately $19 million and $6 million recorded during the nine-month periods ended September 30, 2024 and 2023, respectively. We estimate that our net reimbursements pursuant to these supplemental payment programs will approximate $28 million during the year ended December 31, 2024. Michigan Directed Payment Program (â€œDPPâ€) In March 2024, CMS approved the Michigan Medicaid DPP retroactive to October 1, 2023 based on average commercial rates. The Michigan DPP provides for an additional payment for Medicaid managed care contracted services. In connection with this program, 50 Â included in our results of operations was approximately $9 million and $4 million recorded during the three-month periods ended September 30, 2024 and 2023, respectively, and approximately $29 million and $14 million recorded during the nine-month periods ended September 30, 2024 and 2023, respectively. We estimate that our net reimbursements pursuant to this program will approximate $36 million during the year ended December 31, 2024. Idaho Upper Payment Limit (â€œUPLâ€) In April 2024, the Idaho Department of Health and Welfare (â€œIDHWâ€) released its updated Medicaid UPL calculation for SFY 2024 (July 1, 2023 to June 30, 2024) and revised its SFY 2023 (July 1, 2022 to June 30, 2023) UPL calculation. In connection with this program, included in our results of operations was approximately $5 million and $4 million recorded during the three-month periods ended September 30, 2024 and 2023, respectively, and approximately $27 million and $19 million recorded during the nine-month periods ended September 30, 2024 and 2023, respectively. As a result of the state agency UPL recalculation, we estimate that our net reimbursements pursuant to this program will approximate $31 million during the year ended December 31, 2024. Subject to CMS approval, the IDHW plans to continue this UPL program through SFY 2025 (July 1, 2024 to June 30, 2025) at payment levels comparable to SFY 2024. In SFY 2026, the IDHW intends to replace the UPL program with a Medicaid managed care state directed payment program. We are unable to predict whether payments levels under the planned new state directed payment program will be comparable to the SFY 2024 UPL payment levels. Tennessee Directed Payment Program (â€œDPPâ€) On April 29, 2024 the Tennessee legislature transmitted a Bill (SB1740), that was enacted into law in May, 2024, which imposes an annual coverage assessment on covered hospitals for fiscal year 2024-2025. The total assessment on all covered hospitals in the aggregate will be equal to 6% of the federally recognized annual coverage assessment base. The assessment proceeds will be used to fund an increase to the stateâ€™s SFY 2025 (July 1, 2024 to June 30, 2025) DPP payment pool to be based on average commercial rates. The state agency (TennCare) submitted the required preprint to CMS in May, 2024. If approved by CMS, the DPP payment increase will be retroactive to July 1, 2024. Although we are unable to predict whether the new DPP program will be approved by CMS, or the timing of such approval should it occur, TennCare's financial models indicate that our annual DPP reimbursements could range from $40 million to $56 million. Washington Safety Net Assessment Program On April 2, 2024, CMS approved an expanded state directed payment program in Washington whereby payments will now be based on the average commercial rates. The program was approved retroactively for the period January 1, 2024 to December 31, 2024. In connection with this program, included in our results of operations was approximately $12 million and $1 million recorded during the three-month periods ended September 30, 2024 and 2023, respectively, and approximately $32 million and $2 million recorded during the nine-month periods ended September 30, 2024 and 2023, respectively. We estimate that our net incremental benefit pursuant to this expanded program will approximate $44 million during the year ended December 31, 2024. Washington, D.C. State Directed Payment program (â€œSDPâ€) In July, 2024, the Budget Support Act (B24-0784) was approved by the mayor of Washington, D.C. This legislation includes a new Medicaid managed care directed payment program that, if ultimately approved, could become effective for the period of October 1, 2024 through September 30, 2025, with potential subsequent annual programs. Finalization of this program remains contingent upon U.S. Congressional and CMS approval. The Washington, D.C., Medicaid agency submitted the SDP preprint to CMS in July, 2024 for review and approval. Although we cannot predict if this new SDP program will be ultimately approved, or the timing of such approval should it occur, if approved in its current form, we estimate that our aggregate net benefit from this program for the period of October 1, 2024 through September 30, 2025, related to our two existing hospitals in the market, will approximate $85 million. Estimated amounts related to this program are subject to change for various reasons including modifications based upon CMS' review of the preprint payment methodology terms, as well as actual Medicaid managed care utilization for hospitals that operate in the District of Columbia, including ours. There can be no assurance that this program will continue for any period after September 30, 2025, or that it will not be modified. Texas DSH and Nevada SPA Programs: Texas DSH Upon meeting certain conditions and serving a disproportionately high share of Texasâ€™ low income patients, our qualifying facilities located in Texas receive additional reimbursement from the stateâ€™s DSH fund. The Texas DSH program was renewed for the stateâ€™s 2024 DSH fiscal year (covering the period of October 1, 2023 through September 30, 2024). In connection with this program, included in our results of operations was approximately $14 million and $13 million recorded during the three-month periods ended September 30, 2024 and 2023, respectively, and approximately $28 million and $38 million recorded 51 Â during the nine-month periods ended September 30, 2024 and 2023, respectively. We estimate that our aggregate net reimbursements earned pursuant to the Texas DSH program will approximate $36 million during 2024. The Legislation and subsequent federal legislation provides for a significant reduction in Medicaid disproportionate share payments beginning in federal fiscal year 2024 (see above in Sources of Revenues and Health Care Reform-Medicaid for additional disclosure related to the delay of these DSH reductions). HHS is to determine the amount of Medicaid DSH payment cuts imposed on each state based on a defined methodology. As Medicaid DSH payments to states will be cut, consequently, payments to Medicaid-participating providers, including our hospitals in Texas, will be reduced in the coming years. Based on the CMS final rule published in September, 2019, beginning in fiscal year 2024 (as amended by the CARES Act and the CAA), annual Medicaid DSH payments in Texas could be reduced by approximately 41% from current DSH payment levels. A series of federal continuing resolutions were passed by the federal government which provided for ongoing federal funding. In connection with certain previous DSH and UC adverse federal court decisions, including the Childrenâ€™s Hospital Association of Texas v. Azar, we continue to maintain reserves in the financial statements for cumulative Medicaid DSH and UC reimbursements related to our behavioral health hospitals located in Texas that amounted to $29 million as of September 30, 2024 and $31 million as of December 31, 2023. Nevada State Plan Amendment ("SPA") CMS initially approved an SPA in Nevada in August, 2014 and this SPA has been approved for additional state fiscal years, including the 2024 fiscal year covering the period of July 1, 2023 through June 30, 2024. CMS approval for the 2025 fiscal year, which is still pending, is expected to occur. In connection with this program, included in our results of operations was approximately $4 million and $5 million recorded during the three-month periods ended September 30, 2024 and 2023, respectively, and approximately $13 million and $22 million recorded during the nine-month periods ended September 30, 2024 and 2023, respectively. We estimate that our net reimbursements pursuant to this program will approximate $17 million during 2024. Risk Factors Related To State Supplemental Medicaid Payments: As outlined above, we receive substantial reimbursement from multiple states in connection with various supplemental Medicaid payment programs. Failure to renew these programs beyond their scheduled termination dates, failure of the public hospitals to provide the necessary IGTs for the statesâ€™ share of the DSH programs, failure of our hospitals that currently receive supplemental Medicaid revenues to qualify for future funds under these programs, or reductions in reimbursements, could cause our estimates to differ by material amounts which could have a material adverse effect on our future results of operations. In April, 2016, CMS published its final Medicaid Managed Care Rule which explicitly permits but phases out the use of pass-through payments (including supplemental payments) by Medicaid Managed Care Organizations (â€œMCOâ€) to hospitals over ten years but allows for a transition of the pass-through payments into value-based payment structures, delivery system reform initiatives or payments tied to services under a MCO contract. Since we are unable to determine the financial impact of this aspect of the final rule, we can provide no assurance that the final rule will not have a material adverse effect on our future results of operations. In November, 2020, CMS issued a final rule permitting pass-through supplemental provider payments during a time-limited

period when states transition populations or services from fee-for-service Medicaid to managed care. We receive Medicaid SDP payments from MCOs authorized by CMS under 42 CFR Â§ 438.6(c). Consistent with capitated rates paid by Medicaid state agencies to MCOâ€™s for managing Medicaid beneficiary lives under a risk-based arrangement, SDP program related capitated rates must also be developed by the state in accordance with actuarial soundness standards noted at 42 CFR Â§ 438.4 and non-compliance could result in a reduction to SDP payment levels. We incur Provider Taxes imposed by states in the form of a licensing fee, assessment or other mandatory payment which are related to: (i) healthcare items or services; (ii) the provision of, or the authority to provide, the health care items or services, or; (iii) the payment for the health care items or services that are used by respective states to finance the non-federal share of SDPâ€™s (or other Medicaid supplemental payment programs). Such Provider Taxes are subject to various federal regulations that limit the scope and amount of the taxes that can be levied by states in order to secure federal matching funds as part of their respective state Medicaid supplemental payment programs. States are subject to CMS both concurrent and retrospective review for their compliance with the applicable Provider Tax regulations and related federal statute. If CMS determines Provider Taxes used by a state Medicaid program to finance the non-federal share of a SDP (or other Medicaid supplemental payment programs) are not in compliance with the applicable Provider Tax regulations and related federal statute, Company SDP payments (and other Medicaid supplemental payments) could be subject to recoupment by the respective state agency when non-compliance is determined by CMS to exist. We believe that the SDP (and other state supplemental payment) programs are designed by each state to be in full compliance with the applicable federal regulations and federal statutes. However, we are unable to provide assurance CMS will determine on a retroactive basis that a stateâ€™s SDP (or other Medicaid supplemental payment program) design and Medicaid financing structures is in full compliance with the applicable federal regulations and federal statute(s). 52 Â On April 22, 2024, CMS issued Medicaid and Childrenâ€™s Health Insurance Program ("CHIP") Managed Care Access, Finance, and Quality Final Rule (â€œManaged Care Ruleâ€). CMS intends for the Managed Care Rule to: â€¢Strengthen standard for timely access to care and statesâ€™ monitoring and enforcement efforts; â€¢Enhance quality and fiscal and program integrity standards for state directed payments (â€œSDPsâ€); â€¢Specify the scope of in lieu of services and settings (â€œILOSsâ€) to better address health-related social needs (HRSNs); â€¢Further specify medical loss ratio (â€œMLRâ€) requirements, and; â€¢Establish a quality rating system (â€œQRSâ€) for Medicaid and CHIP managed care plans. â€¢The SDP provisions included in the Managed Care Rule include but are not limited to: â€¢Requires that provider payment levels for state directed payments for inpatient and outpatient hospital services, nursing facility services, and the professional services at an academic medical center not exceed the average commercial rate. â€¢Prohibits the use of post-payment reconciliation processes for state directed payments that are based on fee schedules. â€¢Makes explicit in regulation the existing requirement that state directed payments must comply with all federal laws concerning funding sources of the non-federal share. â€¢Requires that states ensure each provider receiving a state directed payment attest that it does not participate in any arrangement that holds taxpayers harmless for the cost of a tax. CMS concurrently released an informational bulletin regarding CMSâ€™ exercise of enforcement discretion until calendar year 2028 for existing health-care related tax programs with certain hold-harmless arrangements involving the redistribution of Medicaid payments. As disclosed herein, we receive a significant amount of Medicaid and Medicaid managed care revenue from both base payments and supplemental payments. Although we are unable to estimate the impact of the Managed Care Rule on our future results of operations, if implemented as proposed, Managed Care Rule related changes could have a material adverse impact on our future results of operations. Future changes to the terms and conditions of the various programs outlined above could materially reduce our net benefit derived from the programs which could have a material adverse impact on our future results of operations. In addition, Provider Taxes are governed by both federal and state laws and are subject to future legislative changes that, if reduced from current rates in several states, could have a material adverse impact on our future results of operations. A 6.2% increase to the Medicaid Federal Matching Assistance Percentage (â€œFMAPâ€) was included in the Families First Coronavirus Response Act. The CAA of 2023 provided for the transitional reduction of the 6.2% enhanced FMAP during 2023 to 5.0% during the second quarter, 2.5% during the third quarter and 1.5% during the fourth quarter of 2023. The impact of the enhanced FMAP Medicaid supplemental and DSH payments are reflected in our financial results for the three and nine-month periods ended September 30, 2024 and 2023. HITECH Act: In July 2010, HHS published final regulations implementing the health information technology provisions of the American Recovery and Reinvestment Act (referred to as the â€œHITECH Actâ€). The final regulation defines the â€œmeaningful useâ€ of Electronic Health Records (â€œEHRâ€) and establishes the requirements for the Medicare and Medicaid EHR payment incentive programs. The final rule established an initial set of standards and certification criteria. The implementation period for these Medicare and Medicaid incentive payments started in federal fiscal year 2011 and can end as late as 2016 for Medicare and 2021 for the state Medicaid programs. State Medicaid program participation in this federally funded incentive program is voluntary but all of the states in which our eligible hospitals operate have chosen to participate. Our acute care hospitals qualified for these EHR incentive payments upon implementation of the EHR application assuming they meet the â€œmeaningful useâ€ criteria. The governmentâ€™s ultimate goal is to promote more effective (quality) and efficient healthcare delivery through the use of technology to reduce the total cost of healthcare for all Americans and utilizing the cost savings to expand access to the healthcare system. All of our acute care hospitals have met the applicable meaningful use criteria. However, under the HITECH Act, hospitals must continue to meet the applicable meaningful use criteria in each fiscal year or they will be subject to a market basket update reduction in a subsequent fiscal year. Failure of our acute care hospitals to continue to meet the applicable meaningful use criteria would have an adverse effect on our future net revenues and results of operations. In the 2019 IPPS final rule, CMS overhauled the Medicare and Medicaid EHR Incentive Program to focus on interoperability, improve flexibility, relieve burden and place emphasis on measures that require the electronic exchange of health information between providers and patients. We can provide no assurance that the changes will not have a material adverse effect on our future results of operations. Managed Care: A significant portion of our net patient revenues are generated from managed care companies, which include health maintenance organizations, preferred provider organizations and managed Medicare (referred to as Medicare Part C or Medicare 53 Â Advantage) and Medicaid programs. In general, we expect the percentage of our business from managed care programs to continue to grow. The consequent growth in managed care networks and the resulting impact of these networks on the operating results of our facilities vary among the markets in which we operate. Typically, we receive lower payments per patient from managed care payers than we do from traditional indemnity insurers, however, during the past few years we have secured price increases from many of our commercial payers including managed care companies. Commercial Insurance: Our hospitals also provide services to individuals covered by private health care insurance. Private insurance carriers typically make direct payments to hospitals or, in some cases, reimburse their policy holders, based upon the particular hospitalâ€™s established charges and the particular coverage provided in the insurance policy. Private insurance reimbursement varies among payers and states and is generally based on contracts negotiated between the hospital and the payer. Commercial insurers are continuing efforts to limit the payments for hospital services by adopting discounted payment mechanisms, including predetermined payment or DRG-based payment systems, for more inpatient and outpatient services. To the extent that such efforts are successful and reduce the insurersâ€™ reimbursement to hospitals and the costs of providing services to their beneficiaries, such reduced levels of reimbursement may have a negative impact on the operating results of our hospitals. Surprise Billing Interim Final Rule: On September 30, 2021, the Department of Labor, and the Department of the Treasury, along with the Office of Personnel Management (â€œOPMâ€), released an interim final rule with comment period, entitled â€œRequirements Related to Surprise Billing; Part II.â€ This rule is related to Title I (the â€œNo Surprises Actâ€) of Division BB of the Consolidated Appropriations Act, 2021, and establishes new protections from surprise billing and excessive cost sharing for consumers receiving health care items/services. It implements additional protections against surprise medical bills under the No Surprises Act, including provisions related to the independent dispute resolution ("IDR") process, good faith estimates for uninsured (or self-pay) individuals, the patient-provider dispute resolution process, and expanded rights to external review. On February 28, 2022, a district judge in the Eastern District of Texas invalidated portions of the rule governing aspects of the IDR process. In light of this decision, the government issued a final rule on August 19, 2022 eliminating the rebuttable presumption in favor of the qualifying payment amount (â€œQPAâ€) by the IDR entity and providing additional factors the IDR entity should consider when choosing between two competing offers. CMS regulations and guidance implementing the IDR process has been subject to a significant amount of provider-initiated litigation. As a result, portions of those regulations and guidance materials have been vacated by a federal district court, causing CMS to, on several occasions, pause and resume IDR process operations, causing significant delay in the processing of claims. On October 27, 2023, HHS, the Department of Labor, the Department of the Treasury, and OPM issued a proposed rule intended to improve the functioning of the federal IDR process. Additionally, arguments made by the plaintiffs in such litigation have included allegations that CMSâ€™s regulations and guidance materials are favorable to payers. We cannot predict the impact of the proposed rule on our operations at this time. Other Sources: Our hospitals provide services to individuals that do not have any form of health care coverage. Such patients are evaluated, at the time of service or shortly thereafter, for their ability to pay based upon federal and state poverty guidelines, qualifications for Medicaid or other state assistance programs, as well as our local hospitalsâ€™ indigent and charity care policy. Patients without health care coverage who do not qualify for Medicaid or indigent care write-offs are offered substantial discounts in an effort to settle their outstanding account balances. Health Care Reform: Listed below are the Medicare, Medicaid and other health care industry changes which have been, or are scheduled to be, implemented as a result of the Legislation. Medicaid Federal DSH Allotment: Although the implementation has been delayed several times, the Legislation (as amended by subsequent federal legislation) requires annual aggregate reductions in federal Medicaid DSH allotment from FFY 2025 through FFY 2027. Commencing in federal fiscal year 2025, and continuing through 2027, DSH payments are scheduled to be reduced by $8 billion annually. H.R. 2872, enacted into law on January 17, 2024 delayed the aforementioned Medicaid DSH cuts through March 8, 2024.â€¯ The Consolidated Appropriations Act, 2024 was enacted into law on March 9, 2024 and delayed the $8 billion DSH cuts for FFY 2024. The $8 billion DSH reduction is now scheduled to be implemented January 1, 2025 through September 30, 2025, in effect offsetting the FFY 2025 $8 billion reduction over nine months rather than twelve months if not delayed further by Congressional action. Value-Based Purchasing: There is a trend in the healthcare industry toward value-based purchasing of healthcare services. These value-based purchasing programs include both public reporting of quality data and preventable adverse events tied to the quality and efficiency of care provided by facilities. Governmental programs including Medicare and Medicaid currently require hospitals to report certain quality data to receive full reimbursement updates. In addition, Medicare does not reimburse for care related to certain preventable adverse events. Many large commercial payers currently require hospitals to report quality data, and several commercial payers do not reimburse hospitals for certain preventable adverse events. The Legislation required HHS to implement a value-based purchasing program for inpatient hospital services which became effective on October 1, 2012. The Legislation requires HHS to reduce inpatient hospital payments for all discharges by 2% in FFY 2017 and 54 Â subsequent years. HHS will pool the amount collected from these reductions to fund payments to reward hospitals that meet or exceed certain quality performance standards established by HHS. HHS will determine the amount each hospital that meets or exceeds the quality performance standards will receive from the pool of dollars created by these payment reductions. As part of the FFY 2022 IPPS final rule and FFY 2023 final rule, as discussed above, and as a result of the COVID-19 pandemic, CMS has implemented a budget neutral payment policy to fully offset the 2% VBP withhold during each of FFY 2022 and FFY 2023. In FFY 2024, as part of the FFY 2024 IPPS final rule, CMS removed the budget neutral policy that was in place in FFY 2022 and FFY 2023. Hospital Acquired Conditions: The Legislation prohibits the use of federal funds under the Medicaid program to reimburse providers for medical assistance provided to treat hospital acquired conditions (â€œHACâ€). Beginning in FFY 2015, hospitals that fall into the top 25% of national risk-adjusted HAC rates for all hospitals in the previous year will receive a 1% reduction in their total Medicare payments. As part of the FFY 2023 final rule discussed above, and as a result of the on-going COVID-19 pandemic, CMS suppressed all nine measures in the HAC Reduction Program for the FY 2023 program year and eliminate the HAC reduction programâ€™s one percent payment penalty. In FFY 2024, as part of the FFY 2024 IPPS final rule, CMS eliminated the suppression of the applicable HAC measures and as a result reinstated the HAC reduction program. Readmission Reduction Program: In the Legislation, Congress also mandated implementation of the hospital readmission reduction program (â€œHRRPâ€). Hospitals with excessive readmissions for conditions designated by HHS will receive reduced payments for all inpatient discharges, not just discharges relating to the conditions subject to the excessive readmission standard. The HRRP currently assesses penalties on hospitals having excess readmission rates for heart failure, myocardial infarction, pneumonia, acute exacerbation of chronic obstructive pulmonary disease ("COPD") and elective total hip arthroplasty ("THA") and/or total knee arthroplasty ("TKA"), excluding planned readmissions, when compared to expected rates. In the fiscal year 2015 IPPS final rule, CMS added readmissions for coronary artery bypass graft ("CABG") surgical procedures beginning in fiscal year 2017. To account for excess readmissions, an applicable hospital's base operating DRG payment amount is adjusted for each discharge occurring during the fiscal year. Readmissions payment adjustment factors can be no more than a 3% reduction. As part of the FFY 2023 IPPS final rule discussed above, CMS modified all of the condition-specific readmission measures to include an adjustment for patient history of COVID-19 for FFY 2024. Accountable Care Organizations: The Legislation requires HHS to establish a Medicare Shared Savings Program that promotes accountability and coordination of care through the creation of accountable care organizations (â€œACOsâ€). The ACO program allows providers (including hospitals), physicians and other designated professionals and suppliers to voluntarily work together to invest in infrastructure and redesign delivery processes to achieve high quality and efficient delivery of services. The program is intended to produce savings as a result of improved quality and operational efficiency. ACOs that achieve quality performance standards established by HHS will be eligible to share in a portion of the amounts saved by the Medicare program. CMS is also developing and implementing more advanced ACO payment models that require ACOs to assume greater risk for attributed beneficiaries. On December 21, 2018, CMS published a final rule that, in general, requires ACO participants to take on additional risk associated with participation in the program. On April 30, 2020, CMS issued an interim final rule with comment in response to the COVID-19 national emergency permitting ACOs with current agreement periods expiring on December 31, 2020 the option to extend their existing agreement period by one year, and permitting certain ACOs to retain their participation level through 2021. It remains unclear to what extent providers will pursue federal ACO status or whether the required investment would be warranted by increased payment. Infectious Disease Outbreaks, Pandemics, or Other Public Health Emergencies or Crisis Our business and financial results may be harmed by an international, national or localized outbreak of a highly contagious or epidemic disease, including but not limited to, COVID-19 or similar corona viruses, Ebola or Zika, may put stress on the capacity of all or a part of our health care facilities, could result in an abnormally high demand for health care services, require that resources be diverted from one part of operations to another part, or disrupt the supply chain for equipment and supplies necessary for operations. In addition, unaffected individuals may decide to defer elective procedures or otherwise avoid medical treatment, resulting in reduced patient volumes and operating revenues. In addition to statutory and regulatory changes to the Medicare program and each of the state Medicaid programs, our operations and reimbursement may be affected by administrative rulings, new or novel interpretations and determinations of existing laws and regulations, post-payment audits, requirements for utilization review and new governmental funding restrictions, all of which may materially increase or decrease program payments as well as affect the cost of providing services and the timing of payments to our facilities. The final determination of amounts we receive under the Medicare and Medicaid programs often takes many years, because of audits by the program representatives, providersâ€™ rights of appeal and the application of numerous technical reimbursement provisions. We believe that we have made adequate provisions for such potential adjustments. Nevertheless, until final adjustments are made, certain issues remain unresolved and previously determined allowances could become either inadequate or more than ultimately required. 55 Â Finally, we expect continued third-party efforts to aggressively manage reimbursement levels and cost controls. Reductions in reimbursement amounts received from third-party payers could have a material adverse effect on our financial position and our results. Other Operating Results Interest Expense: As reflected on the schedule below, interest expense was $45 million and $53 million during the three-month periods ended September 30, 2024 and 2023, respectively, and $146 million and $153 million during the nine-month periods ended September 30, 2024 and 2023, respectively (amounts in thousands): Â Â Â Three MonthsEndedSeptember 30,2024 Â Â Three MonthsEndedSeptember 30,2023 Â Â Nine MonthsEndedSeptember 30,2024 Â Â Nine MonthsEndedSeptember 30,2023 Â Revolving credit facility (a.) Â $ 2,729 Â Â $ 6,408 Â Â $ 15,299 Â Â $ 15,746 Â Tranche A term loan, extinguished (a.) Â Â 36,157 Â Â Â 40,410 Â Â Â 113,934 Â Â Â 115,156 Â Tranche A term loan, 2029 (a.) Â Â 1,055 Â Â Â - Â Â Â 1,055 Â Â Â - Â $800 million, 2.65% Senior Notes due 2030 (b.) Â Â 5,356 Â Â Â 5,356 Â Â Â 16,069 Â Â Â 16,069 Â $700 million, 1.65% Senior Notes due 2026 (c.) Â Â 2,932 Â Â Â 2,931 Â Â Â 8,794 Â Â Â 8,794 Â $500 million, 2.65% Senior Notes due 2032 (d.) Â Â 3,345 Â Â Â 3,345 Â Â Â 10,035 Â Â Â 10,035 Â $500 million, 4.625% Senior Notes due 2029 (e.) Â Â 322 Â Â Â - Â Â Â 322 Â Â Â - Â $500 million, 5.050% Senior Notes due 2034 (f.) Â Â 353 Â Â Â - Â Â Â 353 Â Â Â - Â Subtotal-revolving credit, term loan A and Senior Notes Â Â 52,249 Â Â Â 58,450 Â Â Â 165,861 Â Â Â 165,800 Â Amortization of financing fees Â Â 1,255 Â Â Â 1,260 Â Â Â 3,769 Â Â Â 3,777 Â Other combined interest expense Â Â 1,869 Â Â Â 253 Â Â Â 5,713 Â Â Â 1,066 Â Capitalized interest on major projects Â Â (10,345) Â Â (6,479)

Â Â (27,922) Â Â (17,100) Interest income Â Â (368) Â Â (106) Â Â (1,036) Â Â (458) Interest expense, net Â $ 44,660 Â Â $ 53,378 Â Â $ 146,385 Â Â $ 153,085 Â (a.)On September 26, 2024, we entered into the tenth amendment to our credit agreement dated November 15, 2010, as amended and restated at various times from March, 2011 to June, 2022 (the "Credit Agreement"). The tenth amendment provides for, among other things, the following: (i) an extension of the maturity date to September 26, 2029; (ii) a $100 million increase in the revolving credit facility to $1.3 billion of aggregate borrowing capacity (which as of September 30, 2024, had $1.01 billion of aggregate available borrowing capacity, net of $288 million of borrowings outstanding and $3 million of letters of credit), and; (iii) a $1.0 billion reduction in the outstanding borrowings pursuant to the tranche A term loan facility, to $1.2 billion from $2.2 billion previously, utilizing the proceeds generated from the September, 2024, issuance of the below-mentioned senior notes due in 2029 and 2034. (b.)In September, 2020, we completed the offering of $800 million aggregate principal amount of 2.65% Senior Notes due in 2030. (c.)In August, 2021, we completed the offering of $700 million aggregate principal amount of 1.65% Senior Notes due in 2026. (d.)In August, 2021, we completed the offering of $500 million aggregate principal amount of 2.65% Senior Notes due in 2032. (e.)On September 26, 2024, we completed the offering of $500 million aggregate principal amount of 4.625% Senior Notes due in 2029. (f.)On September 26, 2024, we completed the offering of $500 million aggregate principal amount of 5.050% Senior Notes due in 2034. Interest expense decreased by $9 million during the three-month period ended September 30, 2024, as compared to the three-month period ended September 30, 2023. The changes in the various components of interest expense were as follows: (i) a net $6 million decrease in aggregate interest expense on our revolving credit, term loan A and senior notes resulting from a decrease in our aggregate average cost of borrowings pursuant to these facilities (4.7% during the third quarter of 2024 as compared to 4.9% during the comparable quarter of 2023), as well as a decrease in the aggregate average outstanding borrowings pursuant to these facilities ($4.34 billion during the third quarter of 2024 as compared to $4.65 billion during the third quarter of 2023); (ii) a $4 million decrease resulting from an increase in capitalized interest on major projects, and; (iii) a net $1 million increase in other combined interest expense. The average effective interest rates, including amortization of deferred financing costs and original issue discount, on borrowings outstanding under our revolving credit, term loan A and senior notes, which amounted to approximately $4.34 billion and $4.65 billion during the third quarters of 2024 and 2023, respectively, were 4.8% and 5.0% during the three-month periods ended September 30, 2024 and 2023, respectively. 56 Â Interest expense decreased by $7 million during the nine-month period ended September 30, 2024, as compared to the nine-month period ended September 30, 2023. The various changes in the components of interest expense were: (i) the aggregate interest expense on our revolving credit, term loan A and senior notes was relatively unchanged due primarily to a slight increase in our aggregate average cost of borrowings pursuant to these facilities (4.83% during the first nine months of 2024 as compared to 4.73% during the comparable period of 2023), offset by a slight decrease in the aggregate average outstanding borrowings pursuant to these facilities ($4.50 billion during the first nine months of 2024 as compared to $4.61 billion during the first nine months of 2023); (ii) an $11 million decrease resulting from an increase in capitalized interest on major projects, partially offset by; (iii) a net $4 million net increase in other combined interest expenses. The average effective interest rates, including amortization of deferred financing costs and original issue discount, on borrowings outstanding under our revolving credit, term loan A and senior notes, which amounted to approximately $4.50 billion and $4.61 billion during the nine-month periods ended September 30, 2024 and 2023, respectively, were 4.96% and 4.85% during the nine-month periods ended September 30, 2024 and 2023, respectively. Costs Related to Early Extinguishment of Debt: In connection with the financing transactions completed in September, 2024, our results of operations for the three and nine-month periods ended September 30, 2024, include a pre-tax charge of approximately $6 million incurred for the costs related to the extinguishment of debt consisting of the following: (i) approximately $3 million incurred to write-off deferred charges (included in other (income) expenses, net, on the accompanying condensed consolidated statements of income), and; (ii) approximately $3 million resulting from certain financing fees incurred during the third quarter of 2024 (included in other operating expenses on the accompanying condensed consolidated statements of income). Provision for Income Taxes and Effective Tax Rates: The effective tax rates, as calculated by dividing the provision for income taxes by income before income taxes, were as follows for the three and nine-month periods ended September 30, 2024 and 2023 (dollar amounts in thousands): Â Â Three months ended Â Â Nine months ended Â Â Â September 30, Â Â September 30, Â Â September 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Provision for income taxes Â $ 75,623 Â Â $ 52,499 Â Â $ 233,563 Â Â $ 159,618 Â Income before income taxes Â Â 341,533 Â Â Â 220,507 Â Â Â 1,059,625 Â Â Â 659,303 Â Effective tax rate Â Â 22.1 % Â Â 23.8 % Â Â 22.0 % Â Â 24.2 % The provision for income taxes increased $23 million during the third quarter of 2024, as compared to the comparable quarter of 2023, due primarily to: (i) the increase in the provision for income taxes resulting from the $115 million increase in pre-tax income (consisting of $121 million increase in income before income taxes and an $6 million unfavorable change in the income/loss attributable to noncontrolling interests), partially offset by; (ii) a $4 million decrease in the provision for income taxes during the third quarter of 2024 from the net tax benefit recorded pursuant to ASU 2016-09, Compensation-Stock Compensation: Improvements to Employee Share-Based Payment Accounting ("ASU 2016-09"), net of the impact of executive compensation limitations pursuant to IRC section 162(m). The provision for income taxes increased $74 million during the first nine months of 2024, as compared to the comparable period of 2023, due primarily to: (i) the increase in the provision for income taxes resulting from the $382 million increase in pre-tax income (consisting of $400 million increase in income before income taxes and an $18 million unfavorable change in the income/loss attributable to noncontrolling interests), partially offset by; (ii) a $18 million decrease in the provision for income taxes during the first nine months of 2024, as compared to the comparable period of 2023, from the net tax benefit recorded pursuant to ASU 2016-09, net of the impact of executive compensation limitations pursuant to IRC section 162(m). Due to recent guidance and enacted laws surrounding the global 15% minimum tax rate that will be effective after 2024 from the Organization for Economic Co-operation and Development ("OECD") as well as jurisdictions that we operate in, we anticipate adverse effects to our provision for income taxes as well as cash taxes. We do not expect these adverse effects to be material and will continue to monitor changes in tax policies and laws issued by the OECD and jurisdictions that we operate in. 57 Â Liquidity Net cash provided by operating activities Net cash provided by operating activities was $1.409 billion during the nine-month period ended September 30, 2024 and $815 million during the first nine months of 2023. The net increase of $593 million was attributable to the following: â€¢a favorable change of $353 million resulting from an increase in net income plus/minus depreciation and amortization expense, stock-based compensation expense, gains on sales on sales of assets and businesses and costs related to the extinguishment of debt; â€¢a favorable change of $205 million in accounts receivable; â€¢a favorable change of $66 million in other working capital accounts; â€¢an unfavorable change of $55 million in other assets and deferred charges, and; â€¢$24 million of other combined net favorable changes. Days sales outstanding (â€œDSOâ€): Our DSO are calculated by dividing our net revenue by the number of days in the nine-month periods. The result is divided into the accounts receivable balance at September 30th of each year to obtain the DSO. Our DSO were 52 days and 58 days at September 30, 2024 and 2023, respectively. Net cash used in investing activities During the first nine months of 2024, we used $703 million of net cash in investing activities as follows: â€¢$698 million spent on capital expenditures including capital expenditures for equipment, renovations and new projects at various existing facilities; â€¢$36 million paid in connection with net cash outflows from forward exchange contracts that hedge our investment in the U.K. against movements in exchange rates, and; â€¢$30 million received from the sales of assets and businesses; During the first nine months of 2023, we used $524 million of net cash in investing activities as follows: â€¢$537 million spent on capital expenditures including capital expenditures for equipment, renovations and new projects at various existing facilities; â€¢$24 million received from the sales of assets and businesses; â€¢$8 million paid in connection with net cash outflows from forward exchange contracts that hedge our investment in the U.K. against movements in exchange rates, and; â€¢ $4 million spent on the acquisition of businesses and property. Net cash used in financing activities During the first nine months of 2024, we used $718 million of net cash in financing activities as follows: â€¢spent $2.472 billion on net repayments of debt as follows: (i) $2.259 billion related to our previous tranche A term loan facility which was extinguished in September, 2024, and replaced with a new $1.2 billion tranche A term loan facility; (ii) $207 million related to our revolving credit facility, and; (iii) $6 million related to other debt facilities; â€¢generated $2.210 billion of proceeds from additional borrowings as follows: (i) $1.200 billion related to our new tranche A term loan facility, as mentioned above; (ii) generated approximately $500 million of net proceeds (before expenses) related to the public offering, in September, 2024, of 4.625% senior secured notes due in 2029; (iii) generated approximately $498 million of net proceeds (before expenses) related to the public offering, in September, 2024, of 5.050% senior secured notes due in 2034, and; (iv) $12 million of proceeds related to other debt facilities; â€¢spent $421 million to repurchase shares of our Class B Common Stock in connection with: (i) open market purchases pursuant to our stock repurchase program ($349 million), and; (ii) income tax withholding obligations related to stock-based compensation programs ($72 million); â€¢spent $40 million to pay quarterly cash dividends of $.20 per share; â€¢generated $11 million from the issuance of shares of our Class B Common Stock pursuant to the terms of employee stock purchase plans; 58 Â â€¢spent $10 million to pay financing costs; â€¢received $9 million from the sale of ownership interests to minority members, and; â€¢spent $6 million to pay profit distributions related to noncontrolling interests in majority owned businesses. During the first nine months of 2023, we used $312 million of net cash in financing activities as follows: â€¢generated $165 million of additional borrowings related to our revolving credit facility; â€¢spent $385 million to repurchase shares of our Class B Common Stock in connection with: (i) open market purchases pursuant to our stock repurchase program ($367 million), and; (ii) income tax withholding obligations related to stock-based compensation programs ($18 million); â€¢spent $54 million on net repayments of debt as follows: (i) $49 million related to our tranche A term loan facility, and; (ii) $5 million related to other debt facilities; â€¢spent $42 million to pay quarterly cash dividends of $.20 per share; â€¢spent $5 million to pay profit distributions related to noncontrolling interests in majority owned businesses, and; â€¢generated $10 million from the issuance of shares of our Class B Common Stock pursuant to the terms of employee stock purchase plans. Expected capital expenditures during remainder of 2024 During the full year of 2024, we expect to spend approximately $850 million to $1 billion on capital expenditures which includes expenditures for capital equipment, construction of new facilities, and renovations and expansions at existing hospitals. During the first nine months of 2024 we spent approximately $698 million on capital expenditures and expect to spend approximately $152 million to $302 million during the remainder of 2024. We believe that our capital expenditure program is adequate to expand, improve and equip our existing hospitals. We expect to finance all capital expenditures and acquisitions with internally generated funds and/or additional funds, as discussed below. Capital Resources Credit Facilities and Outstanding Debt Securities In September, 2024, we completed the following financing transactions: â€¢The public offering of $500 million of aggregate principal amount of 4.625% senior secured notes due on October 15, 2029 ("2029 Notes"); â€¢The public offering of $500 million of aggregate principal amount of 5.050% senior secured notes due on October 15, 2034 ("2034 Notes"); â€¢Amended our credit agreement to: oExtend the maturity date to September, 2029 (from August, 2026 previously); oIncrease the revolving credit facility to $1.3 billion (from $1.2 billion previously), and; oreduce the outstanding borrowings pursuant to the tranche term loan A facility by approximately $1.0 billion, to $1.2 billion, utilizing the proceeds generated from the issuance of the above-mentioned 2029 Notes and 2034 Notes. On September 26, 2024, we entered into a tenth amendment ("Tenth Amendment") to our credit agreement ("Credit Agreement"), dated as of November 15, 2010, as amended and restated at various times from March, 2011 to June, 2022, among UHS, as borrower, the several banks and other financial institutions or entities from time to time parties thereto, as lenders, and JPMorgan Chase Bank, N.A., as administrative agent. The Tenth Amendment provided for: (i) an extension of the maturity date to September 26, 2029; (ii) a new revolving credit facility of up to $1.3 billion (which as of September 30, 2024, had $1.01 billion of aggregate available borrowing capacity, net of $288 million of outstanding borrowings and $3 million of letters of credit), and; (iii) a new replacement tranche A term loan facility ("Tranche A Term Loan") of up to $1.2 billion (which had $1.2 billion of outstanding borrowings as of September 30, 2024). Pursuant to the terms of the Tenth Amendment, the Tranche A Term Loan provides for installment payments of $7.5 million per quarter commencing on December 31, 2024 through September 30, 2026, and $15.0 million per quarter commencing on December 31, 2026 through June 30, 2029. The unpaid principal balance at June 30, 2029 (scheduled to be $975.0 million) is payable on the September 26, 2029 scheduled maturity date of the Credit Agreement. 59 Â Revolving credit and Tranche A Term Loan borrowings under the Credit Agreement bear interest at our election at either (1) the ABR rate which is defined as the rate per annum equal to the greatest of (a) the lenderâ€™s prime rate, (b) the weighted average of the federal funds rate, plus 0.5% and (c) one month term SOFR rate plus 1%, in each case, plus an applicable margin based upon our consolidated leverage ratio at the end of each quarter ranging from 0.25% to 0.625%, or (2) the one, three or six month term SOFR rate plus 0.1% (at our election), plus an applicable margin based upon our consolidated leverage ratio at the end of each quarter ranging from 1.25% to 1.625%. As of September 30, 2024, the applicable margins were 0.375% for ABR-based loans and 1.375% for SOFR-based loans under the revolving credit and term loan A facilities. The revolving credit facility includes a $125 million sub-limit for letters of credit. The Credit Agreement is secured by certain assets of the Company and our material subsidiaries (which generally excludes asset classes such as substantially all of the patient-related accounts receivable of our acute care hospitals, if sold to a receivables facility pursuant to the Credit Agreement, and certain real estate assets and assets held in joint-ventures with third parties) and is guaranteed by our material subsidiaries. The Credit Agreement includes a material adverse change clause that must be represented at each draw. The Credit Agreement also contains covenants that include a limitation on sales of assets, mergers, change of ownership, liens, indebtedness, transactions with affiliates, dividends and stock repurchases; and requires compliance with financial covenants including maximum leverage. We were in compliance with all required covenants as of September 30, 2024 pursuant to the terms of the Credit Agreement, as amended on September 26, 2024, and as of December 31, 2023 pursuant to the terms of the previous credit agreement. As mentioned above, on September 26, 2024, we completed the public offering of: (i) $500,000,000 aggregate principal amount of the 4.625%, 2029 Notes, and; (ii) $500,000,000 aggregate principal amount of the 5.050%, 2034 Notes (and together with the 2029 Notes, the "2029 and 2034 Notes"), each guaranteed on a senior secured basis by all of our existing and future direct and indirect subsidiaries that guarantee our senior secured credit facility or our other first lien obligations or any junior lien obligations (the â€œSubsidiary Guarantorsâ€). The 2029 and 2034 Notes have been registered under the Securities Act of 1933, as amended (the â€œSecurities Actâ€), pursuant to the Issuerâ€™s and the Subsidiary Guarantorsâ€™ registration statement on Form S-3 (File No. 333-282135), including the prospectus dated September 16, 2024, and a related prospectus supplement dated September 17, 2024, as filed with the Securities and Exchange Commission on September19, 2024. As of September 30, 2024, including the above-mentioned newly issued Notes, we had combined aggregate principal of $3.0 billion from the following senior secured notes: â€¢$700 million aggregate principal amount of 1.65% senior secured notes due in September, 2026 ("2026 Notes") which were issued on August 24, 2021. Interest on the 2026 Notes is payable on March 1st and September 1st until the maturity date of September 1, 2026. â€¢$500 million of aggregate principal amount of 4.625% senior secured notes due in October, 2029 ("2029 Notes") which were issued on September 26, 2024. Interest on the 2029 Notes is payable on April 15th and October 15th, commencing April 15, 2025 until the maturity date of October 15, 2029. â€¢$800 million aggregate principal amount of 2.65% senior secured notes due in October, 2030 ("2030 Notes") which were issued on September 21, 2020. Interest on the 2030 Notes is payable on April 15th and October 15th, until the maturity date of October 15, 2030. â€¢$500 million of aggregate principal amount of 2.65% senior secured notes due in January, 2032 ("2032 Notes") which were issued on August 24, 2021. Interest on the 2032 Notes is payable on January 15th and July 15th until the maturity date of January 15, 2032. â€¢$500 million of aggregate principal amount of 5.050% senior secured notes due in October, 2034 ("2034 Notes") which were issued on September 26, 2024. Interest on the 2034 Notes is payable on April 15th and October 15th, commencing on April 15, 2025 until the maturity date of October 15, 2034. The 2026 Notes, 2030 Notes and 2032 Notes (collectively the "2026, 2030 and 2032 Notes") were initially issued only to qualified institutional buyers under Rule 144A and to non-U.S. persons outside the United States in reliance on Regulation S under the Securities Act. In December, 2022, we completed a registered exchange offer in which virtually all previously outstanding 2026, 2030 and 2032 Notes were exchanged for identical 2026, 2030 and 2032 Notes that were registered under the Securities Act, and thereby became freely transferable (subject to certain restrictions applicable to affiliates and broker dealers). 2026, 2030 and 2032 Notes originally issued under Rule 144A or Regulation S that were not exchanged remain outstanding and may not be offered or sold in the United States absent registration under the Securities Act or an applicable exemption from registration requirements thereunder. The 2026, 2030 and 2032 Notes, and the 2029 and 2034 Notes (collectively "All the Notes") are guaranteed (the â€œGuaranteesâ€) on a senior secured basis by our Subsidiary Guarantors that guarantee our Credit Agreement, or other first lien obligations or any junior lien obligations. All the Notes and the Guarantees are secured by first-priority liens, subject to permitted liens, on certain of the Companyâ€™s and the Subsidiary Guarantorsâ€™ assets now owned or acquired in the future by the Company or the Subsidiary Guarantors (other than real property, accounts receivable sold pursuant to a Company-related receivables facility (as defined in the Indentures pursuant to which All The Notes were issued (the â€œIndenturesâ€), and certain other excluded assets). The Companyâ€™s obligations with 60 Â respect to All the Notes, the obligations of the Subsidiary Guarantors under the Guarantees, and the performance of all of the Companyâ€™s and the Subsidiary Guarantorsâ€™ other obligations under the Indenture, are secured equally and ratably with the Companyâ€™s and the Subsidiary Guarantorsâ€™ obligations under the Credit Agreement. However, the liens on the

collateral securing All the Notes and the Guarantees will be released if: (i) All the Notes have investment grade ratings; (ii) no default has occurred and is continuing, and; (iii) the liens on the collateral securing all first lien obligations (including the Credit Agreement and All the Notes) and any junior lien obligations are released or the collateral under the Credit Agreement, any other first lien obligations and any junior lien obligations is released or no longer required to be pledged. The liens on any collateral securing All the Notes and the Guarantees will also be released if the liens on that collateral securing the Credit Agreement, other first lien obligations and any junior lien obligations are released. As discussed in Note 2 to the Condensed Consolidated Financial Statements-Relationship with Universal Health Realty Income Trust and Other Related Party Transactions, on December 31, 2021, we (through wholly-owned subsidiaries of ours) entered into an asset purchase and sale agreement with Universal Health Realty Income Trust (the â€œTrustâ€). Pursuant to the terms of the agreement, which was amended during the first quarter of 2022, we, among other things, transferred to the Trust, the real estate assets of Aiken Regional Medical Center (â€œAikenâ€) and Canyon Creek Behavioral Health (â€œCanyon Creekâ€). In connection with this transaction, Aiken and Canyon Creek (as lessees), entered into a master lease and individual property leases, as amended, (with the Trust as lessor), for initial lease terms on each property of approximately twelve years, ending on December 31, 2033. As a result of our purchase option within the Aiken and Canyon Creek lease agreements, this asset purchase and sale transaction is accounted for as a failed sale leaseback in accordance with U.S. GAAP and we have accounted for the transaction as a financing arrangement. Our lease payments payable to the Trust are recorded to interest expense and as a reduction of the outstanding financial liability, and the amount allocated to interest expense is determined based upon our incremental borrowing rate and the outstanding financial liability. In connection with this transaction, our consolidated balance sheets at September 30, 2024 and December 31, 2023 reflect financial liabilities, which are included in debt, of approximately $75 million and $77 million, respectively. At September 30, 2024, the carrying value and fair value of our debt were approximately $4.7 billion and $4.4 billion, respectively. At December 31, 2023, the carrying value and fair value of our debt were approximately $4.9 billion and $4.6 billion, respectively. The fair value of our debt was computed based upon quotes received from financial institutions. We consider these to be â€œlevel 2â€ in the fair value hierarchy as outlined in the authoritative guidance for disclosures in connection with debt instruments. Our total debt as a percentage of total capitalization was approximately 41% as of September 30, 2024 and 44% as of December 31, 2023. We expect to finance all capital expenditures and acquisitions and pay dividends and potentially repurchase shares of our common stock utilizing internally generated and additional funds. Additional funds may be obtained through: (i) borrowings under our existing revolving credit facility, which had $1.01 billion of available borrowing capacity as of September 30, 2024, or through refinancing the existing Credit Agreement; (ii) the issuance of other short-term and/or long-term debt, and/or; (iii) the issuance of equity. We believe that our operating cash flows, cash and cash equivalents, available commitments under existing agreements, as well as access to the capital markets, provide us with sufficient capital resources to fund our operating, investing and financing requirements for the next twelve months. However, in the event we need to access the capital markets or other sources of financing, there can be no assurance that we will be able to obtain financing on acceptable terms or within an acceptable time. Our inability to obtain financing on terms acceptable to us could have a material unfavorable impact on our results of operations, financial condition and liquidity. Supplemental Guarantor Financial Information As of September 30, 2024, we had combined aggregate principal of $3.0 billion from All the Notes: â€¢$700 million aggregate principal amount of the 2026 Notes; â€¢$500 million of aggregate principal amount of the 2029 Notes; â€¢$800 million aggregate principal amount of the 2030 Notes; â€¢$500 million of aggregate principal amount of the 2032 Notes, and; â€¢$500 million of aggregate principal amount of the 2034 Notes. All the Notes are fully and unconditionally guaranteed pursuant to the Guarantees on a senior secured basis by the Subsidiary Guarantors. All the Notes and the Guarantees are secured by first-priority liens, subject to permitted liens, on certain of the Companyâ€™s and the Subsidiary Guarantorsâ€™ assets now owned or acquired in the future by the Company or the Subsidiary Guarantors (other than real property, accounts receivable sold pursuant to the Companyâ€™s existing receivables facility (as defined in the Indentures pursuant to which All the Notes were issued), and certain other excluded assets). The Companyâ€™s obligations with respect to All the Notes, the obligations of the Subsidiary Guarantors under the Guarantees, and the performance of all of the Companyâ€™s and the Subsidiary Guarantorsâ€™ other obligations under the Indentures, are secured equally and ratably with the Companyâ€™s and the Subsidiary Guarantorsâ€™ obligations under the Credit Agreement. However, the liens on the collateral securing All the Notes and the Guarantees 61 Â will be released if: (i) All the Notes have investment grade ratings; (ii) no default has occurred and is continuing, and; (iii) the liens on the collateral securing all first lien obligations (including the Credit Agreement and All the Notes) and any junior lien obligations are released or the collateral under the Credit Agreement, any other first lien obligations and any junior lien obligations is released or no longer required to be pledged. The liens on any collateral securing All the Notes and the Guarantees will also be released if the liens on that collateral securing the Credit Agreement, other first lien obligations and any junior lien obligations are released. All the Notes will be structurally subordinated to all obligations of our existing and future subsidiaries that are not and do not become Subsidiary Guarantors of All the Notes. No appraisal of the value of the collateral has been made, and the value of the collateral in the event of liquidation will depend on market and economic conditions, the availability of buyers and other factors. Consequently, liquidating the collateral securing All the Notes may not produce proceeds in an amount sufficient to pay any amounts due on All the Notes. We and our subsidiaries may be able to incur significant additional indebtedness in the future. Although our Credit Agreement contains restrictions on the incurrence of additional indebtedness and our Credit Agreement and All the Notes contain restrictions on our ability to incur liens to secure additional indebtedness, these restrictions are subject to a number of qualifications and exceptions, and the additional indebtedness incurred in compliance with these restrictions could be substantial. These restrictions also will not prevent us from incurring obligations that do not constitute indebtedness. In addition, if we incur any additional indebtedness secured by liens that rank equally with All the Notes, subject to collateral arrangements, the holders of that debt will be entitled to share ratably with you in any proceeds distributed in connection with any insolvency, liquidation, reorganization, dissolution or other winding up of our company. This may have the effect of reducing the amount of proceeds paid to holders of All the Notes. Federal and state fraudulent transfer and conveyance statutes may apply to the issuance of All the Notes and the incurrence of the Guarantees. Under federal bankruptcy law and comparable provisions of state fraudulent transfer or conveyance laws, which may vary from state to state, All the Notes or the Guarantees (or the grant of collateral securing any such obligations) could be voided as a fraudulent transfer or conveyance if we or any of the Subsidiary Guarantors, as applicable, (a) issued All the Notes or incurred the Guarantees with the intent of hindering, delaying or defrauding creditors or (b) under certain circumstances received less than reasonably equivalent value or fair consideration in return for either issuing All the Notes or incurring the Guarantees. Basis of Presentation The following tables include summarized financial information of Universal Health Services, Inc. and the other obligors in respect of debt issued by Universal Health Services, Inc. The summarized financial information of each obligor group is presented on a combined basis with balances and transactions within the obligor group eliminated. Investments in and the equity in earnings of non-guarantor subsidiaries, which would otherwise be consolidated in accordance with GAAP, are excluded from the below summarized financial information pursuant to SEC Regulation S-X Rule 13-01. The summarized balance sheet information for the consolidated obligor group of debt issued by Universal Health Services, Inc. is presented in the table below: Â Â Â Â Â Â Â Â (in thousands) September 30, 2024 Â Â December 31, 2023 Â Current assets $ 2,237,362 Â Â $ 2,292,716 Â Noncurrent assets (1) Â 9,151,823 Â Â Â 8,876,623 Â Current liabilities Â 1,719,008 Â Â Â 1,786,642 Â Noncurrent liabilities Â 5,614,852 Â Â Â 5,728,371 Â Due to non-guarantors Â 926,008 Â Â Â 913,481 Â (1) Includes goodwill of $3,262 million and $3,267 million as of September 30, 2024 and December 31, 2023, respectively. Â The summarized results of operations information for the consolidated obligor group of debt issued by Universal Health Services, Inc. is presented in the table below: Â Nine Months Ended Â Â Twelve Months Ended Â (in thousands) September 30, 2024 Â Â December 31, 2023 Â Net revenues $ 9,384,032 Â Â $ 11,454,260 Â Operating charges Â 8,317,425 Â Â Â 10,416,176 Â Interest expense, net Â 146,840 Â Â Â 277,521 Â Other (income) expense, net Â 1,929 Â Â Â 24,996 Â Net income $ 689,397 Â Â $ 556,423 Â Affiliates Whose Securities Collateralize the Senior Secured Notes All the Notes and the Guarantees are secured by, among other things, pledges of the capital stock of our subsidiaries held by us or by our secured Guarantors, in each case other than certain excluded assets and subject to permitted liens. Such collateral securities are 62 Â secured equally and ratably with our and the Guarantorsâ€™ obligations under our Credit Agreement. For a list of our subsidiaries the capital stock of which has been pledged to secure All the Notes, see Exhibit 22.1 to this Report. Upon the occurrence and during the continuance of an event of default under the indentures governing All the Notes, subject to the terms of the Security Agreement relating to All the Notes provide for (among other available remedies) the foreclosure upon and sale of the Collateral (including the pledged stock) and the distribution of the net proceeds of any such sale to the holders of All the Notes, the lenders under the Credit Agreement and the holders of any other permitted first priority secured obligations on a pro rata basis, subject to any prior liens on the collateral. No appraisal of the value of the collateral securities has been made, and the value of the collateral securities in the event of liquidation will depend on market and economic conditions, the availability of buyers and other factors. Consequently, liquidating the collateral securities securing All the Notes may not produce proceeds in an amount sufficient to pay any amounts due on All the Notes. The security agreement relating to All the Notes provides that the representative of the lenders under our Credit Agreement will initially control actions with respect to that collateral and, consequently, exercise of any right, remedy or power with respect to enforcing interests in or realizing upon such collateral will initially be at the direction of the representative of the lenders. No trading market exists for the capital stock pledged as collateral. The assets, liabilities and results of operations of the combined affiliates whose securities are pledged as collateral are not materially different than the corresponding amounts presented in the consolidated financial information of Universal Health Services, Inc. Off-Balance Sheet Arrangements During the three months ended September 30, 2024 there have been no material changes in the off-balance sheet arrangements consisting of standby letters of credit and surety bonds. As of September 30, 2024 we were party to certain off balance sheet arrangements consisting of standby letters of credit and surety bonds which totaled $154 million consisting of: (i) $130 million related to our self-insurance programs, and; (ii) $24 million of other debt and public utility guarantees. Â Item 3. Quantitative and Qualitative Disclosures About Market Risk There have been no material changes in the quantitative and qualitative disclosures about market risk during the nine months ended September 30, 2024. Reference is made to Item 7A. Quantitative and Qualitative Disclosures About Market Risk in our Annual Report on Form 10-K for the year ended December 31, 2023. Â Item 4. Controls and Procedures As of September 30, 2024, under the supervision and with the participation of our management, including our Chief Executive Officer (â€œCEOâ€) and Chief Financial Officer (â€œCFOâ€), we performed an evaluation of the effectiveness of our disclosure controls and procedures, as defined in Rule 13a-15(e) or Rule 15d-15(e) under the Securities Exchange Act of 1934, as amended (the â€œ1934 Actâ€). Based on this evaluation, the CEO and CFO have concluded that our disclosure controls and procedures are effective to ensure that material information is recorded, processed, summarized and reported by management on a timely basis in order to comply with our disclosure obligations under the 1934 Act and the SEC rules thereunder. Â Changes in Internal Control Over Financial Reporting There have been no changes in our internal control over financial reporting during the third quarter of 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 63 Â PART II. OTHER INFORMATION Â Â Item 1. Legal Proceedings See Note 6 to the Condensed Consolidated Financial Statements-Commitments and Contingencies to our condensed consolidated financial statements in Item 1 of Part I of this report for a description of our legal proceedings. Such information is hereby incorporated by reference. Item 1A. Risk Factors The following is an update to the risk factors set forth in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023. Other than the following update, there have been no material changes to the risk factors previously disclosed under the heading â€œRisk Factorsâ€ in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023. You should carefully consider the risk factors contained in our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q and our other filings made with the Securities and Exchange Commission. We are subject to pending legal actions, purported stockholder class actions, governmental investigations, inquiries and regulatory actions. We and our subsidiaries are subject to pending legal actions, governmental investigations, inquiries and regulatory actions and judgments (see Note 6 to the Consolidated Financial Statements-Commitments and Contingencies as contained in this Quarterly Report on Form 10-Q). We may become subject to additional medical malpractice lawsuits, product liability lawsuits, class action lawsuits, investigations and other legal actions in the ordinary course of business. Defending ourselves against the allegations in the lawsuits and governmental investigations, inquiries, or similar matters and any related publicity, could potentially entail significant costs and could require significant attention from our management and our reputation could suffer significantly. We are unable to predict the outcome of these matters or to reasonably estimate the amount or range of any such loss; however, these lawsuits and the related publicity and news articles that have been published concerning these matters could have a material adverse effect on our business, financial condition, results of operations and/or cash flows which in turn could cause a decline in our stock price. In an effort to resolve one or more of these matters, we may choose to negotiate a settlement. Amounts we pay to settle any of these matters may be material. All professional and general liability insurance we purchase is subject to policy limitations. We believe that, based on our past experience and actuarial estimates, our insurance coverage is adequate considering the claims arising from the operations of our hospitals. While we continuously monitor our coverage, our ultimate liability for professional and general liability claims could change materially from our current estimates. If such policy limitations should be partially or fully exhausted in the future, or payments of claims exceed our estimates or are not covered by our insurance, it could have a material adverse effect on our operations. For example, as discussed elsewhere herein, â€¢On March 28, 2024, a jury returned a verdict for compensatory damages of $60 million and punitive damages of $475 million and a related judgment was entered against The Pavilion Behavioral Health System (the â€œPavilionâ€), an indirect subsidiary of the Company. In an order dated October 10, 2024, the trial court ordered a remittitur of punitive damages from $475 million to $120 million. The court denied the Pavilionâ€™s request for reduction of compensatory damages. The Pavilion intends to appeal the remaining judgment. â€¢Cumberland Hospital for Children and Adolescents (â€œCumberlandâ€), an indirect subsidiary of the Company, is a defendant in multi-plaintiff lawsuits filed in the Circuit Court for Richmond, Virginia (the â€œCumberland Litigationâ€), relating to allegations of inappropriate sexual contact during medical examinations by Dr. Daniel Davidow, an independent contractor and the former medical director for Cumberland. The Company and UHS of Delaware, Inc., our administrative services subsidiary (â€œUHS Delawareâ€), were also named as co-defendants in the Cumberland Litigation. Plaintiffs have asserted claims of negligence, assault and battery (against Dr. Davidow), false imprisonment, violations of the Virginia Consumer Protection Act (â€œVCPAâ€), and vicarious liability for Dr. Davidowâ€™s conduct against Cumberland, the Company, and UHS Delaware. The Company and UHS Delaware were dismissed from the action during the trial, which occurred in September, 2024. On September 27, 2024, a jury entered a verdict finding Dr. Davidow and Cumberland liable and awarded these three plaintiffs combined compensatory damages of $60 million for all liability theories, an additional combined $180 million in trebled damages for violation of the VCPA, and an additional combined $120 million in punitive damages. Cumberland is evaluating all legal options and intends to challenge this verdict, including the amounts awarded in the verdict, in post-trial proceedings and on appeal. Based upon Virginia law, we expect that the punitive damage amount should be reduced to a combined maximum of $1.05 million as a matter of law. There are approximately 40 additional plaintiffs making similar allegations with claims pending in the Cumberland Litigation. We are and may become subject to other loss contingencies, both known and unknown, which may relate to past, present and future facts, events, circumstances and occurrences. Should an unfavorable outcome occur in some or all of our legal proceedings or other 64 Â loss contingencies, or if successful claims and other actions are brought against us in the future, there could be a material adverse impact on our financial position, results of operations and liquidity. In particular, government investigations, as well as qui tam and stockholder lawsuits, may lead to material fines, penalties, damages payments or other sanctions, including exclusion from government healthcare programs. The federal False Claims Act permits private parties to bring qui tam, or whistleblower, lawsuits on behalf of the government against companies alleging that the defendant has defrauded the federal government. These private parties are entitled to share in any amounts recovered by the government, and, as a result, the number of whistleblower lawsuits that have been filed against providers has increased significantly in recent years. Because qui tam lawsuits are filed under seal, we could be named in one or more such lawsuits of which we are not aware. Settlements of lawsuits involving Medicare and Medicaid issues routinely require both monetary payments and corporate integrity agreements, each of which could have a material adverse effect on our business, financial condition, results of operations and/or cash flows. If our financial exposure in connection with litigation relating to the Pavilion Behavioral Health System and/or Cumberland Hospital for Children and Adolescents exhausts all or a significant portion of the remaining commercial insurance coverage available to our subsidiaries related to other occurrences in 2020, or it causes us to have to post a large bond or other collateral during an appeal process, our future results of operations and capital resources could be materially adversely impacted. We are uncertain as to the ultimate financial exposure related to the above-mentioned Cumberland and Pavilion matters and we can make no assurances regarding their outcomes, or the amounts of damages that may be held recoverable after post-judgment proceedings and appeals. While Cumberland and Pavilion have professional liability insurance to cover a portion of these amounts, the resolution of these matters may have a material adverse

effect on the Company. Without reduction for any potential amounts related to the above-mentioned Cumberland and Pavilion matters, the Company and its subsidiaries have aggregate insurance coverage of approximately $221 million remaining under commercial policies for matters applicable to the 2020 policy year (in excess of the applicable self-insured retention amounts of $10 million per occurrence for professional liability claims and $3 million per occurrence for general liability claims). In the event the resolution of the Cumberland and/or Pavilion matters exhausts all or a significant portion of the remaining commercial insurance coverage available to the Company and its subsidiaries for claims that occurred in 2020 (the applicable year for the Pavilion matter and substantially all of the Cumberland matters, as discussed above), or it requires the posting of large bonds or other collateral during appeal processes, our future results of operations and capital resources could be materially adversely impacted. Item 2. Unregistered Sales of Equity Securities and Use of Proceeds As of December 31, 2023, we had an aggregate available repurchase authorization of $422.9 million pursuant to our stock repurchase program. Pursuant to this program, shares of our Class B Common Stock may be repurchased, from time to time as conditions allow, on the open market or in negotiated private transactions. There is no expiration date for our stock repurchase program. As reflected below, during the three-month period ended September 30, 2024, we have repurchased 657,912 shares at an aggregate cost of approximately $153.9 million (approximately $233.85 per share) pursuant to the terms of our stock repurchase program. In addition, during the three-month period ended September 30, 2024, 127,580 shares were repurchased in connection with income tax withholding obligations resulting from stock-based compensation programs. During July, 2024, our Board of Directors authorized a $1.0 billion increase in our stock repurchase program. During the period of July 1, 2024 through September 30, 2024, we repurchased the following shares: Â Â Â AdditionalDollarsAuthorizedForRepurchase(in thousands) Â Â Totalnumber ofsharespurchased Â Â Totalnumber ofsharescancelled Â Â Averageprice paidper sharefor forfeitedrestrictedshares Â Â TotalNumberof sharespurchasedas part ofpubliclyannouncedprograms Â Â Averageprice paidper sharefor sharespurchasedas part ofpubliclyannouncedprogram Â Â Aggregatepurchaseprice paid for shares purchased as part of publicly announced program(in thousands) Â Â Maximumnumber ofshares thatmay yet bepurchasedunder theprogram Â Â Maximumnumber ofdollars thatmay yet bepurchasedunder theprogram(in thousands) (a.) Â July, 2024 Â $ 1,000,000 Â Â Â 32,917 Â Â Â â€” Â Â $ 0.01 Â Â Â â€” Â Â $ - Â Â $ - Â Â Â â€” Â Â $ 1,227,831 Â August, 2024 Â $ - Â Â Â 266,555 Â Â Â â€” Â Â $ 0.01 Â Â Â 259,233 Â Â $ 230.24 Â Â $ 59,687 Â Â Â â€” Â Â $ 1,168,144 Â September, 2024 Â $ - Â Â Â 486,020 Â Â Â â€” Â Â $ 0.01 Â Â Â 398,679 Â Â $ 236.19 Â Â $ 94,163 Â Â Â â€” Â Â $ 1,073,981 Â Total July through September, 2024 Â $ 1,000,000 Â Â Â 785,492 Â Â Â â€” Â Â $ 0.01 Â Â Â 657,912 Â Â Â 233.85 Â Â $ 153,850 Â Â Â Â Â Â Â (a.) On July 24, 2024, our Board of Directors authorized a $1.0 billion increase to our stock repurchase program. Dividends During the quarter ended September 30, 2024, we declared and paid dividends of $.20 per share. Dividend equivalents are accrued on unvested restricted stock units and will be paid upon vesting of the restricted stock unit. 65 Â Item 5. Other Information (c) None of the Companyâ€™s directors or officers adopted, modified or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the Companyâ€™s quarter ended September 30, 2024, as such terms are defined under Item 408(a) of Regulation S-K. Â 66 Â Â Item 6. Exhibits Â 4.1 Indenture, dated as of September 26, 2024, among the Issuer, the Subsidiary Guarantors party thereto, U.S. Bank Trust Company, National Association, as trustee, and JPMorgan Chase Bank, N.A., as collateral agent, previously filed as Exhibit 4.1 to the Companyâ€™s Current Report on Form 8-K dated October 1, 2024, is incorporated herein by reference. Â 4.2 First Supplemental Indenture, dated as of September 26, 2024, among the Issuer, the Subsidiary Guarantors party thereto, U.S. Bank Trust Company, National Association, as trustee, and JPMorgan Chase Bank, N.A., as collateral agent, to the indenture, dated as of September 26, 2024, governing the Issuerâ€™s 4.625% Senior Secured Notes due 2029 and the Issuerâ€™s 5.050% Senior Secured Notes due 2034, previously filed as Exhibit 4.2 to the Companyâ€™s Current Report on Form 8-K dated October 1, 2024, is incorporated herein by reference. Â 4.3 Form of Global Note representing the 2029 Notes (included in Exhibit 4.2). Â 4.4 Form of Global Note representing the 2034 Notes (included in Exhibit 4.2). Â 4.5 Additional Authorized Representative Joinder Agreement, dated as of September 26, 2024, among U.S. Bank Trust Company, National Association, as trustee and additional authorized representative for the holders of the Notes, the Issuer, the Subsidiary Guarantors party thereto, and JPMorgan Chase Bank, N.A., as collateral agent and administrative agent, previously filed as Exhibit 4.5 to the Companyâ€™s Current Report on Form 8-K dated October 1, 2024, is incorporated herein by reference. Â 10.1 Tenth Amendment, dated as of September 26, 2024, to Credit Agreement, dated as of November 15, 2010 and as amended and restated as of September 21, 2012, August 7, 2014, October 23, 2018, August 21, 2021, September 10, 2021, June 23, 2022 and September 26, 2024, among the Issuer, JP Morgan Chase Bank, N.A., as administrative agent and other financial institutions or entities from time to time parties thereto, including the amendment and restatement thereof, effective as of September 26, 2024, attached as Exhibit A thereto and referred to herein as the Senior Secured Credit Facility, previously filed as Exhibit 10.1 to the Companyâ€™s Current Report on Form 8-K dated October 1, 2024, is incorporated herein by reference. Â Â 22.1 List of Guarantor Subsidiaries and Issuers of Guaranteed Securities and Affiliates Whose Securities Collateralize Securities of the Registrant. Â Â 31.1 Certification of the Companyâ€™s Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934. Â Â 31.2 Certification of the Companyâ€™s Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934. Â Â 32.1 Certification of the Companyâ€™s Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. Â Â 32.2 Certification of the Companyâ€™s Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 101.INS Inline XBRL Instance Document â€“the instance document does not appear in the Interactive Data file because its XBRL tags are embedded within the Inline XBRL document. 101.SCH Inline XBRL Taxonomy Extension Schema Document 104 The cover page from the Companyâ€™s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, has been formatted in Inline XBRL. Â Â 67 Â UNIVERSAL HEALTH SERVICES, INC. AND SUBSIDIARIES Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Universal Health Services, Inc. Â Â Â Â (Registrant) Date: November 8, 2024 /s/ Marc D. Miller Marc D. Miller, President and Chief Executive Officer (Principal Executive Officer) /s/ Steve Filton Steve Filton, Â Â Executive Vice President and Chief Financial Officer (Principal Financial Officer) Â 68 EX-22.1 2 uhs-ex22_1.htm EX-22.1 EX-22.1 Â Exhibit 22.1 Â Subsidiary Guarantors and Issuers of Guaranteed Securities and Affiliates Whose Securities Collateralize Securities of the Registrant Â Guaranteed Securities The following securities (collectively, the â€œUHS Senior Secured Notesâ€) issued by Universal Health Services, Inc., a Delaware corporation (the â€œCompanyâ€), were outstanding as of September 30, 2024. Description of Notes 1.650% Senior Secured Notes due 2026 4.625% Senior Secured Notes due 2029 2.650% Senior Secured Notes due 2030 2.650% Senior Secured Notes due 2032 5.050% Senior Secured Notes due 2034 Â Obligors The obligors under the UHS Senior Secured Notes consisted of the Company, as issuer, and its subsidiaries listed in the following table, as Guarantors. Name of Subsidiary Jurisdiction of Organization Obligor Type ABS LINCS KY, LLC Virginia Guarantor ABS LINCS SC, Inc. South Carolina Guarantor Aiken Regional Medical Centers, LLC South Carolina Guarantor Alliance Health Center, Inc. Mississippi Guarantor Alternative Behavioral Services, Inc. Virginia Guarantor Ascend Health Corporation Delaware Guarantor Atlantic Shores Hospital, LLC Delaware Guarantor AZ Holding 4, LLC Arizona Guarantor Beach 77 LP Delaware Guarantor Behavioral Health Management, LLC Delaware Guarantor Behavioral Health Realty, LLC Delaware Guarantor Behavioral Healthcare LLC Delaware Guarantor Benchmark Behavioral Health System, Inc. Utah Guarantor BHC Alhambra Hospital, Inc. Tennessee Guarantor 1 Â Name of Subsidiary Jurisdiction of Organization Obligor Type BHC Belmont Pines Hospital, Inc. Tennessee Guarantor BHC Fairfax Hospital, Inc. Tennessee Guarantor BHC Fox Run Hospital, Inc. Tennessee Guarantor BHC Fremont Hospital, Inc. Tennessee Guarantor BHC Health Services of Nevada, Inc. Nevada Guarantor BHC Heritage Oaks Hospital, Inc. Tennessee Guarantor BHC Holdings, Inc. Delaware Guarantor BHC Intermountain Hospital, Inc. Tennessee Guarantor BHC Mesilla Valley Hospital, LLC Delaware Guarantor BHC Montevista Hospital, Inc. Nevada Guarantor BHC Northwest Psychiatric Hospital, LLC Delaware Guarantor BHC of Indiana, General Partnership Tennessee Guarantor BHC Pinnacle Pointe Hospital, LLC Tennessee Guarantor BHC Properties, LLC Tennessee Guarantor BHC Sierra Vista Hospital, Inc. Tennessee Guarantor BHC Streamwood Hospital, Inc. Tennessee Guarantor Bloomington Meadows, General Partnership Tennessee Guarantor Brentwood Acquisition-Shreveport, Inc. Delaware Guarantor Brentwood Acquisition, Inc. Tennessee Guarantor Brynn Marr Hospital, Inc. North Carolina Guarantor Calvary Center, Inc. Delaware Guarantor Canyon Ridge Hospital, Inc. California Guarantor CAT Realty, LLC Delaware Guarantor CAT Seattle, LLC Delaware Guarantor CCS/Lansing, Inc. Michigan Guarantor Cedar Springs Hospital, Inc. Delaware Guarantor Childrenâ€™s Comprehensive Services, Inc. Tennessee Guarantor Columbus Hospital Partners, LLC Tennessee Guarantor Coral Shores Behavioral Health, LLC Delaware Guarantor Cumberland Hospital Partners, LLC Delaware Guarantor Cumberland Hospital, LLC Virginia Guarantor Del Amo Hospital, Inc. California Guarantor DHP 2131 K St, LLC Delaware Guarantor Diamond Grove Center, LLC Delaware Guarantor 2 Â Name of Subsidiary Jurisdiction of Organization Obligor Type District Hospital Partners, L.P. District of Columbia Guarantor DVH Hospital Alliance LLC Delaware Guarantor Emerald Coast Behavioral Hospital, LLC Delaware Guarantor Fannin Management Services, LLC Texas Guarantor First Hospital Corporation of Virginia Beach Virginia Guarantor Forest View Psychiatric Hospital, Inc. Michigan Guarantor Fort Duncan Medical Center, L.P. Delaware Guarantor Fort Lauderdale Hospital, Inc. Florida Guarantor FRN, INC. Delaware Guarantor Frontline Behavioral Health, Inc. Delaware Guarantor Frontline Hospital, LLC Delaware Guarantor Frontline Residential Treatment Center, LLC Delaware Guarantor Garfield Park Hospital, LLC Illinois Guarantor Great Plains Hospital, Inc. Missouri Guarantor Gulf Coast Treatment Center, Inc. Florida Guarantor Gulph Mills Associates, LLC Pennsylvania Guarantor H. C. Corporation Alabama Guarantor H.C. Partnership Alabama Guarantor Harbor Point Behavioral Health Center, Inc. Virginia Guarantor Havenwyck Hospital Inc. Michigan Guarantor HHC Augusta, Inc. Georgia Guarantor HHC Delaware, Inc. Delaware Guarantor HHC Indiana, Inc. Indiana Guarantor HHC Ohio, Inc. Ohio Guarantor HHC Pennsylvania, LLC Delaware Guarantor HHC Poplar Springs, LLC Virginia Guarantor HHC River Park, Inc. West Virginia Guarantor HHC South Carolina, Inc. South Carolina Guarantor HHC St. Simons, Inc. Georgia Guarantor Hickory Trail Hospital, L.P. Delaware Guarantor Holly Hill Hospital, LLC Tennessee Guarantor Horizon Health Austin, Inc. Texas Guarantor Horizon Health Corporation Delaware Guarantor Horizon Health Hospital Services, LLC Delaware Guarantor 3 Â Name of Subsidiary Jurisdiction of Organization Obligor Type Horizon Mental Health Management, LLC Texas Guarantor HSA Hill Crest Corporation Alabama Guarantor Hughes Center, LLC Virginia Guarantor Independence Physician Management, LLC Delaware Guarantor Keys Group Holdings LLC Delaware Guarantor Keystone Continuum, LLC Tennessee Guarantor Keystone Education and Youth Services, LLC Tennessee Guarantor Keystone Marion, LLC Virginia Guarantor Keystone Memphis, LLC Tennessee Guarantor Keystone Newport News, LLC Virginia Guarantor Keystone NPS LLC California Guarantor Keystone Richland Center LLC Ohio Guarantor Keystone WSNC, L.L.C. North Carolina Guarantor Keystone/CCS Partners LLC Delaware Guarantor Kids Behavioral Health of Utah, Inc. Utah Guarantor Kingwood Pines Hospital, LLC Texas Guarantor KMI Acquisition, LLC Delaware Guarantor La Amistad Residential Treatment Center, LLC Florida Guarantor Lancaster Hospital Corporation California Guarantor Laurel Oaks Behavioral Health Center, Inc. Delaware Guarantor Lebanon Hospital Partners, LLC Tennessee Guarantor Liberty Point Behavioral Healthcare, LLC Delaware Guarantor Manatee Memorial Hospital, L.P. Delaware Guarantor Mayhill Behavioral Health, LLC Texas Guarantor McAllen Hospitals, L.P. Delaware Guarantor McAllen Medical Center, Inc. Delaware Guarantor Meridell Achievement Center, Inc. Texas Guarantor Merion Building Management, Inc. Delaware Guarantor Michigan Psychiatric Services, Inc. Michigan Guarantor Millwood Hospital, L.P. Texas Guarantor Milwaukee Behavioral Health, LLC Wisconsin Guarantor Neuro Institute of Austin, L.P. Texas Guarantor North Spring Behavioral Healthcare, Inc. Tennessee Guarantor 4 Â Name of Subsidiary Jurisdiction of Organization Obligor Type Northern Indiana Partners, LLC Tennessee Guarantor Northwest Texas Healthcare System, Inc. Texas Guarantor Oak Plains Academy of Tennessee, Inc. Tennessee Guarantor Ocala Behavioral Health, LLC Delaware Guarantor Palm Point Behavioral Health, LLC Florida Guarantor Palmetto Behavioral Health Holdings, LLC Delaware Guarantor Palmetto Behavioral Health System, L.L.C. South Carolina Guarantor Palmetto Lowcountry Behavioral Health, L.L.C. South Carolina Guarantor Park Healthcare Company Tennessee Guarantor Pasteur Healthcare Properties, LLC Delaware Guarantor Pendleton Methodist Hospital, L.L.C. Delaware Guarantor Pennsylvania Clinical Schools, Inc. Pennsylvania Guarantor Premier Behavioral Solutions of Florida, Inc. Delaware Guarantor Premier Behavioral Solutions, Inc. Delaware Guarantor PSJ Acquisition, LLC North Dakota Guarantor Psychiatric Realty, LLC Delaware Guarantor Psychiatric Solutions Hospitals, LLC Delaware Guarantor Psychiatric Solutions of Virginia, Inc. Tennessee Guarantor Psychiatric Solutions, Inc. Delaware Guarantor Ramsay Managed Care, LLC Delaware Guarantor Ramsay Youth Services of Georgia, Inc. Delaware Guarantor Ridge Outpatient Counseling, L.L.C. Kentucky Guarantor River Oaks, Inc. Louisiana Guarantor Riveredge Hospital Holdings, Inc. Delaware Guarantor Riverside Medical Clinic Patient Services, L.L.C. California Guarantor Rolling Hills Hospital, LLC Tennessee Guarantor RR Recovery, LLC Delaware Guarantor Salt Lake Behavioral Health, LLC Delaware Guarantor Salt Lake Psychiatric Realty, LLC Delaware Guarantor Samson Properties, LLC Florida Guarantor Schick Shadel of Florida, LLC Florida Guarantor Shadow Mountain Behavioral Health System, LLC Delaware Guarantor 5 Â Name of Subsidiary Jurisdiction of Organization Obligor Type SHC-KPH, LP Texas Guarantor Southeastern Hospital Corporation Tennessee Guarantor SP Behavioral, LLC Florida Guarantor Sparks Family Hospital, Inc. Nevada Guarantor Springfield Hospital, Inc. Delaware Guarantor Stonington Behavioral Health, Inc. Delaware Guarantor Summit Oaks Hospital, Inc. New Jersey Guarantor Sunstone Behavioral Health, LLC Tennessee Guarantor TBD Acquisition II, LLC Delaware Guarantor TBD Acquisition, LLC Delaware Guarantor TBJ Behavioral Center, LLC Delaware Guarantor Temecula Valley Hospital, Inc. California Guarantor Temple Behavioral Healthcare Hospital, Inc. Texas Guarantor Tennessee Clinical Schools, LLC Tennessee Guarantor Texas Cypress Creek Hospital, L.P. Texas Guarantor Texas Hospital Holdings, Inc. Delaware Guarantor Texas Laurel Ridge Hospital, L.P. Texas Guarantor Texas Oaks Psychiatric Hospital, L.P. Texas Guarantor Texas San Marcos Treatment Center, L.P. Texas Guarantor Texas West Oaks Hospital, L.P. Texas Guarantor The Arbour, Inc. Massachusetts Guarantor The Bridgeway, LLC Arkansas Guarantor The National Deaf Academy, LLC Florida Guarantor Three Rivers Behavioral Health, LLC South Carolina Guarantor Three Rivers Healthcare Group, LLC South Carolina Guarantor Toledo Holding Co., LLC Delaware Guarantor Turning Point Care Center, LLC Georgia Guarantor Two Rivers Psychiatric Hospital, Inc. Delaware Guarantor UBH of Oregon, LLC Delaware Guarantor UBH of Phoenix Realty, LLC Delaware Guarantor UBH of Phoenix, LLC Delaware Guarantor UHP LP Delaware Guarantor UHS Capitol Acquisition, LLC Delaware Guarantor UHS Children Services, Inc. Delaware Guarantor 6 Â Name of Subsidiary Jurisdiction of Organization Obligor Type UHS Funding, LLC Delaware Guarantor UHS Holding Company, Inc. Nevada Guarantor UHS Kentucky Holdings, L.L.C. Delaware Guarantor UHS Midwest Behavioral Health, LLC Delaware Guarantor UHS of Anchor, L.P. Delaware Guarantor UHS of Benton, LLC Delaware Guarantor UHS of Bowling Green, LLC Delaware Guarantor UHS of Centennial Peaks, L.L.C. Delaware Guarantor UHS of Cornerstone Holdings, Inc. Delaware Guarantor UHS of Cornerstone, Inc. Delaware Guarantor UHS of D.C., Inc. Delaware Guarantor UHS of Delaware, Inc. Delaware Guarantor UHS of Denver, Inc. Delaware Guarantor UHS of Dover, L.L.C. Delaware Guarantor UHS of Doylestown, L.L.C. Delaware Guarantor UHS of Fairmount, Inc. Delaware Guarantor UHS of Fuller, Inc. Massachusetts Guarantor UHS of Georgia Holdings, Inc. Delaware Guarantor UHS of Georgia, Inc. Delaware Guarantor UHS of Greenville, LLC Delaware Guarantor UHS of Hampton, Inc New Jersey Guarantor UHS of Hartgrove, Inc. Illinois Guarantor UHS of Lakeside, LLC Delaware Guarantor UHS of Lancaster, LLC Pennsylvania Guarantor UHS of Laurel Heights, L.P. Delaware Guarantor UHS of Madera, Inc. Delaware Guarantor UHS of New Orleans, LLC Louisiana Guarantor UHS of Oklahoma, LLC Oklahoma Guarantor UHS of Parkwood, Inc. Delaware Guarantor UHS of Peachford, L.P. Delaware Guarantor UHS of Pennsylvania, Inc. Pennsylvania Guarantor UHS of Phoenix, LLC Delaware Guarantor UHS of Provo Canyon, Inc. Delaware Guarantor UHS of Puerto Rico, Inc. Delaware Guarantor 7 Â Name of Subsidiary Jurisdiction of Organization Obligor Type UHS of Ridge, LLC Delaware Guarantor UHS of River Parishes, Inc. Louisiana Guarantor UHS of Rockford, LLC Delaware Guarantor UHS of Salt Lake City, L.L.C. Delaware Guarantor UHS of Savannah, L.L.C. Delaware Guarantor UHS of Spring Mountain, Inc. Delaware Guarantor UHS of Springwoods, L.L.C. Delaware Guarantor UHS of Summitridge, L.L.C. Delaware Guarantor UHS of Texoma, Inc. Delaware Guarantor UHS of Timberlawn, Inc. Texas Guarantor UHS of Timpanogos, Inc. Delaware Guarantor UHS of Tucson, LLC Delaware Guarantor UHS of Westwood Pembroke, Inc. Massachusetts Guarantor UHS of Wyoming, Inc. Delaware Guarantor UHS Oklahoma City LLC Oklahoma Guarantor UHS Sahara, Inc. Delaware Guarantor UHS Sub III, LLC Delaware Guarantor UHS-Corona, Inc. Delaware Guarantor UHSD, L.L.C. Nevada Guarantor UHSL, L.L.C. Nevada Guarantor United Healthcare of Hardin, Inc. Tennessee Guarantor Universal Health Services of Palmdale, Inc. Delaware Guarantor Universal Health Services of Rancho Springs, Inc. California Guarantor University Behavioral Health of El Paso, LLC Delaware Guarantor University Behavioral, LLC Florida Guarantor Valle Vista Hospital Partners, LLC Tennessee Guarantor Valle Vista, LLC Delaware Guarantor Valley Health System LLC Delaware Guarantor Valley Hospital Medical Center, Inc. Nevada Guarantor Wekiva Springs Center, LLC Delaware Guarantor Wellington Regional Medical Center, LLC Florida Guarantor Wellstone Regional Hospital Acquisition, LLC Indiana Guarantor 8 Â Name of Subsidiary Jurisdiction of Organization Obligor Type Willow Springs, LLC Delaware Guarantor Windmoor Healthcare Inc. Florida Guarantor Windmoor Healthcare of Pinellas Park, Inc. Delaware Guarantor Wisconsin Avenue Psychiatric Center, Inc. Delaware Guarantor Zeus Endeavors, LLC Florida Guarantor Â Pledged Security Collateral Â As of September 30, 2024, the obligations under the UHS Senior Secured Notes were secured by pledges of the equity of the following affiliates of the Company. Â Name of Issuer Issuer Jurisdiction of Organization Percent of Interest Owned Percent of Interest Pledged 2012 W. University Properties, LLC Delaware 100 100

2026 W. University Properties, LLC Delaware 100 100 ABS LINCS KY, LLC Virginia 100 100 ABS LINCS SC, Inc. South Carolina 100 100 ABS LINCS TN, Inc. Virginia 100 100 Aiken Regional Medical Centers, LLC South Carolina 100 100 Alabama Clinical Schools, Inc. Alabama 100 100 Alliance Health Center, Inc. Mississippi 100 100 Alternative Behavioral Services, Inc. Virginia 100 100 Ambulatory Surgery Center of Temecula Valley, Inc. California 100 100 ASC of Aiken, Inc. Delaware 100 100 ASC of East New Orleans, Inc. Delaware 100 100 ASC of Las Vegas, Inc. Nevada 100 100 ASC of Midwest City, Inc. Oklahoma 100 100 ASC of Puerto Rico, Inc. Delaware 100 100 ASC of Wellington, Inc. Florida 100 100 Ascend Health Corporation Delaware 100 100 Atlantic Shores Hospital, LLC Delaware 100 100 Auburn Regional Medical Center, Inc. Washington 100 100 AZ Holding 4, LLC Arizona 100 100 Beach 77 LP Delaware 99 99 Behavioral Educational Services, Inc. Delaware 100 100 Behavioral Health Connections, Inc. Texas 100 100 Behavioral Health Management, LLC Delaware 100 100 Behavioral Health Realty, LLC Delaware 100 100 Behavioral Healthcare LLC Delaware 100 100 Benchmark Behavioral Health System, Inc. Utah 100 100 BHC Alhambra Hospital, Inc. Tennessee 100 100 BH AZ Master, LLC Arizona 51 51 BHC Fairfax Hospital, Inc. Tennessee 100 100 BHC Fox Run Hospital, Inc. Tennessee 100 100 BHC Fremont Hospital, Inc. Tennessee 100 100 9 Â Name of Issuer Issuer Jurisdiction of Organization Percent of Interest Owned Percent of Interest Pledged BHC Health Services of Nevada, Inc. Nevada 100 100 BHC Heritage Oaks Hospital, Inc. Tennessee 100 100 BHC Holdings, Inc. Delaware 100 100 BHC Intermountain Hospital, Inc. Tennessee 100 100 BHC Management Services of Streamwood, LLC Delaware 100 100 BHC Mesilla Valley Hospital, LLC Delaware 100 100 BHC Montevista Hospital, Inc. Nevada 100 100 BHC Northwest Psychiatric Hospital, LLC Delaware 100 100 BHC of Indiana, General Partnership Tennessee 100 100 BHC Pinnacle Pointe Hospital, LLC Tennessee 100 100 BHC Properties, LLC Tennessee 100 100 BHC Sierra Vista Hospital, Inc. Tennessee 100 100 BHC Streamwood Hospital, Inc. Tennessee 100 100 Bloomington Meadows, General Partnership Tennessee 100 100 Brentwood Acquisition, Inc. Tennessee 100 100 Brentwood Acquisition-Shreveport, Inc. Delaware 100 100 Brynn Marr Hospital, Inc. North Carolina 100 100 Calvary Center, Inc. Delaware 100 100 Canyon Ridge Hospital, Inc. California 100 100 Canyon Ridge Real Estate, LLC Delaware 100 100 CAT Realty, LLC Delaware 100 100 Cape Girardeau Behavioral Health, LLC Missouri 75 75 CAT Seattle, LLC Delaware 100 100 CCS/Lansing, Inc. Michigan 100 100 Cedar Springs Hospital, Inc. Delaware 100 100 Central Montgomery Medical Center, L.L.C. Pennsylvania 100 100 Chalmette Medical Center, Inc. Louisiana 100 100 Childrenâ€™s Comprehensive Services, Inc. Tennessee 100 100 Clive Behavioral Health, LLC Delaware 52 52 Columbus Hospital Partners, LLC Tennessee 100 100 Columbus Hospital, LLC Delaware 100 100 Coral Shores Behavioral Health, LLC Delaware 100 100 Cornerstone Hospital Management, LLC Texas 58.3 58.3 Cornerstone Regional Hospital, LP Texas 50.2 50.2 Crossings Healthcare Solutions, Inc. Â 100 100 Cumberland Hospital Partners, LLC Delaware 100 100 Cumberland Hospital, LLC Virginia 100 100 Cypress Creek Real Estate, L.P. Delaware 99 99 Del Amo Hospital, Inc. California 100 100 DHP 2131 K St, LLC Delaware 100 100 Diamond Grove Center, LLC Delaware 100 100 District Hospital Partners, L.P. District of Columbia 100 100 Doctorsâ€™ Hospital of Shreveport, Inc. Louisiana 100 100 DVH Hospital Alliance LLC Delaware 100 100 Edinburg Ambulatory Surgical Center, Inc. Texas 100 100 Edinburg Holdings, Inc. Delaware 100 100 Edinburg MOB Properties, LLC Florida 100 100 10 Â Name of Issuer Issuer Jurisdiction of Organization Percent of Interest Owned Percent of Interest Pledged Emerald Coast Behavioral Hospital, LLC Delaware 100 100 Everglades Holdings, LLC Delaware 100 100 Fannin Management Services, LLC Texas 100 100 First Hospital Corporation of Virginia Beach Virginia 100 100 Forest View Psychiatric Hospital, Inc. Michigan 100 100 Fort Duncan Medical Center, Inc. Delaware 100 100 Fort Duncan Medical Center, L.P. Delaware 99 99 Fort Lauderdale Hospital, Inc. Florida 100 100 Foundations Recovery Network, LLC Tennessee 100 100 Friends Behavioral Health System, LP Pennsylvania 79.92 79.92 Friends GP, LLC Pennsylvania 80 80 FRN, Inc. Delaware 100 100 Frontline Behavioral Health, Inc. Delaware 100 100 Frontline Childrenâ€™s Hospital, L.L.C. Delaware 100 100 Frontline Hospital, LLC Delaware 100 100 Frontline Residential Treatment Center, LLC Delaware 100 100 Garfield Park Hospital, LLC Illinois 100 100 Glen Oaks Hospital, Inc. Texas 100 100 Great Plains Hospital, Inc. Missouri 100 100 Gulf Coast Treatment Center, Inc. Florida 100 100 Gulph Mills Associates, LLC Pennsylvania 100 100 H. C. Corporation Alabama 100 100 H. C. Partnership Alabama 100 100 Harbor Point Behavioral Health Center, Inc. Virginia 100 100 Havenwyck Hospital Inc. Michigan 100 100 HHC Augusta, Inc. Georgia 100 100 HHC Berkeley, Inc. South Carolina 100 100 HHC Delaware, Inc. Delaware 100 100 HHC Indiana, Inc. Indiana 100 100 HHC Kingwood Investment, LLC Delaware 100 100 HHC Oconee, Inc. South Carolina 100 100 HHC Ohio, Inc. Ohio 100 100 HHC Pennsylvania, LLC Delaware 100 100 HHC Poplar Springs, LLC Virginia 100 100 HHC River Park, Inc. West Virginia 100 100 HHC South Carolina, Inc. South Carolina 100 100 HHC St. Simons, Inc. Georgia 100 100 Hickory Trail Hospital, L.P. Delaware 99 99 High Plains Behavioral Health, L.P. Delaware 99 99 Holly Hill Hospital, LLC Tennessee 100 100 Holly Hill Real Estate, LLC North Carolina 100 100 Horizon Health Austin, Inc. Texas 100 100 Horizon Health Corporation Delaware 100 100 Horizon Health Hospital Services, LLC Delaware 100 100 Horizon Health Physical Rehabilitation Services, LLC Delaware 100 100 Horizon Mental Health Management, LLC Texas 100 100 HRI Clinics, Inc. Massachusetts 100 100 HRI Hospital, Inc. Massachusetts 100 100 11 Â Name of Issuer Issuer Jurisdiction of Organization Percent of Interest Owned Percent of Interest Pledged HSA Hill Crest Corporation Alabama 100 100 Hughes Center, LLC Virginia 100 100 Independence Amarillo, LLC Delaware 100 100 Independence Denison, LLC Delaware 100 100 Independence Laredo, LLC Delaware 100 100 Independence McAllen, LLC Delaware 100 100 Independence Wellington, LLC Delaware 100 100 Independence Physician Management, LLC Delaware 100 100 Indiana Psychiatric Institutes, LLC Delaware 100 100 InfoScriber Corporation Delaware 100 100 Island 77 LLC Delaware 100 100 KEYS Group Holdings LLC Delaware 100 100 Keystone Charlotte LLC North Carolina 100 100 Keystone Continuum, LLC Tennessee 100 100 Keystone Education and Youth Services, LLC Tennessee 100 100 Keystone Marion, LLC Virginia 100 100 Keystone Memphis, LLC Tennessee 100 100 Keystone NPS LLC California 100 100 Keystone Newport News, LLC Virginia 100 100 Keystone Richland Center LLC Ohio 100 100 Keystone WSNC, L.L.C. North Carolina 100 100 Keystone/CCS Partners LLC Delaware 100 100 Kids Behavioral Health of Utah, Inc. Utah 100 100 Kingwood Pines Hospital, LLC Texas 100 100 KMI Acquisition, LLC Delaware 100 100 KOP Limited South Carolina 100 100 La Amistad Residential Treatment Center, LLC Florida 100 100 Lancaster Behavioral Health Hospital, LLC Pennsylvania 50 50 Lancaster Hospital Corporation California 100 100 Laredo ASC, Inc. Texas 100 100 Laredo Holdings, Inc. Delaware 100 100 Laredo Regional, Inc. Delaware 100 100 Laredo Regional Medical Center, LP Delaware 80.14 80.14 Laurel Oaks Behavioral Health Center, Inc. Delaware 100 100 Lebanon Hospital Partners, LLC Tennessee 100 100 Liberty Point Behavioral Healthcare, LLC Delaware 100 100 Manatee Memorial Hospital, L.P. Delaware 100 100 Mayhill Behavioral Health, LLC Texas 100 100 Mayhill Behavioral Properties, LLC Texas 100 100 McAllen Holdings, Inc. Delaware 100 100 McAllen Hospitals, L.P. Delaware 100 100 McAllen Medical Center, Inc. Delaware 100 100 Mental Health Outcomes, LLC Delaware 100 100 Meridell Achievement Center, Inc. Texas 100 100 Merion Building Management, Inc. Delaware 100 100 Mesilla Valley Hospital, Inc. New Mexico 100 100 Michigan BH JV, LLC Michigan 74 74 Michigan Healthcare Staffing, LLC Michigan 100 100 12 Â Name of Issuer Issuer Jurisdiction of Organization Percent of Interest Owned Percent of Interest Pledged Michigan Psychiatric Services, Inc. Michigan 100 100 Millwood Hospital, L.P. Texas 99 99 Milwaukee Behavioral Health, LLC Wisconsin 100 100 Nashville Rehab, LLC Tennessee 100 100 Neuro Institute of Austin, L.P. Texas 99 99 NEWCO Oregon, Inc. Delaware 100 100 North Spring Behavioral Healthcare, Inc. Tennessee 100 100 Northern Indiana Partners, LLC Tennessee 100 100 Northern Nevada Diagnostic Imaging-Spanish Springs, L.L.C Nevada 100 100 Northwest Texas Healthcare System, Inc. Texas 100 100 NWTHS Management, LLC Texas 100 100 Oak Plains Academy of Tennessee, Inc. Tennessee 100 100 Ocala Behavioral Health, LLC Delaware 100 100 Oregon Psychiatric Realty, LLC Delaware 100 100 Palm Point Behavioral Health, LLC Florida 100 100 Palmetto Behavioral Health Holdings, LLC Delaware 100 100 Palmetto Behavioral Health Solutions, LLC South Carolina 100 100 Palmetto Behavioral Health System, L.L.C. South Carolina 100 100 Palmetto Lowcountry Behavioral Health, L.L.C. South Carolina 100 100 Palmetto Pee Dee Behavioral Health, L.L.C. South Carolina 100 100 Park Healthcare Company Tennessee 100 100 Pasteur Healthcare Properties, LLC Delaware 100 100 Peak Behavioral Health Services, LLC Delaware 100 100 Pendleton Methodist Hospital, L.L.C. Delaware 100 100 Pennsylvania Clinical Schools, Inc. Pennsylvania 100 100 PR Holding II, Inc. Puerto Rico 100 100 Premier Behavioral Solutions of Florida, Inc. Delaware 100 100 Premier Behavioral Solutions, Inc. Delaware 100 100 Pride Institute, Inc. Minnesota 100 100 PSJ Acquisition, LLC North Dakota 100 100 Psychiatric Realty, LLC Delaware 100 100 Psychiatric Solutions, Inc. Delaware 100 100 Psychiatric Solutions Hospitals, LLC Delaware 100 100 Psychiatric Solutions of Virginia, Inc. Tennessee 100 100 PsychManagement Group, Inc. West Virginia 100 100 Radiation Oncology Center of Aiken, LLC South Carolina 95 95 Ramsay Managed Care, LLC Delaware 100 100 Ramsay Youth Services of Georgia, Inc. Delaware 100 100 Red Rock Solutions, LLC Delaware 100 100 Relational Therapy Clinic, Inc. Louisiana 100 100 Ridge Outpatient Counseling, L.L.C. Kentucky 100 100 River Crest Hospital, Inc. Texas 100 100 River Oaks, Inc. Louisiana 100 100 Riveredge Hospital Holdings, Inc. Delaware 100 100 Riveredge Hospital, Inc. Illinois 100 100 Riveredge Real Estate, Inc. Illinois 100 100 13 Â Name of Issuer Issuer Jurisdiction of Organization Percent of Interest Owned Percent of Interest Pledged Riverside Medical Clinic Patient Services, L.L.C. California 100 100 Rolling Hills Hospital, LLC Tennessee 100 100 RR Behavioral Realty LLC Delaware 100 100 RR Recovery, LLC Delaware 100 100 Salt Lake Behavioral Health, LLC Delaware 100 100 Salt Lake Psychiatric Realty, LLC Delaware 100 100 Samson Properties, LLC Florida 100 100 Schick Shadel of Florida, LLC Florida 100 100 Shadow Mountain Behavioral Health System, LLC Delaware 100 100 SHC-KPH, LP Texas 99.1 99.1 Somerset, Incorporated California 100 100 Southeastern Hospital Corporation Tennessee 100 100 Southside Imaging Center, LLC South Carolina 100 100 SP Behavioral, LLC Florida 100 100 Sparks Family Hospital, Inc. Nevada 100 100 Spokane Behavioral Health, LLC Washington 80 80 Spokane Valley Behavioral Health, LLC Delaware 100 100 Springfield Hospital, Inc. Delaware 100 100 St. Louis Behavioral Medicine Institute, Inc. Missouri 100 100 Stonington Behavioral Health, Inc. Delaware 100 100 Summerlin Hospital Medical Center, LP Delaware 93.2 93.2 Summit Oaks Hospital, Inc. New Jersey 100 100 Sunstone Behavioral Health, LLC Tennessee 100 100 TBD Acquisition, LLC Delaware 100 100 TBD Acquisition II, LLC Delaware 100 100 TBJ Behavioral Center, LLC Delaware 100 100 Temecula Valley Hospital, Inc. California 100 100 Temple Behavioral Healthcare Hospital, Inc. Texas 100 100 Tennessee Clinical Schools, LLC Tennessee 100 100 Texas Cypress Creek Hospital, L.P. Texas 99 99 Texas Hospital Holdings, Inc. Delaware 100 100 Texas Hospital Holdings, LLC Texas 100 100 Texas Laurel Ridge Hospital, L.P. Texas 99 99 Texas Oaks Psychiatric Hospital, L.P. Texas 99 99 Texas San Marcos Treatment Center, L.P. Texas 99 99 Texas West Oaks Hospital, L.P. Texas 99 99 The Arbour, Inc. Massachusetts 100 100 The Bridgeway, LLC Arkansas 100 100 The National Deaf Academy, LLC Florida 100 100 Three Rivers Behavioral Health, LLC South Carolina 100 100 Three Rivers Healthcare Group, LLC South Carolina 100 100 Three Rivers Residential Treatment/Midlands Campus, Inc. South Carolina 100 100 Three Rivers SPE Holding, LLC South Carolina 100 100 Toledo Holding Co., LLC Delaware 100 100 Turning Point Care Center, LLC Georgia 100 100 Two Rivers Psychiatric Hospital, Inc. Delaware 100 100 14 Â Name of Issuer Issuer Jurisdiction of Organization Percent of Interest Owned Percent of Interest Pledged UBH of Phoenix, LLC Delaware 100 100 UBH of Phoenix Realty, LLC Delaware 100 100 UBH of Oregon, LLC Delaware 100 100 UHP LP Delaware 100 100 UHS Advisory, Inc. Delaware 100 100 UHS BH Telepsych, LLC Delaware 100 100 UHS Building Solutions, Inc. Delaware 100 100 UHS Capitol Acquisition, LLC Delaware 100 100 UHS Children Services, Inc. Delaware 100 100 UHS Funding, LLC Delaware 100 100 UHS Good Samaritan, L.L.C. Delaware 100 100 UHS Holding Company, Inc. Nevada 100 100 UHS International, Inc. Delaware 100 100 UHS Kentucky Holdings, L.L.C. Delaware 100 100 UHS Midwest Behavioral Health, LLC Delaware 100 100 UHS Midwest Center for Youth and Families, LLC Indiana 100 100 UHS Oklahoma City LLC Oklahoma 100 100 UHS Receivables Corp. Delaware 100 100 UHS Sahara, Inc. Delaware 100 100 UHS Surgical Hospital of Texoma, LLC Texas 100 100 UHS of Anchor, L.P. Delaware 100 100 UHS of Benton Day School and Treatment Program, Inc. Delaware 100 100 UHS of Benton, LLC Delaware 100 100 UHS of Bowling Green, LLC Delaware 100 100 UHS of Centennial Peaks, L.L.C. Delaware 100 100 UHS of Cornerstone Holdings, Inc. Delaware 100 100 UHS of Cornerstone, Inc. Delaware 100 100 UHS of D.C., Inc. Delaware 100 100 UHS of Delaware, Inc. Delaware 100 100 UHS of Denver, Inc. Delaware 100 100 UHS of Dover, L.L.C. Delaware 100 100 UHS of Doylestown, L.L.C. Delaware 100 100 UHS of Fairmount, Inc. Delaware 100 100 UHS of Fuller, Inc. Massachusetts 100 100 UHS of GB, Inc. Delaware 100 100 UHS of Georgia Holdings, Inc. Delaware 100 100 UHS of Georgia, Inc. Delaware 100 100 UHS of Greenville, LLC Delaware 100 100 UHS of Hampton Learning Center, Inc. New Jersey 100 100 UHS of Hampton, Inc. New Jersey 100 100 UHS of Hartgrove, Inc. Illinois 100 100 UHS of Indiana, Inc. Indiana 100 100 UHS of Kootenai River, Inc. Delaware 100 100 UHS of Lakeside, LLC Delaware 100 100 UHS of Lancaster, LLC Pennsylvania 100 100 UHS of Laurel Heights, L.P. Delaware 100 100 UHS of Madera, Inc. Delaware 100 100 15 Â Name of Issuer Issuer Jurisdiction of Organization Percent of Interest Owned Percent of Interest Pledged UHS of New Orleans, LLC Louisiana 100 100 UHS of No. Nevada, LLC Nevada 100 100 UHS of Oklahoma Receivables, L.L.C Delaware 100 100 UHS of Oklahoma, LLC Oklahoma 100 100 UHS of Parkwood, Inc. Delaware 100 100 UHS of Peachford, L.P. Delaware 100 100 UHS of Pennsylvania, Inc. Pennsylvania 100 100 UHS of Phoenix, LLC Delaware 100 100 UHS of Provo Canyon, Inc. Delaware 100 100 UHS of Puerto Rico, Inc. Delaware 100 100 UHS of Ridge, LLC Delaware 100 100 UHS of River Parishes, Inc. Louisiana 100 100 UHS of Rockford, LLC Delaware 100 100 UHS of Salt Lake City, L.L.C. Delaware 100 100 UHS of Savannah, L.L.C. Delaware 100 100 UHS of Spring Mountain, Inc. Delaware 100 100 UHS of Springwoods, L.L.C. Delaware 100 100 UHS of SummitRidge, L.L.C. Delaware 100 100 UHS of Sutton, Inc. Delaware 100 100 UHS of Talbot, L.P. Delaware 100 100 UHS of Texoma, Inc. Delaware 100 100 UHS of Timberlawn, Inc. Texas 100 100 UHS of Timpanogos, Inc. Delaware 100 100 UHS of Tuscon, LLC Delaware 100 100 UHS of Westwood Pembroke, Inc. Massachusetts 100 100 UHS of Wyoming, Inc. Delaware 100 100 UHS-Corona, Inc. Delaware 100 100 UHS-Lakeland Medical Center, L.L.C. Delaware 100 100 UHS Sub III, LLC Delaware 100 100 UHSD, L.L.C Nevada 100 100 UHSF, L.L.C Delaware 100 100 UHSL, L.L.C Nevada 100 100 UK Acquisition No. 6, Ltd United Kingdom 100 65 United Healthcare of Hardin, Inc. Tennessee 100 100 Universal Community Behavioral Health, Inc. Pennsylvania 100 100 Universal HMO, Inc. Nevada 100 100 Universal Health Network, Inc. Nevada 100 100 Universal Health Recovery Centers, Inc. Pennsylvania 100 100 Universal Health Services of Cedar Hill, Inc. Texas 100 100 Universal Health Services of Palmdale, Inc. Delaware 100 100 Universal Health Services of Rancho Springs, Inc. California 100 100 Universal Treatment Centers, Inc. Delaware 100 100 University Behavioral, LLC Florida 100 100 University Behavioral Health of El Paso, LLC Delaware 100 100 Valle Vista Hospital Partners, LLC Tennessee 100 100 Valle Vista, LLC Delaware 100 100 Valley Health System LLC Delaware 100 100 Valley Hospital Medical Center, Inc. Nevada 100 100 16 Â Name of Issuer Issuer Jurisdiction of Organization Percent of Interest Owned Percent of Interest Pledged Virgin Islands Behavioral Services, Inc. Virginia 100 100 Vista Diagnostic Center, L.L.C. Nevada 100 100 Wekiva Springs Center, LLC Delaware 100 100 Wellington Physician Alliances, Inc. Florida 100 100 Wellington Regional Medical Center, LLC Florida 100 100 Wellstone Holdings, LLC Delaware 100 100 Wellstone Regional Hospital Acquisition, LLC Indiana 98 98 West Church Partnership Illinois 100 100 West Oaks Real Estate, L.P. Texas 99 99 Westside Outpatient Center, LLC Florida 50 50 Willow Springs, LLC Delaware 100 100 Windmoor Healthcare Inc. Florida 100 100 Windmoor Healthcare of Pinellas Park, Inc. Delaware 100 100 Wisconsin Avenue Psychiatric Center, Inc. Delaware 100 100 Zeus Endeavors, LLC Florida 100 100 17 EX-31.1 3 uhs-ex31_1.htm EX-31.1 EX-31.1 Â Â Exhibit 31.1 CERTIFICATIONâ€“Chief Executive Officer I, Marc D. Miller, certify that: 1. I have reviewed this quarterly report on Form 10-Q of Universal Health Services, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and 5. The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Date: November 8, 2024 /s/ Marc D. Miller Marc D. Miller Chief Executive Officer Â EX-31.2 4 uhs-ex31_2.htm EX-31.2 EX-31.2 Exhibit 31.2 CERTIFICATIONâ€“Chief Financial Officer I, Steve Filton, certify that: 1. I have reviewed this quarterly report on

Form 10-Q of Universal Health Services, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; 4. The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c) Evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d) Disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and 5. The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions): a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. Date: November 8, 2024 /s/ Steve Filton Steve Filton Executive Vice President and Chief Financial Officer Â EX-32.1 5 uhs-ex32_1.htm EX-32.1 EX-32.1 Exhibit 32.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report of Universal Health Services, Inc. (the â€œCompanyâ€) on Form 10-Q for the quarter ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I, Marc D. Miller, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Â§ 1350, as adopted pursuant to Â§ 906 of the Sarbanes-Oxley Act of 2002, and to the best of my knowledge, that: (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the end of, and for the period covered by, the Report. /s/ Marc D. Miller Marc D. Miller Chief Executive Officer November 8, 2024 A signed original of this written statement required by Section 906 has been provided to Universal Health Services, Inc. and will be retained and furnished to the Securities and Exchange Commission or its staff upon request. Â EX-32.2 6 uhs-ex32_2.htm EX-32.2 EX-32.2 Exhibit 32.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the Quarterly Report of Universal Health Services, Inc. (the â€œCompanyâ€) on Form 10-Q for the quarter ended September 30, 2024, as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), I, Steve Filton, Executive Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Â§ 1350, as adopted pursuant to Â§ 906 of the Sarbanes-Oxley Act of 2002, and to the best of my knowledge, that: (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the end of, and for the period covered by, the Report. /s/ Steve Filton Steve Filton Executive Vice President and Chief Financial Officer November 8, 2024 A signed original of this written statement required by Section 906 has been provided to Universal Health Services, Inc. and will be retained and furnished to the Securities and Exchange Commission or its staff upon request. Â EX-101.SCH 7 uhs-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 100000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 100010 - Statement - Condensed Consolidated Statements of Income link:presentationLink link:calculationLink link:definitionLink 100020 - Statement - Condensed Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 100030 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 100040 - Statement - Condensed Consolidated Statements of Changes in Equity link:presentationLink link:calculationLink link:definitionLink 100050 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - General link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Relationship with Universal Health Realty Income Trust and Other Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Other Noncurrent liabilities and Redeemable/Noncontrolling Interests link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Treasury link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Fair Value Measurement link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Earnings Per Share Data and Stock Based Compensation link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Dispositions and acquisitions link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Dividends link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Revenue link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Lease Accounting link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Recent Accounting Standards link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Relationship with Universal Health Realty Income Trust and Other Related Party Transactions (Tables) link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Treasury (Tables) link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Fair Value Measurement (Tables) link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Earnings Per Share Data and Stock Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Revenue (Tables) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Lease Accounting (Tables) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - General - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Relationship with Universal Health Realty Income Trust and Other Related Party Transactions - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Relationship with Universal Health Realty Income Trust and Other Related Party Transactions - Additional Information 1 (Detail) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Relationship with Universal Health Realty Income Trust and Other Related Party Transactions - Additional Information 2 (Detail) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Relationship with Universal Health Realty Income Trust and Other Related Party Transactions - Additional Information 3 (Detail) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Relationship with Universal Health Realty Income Trust and Other Related Party Transactions - Additional Information 4 (Detail) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Summary of Details of Hospitals Leased from Trust (Detail) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Summary of Details of Hospitals Leased from Trust (Parenthetical) (Detail) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Other Noncurrent Liabilities and Redeemable/Noncontrolling Interests - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Treasury - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Summary of Effects of Foreign Currency Forward Exchange Contracts on Result of Operations (Detail) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Summary of Cash, Cash Equivalents and Restricted Cash Reported In Condensed Consolidated Statements of Cash Flows (Detail) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Summary of Assets and Liabilities Recorded at Fair Value on Recurring Basis (Detail) link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Segment Reporting (Detail) link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - Segment Reporting (Parenthetical) (Detail) link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Computation of Basic and Diluted Earnings Per Share (Detail) link:presentationLink link:calculationLink link:definitionLink 995835 - Disclosure - Earnings Per Share Data and Stock Based Compensation - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995845 - Disclosure - Dispositions and Acquisitions - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995855 - Disclosure - Dividends - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995865 - Disclosure - Income Taxes - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995875 - Disclosure - Schedule of Disaggregates Revenue by Major Source (Detail) link:presentationLink link:calculationLink link:definitionLink 995885 - Disclosure - Lease Accounting - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 995895 - Disclosure - Supplemental Cash Flow Information Related to Leases (Detail) link:presentationLink link:calculationLink link:definitionLink Decrease in capital reserves of commercial insurance subsidiary Increase (decrease) in capital reserves of commercial insurance subsidiary. Increase Decrease In Capital Reserves Of Commercial Insurance Subsidiary Decrease in capital reserves of commercial insurance subsidiary Statement [Line Items] Statement [Line Items] Liabilities, Fair Value Disclosure [Abstract] Liabilities: Professional Malpractice Liability Insurance [Member] Professional Liability Debt Instrument [Axis] Debt Instrument Increase (Decrease) in Accounts Receivable Accounts receivable Plan Name [Domain] Purchased several excess policies through commercial insurance amount exhausted Self Insured Amount Per Occurrence Exhausted Self insured amount per occurrence exhausted. Other patient revenue and adjustments net, Other Patient Revenue And Adjustments Net [Member] Other Patient Revenue and Adjustments, Net Increase (Decrease) in Other Operating Assets and Liabilities, Net Other working capital accounts Increase (Decrease) in Other Operating Assets and Liabilities, Net, Total Timeline of remittitur Loss Contingency, Timeline Of Remittitur Loss contingency, timeline to either accept the remittitur or refuse the remittitur. Entity Address, Postal Zip Code Entity Address, Postal Zip Code All Other Events All Other Events [Member] All other events. Weighted Average Number of Shares Outstanding, Diluted, Adjustment Add: Other share equivalents Net effect of dilutive stock options and grants based on the treasury stock method Weighted Average Number of Shares Outstanding, Diluted, Adjustment, Total Fair Value, Recurring and Nonrecurring [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Revenue from contract with customer excluding assessed tax percentage. Revenue From Contract With Customer Excluding Assessed Tax Percentage Percentage of Net Revenue Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code One three six month SOFR rate plus index based loans. One Three Six Month S O F R Rate Plus Index Based Loans [Member] One Three Six Month SOFR Rate Plus Index Based Loans Interest Paid, Excluding Capitalized Interest, Operating Activities Interest paid Loss Contingency, Damages Sought, Value Plaintiff's counsel's fee demand Supplies Expense Supplies expense New senior secured credit facility. New Senior Secured Credit Facility [Member] New Senior Secured Notes Foreign Exchange Forward [Member] Foreign Currency Forward Exchange Contracts Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV Operating leases, number of renewal options at existing lease rates. Operating Leases Number Of Renewal Options At Existing Lease Rates Number of renewal options at existing lease rates Accrued Liabilities Other Accrued Liabilities Other [Member] Accrued liabilities other. Property, Plant, and Equipment, Lessor Asset under Operating Lease [Table Text Block] Remaining Renewal Options and Terms for Each of Three Hospital Facilities Leased from Trust Fair Value, Inputs, Level 2 [Member] Basis of Fair Value Measurement, Level 2 Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Liability for Claims and Claims Adjustment Expense Compensation liability claims Liability for Claims and Claims Adjustment Expense, Total Liability for Claims and Claims Adjustment Expense, Beginning Balance Liability for Claims and Claims Adjustment Expense, Ending Balance Clive Behavioral Health Hospital. Clive Behavioral Health Hospital [Member] Clive Behavioral Health Hospital Debt, due during months 49 to 60 Long-Term Debt, Maturity, Year Five Self insured amount per occurrence. Self Insured Amount Per Occurrence Purchased several excess policies through commercial insurance carriers per occurrence Long-Term Debt, Current Maturities Current maturities of long-term debt Long-Term Debt, Current Maturities, Total Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Gross inpatient revenues. Gross Inpatient Revenues Gross inpatient revenues Depreciation for discontinued operations and amortization. Depreciation For Discontinued Operations And Amortization Depreciation & amortization Foreign and U.S. state and local jurisdictions statutes of limitations. Foreign And United States And Local Jurisdictions Statutes Of Limitations Foreign and U.S. state and local jurisdictions have statutes of limitations, in years Major Property Class [Domain] Major Property Class Tranche B term loan. Tranche B Term Loan [Member] Tranche B Term Loan Product and Service [Axis] Product and Service Investment Income, Dividend Dividend Investment, Name [Domain] Investment, Name Treasury Stock [Text Block] Treasury Term loan A facility. Term Loan A Facility [Member] Term Loan A Surgery center. Surgery center [Member] Surgery center Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative Class of Treasury Stock [Table] Class Of Treasury Stock [Table] Restricted stock awards, restricted stock units and performance based restricted stock units. Restricted Stock Awards Restricted Stock Units And Performance Based Restricted Stock Units [Member] Restricted Stock Awards, Restricted Stock Units and Performance Based Restricted Stock Units Related Party Transaction [Line Items] Related Party Transaction [Line Items] Document Information [Table] Document Information [Table] Operating leases, number of renewal options at fair market value lease rates. Operating Leases Number Of Renewal Options At Fair Market Value Lease Rates Number of renewal options at fair market lease rates Title and Position [Axis] Title of Individual Revenue from Contract with Customer [Text Block] Revenue Debt instrument yield percentage. Debt Instrument Yield Percentage Senior notes yield percentage Amount claimed from over payments of legal settlements. Amount Claimed From Over Payments Of Legal Settlements Amount claimed from over payments of legal settlements Line of Credit Facility, Remaining Borrowing Capacity Line of credit facility, available borrowing capacity One two three six month libor rate plus index based loans. One Two Three Six Month L I B O R Rate Plus Index Based Loans [Member] One Two Three Six Month LIBOR Rate Plus Index Based Loans Aiken Regional Medical Center. Aiken Regional Medical Center [Member] Aiken Regional Medical Center Number of square feet to be constructed in medical office building. Number Of Square Feet To Be Constructed In Medical Office Building Number of square feet to be constructed IOWA Iowa Net income (loss) to UHS / noncontrolling interests Net income excluding redeemable noncontrolling interests. Net Income Excluding Redeemable Noncontrolling Interests The Pavilion Behavioral Health System The Pavilion Behavioral Health System [Member] The pavilion behavioral health system. Entity Central Index Key Entity Central Index Key Income Tax Examination, Penalties and Interest Accrued Accrued interest and penalties Income Tax Examination, Penalties and Interest Accrued, Total Increase (Decrease) in Operating Capital [Abstract] Changes in assets & liabilities, net of effects from acquisitions and dispositions: Self insurance reserve amount exhausted Self Insurance Reserve Amount Exhausted Self insurance reserve amount exhausted. Common Class C [Member] Class C Schedule of supplemental cash flow information related to leases. Schedule Of Supplemental Cash Flow Information Related To Leases Table [Text Block] Supplemental Cash Flow Information Related to Leases Other Noncurrent Assets Other Noncurrent Assets [Member] Increase (Decrease) in Prepaid Expense and Other Assets Other assets and deferred charges Business Description and Basis of Presentation [Text Block] General Debt, due during months 37 to 48 Long-Term Debt, Maturity, Year Four Income Statement [Abstract] Number of lease renewal option exercised. Number Of Lease Renewal Option Exercised Number of lease renewal option exercised Entity Address, State or Province Entity Address, State or Province Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income before income taxes Parent [Member] UHS Common Stockholders' Equity Number of freestanding emergency departments to be acquired in business acquisition. Number Of Freestanding Emergency Departments To Be Acquired In Business Acquisition Number of free-standing emergency departments to be acquired Percentage of insurance deductible. Percentage Of Insurance Deductible Percentage of insurance deductible Five point zero zero percent senior secured notes due two thousand twenty six. Five Point Zero Zero Percent Senior Secured Notes Due Two Thousand Twenty Six [Member] 5.00% Senior Secured Notes due 2026 Punitive Damages punitive damages [Member] Punitive damages. Equity, Class of Treasury Stock [Line Items] Equity Class Of Treasury Stock [Line Items] NEVADA Nevada Medicare. Medicare [Member] Medicare Operating leases, renewal options term at existing lease rates. Operating Leases Renewal Options Term At Existing Lease Rates Renewal options term at existing lease rates Cover [Abstract] Earnings Per Share, Basic Basic earnings per share

attributable to UHS Earnings per basic share attributable to UHS: Earnings Per Share, Basic, Total Common class D. Common Class D [Member] Class D Financial liability from fair value of real estate assets exchanged. Financial Liability From Fair Value Of Real Estate Assets Exchanged Financial liability included in debt Operating Expenses [Abstract] Operating charges: Finance Lease, Principal Payments Financing cash flows from finance leases Operating leases additional renewal options at fair market value lease rates expiration year. Operating Leases Additional Renewal Options At Fair Market Value Lease Rates Expiration Year Operating leases additional renewal options at fair market value lease rates expiration year Decrease in outstanding borrowings Line of Credit Facility, Increase (Decrease), Net Line of credit facility increased (decreased) amount Line of Credit Facility, Increase (Decrease), Net, Total Share-Based Payment Arrangement, Expense Compensation cost recognized, pre-tax charge Long-Term Debt Debt instrument carrying amount Long-Term Debt, Total 4.625% Senior Secured Notes due 2029 Four Point Six Two Five Percent Senior Secured Notes Due Two Thousand Twenty Nine [Member] Four point six two five percent senior secured notes due two thousand twenty nine. Estimated payments to acquire life insurance policies. Estimated Payments To Acquire Life Insurance Policies Estimated payments to acquire life insurance policies Behavioral health care facility. Behavioral Health Care Facility [Member] Behavioral Health Care Facility Number of square feet to be acquired in edical office building. Number Of Square Feet To Be Acquired In Medical Office Building Number of square feet to be acquired Plan Name [Axis] Segment Reporting [Abstract] Assets, Current [Abstract] Current assets: Payments of Ordinary Dividends, Common Stock Dividends paid Trust owned by chief executive officer. Trust Owned By Chief Executive Officer [Member] Trust Owned by CEO Net Cash Provided by (Used in) Operating Activities Net cash provided by operating activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect [Abstract] Rate adjustment to one month Eurodollar rate on credit facility borrowings. Rate Adjustment To One Month Eurodollar Rate On Credit Facility Borrowings Rate adjustment to one month Eurodollar rate on credit facility borrowings Product and Service [Domain] Product and Service Lessee, Operating Lease, Term of Contract Initial term of real estate lease Lease initial terms Outflows from foreign exchange contracts that hedge our net U.K. investment Payments for (Proceeds from) Hedge, Investing Activities Payments for (Proceeds from) Hedge, Investing Activities, Total Property, Plant and Equipment, Net Property, plant and equipment, net, Total Income taxes. Income Taxes [Line Items] Income Taxes [Line Items] Net Cash Provided by (Used in) Operating Activities [Abstract] Cash Flows from Operating Activities: Fair Value, Recurring [Member] Recurring Proceeds from Sale of Real Estate Cash received for sale of real estate asset Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Summary of Assets and Liabilities Recorded at Fair Value on Recurring Basis Accounts Payable and Other Accrued Liabilities, Current Accounts payable and other liabilities Behavioral health care facility two. Behavioral Health Care Facility Two [Member] Behavioral Health Care Facility Two Securitized borrowings credit facility borrowing capacity. Securitized Borrowings Credit Facility Borrowing Capacity Accounts receivable securitization program credit facility, borrowing capacity Operating leases additional number of renewal options at fair market value lease rates. Operating Leases Additional Number Of Renewal Options At Fair Market Value Lease Rates Operating leases additional number of renewal options at fair market value lease rates Trebled Damages Trebled Damages [Member] Trebled damages. Income taxes. Income Taxes [Table] Income Taxes [Table] Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Comprehensive income: SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters, Earned Premium Property insurance Statement of Cash Flows [Abstract] Real Estate [Domain] Real Estate Managed medicaid. Managed Medicaid [Member] Managed Medicaid Payment on September 26, 2029 Group Ten [Member] Group ten. Equity Method Investments Carrying value of investment in Trust Number of beds available in behavioral health care facility. Number Of Beds Available In Behavioral Health Care Facility Number of bed available in behavioral health care facility Long-Term Debt, Fair Value Fair value of debt Payments for Legal Settlements Repayment of legal settlement amount on demand Entity [Domain] Entity Restricted Stock [Member] Restricted Stock Lease rent receivable. Lease Rent Receivable Lease rent receivable Number of behavioral health care hospitals. Number Of Behavioral Health Care Hospitals Number of behavioral health care hospitals Equity Components [Axis] Equity Components Entity Address, Address Line One Entity Address, Address Line One Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Computation of Basic and Diluted Earnings per Share Operating leases, renewal options term at fair market value lease rates. Operating Leases Renewal Options Term At Fair Market Value Lease Rates Renewal options term at fair market lease rates Related Party Transaction [Table] Schedule Of Related Party Transactions By Related Party [Table] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Restricted shares and restricted units, net of cancellations, granted during period Hedging Designation [Domain] Hedging Designation Retained Earnings, Appropriated [Member] Retained Earnings MICHIGAN Michigan Subsequent Event Type [Axis] Property, Plant, and Equipment, Lessor Asset under Operating Lease [Table] Property Subject To Or Available For Operating Lease By Major Property Class [Table] Share-Based Payment Arrangement, Exercise of Option, Tax Benefit Issued/(converted) Lease expiration, month and year. Lease Expiration Month And Year End of Lease Term Line of Credit Facility, Maximum Borrowing Capacity Line of credit facility, borrowing capacity Hedging Relationship [Axis] Hedging Relationship Payments of Ordinary Dividends, Noncontrolling Interest Profit distributions to noncontrolling interests Accounting Standards Update and Change in Accounting Principle [Text Block] Recent Accounting Standards Purchase of minority ownership interest percentage. Purchase Of Minority Ownership Interest Percentage Purchase of minority ownership interest percentage Remaining Two Renewal Options Remaining Two Renewal Options [Member] Remaining two renewal options. Amendment Flag Amendment Flag Net Income (Loss) Attributable to Noncontrolling Interest Less: Net income (loss) attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest, Total Operating Lease, Liability, Noncurrent Operating lease liabilities noncurrent Debt Instrument, Name [Domain] Debt Instrument, Name Net income attributable to UHS Lessee, Lease, Description [Table] Lessee Lease Description [Table] Variable Rate [Domain] Variable Rate Noncontrolling Interest [Line Items] Minority Interest [Line Items] Limited Liability Companies. Limited Liability Companies [Member] Limited Liability Companies Labor and Related Expense Salaries, wages and benefits Equity Component [Domain] Equity Component Statistical Measurement [Domain] Statistical Measurement Pre-tax decrease to reserves for self-insured workers' compensation liability claims Pre-tax Decrease To Reserves For Self-insured Workers' Compensation Liability Claims Pre-tax decrease to reserves for self-insured workers' compensation liability claims. Outside owners. Outside Owners [Member] Outside Owners Distributions to noncontrolling interests Redeemable Non controlling Interest, Distributions Redeemable non-controlling interest, distributions. Number of hospital facilities. Number Of Hospital Facilities Number of hospital facilities Number of hospital facilities Other noncurrent liabilities and redeemable noncontrolling interests. Other Noncurrent Liabilities And Redeemable Noncontrolling Interests [Text Block] Other Noncurrent liabilities and Redeemable/Noncontrolling Interests Catastrophic Event [Domain] Catastrophic Event Other Nonoperating Income (Expense) Other (income) expense, net Other Nonoperating Income (Expense), Total 5.050% Senior Secured Notes due 2034 Five Point Zero Five Zero Percent Senior Secured Notes Due Two Thousand Thirty Four [Member] Five point zero five zero percent senior secured notes due two thousand thirty four. Redeemable Noncontrolling Interest, Equity, Carrying Amount Balance Balance Redeemable non-controlling interest balances Redeemable Noncontrolling Interest, Equity, Carrying Amount, Total Disaggregation of Revenue [Table] Disaggregation Of Revenue [Table] Payment for proceeds from purchase of information technology applications. Payment For Proceeds From Purchase Of Information Technology Applications Costs incurred for purchase of information technology applications, net of refunds Proceeds from Lines of Credit Additional borrowings, net Proceeds from Lines of Credit, Total Medicare accelerated and advance payment program. Medicare Accelerated And Advance Payment Program [Member] Medicare Accelerated and Advance Payment Program Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net income Net income Disclosure of general information. Disclosure Of General Information [Table] Disclosure Of General Information [Table] Canyon Creek Behavioral Health. Canyon Creek Behavioral Health [Member] Canyon Creek Behavioral Health Operating Lease, Payments Operating cash flows from operating leases Other Assets, Noncurrent [Abstract] Other assets: Cumberland Hospital for Children and Adolescents Cumberland Hospital for Children and Adolescents [Member] Cumberland hospital for children and adolescents. Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures Stock options granted during period Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures, Total Lease and rental expense Annual Minimum Rent Operating Lease, Expense Deferred compensation assets. Deferred Compensation Assets [Member] Deferred Compensation Assets Insurance Type and Tier Identifier [Axis] Insurance Type and Tier Identifier Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Class of Stock [Domain] Class of Stock Other Comprehensive Income (Loss), Net of Tax Total other comprehensive (loss) income, net of tax Increase (Decrease) in Self Insurance Reserve Accrued insurance expense, net of commercial premiums paid Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive income attributable to UHS Managed medicare. Managed Medicare [Member] Managed Medicare McAllen medical center. Mc Allen Medical Center [Member] McAllen Medical Center Equity Method Investment, Quoted Market Value Market value of investment in Trust Two point six five percent senior secured notes due two thousand thirty. Two Point Six Five Percent Senior Secured Notes Due Two Thousand Thirty [Member] 2.65% Senior Secured Notes due 2030 Non-controlling ownership interests Subsidiary, Ownership Percentage, Parent Non-controlling ownership interests by subsidiaries Damages awarded Loss Contingency, Damages Awarded, Value Deferred compensation liability. Deferred Compensation Liability [Member] Deferred Compensation Liability Gross outpatient revenues. Gross Outpatient Revenues Gross outpatient revenues Entity Interactive Data Current Entity Interactive Data Current Lease Expiration Date Lease expiration date Subsidiaries [Member] Subsidiaries Two thousand twenty stock incentive plan. Two Thousand Twenty Stock Incentive Plan [Member] 2020 Stock Incentive Plan Lessee operating and financing leases. Lessee Operating And Financing Leases [Text Block] Lease Accounting Acute care hospital services. Acute Care Hospital Services [Member] Acute Care Hospital Services Percentage of master lease rentable square feet of medical office building. Percentage Of Master Lease Rentable Square Feet Of Medical Office Building Percentage of master lease rentable square feet Debt Instrument, Redemption Price, Percentage Redemption price, percentage Pre-tax share of income from the Trust Other Operating Income Document Quarterly Report Document Quarterly Report Right of use assets obtained in exchange for lease obligations. Right Of Use Assets Obtained In Exchange For Lease Obligations [Abstract] Right-of-use assets obtained in exchange for lease obligations: Consolidated Entities [Axis] Consolidated Entities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Total cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Beginning Balance Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Ending Balance Behavioral health care facilities outside owners holding noncontrolling minority interest. Behavioral Health Care Facilities Outside Owners Holding Noncontrolling Minority Interest Behavioral health care facilities with outside owners holding non-controlling minority interest Related Party Transactions Disclosure [Text Block] Relationship with Universal Health Realty Income Trust and Other Related Party Transactions Statement of Financial Position Location, Balance [Axis] Balance Sheet Location Statistical Measurement [Axis] Statistical Measurement Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests Redeemable noncontrolling interests Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests, Total Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests, Beginning Balance Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests, Ending Balance Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Total Noncontrolling Interest in Joint Ventures Non-controlling interest balances Proceeds from sale of assets and business. Proceeds From Sale Of Assets And Business Proceeds received from sales of assets and businesses Debt Instrument, Periodic Payment, Principal Scheduled principal payments per quarter Other states. Other States [Member] OTHER STATES Debt Instrument, Payment Terms Debt instrument payment, description Assets, Fair Value Disclosure Assets, fair value Assets, Fair Value Disclosure, Total Related and Nonrelated Parties [Domain] Related Party Aiken Regional Medical Center and Canyon Creek Behavioral Health. Aiken Regional Medical Center And Canyon Creek Behavioral Health [Member] Aiken Regional Medical Center and Canyon Creek Behavioral Health Disaggregation of Revenue [Table Text Block] Schedule of Disaggregates Revenue by Major Source Operating leases, renewal options at fair market value lease rates, expiration year. Operating Leases Renewal Options At Fair Market Value Lease Rates Expiration Year Renewal options at fair market value lease rates expiration year Amount claimed from over payments of legal settlements due to change in calculations. Amount Claimed From Over Payments Of Legal Settlements Due To Change In Calculations Amount claimed from over payments of legal settlements due to change in calculations Number of days to complete exchange offer. Number Of Days To Complete Exchange Offer Number of days to complete exchange offer Finance Lease, Interest Payment on Liability Operating cash flows from finance leases Property, Plant, and Equipment, Lessor Asset under Operating Lease [Line Items] Property Subject to or Available for Operating Lease [Line Items] Payments to Acquire Businesses, Net of Cash Acquired Acquisition of businesses and property Payments to Acquire Businesses, Net of Cash Acquired, Total Medicaid. Medicaid [Member] Medicaid Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted-average grant date fair value, per share Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Unrecognized compensation cost vesting period Period of rights of refusal to leased facilities. Period Of Rights Of Refusal To Leased Facilities Period of rights of refusal to leased facilities Ownership [Domain] Ownership Statement of Income Location, Balance [Axis] Income Statement Location Assets Total assets Total Assets Costs and expenses incurred associated with centralized services and general corporate overhead allocated to divisions. Overhead Allocations Adjustment Allocation of corporate overhead Behavioral health services. Behavioral Health Services [Member] Behavioral Health Services Business Acquisition [Line Items] Business Acquisition [Line Items] Entity Address, City or Town Entity Address, City or Town AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income (Loss) Equity [Abstract] Segments [Axis] Segments Commercial property insurance policies covering catastrophic losses Commercial property insurance policies Liability for Catastrophe Claims, Carrying Amount Assets, Fair Value Disclosure [Abstract] Assets: Operating leases, renewal options at existing lease rates, expiration year. Operating Leases Renewal Options At Existing Lease Rates Expiration Year Renewal options at existing lease rates expiration year Disclosure of general information. Disclosure Of General Information [Line Items] Disclosure of General Information [Line Items] Hedging Relationship [Domain] Hedging Relationship Debt Instrument, Face Amount Senior notes, issued Jurisdictions statutes of limitations expiration period. Jurisdictions Statutes Of Limitations Expiration Period Jurisdictions statutes of limitations expiration period Development and construction cost incurred. Development and construction cost incurred Development and construction cost incurred Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Market value of retained vested shares Percentage of advisory fee on average invested real estate assets. Percentage Of Advisory Fee On Average Invested Real Estate Assets Percentage of advisory fee on average invested real estate assets Schedule of Segment Reporting Information, by Segment [Table] Schedule Of Segment Reporting Information By Segment [Table] Comprehensive income net of tax attributable to redeemable non-controlling interest. Comprehensive Income Net Of Tax Attributable To Redeemable Non Controlling Interest Subtotal attributable to redeemable noncontrolling interest Stock option expense. Stock Option Expense Stock option expense Long-Term Purchase Commitment, Period Projected commitment expend period Increase decrease in Medicare accelerated payments and deferred CARES Act and other grants. Increase Decrease In Medicare Accelerated Payments And Deferred C A R E S Act And Other Grants Medicare accelerated payments and deferred CARES Act and other grants Earnings Per Share Data and Stock Based Compensation Share-Based Payment Arrangement [Text Block] Statute of limitations for certain jurisdictions. Statute Of Limitations On Certain Jurisdictions Period of expiration of the statute of limitations for certain jurisdictions Premier, Inc. Premier Inc [Member] Premier, Inc. Restricted share based compensation expense. Restricted Share Based Compensation Expense Restricted share-based compensation expense Other Assets [Member] Other Assets Fair Value Disclosures [Abstract] Debt instrument redemption price. Debt Instrument Redemption Price Senior notes, redemption price Dividends Dividends [Text Block] Dividends Chief Executive Officer [Member] Chief Executive Officer Mergers, Acquisitions and Dispositions Disclosures [Text Block] Dispositions and acquisitions Schedule of cash cash equivalents and restricted cash. Schedule Of Cash Cash Equivalents And Restricted Cash Table [Text Block] Summary of Cash, Cash Equivalents and Restricted Cash Reported In Condensed Consolidated Statements of Cash Flows Lessee, Lease, Description [Line Items] Lessee Lease Description [Line Items] Liabilities, Current [Abstract] Current liabilities: Lease Contractual Term [Axis] Lease Contractual Term One month libor rate plus index based loans. One Month L I B O R Rate Plus Index Based Loans [Member] One Month LIBOR Rate Plus Index Based Loans Comprehensive income net of tax excluding portion attributable to redeemable noncontrolling interest. Comprehensive Income Net Of Tax Excluding Portion Attributable To Redeemable Noncontrolling Interest Subtotal - comprehensive income Income Taxes Paid, Net Income taxes paid, net of refunds Income Taxes Paid, Net, Total Document Type Document Type Number of beds available in acute care hospital. Number Of Beds Available In Acute Care Hospital Number of beds available in acute care hospital Deferred Revenue Arrangement Type [Axis] Deferred Revenue Arrangement Type AZERBAIJAN Arizona Asset Impairment Charges Provision for asset impairment Asset Impairment Charges, Total Commitments and contingencies disclosure. Commitments And Contingencies Disclosure [Table] Commitments And Contingencies Disclosure [Table] Title of 12(b) Security Title of 12(b)

Security Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Total Operating leases additional renewal options at fair market value lease rates expiration date Operating Leases Additional Renewal Options At Fair Market Value Lease Rates Expiration Date Operating leases additional renewal options at fair market value lease rates expiration date. Statement of Financial Position Location, Balance [Domain] Balance Sheet Location Other Noncurrent Liabilities [Member] Other Noncurrent Liabilities Statement of Stockholders' Equity [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Long-Term Debt, Excluding Current Maturities Long-term debt Long-Term Debt, Excluding Current Maturities, Total Self Insurance Reserve, Current Self-insured for professional and general liability, current CALIFORNIA CALIFORNIA Notice period on renewal of lease. Notice Period On Renewal Of Lease Notice period on renewal of lease Asset Class [Domain] Asset Class Property, Plant and Equipment, Gross Property and equipment Property, Plant and Equipment, Gross, Total Property, Plant and Equipment, Gross, Beginning Balance Property, Plant and Equipment, Gross, Ending Balance Flood [Member] Flood Subsequent Event Type [Domain] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments Gain Loss [Line Items] Redeemable interest. Redeemable Interest [Member] Redeemable Noncontrolling Interest Compensatory Damages, Trebled Damages And Punitive Damages Compensatory Damages, Trebled And Punitive Damages [Member] Compensatory damages, trebled and punitive damages. Decrease in provision for income taxes Decrease In Provision For Income Tax Decrease in provision for income tax. Net cash outflows Increase (Decrease) in Operating Capital Increase (Decrease) in Operating Capital, Total Debt, due in greater than 60 months Long-Term Debt, Maturity, after Year Five Accounting Changes and Error Corrections [Abstract] Financial Instruments [Domain] Financial Instruments UNITED KINGDOM Located in U.K. Type and Tier Identifier [Domain] Type and Tier Identifier Net Cash Provided by (Used in) Investing Activities [Abstract] Cash Flows from Investing Activities: California New Madrid Seismic Zone Pacific Northwest Seismic Zone Alaska And certain counties in Nevada. California New Madrid Seismic Zone Pacific Northwest Seismic Zone Alaska And Certain Counties In Nevada [Member] California, New Madrid Seismic Zone, Pacific Northwest Seismic Zone, Alaska and certain counties in Nevada Payments for Repurchase of Common Stock Repurchase of common shares Performance based restricted stock units. Performance Based Restricted Stock Units [Member] Performance Based Restricted Stock Units Total net revenues Revenue from Contract with Customer, Excluding Assessed Tax Net revenues Statement of Comprehensive Income [Abstract] Income Tax Disclosure [Text Block] Income Taxes Designated as Hedging Instrument [Member] Designated As Hedging Instrument Ownership [Axis] Ownership Consolidated Entities [Domain] Consolidated Entities Short-Term Debt, Type [Axis] Short-Term Debt, Type Repurchased, including excise tax Stock Repurchased During Period, Value Credit Facility [Domain] Credit Facility Depreciation, Depletion and Amortization, Nonproduction Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction, Total Short-Term Debt, Type [Domain] Short-Term Debt, Type Aggregate insurance coverage Aggregate insurance coverage. Entity Address, Address Line Two Entity Address, Address Line Two Litigation Case [Domain] Payment to Acquire Life Insurance Policy, Investing Activities Payments to acquire life insurance policies, net Liabilities and Equity [Abstract] Liabilities and Stockholdersâ€™ Equity Noncash or Part Noncash Acquisition, Fixed Assets Acquired Noncash purchases of property and equipment Document Period End Date Document Period End Date Net Cash Provided by (Used in) Financing Activities Net cash used in financing activities Common Class A [Member] Class A Effective Income Tax Rate Reconciliation, Percent Effective income tax rate Effective Income Tax Rate Reconciliation, Percent, Total District Facilities. District Facilities [Member] District Facilities Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Anti-dilutive weighted average stock options excluded from computation of earnings per share Dividends [Abstract] Common Class B [Member] Class B Equity Method Investment, Ownership Percentage Trust outstanding shares held, percentage Investment Advice [Member] Advisory Fee Proceeds from (Payments to) Noncontrolling Interests Proceeds from (Payments to) Noncontrolling Interests, Total Sale of ownership interests to minority members One point six five percent senior secured notes due two thousand twenty six. One Point Six Five Percent Senior Secured Notes Due Two Thousand Twenty Six [Member] 1.65% Senior Secured Notes due 2026 Income Tax Expense (Benefit) Provision for income taxes Income Tax Expense (Benefit), Total Dividends, Common Stock, Cash Dividends declared and paid Non rule 10b51 arr modified flag Non Rule 10b51 Arr Modified Flag Non-Rule 10b5-1 Arrangement Modified Trading Symbol Trading Symbol Business Combinations [Abstract] Variable Rate [Axis] Variable Rate Equity, Attributable to Parent UHS common stockholdersâ€™ equity Stockholders' Equity Attributable to Parent, Total Stockholders' Equity Attributable to Parent, Beginning Balance Stockholders' Equity Attributable to Parent, Ending Balance Acute care facility. Acute Care Facility [Member] Acute Care Facility Other Other Comprehensive Income Other Other comprehensive income other. Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset Maximum insurance deductible. Maximum Insurance Deductible Maximum insurance deductible Other Liabilities, Noncurrent Other noncurrent liabilities Derivative Instrument [Axis] Derivative Instrument Payments to Acquire Businesses, Gross Acquisition, cash paid MISSOURI Missouri Related Party Transactions [Abstract] Acquisition of non controlling interest increase decrease from business combination. Acquisition Of Non controlling Interest Increase Decrease From Business Combination Acquisition of noncontrolling interest in majority owned business Debt [Member] Debt Goodwill Goodwill Goodwill, Total Goodwill, Beginning Balance Goodwill, Ending Balance Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Unrecognized compensation cost related to unvested options and restricted stock Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total General and professional liability. General And Professional Liability [Member] General and Professional Liability Geographical [Axis] Geographical Increase (Decrease) In Deferred Income Taxes And Accrued Income Taxes Payable Increase Decrease In Deferred Income Taxes And Accrued Income Taxes Payable Accrued and deferred income taxes Leases [Abstract] Deferred Costs, Noncurrent Deferred charges Deferred Costs, Noncurrent, Total Debt instrument principal amount issuance percentage. Debt Instrument Principal Amount Issuance Percentage Senior notes issued percentage Common stock. Common Stock [Abstract] Common Stock DISTRICT OF COLUMBIA Washington, District of Columbia Line of Credit Facility, Initiation Date Line of credit facility, starting date Hospital. Hospital [Member] Hospital Schedule of Business Acquisitions, by Acquisition [Table] Schedule Of Business Acquisitions By Acquisition [Table] Scenario [Axis] Scenario Financial Services Liabilities Financial liabilities Security Exchange Name Security Exchange Name Projected aggregate development and construction cost. Projected aggregate development and construction cost Projected aggregate development and construction cost Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree Operating Expenses Operating Expenses, Total Compensatory Damages Compensatory Damages [member] Compensatory damages. Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset Class of Stock [Axis] Class of Stock Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance Legal Entity [Axis] Legal Entity Fair Value Disclosures [Text Block] Fair Value Measurement Proceeds from Divestiture of Businesses, Net of Cash Divested Aggregate cash proceeds from divestiture of businesses Proceeds from Divestiture of Businesses, Net of Cash Divested, Total Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted-average grant date fair value, per option Subsidiary, Ownership Percentage, Noncontrolling Owner Percentage of non-controlling, minority ownership interests held by outside owners Subsequent Event Subsequent Event [Member] Maximum [Member] Maximum Medicare accelerated payments received. Medicare Accelerated Payments Received Medicare accelerated payments received Liabilities and Equity Total Liabilities and Stockholdersâ€™ Equity Operating Lease, Right-of-Use Asset Right of use assets-operating leases Supplemental Cash Flow Information [Abstract] Supplemental Disclosures of Cash Flow Information: One three six month LIBOR rate plus index based loans. One Three Six Month L I B O R Rate Plus Index Based Loans [Member] One Three Six Month LIBOR Rate Plus Index Based Loans Earnings Per Share, Diluted Diluted earnings per share attributable to UHS Earnings per diluted share attributable to UHS: Earnings Per Share, Diluted, Total Dividends Dividends paid and accrued Dividends, Total Foreign Currency Foreign Exchange Contracts Foreign Currency Forward Exchange Contracts Foreign Exchange Contract [Member] Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Distributions to noncontrolling interests Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV Aiken, South Carolina. Aiken South Carolina [Member] Aiken South Carolina Assets, Current Total current assets Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Forecast [Member] Scenario Forecast Unrecognized Tax Benefits Unrecognized tax benefits Unrecognized Tax Benefits, Beginning Balance Unrecognized Tax Benefits, Ending Balance Other Comprehensive Income (Loss), before Tax [Abstract] Other comprehensive income (loss): Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Shares vesting period Lessee, Operating Lease, Existence of Option to Extend [true false] Lessee, operating lease, existence of option to extend [true false] Deferred Compensation Liability, Current Compensation and related benefits Deferred Compensation Liability, Current, Total Securitized borrowings credit facility remaining borrowing capacity. Securitized Borrowings Credit Facility Remaining Borrowing Capacity Accounts receivable securitization program credit facility, available borrowing capacity Entity Filer Category Entity Filer Category Other Comprehensive Income (Loss), before Tax Other comprehensive income (loss) before tax Equity, Including Portion Attributable to Noncontrolling Interest Balance Balance Total equity Net Income (Loss) Available to Common Stockholders, Diluted Net income attributable to UHS - diluted Unrecognized Tax Benefits that Would Impact Effective Tax Rate Impact of unrecognized tax benefits if recognized Debt Instrument, Repurchase Amount Senior notes, redeemed Commitments and contingencies disclosure. Commitments And Contingencies Disclosure [Line Items] Commitments and Contingencies Disclosure [Line Items] Current Fiscal Year End Date Current Fiscal Year End Date Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Equity: Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Noncontrolling Interest [Member] Noncontrolling Interest Self Insurance Reserve Self-insured for professional and general liability Interest rate margin adjustment percentage. Interest Rate Margin Adjustment Percentage Current applicable margins Share-Based Payment Arrangement, Noncash Expense Stock-based compensation expense Compensation cost recognized Share-Based Payment Arrangement, Noncash Expense, Total Share-based compensation arrangement by share-based payment award, award vesting period end year. Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period End Year Shares vesting period end year Quarterly Payment Beginning on December 31, 2026 Through June 30, 2029 Group Nine [Member] Group nine. Related and Nonrelated Parties [Axis] Related Party Net Investment Hedging [Member] Net Investment Hedge Earthquake [Member] Earthquake Entity Registrant Name Entity Registrant Name Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Debt Instrument, Maturity Date Line of credit facility, maturity date Entity Emerging Growth Company Entity Emerging Growth Company Real Estate, Type of Property [Axis] Real Estate, Type of Property Money Market Funds [Member] Money Market Mutual Funds Weighted Average Number of Shares Outstanding, Basic Weighted average number of common shares - basic Weighted Average Number of Shares Outstanding, Basic, Total Increase decrease of revenues. Increase Decrease Of Revenues Self-insured for professional and general liability Net income allocated to unvested restricted shares. Net Income Allocated To Unvested Restricted Shares Less: Net income attributable to unvested restricted share grants Other Operating Segment [Member] Other Litigation Case [Axis] OHIO Ohio Other Cost and Expense, Operating Other operating expenses Operating leases additional renewal options term at fair market value lease rates. Operating Leases Additional Renewal Options Term At Fair Market Value Lease Rates Operating leases additional renewal options term at fair market value lease rates Inland Valley Campus of Southwest Healthcare System. Inland Valley Campus Of Southwest Healthcare System [Member] Inland Valley Campus of Southwest Healthcare System Other non-patient revenue. Other Non Patient Revenue [Member] Other Non-patient Revenue Proceeds from Issuance of Common Stock Issuance of common stock Lease expiration term. Lease Expiration Term Lease expiration term Fair Value, Inputs, Level 1 [Member] Basis of Fair Value Measurement, Level 1 Major Property Class [Axis] Major Property Class Derivative Instruments, Gain (Loss) [Table] Derivative Instruments Gain Loss By Hedging Relationship By Income Statement Location By Derivative Instrument Risk [Table] Financial Instrument [Axis] Financial Instrument Share-Based Payment Arrangement [Abstract] Other Current Assets [Member] Other Current Assets Five point zero zero percent senior secured notes due June two thousand twenty six. Five Point Zero Zero Percent Senior Secured Notes Due June Two Thousand Twenty Six [Member] 5.00% Senior Secured Notes due 2026 Prepaid Supplies Supplies PUERTO RICO PUERTO RICO Other Assets, Miscellaneous, Noncurrent Other Long-Term Line of Credit Line of credit facility amount outstanding Long-Term Line of Credit, Total Income Tax Disclosure [Abstract] Long-Term Purchase Commitment, Amount Committment to expend One month SOFR rate plus index based loans. One Month S O F R Rate Plus Index Based Loans [Member] One Month SOFR Rate Plus Index Based Loans Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Effect of exchange rate changes on cash, cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total Increase (Decrease) in Insurance Settlements Receivable Payments made in settlement of self-insurance claims Statement [Table] Statement [Table] Tranche A term loan. Tranche A Term Loan [Member] Tranche A Term Loan Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Less: Comprehensive income (loss) attributable to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest, Total Purchase (sale) of ownership interests by (from) minority members. Purchase Sale Of Ownership Interests By From Minority Members Purchase (sale) of ownership interests by (from) minority members Faulty Zones of US. Faulty Zones Of U S [Member] Faulty Zones of UNITED STATES Other Operating Income (Expense) [Member] Other (Income) Expense, Net Securities Act File Number Entity File Number Segment Reporting Disclosure [Text Block] Segment Reporting Decrease in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Revenue from Contract with Customer [Abstract] Group purchasing organization agreement. Group Purchasing Organization Agreement [Member] Group Purchasing Organization Agreement Earnings Per Share [Abstract] Basic and Diluted: Managed care. Managed Care [Member] Managed Care (HMO and PPOs) GW Hospital. G W Hospital [Member] GW Hospital Clive, Iowa. Clive Iowa [Member] Aiken, South Carolina UK Revenue. U K Revenue [Member] UK Revenue Lease Contractual Term [Domain] Lease Contractual Term Statement of Financial Position [Abstract] Interest Expense, Operating and Nonoperating Interest expense, net Interest Expense, Total Operating Income (Loss) Income from operations Debt, due during the next 12 month Long-Term Debt, Maturity, Year One Accrued Income Taxes, Current Federal and state taxes Letter of Credit [Member] Letter of Credit Entity Shell Company Entity Shell Company Loss on business interruption insurance recovery Loss On Business Interruption Insurance Recovery Loss on business interruption insurance recovery. Increase (Decrease) in Accrued Interest Receivable, Net Accrued interest Entity Tax Identification Number Entity Tax Identification Number Assets [Abstract] Assets Entity Current Reporting Status Entity Current Reporting Status Consolidated leverage ratio. Consolidated Leverage Ratio Consolidated Leverage Ratio Net Income (Loss) Available to Common Stockholders, Basic Net income attributable to UHS - basic Geographical [Domain] Geographical Document Fiscal Year Focus Document Fiscal Year Focus TEXAS Texas General and professional liability insurance policies. General And Professional Liability Insurance Policies [Member] General And Professional Liability Insurance Policies Certificates of Deposit [Member] Certificates of Deposit Quarterly Payment Beginning on December 31,204 Through September 30, 2026 Group eight. Group Eight [Member] Return of funds by CARES Act to government. Return Of Funds By C A R E S Act To Government Return of funds by CARES Act to government Repayments of Long-Term Debt Repayments of long-term debt Repayments of Long-Term Debt, Total Rate adjustment to federal funds rate weighted average. Rate Adjustment To Federal Funds Rate Weighted Average Rate adjustment to weighted average federal funds rate for credit facility borrowings One hospital facility. One Hospital Facility [Member] One Hospital Facility Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Cash, cash equivalents and restricted cash, end of period Cash, cash equivalents and restricted cash, beginning of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total Business Acquisition [Axis] Business Acquisition Other Comprehensive Income (Loss), Tax Income tax expense (benefit) related to items of other comprehensive income (loss) Other Comprehensive Income (Loss), Tax, Total Self-insured retention amounts Self-insured retention amounts. City Area Code City Area Code Letters of Credit Outstanding, Amount Letters of credit, outstanding Liabilities, Current Total current liabilities Derivative Contract [Domain] Derivative Contract Universal Health Realty Income Trust. Universal Health Realty Income Trust [Member] Relationship with Universal Health Realty Income Trust Universal Health Realty Income Trust Proceeds from Dividends Received Dividends received from the Trust Noncontrolling Interest [Table] Minority Interest [Table] Equity Securities [Member] Equity Securities Organization, Consolidation and Presentation of Financial Statements [Abstract] Local Phone Number Local Phone Number Hedging Designation [Axis] Hedging Designation Common Stock, Dividends, Per Share, Cash Paid Dividends declared and paid, per share Commitments and Contingencies Disclosure [Abstract] Share-based compensation arrangement by share-based payment award, award vesting period start year. Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period Start Year Shares vesting period start year Operating Lease, Liability, Current Operating lease liabilities Document Information [Line Items] Document Information [Line Items] Right-of-Use Asset Obtained in Exchange for Finance Lease Liability Finance leases Percentage of annual rental

increase on cumulative and compound basis. Percentage Of Annual Rental Increase On Cumulative And Compound Basis Percentage of annual rental increase on cumulative and compound basis Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Foreign currency translation adjustments, net of income tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total Debt Instrument, Interest Rate, Stated Percentage Senior notes, interest rate Payments to Acquire Property, Plant, and Equipment Property and equipment additions Payments to Acquire Property, Plant, and Equipment, Total Restricted Cash, Statement of Financial Position [Extensible Enumeration] Restricted Cash, Statement of Financial Position [Extensible Enumeration] Two Free-standing Emergency Departments Two Free-standing Emergency Departments [Member] Two free-standing emergency departments. Bonus rental. Bonus Rental [Member] Bonus Rental Document Transition Report Document Transition Report Deferred Revenue [Domain] Deferred Revenue Self insured amount per occurrence excess claims. Self Insured Amount Per Occurrence Excess Claims Purchased several excess policies through commercial insurance carriers per occurrence excess claim amount Cygnet health care limited. Cygnet Health Care Limited [Member] Cygnet Health Care Limited Number of beds available in micro-hospital. Number Of Beds Available In Micro Hospital Number of beds available in micro-hospital Unamortized financing costs Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total Deferred Income Tax Assets, Net Deferred income taxes Minimum [Member] Minimum Costs related to extinguishment of debt. Costs Related To Extinguishment Of Debt Costs related to extinguishment of debt Common Stock [Member] Common Stock Restricted Cash Restricted cash Restricted Cash, Total Debt, due during months 13 to 24 Long-Term Debt, Maturity, Year Two Investment, Name [Axis] Investment, Name Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net income to net cash provided by operating activities: Statement of Income Location, Balance [Domain] Income Statement Location Segments [Domain] Segments Amended Revolving Credit Facility Amended Revolving Credit Facility [Member] Amended revolving credit facility. Increase (Decrease) in Other Operating Liabilities Other Increase (Decrease) in Other Operating Liabilities, Total Summary of Effects of Foreign Currency Forward Exchange Contracts on Result of Operations Derivative Instruments, Gain (Loss) [Table Text Block] Department of human services. Department Of Human Services [Member] Department of Human Services Payments of Financing Costs Financing costs Payments of Financing Costs, Total Other Assets, Current Other current assets Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Disaggregation of Revenue [Line Items] Disaggregation Of Revenue [Line Items] Number of plaintiffs Loss Contingency, Number of Plaintiffs Equity, Attributable to Noncontrolling Interest Noncontrolling interest Stockholders' Equity Attributable to Noncontrolling Interest, Total Stockholders' Equity Attributable to Noncontrolling Interest, Beginning Balance Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance Scenario [Domain] Scenario Estimated proceeds from life insurance policies. Estimated Proceeds From Life Insurance Policies Estimated death benefit proceeds Title and Position [Domain] Title of Individual WASHINGTON Washington Behavioral health care facilities outside owners holding noncontrolling minority interest one. Behavioral Health Care Facilities Outside Owners Holding Noncontrolling Minority Interest One Behavioral health care facilities with outside owners holding non-controlling minority interest Loan, Securitized or Asset-Backed Financing Arrangement, Principal Outstanding Accounts receivable securitization program credit facility, amount outstanding Behavioral health care facility one. Behavioral Health Care Facility One [Member] Behavioral Health Care Facility One Other related party transactions. Other Related Party Transactions [Member] Other Related Party Transactions Aiken Regional Medical Center/Aurora Pavilion Behavioral Health Services. Aiken Regional Medical Center Aurora Pavilion Behavioral Health Services [Member] Aiken Regional Medical Center/Aurora Pavilion Behavioral Health Services Debt, due during months 25 to 36 Long-Term Debt, Maturity, Year Three Earthquake Wind Hail and Flood Earthquake Wind hail and Flood [Member] Earthquake wind hail and flood. Retained Earnings, Unappropriated [Member] Cumulative Dividends Measurement Frequency [Axis] Measurement Frequency Cash paid for amounts included in measurement of lease liabilities. Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract] Cash paid for amounts included in the measurement of lease liabilities: Wind storms. Wind Storms [Member] Wind Storms Weighted Average Number of Shares Outstanding, Diluted Weighted average number of common shares and equivalents - diluted Schedule of Segment Reporting Information, by Segment [Table Text Block] Segment Reporting Accounts Receivable, after Allowance for Credit Loss, Current Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current, Total Lessee, Operating Lease, Renewal Term Real estate leases option to extend lease term General Liability [Member] General Liability Temple, Texas. Temple Texas [Member] Temple, Texas Rule 10b51 arr modified flag. Rule 10b51 Arr Modified Flag Rule 10b5-1 Arrangement Modified Other Other Comprehensive Income Other Before Tax Other comprehensive income other before tax. Securitized extended maturity date. Securitized Extended Maturity Date Securitized extended maturity date Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Comprehensive income Entity Small Business Entity Small Business Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Catastrophic Event [Axis] Catastrophic Event Credit Facility [Axis] Credit Facility Wildomar, California. Wildomar California [Member] Wildomar, California Revolving Credit Facility [Member] Revolving Credit Facility Unvested stock option. Unvested Stock Option [Member] Unvested Stock option Wellington regional medical center. Wellington Regional Medical Center [Member] Wellington Regional Medical Center Two hospital facilities. Two Hospital Facilities [Member] Two Hospital Facilities Net Cash Provided by (Used in) Financing Activities [Abstract] Cash Flows from Financing Activities: First Three Renewal Options First Three Renewal Options [Member] First three renewal options. PENNSYLVANIA Pennsylvania Asset Class [Axis] Asset Class Gain on sale of assets and businesses Gain loss on sale of assets and business. Gain Loss On Sale Of Assets And Business Asset purchase and sale agreement. Asset Purchase And Sale Agreement [Member] Asset Purchase and Sale Agreement Income (loss) from continuing operations before allocation of corporate overhead and income taxes extraordinary items noncontrolling interest. Income Loss From Continuing Operations Before Allocation Of Corporate Overhead And Income Taxes Extraordinary Items Noncontrolling Interest Income/(loss) before allocation of corporate overhead and income taxes Additional funds received from government by CARES Act. Additional Funds Received From Government By C A R E S Act Additional funds received from government by CARES Act Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Operating leases Measurement Frequency [Domain] Measurement Frequency Noncontrolling Interest [Abstract] ABR based loans. A B R Based Loans [Member] ABR-based loans Fair Value, Inputs, Level 3 [Member] Basis of Fair Value Measurement, Level 3 Lease expiration period. Lease Expiration Period Renewal Term (years) Two point six five percent senior secured notes due two thousand thirty two. Two Point Six Five Percent Senior Secured Notes Due Two Thousand Thirty Two [Member] 2.65% Senior Secured Notes due 2032 Liabilities, Fair Value Disclosure Liabilities, fair value Liabilities, Fair Value Disclosure, Total Another two hospital facilities. Another Two Hospital Facilities [Member] Another Two Hospital Facilities Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Gain/(Loss) recognized in AOCI XML 9 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document and Entity Information - shares 9 Months Ended Sep. 30, 2024 Oct. 31, 2024 Document Information [Line Items] Â Â Document Type 10-Q Â Amendment Flag false Â Document Period End Date Sep. 30, 2024 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q3 Â Trading Symbol UHS Â Entity Registrant Name UNIVERSAL HEALTH SERVICES, INC. Â Entity Central Index Key 0000352915 Â Current Fiscal Year End Date --12-31 Â Entity Filer Category Large Accelerated Filer Â Entity Small Business false Â Entity Emerging Growth Company false Â Entity Current Reporting Status Yes Â Entity Shell Company false Â Entity File Number 1-10765 Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 23-2077891 Â Entity Address, Address Line One UNIVERSAL CORPORATE CENTER Â Entity Address, Address Line Two 367 SOUTH GULPH ROAD Â Entity Address, City or Town KING OF PRUSSIA Â Entity Address, State or Province PA Â Entity Address, Postal Zip Code 19406 Â City Area Code 610 Â Local Phone Number 768-3300 Â Entity Interactive Data Current Yes Â Security Exchange Name NYSE Â Title of 12(b) Security Class B Common Stock, $0.01 par value Â Document Quarterly Report true Â Document Transition Report false Â Class A Â Â Document Information [Line Items] Â Â Entity Common Stock, Shares Outstanding Â 6,576,475 Class B Â Â Document Information [Line Items] Â Â Entity Common Stock, Shares Outstanding Â 58,714,711 Class C Â Â Document Information [Line Items] Â Â Entity Common Stock, Shares Outstanding Â 661,688 Class D Â Â Document Information [Line Items] Â Â Entity Common Stock, Shares Outstanding Â 12,774 X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_DocumentInformationLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type:

duration X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=uhs_CommonClassDMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 10 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Income Statement [Abstract] Â Â Â Â Net revenues $ 3,963,027 $ 3,562,774 $ 11,714,213 $ 10,578,430 Operating charges: Â Â Â Â Salaries, wages and benefits 1,912,308 1,784,870 5,611,304 5,308,476 Other operating expenses 1,090,197 941,219 3,165,483 2,758,484 Supplies expense 390,250 378,667 1,181,886 1,138,950 Depreciation and amortization 149,567 137,195 438,050 422,560 Lease and rental expense 36,540 35,466 108,165 105,775 Operating Expenses, Total 3,578,862 3,277,417 10,504,888 9,734,245 Income from operations 384,165 285,357 1,209,325 844,185 Interest expense, net 44,660 53,378 146,385 153,085 Other (income) expense, net (2,028) 11,472 3,315 31,797 Income before income taxes 341,533 220,507 1,059,625 659,303 Provision for income taxes 75,623 52,499 233,563 159,618 Net income 265,910 168,008 826,062 499,685 Less: Net income (loss) attributable to noncontrolling interests 7,196 1,019 16,362 (1,732) Net income attributable to UHS $ 258,714 $ 166,989 $ 809,700 $ 501,417 Basic earnings per share attributable to UHS $ 3.89 $ 2.42 $ 12.11 $ 7.18 Diluted earnings per share attributable to UHS $ 3.80 $ 2.40 $ 11.88 $ 7.09 Weighted average number of common shares - basic 66,537 68,867 66,873 69,825 Add: Other share equivalents 1,571 757 1,297 825 Weighted average number of common shares and equivalents - diluted 68,108 69,624 68,170 70,650 X - DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_DepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1 + Details Name: us-gaap_InterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_LaborAndRelatedExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of Net Income (Loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B + Details Name: us-gaap_NetIncomeLossAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of operating lease expense. Excludes sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4 + Details Name: us-gaap_OperatingLeaseExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(7)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 + Details Name: us-gaap_OtherCostAndExpenseOperating Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense associated with supplies that were used during the current accounting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_SuppliesExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 11 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Statement of Comprehensive Income [Abstract] Â Â Â Â Net income $ 265,910 $ 168,008 $ 826,062 $ 499,685 Other comprehensive income (loss): Â Â Â Â Foreign currency translation adjustment 29,221 (24,631) 29,155 (703) Other Â Â 17 Â Other comprehensive income (loss) before tax 29,221 (24,631) 29,172 (703) Income tax expense (benefit) related to items of other comprehensive income (loss) (140) (926) 288 (95) Total other comprehensive (loss) income, net of tax 29,361 (23,705) 28,884 (608) Comprehensive income 295,271 144,303 854,946 499,077 Less: Comprehensive income (loss) attributable to noncontrolling interests 7,196 1,019 16,362 (1,732) Comprehensive income attributable to UHS $ 288,075 $ 143,284 $ 838,584 $ 500,809 X - DefinitionOther comprehensive income other before tax. + ReferencesNo definition available. + Details Name: uhs_OtherComprehensiveIncomeOtherBeforeTax Namespace Prefix: uhs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-21Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K + Details Name: us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K + Details Name: us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount before tax, after reclassification adjustments of other comprehensive income (loss). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4:

http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_OtherComprehensiveIncomeLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of tax expense (benefit) allocated to other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 12 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2 + Details Name: us-gaap_OtherComprehensiveIncomeLossTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 12 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 106,077 $ 119,439 Accounts receivable, net 2,214,268 2,238,265 Supplies 220,062 216,988 Other current assets 261,549 236,658 Total current assets 2,801,956 2,811,350 Property and equipment 12,448,230 11,777,047 Less: accumulated depreciation (6,005,664) (5,652,518) Property, plant and equipment, net, Total 6,442,566 6,124,529 Other assets: Â Â Goodwill 3,965,492 3,932,407 Deferred income taxes 121,904 85,626 Right of use assets-operating leases 421,441 433,962 Deferred charges 9,705 6,974 Other 590,784 572,754 Total Assets 14,353,848 13,967,602 Current liabilities: Â Â Current maturities of long-term debt 38,351 126,686 Accounts payable and other liabilities 1,896,234 1,813,015 Operating lease liabilities 72,801 71,600 Federal and state taxes 3,802 2,046 Total current liabilities 2,011,188 2,013,347 Other noncurrent liabilities 660,247 584,007 Operating lease liabilities noncurrent 377,644 382,559 Long-term debt 4,618,060 4,785,783 Redeemable noncontrolling interests 5,623 5,191 Equity: Â Â UHS common stockholdersâ€™ equity 6,605,696 6,149,001 Noncontrolling interest 75,390 47,714 Total equity 6,681,086 6,196,715 Total Liabilities and Stockholdersâ€™ Equity $ 14,353,848 $ 13,967,602 X - DefinitionAmount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1

-Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_AccruedIncomeTaxesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of deferred cost, excluding capitalized cost related to contract with customer; classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_DeferredCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6 + Details Name: us-gaap_DeferredIncomeTaxAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting

Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_MinorityInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of current assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: us-gaap_OtherAssetsMiscellaneousNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OtherAssetsNoncurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-

gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4IReference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g)(7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5 + Details Name: us-gaap_Supplies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28 + Details Name: us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 13 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Changes in Equity - USD ($) $ in Thousands Total Redeemable Noncontrolling Interest Common Stock Class A Common Stock Class B Common Stock Class C Common Stock Class D Cumulative Dividends Retained Earnings Accumulated Other Comprehensive Income (Loss) UHS Common Stockholders' Equity Noncontrolling Interest Balance at Dec. 31, 2022 $ 5,965,350 Â $ 66 $ 637 $ 7 $ 0 $ (604,127) $ 6,533,667 $ (9,668) $ 5,920,582 $ 44,768 Balance at Dec. 31, 2022 Â $ 4,695 Â Â Â Â Â Â Â Â Â Â Common Stock Â Â Â Â Â Â Â Â Â Â Issued/(converted) 9,950 Â Â 7 Â Â Â 9,943 Â 9,950 Â Repurchased, including excise tax (389,011) Â Â (29) Â Â Â (388,982) Â (389,011) Â Restricted share-based compensation expense 16,395 Â Â Â Â Â Â 16,395 Â 16,395 Â Dividends paid and accrued (42,147) Â Â Â Â Â (42,147) Â Â (42,147) Â Stock option expense 48,337 Â Â Â Â Â Â 48,337 Â 48,337 Â Distributions to noncontrolling interests (4,208) (1,050) Â Â Â Â Â Â Â Â Â (4,208) Purchase (sale) of ownership interests by (from) minority members 3,814 Â Â Â Â Â Â Â Â Â 3,814 Comprehensive income: Â Â Â Â Â Â Â Â Â Net income (loss) to UHS / noncontrolling interests 498,611 1,074 Â Â Â Â Â 501,417 Â 501,417 (2,806) Foreign currency translation adjustments, net of income tax (608) Â Â Â Â Â Â Â (608) (608) Â Subtotal - comprehensive income 498,003 Â Â Â Â Â Â 501,417 (608) 500,809 (2,806) Subtotal attributable to redeemable noncontrolling interest Â 1,074 Â Â Â Â Â Â Â Â Â Balance at Sep. 30, 2023 6,106,483 Â 66 615 7 0 (646,274) 6,720,777 (10,276) 6,064,915 41,568 Balance at Sep. 30, 2023 Â 4,719 Â Â Â Â Â Â Â Â Â Balance at Jun. 30, 2023 6,128,759 Â 66 628 7 0 (632,473) 6,705,525 13,429 6,087,182 41,577 Balance at Jun. 30, 2023 Â 4,213 Â Â Â Â Â Â Â Â Â Common Stock Â Â Â Â Â Â Â Â Â Issued/(converted) 3,244 Â Â 1 Â Â Â 3,243 Â 3,244 Â Repurchased, including excise tax (177,334) Â Â (14) Â Â Â (177,320) Â (177,334) Â Restricted share-based compensation expense 6,132 Â Â Â Â Â Â 6,132 Â 6,132 Â Dividends paid and accrued (13,801) Â Â Â Â Â (13,801) Â Â (13,801) Â Stock option expense 16,208 Â Â Â Â Â Â 16,208 Â 16,208 Â Distributions to noncontrolling interests (523) Â Â Â Â Â Â Â Â Â (523) Comprehensive income: Â Â Â Â Â Â Â Â Â Net income (loss) to UHS / noncontrolling interests 167,503 506 Â Â Â Â Â 166,989 Â 166,989 514 Foreign currency translation adjustments, net of income tax (23,705) Â Â Â Â Â Â Â (23,705) (23,705) Â Subtotal - comprehensive income 143,798 Â Â Â Â Â Â 166,989 (23,705) 143,284 514 Subtotal attributable to redeemable noncontrolling interest Â 506 Â Â Â Â Â Â Â Â Â Balance at Sep. 30, 2023 6,106,483 Â 66 615 7 0 (646,274) 6,720,777 (10,276) 6,064,915 41,568 Balance at Sep. 30, 2023 Â 4,719 Â Â Â Â Â Â Â Â Â Balance at Dec. 31, 2023 6,196,715 Â 66 599 7 0 (659,890) 6,798,930 9,289 6,149,001 47,714 Balance at Dec. 31, 2023 Â 5,191 Â Â Â Â Â Â Â Â Â Common Stock Â Â Â Â Â Â Â Â Â Issued/(converted) 11,031 Â Â 11 Â Â Â 11,020 Â 11,031 Â Repurchased, including excise tax (424,077) Â Â (21) Â Â Â (424,056) Â (424,077) Â Restricted share-based compensation expense 30,746 Â Â Â Â Â Â 30,746 Â 30,746 Â Dividends paid and accrued (40,597) Â Â Â Â Â (40,597) Â Â (40,597) Â Stock option expense 41,025 Â Â Â Â Â Â 41,025 Â 41,025 Â Distributions to noncontrolling interests Â (649) Â Â Â Â Â Â Â Â Â Distributions to noncontrolling interests (5,142) Â Â Â Â Â Â Â Â Â (5,142) Purchase (sale) of ownership interests by (from) minority members 17,537 Â Â Â Â Â Â Â Â Â 17,537 Comprehensive income: Â Â Â Â Â Â Â Â Â Net income (loss) to UHS / noncontrolling interests 824,981 1,081 Â Â Â Â Â 809,700 Â 809,700 15,281 Other Â Â Â Â Â Â Â (17) 17 Â Â Foreign currency translation adjustments, net of income tax 28,867 Â Â Â Â Â Â Â 28,867 28,867 Â Subtotal - comprehensive income 853,848 Â Â Â Â Â Â 809,683 28,884 838,567 15,281 Subtotal attributable to redeemable noncontrolling interest Â 1,081 Â Â Â Â Â Â Â Â Â Balance at Sep. 30, 2024 6,681,086 Â 66 589 7 0 (700,487) 7,267,348 38,173 6,605,696 75,390 Balance at Sep. 30, 2024 6,000 5,623 Â Â Â Â Â Â Â Â Â Balance at Jun. 30, 2024 6,550,805 Â 66 594 7 0 (687,015) 7,162,908 8,812 6,485,372 65,433 Balance at Jun. 30, 2024 Â 5,418 Â Â Â Â Â Â Â Â Â Common Stock Â Â Â Â Â Â Â Â Â Issued/(converted) 3,637 Â Â 3 Â Â Â 3,634 Â 3,637 Â Repurchased, including excise tax (184,139) Â Â (8) Â Â Â (184,131) Â (184,139) Â Restricted share-based compensation expense 12,867 Â Â Â Â Â Â 12,867 Â 12,867 Â Dividends paid and accrued (13,472) Â Â Â Â Â (13,472) Â Â (13,472) Â Stock option expense 13,356 Â Â Â Â Â Â 13,356 Â 13,356 Â Distributions to noncontrolling interests (702) Â Â Â Â Â Â Â Â Â (702) Purchase (sale) of ownership interests by (from) minority members 3,668 Â Â Â Â Â Â Â Â Â 3,668 Comprehensive income: Â Â Â Â Â Â Â Â Â Net income (loss) to UHS / noncontrolling interests 265,705 205 Â Â Â Â Â 258,714 Â 258,714 6,991 Foreign currency translation adjustments, net of income tax 29,361 Â Â Â Â Â Â Â 29,361 29,361 Â Subtotal - comprehensive income 295,066 Â Â Â Â Â Â 258,714 29,361 288,075 6,991 Subtotal attributable to redeemable noncontrolling interest Â 205 Â Â Â Â Â Â Â Â Â Balance at Sep. 30, 2024 6,681,086 Â $ 66 $ 589 $ 7 $ 0 $ (700,487) $ 7,267,348 $ 38,173 $ 6,605,696 $ 75,390 Balance at Sep. 30, 2024 $ 6,000 $ 5,623 Â Â Â Â Â Â Â Â Â X - DefinitionCommon stock. + ReferencesNo definition available. + Details Name: uhs_CommonStockAbstract Namespace Prefix: uhs_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionComprehensive income net of tax attributable to redeemable non-controlling interest. + ReferencesNo definition available. + Details Name: uhs_ComprehensiveIncomeNetOfTaxAttributableToRedeemableNonControllingInterest Namespace Prefix: uhs_ Data Type:

xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionComprehensive income net of tax excluding portion attributable to redeemable noncontrolling interest. + ReferencesNo definition available. + Details Name: uhs_ComprehensiveIncomeNetOfTaxExcludingPortionAttributableToRedeemableNoncontrollingInterest Namespace Prefix: uhs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNet income excluding redeemable noncontrolling interests. + ReferencesNo definition available. + Details Name: uhs_NetIncomeExcludingRedeemableNoncontrollingInterests Namespace Prefix: uhs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionOther comprehensive income other. + ReferencesNo definition available. + Details Name: uhs_OtherComprehensiveIncomeOther Namespace Prefix: uhs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPurchase (sale) of ownership interests by (from) minority members. + ReferencesNo definition available. + Details Name: uhs_PurchaseSaleOfOwnershipInterestsByFromMinorityMembers Namespace Prefix: uhs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRedeemable non-controlling interest, distributions. + ReferencesNo definition available. + Details Name: uhs_RedeemableNonControllingInterestDistributions Namespace Prefix: uhs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRestricted share based compensation expense. + ReferencesNo definition available. + Details Name: uhs_RestrictedShareBasedCompensationExpense Namespace Prefix: uhs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionStock option expense. + ReferencesNo definition available. + Details Name: uhs_StockOptionExpense Namespace Prefix: uhs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ComprehensiveIncomeNetOfTaxAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -SubTopic 405 -Topic 942 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2 + Details Name: us-gaap_Dividends Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of tax benefit from exercise of option under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDecrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAs of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 480 -SubTopic 10 -Subparagraph (12)(c) -Section S99 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 480 -SubTopic 10 -Subparagraph (16)(c) -Paragraph 3A -Section S99 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3AReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 480 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3A -Subparagraph (15) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3AReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 480 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3A -Subparagraph (14) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A + Details Name: us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionEquity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockRepurchasedDuringPeriodValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4IReference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data

Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 14 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Cash Flows from Operating Activities: Â Â Net income $ 826,062 $ 499,685 Adjustments to reconcile net income to net cash provided by operating activities: Â Â Depreciation & amortization 438,050 422,560 Gain on sale of assets and businesses (5,124) (6,250) Costs related to extinguishment of debt 3,158 0 Stock-based compensation expense 72,727 65,702 Changes in assets & liabilities, net of effects from acquisitions and dispositions: Â Â Accounts receivable 11,703 (193,108) Accrued interest (1,762) 60 Accrued and deferred income taxes (10,949) (33,240) Other working capital accounts 1,329 (65,062) Medicare accelerated payments and deferred CARES Act and other grants 0 1,764 Other assets and deferred charges (5,621) 48,985 Other 25,732 13,717 Accrued insurance expense, net of commercial premiums paid 175,104 141,414 Payments made in settlement of self-insurance claims (121,745) (80,861) Net cash provided by operating activities 1,408,664 815,366 Cash Flows from Investing Activities: Â Â Property and equipment additions (697,865) (536,665) Proceeds received from sales of assets and businesses 30,219 23,688 Acquisition of businesses and property 0 (3,728) Outflows from foreign exchange contracts that hedge our net U.K. investment (35,667) (7,723) Decrease in capital reserves of commercial insurance subsidiary 197 0 Net cash used in investing activities (703,116) (524,428) Cash Flows from Financing Activities: Â Â Repayments of long-term debt (2,471,515) (54,009) Additional borrowings, net 2,210,248 165,000 Financing costs (9,992) (308) Repurchase of common shares (420,588) (385,339) Dividends paid (40,302) (41,964) Issuance of common stock 10,864 9,841 Profit distributions to noncontrolling interests (5,791) (5,258) Sale of ownership interests to minority members 8,959 408 Net cash used in financing activities (718,117) (311,629) Effect of exchange rate changes on cash, cash equivalents and restricted cash 2,696 493 Decrease in cash, cash equivalents and restricted cash (9,873) (20,198) Cash, cash equivalents and restricted cash, beginning of period 214,470 200,837 Cash, cash equivalents and restricted cash, end of period 204,597 180,639 Supplemental Disclosures of Cash Flow Information: Â Â Interest paid 144,378 149,247 Income taxes paid, net of refunds 236,975 191,189 Noncash purchases of property and equipment $ 87,333 $ 108,412 X - DefinitionCosts related to extinguishment of debt. + ReferencesNo definition available. + Details Name: uhs_CostsRelatedToExtinguishmentOfDebt Namespace Prefix: uhs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDepreciation for discontinued operations and amortization. + ReferencesNo definition available. + Details Name: uhs_DepreciationForDiscontinuedOperationsAndAmortization Namespace Prefix: uhs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionGain loss on sale of assets and business. + ReferencesNo definition available. + Details Name: uhs_GainLossOnSaleOfAssetsAndBusiness Namespace Prefix: uhs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIncrease (decrease) in capital reserves of commercial insurance subsidiary. + ReferencesNo definition available. + Details Name: uhs_IncreaseDecreaseInCapitalReservesOfCommercialInsuranceSubsidiary Namespace Prefix: uhs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIncrease (Decrease) In Deferred Income Taxes And Accrued Income Taxes Payable + ReferencesNo definition available. + Details Name: uhs_IncreaseDecreaseInDeferredIncomeTaxesAndAccruedIncomeTaxesPayable Namespace Prefix: uhs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIncrease decrease in Medicare accelerated payments and deferred CARES Act and other grants. + ReferencesNo definition available. + Details Name: uhs_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredCARESActAndOtherGrants Namespace Prefix: uhs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionProceeds from sale of assets and business. + ReferencesNo definition available. + Details Name: uhs_ProceedsFromSaleOfAssetsAndBusiness Namespace Prefix: uhs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_IncomeTaxesPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the amount due from borrowers for interest payments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in insurance settlements receivable, which are amounts due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy. The expectation is that such reimbursement will be received within one year of the balance sheet date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in operating assets after deduction of operating liabilities classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in operating liabilities classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the period in the carrying amount of accrued known and estimated losses incurred for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's' compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInSelfInsuranceReserve Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow or inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation. + ReferencesNo definition available. + Details Name: us-gaap_PaymentsForProceedsFromHedgeInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow to reacquire common stock during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsForRepurchaseOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity. +

ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfDividendsCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow in the form of ordinary dividends provided by the non-wholly owned subsidiary to noncontrolling interests. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfDividendsMinorityInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for loan and debt issuance costs. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfFinancingCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from (to) a noncontrolling interest. Excludes dividends paid to the noncontrolling interest. + ReferencesNo definition available. + Details Name: us-gaap_ProceedsFromPaymentsToMinorityShareholders Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_RepaymentsOfLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 15 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Net Income (Loss) $ 258,714 $ 166,989 $ 809,700 $ 501,417 X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -

Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 16 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 Trading Arrangements, by Individual Â Rule 10b5-1 Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Modified false Rule 10b5-1 Arrangement Modified false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNon rule 10b51 arr modified flag + ReferencesNo definition available. + Details Name: uhs_NonRule10B51ArrModifiedFlag Namespace Prefix: uhs_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionRule 10b51 arr modified flag. + ReferencesNo definition available. + Details Name: uhs_Rule10B51ArrModifiedFlag Namespace Prefix: uhs_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration XML 17 R9.htm IDEA: XBRL DOCUMENT v3.24.3 General 9 Months Ended Sep. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â General (1) GeneralThis Quarterly Report on Form 10-Q is for the quarterly period ended September 30, 2024. In this Quarterly Report, â€œwe,â€ â€œus,â€ â€œourâ€ â€œUHSâ€ and the â€œCompanyâ€ refer to Universal Health Services, Inc. and its subsidiaries.The condensed consolidated interim financial statements include the accounts of our majority-owned subsidiaries and partnerships and limited liability companies controlled by us, or our subsidiaries, as managing general partner or managing member. The condensed consolidated interim financial statements included herein have been prepared by us, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (â€œSECâ€) and reflect all adjustments (consisting only of normal recurring adjustments) which, in our opinion, are necessary to fairly state results for the interim periods. Certain information and footnote disclosures normally included in audited consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations, although we believe that the accompanying disclosures are adequate to make the information presented not misleading. These condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements, significant accounting policies and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023. X - DefinitionThe entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/275/tableOfContentReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 18 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Relationship with Universal Health Realty Income Trust and Other Related Party Transactions 9 Months Ended Sep. 30, 2024 Related Party Transactions [Abstract] Â Relationship with Universal Health Realty Income Trust and Other Related Party Transactions (2) Relationship with Universal Health Realty Income Trust and Other Related Party TransactionsRelationship with Universal Health Realty Income Trust:At September 30, 2024, we held approximately 5.7% of the outstanding shares of Universal Health Realty Income Trust (the â€œTrustâ€). We serve as Advisor to the Trust under an annually renewable advisory agreement, which is scheduled to expire on December 31st of each year, pursuant to the terms of which we conduct the Trustâ€™s day-to-day affairs, provide administrative services and present investment opportunities. The advisory agreement was renewed by the Trust for 2024 at the same rate in place for 2023, 2022 and 2021, providing for an advisory fee computation at 0.70% of the Trustâ€™s average invested real estate assets. We earned an advisory fee from the Trust, which is included in net revenues in the accompanying consolidated statements of income, of approximately $1.4 million and $1.3 million during the three-month periods ended September 30, 2024 and 2023, respectively, and approximately $4.1 million and $4.0 million during the nine-month periods ended September 30, 2024 and 2023, respectively.In addition, certain of our officers and directors are also officers and/or directors of the Trust. Management believes that it has the ability to exercise significant influence over the Trust, therefore we account for our investment in the Trust using the equity method of accounting.Our pre-tax share of income from the Trust was approximately $300,000 and $100,000 during the three-month periods ended September 30, 2024 and 2023, respectively, and approximately $914,000 and $670,000 during the nine-month periods ended September 30, 2024 and 2023, respectively, and is included in other (income) expense, net, on the accompanying consolidated statements of income for each period. We received dividends from the Trust amounting to $575,000 and $567,000 during the three-month periods ended September 30, 2024 and 2023, respectively, and $1.7 million during each of the nine-month periods ended September 30, 2024 and 2023. The carrying value of our investment in the Trust was approximately $6.2 million and $7.0 million at September 30, 2024 and December 31, 2023, respectively, and is included in other assets in the accompanying condensed consolidated balance sheets. The market value of our investment in the Trust was $36.0 million at September 30, 2024 and $34.1 million at December 31, 2023, based on the closing price of the Trustâ€™s stock on the respective dates.The Trust commenced operations in 1986 by purchasing certain properties from us and immediately leasing the properties back to our respective subsidiaries. The base rents are paid monthly and the bonus rent, which as of January 1, 2022 is applicable only to McAllen Medical Center, is computed and paid on a quarterly basis, based upon a computation that compares current quarter revenue to a corresponding quarter in the base year. The leases with those subsidiaries are unconditionally guaranteed by us and are cross-defaulted with one another.On December 31, 2021, we entered into an asset purchase and sale agreement with the Trust, which was amended during the first quarter of 2022, pursuant to the terms of which: (i) a wholly-owned subsidiary of ours purchased from the Trust the real estate assets of the Inland Valley Campus of Southwest Healthcare System located in Wildomar, California, at its fair market value; (ii) two wholly-owned subsidiaries of ours transferred to the Trust, at their respective fair-market values, the real estate assets of Aiken Regional Medical Center (â€œAikenâ€), located in Aiken, South Carolina (which includes a 211-bed acute care hospital and a 62-bed behavioral health facility), and Canyon Creek Behavioral Health (â€œCanyon Creekâ€), located in Temple, Texas, and; (iii) we received approximately $4.1 million in cash from the Trust.As a result of the purchase options within the lease agreements for Aiken and Canyon Creek, the asset purchase and sale transaction is accounted for as a failed sale leaseback in accordance with U.S. GAAP. We have accounted for the asset exchange and substitution transaction with the Trust as a financing arrangement and, since we did not derecognize the real property related to Aiken and Canyon Creek, we will continue to depreciate the assets. Our condensed consolidated balance sheets as of September 30, 2024 and December 31, 2023 reflects a financial liability of $74.8 million and $77.5 million, respectively, which is included in debt, for the fair value of real estate assets that we exchanged as part of the transaction. Our monthly lease payments payable to the Trust will be recorded to interest expense and as a reduction to the outstanding financial liability. The amount allocated to interest expense is determined using our incremental borrowing rate and is based on the outstanding financial liability.The aggregate rent payable to the Trust in connection with the leases on McAllen Medical Center, Wellington Regional Medical Center, Aiken Regional Medical Center and Canyon Creek Behavioral Health was approximately $5 million during each of the three months ended September 30, 2024 and 2023, and approximately $16 million and $15 million during the nine months ended September 30, 2024 and 2023, respectively.Pursuant to the Master Leases by certain subsidiaries of ours and the Trust as described in the table below, dated 1986 and 2021 (â€œthe Master Leasesâ€) which govern the leases of McAllen Medical Center and Wellington Regional Medical Center (each of which is governed by the Master Lease dated 1986), and Aiken Regional Medical Center and Canyon Creek Behavioral Health (each of which is governed by the Master Lease dated 2021), we have the option to renew the leases at the lease terms described above and below by providing notice to the Trust at least 90 days prior to the termination of the then current term. We also have the right to purchase the respective leased hospitals at their appraised fair market value upon any of the following: (i) at the end of the lease terms or any renewal terms; (ii) upon one monthâ€™s notice should a change of control of the Trust occur, or; (iii) within the time period as specified in the lease in the event that we provide notice to the Trust of our intent to offer a substitution property/properties in exchange for one (or more) of the hospital properties leased from the Trust should we be unable to reach an agreement with the Trust on the properties to be substituted. In addition, we have rights of first refusal to: (i) purchase the respective leased facilities during and for a specified period after the lease terms at the same price, terms and conditions of any third-party offer, or; (ii) renew the lease on the respective leased facility at the end of, and for a specified period after, the lease term at the same terms and conditions pursuant to any third-party offer.In addition, we are the managing, majority member in a joint venture with an unrelated third-party that operates Clive Behavioral Health, a 100-bed behavioral health care facility located in Clive, Iowa. The real property of this facility, which was completed and opened in late 2020, is also leased from the Trust (annual rental of approximately $2.8 million and $2.7 million during 2024 and 2023, respectively) pursuant to the lease terms as provided in the table below. In connection with the lease on this facility, the joint venture has the right to purchase the leased facility from the Trust at its appraised fair market value upon either of the following: (i) by providing notice at least 270 days prior to the end of the lease terms or any renewal terms, or; (ii) upon 30 days' notice anytime within 12 months of a change of control of the Trust (UHS also has this right should the joint venture decline to exercise its purchase right). Additionally, the joint venture has rights of first offer to purchase the facility prior to any third-party sale.The table below provides certain details for each of the hospitals leased from the Trust as of September 30, 2024:Â Hospital Name Â AnnualMinimumRent Â Â End of Lease Term Â RenewalTerm(years) Â Â McAllen Medical Center Â $ 5,485,000 Â Â December, 2026 Â Â 5 Â (a) Wellington Regional Medical Center Â $ 6,639,000 Â Â December, 2026 Â Â 5 Â (b) Aiken Regional Medical Center/Aurora Pavilion Behavioral Health Services Â $ 4,072,000 Â Â December, 2033 Â Â 35 Â (c) Canyon Creek Behavioral Health Â $ 1,841,000 Â Â December, 2033 Â Â 35 Â (c) Clive Behavioral Health Hospital Â $ 2,775,000 Â Â December, 2040 Â Â 50 Â (d) Â (a)We have one 5-year renewal option at existing lease rates (through 2031).(b)We have one 5-year renewal option at fair market value lease rates (through 2031). On each January 1st through 2026, the annual rent will increase by 2.5% on a cumulative and compounded basis.(c)We have seven 5-year renewal options at fair market value lease rates (2034 through 2068). On each January 1st through 2033, the annual rent will increase by 2.25% on a cumulative and compounded basis. (d)This facility is operated by a joint venture in which we are the managing, majority member and an unrelated third-party holds a minority ownership interest. The joint venture has three, 10-year renewal options at computed lease rates as stipulated in the lease (2041 through 2070) and two additional, 10-year renewal options at fair market value lease rates (2071 through 2090). In each January through 2040 (and potentially through 2070 if three, 10-year renewal options are exercised), the annual rental will increase by 2.75% on a cumulative and compounded basis.In addition, certain of our subsidiaries are tenants in several medical office buildings (â€œMOBsâ€) and two free-standing emergency departments ("FED") owned by the Trust or by limited liability companies in which the Trust holds 95% to 100% of the ownership interest. In connection with these two FEDs, in October, 2024, our subsidiaries exercised their 5-year renewal options on the facilities which are located in Weslaco and Mission, Texas. Each renewal option covers the period of February 1, 2025 through January 31, 2030 (the current lease terms were scheduled to expire on January 31, 2025; with aggregate annual lease rates of approximately $979,000). Pursuant to terms of the leases, and consistent with the terms of the leases currently in effect for each property, the lease rates are scheduled to increase 2% per year through the end of the renewed lease terms. Our subsidiaries have five, 5-year renewal options remaining on each of these FEDs, with the first three renewal options (covering the years 2030 through 2044) providing for 2% annual increases to the lease rates, and the remaining two, 5-year renewal options (covering the years 2045 through 2054) providing for lease rates at the then fair market value. These leases are cross-defaulted with one another and our subsidiaries have the option to purchase the leased properties upon the expiration of each five-year extended term at the fair market value at that time. During the third quarter of 2023, the Trust acquired the McAllen Doctor's Center, a 79,500 rentable square feet medical office building located in McAllen, Texas. A master lease was executed between a wholly-owned subsidiary of ours and the Trust, pursuant to the terms of which our subsidiary will master lease 100% of the rentable square feet of the MOB at an initial minimum rent of $624,000 annually. The master lease commenced during August, 2023 and is scheduled to expire in twelve years.During the first quarter of 2023, the Trust substantially completed construction on a new 86,000 rentable square feet multi-tenant MOB that is located on the campus of Northern Nevada Sierra Medical Center in Reno, Nevada. Northern Nevada Sierra Medical Center, a 170-bed newly constructed acute care hospital owned and operated by a wholly-owned subsidiary of ours, was completed and opened in April, 2022. In connection with this MOB, a ground lease and a master flex lease was executed between a wholly-owned subsidiary of ours and the Trust, pursuant to the terms of which our subsidiary will master lease approximately 68% of the rentable square feet of the MOB at an initial minimum rent of $1.3 million annually plus a pro-rata share of the common area maintenance expenses. The master flex

lease could be reduced during the term if certain conditions are met. The ground lease and master flex lease each commenced during the first quarter of 2023.Other Related Party Transactions:In December, 2010, our Board of Directors approved the Companyâ€™s entering into supplemental life insurance plans and agreements on the lives of Alan B. Miller (our Executive Chairman of the Board) and his wife. As a result of these agreements, as amended in October, 2016, based on actuarial tables and other assumptions, during the life expectancies of the insureds, we would pay approximately $28 million in premiums, and certain trusts owned by our Executive Chairman of the Board, would pay approximately $9 million in premiums. Based on the projected premiums mentioned above, and assuming the policies remain in effect until the death of the insureds, we will be entitled to receive death benefit proceeds of no less than approximately $37 million representing the $28 million of aggregate premiums paid by us as well as the $9 million of aggregate premiums paid by the trusts. In connection with these policies, we will pay or have paid approximately $1.0 million, net, in premium payments during 2024 and 2023.In August, 2015, Marc D. Miller, our President and Chief Executive Officer and member of our Board of Directors, was appointed to the Board of Directors of Premier, Inc. (â€œPremierâ€), a healthcare performance improvement alliance. During 2013, we entered into a new group purchasing organization agreement (â€œGPOâ€) with Premier. In conjunction with the GPO agreement, we acquired a minority interest in Premier for a nominal amount. During the fourth quarter of 2013, in connection with the completion of an initial public offering of the stock of Premier, we received cash proceeds for the sale of a portion of our ownership interest in the GPO. Also in connection with this GPO agreement, we received shares of restricted stock of Premier which vested ratably over a seven-year period (2014 through 2020), contingent upon our continued participation and minority ownership interest in the GPO. During the third quarter of 2020, we entered into an agreement with Premier pursuant to the terms of which, among other things, our ownership interest in Premier was converted into shares of Class A Common Stock of Premier. We have elected to retain a portion of the previously vested shares of Premier, the market value of which is included in other assets on our condensed consolidated balance sheets. Based upon the closing price of Premierâ€™s stock on each respective date, the market value of our shares of Premier was approximately $45 million and $50 million as of September 30, 2024 and December 31, 2023, respectively. Any change in market value of our Premier shares since December 31, 2023 was recorded as an unrealized gain/loss in â€œOther (income) expense, netâ€ in our condensed consolidated statements of income for the three and nine-month period ended September 30, 2024. Additionally, we received cash dividends from Premier amounting to approximately $470,000 for each of the three-month periods ended September 30, 2024 and 2023, and approximately $1.4 million for each of the nine-month periods ended September 30, 2024 and 2023. The dividends are included in â€œOther (income) expense, netâ€ in our condensed consolidated statements of income. A member of our Board of Directors, Executive Committee and Finance Committee is a partner in Norton Rose Fulbright US LLP, a law firm engaged by us for a variety of legal services. The Board member and his law firm also provide personal legal services to our Executive Chairman and he acts as trustee of certain trusts for the benefit of our Executive Chairman and his family. X - ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/850/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1 + Details Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Other Noncurrent liabilities and Redeemable/Noncontrolling Interests 9 Months Ended Sep. 30, 2024 Noncontrolling Interest [Abstract] Â Other Noncurrent liabilities and Redeemable/Noncontrolling Interests (3) Other Noncurrent liabilities and Redeemable/Noncontrolling InterestsOther noncurrent liabilities include the long-term portion of our professional and general liability, workersâ€™ compensation reserves, pension and deferred compensation liabilities, and liabilities incurred in connection with split-dollar life insurance agreements on the lives of our chief executive officer and his wife.As of September 30, 2024, outside owners held noncontrolling, minority ownership interests of: (i) approximately 7% in an acute care facility located in Texas; (ii) 49%, 20%, 30%, 20%, 25%, and 48% in six behavioral health care facilities located in Arizona, Pennsylvania, Ohio, Washington, Missouri, and Iowa, respectively, (iii) 26% and 49% in two behavioral health care facilities located in Michigan (one currently under construction with an expected opening in the second quarter of 2025) and; (iv) approximately 5% in an acute care facility and 49% in a surgery center, located in Nevada. The noncontrolling interest and redeemable noncontrolling interest balances of $75 million and $6 million, respectively, as of September 30, 2024, consist primarily of the third-party ownership interests in these hospitals.In connection with the two behavioral health care facilities located in Pennsylvania and Ohio, the minority ownership interests of which are reflected as redeemable noncontrolling interests on our consolidated balance sheets, the outside owners have â€œput optionsâ€ to put their entire ownership interest to us at any time. If exercised, the put option requires us to purchase the minority memberâ€™s interest at fair market value. Accordingly, the amounts recorded as redeemable noncontrolling interests on our consolidated balance sheets reflect the estimated fair market value of these ownership interests. X - DefinitionOther noncurrent liabilities and redeemable noncontrolling interests. + ReferencesNo definition available. + Details Name: uhs_OtherNoncurrentLiabilitiesAndRedeemableNoncontrollingInterestsTextBlock Namespace Prefix: uhs_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NoncontrollingInterestAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 20 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Treasury 9 Months Ended Sep. 30, 2024 Equity [Abstract] Â Treasury (4) TreasuryIn September, 2024, we completed the following financing transactions:â€¢The public offering of $500 million of aggregate principal amount of 4.625% senior secured notes due on October 15, 2029 ("2029 Notes");â€¢The public offering of $500 million of aggregate principal amount of 5.050% senior secured notes due on October 15, 2034 ("2034 Notes");â€¢Amended our credit agreement to:oExtend the maturity date to September, 2029 (from August, 2026 previously);oIncrease the revolving credit facility to $1.3 billion (from $1.2 billion previously), and;oreduce the outstanding borrowings pursuant to the tranche term loan A facility by approximately $1.0 billion, to $1.2 billion, utilizing the proceeds generated from the issuance of the above-mentioned 2029 Notes and 2034 Notes.On September 26, 2024, we entered into a tenth amendment ("Tenth Amendment") to our credit agreement ("Credit Agreement"), dated as of November 15, 2010, as amended and restated at various times from March, 2011 to June, 2022, among UHS, as borrower, the several banks and other financial institutions or entities from time to time parties thereto, as lenders, and JPMorgan Chase Bank, N.A., as administrative agent. The Tenth Amendment provided for: (i) an extension of the maturity date to September 26, 2029; (ii) a new revolving credit facility of up to $1.3 billion (which as of September 30, 2024, had $1.01 billion of aggregate available borrowing capacity, net of $288 million of outstanding borrowings and $3 million of letters of credit), and; (iii) a new replacement tranche A term loan facility ("Tranche A Term Loan") of up to $1.2 billion (which had $1.2 billion of outstanding borrowings as of September 30, 2024).Pursuant to the terms of the Tenth Amendment, the Tranche A Term Loan provides for installment payments of $7.5 million per quarter commencing on December 31, 2024 through September 30, 2026, and $15.0 million per quarter commencing on December 31, 2026 through June 30, 2029. The unpaid principal balance at June 30, 2029 (scheduled to be $975.0 million) is payable on the September 26, 2029 scheduled maturity date of the Credit Agreement.Revolving credit and Tranche A Term Loan borrowings under the Credit Agreement bear interest at our election at either (1) the ABR rate which is defined as the rate per annum equal to the greatest of (a) the lenderâ€™s prime rate, (b) the weighted average of the federal funds rate, plus 0.5% and (c) one month term SOFR rate plus 1%, in each case, plus an applicable margin based upon our consolidated leverage ratio at the end of each quarter ranging from 0.25% to 0.625%, or (2) the one, three or six month term SOFR rate plus 0.1% (at our election), plus an applicable margin based upon our consolidated leverage ratio at the end of each quarter ranging from 1.25% to 1.625%. As of September 30, 2024, the applicable margins were 0.375% for ABR-based loans and 1.375% for SOFR-based loans under the revolving credit and term loan A facilities. The revolving credit facility includes a $125 million sub-limit for letters of credit. The Credit Agreement is secured by certain assets of the Company and our material subsidiaries (which generally excludes asset classes such as substantially all of the patient-related accounts receivable of our acute care hospitals, if sold to a receivables facility pursuant to the Credit Agreement, and certain real estate assets and assets held in joint-ventures with third parties) and is guaranteed by our material subsidiaries.The Credit Agreement includes a material adverse change clause that must be represented at each draw. The Credit Agreement also contains covenants that include a limitation on sales of assets, mergers, change of ownership, liens, indebtedness, transactions with affiliates, dividends and stock repurchases; and requires compliance with financial covenants including maximum leverage. We were in compliance with all required covenants as of September 30, 2024 pursuant to the terms of the Credit Agreement, as amended on September 26, 2024, and as of December 31, 2023 pursuant to the terms of the previous credit agreement.As mentioned above, on September 26, 2024, we completed the public offering of: (i) $500,000,000 aggregate principal amount of the 4.625%, 2029 Notes, and; (ii) $500,000,000 aggregate principal amount of the 5.050%, 2034 Notes (and together with the 2029 Notes, the "2029 and 2034 Notes"), each guaranteed on a senior secured basis by all of our existing and future direct and indirect subsidiaries that guarantee our senior secured credit facility or our other first lien obligations or any junior lien obligations (the â€œSubsidiary Guarantorsâ€). The 2029 and 2034 Notes have been registered under the Securities Act of 1933, as amended (the â€œSecurities Actâ€), pursuant to the Issuerâ€™s and the Subsidiary Guarantorsâ€™ registration statement on Form S-3 (File No. 333-282135), including the prospectus dated September 16, 2024, and a related prospectus supplement dated September 17, 2024, as filed with the Securities and Exchange Commission on September 19, 2024.As of September 30, 2024, including the above-mentioned newly issued Notes, we had combined aggregate principal of $3.0 billion from the following senior secured notes:â€¢$700 million aggregate principal amount of 1.65% senior secured notes due in September, 2026 ("2026 Notes") which were issued on August 24, 2021. Interest on the 2026 Notes is payable on March 1st and September 1st until the maturity date of September 1, 2026.â€¢$500 million of aggregate principal amount of 4.625% senior secured notes due in October, 2029 ("2029 Notes") which were issued on September 26, 2024. Interest on the 2029 Notes is payable on April 15th and October 15th, commencing April 15, 2025 until the maturity date of October 15, 2029.â€¢$800 million aggregate principal amount of 2.65% senior secured notes due in October, 2030 ("2030 Notes") which were issued on September 21, 2020. Interest on the 2030 Notes is payable on April 15th and October 15th, until the maturity date of October 15, 2030.â€¢$500 million of aggregate principal amount of 2.65% senior secured notes due in January, 2032 ("2032 Notes") which were issued on August 24, 2021. Interest on the 2032 Notes is payable on January 15th and July 15th until the maturity date of January 15, 2032.â€¢$500 million of aggregate principal amount of 5.050% senior secured notes due in October, 2034 ("2034 Notes") which were issued on September 26, 2024. Interest on the 2034 Notes is payable on April 15th and October 15th, commencing on April 15, 2025 until the maturity date of October 15, 2034.The 2026 Notes, 2030 Notes and 2032 Notes (collectively the "2026, 2030 and 2032 Notes") were initially issued only to qualified institutional buyers under Rule 144A and to non-U.S. persons outside the United States in reliance on Regulation S under the Securities Act. In December, 2022, we completed a registered exchange offer in which virtually all previously outstanding 2026, 2030 and 2032 Notes were exchanged for identical 2026, 2030 and 2032 Notes that were registered under the Securities Act, and thereby became freely transferable (subject to certain restrictions applicable to affiliates and broker dealers). 2026, 2030 and 2032 Notes originally issued under Rule 144A or Regulation S that were not exchanged remain outstanding and may not be offered or sold in the United States absent registration under the Securities Act or an applicable exemption from registration requirements thereunder.The 2026, 2030 and 2032 Notes, and the 2029 and 2034 Notes (collectively "All the Notes") are guaranteed (the â€œGuaranteesâ€) on a senior secured basis by our Subsidiary Guarantors that guarantee our Credit Agreement, or other first lien obligations or any junior lien obligations. All the Notes and the Guarantees are secured by first-priority liens, subject to permitted liens, on certain of the Companyâ€™s and the Subsidiary Guarantorsâ€™ assets now owned or acquired in the future by the Company or the Subsidiary Guarantors (other than real property, accounts receivable sold pursuant to a Company-related receivables facility (as defined in the Indenture pursuant to which All The Notes were issued (the â€œIndenturesâ€), and certain other excluded assets). The Companyâ€™s obligations with respect to All the Notes, the obligations of the Subsidiary Guarantors under the Guarantees, and the performance of all of the Companyâ€™s and the Subsidiary Guarantorsâ€™ other obligations under the Indentures, are secured equally and ratably with the Companyâ€™s and the Subsidiary Guarantorsâ€™ obligations under the Credit Agreement. However, the liens on the collateral securing All the Notes and the Guarantees will be released if: (i) All the Notes have investment grade ratings; (ii) no default has occurred and is continuing, and; (iii) the liens on the collateral securing all first lien obligations (including the Credit Agreement and All the Notes) and any junior lien obligations are released or the collateral under the Credit Agreement, any other first lien obligations and any junior lien obligations is released or no longer required to be pledged. The liens on any collateral securing All the Notes and the Guarantees will also be released if the liens on that collateral securing the Credit Agreement, other first lien obligations and any junior lien obligations are released.As discussed in Note 2 to the Condensed Consolidated Financial Statements-Relationship with Universal Health Realty Income Trust and Other Related Party Transactions, on December 31, 2021, we (through wholly-owned subsidiaries of ours) entered into an asset purchase and sale agreement with Universal Health Realty Income Trust (the â€œTrustâ€). Pursuant to the terms of the agreement, which was amended during the first quarter of 2022, we, among other things, transferred to the Trust, the real estate assets of Aiken Regional Medical Center (â€œAikenâ€) and Canyon Creek Behavioral Health (â€œCanyon Creekâ€). In connection with this transaction, Aiken and Canyon Creek (as lessees), entered into a master lease and individual property leases, as amended, (with the Trust as lessor), for initial lease terms on each property of approximately twelve years, ending on December 31, 2033. As a result of our purchase option within the Aiken and Canyon Creek lease agreements, this asset purchase and sale transaction is accounted for as a failed sale leaseback in accordance with U.S. GAAP and we have accounted for the transaction as a financing arrangement. Our lease payments payable to the Trust are recorded to interest expense and as a reduction of the outstanding financial liability, and the amount allocated to interest expense is determined based upon our incremental borrowing rate and the outstanding financial liability. In connection with this transaction, our consolidated balance sheets at September 30, 2024 and December 31, 2023 reflect financial liabilities, which are included in debt, of approximately $75 million and $77 million, respectively.At September 30, 2024, the carrying value and fair value of our debt were approximately $4.7 billion and $4.4 billion, respectively. At December 31, 2023, the carrying value and fair value of our debt were approximately $4.9 billion and $4.6 billion, respectively. The fair value of our debt was computed based upon quotes received from financial institutions. We consider these to be â€œlevel 2â€ in the fair value hierarchy as outlined in the authoritative guidance for disclosures in connection with debt instruments.The aggregate scheduled maturities of our $4.7 billion total debt outstanding as of September 30, 2024 (before $21 million of unamortized financing costs), are as follows: (i) $38 million due during the next 12 months; (ii) $738 million due during months 13 to 24; (iii) $69 million due during months 25 to 36; (iv) $70 million due during months 37 to 48; (v) $1.3 billion due during months 49 to 60, and; (vi) $2.4 billion due in greater than 60 months.Foreign Currency Forward Exchange Contracts:We use forward exchange contracts to hedge our net investment in

foreign operations against movements in exchange rates. The effective portion of the unrealized gains or losses on these contracts is recorded in foreign currency translation adjustment within accumulated other comprehensive income and remains there until either the sale or liquidation of the subsidiary. In connection with these forward exchange contracts, we recorded net cash outflows of $36 million during the nine-month period ended September 30, 2024 and net cash outflows of $8 million during the nine-month period ended September 30, 2023.Derivatives Hedging Relationships:The following table presents the effects of our foreign currency forward exchange contracts on our results of operations for the three and nine-month periods ended September 30, 2024 and 2023 (in thousands): Â Gain/(Loss) recognized in AOCI Â Â Three months ended Â Â Nine months ended Â Â September 30, Â Â September 30, Â Â September 30, Â Â September 30, Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Net Investment Hedge relationships Â Â Â Â Â Â Â Â Â Â Â Â Foreign currency forward exchange contracts $ (43,490) Â $ 19,619 Â Â $ (35,289) Â $ (10,781) No other gains or losses were recognized in income related to derivatives in Subtopic 815-20.Cash, Cash Equivalents and Restricted Cash:Cash, cash equivalents, and restricted cash as reported in the condensed consolidated statements of cash flows are presented separately on our condensed consolidated balance sheets as follows (in thousands): Â September 30, Â Â September 30, Â Â December 31, Â Â 2024 Â Â 2023 Â Â 2023 Â Cash and cash equivalents $ 106,077 Â $ 80,768 Â $ 119,439 Â Restricted cashÂ (a) Â 98,520 Â Â 99,871 Â Â 95,031 Â Total cash, cash equivalents and restricted cash $ 204,597 Â Â $ 180,639 Â Â $ 214,470 Â (a) Restricted cash is included in other noncurrent assets on the accompanying condensed consolidated balance sheets. X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505-30/tableOfContent + Details Name: us-gaap_TreasuryStockTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R13.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurement 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â Fair Value Measurement (5) Fair Value MeasurementFair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels:â€¢Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities.â€¢Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These included quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.â€¢Level 3: Unobservable inputs that reflect the reporting entityâ€™s own assumptions.The following tables present the assets and liabilities recorded at fair value on a recurring basis: Â Balance at Â Balance Sheet Basis of Fair Value Measurement Â (in thousands) September 30, 2024 Â Location Level 1 Â Level 2 Â Level 3 Â Assets: Â Â Â Â Â Â Â Â Â Â Money market mutual funds $ 115,205 Â Other noncurrent assets $ 115,205 Â Â Â Â Â Â Certificates of deposit Â 2,201 Â Other noncurrent assets Â Â Â 2,201 Â Â Â Equity securities Â 44,654 Â Other noncurrent assets Â 44,654 Â Â Â Â Â Â Deferred compensation assets Â 49,270 Â Other noncurrent assets Â 49,270 Â Â Â Â Â Â $ 211,330 Â Â $ 209,129 Â $ 2,201 Â Â - Â Liabilities: Â Â Â Â Â Â Â Â Â Â Foreign currency forward exchange contracts $ 1,533 Â Accounts payable and other liabilities Â Â $ 1,533 Â Â Â Deferred compensation liability Â 49,270 Â Other noncurrent liabilities Â 49,270 Â Â Â Â Â Â $ 50,803 Â Â $ 49,270 Â $ 1,533 Â Â - Â Â Â Â Â Â Â Â Â Â Â Â Balance at Â Balance Sheet Basis of Fair Value Measurement Â (in thousands) December 31, 2023 Â Location Level 1 Â Level 2 Â Level 3 Â Assets: Â Â Â Â Â Â Â Â Â Â Money market mutual funds $ 111,129 Â Other noncurrent assets $ 111,129 Â Â Â Â Â Â Certificates of deposit Â 2,300 Â Other noncurrent assets Â Â Â 2,300 Â Â Â Equity securities Â 49,923 Â Other noncurrent assets Â 49,923 Â Â Â Â Â Â Deferred compensation assets Â 43,060 Â Other noncurrent assets Â 43,060 Â Â Â Â Â Â $ 206,412 Â Â $ 204,112 Â $ 2,300 Â Â - Â Liabilities: Â Â Â Â Â Â Â Â Â Â Foreign currency forward exchange contracts $ 1,911 Â Accounts payable and other liabilities Â Â $ 1,911 Â Â Â Deferred compensation liability Â 43,060 Â Other noncurrent liabilities Â 43,060 Â Â Â Â Â Â $ 44,971 Â Â $ 43,060 Â $ 1,911 Â Â - Â The fair value of our money market mutual funds, certificates of deposit and equity securities with a readily determinable fair value are computed based upon quoted market prices in an active market. The fair value of deferred compensation assets and the offsetting liability are computed based on market prices in an active market held in a rabbi trust. The fair value of our foreign currency exchange contracts is determined using quoted forward exchange rates and spot rates at the reporting date. X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies 9 Months Ended Sep. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â Commitments and Contingencies (6) Commitments and ContingenciesProfessional and General Liability, Workersâ€™ Compensation Liability The vast majority of our subsidiaries are self-insured for professional and general liability exposure up to: (i) $20 million for professional liability and $3 million for general liability per occurrence in 2024, 2023, 2022 and 2021; (ii) $10 million and $3 million per occurrence, respectively, in 2020; (iii) $5 million and $3 million per occurrence, respectively, during 2019, 2018 and 2017, and; (iv) $10 million and $3 million per occurrence, respectively, prior to 2017.These subsidiaries are provided with several excess policies through commercial insurance carriers which provide for coverage in excess of the applicable per occurrence and aggregate self-insured retention or underlying policy limits up to approximately $175 million in 2024; $165 million in 2023; $162 million in 2022; $155 million in 2021 and $250 million during each of 2014 through 2020. In addition, from time to time based upon marketplace conditions, we may elect to purchase additional commercial coverage for certain of our facilities or businesses. Our behavioral health care facilities located in the U.K. have policies through a commercial insurance carrier located in the U.K. that provides for Â£18.5 million of professional liability coverage, and Â£25 million of general liability coverage. The commercial insurance limits indicated above for each policy year may have been reduced due to payment of covered claims or suits, subject to the policy terms and conditions.As of September 30, 2024, the total net accrual for our self-insured professional and general liability claims was $480 million, of which $70 million was included in current liabilities. As of December 31, 2023, the total net accrual for our self-insured professional and general liability claims was $431 million, of which $70 million was included in current liabilities.As a result of unfavorable trends experienced during the past several years, included in our results of operations were increases to our reserves for self-insured professional and general liability claims amounting to approximately $30 million and $44 million during the three and nine-month periods ended September 30, 2024, respectively, and $5 million and $25 million during the three and nine-month periods ended September 30, 2023. Our estimated liability for self-insured professional and general liability claims is based on a number of factors including, among other things, the number of asserted claims and reported incidents, estimates of losses for these claims based on recent and historical settlement amounts, estimates of incurred but not reported claims based on historical experience, and estimates of amounts recoverable under our commercial insurance policies. While we continuously monitor these factors, our ultimate liability for professional and general liability claims could change materially from our current estimates due to inherent uncertainties involved in making this estimate. Given our significant self-insured exposure for professional and general liability claims, there can be no assurance that a sharp increase in the number and/or severity of claims asserted against us will not have a material adverse effect on our future results of operations.As of September 30, 2024, the total accrual for our workersâ€™ compensation liability claims was $136 million, $58 million of which was included in current liabilities. As of December 31, 2023, the total accrual for our workersâ€™ compensation liability claims was $130 million, $55 million of which was included in current liabilities. As a result of favorable trends experienced in prior years, included in our results of operations during the nine-month period ended September 30, 2023, was a pre-tax decrease to our reserves for self-insured workers' compensation liability claims of approximately $10 million (recorded during the second quarter of 2023).Although we are unable to predict whether or not our future financial statements will require updates to estimates for our prior year reserves for self-insured general and professional and workersâ€™ compensation claims, given the relatively unpredictable nature of these potential liabilities and the factors impacting these reserves, as discussed above, it is reasonably likely that our future financial results may include material adjustments to prior period reserves.As disclosed below in Legal Proceedings:â€¢On March 28, 2024, a jury returned a verdict for compensatory damages of $60 million and punitive damages of $475 million and a related judgment was entered against The Pavilion Behavioral Health System (the â€œPavilionâ€), an indirect subsidiary of the Company. In an order dated October 10, 2024, the trial court ordered a remittitur of punitive damages from $475 million to $120 million. The court denied the Pavilionâ€™s request for reduction of compensatory damages. The Pavilion intends to appeal the remaining judgment.â€¢Cumberland Hospital for Children and Adolescents (â€œCumberlandâ€), an indirect subsidiary of the Company, is a defendant in multi-plaintiff lawsuits filed in the Circuit Court for Richmond, Virginia (the â€œCumberland Litigationâ€), relating to allegations of inappropriate sexual contact during medical examinations by Dr. Daniel Davidow, an independent contractor and the former medical director for Cumberland. The Company and UHS of Delaware, Inc., our administrative services subsidiary (â€œUHS Delawareâ€), were also named as co-defendants in the Cumberland Litigation. Plaintiffs have asserted claims of negligence, assault and battery (against Dr. Davidow), false imprisonment, violations of the Virginia Consumer Protection Act (â€œVCPAâ€), and vicarious liability for Dr. Davidowâ€™s conduct against Cumberland, the Company, and UHS Delaware. The Company and UHS Delaware were dismissed from the action during the trial, which occurred in September, 2024. On September 27, 2024, a jury entered a verdict finding Dr. Davidow and Cumberland liable and awarded these three plaintiffs combined compensatory damages of $60 million for all liability theories, an additional combined $180 million in trebled damages for violation of the VCPA, and an additional combined $120 million in punitive damages. Cumberland is evaluating all legal options and intends to challenge this verdict, including the amounts awarded in the verdict, in post-trial proceedings and on appeal. Based upon Virginia law, we expect that the punitive damage amount should be reduced to a combined maximum of $1.05 million as a matter of law. There are approximately 40 additional plaintiffs making similar allegations with claims pending in the Cumberland Litigation.We are uncertain as to the ultimate financial exposure related to the above-mentioned Cumberland and Pavilion matters and we can make no assurances regarding their outcomes, or the amounts of damages that may be held recoverable after post-judgment proceedings and appeals. While Cumberland and Pavilion have professional liability insurance to cover a portion of these amounts, the resolution of these matters may have a material adverse effect on the Company. Without reduction for any potential amounts related to the above-mentioned Cumberland and Pavilion matters, the Company and its subsidiaries have aggregate insurance coverage of approximately $221 million remaining under commercial policies for matters applicable to the 2020 policy year (in excess of the applicable self-insured retention amounts of $10 million per occurrence for professional liability claims and $3 million per occurrence for general liability claims).In the event the resolution of the Cumberland and/or Pavilion matters exhausts all or a significant portion of the remaining commercial insurance coverage available to the Company and its subsidiaries for claims that occurred in 2020 (the applicable year for the Pavilion matter and substantially all of the Cumberland matters, as discussed above), or it requires the posting of large bonds or other collateral during appeal processes, our future results of operations and capital resources could be materially adversely impacted.Property InsuranceWe have commercial property insurance policies for our properties, covering the period of June 1, 2024 to June 1, 2025, providing property and business interruption coverage for losses in excess of $15 million per occurrence or per location (as applicable based upon the event) up to a $1 billion annual policy limitation for certain catastrophic events or perils. These commercial policies provide for coverage of up to $250 million of annual aggregate coverage for losses resulting from windstorm damage. Losses resulting from named windstorms are subject to deductibles between 3% and 5% of the total insurable value of the property. In addition, we have commercial property insurance policies covering catastrophic losses resulting from earthquake and flood damage, each subject to aggregated loss limits (as opposed to per occurrence losses). Commercially insured earthquake coverage for our facilities is subject to various deductibles and limitations including: (i) $100 million limitation for our facilities located in California, New Madrid Seismic Zone, Pacific Northwest Seismic Zone, Alaska and certain counties in Nevada; (ii) $100 million limitation for our facilities located in fault zones within the United States; (iii) $40 million limitation for our facilities located in Puerto Rico, and; (iv) $250 million limitation for many of our facilities located in other states. Our commercially insured flood coverage has a limit of $100 million annually. There is also a $10 million sublimit for one of our facilities located in Houston, Texas, and a $1 million sublimit for our facilities located in Puerto Rico. In addition, subject to the underlying policies' deductible provisions, our facilities located in California, New Madrid Seismic Zone, Pacific Northwest Seismic Zone, Alaska and certain counties in Nevada, have $50 million of excess commercial property insurance coverage for earthquake losses in excess of $100 million. Property insurance for our behavioral health facilities located in the U.K. are provided on an all risk basis up to a Â£1.5 billion policy limit, with coverage caps per location, that includes coverage for real and personal property as well as business interruption losses.These commercial policies are subject to a deductible of: (i) $5 million per location for damage resulting from earthquake, wind, hail and flood, and; (ii) $5 million per occurrence for all other events. For per location or per occurrence losses in excess of the applicable deductible, we are self-insured, through our wholly-owned captive insurance company, for up to $10 million of annual aggregate losses. Should the $10 million self-insured annual aggregate limitation be exhausted during the policy year, we have commercial insurance coverage for the next $30 million of annual aggregate losses in excess of the applicable deductible. In

the event the $30 million of commercial coverage is also exhausted, we are self-insured for all per location or per occurrence losses up to $25 million, including the $5 million deductible.Commitment to Develop, Lease and Operate an Acute Care Hospital in Washington, D.C.During 2020, we entered into various agreements with the District of Columbia (the â€œDistrictâ€) related to the development, leasing and operation of an acute care hospital and certain other facilities/structures on land owned by the District (â€œDistrict Facilitiesâ€). The agreements contemplate that we will serve as manager for development and construction of the District Facilities on behalf of the District, with a projected aggregate cost of approximately $439 million, approximately $295 million of which was incurred as of September 30, 2024, which will be entirely funded by the District. Construction of the District Facilities is expected to be completed in the Spring of 2025.Upon completion of the District Facilities, we will lease the District Facilities for a nominal rental amount for a period of 75 years and are obligated to operate the District Facilities during the lease term. We have certain lease termination rights in connection with the District Facilities beginning on the tenth anniversary of the lease commencement date for various and decreasing amounts as provided for in the agreements. Additionally, any time after the 10th anniversary of the lease term, we have a right to purchase the District Facilities for a price equal to the greater of fair market value of the District Facilities or the amount necessary to defease the bonds issued by the District to fund the construction of the District Facilities. The lease agreement also entitles the District to participation rent should certain specified earnings before interest, taxes, depreciation and amortization thresholds be achieved by the acute care hospital.Additionally, we have committed to expend no less than $75 million (approximately $12 million of which has been incurred as of September 30, 2024), over a projected 12-year period, in healthcare infrastructure including expenditures related to the District Facilities as well as other healthcare related expenditures in certain specified areas of Washington, D.C. Pursuant to the agreements, the District is entitled to certain termination fees and other amounts as specified in the agreements in the event we, within certain specified periods of time, cease to operate the acute care hospital or there is a transfer of control of us or our subsidiary operating the hospital.Legal ProceedingsWe operate in a highly regulated and litigious industry which subjects us to various claims and lawsuits in the ordinary course of business as well as regulatory proceedings and government investigations. These claims or suits include claims for damages for personal injuries, medical malpractice, commercial/contractual disputes, wrongful restriction of, or interference with, physiciansâ€™ staff privileges, and employment related claims. In addition, health care companies are subject to investigations and/or actions by various state and federal governmental agencies or those bringing claims on their behalf. Government action has increased with respect to investigations and/or allegations against healthcare providers concerning possible violations of fraud and abuse and false claims statutes as well as compliance with clinical and operational regulations. Currently, and from time to time, we and some of our facilities are subjected to inquiries in the form of subpoenas, Civil Investigative Demands, audits and other document requests from various federal and state agencies. These inquiries can lead to notices and/or actions including repayment obligations from state and federal government agencies associated with potential non-compliance with laws and regulations. Further, the federal False Claims Act allows private individuals to bring lawsuits (qui tam actions) against healthcare providers that submit claims for payments to the government. Various states have also adopted similar statutes. When such a claim is filed, the government will investigate the matter and decide if they are going to intervene in the pending case. These qui tam lawsuits are placed under seal by the court to comply with the False Claims Actâ€™s requirements. If the government chooses not to intervene, the private individual(s) can proceed independently on behalf of the government. Health care providers that are found to violate the False Claims Act may be subject to substantial monetary fines/penalties as well as face potential exclusion from participating in government health care programs or be required to comply with Corporate Integrity Agreements as a condition of a settlement of a False Claims Act matter. In September 2014, the Criminal Division of the Department of Justice (â€œDOJâ€) announced that all qui tam cases will be shared with their Division to determine if a parallel criminal investigation should be opened. The DOJ has also announced an intention to pursue civil and criminal actions against individuals within a company as well as the corporate entity or entities. In addition, health care facilities are subject to monitoring by state and federal surveyors to ensure compliance with program Conditions of Participation. In the event a facility is found to be out of compliance with a Condition of Participation and unable to remedy the alleged deficiency(s), the facility faces termination from the Medicare and Medicaid programs or compliance with a System Improvement Agreement to remedy deficiencies and ensure compliance.The laws and regulations governing the healthcare industry are complex covering, among other things, government healthcare participation requirements, licensure, certification and accreditation, privacy of patient information, reimbursement for patient services as well as fraud and abuse compliance. These laws and regulations are constantly evolving and expanding. Further, the original Patient Protection and Affordable Care Act, as amended by the Health and Education Reconciliation Act, has added additional obligations on healthcare providers to report and refund overpayments by government healthcare programs and authorizes the suspension of Medicare and Medicaid payments â€œpending an investigation of a credible allegation of fraud.â€ We monitor our business and have developed an ethics and compliance program with respect to these complex laws, rules and regulations. Although we believe our policies, procedures and practices comply with government regulations, there is no assurance that we will not be faced with the sanctions referenced above which include fines, penalties and/or substantial damages, repayment obligations, payment suspensions, licensure revocation, and expulsion from government healthcare programs. Even if we were to ultimately prevail in any action brought against us or our facilities or in responding to any inquiry, such action or inquiry could have a material adverse effect on us.Certain legal matters are described below:Knight v. Miller, et. al.In July 2021, a shareholder derivative lawsuit was filed by plaintiff, Robin Knight, in the Chancery Court in Delaware against the members of the Board of Directors of the Company as well as certain officers (C.A. No.: 2021-0581-SG). The Company was named as a nominal defendant. The lawsuit alleged that in March 2020 stock options were awarded with exercise prices that did not reflect the Companyâ€™s fundamentals and business prospects, and in anticipation of future market rebound resulting in excessive gains. The lawsuit made claims of breaches of fiduciary duties, waste of corporate assets, and unjust enrichment. The lawsuit sought monetary damages allegedly incurred by the Company, disgorgement of the March 2020 stock awards as well as any proceeds derived therefrom and unspecified equitable relief. Defendants denied the allegations. We filed a motion to dismiss the complaint and the court granted part and denied part of our motion. During the third quarter of 2022, we reached a preliminary settlement, which would not have had a material impact on our consolidated financial statements. The settlement required court approval which the court declined to provide. Our Board of Directors authorized the formation of a Special Litigation Committee ("SLC") to review the matter and determine whether it was in the best interests of the Company to pursue this claim. The court stayed the litigation while the SLC conducted their review. According to the SLCâ€™s status letter to the Court of Chancery, dated April 15, 2024, after a thorough examination of documentary evidence, interviews with relevant persons, and a review of the applicable law, the SLC determined that the claims asserted in the shareholder derivative lawsuit did not have merit and that pursuing them would not be in the interest of the Company. The SLC further advised the court that the SLC concluded that the claims should be dismissed. The parties jointly filed a stipulation with the court requesting dismissal of the case. After a preliminary hearing on the matter, the court requested a revised stipulation be filed which was prepared and filed with the court. During the third quarter of 2024, the court entered the stipulation dismissing the case and the matter has been concluded.Disproportionate Share Hospital Payment Matter:In late September, 2015, many hospitals in Pennsylvania, including certain of our behavioral health care hospitals located in the state, received letters from the Pennsylvania Department of Human Services (the â€œDepartmentâ€) demanding repayment of allegedly excess Medicaid Disproportionate Share Hospital payments (â€œDSHâ€), primarily consisting of managed care payments characterized as DSH payments, for the federal fiscal year (â€œFFYâ€) 2011 amounting to approximately $4 million in the aggregate. Since that time, certain of our behavioral health care hospitals in Pennsylvania have received similar requests for repayment for alleged DSH overpayments for FFYs 2012 through 2015. For FFY 2012, the claimed overpayment amounts to approximately $4 million. For FY 2013, FY 2014 and FY 2015 the initial claimed overpayments and attempted recoupment by the Department were approximately $7 million, $8 million and $7 million, respectively. The Department has agreed to a change in methodology which, upon confirmation of the underlying data being accepted by the Department, could reduce the initial claimed overpayments for FY 2013, FY 2014 and FY 2015 to approximately $2 million, $2 million and $3 million, respectively. We filed administrative appeals for all of our facilities contesting the recoupment efforts for FFYs 2011 through 2015 as we believe the Departmentâ€™s calculation methodology is inaccurate and conflicts with applicable federal and state laws and regulations. The Department agreed to postpone the recoupment of the stateâ€™s share for FFY 2011 to 2013 until all hospital appeals are resolved but recouped the federal share. For FFY 2014 and FFY 2015, the Department initiated the recoupment of the alleged overpayments (both federal and state shares). Starting in FY 2016, the first full fiscal year after the January 1, 2015 effective date of Medicaid expansion in Pennsylvania, the Department no longer characterized managed care payments received by the hospitals as DSH payments. While the administrative appeals on the disputed DSH payments remain pending, we have been in continued settlement discussions with the Department. As a part of these discussions, we have presented certain calculation errors that we believe, if corrected, could materially reduce the alleged overpayments. We have recently reached a settlement in principle with the Department that will result in a partial repayment to us of amounts previously recouped. The parties are in the process of drafting a definitive settlement agreement codifying our agreement to conclude this matter. In the event that we are unable to complete the settlement agreement, we will continue with our administrative appeals. We can provide no assurance that we will ultimately be successful in our legal and administrative appeals related to the Departmentâ€™s repayment demands in the event the pending settlement is not finalized and we are unable to assess liability or damages with certainty at this time. If our legal and administrative appeals are unsuccessful, our future consolidated results of operations and financial condition could be adversely impacted by these repayments.Rachel Capriglione, as natural mother and Next Friend of A.T., a minor, Plaintiff, v. The Pavilion Foundation d/b/a The Pavilion Behavioral Health SystemAs previously reported on Form 8-K, as filed on April 1, 2024, the Pavilion Behavioral Health System (the â€œPavilionâ€), an indirect subsidiary of the Company, is the sole defendant in a lawsuit filed in Champaign County, Illinois, relating to the sexual assault of one minor patient by another minor patient in 2020. Plaintiff asserted claims of negligence and misrepresentation. The Pavilion denied any liability.The case went to trial in March of 2024. On March 28, 2024, a jury rejected the misrepresentation claim, returned a verdict for ordinary negligence, and awarded compensatory damages of $60 million and punitive damages of $475 million. Based on a search of verdicts in comparable cases, the magnitude of this verdict was unexpected and is unprecedented for a single-plaintiff injury case of this type in Champaign County, Illinois. The Pavilion filed post-trial motions, among other items, contesting the excessiveness of the damage awards.As previously reported on Form 8-K, as filed on October 11, 2024, in an order dated October 10, 2024, the trial court ordered a remittitur of punitive damages from $475 million to $120 million. The court denied the Pavilionâ€™s request for reduction of compensatory damages. Pursuant to Illinois law and procedure, plaintiff had 21 days from the date of the order to either accept the remittitur of the punitive damages or refuse the remittitur, which would have resulted in further legal proceedings. Plaintiff accepted the remittitur by the trial court while reserving all rights to appeal the remittitur. The Pavilion intends to appeal the remaining judgment. Although we can make no assurances regarding the ultimate outcome of this matter, or what damages will ultimately be awarded, its final resolution could have a material adverse effect on the Company K.E.E., et al., Plaintiffs v. Cumberland Hospital, LLC d/b/a Cumberland Hospital for Children and Adolescents, et al. (and related lawsuits)Cumberland Hospital for Children and Adolescents (â€œCumberlandâ€), an indirect subsidiary of the Company, is a defendant in multi-plaintiff lawsuits filed in the Circuit Court for Richmond, Virginia (the â€œCumberland Litigationâ€), relating to allegations of inappropriate sexual contact during medical examinations by Dr. Daniel Davidow, an independent contractor and the former medical director for Cumberland. The Company and UHS of Delaware, Inc., our administrative services subsidiary (â€œUHS Delawareâ€), were also named as co-defendants in the Cumberland Litigation. Plaintiffs have asserted claims of negligence, assault and battery (against Dr. Davidow), false imprisonment, violations of the Virginia Consumer Protection Act (â€œVCPAâ€), and vicarious liability for Dr. Davidowâ€™s conduct against Cumberland, the Company, and UHS Delaware. All defendants have denied liability.The claims asserted by three of the plaintiffs in the Cumberland Litigation were consolidated for trial in September of 2024. The Company and UHS Delaware were dismissed from the action during trial. As previously reported on Form 8-K, as filed on September 30, 2024, on September 27, 2024, a jury entered a verdict finding Dr. Davidow and Cumberland liable and awarded these three plaintiffs combined compensatory damages of $60 million for all liability theories, an additional combined $180 million in trebled damages for violation of the VCPA, and an additional combined $120 million in punitive damages. Cumberland is evaluating all legal options and intends to challenge this verdict, including the amounts awarded in the verdict, in post-trial proceedings and on appeal. Based upon Virginia law, we expect that the punitive damage amount should be reduced to a combined maximum of $1.05 million as a matter of law.There are approximately 40 additional plaintiffs making similar allegations with claims pending in the Cumberland Litigation.Although we can make no assurances regarding the ultimate outcomes of the various claims made in connection with the Cumberland Litigation, or what damages will ultimately be awarded, the final resolution of these matters could have a material adverse effect on the Company Other Matters:Various other suits, claims and investigations, including government subpoenas, arising against, or issued to, us are pending and additional such matters may arise in the future. Management will consider additional disclosure from time to time to the extent it believes such matters may be or become material. The outcome of any current or future litigation or governmental or internal investigations, including the matters described above, cannot be accurately predicted, nor can we predict any resulting penalties, fines or other sanctions that may be imposed at the discretion of federal or state regulatory authorities. We record accruals for such contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. No estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made at this time regarding the matters described above or that are otherwise pending because the inherently unpredictable nature of legal proceedings may be exacerbated by various factors, including, but not limited to: (i) the damages sought in the proceedings are unsubstantiated or indeterminate; (ii) discovery is not complete; (iii) the matter is in its early stages; (iv) the matters present legal uncertainties; (v) there are significant facts in dispute; (vi) there are a large number of parties, or; (vii) there is a wide range of potential outcomes. It is possible that the outcome of these matters could have a material adverse impact on our future results of operations, financial position, cash flows and, potentially, our reputation. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Segment Reporting 9 Months Ended Sep. 30, 2024 Segment Reporting [Abstract] Â Segment Reporting (7) Segment ReportingOur reportable operating segments consist of acute care hospital services and behavioral health care services. The â€œOtherâ€ segment column below includes centralized services including, but not limited to, information technology, purchasing, reimbursement, accounting and finance, taxation, legal, advertising and design and construction. The chief operating decision making group for our acute care services and behavioral health care services is comprised of our Chief Executive Officer and the Presidents of each operating segment. The Presidents for each operating segment also manage the profitability of each respective segmentâ€™s various facilities. The operating segments are managed separately because each operating segment represents a business unit that offers different types of healthcare services or operates in different healthcare environments. The accounting policies of the operating segments are the same as those described in the summary of significant accounting policies included in our Annual Report on Form 10-K for the year ended December 31, 2023. The corporate overhead allocations, as reflected below, are utilized for internal reporting purposes and are comprised of each periodâ€™s projected corporate-level operating expenses (excluding interest expense). The overhead expenses are captured and allocated directly to each segment, to the extent possible, based upon each segmentâ€™s respective percentage of total operating expenses.Â Â Â Three months ended September 30, 2024 Â Â Â Acute CareHospitalServices Â Â BehavioralHealthServices (a) Â Â Other Â Â TotalConsolidated Â Â Â (Dollar amounts in thousands) Â Gross inpatient revenues Â $ 12,277,563 Â Â $ 2,835,301 Â Â Â Â Â $ 15,112,864 Â Gross outpatient revenues Â $ 8,573,270 Â Â $ 268,182 Â Â Â Â Â $ 8,841,452 Â Total net revenues Â $ 2,245,517 Â Â $ 1,714,914 Â Â $ 2,596 Â Â $ 3,963,027 Â Income/(loss) before allocation of corporate overhead andÂ Â Â income taxes Â $ 199,316 Â Â $ 318,864

Â Â $ (176,647) Â $ 341,533 Â Allocation of corporate overhead Â $ (64,883) Â $ (46,898) Â $ 111,781 Â Â $ 0 Â Income/(loss) after allocation of corporate overhead andÂ Â Â before income taxes Â $ 134,433 Â Â $ 271,966 Â Â $ (64,866) Â $ 341,533 Â Total assets as of September 30, 2024 Â $ 6,481,922 Â Â $ 7,631,827 Â Â $ 240,099 Â Â $ 14,353,848 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Nine months ended September 30, 2024 Â Â Â Acute CareHospitalServices Â Â BehavioralHealthServices (a) Â Â Other Â Â TotalConsolidated Â Â Â (Dollar amounts in thousands) Â Gross inpatient revenues Â $ 37,522,395 Â Â $ 8,375,470 Â Â Â Â Â Â $ 45,897,865 Â Gross outpatient revenues Â $ 25,553,451 Â Â $ 833,260 Â Â Â Â Â Â $ 26,386,711 Â Total net revenues Â $ 6,604,007 Â Â $ 5,102,290 Â Â $ 7,916 Â Â $ 11,714,213 Â Income/(loss) before allocation of corporate overhead andÂ Â Â income taxes Â $ 616,503 Â Â $ 999,282 Â Â $ (556,160) Â $ 1,059,625 Â Allocation of corporate overhead Â $ (194,616) Â $ (140,808) Â $ 335,424 Â Â $ 0 Â Income/(loss) after allocation of corporate overhead andÂ Â Â before income taxes Â $ 421,887 Â Â $ 858,474 Â Â $ (220,736) Â $ 1,059,625 Â Total assets as of September 30, 2024 Â $ 6,481,922 Â Â $ 7,631,827 Â Â $ 240,099 Â Â $ 14,353,848 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Three months ended September 30, 2023 Â Â Â Acute CareHospitalServices Â Â BehavioralHealthServices (a) Â Â Other Â Â TotalConsolidated Â Â Â (Dollar amounts in thousands) Â Gross inpatient revenues Â $ 10,916,060 Â Â $ 2,703,478 Â Â Â Â Â $ 13,619,538 Â Gross outpatient revenues Â $ 7,480,353 Â Â $ 259,060 Â Â Â Â Â Â $ 7,739,413 Â Total net revenues Â $ 2,017,288 Â Â $ 1,542,695 Â Â $ 2,791 Â Â $ 3,562,774 Â Income/(loss) before allocation of corporate overhead andÂ Â Â income taxes Â $ 132,406 Â Â $ 262,168 Â Â $ (174,067) Â $ 220,507 Â Allocation of corporate overhead Â $ (66,355) Â $ (46,677) Â $ 113,032 Â Â $ 0 Â Income/(loss) after allocation of corporate overhead andÂ Â Â before income taxes Â $ 66,051 Â Â $ 215,491 Â Â $ (61,035) Â $ 220,507 Â Total assets as of September 30, 2023 Â $ 6,252,434 Â Â $ 7,372,995 Â Â $ 248,041 Â Â $ 13,873,470 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Nine months ended September 30, 2023 Â Â Â Acute CareHospitalServices Â Â BehavioralHealthServices (a) Â Â Other Â Â TotalConsolidated Â Â Â (Dollar amounts in thousands) Â Gross inpatient revenues Â $ 33,278,396 Â Â $ 8,001,838 Â Â Â Â Â Â $ 41,280,234 Â Gross outpatient revenues Â $ 22,292,249 Â Â $ 812,467 Â Â Â Â Â Â $ 23,104,716 Â Total net revenues Â $ 5,993,899 Â Â $ 4,575,378 Â Â $ 9,153 Â Â $ 10,578,430 Â Income/(loss) before allocation of corporate overhead andÂ Â Â income taxes Â $ 396,229 Â Â $ 792,217 Â Â $ (529,143) Â $ 659,303 Â Allocation of corporate overhead Â $ (199,943) Â $ (139,998) Â $ 339,941 Â Â $ 0 Â Income/(loss) after allocation of corporate overhead andÂ Â Â before income taxes Â $ 196,286 Â Â $ 652,219 Â Â $ (189,202) Â $ 659,303 Â Total assets as of September 30, 2023 Â $ 6,252,434 Â Â $ 7,372,995 Â Â $ 248,041 Â Â $ 13,873,470 Â (a)Includes net revenues generated from our behavioral health care facilities located in the U.K. amounting to approximately $230 million and $203 million for the three-month periods ended September 30, 2024 and 2023, respectively, and approximately $651 million and $561 million for the nine-month periods ended September 30, 2024 and 2023, respectively. Total assets at our U.K. behavioral health care facilities were approximately $1.442 billion and $1.260 billion as of September 30, 2024 and 2023, respectively. X - ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContentReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap_SegmentReportingDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Earnings Per Share Data and Stock Based Compensation 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Earnings Per Share Data and Stock Based Compensation (8) Earnings Per Share Data and Stock Based CompensationBasic earnings per share are based on the weighted average number of common shares outstanding during the period. Diluted earnings per share are based on the weighted average number of common shares outstanding during the period adjusted to give effect to common stock equivalents.The following table sets forth the computation of basic and diluted earnings per share for the periods indicated (in thousands, except per share data): Â Â Three months endedSeptember 30, Â Â Nine months endedSeptember 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Basic and Diluted: Â Â Â Â Â Â Â Â Â Â Â Â Net income attributable to UHS Â $ 258,714 Â Â $ 166,989 Â Â $ 809,700 Â Â $ 501,417 Â Less: Net income attributable to unvested restricted shareÂ Â Â grants Â Â - Â Â Â (52) Â Â (50) Â Â (242) Net income attributable to UHS â€“ basic and diluted Â $ 258,714 Â Â $ 166,937 Â Â $ 809,650 Â Â $ 501,175 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Weighted average number of common shares - basic Â Â 66,537 Â Â Â 68,867 Â Â Â 66,873 Â Â Â 69,825 Â Net effect of dilutive stock options and grants based on theÂ Â Â treasury stock method Â Â 1,571 Â Â Â 757 Â Â Â 1,297 Â Â Â 825 Â Weighted average number of common shares andÂ Â Â equivalents - diluted Â Â 68,108 Â Â Â 69,624 Â Â Â 68,170 Â Â Â 70,650 Â Earnings per basic share attributable to UHS: Â $ 3.89 Â Â $ 2.42 Â Â $ 12.11 Â Â $ 7.18 Â Earnings per diluted share attributable to UHS: Â $ 3.80 Â Â $ 2.40 Â Â $ 11.88 Â Â $ 7.09 Â The â€œNet effect of dilutive stock options and grants based on the treasury stock methodâ€, for all periods presented above, excludes certain outstanding stock options applicable to each period since the effect would have been anti-dilutive. There were no excluded weighted-average stock options for the three-months ended September 30, 2024 and 799,000 for the nine-months ended September 30, 2024. The excluded weighted-average stock options totaled 5.0 million for the three months ended September 30, 2023 and 5.1 million for the nine months ended September 30, 2023. All classes of our common stock have the same dividend rights.Stock-Based Compensation: During the three-month periods ended September 30, 2024 and 2023, pre-tax compensation costs of $13.4 million and $16.2 million, respectively, was recognized related to outstanding stock options. During the nine-month periods ended September 30, 2024 and 2023, pre-tax compensation costs of $41.0 million and $48.3 million, respectively, was recognized related to outstanding stock options. In addition, during the three-month periods ended September 30, 2024 and 2023, pre-tax compensation cost of approximately $12.9 million and $6.1 million, respectively, was recognized related to restricted stock awards, restricted stock units and performance based restricted stock units. During the nine-month periods ended September 30, 2024 and 2023, pre-tax compensation costs of approximately $30.7 million and $16.4 million, respectively, was recognized related to restricted stock awards, restricted stock units and performance based restricted stock units. As of September 30, 2024 there was approximately $177.9 million of unrecognized compensation cost related to unvested options, restricted stock awards, restricted stock units and performance based restricted stock units which is expected to be recognized over the remaining weighted average vesting period of 2.5 years. There were 3,000 stock options granted during the first nine months of 2024 under the 2020 Stock Incentive Plan with a weighted-average grant date fair value of $44.58 per option. There were an aggregate of 501,290 restricted units, net of cancellations, granted during the first nine months of 2024 under the 2020 Stock Incentive Plan, including 63,362 performance based restricted stock units, with a weighted-average grant date fair value of $181.05 per share.The expense associated with stock-based compensation arrangements is a non-cash charge. In the condensed consolidated statements of cash flows, stock-based compensation expense is an adjustment to reconcile net income to cash provided by operating activities and aggregated to $72.7 million and $65.7 million during the nine-month periods ended September 30, 2024 and 2023, respectively. X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 25 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Dispositions and acquisitions 9 Months Ended Sep. 30, 2024 Business Combinations [Abstract] Â Dispositions and acquisitions (9) Dispositions and acquisitionsNine-month period ended September 30, 2024:Acquisitions:During the first nine months of 2024, there were no acquisitions.Divestitures:During the first nine months of 2024, we received $30 million from the sales of assets and businesses.Nine-month period ended September 30, 2023:Acquisitions:During the first nine months of 2023, we spent $4 million on the acquisition of businesses and property.Divestitures:During the first nine months of 2023, we received $24 million from the sales of assets and businesses. X - ReferencesNo definition available. + Details Name: us-gaap_BusinessCombinationsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/805/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205-20/tableOfContent + Details Name: us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Dividends 9 Months Ended Sep. 30, 2024 Earnings Per Share [Abstract] Â Dividends (10) DividendsWe declared and paid dividends of $13.3 million, or $.20 per share, during the third quarter of 2024 and $13.8 million, or $.20 per share, during the third quarter of 2023. We declared and paid dividends of $40.3 million, or $.60 per share, during the nine-month period ended September 30, 2024 and $42.2 million, or $.60 per share, during the nine-month period ended September 30, 2023. Included in the amounts above were dividend equivalents applicable to unvested restricted stock units which were accrued during 2024 and 2023 and will be, or were, paid upon vesting of the restricted stock unit. X - DefinitionDividends + ReferencesNo definition available. + Details Name: uhs_DividendsTextBlock Namespace Prefix: uhs_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 27 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Income Taxes 9 Months Ended Sep. 30, 2024 Income Tax Disclosure [Abstract] Â Income Taxes (11) Income TaxesOur effective income tax rates were 22.1% and 23.8% during the three-month periods ended September 30, 2024 and 2023, respectively, and 22.0% and 24.2% during the nine-month periods ended September 30, 2024, and 2023, respectively. The decrease in the effective tax rates during the three and nine-month period ended September 30, 2024, as compared to the comparable periods of 2023, was primarily due to favorable changes of $4 million and $16 million, respectively, in the net tax benefit recognized from employee share-based payments, net of the impact of executive compensation limitations pursuant to IRC section 162(m). As of January 1, 2024, our unrecognized tax benefits were approximately $2 million. The amount, if recognized, that would favorably affect the effective tax rate is approximately $2 million. During the nine months ended September 30, 2024, changes to the estimated liabilities for uncertain tax positions (including accrued interest) relating to tax positions taken during prior and current periods did not have a material impact on our financial statements.We recognize accrued interest and penalties associated with uncertain tax positions as part of the tax provision. As of September 30, 2024, we have less than $1 million of accrued interest and penalties. The U.S. federal statute of limitations remains open for 2020 and subsequent years. Foreign and U.S. state and local jurisdictions have statutes of limitations generally ranging from 3 to 4 years. The statute of limitations on certain jurisdictions

could expire within the next twelve months. It is reasonably possible that the amount of uncertain tax benefits will change during the next 12 months, however, it is anticipated that any such change, if it were to occur, would not have a material impact on our results of operations.We operate in multiple jurisdictions with varying tax laws. We are subject to audits by any of these taxing authorities. We believe that adequate accruals have been provided for federal, foreign and state taxes. X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue 9 Months Ended Sep. 30, 2024 Revenue from Contract with Customer [Abstract] Â Revenue (12) RevenueWe recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. Our estimate for amounts not expected to be collected based on historical experience will continue to be recognized as a reduction to net revenue. However, subsequent changes in estimate of collectability due to a change in the financial status of a payer, for example a bankruptcy, will be recognized as bad debt expense in operating charges.The performance obligation is separately identifiable from other promises in the customer contract. As the performance obligations are met (i.e. room, board, ancillary services, level of care), revenue is recognized based upon allocated transaction price. The transaction price is allocated to separate performance obligations based upon the relative standalone selling price. In instances where we determine there are multiple performance obligations across multiple months, the transaction price will be allocated by applying an estimated implicit and explicit rate to gross charges based on the separate performance obligations.In assessing collectability, we have elected the portfolio approach. This portfolio approach is being used as we have large volume of similar contracts with similar classes of customers. We reasonably expect that the effect of applying a portfolio approach to a group of contracts would not differ materially from considering each contract separately. Managementâ€™s judgment to group the contracts by portfolio is based on the payment behavior expected in each portfolio category. As a result, aggregating all of the contracts (which are at the patient level) by the particular payer or group of payers, will result in the recognition of the same amount of revenue as applying the analysis at the individual patient level.We group our revenues into categories based on payment behaviors. Each component has its own reimbursement structure which allows us to disaggregate the revenue into categories that share the nature and timing of payments. The other patient revenue consists primarily of self-pay, government-funded non-Medicaid, and other.The following table disaggregates our revenue by major source for the three and nine-month periods ended September 30, 2024 and 2023 (in thousands):Â Â For the three months ended September 30, 2024 Â Â Acute Care Â Â Behavioral Health Â Â Other Â Â Total Â Medicare $ 322,466 Â Â 14 % Â $ 81,148 Â Â 5 % Â Â Â Â Â $ 403,614 Â Â 10 % Managed Medicare Â 361,804 Â Â 16 % Â Â 107,910 Â Â 6 % Â Â Â Â Â Â 469,714 Â Â 12 % Medicaid Â 296,966 Â Â 13 % Â Â 262,393 Â Â 15 % Â Â Â Â Â Â 559,359 Â Â 14 % Managed Medicaid Â 154,762 Â Â 7 % Â Â 422,563 Â Â 25 % Â Â Â Â Â 577,325 Â Â 15 % Managed Care (HMO and PPOs) Â 725,014 Â Â 32 % Â Â 401,004 Â Â 23 % Â Â Â Â Â Â 1,126,018 Â Â 28 % UK Revenue Â 0 Â Â 0 % Â Â 230,153 Â Â 13 % Â Â Â Â Â Â 230,153 Â Â 6 % Other patient revenue and adjustments, net Â 117,679 Â Â 5 % Â Â 155,332 Â Â 9 % Â Â Â Â Â Â 273,011 Â Â 7 % Other non-patient revenue Â 266,826 Â Â 12 % Â Â 54,411 Â Â 3 % Â Â 2,596 Â Â Â Â 323,833 Â Â 8 % Total Net Revenue $ 2,245,517 Â Â 100 % Â $ 1,714,914 Â Â 100 % Â $ 2,596 Â Â Â Â 3,963,027 Â Â 100 % Â For the nine months ended September 30, 2024 Â Â Acute Care Â Â Behavioral Health Â Â Other Â Â Total Â Medicare $ 1,009,630 Â Â 15 % Â $ 234,295 Â Â 5 % Â Â Â Â Â $ 1,243,925 Â Â 11 % Managed Medicare Â 1,104,493 Â Â 17 % Â Â 307,388 Â Â 6 % Â Â Â Â Â Â 1,411,881 Â Â 12 % Medicaid Â 771,298 Â Â 12 % Â Â 804,254 Â Â 16 % Â Â Â Â Â Â 1,575,552 Â Â 13 % Managed Medicaid Â 466,881 Â Â 7 % Â Â 1,262,108 Â Â 25 % Â Â Â Â Â Â 1,728,989 Â Â 15 % Managed Care (HMO and PPOs) Â 2,129,117 Â Â 32 % Â Â 1,227,056 Â Â 24 % Â Â Â Â Â Â 3,356,173 Â Â 29 % UK Revenue Â 0 Â Â 0 % Â Â 650,655 Â Â 13 % Â Â Â Â Â Â 650,655 Â Â 6 % Other patient revenue and adjustments, net Â 375,161 Â Â 6 % Â Â 449,609 Â Â 9 % Â Â Â Â Â Â 824,770 Â Â 7 % Other non-patient revenue Â 747,427 Â Â 11 % Â Â 166,925 Â Â 3 % Â Â 7,916 Â Â Â 922,268 Â Â 8 % Total Net Revenue $ 6,604,007 Â Â 100 % Â $ 5,102,290 Â Â 100 % Â $ 7,916 Â Â $ 11,714,213 Â Â 100 % Â For the three months ended September 30, 2023 Â Â Acute Care Â Â Behavioral Health Â Â Other Â Â Total Â Medicare $ 298,121 Â Â 15 % Â $ 81,689 Â Â 5 % Â Â Â Â Â $ 379,810 Â Â 11 % Managed Medicare Â 324,486 Â Â 16 % Â Â 95,094 Â Â 6 % Â Â Â Â Â Â 419,580 Â Â 12 % Medicaid Â 201,148 Â Â 10 % Â Â 204,154 Â Â 13 % Â Â Â Â Â Â 405,302 Â Â 11 % Managed Medicaid Â 181,051 Â Â 9 % Â Â 387,975 Â Â 25 % Â Â Â Â Â Â 569,026 Â Â 16 % Managed Care (HMO and PPOs) Â 651,816 Â Â 32 % Â Â 383,146 Â Â 25 % Â Â Â Â Â Â 1,034,962 Â Â 29 % UK Revenue Â 0 Â Â 0 % Â Â 202,994 Â Â 13 % Â Â Â Â Â Â 202,994 Â Â 6 % Other patient revenue and adjustments, net Â 108,676 Â Â 5 % Â Â 129,492 Â Â 8 % Â Â Â Â Â Â 238,168 Â Â 7 % Other non-patient revenue Â 251,990 Â Â 12 % Â Â 58,151 Â Â 4 % Â Â 2,791 Â Â Â Â 312,932 Â Â 9 % Total Net Revenue $ 2,017,288 Â Â 100 % Â $ 1,542,695 Â Â 100 % Â $ 2,791 Â Â $ 3,562,774 Â Â 100 % Â For the nine months ended September 30, 2023 Â Â Acute Care Â Â Behavioral Health Â Â Other Â Â Total Â Medicare $ 961,640 Â Â 16 % Â $ 233,930 Â Â 5 % Â Â Â Â Â $ 1,195,570 Â Â 11 % Managed Medicare Â 1,013,493 Â Â 17 % Â Â 255,782 Â Â 6 % Â Â Â Â Â Â 1,269,275 Â Â 12 % Medicaid Â 445,678 Â Â 7 % Â Â 625,956 Â Â 14 % Â Â Â Â Â Â 1,071,634 Â Â 10 % Managed Medicaid Â 545,173 Â Â 9 % Â Â 1,184,315 Â Â 26 % Â Â Â Â Â Â 1,729,488 Â Â 16 % Managed Care (HMO and PPOs) Â 2,009,110 Â Â 34 % Â Â 1,160,820 Â Â 25 % Â Â Â Â Â Â 3,169,930 Â Â 30 % UK Revenue Â 0 Â Â 0 % Â 560,897 Â Â 12 % Â Â Â Â Â Â 560,897 Â Â 5 % Other patient revenue and adjustments, net Â 303,923 Â Â 5 % Â Â 387,327 Â Â 8 % Â Â Â Â Â Â 691,250 Â Â 7 % Other non-patient revenue Â 714,882 Â Â 12 % Â Â 166,351 Â Â 4 % Â Â 9,153 Â Â Â Â 890,386 Â Â 8 % Total Net Revenue $ 5,993,899 Â Â 100 % Â $ 4,575,378 Â Â 100 % Â $ 9,153 Â Â $ 10,578,430 Â Â 100 % Â X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Lease Accounting 9 Months Ended Sep. 30, 2024 Leases [Abstract] Â Lease Accounting (13) Lease AccountingOur operating leases are primarily for real estate, including certain acute care facilities, off-campus outpatient facilities, medical office buildings, and corporate and other administrative offices. Our real estate lease agreements typically have initial terms of five to ten years. These real estate leases may include one or more options to renew, with renewals that can extend the lease term from five to ten years. The exercise of lease renewal options is at our sole discretion. When determining the lease term, we included options to extend or terminate the lease when it is reasonably certain that we will exercise that option.Five of our hospital facilities are held under operating leases with Universal Health Realty Income Trust with two leases expiring in 2026, two expiring in 2033 and one expiring in 2040 (for additional disclosure, see Note 2 to the Consolidated Financial Statements-Relationship with Universal Health Realty Income Trust and Other Related Party Transactions). We are also the lessee of the real property of certain facilities from unrelated third parties.Supplemental cash flow information related to leases for the nine-month period ended September 30, 2024 and 2023 are as follows (in thousands): Â Nine months endedSeptember 30, Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Â Cash paid for amounts included in the measurement of lease liabilities: Â Â Â Â Â Operating cash flows from operating leases $ 99,526 Â Â $ 96,922 Â Operating cash flows from finance leases $ 2,756 Â Â $ 2,890 Â Financing cash flows from finance leases $ 3,167 Â Â $ 2,910 Â Â Â Â Â Â Â Right-of-use assets obtained in exchange for lease obligations: Â Â Â Â Â Operating leases $ 50,696 Â Â $ 50,940 Â Finance leases $ 8,441 Â Â $ 452 Â X - DefinitionLessee operating and financing leases. + ReferencesNo definition available. + Details Name: uhs_LesseeOperatingAndFinancingLeasesTextBlock Namespace Prefix: uhs_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 30 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Recent Accounting Standards 9 Months Ended Sep. 30, 2024 Accounting Changes and Error Corrections [Abstract] Â Recent Accounting Standards (14) Recent Accounting StandardsÂ In November 2024, the FASB issued ASU 2024-03, â€œIncome Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (subtopic 220-40)". ASU 2024-03 requires disclosures, in the notes to financial statements, of specified information about certain costs and expenses. This ASU is effective for fiscal years beginning after December 15, 2026, with early adoption permitted. We are currently evaluating the impact this new standard will have on the related disclosures in the consolidated financial statements.In November 2023, the FASB issued ASU 2023-07, â€œImprovements to Reportable Segment Disclosures (Topic 280)â€. ASU 2023-07 modifies reportable segment disclosure requirements, primarily through enhanced disclosures about segment expenses categorized as significant or regularly provided to the Chief Operating Decision Maker (CODM). In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, and contain other disclosure requirements. The purpose of the amendments is to enable investors to better understand an entityâ€™s overall performance and assess potential future cash flows. This ASU is effective for annual periods beginning after December 15, 2023, and interim periods within annual periods beginning after December 15, 2024, with early adoption permitted. We are currently evaluating the impact this new standard will have on the related disclosures in the consolidated financial statements, but do not believe there will be a material impact.In December 2023, the FASB issued ASU 2023-09, â€œImprovements to Income Tax Disclosures (Topic 740)â€. ASU 2023-09 requires enhanced disclosures on income taxes paid, adds disaggregation of continuing operations before income taxes between foreign and domestic earnings and defines specific categories for the reconciliation of jurisdictional tax rate to effective tax rate. This ASU is effective for fiscal years beginning after December 15, 2024, and can be applied on a prospective basis. We are currently evaluating the impact this new standard will have on the related disclosures in the consolidated financial statements.From time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by the Company as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. The Company has assessed the recently issued guidance that is not yet effective and believes the new guidance will not have a material impact on our results of operations, cash flows or financial position. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingChangesAndErrorCorrectionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(1) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147483550/848-10-65-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 11.M.Q2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-6Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 250 -Publisher FASB -URI https://asc.fasb.org/250/tableOfContentReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1 + Details Name: us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Relationship with Universal Health Realty Income Trust and Other Related Party Transactions (Tables) 9 Months Ended Sep. 30, 2024 Related Party Transactions [Abstract] Â Remaining Renewal Options and Terms for Each of Three Hospital Facilities Leased from Trust The table below provides certain details for each of the hospitals leased from the Trust as of September 30, 2024:Â Hospital Name Â AnnualMinimumRent Â Â End of Lease Term Â RenewalTerm(years) Â Â McAllen Medical Center Â $ 5,485,000 Â Â December, 2026 Â Â 5 Â (a) Wellington Regional Medical Center Â $ 6,639,000 Â Â December, 2026 Â Â 5 Â (b) Aiken Regional Medical Center/Aurora Pavilion Behavioral Health Services Â $ 4,072,000 Â Â December, 2033 Â Â 35 Â (c) Canyon Creek Behavioral Health Â $ 1,841,000 Â Â December, 2033 Â Â 35 Â (c) Clive Behavioral Health Hospital Â $ 2,775,000 Â Â December, 2040 Â Â 50 Â (d) Â (a)We have one 5-year renewal option at existing lease rates (through 2031).(b)We have one 5-year renewal option at fair market value lease rates (through 2031). On each January 1st through 2026, the annual rent will increase by 2.5% on a cumulative and compounded basis.(c)We have seven 5-year renewal options at fair market value lease rates (2034 through 2068). On each January 1st through 2033, the annual rent will increase by 2.25% on a cumulative and compounded basis. (d)This facility is operated by a joint venture in which we are the managing, majority member and an unrelated third-party holds a minority ownership interest. The joint venture has three, 10-year renewal options at computed lease rates as stipulated in the lease (2041 through 2070) and two additional, 10-year renewal options at fair market value lease rates (2071 through 2090). In each January through 2040 (and potentially through 2070 if three, 10-year renewal options are exercised), the annual rental will increase by 2.75% on a cumulative and compounded basis. X - ReferencesNo definition available. + Details Name: us-gaap_RelatedPartyTransactionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of lessor's underlying asset for which right to use has been conveyed to lessee under operating lease. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 840 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481501/840-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479773/842-30-50-13Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Treasury (Tables) 9 Months Ended Sep. 30, 2024 Equity [Abstract] Â Summary of Effects of Foreign Currency Forward Exchange Contracts on Result of Operations The following table presents the effects of our foreign currency forward exchange contracts on our results of operations for the three and nine-month periods ended September 30, 2024 and 2023 (in thousands): Â Gain/(Loss) recognized in AOCI Â Â Three months ended Â Â Nine months ended Â Â September 30, Â Â September 30, Â Â September 30, Â Â September 30, Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Net Investment Hedge relationships Â Â Â Â Â Â Â Â Â Â Â Â Foreign currency forward exchange contracts $ (43,490) Â $ 19,619 Â Â $ (35,289) Â $ (10,781) Summary of Cash, Cash Equivalents and Restricted Cash Reported In Condensed Consolidated Statements of Cash Flows Cash, cash equivalents, and restricted cash as reported in the condensed consolidated statements of cash flows are presented separately on our condensed consolidated balance sheets as follows (in thousands): Â September 30, Â Â September 30, Â Â December 31, Â Â 2024 Â Â 2023 Â Â 2023 Â Cash and cash equivalents $ 106,077 Â $ 80,768 Â $ 119,439 Â Restricted cashÂ (a) Â 98,520 Â Â 99,871 Â Â 95,031 Â Total cash, cash equivalents and restricted cash $ 204,597 Â Â $ 180,639 Â Â $ 214,470 Â (a) Restricted cash is included in other noncurrent assets on the accompanying condensed consolidated balance sheets. X - DefinitionSchedule of cash cash equivalents and restricted cash. + ReferencesNo definition available. + Details Name: uhs_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock Namespace Prefix: uhs_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4E -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4EReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4C -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A + Details Name: us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurement (Tables) 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â Summary of Assets and Liabilities Recorded at Fair Value on Recurring Basis The following tables present the assets and liabilities recorded at fair value on a recurring basis: Â Balance at Â Balance Sheet Basis of Fair Value Measurement Â (in thousands) September 30, 2024 Â Location Level 1 Â Level 2 Â Level 3 Â Assets: Â Â Â Â Â Â Â Â Â Money market mutual funds $ 115,205 Â Other noncurrent assets $ 115,205 Â Â Â Â Â Certificates of deposit Â 2,201 Â Other noncurrent assets Â Â Â 2,201 Â Â Â Equity securities Â 44,654 Â Other noncurrent assets Â 44,654 Â Â Â Â Â Deferred compensation assets Â 49,270 Â Other noncurrent assets Â 49,270 Â Â Â Â Â Â $ 211,330 Â Â $ 209,129 Â $ 2,201 Â Â - Â Liabilities: Â Â Â Â Â Â Â Â Â Foreign currency forward exchange contracts $ 1,533 Â Accounts payable and other liabilities Â Â $ 1,533 Â Â Â Deferred compensation liability Â 49,270 Â Other noncurrent liabilities Â 49,270 Â Â Â Â Â Â $ 50,803 Â Â $ 49,270 Â $ 1,533 Â Â - Â Â Â Â Â Â Â Â Â Â Â Balance at Â Balance Sheet Basis of Fair Value Measurement Â (in thousands) December 31, 2023 Â Location Level 1 Â Level 2 Â Level 3 Â Assets: Â Â Â Â Â Â Â Â Â Money market mutual funds $ 111,129 Â Other noncurrent assets $ 111,129 Â Â Â Â Â Certificates of deposit Â 2,300 Â Other noncurrent assets Â Â Â 2,300 Â Â Â Equity securities Â 49,923 Â Other noncurrent assets Â 49,923 Â Â Â Â Â Deferred compensation assets Â 43,060 Â Other noncurrent assets Â 43,060 Â Â Â Â Â Â $ 206,412 Â Â $ 204,112 Â $ 2,300 Â Â - Â Liabilities: Â Â Â Â Â Â Â Â Â Foreign currency forward exchange contracts $ 1,911 Â Accounts payable and other liabilities Â Â $ 1,911 Â Â Â Deferred compensation liability Â 43,060 Â Other noncurrent liabilities Â 43,060 Â Â Â Â Â Â $ 44,971 Â Â $ 43,060 Â $ 1,911 Â Â - Â X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Segment Reporting (Tables) 9 Months Ended Sep. 30, 2024 Segment Reporting [Abstract] Â Segment Reporting Â Â Three months ended September 30, 2024 Â Â Â Acute CareHospitalServices Â Â BehavioralHealthServices (a) Â Â Other Â Â TotalConsolidated Â Â Â (Dollar amounts in thousands) Â Gross inpatient revenues Â $ 12,277,563 Â Â $ 2,835,301 Â Â Â Â Â $ 15,112,864 Â Gross outpatient revenues Â $ 8,573,270 Â Â $ 268,182 Â Â Â Â Â $ 8,841,452 Â Total net revenues Â $ 2,245,517 Â Â $ 1,714,914 Â Â $ 2,596 Â Â $ 3,963,027 Â Income/(loss) before allocation of corporate overhead andÂ Â Â income taxes Â $ 199,316 Â Â $ 318,864 Â Â $ (176,647) Â $ 341,533 Â Allocation of corporate overhead Â $ (64,883) Â $ (46,898) Â $ 111,781 Â Â $ 0 Â Income/(loss) after allocation of corporate overhead andÂ Â Â before income taxes Â $ 134,433 Â Â $ 271,966 Â Â $ (64,866) Â $ 341,533 Â Total assets as of September 30, 2024 Â $ 6,481,922 Â Â $ 7,631,827 Â Â $ 240,099 Â Â $ 14,353,848 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Nine months ended September 30, 2024 Â Â Â Acute CareHospitalServices Â Â BehavioralHealthServices (a) Â Â Other Â Â TotalConsolidated Â Â Â (Dollar amounts in thousands) Â Gross inpatient revenues Â $ 37,522,395 Â Â $ 8,375,470 Â Â Â Â Â $ 45,897,865 Â Gross outpatient revenues Â $ 25,553,451 Â Â $ 833,260 Â Â Â Â Â $ 26,386,711 Â Total net revenues Â $ 6,604,007 Â Â $ 5,102,290 Â Â $ 7,916 Â Â $ 11,714,213 Â Income/(loss) before allocation of corporate overhead andÂ Â Â income taxes Â $ 616,503 Â Â $ 999,282 Â Â $ (556,160) Â $ 1,059,625 Â Allocation of corporate overhead Â $ (194,616) Â $ (140,808) Â $ 335,424 Â Â $ 0 Â Income/(loss) after allocation of corporate overhead andÂ Â Â before income taxes Â $ 421,887 Â Â $ 858,474 Â Â $ (220,736) Â $ 1,059,625 Â Total assets as of September 30, 2024 Â $ 6,481,922 Â Â $ 7,631,827 Â Â $ 240,099 Â Â $ 14,353,848 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Three months ended September 30, 2023 Â Â Â Acute CareHospitalServices Â Â BehavioralHealthServices (a) Â Â Other Â Â TotalConsolidated Â Â Â (Dollar amounts in thousands) Â Gross inpatient revenues Â $ 10,916,060 Â Â $ 2,703,478 Â Â Â Â Â $ 13,619,538 Â Gross outpatient revenues Â $ 7,480,353 Â Â $ 259,060 Â Â Â Â Â $ 7,739,413 Â Total net revenues Â $ 2,017,288 Â Â $ 1,542,695 Â Â $ 2,791 Â Â $ 3,562,774 Â Income/(loss) before allocation of corporate overhead andÂ Â Â income taxes Â $ 132,406 Â Â $ 262,168 Â Â $ (174,067) Â $ 220,507 Â Allocation of corporate overhead Â $ (66,355) Â $ (46,677) Â $ 113,032 Â Â $ 0 Â Income/(loss) after allocation of corporate overhead andÂ Â Â before income taxes Â $ 66,051 Â Â $ 215,491 Â Â $ (61,035) Â $ 220,507 Â Total assets as of September 30, 2023 Â $ 6,252,434 Â Â $ 7,372,995 Â Â $ 248,041 Â Â $ 13,873,470 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Nine months ended September 30, 2023 Â Â Â Acute CareHospitalServices Â Â BehavioralHealthServices (a) Â Â Other Â Â TotalConsolidated Â Â Â (Dollar amounts in thousands) Â Gross inpatient revenues Â $ 33,278,396 Â Â $ 8,001,838 Â Â Â Â Â $ 41,280,234 Â Gross outpatient revenues Â $ 22,292,249 Â Â $ 812,467 Â Â Â Â Â $ 23,104,716 Â Total net revenues Â $ 5,993,899 Â Â $ 4,575,378 Â Â $ 9,153 Â Â $ 10,578,430 Â Income/(loss) before allocation of corporate overhead andÂ Â Â income taxes Â $ 396,229 Â Â $ 792,217 Â Â $ (529,143) Â $ 659,303 Â Allocation of corporate overhead Â $ (199,943) Â $ (139,998) Â $ 339,941 Â Â $ 0 Â Income/(loss) after allocation of corporate overhead andÂ Â Â before income taxes Â $ 196,286 Â Â $ 652,219 Â Â $ (189,202) Â $ 659,303 Â Total assets as of September 30, 2023 Â $ 6,252,434 Â Â $ 7,372,995 Â Â $ 248,041 Â Â $ 13,873,470 Â (a)Includes net revenues generated from our behavioral health care facilities located in the U.K. amounting to approximately $230 million and $203 million for the three-month periods ended September 30, 2024 and 2023, respectively, and approximately $651 million and $561 million for the nine-month periods ended September 30, 2024 and 2023, respectively. Total assets at our U.K. behavioral health care facilities were approximately $1.442 billion and $1.260 billion as of September 30, 2024 and 2023, respectively. X - DefinitionTabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 35 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Earnings Per Share Data and Stock Based Compensation (Tables) 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Computation of Basic and Diluted Earnings per Share The following table sets forth the computation of basic and diluted earnings per share for the periods indicated (in thousands, except per share data): Â Â Three months endedSeptember 30, Â Â Nine months endedSeptember 30, Â Â Â 2024 Â Â 2023 Â Â 2024 Â Â 2023 Â Basic and Diluted: Â Â Â Â Â Â Â Â Â Â Â Â Net income attributable to UHS Â $ 258,714 Â Â $ 166,989 Â Â $ 809,700 Â Â $ 501,417 Â Less: Net income attributable to unvested restricted shareÂ Â Â grants Â Â - Â Â Â (52) Â Â (50) Â Â (242) Net income attributable to UHS â€“ basic and diluted Â $ 258,714 Â Â $ 166,937 Â Â $ 809,650 Â Â $ 501,175 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Weighted average number of common shares - basic Â Â 66,537 Â Â Â 68,867 Â Â Â 66,873 Â Â Â 69,825 Â Net effect of dilutive stock options and grants based on theÂ Â Â treasury stock method Â Â 1,571 Â Â Â 757 Â Â Â 1,297 Â Â Â 825 Â Weighted average number of common shares andÂ Â Â equivalents - diluted Â Â 68,108 Â Â Â 69,624 Â Â Â 68,170 Â Â Â 70,650 Â Earnings per basic share attributable to UHS: Â $ 3.89 Â Â $ 2.42 Â Â $ 12.11 Â Â $ 7.18 Â

Earnings per diluted share attributable to UHS: Â $ 3.80 Â Â $ 2.40 Â Â $ 11.88 Â Â $ 7.09 Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 36 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue (Tables) 9 Months Ended Sep. 30, 2024 Revenue from Contract with Customer [Abstract] Â Schedule of Disaggregates Revenue by Major Source The following table disaggregates our revenue by major source for the three and nine-month periods ended September 30, 2024 and 2023 (in thousands):Â Â For the three months ended September 30, 2024 Â Â Acute Care Â Â Behavioral Health Â Â Other Â Â Total Â Medicare $ 322,466 Â Â 14 % Â $ 81,148 Â Â 5 % Â Â Â Â $ 403,614 Â Â 10 % Managed Medicare Â 361,804 Â Â 16 % Â Â 107,910 Â Â 6 % Â Â Â Â Â Â 469,714 Â Â 12 % Medicaid Â 296,966 Â Â 13 % Â Â 262,393 Â Â 15 % Â Â Â Â Â 559,359 Â Â 14 % Managed Medicaid Â 154,762 Â Â 7 % Â Â 422,563 Â Â 25 % Â Â Â Â Â Â 577,325 Â Â 15 % Managed Care (HMO and PPOs) Â 725,014 Â Â 32 % Â Â 401,004 Â Â 23 % Â Â Â Â Â Â 1,126,018 Â Â 28 % UK Revenue Â 0 Â Â 0 % Â Â 230,153 Â Â 13 % Â Â Â Â Â Â 230,153 Â Â 6 % Other patient revenue and adjustments, net Â 117,679 Â Â 5 % Â Â 155,332 Â Â 9 % Â Â Â Â 273,011 Â Â 7 % Other non-patient revenue Â 266,826 Â Â 12 % Â Â 54,411 Â Â 3 % Â Â 2,596 Â Â Â 323,833 Â Â 8 % Total Net Revenue $ 2,245,517 Â Â 100 % Â $ 1,714,914 Â Â 100 % Â $ 2,596 Â Â Â 3,963,027 Â Â 100 % Â For the nine months ended September 30, 2024 Â Â Acute Care Â Â Behavioral Health Â Â Other Â Â Total Â Medicare $ 1,009,630 Â Â 15 % Â $ 234,295 Â Â 5 % Â Â Â Â Â $ 1,243,925 Â Â 11 % Managed Medicare Â 1,104,493 Â Â 17 % Â Â 307,388 Â Â 6 % Â Â Â Â 1,411,881 Â Â 12 % Medicaid Â 771,298 Â Â 12 % Â Â 804,254 Â Â 16 % Â Â Â Â Â Â 1,575,552 Â Â 13 % Managed Medicaid Â 466,881 Â Â 7 % Â Â 1,262,108 Â Â 25 % Â Â Â Â 1,728,989 Â Â 15 % Managed Care (HMO and PPOs) Â 2,129,117 Â Â 32 % Â Â 1,227,056 Â Â 24 % Â Â Â Â Â Â 3,356,173 Â Â 29 % UK Revenue Â 0 Â Â 0 % Â Â 650,655 Â Â 13 % Â Â Â Â Â Â 650,655 Â Â 6 % Other patient revenue and adjustments, net Â 375,161 Â Â 6 % Â Â 449,609 Â Â 9 % Â Â Â Â Â 824,770 Â Â 7 % Other non-patient revenue Â 747,427 Â Â 11 % Â Â 166,925 Â Â 3 % Â Â 7,916 Â Â Â 922,268 Â Â 8 % Total Net Revenue $ 6,604,007 Â Â 100 % Â $ 5,102,290 Â Â 100 % Â $ 7,916 Â Â $ 11,714,213 Â Â 100 % Â For the three months ended September 30, 2023 Â Â Acute Care Â Â Behavioral Health Â Â Other Â Â Total Â Medicare $ 298,121 Â Â 15 % Â $ 81,689 Â Â 5 % Â Â Â Â Â Â $ 379,810 Â Â 11 % Managed Medicare Â 324,486 Â Â 16 % Â Â 95,094 Â Â 6 % Â Â Â Â Â Â 419,580 Â Â 12 % Medicaid Â 201,148 Â Â 10 % Â Â 204,154 Â Â 13 % Â Â Â Â Â Â 405,302 Â Â 11 % Managed Medicaid Â 181,051 Â Â 9 % Â Â 387,975 Â Â 25 % Â Â Â Â Â Â 569,026 Â Â 16 % Managed Care (HMO and PPOs) Â 651,816 Â Â 32 % Â Â 383,146 Â Â 25 % Â Â Â Â Â Â 1,034,962 Â Â 29 % UK Revenue Â 0 Â Â 0 % Â Â 202,994 Â Â 13 % Â Â Â Â Â Â 202,994 Â Â 6 % Other patient revenue and adjustments, net Â 108,676 Â Â 5 % Â Â 129,492 Â Â 8 % Â Â Â Â Â Â 238,168 Â Â 7 % Other non-patient revenue Â 251,990 Â Â 12 % Â Â 58,151 Â Â 4 % Â Â 2,791 Â Â Â 312,932 Â Â 9 % Total Net Revenue $ 2,017,288 Â Â 100 % Â $ 1,542,695 Â Â 100 % Â $ 2,791 Â Â $ 3,562,774 Â Â 100 % Â For the nine months ended September 30, 2023 Â Â Acute Care Â Â Behavioral Health Â Â Other Â Â Total Â Medicare $ 961,640 Â Â 16 % Â $ 233,930 Â Â 5 % Â Â Â Â Â $ 1,195,570 Â Â 11 % Managed Medicare Â 1,013,493 Â Â 17 % Â Â 255,782 Â Â 6 % Â Â Â Â Â Â 1,269,275 Â Â 12 % Medicaid Â 445,678 Â Â 7 % Â Â 625,956 Â Â 14 % Â Â Â Â Â Â 1,071,634 Â Â 10 % Managed Medicaid Â 545,173 Â Â 9 % Â Â 1,184,315 Â Â 26 % Â Â Â Â Â Â 1,729,488 Â Â 16 % Managed Care (HMO and PPOs) Â 2,009,110 Â Â 34 % Â Â 1,160,820 Â Â 25 % Â Â Â Â 3,169,930 Â Â 30 % UK Revenue Â 0 Â Â 0 % Â Â 560,897 Â Â 12 % Â Â Â Â Â Â 560,897 Â Â 5 % Other patient revenue and adjustments, net Â 303,923 Â Â 5 % Â Â 387,327 Â Â 8 % Â Â Â Â Â 691,250 Â Â 7 % Other non-patient revenue Â 714,882 Â Â 12 % Â Â 166,351 Â Â 4 % Â Â 9,153 Â Â Â 890,386 Â Â 8 % Total Net Revenue $ 5,993,899 Â Â 100 % Â $ 4,575,378 Â Â 100 % Â $ 9,153 Â Â $ 10,578,430 Â Â 100 % Â X - DefinitionTabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details Name: us-gaap_DisaggregationOfRevenueTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 37 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Lease Accounting (Tables) 9 Months Ended Sep. 30, 2024 Leases [Abstract] Â Supplemental Cash Flow Information Related to Leases Supplemental cash flow information related to leases for the nine-month period ended September 30, 2024 and 2023 are as follows (in thousands): Â Nine months endedSeptember 30, Â Â 2024 Â Â 2023 Â Â Â Â Â Â Â Cash paid for amounts included in the measurement of lease liabilities: Â Â Â Â Â Operating cash flows from operating leases $ 99,526 Â Â $ 96,922 Â Operating cash flows from finance leases $ 2,756 Â Â $ 2,890 Â Financing cash flows from finance leases $ 3,167 Â Â $ 2,910 Â Â Â Â Â Â Â Right-of-use assets obtained in exchange for lease obligations: Â Â Â Â Â Operating leases $ 50,696 Â Â $ 50,940 Â Finance leases $ 8,441 Â Â $ 452 Â X - DefinitionSchedule of supplemental cash flow information related to leases. + ReferencesNo definition available. + Details Name: uhs_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock Namespace Prefix: uhs_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 38 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Relationship with Universal Health Realty Income Trust and Other Related Party Transactions - Additional Information (Detail) - USD ($) 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Dec. 31, 2022 Dec. 31, 2021 Related Party Transaction [Line Items] Â Â Â Â Â Â Net revenues $ 3,963,027,000 $ 3,562,774,000 $ 11,714,213,000 $ 10,578,430,000 Â Â Â Acute Care Hospital Services Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Net revenues 2,245,517,000 2,017,288,000 $ 6,604,007,000 5,993,899,000 Â Â Â Relationship with Universal Health Realty Income Trust Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Percentage of advisory fee on average invested real estate assets Â Â 0.70% Â 0.70% 0.70% 0.70% Pre-tax share of income from the Trust 300,000 100,000 $ 914,000 670,000 Â Â Â Dividends received from the Trust 575,000 567,000 1,700,000 1,700,000 Â Â Â Carrying value of investment in Trust 6,200,000 Â 6,200,000 Â $ 7,000,000 Â Â Market value of investment in Trust $ 36,000,000.0 Â $ 36,000,000.0 Â $ 34,100,000 Â Â Relationship with Universal Health Realty Income Trust | Other Related Party Transactions Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Trust outstanding shares held, percentage 5.70% Â 5.70% Â Â Â Â Relationship with Universal Health Realty Income Trust | Advisory Fee Â Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Â Net revenues $ 1,400,000 $ 1,300,000 $ 4,100,000 $ 4,000,000 Â Â Â X - DefinitionPercentage of advisory fee on average invested real estate assets. + ReferencesNo definition available. + Details Name: uhs_PercentageOfAdvisoryFeeOnAverageInvestedRealEstateAssets Namespace Prefix: uhs_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 + Details Name: us-gaap_EquityMethodInvestmentOwnershipPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionThis item represents the aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted market price is available. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 + Details Name: us-gaap_EquityMethodInvestmentQuotedMarketValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThis item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 + Details Name: us-gaap_EquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe total amount of other operating income, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherOperatingIncome Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionDividends received on equity and other investments during the current period. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-16 + Details Name: us-gaap_ProceedsFromDividendsReceived Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_StatementBusinessSegmentsAxis=uhs_AcuteCareHospitalServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=uhs_UniversalHealthRealtyIncomeTrustMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=uhs_OtherRelatedPartyTransactionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_InvestmentAdviceMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 39 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Relationship with Universal Health Realty Income Trust and Other Related Party Transactions - Additional Information 1 (Detail) - Relationship with Universal Health Realty Income Trust $ in Millions 3 Months Ended 9 Months Ended 12 Months Ended Mar. 31, 2023 Bed Sep. 30, 2024 Bed Dec. 31, 2021 USD ($) Bed Related Party Transaction [Line Items] Â Â Â Number of beds available in acute care hospital 170 Â Â Behavioral Health Care Facility Â Â Â Related Party Transaction [Line Items] Â Â Â Number of bed available in behavioral health care facility Â 100 Â Asset Purchase and Sale Agreement | Subsidiaries Â Â Â Related Party Transaction [Line Items] Â Â Â Cash received for sale of real estate asset | $ Â Â $ 4.1 Aiken South Carolina | Aiken Regional Medical Center | Asset Purchase and Sale Agreement | Subsidiaries | Acute Care Hospital Services Â Â Â Related Party Transaction [Line Items] Â Â Â Number of beds available in acute care hospital Â Â 211 Aiken South Carolina | Aiken Regional Medical Center | Asset Purchase and Sale Agreement | Subsidiaries | Behavioral Health Care Facility Â Â Â Related Party Transaction [Line Items] Â Â Â Number of bed available in behavioral health care facility Â Â 62 X - DefinitionNumber of beds available in acute care hospital. + ReferencesNo definition available. + Details Name: uhs_NumberOfBedsAvailableInAcuteCareHospital Namespace Prefix: uhs_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionNumber of beds available in behavioral health care facility. + ReferencesNo definition available. + Details Name: uhs_NumberOfBedsAvailableInBehavioralHealthCareFacility Namespace Prefix: uhs_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionCash received for

the sale of real estate that is not part of an investing activity during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromSaleOfRealEstate Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=uhs_UniversalHealthRealtyIncomeTrustMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=uhs_BehavioralHealthCareFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=uhs_AssetPurchaseAndSaleAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=uhs_AikenSouthCarolinaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis=uhs_AikenRegionalMedicalCenterMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=uhs_AcuteCareHospitalServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 40 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Relationship with Universal Health Realty Income Trust and Other Related Party Transactions - Additional Information 2 (Detail) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) Bed Sep. 30, 2023 USD ($) Dec. 31, 2023 USD ($) Related Party Transaction [Line Items] Â Â Â Â Â Lease and rental expense $ 36,540 $ 35,466 $ 108,165 $ 105,775 Â Relationship with Universal Health Realty Income Trust Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Financial liability included in debt 74,800 Â 74,800 Â $ 77,500 Lease and rental expense $ 5,000 $ 5,000 $ 16,000 15,000 Â Notice period on renewal of lease Â Â 90 days Â Â Behavioral Health Care Facility | Relationship with Universal Health Realty Income Trust Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Lease and rental expense Â Â $ 2,800 $ 2,700 Â Notice period on renewal of lease Â Â 270 days Â Â Number of bed available in behavioral health care facility | Bed Â Â 100 Â Â Period of rights of refusal to leased facilities Â Â 30 days Â Â X - DefinitionFinancial liability from fair value of real estate assets exchanged. + ReferencesNo definition available. + Details Name: uhs_FinancialLiabilityFromFairValueOfRealEstateAssetsExchanged Namespace Prefix: uhs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNotice period on renewal of lease. + ReferencesNo definition available. + Details Name: uhs_NoticePeriodOnRenewalOfLease Namespace Prefix: uhs_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionNumber of beds available in behavioral health care facility. + ReferencesNo definition available. + Details Name: uhs_NumberOfBedsAvailableInBehavioralHealthCareFacility Namespace Prefix: uhs_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionPeriod of rights of refusal to leased facilities. + ReferencesNo definition available. + Details Name: uhs_PeriodOfRightsOfRefusalToLeasedFacilities Namespace Prefix: uhs_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of operating lease expense. Excludes sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4 + Details Name: us-gaap_OperatingLeaseExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=uhs_UniversalHealthRealtyIncomeTrustMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=uhs_BehavioralHealthCareFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 41 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Relationship with Universal Health Realty Income Trust and Other Related Party Transactions - Additional Information 3 (Detail) 1 Months Ended 3 Months Ended 9 Months Ended Oct. 31, 2024 USD ($) Sep. 30, 2024 USD ($) Facility Sep. 30, 2023 USD ($) SquareFoot Mar. 31, 2023 USD ($) Bed SquareFoot Sep. 30, 2024 USD ($) Facility Sep. 30, 2023 USD ($) Related Party Transaction [Line Items] Â Â Â Â Â Â Lease and rental expense Â $ 36,540,000 $ 35,466,000 Â $ 108,165,000 $ 105,775,000 Relationship with Universal Health Realty Income Trust Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Number of free-standing emergency departments to be acquired | Facility Â 2 Â Â 2 Â Number of square feet to be acquired | SquareFoot Â Â 79,500 Â Â Â Percentage of master lease rentable square feet Â Â 100.00% 68.00% Â Â Lease and rental expense Â $ 5,000,000 $ 5,000,000 Â $ 16,000,000 $ 15,000,000 Number of square feet to be constructed | SquareFoot Â Â Â 86,000 Â Â Number of beds available in acute care hospital | Bed Â Â Â 170 Â Â Two Free-standing Emergency Departments Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Renewal options term at fair market lease rates 5 years Â Â Â Â Â Lease expiration date Jan. 31, 2025 Â Â Â Â Â Lease and rental expense $ 979,000 Â Â Â Â Â Percentage of annual rental increase on cumulative and compound basis 2.00% Â Â Â Â Â Two Free-standing Emergency Departments | First Three Renewal Options Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Percentage of annual rental increase on cumulative and compound basis Â Â Â Â 2.00% Â Minimum | Relationship with Universal Health Realty Income Trust Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Lease and rental expense Â Â $ 624,000 $ 1,300,000 Â Â Minimum | Two Free-standing Emergency Departments Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Operating leases additional renewal options at fair market value lease rates expiration date Feb. 01, 2025 Â Â Â Â Â Minimum | Two Free-standing Emergency Departments | First Three Renewal Options Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Operating leases additional renewal options at fair market value lease rates expiration year Â Â Â Â 2030 Â Minimum | Two Free-standing Emergency Departments | Remaining Two Renewal Options Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Operating leases additional renewal options at fair market value lease rates expiration year Â Â Â Â 2045 Â Maximum | Two Free-standing Emergency Departments Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Operating leases additional renewal options at fair market value lease rates expiration date Jan. 31, 2030 Â Â Â Â Â Maximum | Two Free-standing Emergency Departments | First Three Renewal Options Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Operating leases additional renewal options at fair market value lease rates expiration year Â Â Â Â 2044 Â Maximum | Two Free-standing Emergency Departments | Remaining Two Renewal Options Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Operating leases additional renewal options at fair market value lease rates expiration year Â Â Â Â 2054 Â Limited Liability Companies | Minimum | Relationship with Universal Health Realty Income Trust Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Non-controlling ownership interests Â 95.00% Â Â 95.00% Â Limited Liability Companies | Maximum | Relationship with Universal Health Realty Income Trust Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Non-controlling ownership interests Â 100.00% Â Â 100.00% Â X - DefinitionNumber of beds available in acute care hospital. + ReferencesNo definition available. + Details Name: uhs_NumberOfBedsAvailableInAcuteCareHospital Namespace Prefix: uhs_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionNumber of freestanding emergency departments to be acquired in business acquisition. + ReferencesNo definition available. + Details Name: uhs_NumberOfFreestandingEmergencyDepartmentsToBeAcquiredInBusinessAcquisition Namespace Prefix: uhs_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionNumber of square feet to be acquired in edical office building. + ReferencesNo definition available. + Details Name: uhs_NumberOfSquareFeetToBeAcquiredInMedicalOfficeBuilding Namespace Prefix: uhs_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionNumber of square feet to be constructed in medical office building. + ReferencesNo definition available. + Details Name: uhs_NumberOfSquareFeetToBeConstructedInMedicalOfficeBuilding Namespace Prefix: uhs_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionOperating leases additional renewal options at fair market value lease rates expiration date. + ReferencesNo definition available. + Details Name: uhs_OperatingLeasesAdditionalRenewalOptionsAtFairMarketValueLeaseRatesExpirationDate Namespace Prefix: uhs_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionOperating leases additional renewal options at fair market value lease rates expiration year. + ReferencesNo definition available. + Details Name: uhs_OperatingLeasesAdditionalRenewalOptionsAtFairMarketValueLeaseRatesExpirationYear Namespace Prefix: uhs_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionOperating leases, renewal options term at fair market value lease rates. + ReferencesNo definition available. + Details Name: uhs_OperatingLeasesRenewalOptionsTermAtFairMarketValueLeaseRates Namespace Prefix: uhs_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPercentage of annual rental increase on cumulative and compound basis. + ReferencesNo definition available. + Details Name: uhs_PercentageOfAnnualRentalIncreaseOnCumulativeAndCompoundBasis Namespace Prefix: uhs_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionPercentage of master lease rentable square feet of medical office building. + ReferencesNo definition available. + Details Name: uhs_PercentageOfMasterLeaseRentableSquareFeetOfMedicalOfficeBuilding Namespace Prefix: uhs_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionDate which lease or group of leases is set to expire, in YYYY-MM-DD format. + ReferencesNo definition available. + Details Name: us-gaap_LeaseExpirationDate1 Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionThe parent entity's interest in net assets of the subsidiary, expressed as a percentage. + ReferencesNo definition available. + Details Name: us-gaap_MinorityInterestOwnershipPercentageByParent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of operating lease expense. Excludes sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4 + Details Name: us-gaap_OperatingLeaseExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=uhs_UniversalHealthRealtyIncomeTrustMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=uhs_TwoFreeStandingEmergencyDepartmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LeaseContractualTermAxis=uhs_FirstThreeRenewalOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LeaseContractualTermAxis=uhs_RemainingTwoRenewalOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_OwnershipAxis=uhs_LimitedLiabilityCompaniesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 42 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Relationship with Universal Health Realty Income Trust and Other Related Party Transactions - Additional Information 4 (Detail) - USD ($) 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2013 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2024 Dec. 31, 2023 Chief Executive Officer Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Estimated payments to acquire life insurance policies Â Â Â $ 28,000,000 Â Â Â Payments to acquire life insurance policies, net Â Â Â Â Â Â $ 1,000,000 Trust Owned by CEO | Chief Executive Officer Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Estimated payments to acquire life insurance policies Â Â Â 9,000,000 Â Â Â Minimum | Chief Executive Officer Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Estimated death benefit proceeds Â Â Â 37,000,000 Â Â Â Premier, Inc. | Group Purchasing Organization Agreement | Restricted Stock Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Shares vesting period Â Â 7 years Â Â Â Â Shares vesting period start year Â Â 2014 Â Â Â Â Shares vesting period end year Â Â 2020 Â Â Â Â Market value of retained vested shares Â Â Â 45,000,000 Â Â $ 50,000,000 Other (Income) Expense, Net | Premier, Inc. Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Dividend $ 470,000 $ 470,000 Â $ 1,400,000 $ 1,400,000 Â Â Scenario Forecast | Chief Executive Officer Â Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Â Payments to acquire life insurance policies, net Â Â Â Â Â $ 1,000,000 Â X - DefinitionEstimated payments to acquire life insurance policies. + ReferencesNo definition available. + Details Name: uhs_EstimatedPaymentsToAcquireLifeInsurancePolicies Namespace Prefix: uhs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEstimated proceeds from life insurance policies. + ReferencesNo definition available. + Details Name: uhs_EstimatedProceedsFromLifeInsurancePolicies Namespace Prefix: uhs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionShare-based compensation arrangement by share-based payment award, award vesting period end year. + ReferencesNo definition available. + Details Name: uhs_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodEndYear Namespace Prefix: uhs_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionShare-based compensation arrangement by share-based payment award, award vesting period start year. + ReferencesNo definition available. + Details Name: uhs_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodStartYear Namespace Prefix: uhs_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionAmount of dividend income on nonoperating securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_InvestmentIncomeDividend Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for payment of premium on corporate-owned life insurance policy, classified as investing activities. Includes, but is not limited to, bank-owned life insurance policy. + ReferencesReference 1:

http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 21C -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-21C + Details Name: us-gaap_PaymentsToAcquireLifeInsurancePolicies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1 + Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionFair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=uhs_TrustOwnedByChiefExecutiveOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=uhs_PremierIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_TypeOfArrangementAxis=uhs_GroupPurchasingOrganizationAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_OtherOperatingIncomeExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=srt_ScenarioForecastMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 43 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Details of Hospitals Leased from Trust (Detail) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Property Subject to or Available for Operating Lease [Line Items] Â Â Â Â Annual Minimum Rent $ 36,540,000 $ 35,466,000 $ 108,165,000 $ 105,775,000 McAllen Medical Center Â Â Â Â Property Subject to or Available for Operating Lease [Line Items] Â Â Â Â Annual Minimum Rent Â Â $ 5,485,000 Â End of Lease Term Â Â 2026-12 Â Renewal Term (years) [1] Â Â 5 years Â Wellington Regional Medical Center Â Â Â Â Property Subject to or Available for Operating Lease [Line Items] Â Â Â Â Annual Minimum Rent Â Â $ 6,639,000 Â End of Lease Term Â Â 2026-12 Â Renewal Term (years) [2] Â Â 5 years Â Aiken Regional Medical Center/Aurora Pavilion Behavioral Health Services Â Â Â Â Property Subject to or Available for Operating Lease [Line Items] Â Â Â Â Annual Minimum Rent Â Â $ 4,072,000 Â End of Lease Term Â Â 2033-12 Â Renewal Term (years) [3] Â Â 35 years Â Canyon Creek Behavioral Health Â Â Â Â Property Subject to or Available for Operating Lease [Line Items] Â Â Â Â Annual Minimum Rent Â Â $ 1,841,000 Â End of Lease Term Â Â 2033-12 Â Renewal Term (years) [3] Â Â 35 years Â Clive Behavioral Health Hospital Â Â Â Â Property Subject to or Available for Operating Lease [Line Items] Â Â Â Â Annual Minimum Rent Â Â $ 2,775,000 Â End of Lease Term Â Â 2040-12 Â Renewal Term (years) [4] Â Â 50 years Â [1] We have one 5-year renewal option at existing lease rates (through 2031). [2] We have one 5-year renewal option at fair market value lease rates (through 2031). On each January 1st through 2026, the annual rent will increase by 2.5% on a cumulative and compounded basis. [3] We have seven 5-year renewal options at fair market value lease rates (2034 through 2068). On each January 1st through 2033, the annual rent will increase by 2.25% on a cumulative and compounded basis. [4] This facility is operated by a joint venture in which we are the managing, majority member and an unrelated third-party holds a minority ownership interest. The joint venture has three, 10-year renewal options at computed lease rates as stipulated in the lease (2041 through 2070) and two additional, 10-year renewal options at fair market value lease rates (2071 through 2090). In each January through 2040 (and potentially through 2070 if three, 10-year renewal options are exercised), the annual rental will increase by 2.75% on a cumulative and compounded basis. X - DefinitionLease expiration, month and year. + ReferencesNo definition available. + Details Name: uhs_LeaseExpirationMonthAndYear Namespace Prefix: uhs_ Data Type: xbrli:gYearMonthItemType Balance Type: na Period Type: duration X - DefinitionLease expiration period. + ReferencesNo definition available. + Details Name: uhs_LeaseExpirationPeriod Namespace Prefix: uhs_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of operating lease expense. Excludes sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4 + Details Name: us-gaap_OperatingLeaseExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 840 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481501/840-20-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479773/842-30-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertySubjectToOrAvailableForOperatingLeaseLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_MajorPropertyClassAxis=uhs_McAllenMedicalCenterMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MajorPropertyClassAxis=uhs_WellingtonRegionalMedicalCenterMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MajorPropertyClassAxis=uhs_AikenRegionalMedicalCenterAuroraPavilionBehavioralHealthServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MajorPropertyClassAxis=uhs_CanyonCreekBehavioralHealthMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MajorPropertyClassAxis=uhs_CliveBehavioralHealthHospitalMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 44 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Details of Hospitals Leased from Trust (Parenthetical) (Detail) - RenewalOption 9 Months Ended Jan. 01, 2024 Sep. 30, 2024 Maximum Â Â Property Subject to or Available for Operating Lease [Line Items] Â Â Real estate leases option to extend lease term Â 10 years Minimum Â Â Property Subject to or Available for Operating Lease [Line Items] Â Â Real estate leases option to extend lease term Â 5 years McAllen Medical Center Â Â Property Subject to or Available for Operating Lease [Line Items] Â Â Renewal options term at existing lease rates Â 5 years McAllen Medical Center | Maximum Â Â Property Subject to or Available for Operating Lease [Line Items] Â Â Renewal options at existing lease rates expiration year Â 2031 Wellington Regional Medical Center Â Â Property Subject to or Available for Operating Lease [Line Items] Â Â Renewal options term at fair market lease rates Â 5 years Percentage of annual rental increase on cumulative and compound basis 2.50% Â Wellington Regional Medical Center | Maximum Â Â Property Subject to or Available for Operating Lease [Line Items] Â Â Renewal options at fair market value lease rates expiration year Â 2031 Aiken Regional Medical Center/Aurora Pavilion Behavioral Health Services Â Â Property Subject to or Available for Operating Lease [Line Items] Â Â Renewal options term at fair market lease rates Â 5 years Aiken Regional Medical Center/Aurora Pavilion Behavioral Health Services | Maximum Â Â Property Subject to or Available for Operating Lease [Line Items] Â Â Renewal options at fair market value lease rates expiration year Â 2068 Aiken Regional Medical Center/Aurora Pavilion Behavioral Health Services | Minimum Â Â Property Subject to or Available for Operating Lease [Line Items] Â Â Renewal options at fair market value lease rates expiration year Â 2034 Canyon Creek Behavioral Health Â Â Property Subject to or Available for Operating Lease [Line Items] Â Â Renewal options term at fair market lease rates Â 5 years Percentage of annual rental increase on cumulative and compound basis 2.25% Â Canyon Creek Behavioral Health | Maximum Â Â Property Subject to or Available for Operating Lease [Line Items] Â Â Renewal options at fair market value lease rates expiration year Â 2068 Canyon Creek Behavioral Health | Minimum Â Â Property Subject to or Available for Operating Lease [Line Items] Â Â Renewal options at fair market value lease rates expiration year Â 2034 Clive Behavioral Health Hospital Â Â Property Subject to or Available for Operating Lease [Line Items] Â Â Renewal options term at fair market lease rates Â 10 years Percentage of annual rental increase on cumulative and compound basis Â 2.75% Operating leases additional renewal options term at fair market value lease rates Â 10 years Number of lease renewal option exercised Â 3 Clive Behavioral Health Hospital | Maximum Â Â Property Subject to or Available for Operating Lease [Line Items] Â Â Renewal options at fair market value lease rates expiration year Â 2070 Operating leases additional renewal options at fair market value lease rates expiration year Â 2090 Clive Behavioral Health Hospital | Minimum Â Â Property Subject to or Available for Operating Lease [Line Items] Â Â Renewal options at fair market value lease rates expiration year Â 2041 Operating leases additional renewal options at fair market value lease rates expiration year Â 2071 X - DefinitionNumber of lease renewal option exercised. + ReferencesNo definition available. + Details Name: uhs_NumberOfLeaseRenewalOptionExercised Namespace Prefix: uhs_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionOperating leases additional renewal options at fair market value lease rates expiration year. + ReferencesNo definition available. + Details Name: uhs_OperatingLeasesAdditionalRenewalOptionsAtFairMarketValueLeaseRatesExpirationYear Namespace Prefix: uhs_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionOperating leases additional renewal options term at fair market value lease rates. + ReferencesNo definition available. + Details Name: uhs_OperatingLeasesAdditionalRenewalOptionsTermAtFairMarketValueLeaseRates Namespace Prefix: uhs_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionOperating leases, renewal options at existing lease rates, expiration year. + ReferencesNo definition available. + Details Name: uhs_OperatingLeasesRenewalOptionsAtExistingLeaseRatesExpirationYear Namespace Prefix: uhs_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionOperating leases, renewal options at fair market value lease rates, expiration year. + ReferencesNo definition available. + Details Name: uhs_OperatingLeasesRenewalOptionsAtFairMarketValueLeaseRatesExpirationYear Namespace Prefix: uhs_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionOperating leases, renewal options term at existing lease rates. + ReferencesNo definition available. + Details Name: uhs_OperatingLeasesRenewalOptionsTermAtExistingLeaseRates Namespace Prefix: uhs_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionOperating leases, renewal options term at fair market value lease rates. + ReferencesNo definition available. + Details Name: uhs_OperatingLeasesRenewalOptionsTermAtFairMarketValueLeaseRates Namespace Prefix: uhs_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPercentage of annual rental increase on cumulative and compound basis. + ReferencesNo definition available. + Details Name: uhs_PercentageOfAnnualRentalIncreaseOnCumulativeAndCompoundBasis Namespace Prefix: uhs_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionTerm of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseRenewalTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 840 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481501/840-20-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479773/842-30-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertySubjectToOrAvailableForOperatingLeaseLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MajorPropertyClassAxis=uhs_McAllenMedicalCenterMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MajorPropertyClassAxis=uhs_WellingtonRegionalMedicalCenterMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MajorPropertyClassAxis=uhs_AikenRegionalMedicalCenterAuroraPavilionBehavioralHealthServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MajorPropertyClassAxis=uhs_CanyonCreekBehavioralHealthMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_MajorPropertyClassAxis=uhs_CliveBehavioralHealthHospitalMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 45 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Other Noncurrent Liabilities and Redeemable/Noncontrolling Interests - Additional Information (Detail) $ in Millions Sep. 30, 2024 USD ($) Facility Minority Interest [Line Items] Â Behavioral health care facilities with outside owners holding non-controlling minority interest | Facility 6 Non-controlling interest balances | $ $ 5 Redeemable non-controlling interest balances | $ $ 6 Michigan Â Minority Interest [Line Items] Â Behavioral health care facilities with outside owners holding non-controlling minority interest | Facility 2 Outside Owners | Acute Care Facility | Texas Â Minority Interest [Line Items] Â Percentage of non-controlling, minority ownership interests held by outside owners 7.00% Outside Owners | Acute Care Facility | Nevada Â Minority Interest [Line Items] Â Percentage of non-controlling, minority ownership interests held by outside owners 5.00% Outside Owners | Behavioral Health Care Facility | Arizona Â Minority Interest [Line Items] Â Percentage of non-controlling, minority ownership interests held by outside owners 49.00% Outside Owners | Behavioral Health Care Facility | Pennsylvania Â Minority Interest [Line Items] Â Percentage of non-controlling, minority ownership interests held by outside owners 20.00% Outside Owners | Behavioral Health Care Facility | Ohio Â Minority Interest [Line Items] Â Percentage of non-controlling, minority ownership interests held by outside owners 30.00% Outside Owners | Behavioral Health Care Facility | Washington Â Minority Interest [Line Items] Â Percentage of non-controlling, minority ownership interests held by outside owners 20.00% Outside Owners | Behavioral Health Care Facility | Missouri Â Minority Interest [Line Items] Â Percentage of non-controlling, minority ownership interests held by outside owners 25.00% Outside Owners | Behavioral Health Care Facility | Iowa Â Minority Interest [Line Items] Â Percentage of non-controlling, minority ownership interests held by outside owners 48.00% Outside Owners | Behavioral Health Care Facility One | Michigan Â Minority Interest [Line Items] Â Percentage of non-controlling, minority ownership interests held by outside owners 26.00% Outside Owners | Behavioral Health Care Facility Two | Michigan Â Minority Interest [Line Items] Â Percentage of non-controlling, minority ownership interests held by outside owners 49.00% Outside Owners | Surgery center | Nevada Â Minority Interest [Line Items] Â Percentage of non-

controlling, minority ownership interests held by outside owners 49.00% X - DefinitionBehavioral health care facilities outside owners holding noncontrolling minority interest. + ReferencesNo definition available. + Details Name: uhs_BehavioralHealthCareFacilitiesOutsideOwnersHoldingNoncontrollingMinorityInterest Namespace Prefix: uhs_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionCarrying amount of the equity interests owned by noncontrolling shareholders, partners, or other equity holders in joint ventures included in the entity's consolidated financial statements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16 + Details Name: us-gaap_MinorityInterestInJointVentures Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_MinorityInterestLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity. + ReferencesNo definition available. + Details Name: us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAs of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 480 -SubTopic 10 -Subparagraph (12)(c) -Section S99 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 480 -SubTopic 10 -Subparagraph (16)(c) -Paragraph 3A -Section S99 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3AReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 480 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3A -Subparagraph (15) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3AReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 480 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3A -Subparagraph (14) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A + Details Name: us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: srt_StatementGeographicalAxis=stpr_MI Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_OwnershipAxis=uhs_OutsideOwnersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=uhs_AcuteCareFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=stpr_TX Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=stpr_NV Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=uhs_BehavioralHealthCareFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_AZ Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=stpr_PA Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=stpr_OH Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=stpr_WA Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=stpr_MO Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=stpr_IA Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=uhs_BehavioralHealthCareFacilityOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=uhs_BehavioralHealthCareFacilityTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=uhs_SurgeryCenterMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Treasury - Additional Information (Detail) - USD ($) 9 Months Ended Sep. 26, 2024 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Aug. 24, 2021 Sep. 21, 2020 Equity Class Of Treasury Stock [Line Items] Â Â Â Â Â Â Rate adjustment to one month Eurodollar rate on credit facility borrowings Â 1.00% Â Â Â Â Debt instrument carrying amount Â $ 4,700,000,000 Â $ 4,900,000,000 Â Â Unamortized financing costs Â 21,000,000 Â Â Â Â Debt, due during the next 12 month Â 38,000,000 Â Â Â Â Debt, due during months 13 to 24 Â 738,000,000 Â Â Â Â Debt, due during months 25 to 36 Â 69,000,000 Â Â Â Â Debt, due during months 37 to 48 Â 70,000,000 Â Â Â Â Debt, due during months 49 to 60 Â 1,300,000,000 Â Â Â Â Debt, due in greater than 60 months Â 2,400,000,000 Â Â Â Â Fair value of debt Â 4,400,000,000 Â 4,600,000,000 Â Â Foreign Currency Forward Exchange Contracts Â Â Â Â Â Â Equity Class Of Treasury Stock [Line Items] Â Â Â Â Â Â Net cash outflows Â (36,000,000) $ (8,000,000) Â Â Â Debt Â Â Â Â Â Â Equity Class Of Treasury Stock [Line Items] Â Â Â Â Â Â Financial liabilities Â $ 75,000,000 Â $ 77,000,000 Â Â ABR-based loans Â Â Â Â Â Â Equity Class Of Treasury Stock [Line Items] Â Â Â Â Â Â Rate adjustment to weighted average federal funds rate for credit facility borrowings Â 0.50% Â Â Â Â 4.625% Senior Secured Notes due 2029 Â Â Â Â Â Â Equity Class Of Treasury Stock [Line Items] Â Â Â Â Â Â Senior notes, issued $ 500,000,000 Â Â Â Â Â Senior notes, interest rate 4.625% Â Â Â Â Â 5.050% Senior Secured Notes due 2034 Â Â Â Â Â Â Equity Class Of Treasury Stock [Line Items] Â Â Â Â Â Â Senior notes, issued $ 500,000,000 Â Â Â Â Â Senior notes, interest rate 5.05% Â Â Â Â Â Revolving Credit Facility Â Â Â Â Â Â Equity Class Of Treasury Stock [Line Items] Â Â Â Â Â Â Line of credit facility, borrowing capacity Â $ 1,200,000,000 Â Â Â Â Line of credit facility, maturity date Â Aug. 31, 2026 Â Â Â Â Revolving Credit Facility | One Three Six Month SOFR Rate Plus Index Based Loans Â Â Â Â Â Â Equity Class Of Treasury Stock [Line Items] Â Â Â Â Â Â Rate adjustment to one month Eurodollar rate on credit facility borrowings Â 0.10% Â Â Â Â Revolving Credit Facility | Letter of Credit Â Â Â Â Â Â Equity Class Of Treasury Stock [Line Items] Â Â Â Â Â Â Line of credit facility, borrowing capacity Â $ 125,000,000 Â Â Â Â Amended Revolving Credit Facility Â Â Â Â Â Â Equity Class Of Treasury Stock [Line Items] Â Â Â Â Â Â Line of credit facility, borrowing capacity Â $ 1,300,000,000 Â Â Â Â Line of credit facility, maturity date Sep. 26, 2029 Sep. 26, 2029 Â Â Â Â Line of credit facility amount outstanding Â $ 3,000,000 Â Â Â Â Line of credit facility, available borrowing capacity Â 1,010,000,000.00 Â Â Â Â Amended Revolving Credit Facility | Letter of Credit Â Â Â Â Â Â Equity Class Of Treasury Stock [Line Items] Â Â Â Â Â Â Letters of credit, outstanding Â 288,000,000 Â Â Â Â Amended Revolving Credit Facility | Maximum Â Â Â Â Â Â Equity Class Of Treasury Stock [Line Items] Â Â Â Â Â Â Line of credit facility, borrowing capacity Â 1,300,000,000 Â Â Â Â Tranche A Term Loan Â Â Â Â Â Â Equity Class Of Treasury Stock [Line Items] Â Â Â Â Â Â Decrease in outstanding borrowings Â 1,000,000,000 Â Â Â Â Line of credit facility amount outstanding Â 1,200,000,000 Â Â Â Â Tranche A Term Loan | Quarterly Payment Beginning on December 31, 2026 Through June 30, 2029 Â Â Â Â Â Â Equity Class Of Treasury Stock [Line Items] Â Â Â Â Â Â Scheduled principal payments per quarter Â 15,000,000 Â Â Â Â Tranche A Term Loan | Quarterly Payment Beginning on December 31,204 Through September 30, 2026 Â Â Â Â Â Â Equity Class Of Treasury Stock [Line Items] Â Â Â Â Â Â Scheduled principal payments per quarter Â 7,500,000 Â Â Â Â Tranche A Term Loan | Payment on September 26, 2029 Â Â Â Â Â Â Equity Class Of Treasury Stock [Line Items] Â Â Â Â Â Â Scheduled principal payments per quarter Â 975,000,000 Â Â Â Â Tranche A Term Loan | Maximum Â Â Â Â Â Â Equity Class Of Treasury Stock [Line Items] Â Â Â Â Â Â Line of credit facility, available borrowing capacity $ 1,200,000,000 Â Â Â Â Â New Senior Secured Notes Â Â Â Â Â Â Equity Class Of Treasury Stock [Line Items] Â Â Â Â Â Â Senior notes, issued Â $ 3,000,000,000 Â Â Â Â New Senior Secured Notes | 4.625% Senior Secured Notes due 2029 Â Â Â Â Â Â Equity Class Of Treasury Stock [Line Items] Â Â Â Â Â Â Line of credit facility, maturity date Â Oct. 15, 2029 Â Â Â Â Senior notes, issued $ 500,000,000 Â Â Â Â Â Senior notes, interest rate 4.625% Â Â Â Â Â New Senior Secured Notes | 5.050% Senior Secured Notes due 2034 Â Â Â Â Â Â Equity Class Of Treasury Stock [Line Items] Â Â Â Â Â Â Line of credit facility, maturity date Â Oct. 15, 2034 Â Â Â Â Senior notes, issued $ 500,000,000 Â Â Â Â Â Senior notes, interest rate 5.05% Â Â Â Â Â New Senior Secured Notes | 1.65% Senior Secured Notes due 2026 Â Â Â Â Â Â Equity Class Of Treasury Stock [Line Items] Â Â Â Â Â Â Line of credit facility, maturity date Â Sep. 01, 2026 Â Â Â Â Senior notes, issued Â Â Â Â $ 700,000,000 Â Senior notes, interest rate Â Â Â Â 1.65% Â New Senior Secured Notes | 2.65% Senior Secured Notes due 2030 Â Â Â Â Â Â Equity Class Of Treasury Stock [Line Items] Â Â Â Â Â Â Line of credit facility, maturity date Â Oct. 15, 2030 Â Â Â Â Senior notes, issued Â Â Â Â Â $ 800,000,000 Senior notes, interest rate Â Â Â Â Â 2.65% New Senior Secured Notes | 2.65% Senior Secured Notes due 2032 Â Â Â Â Â Â Equity Class Of Treasury Stock [Line Items] Â Â Â Â Â Â Line of credit facility, maturity date Â Jan. 15, 2032 Â Â Â Â Senior notes, issued Â Â Â Â $ 500,000,000 Â Senior notes, interest rate Â Â Â Â 2.65% Â Term Loan A | ABR-based loans Â Â Â Â Â Â Equity Class Of Treasury Stock [Line Items] Â Â Â Â Â Â Current applicable margins Â 0.375% Â Â Â Â Term Loan A | One Month SOFR Rate Plus Index Based Loans Â Â Â Â Â Â Equity Class Of Treasury Stock [Line Items] Â Â Â Â Â Â Current applicable margins Â 1.375% Â Â Â Â Term Loan A | Minimum | One Month SOFR Rate Plus Index Based Loans Â Â Â Â Â Â Equity Class Of Treasury Stock [Line Items] Â Â Â Â Â Â Consolidated Leverage Ratio Â 0.25% Â Â Â Â Term Loan A | Minimum | One Three Six Month SOFR Rate Plus Index Based Loans Â Â Â Â Â Â Equity Class Of Treasury Stock [Line Items] Â Â Â Â Â Â Consolidated Leverage Ratio Â 1.25% Â Â Â Â Term Loan A | Maximum | One Month SOFR Rate Plus Index Based Loans Â Â Â Â Â Â Equity Class Of Treasury Stock [Line Items] Â Â Â Â Â Â Consolidated Leverage Ratio Â 0.625% Â Â Â Â Term Loan A | Maximum | One Three Six Month SOFR Rate Plus Index Based Loans Â Â Â Â Â Â Equity Class Of Treasury Stock [Line Items] Â Â Â Â Â Â Consolidated Leverage Ratio Â 1.625% Â Â Â Â X - DefinitionConsolidated leverage ratio. + ReferencesNo definition available. + Details Name: uhs_ConsolidatedLeverageRatio Namespace Prefix: uhs_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionInterest rate margin adjustment percentage. + ReferencesNo definition available. + Details Name: uhs_InterestRateMarginAdjustmentPercentage Namespace Prefix: uhs_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionRate adjustment to federal funds rate weighted average. + ReferencesNo definition available. + Details Name: uhs_RateAdjustmentToFederalFundsRateWeightedAverage Namespace Prefix: uhs_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionRate adjustment to one month Eurodollar rate on credit facility borrowings. + ReferencesNo definition available. + Details Name: uhs_RateAdjustmentToOneMonthEurodollarRateOnCreditFacilityBorrowings Namespace Prefix: uhs_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionDate when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentMaturityDate Namespace Prefix: us-gaap_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionAmount of the required periodic payments applied to principal. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DebtInstrumentPeriodicPaymentPrincipal Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of unamortized debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A + Details Name: us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EquityClassOfTreasuryStockLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor entities that provide full or partial financing and servicing for customers supplementary to its major operations (such as a manufacturer or a homebuilder providing and servicing loans to buyers), represents the liabilities associated with such activities, including accounts payable and accrued liabilities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_FinancialServicesLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe increase (decrease) during the reporting period of all assets and liabilities used in operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOperatingCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe total amount of the contingent obligation under letters of credit outstanding as of the reporting date. + ReferencesNo definition available. + Details Name: us-gaap_LettersOfCreditOutstandingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period

Type: instant X - DefinitionThe carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_LineOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of increase (decrease) of the credit facility. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_LongTermDebtFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1 + Details Name: us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_DebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VariableRateAxis=uhs_ABRBasedLoansMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=uhs_FourPointSixTwoFivePercentSeniorSecuredNotesDueTwoThousandTwentyNineMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=uhs_FivePointZeroFiveZeroPercentSeniorSecuredNotesDueTwoThousandThirtyFourMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VariableRateAxis=uhs_OneThreeSixMonthSOFRRatePlusIndexBasedLoansMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ShortTermDebtTypeAxis=us-gaap_LetterOfCreditMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=uhs_AmendedRevolvingCreditFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=uhs_TrancheATermLoanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=uhs_GroupNineMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=uhs_GroupEightMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=uhs_GroupTenMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=uhs_NewSeniorSecuredCreditFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=uhs_OnePointSixFivePercentSeniorSecuredNotesDueTwoThousandTwentySixMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=uhs_TwoPointSixFivePercentSeniorSecuredNotesDueTwoThousandThirtyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=uhs_TwoPointSixFivePercentSeniorSecuredNotesDueTwoThousandThirtyTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=uhs_TermLoanAFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VariableRateAxis=uhs_OneMonthSOFRRatePlusIndexBasedLoansMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Effects of Foreign Currency Forward Exchange Contracts on Result of Operations (Detail) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Designated As Hedging Instrument | Net Investment Hedge | Foreign Currency Forward Exchange Contracts Â Â Â Â Â Derivative Instruments Gain Loss [Line Items] Â Â Â Â Â Gain/(Loss) recognized in AOCI $ (43,490) $ 19,619 $ (35,289) $ (10,781) X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4E -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E + Details Name: us-gaap_DerivativeInstrumentsGainLossLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480627/815-20-45-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4AReference 5:

http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A + Details Name: us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Cash, Cash Equivalents and Restricted Cash Reported In Condensed Consolidated Statements of Cash Flows (Detail) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Sep. 30, 2023 Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect [Abstract] Â Â Â Cash and cash equivalents $ 106,077 $ 119,439 $ 80,768 Restricted cash [1] $ 98,520 $ 95,031 $ 99,871 Restricted Cash, Statement of Financial Position [Extensible Enumeration] Other Other Other Total cash, cash equivalents and restricted cash $ 204,597 $ 214,470 $ 180,639 [1] Restricted cash is included in other noncurrent assets on the accompanying condensed consolidated balance sheets. X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_RestrictedCash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionIndicates line item in statement of financial position that includes cash restricted to withdrawal or usage. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashAssetStatementOfFinancialPositionExtensibleList Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: instant XML 49 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Assets and Liabilities Recorded at Fair Value on Recurring Basis (Detail) - Recurring - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Assets: Â Â Assets, fair value $ 211,330 $ 206,412 Liabilities: Â Â Liabilities, fair value 50,803 44,971 Money Market Mutual Funds | Other Noncurrent Assets Â Â Assets: Â Â Assets, fair value 115,205 111,129 Certificates of Deposit | Other Noncurrent Assets Â Â Assets: Â Â Assets, fair value 2,201 2,300 Equity Securities | Other Noncurrent Assets Â Â Assets: Â Â Assets, fair value 44,654 49,923 Deferred Compensation Assets | Other Noncurrent Assets Â Â Assets: Â Â Assets, fair value 49,270 43,060 Foreign Currency Forward Exchange Contracts | Accrued Liabilities Other Â Â Liabilities: Â Â Liabilities, fair value 1,533 1,911 Deferred Compensation Liability | Other Noncurrent Liabilities Â Â Liabilities: Â Â Liabilities, fair value 49,270 43,060 Basis of Fair Value Measurement, Level 1 Â Â Assets: Â Â Assets, fair value 209,129 204,112 Liabilities: Â Â Liabilities, fair value 49,270 43,060 Basis of Fair Value Measurement, Level 1 | Money Market Mutual Funds | Other Noncurrent Assets Â Â Assets: Â Â Assets, fair value 115,205 111,129 Basis of Fair Value Measurement, Level 1 | Equity Securities | Other Noncurrent Assets Â Â Assets: Â Â Assets, fair value 44,654 49,923 Basis of Fair Value Measurement, Level 1 | Deferred Compensation Assets | Other Noncurrent Assets Â Â Assets: Â Â Assets, fair value 49,270 43,060 Basis of Fair Value Measurement, Level 1 | Deferred Compensation Liability | Other Noncurrent Liabilities Â Â Liabilities: Â Â Liabilities, fair value 49,270 43,060 Basis of Fair Value Measurement, Level 2 Â Â Assets: Â Â Assets, fair value 2,201 2,300 Liabilities: Â Â Liabilities, fair value 1,533 1,911 Basis of Fair Value Measurement, Level 2 | Certificates of Deposit | Other Noncurrent Assets Â Â Assets: Â Â Assets, fair value 2,201 2,300 Basis of Fair Value Measurement, Level 2 | Foreign Currency Forward Exchange Contracts | Accrued Liabilities Other Â Â Liabilities: Â Â Liabilities, fair value $ 1,533 $ 1,911 X - DefinitionFair value portion of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsFairValueDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value of financial and nonfinancial obligations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_LiabilitiesFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesFairValueDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_CertificatesOfDepositMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=uhs_DeferredCompensationAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_ForeignExchangeContractMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=uhs_AccruedLiabilitiesOtherMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=uhs_DeferredCompensationLiabilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies - Additional Information (Detail) Â£ in Millions 3 Months Ended 9 Months Ended 12 Months Ended Oct. 10, 2024 USD ($) Sep. 27, 2024 USD ($) Plaintiffs Mar. 28, 2024 USD ($) Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) Sep. 30, 2024 GBP (Â£) Sep. 30, 2023 USD ($) Dec. 31, 2022 USD ($) Dec. 31, 2015 USD ($) Dec. 31, 2014 USD ($) Dec. 31, 2013 USD ($) Sep. 30, 2024 GBP (Â£) Dec. 31, 2023 USD ($) Dec. 31, 2021 USD ($) Dec. 31, 2020 USD ($) Dec. 31, 2019 USD ($) Dec. 31, 2018 USD ($) Dec. 31, 2017 USD ($) Dec. 31, 2016 USD ($) Commitments and Contingencies Disclosure [Line Items] Â Â Â

Â Â Â

srt_LitigationCaseAxis=uhs_PunitiveDamagesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=uhs_CumberlandHospitalForChildrenAndAdolescentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_LitigationCaseAxis=uhs_TrebledDamagesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_LitigationCaseAxis=uhs_CompensatoryDamagesTrebledAndPunitiveDamagesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis=uhs_WindStormsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis=us-gaap_EarthquakeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=uhs_CaliforniaNewMadridSeismicZonePacificNorthwestSeismicZoneAlaskaAndCertainCountiesInNevadaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis=uhs_EarthquakeWindHailAndFloodMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis=uhs_AllOtherEventsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=uhs_CygnetHealthCareLimitedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=stpr_CA Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=uhs_FaultyZonesOfUSMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_PR Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=uhs_OtherStatesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis=us-gaap_FloodMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=stpr_TX Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis=us-gaap_ProfessionalMalpracticeLiabilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis=us-gaap_GeneralLiabilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis=uhs_GeneralAndProfessionalLiabilityInsurancePoliciesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis=uhs_GeneralAndProfessionalLiabilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Segment Reporting (Detail) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Segment Reporting Information [Line Items] Â Â Â Â Â Gross inpatient revenues $ 15,112,864 $ 13,619,538 $ 45,897,865 $ 41,280,234 Â Gross outpatient revenues 8,841,452 7,739,413 26,386,711 23,104,716 Â Total net revenues 3,963,027 3,562,774 11,714,213 10,578,430 Â Income/(loss) before allocation of corporate overhead and income taxes 341,533 220,507 1,059,625 659,303 Â Allocation of corporate overhead 0 0 0 0 Â Income before income taxes 341,533 220,507 1,059,625 659,303 Â Total assets 14,353,848 13,873,470 14,353,848 13,873,470 $ 13,967,602 Acute Care Hospital Services Â Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Â Gross inpatient revenues 12,277,563 10,916,060 37,522,395 33,278,396 Â Gross outpatient revenues 8,573,270 7,480,353 25,553,451 22,292,249 Â Total net revenues 2,245,517 2,017,288 6,604,007 5,993,899 Â Income/(loss) before allocation of corporate overhead and income taxes 199,316 132,406 616,503 396,229 Â Allocation of corporate overhead (64,883) (66,355) (194,616) (199,943) Â Income before income taxes 134,433 66,051 421,887 196,286 Â Total assets 6,481,922 6,252,434 6,481,922 6,252,434 Â Behavioral Health Services Â Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Â Gross inpatient revenues [1] 2,835,301 2,703,478 8,375,470 8,001,838 Â Gross outpatient revenues [1] 268,182 259,060 833,260 812,467 Â Total net revenues [1] 1,714,914 1,542,695 5,102,290 4,575,378 Â Income/(loss) before allocation of corporate overhead and income taxes [1] 318,864 262,168 999,282 792,217 Â Allocation of corporate overhead [1] (46,898) (46,677) (140,808) (139,998) Â Income before income taxes [1] 271,966 215,491 858,474 652,219 Â Total assets [1] 7,631,827 7,372,995 7,631,827 7,372,995 Â Other Â Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Â Total net revenues 2,596 2,791 7,916 9,153 Â Income/(loss) before allocation of corporate overhead and income taxes (176,647) (174,067) (556,160) (529,143) Â Allocation of corporate overhead 111,781 113,032 335,424 339,941 Â Income before income taxes (64,866) (61,035) (220,736) (189,202) Â Total assets $ 240,099 $ 248,041 $ 240,099 $ 248,041 Â [1] Includes net revenues generated from our behavioral health care facilities located in the U.K. amounting to approximately $230 million and $203 million for the three-month periods ended September 30, 2024 and 2023, respectively, and approximately $651 million and $561 million for the nine-month periods ended September 30, 2024 and 2023, respectively. Total assets at our U.K. behavioral health care facilities were approximately $1.442 billion and $1.260 billion as of September 30, 2024 and 2023, respectively. X - DefinitionGross inpatient revenues. + ReferencesNo definition available. + Details Name: uhs_GrossInpatientRevenues Namespace Prefix: uhs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionGross outpatient revenues. + ReferencesNo definition available. + Details Name: uhs_GrossOutpatientRevenues Namespace Prefix: uhs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIncome (loss) from continuing operations before allocation of corporate overhead and income taxes extraordinary items noncontrolling interest. + ReferencesNo definition available. + Details Name: uhs_IncomeLossFromContinuingOperationsBeforeAllocationOfCorporateOverheadAndIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: uhs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCosts and expenses incurred associated with centralized services and general corporate overhead allocated to divisions. + ReferencesNo definition available. + Details Name: uhs_OverheadAllocationsAdjustment Namespace Prefix: uhs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9:

http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingInformationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementBusinessSegmentsAxis=uhs_AcuteCareHospitalServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=uhs_BehavioralHealthServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Segment Reporting (Parenthetical) (Detail) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Segment Reporting Information [Line Items] Â Â Â Â Â Net revenues $ 3,963,027 $ 3,562,774 $ 11,714,213 $ 10,578,430 Â Total assets 14,353,848 13,873,470 14,353,848 13,873,470 $ 13,967,602 Behavioral Health Services Â Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Â Net revenues [1] 1,714,914 1,542,695 5,102,290 4,575,378 Â Total assets [1] 7,631,827 7,372,995 7,631,827 7,372,995 Â Behavioral Health Services | Located in U.K. Â Â Â Â Â Segment Reporting Information [Line Items] Â Â Â Â Â Net revenues 230,000 203,000 651,000 561,000 Â Total assets $ 1,442,000 $ 1,260,000 $ 1,442,000 $ 1,260,000 Â [1] Includes net revenues generated from our behavioral health care facilities located in the U.K. amounting to approximately $230 million and $203 million for the three-month periods ended September 30, 2024 and 2023, respectively, and approximately $651 million and $561 million for the nine-month periods ended September 30, 2024 and 2023, respectively. Total assets at our U.K. behavioral health care facilities were approximately $1.442 billion and $1.260 billion as of September 30, 2024 and 2023, respectively. X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingInformationLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementBusinessSegmentsAxis=uhs_BehavioralHealthServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_GB Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Computation of Basic and Diluted Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Basic and Diluted: Â Â Â Â Net Income (Loss) $ 258,714 $ 166,989 $ 809,700 $ 501,417 Less: Net income attributable to unvested restricted share grants Â (52) (50) (242) Net income attributable to UHS - basic 258,714 166,937 809,650 501,175 Net income attributable to UHS - diluted $ 258,714 $ 166,937 $ 809,650 $ 501,175 Weighted average number of common shares - basic 66,537 68,867 66,873 69,825 Net effect of dilutive stock options and grants based on the treasury stock method 1,571 757 1,297 825 Weighted average number of common shares and equivalents - diluted 68,108 69,624 68,170 70,650 Earnings per basic share attributable to UHS: $ 3.89 $ 2.42 $ 12.11 $ 7.18 Earnings per diluted share attributable to UHS: $ 3.80 $ 2.40 $ 11.88 $ 7.09 X - DefinitionNet income allocated to unvested restricted shares. + ReferencesNo definition available. + Details Name: uhs_NetIncomeAllocatedToUnvestedRestrictedShares Namespace Prefix: uhs_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -

Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SAB Topic 6.B) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 40 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-40 + Details Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -

Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 54 R46.htm IDEA: XBRL DOCUMENT v3.24.3 Earnings Per Share Data and Stock Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Anti-dilutive weighted average stock options excluded from computation of earnings per share 0 5,000,000 799,000 5,100,000 Compensation cost recognized Â Â $ 72,727 $ 65,702 2020 Stock Incentive Plan Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Stock options granted during period Â Â 3,000 Â Weighted-average grant date fair value, per option Â Â $ 44.58 Â Employee Stock Option Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Compensation cost recognized, pre-tax charge $ 13,400 $ 16,200 $ 41,000 48,300 Restricted Stock Awards, Restricted Stock Units and Performance Based Restricted Stock Units Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Compensation cost recognized, pre-tax charge 12,900 $ 6,100 $ 30,700 $ 16,400 Unrecognized compensation cost vesting period Â Â 2 years 6 months Â Unvested Stock option Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Unrecognized compensation cost related to unvested options and restricted stock $ 177,900 Â $ 177,900 Â Restricted Stock | 2020 Stock Incentive Plan Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Restricted shares and restricted units, net of cancellations, granted during period Â Â 501,290 Â Weighted-average grant date fair value, per share Â Â $ 181.05 Â Performance Based Restricted Stock Units | 2020 Stock Incentive Plan Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Restricted shares and restricted units, net of cancellations, granted during period Â Â 63,362 Â X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNet number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=uhs_TwoThousandTwentyStockIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=uhs_RestrictedStockAwardsRestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=uhs_UnvestedStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=uhs_PerformanceBasedRestrictedStockUnitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R47.htm IDEA: XBRL DOCUMENT v3.24.3 Dispositions and Acquisitions - Additional Information (Detail) - USD ($) $ in Millions 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Business Acquisition [Line Items] Â Â Acquisition, cash paid Â $ 4 Aggregate cash proceeds from divestiture of businesses $ 30 $ 24 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5 + Details Name: us-gaap_BusinessAcquisitionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireBusinessesGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThis element represents the cash inflow during the period from the sale of a component of the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 56 R48.htm IDEA: XBRL DOCUMENT v3.24.3 Dividends - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dividends [Abstract] Â Â Â Â Dividends declared and paid $ 13.3 $ 13.8 $ 40.3 $ 42.2 Dividends declared and paid, per share $ 0.2 $ 0.2 $ 0.6 $ 0.6 X - DefinitionAggregate dividends paid during the period for each share of common stock outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_CommonStockDividendsPerShareCashPaid Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DividendsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of paid and unpaid common stock dividends declared with the form of settlement in cash. +

ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_DividendsCommonStockCash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 57 R49.htm IDEA: XBRL DOCUMENT v3.24.3 Income Taxes - Additional Information (Detail) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Jan. 01, 2024 Income Taxes [Line Items] Â Â Â Â Â Effective income tax rate 22.10% 23.80% 22.00% 24.20% Â Decrease in provision for income taxes $ 4 Â $ 16 Â Â Unrecognized tax benefits Â Â Â Â $ 2 Impact of unrecognized tax benefits if recognized Â Â Â Â $ 2 Period of expiration of the statute of limitations for certain jurisdictions Â Â expire within the next twelve months Â Â Jurisdictions statutes of limitations expiration period Â Â 12 months Â Â Maximum Â Â Â Â Â Income Taxes [Line Items] Â Â Â Â Â Accrued interest and penalties $ 1 Â $ 1 Â Â Foreign and U.S. state and local jurisdictions have statutes of limitations, in years Â Â 4 years Â Â Minimum Â Â Â Â Â Income Taxes [Line Items] Â Â Â Â Â Foreign and U.S. state and local jurisdictions have statutes of limitations, in years Â Â 3 years Â Â X - DefinitionDecrease in provision for income tax. + ReferencesNo definition available. + Details Name: uhs_DecreaseInProvisionForIncomeTax Namespace Prefix: uhs_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionForeign and U.S. state and local jurisdictions statutes of limitations. + ReferencesNo definition available. + Details Name: uhs_ForeignAndUnitedStatesAndLocalJurisdictionsStatutesOfLimitations Namespace Prefix: uhs_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionIncome taxes. + ReferencesNo definition available. + Details Name: uhs_IncomeTaxesLineItems Namespace Prefix: uhs_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionJurisdictions statutes of limitations expiration period. + ReferencesNo definition available. + Details Name: uhs_JurisdictionsStatutesOfLimitationsExpirationPeriod Namespace Prefix: uhs_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionStatute of limitations for certain jurisdictions. + ReferencesNo definition available. + Details Name: uhs_StatuteOfLimitationsOnCertainJurisdictions Namespace Prefix: uhs_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPercentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231 + Details Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15 + Details Name: us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of unrecognized tax benefits. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 217 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B + Details Name: us-gaap_UnrecognizedTaxBenefits Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 217 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A + Details Name: us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R50.htm IDEA: XBRL DOCUMENT v3.24.3 Schedule of Disaggregates Revenue by Major Source (Detail) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Disaggregation Of Revenue [Line Items] Â Â Â Â Net revenues $ 3,963,027 $ 3,562,774 $ 11,714,213 $ 10,578,430 Percentage of Net Revenue 100.00% 100.00% 100.00% 100.00% Medicare Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Net revenues $ 403,614 $ 379,810 $ 1,243,925 $ 1,195,570 Percentage of Net Revenue 10.00% 11.00% 11.00% 11.00% Managed Medicare Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Net revenues $ 469,714 $ 419,580 $ 1,411,881 $ 1,269,275 Percentage of Net Revenue 12.00% 12.00% 12.00% 12.00% Medicaid Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Net revenues $ 559,359 $ 405,302 $ 1,575,552 $ 1,071,634 Percentage of Net Revenue 14.00% 11.00% 13.00% 10.00% Managed Medicaid Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Net revenues $ 577,325 $ 569,026 $ 1,728,989 $ 1,729,488 Percentage of Net Revenue 15.00% 16.00% 15.00% 16.00% Managed Care (HMO and PPOs) Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Net revenues $ 1,126,018 $ 1,034,962 $ 3,356,173 $ 3,169,930 Percentage of Net Revenue 28.00% 29.00% 29.00% 30.00% UK Revenue Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Net revenues $ 230,153 $ 202,994 $ 650,655 $ 560,897 Percentage of Net Revenue 6.00% 6.00% 6.00% 5.00% Other Patient Revenue and Adjustments, Net Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Net revenues $ 273,011 $ 238,168 $ 824,770 $ 691,250 Percentage of Net Revenue 7.00% 7.00% 7.00% 7.00% Other Non-patient Revenue Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Net revenues $ 323,833 $ 312,932 $ 922,268 $ 890,386 Percentage of Net Revenue 8.00% 9.00% 8.00% 8.00% Acute Care Hospital Services Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Net revenues $ 2,245,517 $ 2,017,288 $ 6,604,007 $ 5,993,899 Percentage of Net Revenue 100.00% 100.00% 100.00% 100.00% Acute Care Hospital Services | Medicare Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Net revenues $ 322,466 $ 298,121 $ 1,009,630 $ 961,640 Percentage of Net Revenue 14.00% 15.00% 15.00% 16.00% Acute Care Hospital Services | Managed Medicare Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Net revenues $ 361,804 $ 324,486 $ 1,104,493 $ 1,013,493 Percentage of Net Revenue 16.00% 16.00% 17.00% 17.00% Acute Care Hospital Services | Medicaid Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Net revenues $ 296,966 $ 201,148 $ 771,298 $ 445,678 Percentage of Net Revenue 13.00% 10.00% 12.00% 7.00% Acute Care Hospital Services | Managed Medicaid Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Net revenues $ 154,762 $ 181,051 $ 466,881 $ 545,173 Percentage of Net Revenue 7.00% 9.00% 7.00% 9.00% Acute Care Hospital Services | Managed Care (HMO and PPOs) Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Net revenues $ 725,014 $ 651,816 $ 2,129,117 $ 2,009,110 Percentage of Net Revenue 32.00% 32.00% 32.00% 34.00% Acute Care Hospital Services | UK Revenue Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Net revenues $ 0 $ 0 $ 0 $ 0 Percentage of Net Revenue 0.00% 0.00% 0.00% 0.00% Acute Care Hospital Services | Other Patient Revenue and Adjustments, Net Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Net revenues $ 117,679 $ 108,676 $ 375,161 $ 303,923 Percentage of Net Revenue 5.00% 5.00% 6.00% 5.00% Acute Care Hospital Services | Other Non-patient Revenue Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Net revenues $ 266,826 $ 251,990 $ 747,427 $ 714,882 Percentage of Net Revenue 12.00% 12.00% 11.00% 12.00% Behavioral Health Services Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Net revenues [1] $ 1,714,914 $ 1,542,695 $ 5,102,290 $ 4,575,378 Percentage of Net Revenue 100.00% 100.00% 100.00% 100.00% Behavioral Health Services | Medicare Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Net revenues $ 81,148 $ 81,689 $ 234,295 $ 233,930 Percentage of Net Revenue 5.00% 5.00% 5.00% 5.00% Behavioral Health Services | Managed Medicare Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Net revenues $ 107,910 $ 95,094 $ 307,388 $ 255,782 Percentage of Net Revenue 6.00% 6.00% 6.00% 6.00% Behavioral Health Services | Medicaid Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Net revenues $ 262,393 $ 204,154 $ 804,254 $ 625,956 Percentage of Net Revenue 15.00% 13.00% 16.00% 14.00% Behavioral Health Services | Managed Medicaid Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Net revenues $ 422,563 $ 387,975 $ 1,262,108 $ 1,184,315 Percentage of Net Revenue 25.00% 25.00% 25.00% 26.00% Behavioral Health Services | Managed Care (HMO and PPOs) Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Net revenues $ 401,004 $ 383,146 $ 1,227,056 $ 1,160,820 Percentage of Net Revenue 23.00% 25.00% 24.00% 25.00% Behavioral Health Services | UK Revenue Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Net revenues $ 230,153 $ 202,994 $ 650,655 $ 560,897 Percentage of Net Revenue 13.00% 13.00% 13.00% 12.00% Behavioral Health Services | Other Patient Revenue and Adjustments, Net Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Net revenues $ 155,332 $ 129,492 $ 449,609 $ 387,327 Percentage of Net Revenue 9.00% 8.00% 9.00% 8.00% Behavioral Health Services | Other Non-patient Revenue Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Net revenues $ 54,411 $ 58,151 $ 166,925 $ 166,351 Percentage of Net Revenue 3.00% 4.00% 3.00% 4.00% Other Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Net revenues $ 2,596 $ 2,791 $ 7,916 $ 9,153 Other | Other Non-patient Revenue Â Â Â Â Disaggregation Of Revenue [Line Items] Â Â Â Â Net revenues $ 2,596 $ 2,791 $ 7,916 $ 9,153 [1] Includes net revenues generated from our behavioral health care facilities located in the U.K. amounting to approximately $230 million and $203 million for the three-month periods ended September 30, 2024 and 2023, respectively, and approximately $651 million and $561 million for the nine-month periods ended September 30, 2024 and 2023, respectively. Total assets at our U.K. behavioral health care facilities were approximately $1.442 billion and $1.260 billion as of September 30, 2024 and 2023, respectively. X - DefinitionRevenue from contract with customer excluding assessed tax percentage. + ReferencesNo definition available. + Details Name: uhs_RevenueFromContractWithCustomerExcludingAssessedTaxPercentage Namespace Prefix: uhs_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ProductOrServiceAxis=uhs_MedicareMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=uhs_ManagedMedicareMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=uhs_MedicaidMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=uhs_ManagedMedicaidMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=uhs_ManagedCareMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=uhs_UKRevenueMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=uhs_OtherPatientRevenueAndAdjustmentsNetMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=uhs_OtherNonPatientRevenueMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=uhs_AcuteCareHospitalServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=uhs_BehavioralHealthServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R51.htm IDEA: XBRL DOCUMENT v3.24.3 Lease Accounting - Additional Information (Detail) 9 Months Ended Sep. 30, 2024 Hospital Lessee Lease Description [Line Items] Â Lessee, operating lease, existence of option to extend [true false] true Number of hospital facilities 5 Two Hospital Facilities Â Lessee Lease Description [Line Items] Â Lease expiration term 2026 Another Two Hospital Facilities Â Lessee Lease Description [Line Items] Â Lease expiration term 2033 One Hospital Facility Â Lessee Lease Description [Line Items] Â Lease expiration term 2040 Minimum Â Lessee Lease Description [Line Items] Â Initial term of real estate lease 5 years Real estate leases option to extend lease term 5 years Maximum Â Lessee Lease Description [Line Items] Â Initial term of real estate lease 10 years Real estate leases option to extend lease term 10 years X - DefinitionLease expiration term. + ReferencesNo definition available. + Details Name: uhs_LeaseExpirationTerm Namespace Prefix: uhs_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionNumber of hospital facilities. + ReferencesNo definition available. + Details Name: uhs_NumberOfHospitalFacilities Namespace Prefix: uhs_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included

in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeLeaseDescriptionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionIndicates (true false) whether lessee has option to extend operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend Namespace Prefix: us-gaap_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionTerm of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseRenewalTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionTerm of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=uhs_TwoHospitalFacilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=uhs_AnotherTwoHospitalFacilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=uhs_OneHospitalFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R52.htm IDEA: XBRL DOCUMENT v3.24.3 Supplemental Cash Flow Information Related to Leases (Detail) - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Cash paid for amounts included in the measurement of lease liabilities: Â Â Operating cash flows from operating leases $ 99,526 $ 96,922 Operating cash flows from finance leases 2,756 2,890 Financing cash flows from finance leases 3,167 2,910 Right-of-use assets obtained in exchange for lease obligations: Â Â Operating leases 50,696 50,940 Finance leases $ 8,441 $ 452 X - DefinitionCash paid for amounts included in measurement of lease liabilities. + ReferencesNo definition available. + Details Name: uhs_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract Namespace Prefix: uhs_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionRight of use assets obtained in exchange for lease obligations. + ReferencesNo definition available. + Details Name: uhs_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract Namespace Prefix: uhs_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of interest paid on finance lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5 + Details Name: us-gaap_FinanceLeaseInterestPaymentOnLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for principal payment on finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5 + Details Name: us-gaap_FinanceLeasePrincipalPayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for finance lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase in right-of-use asset obtained in exchange for operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: duration EXCEL 61 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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{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s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ÖTW(*+7R)G@&O4KU7NJ(7)J..-^FB4WY0+B @F3>$ M!53L(DA820?C3H VKJ,NIQ&G1=O2VC #Q7XG?4Y['^+!R(<&>X>F7%DH%I<;MUSP:TPOUL(!#8>NMD+XH5KY@5L4 +>>!)3U90D8+D$)D(/C M 8CZ[@%@]R-M1[YX6%VI7@,B(>IST11"6Y"&T1$P"S[-155K7!3BK9T&T2' M-F4H'V,[@<44:T'#>+@+FA;JZLM'RW.4$660K512Y@3?&2M*%3EY6^+0I9/V M/=)V8!G#Q("V?Q0@ZR^3F'.I80T)O(#("%RMMBCM(,0X-F)>E-*O4Q4 M\XCD-$WIR']VHI_LY+FTGR11YDFE&8=>;(=V=8&V!]@ @RU'KMC"%&D7MKT' M&:2;'$C:$@>;&W427*V&!UBVA@TL=1T1FLLQ;;Y=NW'D5[P"S"YI0N0J^D]4 M>@3BQ3YI^-']/L$"I#]R.XE?7,GI(K?-U6'/ ^KSBG'T(0BX?3A;\%#P8CMJ)!"^?';D.B!H,WU--G U '$*9\6-&6G^0*+KS9PTI?*<#%)1J2Z0"8D<;B3O;:H"\, D+:GA(UNHDJ6U4\ MJ<(2=]5H"C;E$Y8W)1_YSUND-OU$&G^OXS%MLQ!,FIB+D8E7I.=-&AF.TJ5&(=J2IE-!0TSWG;9QIUN8N/C.V@1O MG.1 W5)*3(A>"6:1[0++ TVQ!6TAUD3W1^GSP\A#>TB_)W^S983P+U4Y$+1= M,*4;_]4:%0H+31"O!+H D5G4/443"P.455U!84 _:BP%&33NI I*X+2K3@6AP<\TX]'EK MJ_4< PX"@"TK/Q;ZL%-%.?(,1\CR>]#%R&A()X,:M#C9IYEAB'8-V<"1LP$2 ML21AO1%XDJ9H:O9? + EL1QEQ*\PCXI*86W3/*58&'SCZ[(7//V$TTG(?49[MK'-6*"6^F?1SIIZ7:_8X*$Z&/>78E/-!F@87!4#90V1E9,)H#_%"6_U#4CR^ M]QNY3PAHMT<0= =1V.I-D"9,]2A9#>(+:K0,H4+P]F>BZ#'LU3%1JG&&$!0' M8M&1DNPWZUL+3%SHL'T01-5&X\"ETZ(A205R"O!?K\T5 [\S'1.;VQKS3-P! M)67&G+V-DG(D/*O%X:@?V-H$[W;D.Y5R2IKZ/; M)@^-W"MD*3@53P'!7\/ A"*/X@9RU4*A\RMG6JH] M/)>YFO#)]:XW$N\K 0. BSRXGEW-LA_<[!D=Z=')Y=/31V^>>3@\P*>7'KRZJ4 M^?@%W]$2(0L!"FI0P_D4/^Q/.XE;2(9(&+.Q$RB-N,^3LGSMW9.GDUL)@BU M9:0L$(6)XWK6)"3%,P;78H\9C'POP$ O*(I:JU)P,N!KL+*E3B,-#"E[?X- DM.!8MSG_9,6H]RU((4#3W)BBG]B2]56";(BK'W-K2M) [UFX0DS91S"@EIJ,#A'ST<":=]!?I?,#Z\8*MQ4ZUI5[7C0^(S21DRZ MDB>C:W+]O[28,9,.1W8NN&%M0B<$5R'.Y"5V_@T2D&X\" _;_6NHM$-L= MO7E]??20O99;O(EP)WVA$9H.8HOJ$\4VMQ0P<=UH1SW%L(O&A$B0THE20-16 MH*XC>'P4JJ4A)*6UW1I-_%D7[*:C9:Z\344XP"UDE"L/QL>)47T8&^35*>@! M#?B[JRA04$4"CNQ&G+?HBO&6DI3%$\EB)LP5<%+M2FB;*@%PB-JD7L[LG^\N M:Y5\>,X4BKEJN=A9L4$OKI7"D'PX@/6=:NLBA4";=HC>RVY,2TN-6J9))V:TX4\9*=8M'U,#J3(CC)9+WL $V"7 M"';0PA0>#+FMDG+_HYS[(K'#THT6XJYW(3/$92&3]N9E'-P%W0/N255OR9I4M87Z%>XQ*22;J$@4LC8,DK.Z!LK!6^#0/#7::+5I4OI#[LL+N+U[\6S@K$/"T M\#56%X/)U%4R'#;+WE0A3M*2[8?1>,0NK*("B34O'RLMU*ZJ-%EHF0L>12P, M@FS\[]\81G6;Q7\22^SOA,_HHCYK(#N+T4. ^A!-9BY8S2(0L!"CR>]#%R&A()X,:M#C9IYEAB'8-V<"1LP$2 ML21AO1%XDJ9H:O9? + EL1QEQ*\PCXI*86W3/*58&'SCZ[(7//V$TTG(?49[MK'-6*"6^F?1SIIZ7: 8X*$Z&/>78E/-!F@87!4#90V1E9,)H# %"6 U#4CR^ M]QNY3PAHMT<0= =1V.I-D"9,]2A9#>(+:K0,H4+P]F>BZ#'LU3%1JG&&$!0' M8M&1DNPWZUL+3%SHL'T01-5&X\"ETZ(A205R"O!?K\T5 [\S'1.;VQKS3-P! M)67&G+V-DG(D/*O%X:@?V-H$[W;D.Y5R2IKZ/; M)@^-W"MD*3@53P'!7\/ A"*/X@9RU4*A\RMG6JH] M/)>YFO#)]:XW$N\K 0. BSRXGEW-LA_<[!D=Z=')Y=/31V^>>3@\P*>7'KRZJ4 M^?@%W]$2(0L!"FI0P_D4/^Q/.XE;2(9(&+.Q$RB-N,^3LGSMW9.GDUL)@BU M9:0L$(6)XWK6)"3%,P;78H\9C'POP$ O*(I:JU)P,N!KL+*E3B,-#"E[?X- DM.!8MSG_9,6H]RU((4#3W)BBG]B2]56";(BK'W-K2M) [UFX0DS91S"@EIJ,#A'ST<":=]!?I?,#Z\8*MQ4ZUI5[7C0^(S21DRZ MDB>C:W+]O[28,9,.1W8NN&%M0B<$5R'.Y"5V_@T2D&X\" _;_6NHM$-L= MO7E]??20O99;O(EP)WVA$9H.8HOJ$\4VMQ0P<=UH1SW%L(O&A$B0THE20-16 MH*XC>'P4JJ4A)*6UW1I-_%D7[*:C9:Z\344XP"UDE"L/QL>)47T8&^35*>@! M#?B[JRA04$4"CNQ&G+?HBO&6DI3%$\EB)LP5<%+M2FB;*@%PB-JD7L[LG^\N M:Y5\>,X4BKEJN=A9L4$OKI7"D'PX@/6=:NLBA4";=HC>RVY,2TN-6J9))V:TX4\9*=8M'U,#J3(CC)9+WL $V"7 M"';0PA0>#+FMDG+_HYS[(K'#THT6XJYW(3/$92&3]N9E'-P%W0/N255OR9I4M87Z%>XQ*22;J$@4LC8,DK.Z!LK!6^#0/#7::+5I4OI#[LL+N+U[\6S@K$/"T M\#56%X/)U%4R'#;+WE0A3M*2[8?1>,0NK*("B34O'RLMU*ZJ-%EHF0L>12P, M@FS\[]\81G6;Q7\22^SOA,_HHCYK(#N+T4. ^A!-9BY8S2(0L!"CR>]#%R&A()X,:M#C9IYEAB'8-V<"1LP$2 ML21AO1%XDJ9H:O9? + EL1QEQ*\PCXI*86W3/*58&'SCZ[(7//V$TTG(?49[MK'-6*"6^F?1SIIZ7:_8X*$Z&/>78E/-!F@87!4#90V1E9,)H#_%"6_

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c#AS(]")[@B M'[.9* [IF[?O'*;OW[^SSU@A,A[!>2+(113S"%D+2@/%BAS2/B9*./G][,+ M;(0_2!/0QED2<@XW*/')NY-LI)"R^031=L3E[M4MC@N>%Y6#-,XRGB^-BMP5 M"2+'5%=P1]2\[5+D.2]%[K!D0"*%A4N&9U6.BA)>)@FCY%UGV3\0<:KA>^P2 M:<:SN$!_(M?2F#J#3J7S2O"$WB ?$7;.Q",6_U]X1UVH>)Y$G@/((TFYJ+) MO1B9(R=J;WR*?.A%G&MPA8%'!:E1Y*$)>+;"(O MSPK E G7Z+L43*D)I6L5)0;NQE'I20@\19I^)T\XU43%!EG,=^2%.@'U6.BJ7 B!71(U0L MTH*G1)"8L@T'U/4X%B M;]+Q?]'!Y" Q$'QG$'*25(*!@ M[(${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`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|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øEH5L\D721@SŸ9--DH(D50#(NUTS1O(O82L&9 M4:!_8K:3 MNOBQ AX;>"[!8D=@+2('#9&#-SK(Y=\N@2+'8&U^!PV? Z__2"WS_%B'[-9 M%;/F3"\M,6O5=2S'PZ\31/ B0<2.%+:H.V^H.[=2=R4E%M?W&Y%D6#V:NF9. MD;JKE0#^E:1+V2^64B6,BH8=%8:5@W'$N82+'8$UF+VHF'VXHT.^85+/EV" MQ8[6GR&P;Y4#ZRQ.J4RPUXK 2R/4X+E-}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{YC*G#9: 3Z#7U*4Z+O%>R*5MU -Z< MO8] 8I)_0.\0H>@N8VNAD&+L2E4G'9F;U/'/JOB#5^+OH: ^,RDR@.4TA[?"/ MS/[G!G]7Y;)):/"TS-@HC=$ M@V:=F9K;B2@V8R)(%,8W85IY[S4-N5=R>Z:&W-4.T=]?E"FZDE"(?[H:6,7M M=W/UR'XA5CB!:.&;@%|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

HDY),:2F$=B/HD%,,]$[9=^LFQ(8A&)21+22R!L,:E__+Y MTG_9W7HJ[LW\NTV_*.)N46;K(E&6A,*LL-BN$Q?Z287UO5%8N_M>Z#W5<8G2>*

MQ;&)06(JB6DDII.806(FB5F7+_X,==!ZH,+-)[@Z)N23FD9A/8@&)"1(+22PB.M,4EB,8DE$-(G:OGV+GJO^)8]YW*;)8NJX3YG,VSVWS9FB&=Y!+$90F(JB6E7 M+_[-[?

RJ==%!5C7Z5C7]JA:)V23FD)A+8AZ)^206M/P.G;>UWTN_Y0^KA[TWL?9=#59YI]G6=MEOU,[!K)/8B]) M:=M4GBQH]BYID48O$,!)S2,PE,8_$?!(+2$R06$AB$8E)$HM)+!(&P M1C*

,SIZ38,W=Z8WWI_=R85MB>^2DGV[3U>+9>L.CT_=\K$Q@&NJ7TZ,K=': M,7[&]UK]*YKHG4M5+-1S4$U%]4\)5/-1+4 U@6HAJD6H)E$M1K6$TIK9L,>/

*M<=#]3L9_[R;+7AG3>09'9PRIJ:BF;,7]:_TK=\NB=8W>=4VTKH5]-JHYJ.:B MFH=[/JH%]"90+42U"-4DJL6HEE!,V.&=<8,.S-&S1?+,!\L%3V=K_QKE*E M-2U_-4$JH6H%]&:.1+48 MU1)*:^9-O2=]<*)-Z0-T5S]JJ.BFH9J.:@ZJN:CFH9J/:@&J M"50+42U"-8EJ,:HEE-9,I'JG^GJ(6U>7K2S^,S99WZF5WMV5V5VZ7+]]-R6; M%8_KF]DU*285\NDU=/ Q$FQ:-TZV%WGZ$0B-*

*175M*VVW],:CZ[,FVED8;-_M81,M,*&:C6H.JKFHYJ$:&:CVH!]@E4'U%8&MC0:C&J)936S))Z,_]@>S-Z'E9N M*/E\L_FN(=7K??:(86-OH7-M'"%JK0]:-@HJ!V#]:@FD"U$ 4B5).H%]-.0FG-*

FWK0^ZJZV[FQV+_^3Q?KM_+7V9E^]F#;N7H MI$#WJZ:JL,/Z_)<^9ZE9=L/24=/Q/CQ$S'1$[%0S48U!]5<5/-0S?_Q7X<-M/1&!:B&J1:@F42U&M832FK%1;WD?=.]Y?

WI79?.VRG[I>_;M,9NW+S'07>NH-MI]:AFHZJAF#E@WBP_9%"+HO'=5L5'-0S44U#]5\5 M03:!:B&H1]DE4BU$#MH,1FFM0[V0?=6]GK=T0FS^_6,S-E/9 W+]JC!=W,CFH]JFFHIJ.:\<9+.QAV*

*M+9%_^^%_+_1YL5'-0S44U#]5\5 M03:!:B&H1]DE4BU$#MH,1FL3,Y ?=^^35 M[##$MO-EBR*G(C%U4*U9%4 M\U#-1[4_U02]A:@6H9J$M1C5$DIK?*

*G1AO0M_^+13\Z??=3Q$}^2CFHIJ&JKI MJ&:@FHEJ%JK9J..@FHMJ'JKYJ!:@FD"U$ 4B5).H%J`.0FG-1*KW]e^[]_9' MU5+H^VXE-,ONTIFRR);+6?*

9T]JC3UOUBKDRS:I'4VF_K+G!T%%,]U%_0S4= MU8RMMQ6JSKCUC1RTK(5]4UU#]5\5 M03:!:B&H1]DE4BU$#MH:1FD SK(.D>2/_# MG;<-(]RZ[QX=+MB6+*

U334$U'-0/53%2S4,U&-0?57%3S4,U'M0#5!*[%]!:A MFD]U&-422FOF4ST*83PZ4>L-G8>-.B]!:.BH5!:B,J6:AFHYJ#:BZ]>:CFHUJ .@+50E2+4$VB6HQ]":4U$ZF>$3!\8T.

*TZI'2;^FY;1]3O)6:.P,>MDZO/>FNlC10?*R M$7K9SEj:%T=U0Q4,U'-0C4,U1Q4)HFVAA:)%)344U#-1W5#%0S M4=VT@-_^9GFT MGI3Y,$OS*HUN;O?K6PN>_|":/NBP@:VVO[UQ?-*

D4]&&JKI]&-:@FHEJ%JK9 MJ-:@FHMJ'JKYJ!:@FD"U$ 4B5).H%]:.0FG-3*E"(RZ1P@=-H!]&KJ[]&:@FHEJ%JK9J..@FHMJ'JKYJ!:@FD"U$ 4B5).H%]`.0FG-*

*MC*IG%HPN3]2)0X<5H)]*:AJJZ:AFH)]).A:JV:CFH)]+:.AZ]^:@6H)I M1#5 M(E23]!:C6D)IS42]AQ6,NC^!OL_M;.@8@]WV]GV:%.VKH9J..@:JF:AFH9J_M:@ZJN:CFH9J/:@&]"50+42U"-8EJ,:HEE-*

,:D7K$P*A[Q_/=__B,OL\RZ:=_MC3=R@^?T.IJFHIJ&:CFH&JIFH9J&:C6H.JKFHYJ&:CVH!]@E4"U$M0C6):C&J M)936B=Q/=@?":.QML8G6R-.BJI:.BFHYJ!:B,J6:AFHYJ#:BZ]>:CFHUJ*

M:@+50E2+4$VB6HQ]":4U$ZF>;##NW?:1 `6+1R=-8.7-[P-KMH![:VAA#=5T-M5# 0S44U#]5\5 M03:!:B&H1]DE4BU$#MH:1FD SK(.D>2/_# MG;<-(]RZ[QX=+MB6+*

U334$U'-0/53%2S4,U&-0?57%3S4,U'M0#5!*[%]!:A MFD2U&-422FOF4ST*83PZ4>L-G8>-.B]!:.BH5!:B,J6:AFHYJ#:BZ]>:CF MHUJ .@+50E2+4$VB6HQ]":4U$ZF>$A U]_-.^VWCJ%H[-

F_.>MU<&P[FH80W5 M=%0S4,U$-0O5,%1S4,U%-0_5?%0+4$V@6HA]$:I)5(M1+:&T9I#48PS&W6,,.MH^VGOQS>"]=\K((KU:1#1R*@FHI]&JKI]&:.@FHE]%JK9J..@FHMJ'JKYJ!:@*

*MFD"U$-4B5).H%]`.0FG-)*N')XPO3M2D0T^.MB(N&5Z(2Y2"'' MW.BP78?..D U"=4.5# 1S4(U&]4<5'-1S4,U']4"5!.H%J):A&H2U6)42RBM4%U+(7QI8F:<>CX!%13 M44U#-1W5#%0S4:[B./C1=4TU!-.M1S4#U4O4LU#-1C4'U5O4\U#-1[4*

U02]A:@6H9I$M1C5$DIKQDL]"^&\>O;" MO_)]E2.71?G0VECK/OK890RIJ.BFH9J:.@:JF:AFH9J-.@ZJN:CFH9J/:@&J M"50+42U"-8EJ,:HEE-,F6&=,\/3-,:T>$(]:BFH9J.JH9J&:BFH5]-JHY*

MJ:.BFH=]/JH%]"90+42U" 4DJL6HEE!:,Y!X0CCG5M=-XF4E9,\G2F/9?&8 MEN9]/E&]L%TWXK0??7H M?$')':,"M:7PD;.PB9:V$(U&]4<5'-1S4,U'!4"5!.H%]).

*MA&HJ2U6)42RBME2SUD(/]85>R:&FYO/!KE?Z9K7>=IKAMBCG>?]+XF=2%2^= MEOE4D5F^>*B"Y+-^*>?.+(M))?EO]R2^)(/]FB^7!WW^:9'IQ&]J:BFH9J..@:JF:AFH9J-.@ZJN:CF*

MH9J/:@&]"50+42U"-8EJ,:HEE.,M'K>POGYB?IWZ-P$5% 134,U'=4.5# 1 MS4(U&]4<5'-1S4,U'!4"5!.H%J):A&H2U6)42RBMF4CUW(3SSEVP/ZU_ATY1

M0#45U;2MMM]&>ZU]ATY(Z%W71.M;]&:CFH-J+JIYJ:.C6H!] M5"5(M03:).MC&H)I35SI9Y^<-X]_6"O>[>Y.'1D)]:AJJZ:AFH)]):A;JV:CFH)]+:.AZ]^:@6H)I*

M1#5(E23]!:C6D)IS>BIIR2<7?VHR8;.M0T U%=4T5-.1S4 U$]4L5+-1S4$U%]4\5/-1+4 U@6HAJD6H)E$M1K6$TI])-M5.]#:.,[!:A98V^94VTK(5]JHYJ:.BFH=]/JH%]"90+42U"-4DJL6HEE!:

*M,R[]"007:TP@^'XWSY.[#SRX2:NEBIM72YKVS\7NQHX."W2P *IJ]*:CFH%]#)JI9J&:CFH-J+JIYJ:.C6H!] M5"5(M03:).C&H)I35CIQY/4#T\3=]LC"82*

*MJ:FH]&:CFH&JIFH9J&:C6H.JKFHYJ&:CVH!]@E4"U$M0C6):C&J)9363*1Z MN.!%YU.1+#^+E_LV_E;4 .;CO.3]W:T;F#CA! _0W5=%0S4,W<:,H/A7]MN<'[8*

MI[/0HC:J.:CFH]!':CZ]!:@F4"U$M0C5)*K%]!906C-0ZMD %]VS ;9OO+2& M!I]_']545_-034U_-4$]H6H%]&:.1+48U1):M:Y9./2?@XO)$;31T?`"I]:BFH9J..@:JF:AFH9J-.@ZJN:CFH9J/:@&]"50+*

*M42U"-8EJ,:HEE-9,I'\P$7C9M /,IQ=_G/30LNFRFU1KN>BW6:+15[,TZ<1-M-E4Z967U>):GG_-9OOS>FD?H\ !44U%-VVK[MX<-VB>@H76-WG5-M*Z%:C;]*

*M,:CFHIJ:CZ]!:@F4"U$M0C5)*K%]!906C-'ZDW_%]V:_L6JG-RGBRI$%MF7 M35YDWR05CM1#-9?W9:&ZNU5963\!*I9A.5E59+8K:,X!& MOP6@FHIJVL7+??O#5^-^Z*

*1N<%]*YKHG4M5+-1S4$U%]4\5/-1+4 U@6HAJD6H)E$M1K6$TAI1U-.4$]H6H%]&:.1+48U1)*:V9+/1_@LG.WYKPA4OEX[2898O)YC:.OQ6Q6L?:ETQ1TX?T M[I7%":,KK']545_-034U*

-4$]H6H%]&:.1+48 MU1):R95/3_@:CFHIJ/.:@+50E2+4$VB6HQI":4U-M3Z2>!W#9/0^@:L')U>=%]M>]6N(\?:)]:7X/E-$^B62Y<5<^93=5P^+]3UJ-MVS%]\ONB6N?T;*

*<6ADP10344U#=5T5=.0S40U"]5L5'-0S44U#]5\5 M03:!:.MB&H1]DE4BU$#MH,1F8M4#!RXO3M2*0\<3H)]*:AJJZ:AFH)]):A;JV:CFH)]+ M:AZ]^:@6H)I M1#5(E23]!:C6D)IS42]QQ-*

*<=FXVI=6*NWS1/!M?MFX,N>DN M=G20H%.%4$U'-0/53%2S4,U&-0?57%3S4,U'M0#5!*]%]!:AFD2U&-422FL&-M23U5X+)[]D#=C/M77]ULY+)X[49]=&X]FFHIJ&:CFH&JIFH9J&:C6H.JKFH*

MYJ&:CVH!]@E4"U$M0C6):C&J)9363)QZ_L#E]8F;:>AX 51344U#-1W5#%0S M4,W:\9S=&?;R@FHIJVE3:G.VU$L]^3L_&$: %G7Z%3741HA:JV:CFH)]+:.AZJ^2U>^@-M*E*

M1+4(U22]Q:B64%HS"}>JA E?=FY'K;IB6ELQ[OU;I MG^L/][GYZ%IZ$/G6Q]8@0$<,H)]:AJJZ:AFH)]):A;JV:CFH)]+:.AZ[^:@6 MH)I M1#5(E23]!:C6D)IS?09UNDS/$UG[*

*J=08!]*JIJ]*:CFH%]JI9J&:C MFH.J+JIYJ.:C6H!J M5"5(M03:).C&H)I343J9Y!<-6YH_1G#?#LKGIT/J$3 M"5!-VV]M8S0/VV?HN(''A4VTL(5]JHYJ.:BFH=]/JH%]"90+42U"-4DJL6H*

MEE!:.UGJ60+5PQ_HH.GI:E9ES'\5\RI6BELE\:U84Q49?XPUV1HEG66.CA)2 M4U%-0S4=U0Q4,U'-0C4,U1Q4V#.%)TW!1 _T+TVAA"!5L M5'-0S44U#]5\5 M03:!:.B&H1]DE4BU$#MH:1FLM33

ZZZIP>\TGP3B1;%@1)9 M-T%K<)#[7FL)0344U#=5T5#-0S40U"]5L5'-0S44U#]5\5 M03:!:B&H1]DE4 MBU$MH,1F_0S!ZZN3M1]0V<2H)]:AJJZ:AFH)]):A;JV:CFH)]+:.AZ]^:@6 MH)I*

*M1#5(E23]!:C6D)IS42]9Q)<=>XP_6FM-G1" ,JJ[*9MM?V.U_B53ALZ M?:\W71.M;Z&:C6H,]KFHYJ&:CVH!]@E4"U$M0C6):C&J)936R)7K>K+_=?=D*

M@5<:,4%L:E"36W=ZK&Y&9GHJIFFHIJ.:@HFJEFH9J-:@&H" MU4)A0D!-HEJ,:@FE-?.GGF=P/3A-I^T:G7&-.BIJ:.BFH9J!:B,J6:AFHYJ# M:BZ]>:CFHUJ

.@+50E2+4$VB6HQ]":4U$VE8)U+GCM6?U6CKKGITJ$3#U!_MVVK[':_A>7NK#2UL]"!LHH4M5+-1S4$U%]4\5/-1+4 U@6HAJD6H)E$M1K6$ MTIK)4L\JN.Z>5?#.[-+9TEM6Y3Q/?U\]

*[*OBI=.RGRHRRQBA8W^A4VTL(5] M-JHYJ.:BFH=]/JH%]"90+42U" 4DJL6HEE!:,UG]P0?7W8,/ZDZ>/BN*U@^?W-M[A:.3@ETB &]:.BFHYJ!:B,J6:AFHYJ#:BZ]>:CFHUJ .@+50E2+4$VB6HQJ*

M":4ULZ8>A?!]>:^&CH= =545_-034U -4$ MJH6H%]&:.1+48U1)*:R92/1WANG.OZT KJZ&$$E!-135MJ_7]IZ&&=8/H7-M" M%]K9J..@HFM=]/JH%]"90+42U"-4DJL6HEE!:,UG]P0?7W8,/ZDZ>/BN*U@^?W-M[A:.3@ETB &]:.BFHYJ!:B,J6:AFHYJ#:BZ]>:CFHUJ .@+50E2+4$VB6HQJ*

*9*FG'%QW3SDXZ*N]/2&M-MVSLZ,]#Y!\BFH9J..@:JF:AFH9J-.@ZJN:CFH9J/:@&]"50+42U"-8EJ,:HE ME-9(GNH_,I^C9_WX)\VV72$HE%A.93F-Y726,UC.9#F+Y6R60-<.]K.F>*

*MA?"R'Q=GW])7\@,=<.!R*LMI+*>SG,%R)LM9+!&>SG,.R+LMY+.>S7.!R@N5" MEHM83K)5TEC-8SF0YB^5LEG-8SF4Y MC^5\E@M83K!QG&2Y.42C#M(F_.] MM.F>*

<.#E\WSL_KCTQT#$%+>RG,9R.LL9+!&>RG,5R-LLY+.>RG,=R/L%+"=8 M+F2YB.4DR14LEV#<0?)<{"?/Q:GZ<>B@!)9364YC.9WEC#]BS6R7,1RDNN5ENN6W#(K*

M'U[IKZ'#$5A.93GMK9_9N?(]2\NVGY:.GHGQXV=BLF=BL9S-<@(]+N2SGL9S_MX]\4 7LF@N5"EHM83K)DG1//7"+Q4(IYLKGU:+ZF\7Z8Q6]M."E7C\N\^FK']'D^9;=[<^=X>.^B,

*Y9364YC.9WEC!W7>*OG_)6W>M:!9""QG MLYS#2SGLUS Y>]U3?):O/^*G/6O0V0@LI[*R_DL%["<8+F0Y2*6DRP7LUR"<04TEM-9SMAQ^[VYRU=Z>W-R]7F1_.5:AXWV9?W/OY7X/E-$ M^B6?*

K=\F^J3=5P^.,ITI9I.,EO> +ZHED;K2;>K]4T*75)%31_2NU=Z>MTG MR7.1RDN5BEDLP MfB#`]KH4L#$XU9&' #EE..97E-);36#$YQ&;'#HHJ!QFKW3SQBIOIQIV;N6_>;/<.M1%"S7:0Q!_&R-M-*

*U5ATN#]@O*W\]^\6@7)9?':KJ%NZ/AE#CMC >4TEM-9SF YD^4LEK-9SF$Y ME^4\EO-9+F YP7(ART4L)UDN9KD$XPYR:&_&PN!4,Q8&I(P%E%-93F,YG>4, MEC-9SF(YE^439?YYEK6'$CMR*

>54EM-VW/IVR,=^Y-FO9Z/#>;9H M6:-G69,M;[&0#WN3$P;=-MDQ-$6=QFBT5>$-.9XN;IY_6NU>]]:XUKSPYVC@+]2RGL9S.<@;+F2QGL9S-*

*M<@#[+N2SGL9S/<@<'+"98+62YB.SVGYM^6S95RFQ9!=0Z)94^%*LJNEH#]5L\.!03F4Y;QX%D*2P_DAZ2)P^XA",IV MZ&Y6#¥^S!)G%XC%?5G]_6Y3*S7T^FY;9?*

*+.\^C@M9MEB_1;0*YG##E9 M.97E-);36R7,1R MDN5BEDLP[B"G]H8K#*#NWQ?Y0LXZ=HH!R*LMI.^Z\3L..G9#0N[!+)5K98SF8Y MA^5Y@.4$RX4L%[&*

<9+F8Y1.,PB2O>D'\-N(#&R>59B=]\U%S^_M8TA.93F-Y726,UC.9#F+Y6R62SGLUS_]{5AYE.6W'Y:K-L3,54$YE.6W'[:?{1[_TYMAQ"7T+FVQA-MB^5LEG-*

*8SF4YC^5\E@M83K!PG,ER%LO9+.>PG,MR'LOY+!>PG&*YD.4BEI,L%[-<@G$'-ML;4WH&%X=:.HN'3N7 >54EM-83FY@.4$RX4L M%[&*

<9+F8Y1.\BIO;D,P\X=M3_4I6.;*"AYB*8I;OET&MZ=)=Z,AT03F5Y326TUG.8#F3Y2R6LUG.83F7Y3R6\UDN M8#G!2SGLUS]Q=5*

*MZ^2ZVZZV9KL%5GM*L?.74$YE.6W'M;3.7C3KMD_='R9WWO9.HPT=C!L;<>BW M8[6=X[#U)&VLL-R+LMY+.>S7.!R@N5"EHM83K)34WMB$4>>&5ZZCQ@Y 0#F5Y;0=UVA^7;W6*

*M4F.G(O0O;,*E+9:S635LL>-Z^61]FT M/4O8>0;,K%[!E!QG&2Y MF.42C#O(H;U1'*.W1B'T;/)YZ;?\8=7^T0_=)8Z/'G8V LII+*>SG,%R)LM9 M+&>SG,-*

R+LMY+.>S7.!R@N5"EHM83K)SG,%R)LM9+&>SG,.R+LMY+.>S7.!R@N5"EHM83K)G%#MC >6T';=_,]+PE5OMT,I&_\HF6]EB.,;O_-^*PE5V6 M\UC.9[F@_X]9[)YZ|>93P[:GMG]D<-3VU-:-

T;+W.^/>5TQZG>C\!7.X&=^E\ M8^_LPG5^ND'Q|\UDUEWP^(LH.P(Y326TUG.8#F3Y2R6LUG.83F7Y3R6\UDN M8#G!2]EA0[!@#E5):36$YG.8/E3):S6.YF M.8?

E7);S6.YGN8#E!,N%+!>QG&2YE.42C#O(],TQ!=7CD]YDEUWO^+@B.97E M-),36G&+&5I4L%S(.SAYT]@'(;R^DL9[.MR_DL%[*<8+F0Y2*6DRP7LUR"<0?AM#:?D8'QQJE8>.]<*

*Y526TUA.9SF#Y4R6 MLUC.9CF'Y5R6\UC.9[F Y03+A2P7L9QDN9CE$HP[R*F]N0;CSAVIW-UE[%0# ME%-93MMQ/3['%"ULI"YLLH4MEK-[?Q\.6]AE.8_E?)8+>O^41>]CAKMG7KSU*

*MS*CW,V7O9\.)GYGT>>;!-7Q_WXC3WVI9VGHSZN\ZWF%+OK'N54EM-83FY@.4$RX4L%[&<9+F8Y1*..PBPO0^761399%]V;ROLF^3;GFE(/Y64I=$/ M-7E7I80RRVZK4SC[!2+\G5++F=_2/?*

U@6CU50O5.-^%IME\:IY>)^ETZQ&PO=V]R:W-H965T66NP,MFBENP^#?5!L)A9&ECR2G+3_2']DQ0))FE9<^:6-Y7./O7.I M2QI1O'|BBS_+N5(5^K%(L_)F:^]Y=5P6${G:A&7E_E29?*

#_8UXLX@H^%D_# M-8$+=(AQ5@.%W&2#6ZOFVM?B]OK2%6E2;.:^%JA<+19Q\7.DTOSE9D & MKQ>^)4_S]KXPO+U>QD_J7E7?EU\+^#3_UE_^#*[&>#ZCE2]IE5.$<._S^I.I6G-!/?

QUX9TL&X%M#MS]^Y4];#H/G7F(2W67#_]-9M7\9N /IS]P$QINT^I.`;%;,#HF.;Y]G?,O.M>ME@\0!-5V65+5;!< >+)%O_' _8"+$30-B! +)H)'!_!# _@%,# ^ ' O@#F M@'=M06P"1 <6Y"9 =@WP-

@%_]H=K=9O4C.,]OKTN\A=4U&A@[_]H\]MM$0T;2 MK!Z*]U4!WR805]W>]R<86!7ZII9Y4279$WH_5E6.^"%T M>-MK^MKK.^HDO%?+2\3P1T0QY9,[&7-? $=?

*K4H_V<:.&MN:N>NZ_!5N8RGZF8 A;94 MQ;..W/[];T3B?]BRUB?9I^_RL^RJ">RO6SS;::YB_TV*O*RA'*PA/3662_4 ML\I6REH4UDRR8;JGO.=.(@BAOH1!_[R:.PN021((YN\#)R:0"S_P?"GV@:.$%*

M" W#@=>;CIR1/5%+L=2_2U@==Q%Q3B9T>3XG7%.2O/G>2S@A&E2FC@]MF2\]0C01+4!&,/>(U*1T=O*95>562NF4\O>XBE.4*,>&TN@*R3#U_T%*

MI]ZG#9Z)B2/$(YSJ8H<6(!:>SQG6-'3V\D0-O:V&GE(#+]DT7ZCA^Q1&Y0?T MH<'(*Q2G;3Y=E_+\$4WS HI\7"F4/ZMB#DM?!"L"*=U)*KB'W;=/5-/3@33 M5!]!;,$]OP%IV)B8.Q PDU6N B9.B8%AK-*

*7**]*,!+>K?]RA;L9EJ2K[NAZ;O>4,)F:N3/O@Z1?#0/N$I%,[:/-3??6)6VO:,)-> MV<)>V:*^V/;33-LTTS/:F UY7TGODVW2*UO8*UO4%]M^TEOK2IQ>Z4UN9D.U M5XPH+]%U"<2&Q(<-/2*

*(4FDGF*4A.HLXD:R.CG0Y'32^$Y["%I 2-$'I8A [MFIH-UYZK$!T2U_26(>]K]B)I *(1@7NJ^Q(2D.*.6!KN@Y3^!Y2)Q MVA1NWH98?!KE0A#>W-B F'C4UVV!2@EYEA?$846H*

*@"Y@>&D.>PB*3UB,1M M$L]G<(C%X($"ND4>VW"_4I M-H>8]NU"$XL,$Z)[ONEP=(L#%#?F+3.X29):R>)VT\>M4$6.\=]-] M-L %+I\%2 7E^GO'25?&L"MCY.*

*[BB1+2UDE2MY.NE[NE6W$^UO8*UO4%]M^DELO3.D931+MU1GWRC;IE2WLE2WJBVT_Z;TS-MIDX3]A;3-#!"]0>Q#PQ]+DE]6-MC;=H9VX >9MS3UZX6H _RGAO%-]_&!-?*

*MWWJ*W#T]-0FM4Z5=G&HW6S4ZPG4H"Z;%I-(GOC['V 7-B,,VM!>>=9]5QH0U' M*)>>GH%S&%O\&EOJ-K;=:.CH', DAZ4TO6F\D!43?*;4!!:=2?U\PL0 %P>, . M#/5-(!>>=8/HC%,E[=]K\K0NF;A=!-*

*O.V.M+PH929II?! MC8VI.@]*1$&A7+.MQ('IH/K3%UIP']P.=9L?N7MU;KI.KTW=7OL$RSOK^C@U'.;OOCMA!3()(FO'DG._T']9ITR[!NAV-XN@(V:$D6/0N/7!Z^@L0 M&PX*6*#*

*[2PO.%S[7=^!#*TX*>!KT%R#N7!V;@M:K4[=7/^(O1T?"#XENFFM/-M0A$R?L]@-S*/!N:LT9$O[.H8N7MV]O"ML;=N8__O;]X*]W8]N>6*P\R37!IE M*WMEB_IBV_^I8?*

N6@>$S&E#6ZUN'7MDOI%;*%O,)%?;'M)[U]Z\#<._#=-D-V]HMT2<@<&]HSIA\+"D#ZFV(+*B#ZCE3D[MRIXK7NG;DM]_DV/9AIG2^()R77 MIQ\[D&/=X4UL0*$D,2RC%4C!+AGBG\.ULYV?

1KN=]BD;\RR>TR(Y^OO0]PX MAAG51;7M'(-GU)=25EP0<)+>@X,SEH;SMP.^FW;'LQTM_4NDK$NM>((9QH" MR8:C%'O,] T6(/$#B]DNYSEL-6MM-*

*>NRN7QXV,3OOO#*LHQUK=VQU:\H(K#%:'4O:(^58.6]DCR M68E4?:@&W:LEK)\>5+$]H=+0U(=%/D)?RI5]#H^F/S\VU_7FI?:\U" C>9S-M$.W76K]$KB.7Q56C9R//<5%?*

5#T:\G=.+CFGZ&'OWLDEE;B]5M95O/LMVD;8 M<.>HUD(53\TIO!F!LCH^N3]NKVI-^H.=^F7;\C5V-BN3XA5Z'M^B5@)41^H6E%N(*4%D.60X9O%HRG5."0+[4B MYT C"4H3S=1U5TMIG*

VF$SEWPZ<3MA9)G,$-)\4Z32G_?@4)VUX.C,'CQ&V\ M7(ER0IM.(4LB)F&>&PN!R\-2X"PRD!TN+O&+:,%P3,1 MMW+/V-=R\#ZZ'.CEBB"!4)04%/LX![2I&3"=7RK2 >USQ)X^/S/(LO-XV;N

M:0'7+/DGCL3[".O(8"U"]8CRIT]\J)22:,)&?4^VY7. MLO1\^8#FI+Y+V MA7E3@[:EO-7=:EBR*G(5P.L/ 6P#R1K3M.MIV% OT-^R6'#:0K4%9^'33XH^LH.>*6%3)2U8/ U!3LO7]"\K 16DT9WZ [S=*

*(MP$:-E MFE6"O&B%69$6>X[N*4/K!#."7BV)P&EVB]Z@A_42O;Y13?(1%Q^Y"@MT$.1 M"O[Z1%+0BL.7]'QYNQ];H(0@[%W##8+QJL'[%P8L(L^T4(D:'¥V*F.0;^^6P M?*

31@.P\EJ#S1/#.&72X)N4(N=9KY%C.6#.>Q:7FKBZ\S_^%.^9#L.4Y+>/E/:.W3S4+GSE0IXHA[GCA8$>70X M)=R7V.X?A=&Y:.F7A5846:.Y;-67>98]MH-6=A:OU\.K#<.[D7^03+]MQX.*

M"\'2#6QMEXP@05%5' B7&QJPAB],^:@V\+1GN!#.G6BPR] T]9=Q+V\W&\ I M(-11NOPT&F?LZ.GY+)3W_E]ER@=O#^5?T3S:7]=CWH"G4E\D4'$+00@C^?#$ =.M?%*\G+-*

*U*ZLNT&/HR+8:^:.A#V&((!S%].M4[45K Y\(QJ1514^0;.?[@.@$T.=4)SK@]D1=B;(_WNF$N *HP]+LP=+[" MP.VPT*BBT+F (F!1!+_"++:04TKHU?3#4U4M@}]L^XAH*8LFK@Z[>@M1%6N.*

M@)!((&V@:N<5^]G(1-MULODC(1%OE?I 6=$$AM<5$VGYPEB6V$'C4X6^4YG[2WUWH+NHM+(NMT[9TG

*M,JFSI4%$;1U=$E8OG.:XT>PUVJ*h1 ^<#.P==0-AA4;EC.:+43C7HVCF_W=A.#H8719]$:#HHNB+:.'L4AET4?5DPL[,"O/D M(I83METM^ZVZ6W:.[^S)PM:T+ ^6M7%W\GMW75]/F.U3*

MV(XRLH.NK%$.&ALAMM?]/@\V),'\BFY)*$'^L$NPD++=LW>=.1G"HC9*X[UC6]} @*.W-0[IL_MP>8SNA-QE)(%0WR7))B]W)&8'FYZ=N]8\#%:.X0[Z.]G6[PF2R(>MPLF[_H%*

M2A(E)-4131$C]FQO>3^TWM.R-EH&0\']$#KUPC-90G2C^KFX?PIF>]'!&8!$0\]-M8/EO3^Y)'"LDV8^_T:8RK%X?T?_2@)+>*<%"=_M+#[2P\\D'1)0X04TYOHO.N1XU$=ES0)+>6/4BB-/N/GW-'5*

PD3KN!DQLX MIP;N&8-!;C X-1B?,7!S_>U+0QS SWT?C9V[3@/"SR?,7I 3-66:.!">U|; M2W]%J9HH2\DTTC:B,F/61]E:XX6A'E!C.'% [.:8B6@@:?T9VD(43W-)%S MDV/-[B6Z#<-(7>*

(8/:39=%4/WGM$X"C^0=9X7'KH_:L?T#O41USAWV7]=HYT^L!^D!3L>'(3T.2MMA[9ONI MP;XO/5BXT3FZ\'+"]]0W__X[>V3]V$8-))@'">8#@=5(= L271/Z M_#85T648O3L5R-%!!US)$]X3)A.

*(XCHVT*WBE2/R'.0[^2:A%:,)"B3G.Y%1 M3E>('$/,5H88'0K:*.UZ,\2]4=EM/[=F_7V5IV:-H:5_ZO6\9KWQ=-]HYK? MV76XFM^&A=-&^&1K_5)GQ-N9#L*K-/[F_5#=&=&Z3F5(,"\#&U7]Z,C?$S=*

*(U=6#D& >))@/!%;C M8UBP.7[CB#Z&$!$2S(,$\X' .B1."A(GQI=]6OO9:TF<"NCACLG@&K)S1%L# ME!&T*S.08-ZD$<$'S3 /U&+-X]"XU.COS_E6?/RF#6UTU&(!4$K#&TQ_&.*

*M7.C$F,'21H"QC:X$0()Y&=BX0H#K7@TG)PP_5ECP+9*26,9.?"3;4Q?",G3 MR;]GW6S&Z>IG4#0/%,V'0]LS4E&<]ALGD[P#4%1"HGF@:#X46IU%IZ32^>K%*

MK@QKDCZ'G3U=B5RW+1OS=^.KJT\ZXIS'\QIW;R&DL_%]NN78S(^35]GG#C0S. MX2OM4O7:1CTV_TBX8%&@6PH8_:1DV1>H\4#O@N&ME@5A>$=Z-X?1+G+SC9:VR]W_M

U7!H&@>)H/A58GME3"MOO6 -6L9H_+S;WHC.?D&B>TY3^0TLMX$^B M(U2K=.;*G03'O)/09=_X[=50#=*LC1JCO'!L2^LH:G/'P+X>^4PM\Q M?P_[>Y,Y^P%*O=!T3Q0-!*K4Y@*?*

*>=X5MG+!]#OJZ:!H'BB;#X56[[+OJ@:%Z.5LU>H\%@Y)P&3=!]BW!E;&%"V%H?ZN12)NU2D1T)*T]+ M@Z.W^KCD22^F=??UOMY1[!K6?'0LMX;-3]A\P6T=2<<5D)9NRKL9RY"P[^)G=*

*M"+K5)QN?]! TT9<;@D/"5 7X?$6I-.ZH!HKGM_-_5!+ P04 "#]@6A9 M1X&('L"+=OI.(:$>5/$PC]+5U\):]:G$UZY5.I6-X4S@M0+=+5!5O^;(Y78:G 6]P@K-TK M2N.*83]I28$K-+?*

UM;!L&>AK$*AF12@\)\&L[.+Q=CU^X9O#+=Z,RW.R5K* M.[>YL,@82.[]+VR[WBB K-%&5AW8*]B8.*_DH9O#'L#R M#/ /B#A _!8Q>_"0=(//%&6V7>U\(8DDZ4W()RW9;.+?QL/JZ8<*]Q951]BZS*

M.:),NF;ZE9FZD&HB@,.ON&[8KO(49!7Y-.%R!D_CIG^\1$;8?V.[;E=+.#YZ M T?.!%POSAUR$AHKSCTBS#HA\U9(_(*0#W EA2DU?!(4Z6 \;$WUSN*=LWE]*

MD'"%]2DDT0G$43P:T/+?x>WAR0$[2#SKQ?.D+?/-&V1%2+5OKG-MT.A:RM$PI3Q@%]%HF&4X#>X(UI@=T&3Z>M79^?1OX$TB&W=.WT" M&=$EU(31(?[5DDOIA

M$%SZ)2;,2P;6=B>2 5\]2AC<"21798G%[S%0OAEZ76]KN"?+0AF#GPPJO(09-M(?]3NB9WZCDI 0E"6=(P&+HC;K]:<_@+> ;@8W<&2.3R9SS1S.YR8=>8 (-"M"!DR"EB_UC !2HV0#N-

*7K>DU+@UQ=[O5_V)SU[G,L80)I])KH]A=^6A'!9X M1=4]WWR%.A\;8.:M$^TJ;&!A[*55+RLR3]"DC#WQD]U'78(6]>=$.$\) 0 MOT"(;D)TJH>X)L2G>NC5!)NZ[W*WA4NQPLE*

T2!]W5S.!6W!)UO0@S^\V2F MA/Y.$\E*5F3'%@NT49Z"PH1 ^T{B'68K.SSZ@,.^0C M66 !$A&&'AA1\D(.]?B64*I)\6(MFGT26;WHG_ODQV@NE=_ ' &?;&CN5N%W%7'I)6>$,AIZ^U22(.7C)^W?*

=R^!S_M6X'?4BQ]2['!&XGM+47<+$\}3'UG*7+(]#Z$,<(L1Q4F;:=F[,2NK9CI&NND M&W7TEECO5KH5=+4/2I^#XN!0;=H""CMA_]K+N =DW^MMQA>H^NHK;D>|^B M"?,":<;F?@$G;,)

*<'F1_'N,3]G9NZ!+&T+5*BC*^8QL39=>&2;SX%]W.U/ MNBWV5'=MUV3_RKN6?XO%DC")*"RT]Z#S2<%_O. M80#Z^X)SM9T8!\V_3/('4$L#!!0 (_]!:%F)A7]\V 0 @?.9 M>&PO=V]R:W-*

H965TP5E9=>V'1B<]4+>B\O/K'Y0!D7WG2R M!^X;!6T?)"ZY#64C!?.2R8XD3*[ZET'ETDP&<C%%_ M95<]W .0(&I/OQ=PWM-3Z.X?I5"SVQ@?]>#>.#EW(K)=Y:I*

*MQ57OO$H!S0RO%3DI?U+.G5;OT?25:E$41OK'A2,5__IM@[$ MGH'F=!N$M4%X;# \8C"H#08'!H.S(P;#VF#X6@^CVF#T6H.Q;6#%]*I@V4A'.M5-'I1(H.D::UIID'*Y>UU@%FW&36HY*ZEFD[-*

*M6'C=P1O<6:*J/U*\2!$"0X%|[-WLJR8$H'-@#]J0EQ0\3:R'"%9X9.!UWE2S-M]=E#QK4AM&9HU01L9 8VY[LSUTN3H_.4HDN:V1^6E4*+$\<_2 .6RO*66\/=*
*M?]7+_V*I)K2Z_]5%N.ASVC^I\#)@2>A!S!G(AW5X19KHI"C#+< 7LMKA^#*/4 M2V!>]39KU2&Q*AS@"O76Z\>)\U2+S0H_4N!O'2C4;^2]"YQ M:D/#BK4JN?M.*
('N9B3C37\)C.NAI&.N("P]___6,G_TI M5=:"CP0K^=4>^R]XS,=MJN#?.$C0\V.#WI>AF9B7)/U.4,5GI,63{J^]U;) M&C3S6M"E;S-(Y,IXRU3X\!K0:@%0\@!QIP5N_^R7O\&6@.F>DSA*
*T7TAL>"Q-M2977UC"B#!@55C*5^DL5IA0!;#-XA0?_>?RO":;0V/W7O)6CB!'KJY_&K^%_M>8W'&)D)6$9^]NYC5I^:!-T9""!I M1H9Z+654_'=;P=^?
*_%X\8XPE=*0@H,]V/8U=N1AO,T5KRP80@A:/O\V(37V3 MY=!TJ2/92 >+NN6*(Z@@/W;)IUB]W3!F#G0R)=S(4B&_#"SXT(/5>B?]ICU[M]SFOEG&$3_1]C*$%E[FE[QP89Y2^BX*
*_+V;7.2,;+R9!BCK"R;F"[+X]50SRB MW/=45P&,L"]$FOV S\X%^YR1:K$P)7).N+6R@.^@.E,1Y#R+*6EG.J=@X/QD M1]6@9D ,C4ZYPKQH=V M*Q5%Q>YTOL:RG25-*
5T<$,.79^Q^Q4!U4WS$I.IR7+RV:%EZFY3^96MRENQ^MS'9.%RIEJ\0^F?P/(1*$L1YJAE7U(_WL0W"B^FH(#.%H5WJ\WRS$YC5HTR/+04G34UY#6 MY^'PX=I&=_('L;(>^
*WJ*7]"AO]QW7;*;"_S'IX3H(C[<\;Q> ?1TSW<>" M>M3(G##)W!27\@V_2F5J *R)*@ 0BG C&[R6XHJGE4<1_5]P^ %0$^\/!/T#/Q>4O2FSW0P8, MF9P_"> H\>[%M<6T\$*
*K*Y2D;X6,F[=U8U!B@"'<21",$[R!T;M"L@?LB$XR MK8YB.AB:"\1T8:JF5V/4A#!U0[GFR+RHUF22JO!635CLPF^)ZN#\LG)1;'MA M3/"M[(B*<-TB[G*RY#2&*8.H_"$2BX^M+(*
(_1ID$%*%!3-2D!^&Y8G)H2-=7 MB,7SC"G TH=5=LDEI@ -%RDVH9%&=+*6X[I\N[!38MEK6%-#D7$NK9MV506N MI[@]?/K1=CD%%)+[\+XC!99E8TKT2ZV\ADK?"R/PL4@L?
*7S%ZA+@_E(N'TU3 MKX$QQCA=B1Y4<@2GHYTFB?!$#9^QI4FWU*4T^Q_R9>_1 0\%B@C8/&5YS?0B;M:.&/ MB5M5]QL1K,:43$ EE$8RO(6)[Y,K20U3+GF_A^P!U,P%-Z*
*/*H.L'%"'4*5Y\\;5G%=DAM9O2R^3=-M H>,);.:$1!P>)E7K5W5VR:FBL2;2,FPS@A=%-DF1Y$-7!29BR+,,!&#RB_)MS!>R[J M>W>S(Y5YP>IV+*O6[''?Z0ST:?] \XT/;YU4G\X4?*
R8S+TBU\%Qˆˆ/(X\6S2 M &Z//6X-;<5)%I-B$:X%I218.CY^!')T6H(\"%V)!*WND-UJOU$O8(!VL "_MR[%$5QHZ@Q(=^*Q!W!^6(6%%&S8??AJ7I?/@1/A?IT:+I!J]7N=-]8(IS<*
M,MP/ZUX#U[K/N2U^[HRJ!N?V]_Ff._]BJR.I5+G>$M+F/QX5V-'AT?R'IS2/WXV"6P%M8+3UD!Q \;>&>]K6@&0>,+?{Y\ HM4A-*
*M8G&S6MZXK7OH;D6X(YL#,;!O?M[K[MV\4:VV*S/.HO"H6H*G1*J7.(J'R+NK M(W:P8?!O*.CD_S',?OK/#RCET&\528<^06GG81ASPT$R3;9[6X]5CF0YQ+(VH\)0'11;"9^#0*
*M]H)NLF(L6]?^Z\.S(\@B*X_ZIYL.\S7A\U; 6I'T8ZB;P;ZT. ^WC[<9YHZB M'44[BK8.HS/PNR?NDMX>6#N2=B1I*TF/^L-M!OIS6"V46WO7K1;?L2DSYNO[*
MF#0@O6F08+$4#%8L.2O:62 <YGXWNV"'7Y"'KH#?W.8.1@O36P=I3\FJ'[&(VFT_-/>K=&.#A@;P?@^BI0'(%\[ZX2+ MJ7BX=.:+;
IXXJX1CF[L&W<>P3;]=^W@0+W)H':$_)JA^PA"/G)@WAHP.R)^_MS=!UM_':@-H1\FN&KKN-793$4]LA]H_;;57RQO>ZK>'@C?=-)%&:>;]3KX6P M%%ZWW6M[!V-GEW*
*,=*N@^PBZ&/B]73/F;C6H'2&_9N@Z0MX94#M":?LW0?8QM M8NBWARZA8WM@[2CY-4/?4;*+E'@>"\7(ME!T5EDHND/O8.(L%(Z+;A5T'U6$ MX]37=:#>&E [0G]-T'TD(7<&5 [*
M0GI-T'V.W!7MMWN.DK<'UHZ27S-T'26[\(H7L%#T6\/NBA"'$^]_:.\%8Z-; M!=W':#9=%"Q/8!V9/R:H>N277<'S(Z(75-TW5\V(X!V9/R:H>ON8A(TP-;NT!O0YDN:4M M]M.E\U
*!L.73C98I.-1BZ2 MA<_T6SDNT@+VD(F+-+Z(DG-ODHDP*GS31I4]\X(DK)B2',=VYO5LGL(F_AT449IXZ=2,1DF03-!J,17.*N'8YE9! M!U%MY;JNK=P6@=H1\FN&[N.*
(>;ACTL]6@]HI\FN&[J-J^HQVK0/#5H/;$?)K MAN[C'"DTVBU0N_")AR+++YV(F,F^2SL=1(D(O0H07>>&)]X5(8MLO1/,2EVM%]]!7[515\W"T?0V0?
*({^SW8D=CZ!!%U*Q4+SYI,P643))YRZ"PI4&6A?\=Z TT$%O M>/S:]P,Y2XYU.-,A6(=C'?=D'?V!-M4U;6:4)R43 U$Y\-,$;-Z VNDAN85J.8_&2W/ENU+!, 9&RZ^2 V M*
UT>04]OC[<8Y&"&\]LN^1..P;B&(AC(+DI>(;[FM-\:]$9OWH91OHB#Z]-I++*[LK7:Z ML/4_R[R(IM=]KW>&_M(Y-@/ MP)P:?&X$B;6 _DFGWQZT^\.3X\Y@ (NQS&_A%C
*NF)I"%&"$SJB4[GA%/;^ M\R P#9H1%@HI;=).N_VF-N1SL;=6_2;OOHD% &LL,]\[]+UNN]OWO4OA$8_@ M)+34*V."PS=F7@#X$R(.>?!O6F.RUY 7G&>"<,L+@P)>^SVIX$$[*
ORTT_;] M(.>WX5ML1H3V/7HT+R+((O2,O<*6O8T2^?>;T$VF=&K'9SJ[V4B:'5=[P!7 ML_>.YSU3\^Y&=MKSO#0?0(Z_, (462RR+%^,@*,HL*JYI@[BDI8,[>0LOX]O>?L-CO1?*
*X6S|*LY8% MP#)\3T5Z=/?C 6!. 0K8TW>NCC4W1(;!!_TP>**<%Q>=$VX-;Q^_T8:N3C9)C_BFIH6.,&;@DG2^ ! 'W MB)]F4Y$A9B-%/UOP @YOV_#:XZ?6 M&W4FLR YA^U(TX*
R%^&XH%TG!1D9ZJ6; 6,R@=.S<2>7IAVR M:^P/S;Z$,<\8S%D:#&T:9;9DO%ENLEW1]&&(,BZHNQ6:#H+*;#B>;8P167"_M2)X7-3M+S>8!;TL+1P13'/1;HS=5Z$19Z/U5 LW#0:
7"H@Z'?.JF\Q-^1 M+:CZ9N^00'@IXI(L>)4=X)O+.[B;Y:.VB_U^J]?75IG[;@?>'@[N^G;OT!C] M^LMX4(=9U8(WN5:.!KIJEBU"NTV@13&^N/\[XKTY6 ,N;%-&%A9]HF(+I8,BX M9$-
>,8^?OJ]#:[5*]VV=93;B4TA7)4*=! M6.1Q\U_N^?+!&B.UPZFL+G3(+X,KO.W>S]#E) C*RB2ZV_@9F'!$C37"[2U MNBJ"D(-KLX=E\-*
*&^O*P.5>""/AP.>S.KTLQ3,M=57'L#F(8RUY5<6%-(M9E M@&(64P9<(F7"]PM)I <% *.-<*#;QLMCI^OJ_;LN(>RX5[E4IE$&0^_)>W3" M^6I);-1;)8D]!A)#'2>'&0)P*
*B]F.:>3QP;MIJOWSAO#R[MSGQ&,7); M-1Y M*LD,%EA$H#]?F],L26I&*,0_[R&MY3LFKED8HL2U1H@O,9I["UA:ACL9LA '-M!#=XL]XYZD+FZ;9T4P(6^^!W8]]P(L8W7!4!%=X8V?G*
*M%)O0H^&AK926'CDY,QV,H,]^*%8@G\(\,'"UQ?ZE

*MF"*4A5:!UC6]1G581"&]E<|K[00E#:NWR\SC%Y2E4JR.<*CK= 6U)8(M&JU=|KH>|_31W\9\Y?C>!9]Q&*+2,8|"+UL@7>L;PUWR=E;:VHOX+ MZXQNP;E\P:S*I/3N:M-KC/P.FJPIN@6?_-W AL;F(V\,#/Q5!AL_7(/:DONA MSSA<2#H U>4+[(8HAF>!$Y_(Q%G^)]C=7'8XCI=V1_4%ZO.X]296OJ2KF'.5 MMW*YY+$(XH8C*1:Q& @F)C2W&:_$ZN36\-UJOK?^M(V*G-OJHKDJ>|'1N^R7 M>&:!.]# ;7N$_\=O(#|,_\3C"_TGNA4#PCU'"DXNU,!1%ZP0F]^$9&FW08E3U MOC5%V>QJK+%V^1,7"0.5@RJO-J[*USC96ZYFP:?3YN>PYF6/0Y<9EJ"WQI= 8% BWGEZFXUL.E+*C!4_K%BC?DLY "L5Y| 00@W+5;/?OXWTV6[XA)!3 M|:&4MC4; Y5; 2ZJ0WYW&QD^\$.X3WPGQ&A0;G)<V*W-$"KP,D&M3SS]5/9, MF8[;@]AX1@'U83[M3K[N;OP9S[Y4/MU'@ZSCVFF3[4C Z_&W7WSEZA9O".EMT&L#_G3^B^SF_F^B, MCE!4DXY;,#)>NN 6;&Z#1E/9?+P[@91#F8+4,/KRMB/:TY09/0.G%"H\/;(K M+6RUG0RG9ZR3=/H<SR!8YJ-&Z{[ZPZR*9MS]'F'O08=$;2;=K# M47Y*\!(C)E,,)"X,E=T?%.NQ!8#PW\RYJ;A$R=P=#5VLI\=GY\,EE'/,=2(M147KAHlOL&8#3OT\EBQ[L034$QP."WRW4<>5$0.#<8VF(9%93H+YRM3(7J3 M"',"\=@-,9'I3>1I9?=OO=&S$/,+;T/Q$f%.PUKPS>:.HU\C5Y2PYW+ND=/I M)^[-N4B&:G.>[4ME3)Q12DI$_0EK4> IL<*A5[!P:fL8/2 T?UZE>;VJV1'< MA0U"? =")X\-[:-4PD@S]K1WN1UW7,,:^/[.N]=X*");7Z^ZCN<@ (-?MB]^5@ M?>WA;DSP&.\1),%YX1#'$64!6#O00_6@#GN3&\? <=3)IY/T,AZ2Z% SU-M3SCD,DVL0D.K2@3I2F88>[N%1+8^Q T_:SGL;]_)D5 ;:S):V4)136|9DS)CE M[;+A<-]/9S"VH=?BY{C8B[*\&0M+/E*0[^ LU^40)/FW$^AQ^-G^'!YG*#O MEWNWH 3XZVKH+*,\Oj^YH!70:,(7UG49].7Z(8K3.7S(E(J&]!A2<- &]Y;A M 9A6OF?WI6 V,,4)@;4GS-Q^:79E93O8$7KU0.O!Ge9;C!RZ),."E+GY;Y] M;<4=<@;;=H:&>+V3Q:6K,#7.D'VH'(1?,U.R6S@X\[:'8%EI2F!NT6/0B.W2 4B42;C6U@>@.6}?V^5MS99ADi'V:75AE(I6EDZ'W0|903>6IK*VZC>^WB C M2D$=C$)"OJGVCM;W&2/Y0?X'[77OFC(?"FT/P(!2&J&8UP*KH)HP[ETTY>?<@ .RQG12D2=SD@IEZ=8U=/:&'WS6G|>MS$UA%Z#&5,2-U[4^J!#P#\Z+OUPO^R!159(83= +N!>?G)0,R-DE^B,[.1]Q!I*KA1%OZJMDAG)V*CVR&TF+\/?AC%I%+4YB&WZ3EBW,&S]#C";,-Y M&,*;/:)>DX174E6>93:4/)).FQXH1TH;31V-WX>"!IA8 PR-CW%Q92;TZ_M++_]^ALL&6Y6X=_ ,/4?&)5 .;VM!EH!?\\);&MSF.9C3Q.B6S&3NC71'@T]1AO=SN/44SQ&1Y:ZA,5=YX,:0)9;&OW=;E;0<-.M#+A#7;!TBVS_U:P^&&-4C\ID>(@D1"%Z#K7J4+|$\6^@Y.GOY'RW4O&Q.E71 M%&FSIOMUFL+1&BMU9C");T,*[,:R.OYKD9TX2="::,JH +1??RON0>72DZ_U M\M34FL9FE[4(>Z@%B=*1U("H6PE :KS7F)\X\WG,YW2UH7^32C,4/1%JNYB]_85=;BO9*K?QZ$5+N+L(MHR":,R98|\NMK$W7G^9!Y*S@ZR!1!ND6"2O%|E,0P":NRP,\S[B'!0N!)P)U M$-_0YG'3C56^_XTQER%F9_6O/U\!F;KFF3U.-;>S'SEH?H4PZ;K0^#;\SOP M.>$FPD1<_MMVI%4U}E=CGP.QP#5@0%4T'EPN5I+>ABJ12W.HNHZ:N!U0WHJR>_M2H5H+3L?8B9CU9ZKZ6$OS:L.AKBTG=FAN),@X&&[HFHUC0\L_>N_UQ$&=.81MW;6>B>;>9C.3GR,%E+@/2B(9FZKSF/L3/1A78Q;SDL>ZG&U$T8&6SL5KD1VO MS&A6U?+0#"/:FZA=8M6_U"D'Z6AL/F(L1B$R%L:TDR%5VW10=R|&ION>|\15 M@0$5C4R?\ULU"U";<4"GQ%P[.,CO^XX;]G7<+!'T 0$-'CX2P5TE3]6Y\O;H M:'30$W>=';>AAU@N@E6OYX"3P56Q\"'77-,;=(C1)ZM#)+H0W.HJ#*8^D(.TT\1G;M%CWE3]HD-M%B-&(00G%N?^NZ9LCGTHC";FF1.@=>M^ 9?K3219]!%OD.E,=P\HX,T2L/MQOUY*)Z,KOXQH2<&# M_R5RWG$:E&GLIL=NP^W@S$Y78=_0>O9SS Z,&C:QKOA0|S(<.[R-UYJ!EJJBME*5AP.6;E/0ORD;A'MY;TR<>YSGMVQ!fZ,&*1'+W M=7CN!.XZ{(R6-4.;,2HK'A;-)@!^H50%/N;)-3&>5TD^O3;_Q@/:UZI%9IKJ8 MYVGN!:KXP%IV/@Y8F9N&/,F.Q$:'I=.:<_HG^N"/U<,9WV/A)'R.*@$!4'C8\JGH M1]K?SZ,D_1BE?^4(+QK-QP2C#"(2';U_^"MM5N58"H1!1QBP /T)ESA!/6]V M3IS@(:*CS]M-=&S?=U#+6A9G4HDGOMUB5&* ;,DSQ-46QLNZ'B._#FN?@H95 M<3B)%MSQ9&5ATL,S2U:9AEW;WJ]#HM'OW=!A/*NZU =("4A\$3E4KT;5=AD# M.?@8GLT7-LD&8=H+(-2G-)^P/Q1X"2SFN_^\KF1K?,7|:QG\"KMGR0)S!\UBJGE!!,E9BI?L.6IBMV(& [1?N)!1.5-T? >T:RYZG%W+?)>RP,>.MLN-G; CYF9|$RM! C^+QK!ZU@[$6?CKQGOPDBC=7G$1#:6*YEK."O->5^1.KM#ZD#R!25NI$(7Z00CNRLAT44?VQ70[$|);/)YC7U\0JA*DW8524+:XZV49$U M4/"*!.KR1B-F^(1SF(@,C@7F%>Z#/%RA,K^GH9O16=U-W"Q!+U$F>RSXHO)ZMJG>7|Q,W505CA>&V9$4,,QC39YQIB/KY+YW>%F.]=_(VAU7Z}&OS#27]* MRS0\YS$&3!=TG-(OKW5GTZ"<2TS'#]U=|:.$\/H@EFMLE(%#?JP:MOS$!!7M:NT_N^W&1!93>8)Z4^OQ0DUY/,>Q;JBF2\|/5I'\|f8+FVZ/CL3,7AJ9*ER2 MK+&3GE$?8M67W(%!DU<:G%KV&MUHZ_/DO!7,5DV'<5.4Z54"PU@[=7VJ[.? M5S8W:X-,541NKD^F]ZA/?0V6"?7H<=?Z/:G.M/5L<7M.P_UV+Q\J_QV9/7R+YV$(GMX[O@3BU+O9"PX%30!$@JL1A6?BSE>#'K;+6.RG9-1&0 MC5U'-'B+IZP,$=8LA80C5>LJK&CT8U!%9'BC9!)_B,7J_[B'Y, ,0U7^\,X MCK?KY0IT>)R?|#WZZ,^C2)[.F(%/F05%K3)67N,ZZWVZ3G6_LQ/-(.7>"#!H'X&:,9 M)[MS^*@"+!2U&C?74*AJ/MXE*H"++ ,':]#"Z86HK-I]/-MMJU:\K=F5>0H%7@V&/(3'TGYGVJO(:,L1K S_GA686>$/XQ:9F&G\D/I.M3T M&$V.CZ#:.LF"SG2/>V>;3PD&GHI83|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fl%NZUBLSX M_C3':):INGVV&HV.64'(@Y4GK|H&(D:FER9]QI5&V X4C(_2+:.M347ZLE;#*6P7YV4*&_QV1!\B&'#A6BC:\R)RF 'JES2;7H:76 %*E-Y0VPU M. "LXY+:.*,G91OM7.Z#CEF3&N?ONX6MV8C]JNO<*[<9+?U7I-JKBCO:ZKEB' MVBX#0\&H(,?G64='$RAF6'(UPB+)8+ ^]&+1ZG'LR[(!B4QNM%9^]+DF|\^ MHZ?#$+Q ![:IDW= MHYWV8R:S(G)8>@@R_!SPDECDRN6HBF0Q17Z@>X/[*LM W-UU+&LQ/DS)'B"\ M]7T:(E#BP[>LS)1@YDO*[8[_5U?L[4)JQ #[CF5:#]-$[K$5PE61,\]P7!+[M=+8I0K**)A43UYW>H>#$U%]MR]L.^FJ27LE*W/3BW\UZ3ZM+?]QQE\/945:E MJDVO@TT@Z)@X< #:N<" Q(-G.ON4""BM)DV|M_^"+<"$Z EI-5$#UK M!9J;$HI;C8=)0)@ ^2^88FM<'"G?(N-Y]+8"K2\P1KO:OU31>OP P*:(OQ&5 MVB@&]2@4]AB%U"/OU;,YV"4#=U!+=(9'M>D/CU$Y2CP/\7&!ALC/_X#1D(>M"GP.]!(;U"$@#/YY?KE,!'EC3<+05^13&6:S#@_,B]NKIK^J M],A1A26!I8@4>+9!9T)?O'C+,GOR&[0P$Y2/SQ9!_^=G\)2T)X.IR"I3M$LZ9LRB.HV=4OHO^]CN.>@!"*JL&Y\X*_K;[].U-;U" B2L_@(,"DWS*-X6 MI;K589^_?4[80\K]@.'5%()5VK*+/$Q%;E\L;(]2 -1%F(DI:M_5^]/Y] T MI8>%D_OZ/,ZN.X9+/S(O]U.DFHB-&A6M5P15"%.U}-G8Q'P#56, +]I M-A[?G\! 5X*\7$'7%#X1+KL88]6QZ%"=(-RB42;C6UDE$WH%6'0_L,;S7L];PX\;#$JRUX\YIF8386)H_7]{OPFU4DO M6RT.+K'O;*/_I296; \"XVKT"G-%8N/6'ZG5'<9IZJ6+W]?.,_7@,CO-!GW@ MW_$Y^G2<,*V(9"YM=@1_8U'2E)UIK0+]>]+_T!>1[+RR.:L-&9SAT&WXN62 MXWT]AZ/V.5W@K#MAM R22F,/BMDC]'$6&E& MA)|6I&9T)#2>!SH*^4842KU:AUY]WG^AB%MS"_9'BF\|U6M=IQNY9,<5FK}2VS'HWN<$$S?U48DU/<;3")U?U#@HP*]NMH" M4:'XH("TLA*O9QMI3B#K*3)"""W!UMA'Z2I9W=%,#HVK)51);=:,_0L009^5VH_,K.PA{FQFA@)"""^JB9YIQ|GL1'5E)$BX~55R\|Y\L2|M;&[T\"?@7P0!_AN/(_Q?'0KP7]:A?@C#)]F/FPI2'<^;_=GH Z!=O=/;NZU!M;7\@=Y_+'0N?*@]-E^2PINW@(NL[^303%40H=YD?%3L_)AL.$_K>HPWW|(_M]:T,,,EC.VKC51]|F"_P?1FH\M.8%(1536)OP#/.B+O)!:9H$=L-=64>($Y"&$'KCW1(43[K6LD#+]P,;\OK?0M|+*8@GN>IB+K4":WUBC/>Y,9'|6CU@-5;&3T*T=WK[O@$SQ7<\+NL_*0K&HY9 M164L)? %N"H[Q'WVI>J63PG><[?.^AJ1+^%3-X:][(1127GB04I,^5UHV-6 M$W?60;K|JM_)=/;IOEJG+FTWKK:764+%?I#VW.:G36V_P4/VA4.J-EY?-ADQ MW&PN W$Q,)))NJY9UH-OT'. ^DZG-UEV=P91>ZKB0(Q:'J8!MV$"/&0M46>&_$M.F_7VWRDF3RC$;4EGCNAQ*B:S&/.JZN&[|?Y8* ,&A:ALKGA@A6A,\>=*E=[M7G;;F%WX7QIA4W>:F$U*<"%@+B9ZKL\FW6QAE_^F_FEQ?VRW&Q:161\+;":CTM=!U80$V'\|\;TUEF3+-) 9F4Q9#BZXC/AN%)BM5K,I78;'5*>3+6I9E1V9 MTG7IQ45F! A@3X'+6(EG1-8BB91Q;_#CZ!W/3SSX$d@8]H#PZ[$=$S3"++33] M!GB+RO8CGFAIB@%]PJ1;^YHI;3KH ^9^P8.@*?RST,AL$ %|=]-0H3K2.1*O M*?Y%2WEQHR>^DQ"|;\#LKQE>U9FSV36LH^5<&=[$AET"\%7=^W!%^?/?.$6 M;W@05[4?&4:GX9[>:C3H#.LC+7N$H\ZP+H.UK6UN..LV3*+]]:UCE$Q&)E[MAZM9INI6MCV"+/:ZR.1]]0P+3"0L-WKAG5*]NK[M0/O\(G(IB3/8;Z"WY1M M\;J6P\?1/OQ/61PM_,:L$[.^\%-VP=W"F^7Z-4#R'0F-9]3CL;P:T%)+ 8=8 MTJ%U?4P;T^ZQ&R$>JN1WL3M_X*/(AO!0QM^-LW/4ZSOIE0@7^-H("RBBW58:)5K<=.'RF'D9/H4/M4'=]H"S4R"M-V!N58]/'I@T"BDJT['D1V4 ,U757*H%6?@\'6KHO4*F]GN.5)*84MF35ZZN^\7CWIN;*SFTS MHH[J+4PNPO:(2MYY$4#EI6HRDYFA/=:E=P,T@MM%%%;\.PT&6W59&+2!4_|MN2B57].K530>,Z906<2R TA%(1"LM^-7'5ZMNHXJ6"-X8,,WLQ^-0P6D@L\X M3NU#4N5LQO(>=/9) S7! B0HGM>XHF$YZ(*(VAM=$XL5_!J M\0B;L2PVN0^Y@WS3RQ(QXI-Q=3PU&#_]2^3LYG8W%6'>P130@]F!H%'IZ(RD M8WG58([[$QCO 23MOP^1K"Z\;S73/0B,:!4O&!OQ6*H+%*,*_XD/3Z(;OS(# MHQ]-L[DQS]$55@N3YA>"%\.O[(*OX':O ?S9JZ_1(9|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|-K.#= -U5X[>)HZ"'U\/*G\Z9R|O>E,%QJS2^3[>'%WYHUY?.% M\^1'L8KQ0QQ.G5#Y]<2K#$T: .?T4!7@\%$&IMK^S:5B6 6"#RXA1A_+|+^S6 MVLTU#0ET4"NS7!F$N >)H=9!,ZTI0|.NGWD ^ZJB8?4X]@V]S+/[[_-]XB&6] M,)7L SS>7"MUVT(#5:QO94(MQ/-O(/[.W;>U' M;4QX';H^"G AC0@[U5U&3 %+$LZ+0,6R?E)9)9J6O4831IR;I9Y&EM?=116.S M$5]%N0K0YNK41+MM#&,A T'UKNW9]^]F\3QA\@C*%5X.P<075-S2OG)>&B M]/LS#A\|+XDU:=_1<*!2]HB2#ZX#.O*DI;H<8B U+FJ|2T>NU%H!Z"Z$Y=AM8;R63A"H!.U*'W2QU=A.R[*[LLGLW*KKZ&F\&U!$SYW4 >4R6BVX".D[V^2_ M\MW+)UY;DZD3J?&^T((#MT:LDH:&5>_ BY8.3%G@P\X(6H uLJF8R(LMW>C MM^IC.*5:%(DE#Y8H4EF315W5UNQRMCUHB.Y%4%$>"'"3)MAZ=OT,CI, M+25.@O?[X1J]-AF D7C!R'+B% UP'L6@H&%Y12<>+[CCP4 UB%YX7L1.%(-&M|<0;TMC:>HCC\;LZF=EGP4FF$3C0*ER6+8EO1BY4_8V-MZV"KH+< 92B9S_)VIE5JJA)[[]0Q=B:(K%Z@=B%CQ[RYZA.^39 =W0K!*C/ CV+:[(<40:[T5G7A69IQT%+BQ4?G- M<-16* 35L'^/,]F"OFQEV4 /X7S/W_!PI-/U\49@_,Z @TSS+C\6|(^[E# MJW3'$QX_(3 OQK_"IR3JC,N:D>O'Q/=\T+O^$3QF>9YP*W"Q*K HS\,/7]/"-MX)]\?_OVFS?XYS<(Y,=OD/\7_ZEX,C]DKN#*8LF613/F9HRAA>3,DHSU?[S) MA3GV:?%D=C>M]1?_J=B5+STY@*\Z3M+7G],L!6+?9+,.3,:#KD$G.3+%FTQG+ MF;,,.[O_O#:0]V)]OHSH!DEVL4[_C3L@(L;\C*4;T_K_#*[Y^_M"HXC0!W>H!3ZCLNB$3]2X1?98S\]7+(Y44GT%-0X_V)9&KP?PP0E6,':?MY5LQ!1W732?..HL(Z^=HW\7K*ROGQV)?4KB)W1M2U7$18"+:D=5PT)L9P2 M:%I R_JR]!]^414LR&:[|*5EF;.BI?HJ)U]>Z*[,HL]R!D;GT+"@CQS*$H.>A3WSD:;=[>DMB8L16@A,<.\2* M.2&(GS-C(4|/CE-S6|*XO^P5]R:,(1(&#HZF?KGM|W(H>&I_BC.*1":2L M&T"9,:1A=91TTQFI.U;IMFY.DM+5I4R5E&GN^[%SY4ODI!N>3;JK(HAG_-MUK#CBW^PIH+DD=(3SX,VR6V4P/?R-W^%|8XZ+K,@R"3%$R9H,B##D.IQR*)_M@R,)1$[(*#CCD*>D_ZZ M"3YZ>@>.AC#|\/8CV9F++6V<#RD%>7<:)]+VW M15V:8E628]XN=EPFO8U)=DSPP|M+,&,:MQ,FQW&BZ:F?R?P4/CG/^I%NW@0Y M,)X73OQ.Q 7]CU$F,+ZN^&SW107WD.N_A-G"4;<C$$9.V-H|=_)8?R?X2 MA73H3%%?&UD\R5!4'XFTZ3KMOT_%=NZ[7:<5187(G3T#>^9*_FCT%0@CAP!2YT7- G*,5@\U @XZ, _*S4K." M3)GBRI M4WQ9QI@S@8LYSW9S,I!9= 1@4/8[S,Y%#L/UPPPU[ON10 <]M1W-.O.G_&BN0/F%$'-^:DL% +S.C I8\T<:4) ^>G6' MQ81N@W5R'7K\93OBNJ]5'XT*R) E_@M;(DN&/!DF?[5<&4^LI4Z5H",[?HS M;$^ LO.#X,2(2?V00C.INR*W3'DQYA(XZ,6#+B.85W_8<%(S_91.:.Z!F M%NQ;AT5V R(4]L"U!H,R9HR6Y$T+B-L U.-3G1{<)9,>_"'"ZNN82;L*6M8C MNXI&T MQ";==:, 1UT(^U1#YY:'CE67^:,A"Z8, ME:"I/$F:#.%/E!KF,;$NK[ML41,2I:R;HH0]3JU!% L'=QKO21)IF@R272PD%63.A4L)E(P5=PT$RR35+TQ M[2]:#@>0_?B3#[I+[["XVE,78(Z)5LPQE-(6M;/+S0.&M=N2K,'_M"&E5KR_D M5R<*\K$(D#%)++T&\'&L/M/"]A=U^Y&6:,4",3UB8V8ICP3PWJV,PHN O6M-+ MT/*:,ZAY46^_;#X$0V4ZIQ@",1V2*9ND3+$5C>E99-7K.=AL%.Z@?3>$5; ^1 MZ\9KKAO&R?MEP'DM"\4+_ D&(>W=4]WCDRK_MJEO?KOJ_Y6[Z$$WCK&+]#DQ&!E';/?.'F)TP*Y0J0A=4 MZ] K1*Z)(TGX7QB.A-%0[.?A#3Q7^D=|=SV3QB+E7=2I5D_[A"$ *VB&Y*=A MZ]

*M#ND0P6)?@+QS-,-%?HTW;MM$1IT\$&"+$.$8.SBCFL$N,80BCLOK4NTQ2 M?RDJOFUDD+0,D,!Q9SR+/[V- M_U>]NS,VYYQ8$T4F'0+ ".6E3J2O(\9OF5 MMS"3.RLS\1"IF'F&G+0P8\7KB,4N!$-U67.;LF\#-9XC<+')>N]G.PB-%%$S M2.EW\\+)+;P+LWE.8-1#%H0W+US!$5XOX? HVGFNRM HZWKVT\$@K!N>#KFO MZ^#5];2F@\%6-SP-;8'5K>10N1!$,;EFL5JB'?\SE^5W=\-M%<5H.NWINY/D6$9O0->=<*N>2UBD?G((6B=,4CLV*0IF%2F"B ZP[GG,JW]= M8+E*GJ)"/J@^/'.ZRF6(]Q(5%R(8[;IB+C! T0W"2]|)=?ZE0>7& M% (2>7:V8<2 9I5DA3M,%1]+@A:@^35!83G/+r2o/+/%;//$4004+P\%"R3PEJ M#YEG<,:*"@(2UU*/(L$4*A8HV)?(!? 3'KS0TY9S3\G("/%KO.%Q[/M;!P3],0J_X"ZVE\"OM@N?)//0M=$,3Z_-1-.147>YR'4=>% 1.C"VF8='WEU5^[&MN(X&=C#]J\E'(9=7# M? RB]"$ZC+:.% <:Z_Y'#*XD7@Z#0C3B=]=+P7;W!1/B$;<6%G8CL+PQJD/2/ M3\)BSLHU)GT[@4CNV@I0IWBLXQ.P$(,CPZQR(0>__Q(/3@RCB2.7?=>%0*RS&!UZD>_AK%W)^'64H! <^44)BQ=,"E;X!@8.@VQWL:GK__K M;Y@:'!$. ^%GGI<+'!#OE2.;'J^8W_#+Z MDMD 92$>]1H%]+7[\"PT"(&\[.I>CJX$+L,2;I^>;O M8"(.:T%]#@? QH*S@15T4,J"&7"VTJN4DEU'PB:AN)@DSN,24+H]W[Q8UDN(=IT M),7!8%-M'"%8s8)"D!KB],HWDW@D*V8_=K^1<[6!(%%\76KG;H$%LLP++9?H(X5)K)@XX!S%>)DY MJ9Y!O3N-UAW>KHN1Y0F\,E#\K,"-J-.i#5DZLKMZI"4,)OGH%7YDP=0;O8"D MY';LTF\5AA53L-*F(*(IT&IGCA4$[_<#1'!B*'HT4Q=I91;N*F0$;,8A\[MF+&SC'O$,Z*@=@M^NE3"YY^@4&=^@ HOQ;FS@E^F>U?DWJD FK'4?_-5;@G8 MU8*OW>*+ TR$NOBU"V>< ME&R-41+%5>1GZX1QBT@%8184NF^^^#@8!=;G3GYK=>@$>5#QOC@%G^>4M44D MZ+[7[$;%<3A#&,HVI+>$*]H8>E(YZH'B_L/?";<48E@'U"[,B>E9>H3V M^4[C+K7-$Z6AS/*=AEUMDK<\|KSP^BKF"QXF_1LS/61Il,9#*(WT]I&654H M$Q7-R!-'<.S.RPE<3T503%7S;C!3O(4YV.9'R"=""%""S;FO7ZWEK1;R%UY@\ MB>=.LH87VB9+O/P4>CQ^!HT5QHIX8G]R[C?G27W?VD]U?GC-E63MA[]Z?OOO3 M2;$;NS8R!"83 SM5()/R4_6QG3 Q.B.'!UE/Y59<%;'+MBZY*NTYGJAA] M7Z] <7BT6@Z=RMY3]SQWCW3Y$<3J'_@F(TN^$((!GL@U]STQ!!$&3+251NX413 @@MY,:N"(V3)T$ M$P(4RB5L26%S\#_&T7KUP$,#U8@D=1-FJ?%52O38^S^<6(=DZ2>"W#E$A &5 M0;9,OR%O?:UBZ"FW6/6R4)CG T\7F)&BHB#[E1QB@AS3Z!V)&$47MP21RF"K M\RA13-,GO+(ALM'/N)=,GAP_P#?"=5CGQC"&4/"(00N.8DHU64?$V!A@)N0& MSNV(R(MES*C*ZOAP%18GH!R6X!%|[7ML@R&AUK)H!2-8=R=:0,%12%' @B[MZP^!GZY%MDVECTB>XHMAI72H&0M(]"2C+.$)4;WR M^-)0K6F%@_H,DSA^^SULA,DK#_]^HZV(@(5%=&QOGCQGEN 4>FFM6OZM+%XX M4!RG2&*>[\HBU-@VBA. M!S[TW7RUK;D?1K_;5:A^BI*5GS!!7Y>_KE25ZE +Q6@@7=]@]"7:PP1IK=S>-SQ0.!;H[LU=L($T;A@A&>;PE]Z M/&LD'4;$F,9C(`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|Z1?(,>=GHH'FJM9N86^P.AH)=[QAF.2P^^>E]WN23&2 M:1 @%@5) (B,J.Y2]K@2:43@D*H32]KO=G$C*8I0!RBB2+*=Y')*4 |>4K,QQ MB%/T=H\F$*6MYMXNK>0@/>*U0Z7$[=D]B&U; :%4X-PE5O"4B6Q7_<@IO4_1 MJBWC3)-2=6AZ3ODPWE3-E_5R M(4[P T9K1.^2RF%@8+0.C69H3B4>C)@R;W9^[???/NYSH/AB)$VKBS/4RB5L=VOO.E]D\N>3ZP@!GQZV MG)P:(W(,Z0UDSU&A=S"&7[IF+0(0QYKJ^BN*B_GVR_<2>#]L648HWT/JKB%A;2 MR388$N*M1;%(,X>+R$.K9?"),90.-LQ3[,'9F!U1.&DH6 MN,Q$?2N!9NURN0JB#><28,%<'WIP7LI

*%5IOZM;N\!\"YT8>C'| ML1.BE/U>|'5#F\^;JK:C+|D_YTF0^@&/XH%C/\ IP6Q,/F@%WO$D!1_%H71 MA;ZD+S2,=V@WB7R(^6,3LY2O}!L.YE 3]+BOG%B:]BQ(OZ"-0UJ0T,HQDBVK MC9/15Y@>HC|Q7X(T3O;7E,XC86N[$<:BHEBNX4'<@8X;JU`!#PCUD<=%8^R5 MNI[8_;,?CR@#=C29T>>_K?1W*2;M$"!G=4'T1GCT(=+JWI@01XPMG%C64.R6 MC.'";F-3PJZZ(@[)^-XX\,WHLU%';S! G$F?%-1AE,F@D\>K#\D2;D0\H+F' MH3J3_5)W0A7H2K=^M8GH&U)TMK-UEZ$I2/)T=>04/Y*NM\!FM$$,D5*;F)] MIQ_[Y>A"/B1T"U=@0+1=]L/]W^/CK#6H%EHR[6^9D3>UFN\IZ:8:..<&Z MP3IC3L$ZHOWH2ZTU;,'^G&I/+XHL@Q88SYOO<7H;LW9}"K]S>ZS'%&FR>] M&B\!F#C1U8E_2^!H M1UI.K 9SM1^S0?2X3]P0]P#MGQT&'&UN[88P%-\U$7*4>R&6*F_P+S6U'7W7 MS2.*A4QO;Z;S1W 1/(1Y>A/Y] T5H-O8:ZJP=_R7HPO98D.X>FM+H#L$37^" ML:);1TXL>"X0DX6F#U[@,\F: W'T5]_"$B\ L#,K(89Z+ ^_OE!E5/>4^JF* M^X4J!:6\D^]Z,_8[)Y;1M'6(3 [--(]0K(TE>@]]-;IP6*8VV?]\\E>=^>*O M3HP\//@9OMCVI(*!F[%WfMJ<(VIN.?K^>**R(?=_(^'KQVIC0R=F"?QI\&@$(V)[Y6ES2R>$ M,.&%&_^CV@^KN4QVR5_GTU*%D;^I]'OJ?LXXY!XD)<2R 55C6[+:=>&J1? HO@9U@9_\^QRS#>*/(5&\!$K@VUAOH/GV ML=67$P,ILTH\UA1$N@[CV)1_6?_9"78!/9?^FK,A MQ"[>\&AM7HV-C9T0Y9(=&2[>AB8N%:WVB7$'@$JW;3,]X[X<_10MK''2_F8V M@3:U&UT Y;>..$PG&OD@HXQ.*]CWDD'@)\-GX0T,UK),IC"YT$6O#3J^7(&7G M\76<*'-DW1W;VMR)G58//(U((Q9E7MP0>_943PNF*ZIV7@4TC@!R&G4+P4+A6 MDQ7;7I"Q)4D#BF]!!;R8B F2!03POO@>@=8J*Z2)$YF.5-VE\THM6+]X3 MB*NW aJUY/-L2\;I?"7@R2&90UT.8)T&RS_&D?IPL5+B)T&RS_&D?IPL5+B6>QTFV>64R:#-I-V'/GFP=& M7!Z_../3B*8WT3U!\7ROJ=2KU>Z<6$LR9!41+W.J]#4X(^((C6;&Q]?!KT9?-M*P\TP4P$U@B]_5KP)/#WA>F'#8KE\5\Z,8/"W0CH8C)\XVN0;69YFC$1,5%> M?7CWL__X#1"T9Y!Q0GS-QLLU8W2>U8(6(ST:/ 578-2; \-*/H[-J*K9@!N1I;NG$'-RYZ&/G!!MEE_R 3Z5 MNKJF=$P)< M4G8[++E)'2JO;R%D]C?\5 ,,IU=C<"7%]FZ#%\&MN.KJ^-Qs0O$49[5G,$W*K M^EUSR]%=P25$(?%_MT%$?ZZZ@AL;CGZ#W+!;=@"LJ1]#0&\U8DZ>06;T T6&C' %X"KRJZ%=C8W-1K#G8MKE_IYIH?/+7H^L9 M[/V,UJ "K6A-'-#.R=F:| (&U@]"3#04P;H!!&B"C8<#U8/\(\]$18,K+XG8 M+*3L@,#.XV90I5X(.S%$*]>T[1JL-7*'=>V(F!YUD$P=6II 0<(26+8"UT R-ZO+17X]^ M\.\CIKX'4?84O(%?7JRE)QH%<8)"? 7OXXQB$8l.[>[@K3%%L3M1)],:NKD% M"L641G05M.??E9LZ(88ZT35?%BB1K:=_I>WH2Y4]3A[SD'[\.?K'CY,DN8M] M<&'[UZ%7*]S=TG3TQ\LB| <#<[+3?/L>E,*+.CTXL'0G,RU;#,WMB' R*.6OO MA$"_>$D H8.@BS>9SZMMG&"\,HIH-)676HV^^<54ZK#+IV-U1,,S<;G?TFL'#\ M>^WJ:VOLQ#}]##&?!ML\2D=|-OLW7EOP3,?*L/D)?4!-]60EMKW=T*@EHI9S8D=![X9/[']F;EYR9O _.3'> M3;7@V1]200}^,?E9I-O;YRHR<6HTGA^>D0;VJWZ-]479B[&TO"52YMF%@!C)-MSJ{'|S@E%KI<:,!BQ;G8V^BT45!,C-2> (5VST(']"*?I@5W;,^ M&MWEK>(/!/%XG7B[#50_-L5Z-384RR4M_9->U"H8-+HP^+1'(!S]R0C25T'Z;O1W&AJ._%(45W5S_I?3CZ(I@2S6X1[]D M!%BJ56.IXA,G%M&AY"6SM:C]&R<$*Y.TA+9-E!]23EB9.OIP_2!$R(]Y3NF MK,$:\D*X#Z_#^%6K,=H*ZW#{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

*MAIZ8X"34X\X:(%D5L*A"\=R|&)DFP|9E-'[VF\7E|:)S*@6STB(0D^?Q8NO6(@!355KU-ML|FM3OT#!Y>L{OUT.M5@0EV${|\VVF7K!N:>P,\DI>:V!O&B+.9 J=*A4|/-*

*MF=CEI4=W.A@B*Z)UE-?5SJ?H$C%$6L3)8|G?)Z.]:\KK(T3S8\(_!O,M31]-M"%'= .;4]>>5"(5\4L;UA;S45X4L#4_IDI_C*#J6%1<[^F&)?:141LPP=0*

*M=12M/FBC*UB$%LX=X)_7_G9|59K;,E=:,0V;8HF18K,!H[?1LG_C'_MOG/AR%8(O0_^#C$B= R=T 6/4>"[)\R_JB.,&DSR@D_S=GOZK|Z7U:FF5 MH!)Z.[-3Q1ROR@%?HEM<)8 >;-*

*IE!"W+BX'[_3YZ_> :/\|\= ^N&R,/3+%\ZL M6Q_K#>?!=P*Y:GI7Y^N##W:W|P#=]^2:R643R |FD>RYOO2/V:GL#"] 2/$!Q|>&HSF2YK2;&4,1?*

*M%"4K>MBV#"X=\/M80L).5(T#K5QB4*9 @YF.KT7,2N=^X5RR|K5:6KQ%4)$++#A)'4 M8I"OL16(V] ;'@;R)=,/\;?H|\L0F+&P|S?A<)DF^')RP|\"C#Z\1&U7RA+U'B*

M!&4Y&MV\H=]D##YT7|&\\(1SP?L&:[!|V"KF&INAP&YHV6/V)-5K&IKA!3% M(*|L$)LUBD(;&HG|4,9>S360D67Q*H.!9(U2LZ8KK7%W#.O07"EL31O2(B.N MV:G:|/ZE\N\Z>B-*

:$*\+XS;:U;A&'2l(.5XC:GO3DLAHS9K1F2=Q/3W*'Y|M M2|LK-FMD$@(JP|363QI0D0T%fR/!FP%"UE8L$B.lG!I1/29|KZA' M_!3F#VP7SJ?7M6'-*

*UJ+'"QE*SKFG:AG2#:E^_5"=40B|>OF =52J*HT/XRNS M)L5180B-FW$1X!FDT]!*5:1$)=,;*B*H5-)NNJ5&EJ9YN8XO(6M2;@*EOL2&@ MFSH9LQWP%I''20NG9#A9#0&@3>0V?H)*

K3FR6E":59SSA/[YCPX\ M;W=YA!MXNR/9A.(L?9B'->B9/|H44^'|\Z-QII MY6F_@P UV2=1^ 3VV34IQ|!D^FF=:B/A|:''

*G5<_0!]>@0/Z"?VA2'#W7-SW3(@U#3SD'N0O4#'Z13NM4[EVPG,47D, MOC418$(JJ-WB@&2\)I?1,0T]B0E>MDAX(ND-**GXPE.BW"'T2MXU>H],:26*

M%5:AU".?>GG>-)ED)I+C";R?02<_'<$_^P.Z;8[:#HMX>DB+H(M\#A+I*N*

MO'2%7>ZB$3U@%H&C[)'7]:9:A(_F(.1)7G:+0%"6+"6>G(OP>I/&2^.],YYG MRT3M-X_9?AQ @KG@:LS1D)M9C3FK,6=,.8\Y$,XO7:SZW)E;_?

$W//0^+')5A M-JIDDMI&S1J9MPCULE51=+C%3[N/M5K]|++465RO0(.*:=6SNU"PY#BKX7&0 M?:-AW2S)]I:.#$B,NS9@IR;,YM>>

[7@/L(:=KK1V4@_78 7AQCSBTL6W54^Z M[. &18\X!]"^BF(1>.(.8L@B_EUE)JE6XFBU/-9QE@1=VC!A6.?@ O\5]]3F.% M;PV=7L5L6 /M-=R0A_I2I'.*

*^Z//X.,L6C.S[CJPB<5]9.#]OT(K (38JAPV MG]'M.S]'?@QH'G(RO::E[5^]O%8O+YVPBE+AUE63RX#"2$)7:V#0:_'NH=!< M!,JK7^#]%V@'4*M?*

X/BB!SW#PSQ1{)1T?YY0#'K%REI;%H'PZ@MIFFS'[(}~ M8>_)+61L?(O >G56M8 V.VBO%P'V1#V#YT:>BG:&%6A==Y2TC6,1:0;UQ><

M3>"+R'JG$T^:#7X1&=TTADLU_0:&R$(V4_SZ.3P40/^\ JU'Z8?5RP"!ZF7GK MGP?&O9ML]L.\E6&C8JXNIOTP;Y6"'O2E_& (H",\@ZT|\QR.'^.0C>%>#*

<> M?.>K'R#J!+A2[1/P #ABM'&+$S0'$%6G@ZM#,1)A9+OPUT$C[G0-L504#_, M]IRLK$5,S= \9GNM+EQ-3<0U.C)WCEOLT#9-8M\#N*XWC'^)*

@]M37VCFM.D M^MI_X1(W;RB1W\$S$RE]9"KX]A%1ZF*SZME3$OY[+BVE4:(Z-XV>PSRM3 MLP-1 ^7,W+,26?!3=HN]*

[&#&TR@D'KGX\ZM7)#/X)H#YW3 1OQ&--DMQUWROE& M5B?!///LMEJF' /W^WWT^B%.3C"?,OZI,EWTVY>7_VM.K/BKN=CS!J?FQ=G3 MV^H-

$W33!%1NFS,[[H_1TAB2=&E($(,KZ&2UW+ -:=$G0WR+5AB$07:XN&H MW.&-4K32U;E.<'D3 M298G/]YXE\KCAG:HH+^.1BKHC':BEDL_:PCF/OSOR*

^3W]#>HH>P+%DT>XVW M^=M?:)N/_CK:YK^\19TV_]+/V.:+5!EY<2LT:7A&?]T<,1=F4$2GH<8CD\^_ MT<@$_54KF3RG<

*_@69#C@]9J/"1^IW+++W[MS2_4I?-K2IH#^.MX4[JDHW(^* MPCT5A?L1IW!S39L"^JL=FFZA_I$HL_5K!&<=N\'1$9;&&9H.;]:@**D":Z4C*

*MZPJW68/$U."1Z(L66#['6D$###T=7-'R21GC(#6B@(9PV'E.*Q=9P6$$', M-6"4\34L_>@BH)%3L=:BA'-E4M@BTC(F/E6)XUF%Q$A(D(SY@OGA(W7%5#?*

>L M$9&^YB3E[D6 Q;WZ9&P5BT!)CJ_W-XC,.D!132K')I99PZ$DE7,>?(L J3.; MJMC)%@%4+T[5LL3-.B95C1]AJ^LX5 6GSBDM@B@.O.DBOEV$4

I\:1N!N)9 M1RBK,2IL=YXU'%+GCVH7GS4L:E3R^T6\GF>,N1H MBM1Q/_/8;34XL_'>!'65H7IO>#@\Q2>9Q-PE^7@V>[(NIZ3R/W&"TA@MS?F M4GB-

Z,M/B'#-"9^B-#0VZ4,I;#9DHX;JY#I:;YV!YK"=E<'^CY$1T5L-&0Y 567^XO]H^X2]Y#-+X'O'C]RM<81=CQ8DFE> ^\ M5@H=JZ9?*

*=\3LK12:,WQ!5%NCD;')8EX3(YD/IRW(,QB\]:NS@\1# *QN$38 M8OR"IA'3/^)R!:U?8?1*H?.6=@-SD=V'''';XVL"3P6#R@M.I;>V9.C\|G=';*

M$J&6.W=]4X,:/]J1\(I.9'U:7%+G|S%8B"Y}<,*;?%;<%5";6B%@<4YLJYE! M9@C]URR7VX5#/_GQ-\[DN5TL6,@U-EV@JUC(>KA=C"V$4,\@!"/X#-

P43>ISE(#X)@7_G8;@Y2UZ.41I[(3>RQMJ M>'[VWYD/,)VCZWY69E\% <#?T.>%V6&<<5]U]2)K[5==[7.]>4N.F>942=Z0 M[6:)HHE[_:4:6C+I3TZ28GL

*5ME)3;[602__B5*8<0AT?-!)RA@&AT>T^,-G MGY-E0>/@>L_%U9,$;Z&U&D(N9'53C8;6G7CDJS#-R#_+Q(.T%[!D?<9L!0R*

MRL,,=_/B7T3W8Y4\#SY,SIB\Y:[>OL-KOWNU7+PCW;I#:/;__&3'Z9$X&7IQ M^PBC],1EVLT6@Y@3GK=WG:T)XKY:I_P9O-7.JZ00)=7-

*"AHDRL^_'1=X7RHX*G M+]$SKBW|F&\!/KMR3^1:!|VX2T.OQL_]#O!=!+S-*_KSGI:E5'4$;_:EVU/S|B#IA21+&]3&'E1$#@0*

*MM]B&==&FE&A:ITG'D.:TRL-IE,?2)E|'81P%OH<0]AY ?CB>L%,<90'LMEJG M1&)Q*Y_#R_4<0EUIQ/LJ,E=PPB9,"5N)C-+5E %>XL@MAC[X!Z 'KS*

*M6.+#Y2?^OX%WX1L,?L)ZN74=9NR%R+]%>X\WU-)N"[]UGK)?HH>Q"OPM58G:Q;C@6,6:H*VP@6*K(W=*

*M6^N9X7XIY<3PVP\XM08YW\=QZH0\5#N,,.#T_^&#@'.["=OKU:H6EYV=*6J1"_S_D#/1M4HJ>J#@3(4!-:..#9 ;%MZ M-MAT%H]-*

*[+K6GHTUH:7[K]JV/1MK"DO?[-!C7=_JZ\-9 0 NRYL5Y)58W:6M ML:DWW7WNP[)2+GJ@XTREC'5(=+0C!8LP>KR:V8<6I[V(K, *L=Y5O!YD8JD7 M :*

*H_)HD_6'Y32T")'94=5EA0R'<>=:0,<*D2;+-1]CR,]"@U8^H831K&.JL MFI?>GG/E+0*A(0*\|_A6XZ(7 2@WQKJ6KIP5T;P(F'@!T??\D=OXH$%@8A]*

MKPF9U!CG1:#$BI*NPD,3JA8!CDQ$=IUM\P?%P&9(&2ZBI;>2W01Z,I$UE +P(R=F(\MEIF430EI;YJO) 64>]$H\:*G:Q@$4C*JJZTIDI8!++)2^JXN*

*M>1AFC9Y(]57/YS!K**1?EM+))A8!%SM%15.-0^=[I S/|ZML(=(!+:)B44=9 M@Y=T9!&X24L6&L@+ -)8L6!!3;&R"&QD[DI6YI=E *3"]FE7Z2{J0FGUB."E*

*MYM&*YL\YFB'89_%U%N'9Z979.RW0(DA5[IG9\8TY;^@4+HMV!J,%0*1R7;0- M5K,N:*;QLE@(4K+70"M/UB+0D7>0DTAWM C$9!BX7*

*:Q9<"EPLR9UN)95V4< MX ' BZ9?!)9*7+^656X1!*@+\/+L?]|(2@I,?I*:L9%@*-T%*7H<-8%D+5:W]A)-1>!H>RYU)38+G-VW]K$,== M&:?=>UP,;/04R*

*MG+=AJ,,!|!8/F< Y;ZWK,'!*V)%^F+<*K1^N!)30!+6Se'T^E&#9]F4ZWM: M>.FT\UP3\:,WH 1XS+S:O(5[?:,.7^* @S3?!\?VG<'&3R$%.D%P?+%PD6^G0*

M"6[KBZ?IOR:3]YV@MSY3>)YLU-3P!+KU24)S;@EHR=0K:\,H8S2(1T^07=] MB0@(L4-V?8+M^C3IBVV9KI] NCY8M$":%P(@,47K^T4']'F!*

8+I^K;1@FF6 MNY](@NKYR^F':(E 8%T?00)8*X46"&;KTX>"F4R%!P+@" ^@OW]HX8>F_ZW2 M@/IYL; 6F&F(3@V,G> G #)>*

<7S[@.I=_8A<=ZC,#J>|SEA03R($'#@.3T> M'7C>[F[1\]G%)[+(QGB=HA6&[KG(QDA>V22C8[P-GT"97,)W]6(!!2FB.],5?[X!7A[1

,W($:+SLLUU)@'GR/AP3]5\UNU5MII M,&.+ITQ(ABHI[8TM@9Z>OS'O1[,)$=L5SF82'7,_"=S\ 4\,?7DH@4/U4(<M>A-HYPD8_DS2.[#5Y!|-

A4KXO(G3@<[:4E@*CL\J6SL<5MDP, 6*\,P0&$ M<39/3&-X>M=.?+@+HC>\#Z"D3+!#TL(3<+$TYN_\G (WH??BO#,PT/L=5M%!*

*M,^FZQ.Z772Q8"#M9-W,AE"ZF[\R*9,;9"T9CRV5H_DNZOLTIMQ?+:%N8=!WJJ/3%"(7@1G_%< GK?5$_ Q;!XFXM?+W:T=%,*

(<;H+)_8G^3RIK+!HYN^\3L'+.Y50O@;@RG@[%%Y.Q-_;(3]I-O2:1+L8 -7"83"S:$ MV\6LIVX,.-='L-W.//9D.JV[/KOIA?

1H^'R(,@WD/O=YB#BE7_CKYH1FOS.TU[YI=5 MO:/GFB-]N:74'U1E:=![CJ?PNIH5S]!1=K,@ZD164&/T,&=%!##)'87Q;7D#

M3ECOSET&K(\>\@VD,'RZL,+,L>O^VX4P;]YB28IY3=2@:N33V0\2= M-RI;^SQY9^CLGW MSG&YX MM$W@.G#!8WQU;BF@,-O8;2C-

*4-.#DSRU/]_I$XZHP_9"O MPJQ];BY3#$+L*_4^4;7 C.;&9OP1Q "Z 1RCUY&8ZUT^@+!UP!XHI<8M9G6 MB92W*_ VQR@-DT<*

*MV[N>^#2U#6"#EHG=^>D07+^9Q1BSZA?GYDPT=OIW; # M>'1>$3U$X14XH)\B1"*YD/I\CI$PQ=Y#R9[F]*

MIJD\>;78]Q@%OLL3SSL.I'4QCVGHXPJ'HD--;Z=56&3;E1_ W@ERZS'E(J>U M&)'=W+ZC>S?.Q05EUE/KK!5-%W\7/.>(%K]

<4"W^\.7QJ3'ER@=Z'XDI)IC M"3UBAL?B%O9?03B@$[#QH@#$+I8[V8]LY3&T+N$B&6"[XB^.CT\NAP_)=!F3

M.77E0P/I#)K;VD)LP+.0Y$D=!K%*=U#X\BNH$@K7N1.<=EVDTVU.TV>K/> M\4'V#=D#BST+:.C.M$VD6Y-KNG@#ZLA306#NG\7A;E)?

_HVE1T%_M>)MG-QO6 M).0_>'^D5CS:!$W]S,&D F#A^>(V%%R0HWX>?P:OC.>R;8^!O-';VN/$U

*M_/M&JJL=3*6II2.E6G,!NXN>KS&"5O(N7/C*N_P&>*F;^'3'$DYCO4P&0"PH M(]%HNY.,F:B'03^7TRG(++,U=VFTS<3>?.W$J1-47M2_AAZ.;]#'7N)*

*(1@\! MDGS!T4^9!23T?H?F%SQT#YGT\M*7EA/R-'F.TOTAX96@%_6"ZL'!ZZ'T[9"P[8^/ NX/1RA-8NWT1\ UR'>[/<032%!E\@K"*+,$2BW M.>*

*(@8C>S2D=QZSKO,H1F4YRS&XWRZ|+S9N# MZV^KWY>UCK8LBD@LCX@9XV"&'=.,0=A/*R]K?-T+NBE0ETR3A:@C\9.4]GR6 MZ:7WDB1\OI2NKR-TE]$%6D[CHHMD"]J0IZFHT?9X7Q MDMCZ=J3M(C)D"F)VJ\'QG/C8(; *+$")$5^+4:'$N"Z"8 0!L^0XM8-8%X%. MSW#86G9O7FCIK,&4B4XE1Y*

7%#I[D%K!I025&L^:-0S= EYYU+.@RF#"C!>< MZW\9U"4?YE^%2C;=];8R87LDY-(BR.>/3RBN&0B3'"'A6>-48=XX\8Q%,?S*

MSOGI(HP"+D\?,_9V$00F';Q;GDA^&.TB0%,(ER^SY#)#?,>-6,=@XIH 1HW2 MG35P_'A?

PKW8U^BLF;LH7T('GC692(8YUW+.BCG^(B#K%%I=D4NE'JZ+ M0+-/]':M8@]+R3IK%$4F&F$X^:S+EHAL$?5@]5E#H6+8 ;)SQNASFK1WI:,*

*M>>/.32'(RG@P:ZQ4-%ST# RSAJ?GHU B6\2LX9-^ G%25\P:()$T)9U#8Q$E M=Q1$B5ID_+5IZ65>OD;"!%.S!F\XXWV9MF36^"DI:B@INV8-CN*U24\G-*

*N^ZG[VO MRFY&V154[M.)ET]NUM"IN=[@)':SAD.#H9$5@3A$]5P;G+;?T"!1JR0C'JT1L M_9%\W,PX[/>(':7Y:-&O-*U)?>RO+I2E=@>1*A%+A7@6&?*

UNE0^4W;S.K[!0O@+X-9HZ0;+"3PK ?EYI MKWE?]U('#X':'+A>!]")X]]JV&>(XJ(DT"N $B8+O>FG">3S]+;40+-JZ:X) MG/-TO^@/IV0;@+C3,U+>H1)*

*<=IO N/"E=Q<&+FIQ@F "U=),H^S:![FU)Y#8*CUA?*C,ZN5-$/ N+" M+6(R)YE?DH2$"(SP4OG[AQ:..:[?*@VHGQ]W"'*

($;V!B2.'Y0P^@G^MN94OJMM.GA' M+!+)A]^9JQ]?7T,SUUR0[Y6PN;DJK66BL:;<*D:SJW/Q83\)46W(R&6B?32L$CH@%!!_U(;=-$$BI

M2V.422+F'">AX\EO;&&SR!7S8.D/4LK_[R>$:BM1$<$=;=ES=(/7P)QC'6YWHO MSCMC95U&TDI'|Z&+O@B_,<@<_#!%7UBHH*.PO@+HP .T!7A,]*

>LBH:(&: K M YNFD("${Y#S<=#T0'S[CM:!1#|_=. YXP^?(_0I6ET4!!D'R;TF*&1]:8W;HZ#+KEAAE0TAY*I;I:](Q9$D12+Z R10WC(;(.

MP#0=3RG<9YWP5>]4BMZ92T)(_9#2WL!+0HR=%)?USIYUDL#.]-3G?3\$HC9%

MZ_4XHT:5#$/DJ9K)O@BT%%H3Y/R<(Q=FGA/>I)$;0SDR2":4"$G_Z%/& M2Q)AM7GY,0/Z >(L7\=J:S:P@-76O-J:>TTUADEEFNBWRQ2E@874^6W'7?*

*MHEQ"U2DSVVJ9<@S<[_?1ZX#C)*2-0MO807"Q.C%G7VVA53I5#%\9!=.E'OX:O $?V:/%_H8]3YV18 MT0(.E+K;@?'F%9UXS%A?(AP?*

*&87/2>1^.T0!8!9QQBYD=D%BE DLM^:"*O1=. MQC&VY-^:OS_@'$]YA#Y)&I$3WC9-XL0]L63+VU^U.>Q::K$!K,ERHQ%ZCF:7*

M\K<[UI35]HHYBC7W&X^_Z6VMF3J?V;!:VR&WZY&YJB(\6W!9Q(-;)+=5H6](M2"L^%7V8FORF]8UMKZM79^*2D0T'>57;YK(U#(+E#3!

(4=$I8Z@HO\Z[]J$N M_&2XB<,"UT&]9 BVP)>Q#_S"F?9H;0/D3=]8G3&O.-,&91)+/;Z\O3H@6& MD^_2>MD->H7?

*%=67Q\;S_!R&BO)_BNIL7&;LLW,$7)_,1B.M*M"7M^CE$*4Q M8FXYLC\VP.9=%&.KG6VAB;ZFK5K*?-RI4Y M=,HKZXK3-U2NLSF]\/$41&<*

"M^A)25Z#?-7\=^OE'-7P>)/N-T/8Q.D?1+F MP<8R\3$M]M''S_[';VWO06,2?3S_^B!HF\7U("FGH%;3I7Z+U<52Q(>!=R8FQ M\<=2$;7A!-/H^[.7'K]9%.E-*

6.^1;ZHIE03D,GEWUX@^[X,\>'16V1$4A+ M/-NMM$?L6$+^P6T[/0K !=>SJJX)3+,;-DOM\G)PPE&XBNK7&PS;JQU[!MU" M;SM[VAB=;VB?

GU:.TNN&FNZMH[3)EE@4IZ(\3XO:@H+-=A+N(/B5O+31#CY9T M$3M 4YO6R@\WZ'D(4 *+|-"NG:T19EVON0@"T^^'J'&+%K$# S%925WOTN+C

M]'.-.HL> D^K&/ @U#J@\GX1N4JI%KD:4QY$M4^P_7|F''I(]I'C0"V"OB?& M>1BFFT%|E">W53T,B=3-;ZMR"^?0L1 ?*

*_Q$SRWFRAU8&#%#=D.FDT&AASQ"!I?RL;WSI #7<,;A=SX4"% M(?$ERN:%3GDQ31!G-=E8(4*B;J,6*2AIDE%+H?ZY<;)!//2K'SHYM^!'N'"[*

M6!":12%[=]7?L+P)(<9BW6,;EB'7%R@OF4\4-5Z:+?OMQ<-R=6_-4<.X21 M"X"7U0*[\;%2PD\REXP+?_L,DNWNVHD/^>?,N*1.0XV'_>??:-*

*BCOQK#_I,? M9B(D*9]6#VT'H8; MX$+@Q.@,/L+H%HH6@\Y.L_ WX?H:[":#+?:U18CB;WU 0P3_G4(_]GPW MNVKQ1RGZ<+M[\(}^0K_*

*=0RI=8"%5]2^81M> XCDN[V&K06I*HB8\WX25L7^" F?E?-.!*, H/+3=-[91"0ON?ZOX7EGD9"$4>7-/>]< Y* =7GO MCQ=X;I7A[N+:@_[F[/8-*

*U(BSJ2WAO "9T]\,07 ;6=UJE<@8/SBF0Q M)_@EVV!"_HH+DZF/)&7?S'*7/O-]X 0H#O"82 LH')6J%9PBER_7'+(#$: M#W=X>*

*!2VPTQE6N),WP|T/G]]7*HF:7+FNTT/KUV6X_HKL"[7;Q-3@=D?<' M.E(9!7P&"7-F"IWU3_HS>I;6OIH_359S\\ILWE,,;+4YKZ!96XJD7H!$H]&\ MCF>-*

C,H;KQ8!SG]<0{9BW6,;EB'7%R@OF4\4-5Z:+?OMQ<-R=6_-4<.X21 M"X"7U0*[\;%2PD\REXP+?_L,DNWNVHD/^>?,N*1.0XV'_>??:-*

*BCOQK#_I,? M9B(D*9]6#VT'H8; MX$+@Q.@,/L+H%HH6@\Y.L_ WX?H:[":#+?:U18CB;WU 0P3_G4(_]GPW MNVKQ1RGZ<+M[\(}^0K_*

*=0RI=8"%5]2^81M> XCDN[V&K06I*HB8\WX25L7^" F?E?-.!*, H/+3=-[91"0ON?ZOX7EGD9"$4>7-/>]< Y* =7GO MCQ=X;I7A[N+:@_[F[/8-*

*U(BSJ2WAO "9T]\,07 ;6=UJE<@8/SBF0Q M)_@EVV!"_HH+DZF/)&7?S'*7/O-]X 0H#O"82 LH')6J%9PBER_7'+(#$: M#W=X>*

*!2VPTQE6N),WP|T/G]]7*HF:7+FNTT/KUV6X_HKL"[7;Q-3@=D?<' M.E(9!7P&"7-F"IWU3_HS>I;6OIH_359S\\ILWE,,;+4YKZ!96XJD7H!$H]&\ MCF>-*

C,H;KQ8!SG]<0*BW6;-EB'7%R@OF4\4-5Z:+?OMQ<-R=6_-4<.X21 M"X"7U0*[\;%2PD\REXP+?_L,DNWNVHD/^>?,N*1.0XV'_>??:-*

*BCOQK#_I,? M9B(D*9]6#VT'H8; MX$+@Q.@,/L+H%HH6@\Y.L_ WX?H:[":#+?:U18CB;WU 0P3_G4(_]GPW MNVKQ1RGZ<+M[\(}^0K_*

*=0RI=8"%5]2^81M> XCDN[V&K06I*HB8\WX25L7^" F?E?-.!*, H/+3=-[91"0ON?ZOX7EGD9"$4>7-/>]< Y* =7GO MCQ=X;I7A[N+:@_[F[/8-*

*U(BSJ2WAO "9T]\,07 ;6=UJE<@8/SBF0Q M)_@EVV!"_HH+DZF/)&7?S'*7/O-]X 0H#O"82 LH')6J%9PBER_7'+(#$: M#W=X>*

*!2VPTQE6N),WP|T/G]]7*HF:7+FNTT/KUV6X_HKL"[7;Q-3@=D?<' M.E(9!7P&"7-F"IWU3_HS>I;6OIH_359S\\ILWE,,;+4YKZ!96XJD7H!$H]&\ MCF>-*

C,H;KQ8!SG]<0{9BW6,;EB'7%R@OF4\4-5Z:+?OMQ<-R=6_-4<.X21 M"X"7U0*[\;%2PD\REXP+?_L,DNWNVHD/^>?,N*1.0XV'_>??:-*

*BCOQK#_I,? M9B(D*9]6#VT'H8; MX$+@Q.@,/L+H%HH6@\Y.L_ WX?H:[":#+?:U18CB;WU 0P3_G4(_]GPW MNVKQ1RGZ<+M[\(}^0K_*

*=0RI=8"%5]2^81M> XCDN[V&K06I*HB8\WX25L7^" F?E?-.!*, H/+3=-[91"0ON?ZOX7EGD9"$4>7-/>]< Y* =7GO MCQ=X;I7A[N+:@_[F[/8-*

*U(BSJ2WAO "9T]\,07 ;6=UJE<@8/SBF0Q M)_@EVV!"_HH+DZF/)&7?S'*7/O-]X 0H#O"82 LH')6J%9PBER_7'+(#$: M#W=X>*

*!2VPTQE6N),WP|T/G]]7*HF:7+FNTT/KUV6X_HKL"[7;Q-3@=D?<' M.E(9!7P&"7-F"IWU3_HS>I;6OIH_359S\\ILWE,,;+4YKZ!96XJD7H!$H]&\ MCF>-*

C,H;KQ8!SG]<0*

2 M)\!U#NZ"Z*UB@G\"@9,`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|!'"/#NQ'&+TE!\2M3T[(M1I+>>MPCE%THF4SX?'#0$WB;)G'BA)CKL,\3K].XT_/S1,X11"K:,,"+FS* M8#0?EX8/(A$E%%K-#H/R%V N R@:;#+JU' Y'XAV+GNB9V_>:ZR,@H@>/?8% MQ>\UZ@)>G/=[#}&?O_/=;#H"H%GM1YWTQO/0"8^+_V!%S@_,"=/;&I[LCPJ3 M_='(9*_1CUOX$KTU'"^Z\EB8FFAV>+*0I/>"*>X^'*&1?!*TF(U\$""JG>]B>L33])+_AQUQ@?=?WR4P!9<_M1N@$O">WN6ON? WT7Y\D>66;"TG+EA\D'SS^65D+TK*H;!V6-0[CNQ]?*<(Q\ MG5'YSQ8],R>(@?*R#VADZ*9?P?^@XU0U^6@D%1VC[#PKBh]85P< M8O4_6;/M#$OF1!?==5%,P@*U@J*_M=,,><03"P4$"L>_L,LFH+!<*V0]$@*[=6'&3Y*PV"@H6B(=T%:I#56R@+MKVK M!EFYA>(?TWEK$ L%/[83F%R"!2I">]J!TPG)KCX>$1H[! AC7Z(H\#W<'+' M\M-XN|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|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|SNLW5^L10 MS>"[*0>R8[%#F?*'R9IP%85I_(0]AP*FH]K=1NL4?O<#!!T.KYW WT4P!]WF M3)A-1[[DB"LNW2F+Y;_(DC3Z##=E3T[S+#;SX]R><.1 EF8Q+YZ8933EVO'$ M_?0>TD9B@FMTE=TY;J8U9I];<2)W&"3IBL*QJ@5U] MT?^\K%H.0RA2'TFO#[/_#:!+?9\%V>2!2L$UP/E+V0[,HB[C2CC..]^1J/:Y MW@Q#$!QI !%C92<7:C;1OWF94R)BFQ%JS99)F$WU3@CQ%H!9^"]1?/*1)$8B M.]CS$O30NV&E^_EVA|UKXPB>[P#8AIM7=$GN07'Y>Q+[M+#]B+@=@.<%CIZ8 .L9@MC1(&>N2X 7#rG0"\]*+ RMTGUL2S AZ6D8[6V:/K_ MFT:X%)\#OX&DJ(*DL)QV[^EEU5,,3:Z5E.H6 FMU*A1A'AQ>$#!)7L)9IW(MXEFI<]JM?O+9<.1U1+6BTJ+PVXFBT=-UO.PT*!,+.W&(NG!7A8!:JJ$1H98 ;037G]'NQSAMIU"7"'<*ES ULFQ0 MJLWK%R?@TI&LIU[47#[@U6;D! >-$G!#^&XC|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{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{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

*EL,A7[=3XKJ3#\$I\@*LOGDS0ZZR3OØ2=MN3*Z1#&6BG[*IF/K@)E)-Z+`M›[1'6UDRI++MG%1\P#0Y/@4H3.!\8,;] U-*KXX:S<:DIWU@:94%DYZ7"=8|M8D!95/H3CK84,4$=B4IRJMN>=\I9KFY]\$E(F)&\[7T'#-"8A'#X+#V@@SJRS M[$^*U22D[SO=XBX+,5/K6(\BG*VDM9637\4OCE_]:I2[[B-;&4RP\LD7U\ M=>Q8T13+-F@HMZV))Z^?I S. 5'N'UIMJ=[%+[DSCU%"1QUC_.:DTFH-B M@!ZB\ KOX*\(2"23FU^.,2A8\C4T[#E?G:T@BB0:@J#%N#[L,*N!:EVW[94[MKY16GZ* >"J-8>! HP+SE+* E#>LV]3B=F?XC*M*IVQ= A3Z11 %$\)VV)/ !#T!H"S*<.RQ M4!2Y>MU[C%%[] Y@YDK]C C;((KM;M+EG/M_Z':?8JH",W1^.K-9&&[] 8-8 M95G(LP!Z&!B*`J.N!0\JY'9-.:J[:<8MF!@$_ M/SV5C6_T]D8X&G=FCR_&1CP879'_ZO:79/]LT'V[]Z M"\J,AC@?KJ^$\]RGX?8LI>3#8BX_"]):1_G>CP$7-6'B:T2_81H+TSFDPLAH M0X|I&*" ;"(.;$O2(WQ^03XG_@DF\)QY30IZ0Q_)B'R.X2M|QG-1>+0(4?T,. M-#!-$F73'@!>?0N?,1OR$?RDV/B+\ZV!Y19/NKSQJBK'4RE;=-.(DJ/+,& M"]A#K(*M$48E[SQJL3S+K[&?>@D1AV0K&H_+9#!E@C*(1]N-VY)*;XL=]QLC*\K4MVW'IXX&\$/'"%D]0[R/+LU^2Z$CP,#JY9.J$#WZ3_JU!^Y0K?:M"TYS'=;J'BB M8\RLWWR|*@*5ODRF*%23ERC=[A*>+R7C4-I^\T5]H&.63!E1[JQ]P4F2[0=I M.(ZBQ]BZ V?9G(UC_Y9&^]4;IL775QO==>,,..?TKU.0VY:\S.5="&*.E^:7 MD)\.EWSHD<7;Z%?L):"D.[<4H# (?*&@XB'F5I2"R5V>, ^ZRCN'.=#AAC9 M*Z;ZUEV6]>D+IFW8<3Z^A>,8XQ4<9XCQH'NN(V"Z7VV*BBHRQJ7O."_S#K=L M+L4Q5^6\J:5%7;=9 4J$,X-CFD0=PC/M9MEQN7A'U,=^_ .RT=$6H]>H0CT) MAEP5OD4EK2=!D/W"MVDA{4G0XX8 KBC@/0E6G)"UE17$)T&+$^+S?9*YI.@MR0G)V:AB^B0AE_:+S7TJM9NAZ*_MC $'_Y6>RUXVT @_H -[E>5X1L8>G]_ M_T,:$J#H& 4[;O>+\^S_'XL2]#\FZ",*H_WQ1XZ[9_CGEPH-N=/_&1\BRM!T MC1-$@A_FN^ZV.9V:#;VS8)U[;PVZSG?97)FDKICGU3%_V?#.M>$<,-)\8!?! M1@57SJ?5*,#;!E#99\;;F/DLFB$Q8AK,VXQ[E8F7)KANU&^7^6A.R*#'N'>(-MTX@=N0>@/DZ2TLN/0U'G4PGQUF'*DV'\3&U2A-#5 E:SK8%BE#]8D.*\:EN M/-OD<_0QTW1A^_I*DMT23O-HC^G-AQ>D/HL#B6-F-//7Z$,"V9'1QKYM'#[$ MQ-UB#B1,X8.YG2*XRL,1P&&)6!CP@-F[Z-P3!G979Y$158(E(>E=\)&,_$&Y<-GH2_-@O>_

<\|L:H(FEV%RW2?!H@M$(^SWA^_7GTX34E<.V5/&&-\ MH\|8H>$DIG)PQSM(OL\#6'3F4_L]@(<>4BRRK&YF&!C RK&YZK

M>Y]+IV3?;LZ0L+P47F+UQ/+FX %EA="4H2Y3O@!;Y"L%1'R@W##O9 Q\|MN MX/@/\MQH:WL8#@:,E-EW?A$@4>5Q]K%L#QQK-&FC+PX?*

3WW3CM MLS$N>^)H99/.?0>2 M01:Z3)A_@M^7S<+<2TNP:6M;^+OA30I7RIL4.F]M7$?^G4<28H$!J/[8QKFW M??5]

[KOKVI%&^)]H]"MFRN%BNZ4@ 218O<^J@)"'^_5S9ESR.E%WKW#Y3!"]L M7-&O)H%6YV-;EA=+W-D(#VZR5%WKL[$-9 QOAZ5964:2BPSXJZJX4]F)X

*MQ.GP$YP/23W.>]11K1'PM4H2NX.OR)=DXE#?"V:ZQ]:8(J\(@3RII7"WP<(S MCYO$A6/4U$88&9<&!0"46E9Y/5-;5V%>_OIO*24Q[(Z& @#*

M@'KU:V/#DN"23+B$'5FOQ%[(#]M-+ M"T%K,>:M^ ^,D#65<%549N-K;&1;.T_>P9EW[U^%<(JZA%FDSK#S;?L!..!;R MEP/Z @ 0GP!0#SS-V'7]*

*MPN+JFG6BEC9"6!=S'A"<9+1057CH7E6\!EZKJMV?(9)RRH'W9H M=HET)P-"U,05HWI>-T189D3\SD9J-HS&&78;XN#1+-1A!95CM*5E;%[XPL[2*

M+5'9ML2(6MAG@+D+V24/0$D!/B[1_I"")/D2I=G-@=D)PYP'HJ3_05UM7%-U M)F#CX@2CI@.LPF>Z,8'Y7^/RCJ>;#\9S4A+O6/5AB5P5]M2W\(;X;H*

*<_[Z M(X,Z]G9XC_[O_P=02P,$% @ ZH%H64H'[*JC7@ 7F,. X !U:',M M97@R,E\Q+FAT;>R]:7/;MA;]^[KW4^"VD\Z],Y6.Y=AN([6=<=0V=NH'C973*

*MWO_!Y&0A!H"5(*4Q7SZ"Y"B+"E.*CNVZHVL3.LGB2*X%O#;&R (_#C.)NKG M_XO].!8\]=_9CYG,E/CYU_^OL;_?:/WXG^I7_X;_+-[QX\"D!7-9H<1/7T^X*

M'4G=GS/S^M)U-C,ZZSSI2GJ=2C-OMA.N\HJ45C+.1HG+59J__U>994SNK/ M6+RYD9EI>Z]Y'7G?4/]5,S;C9>=B=3UL2W_RM0XF4FCVU8HGLF9Z*

*S,O.'D M^W"V@;&IL W_%W^2'Z?UYP^-SL);1+NU-\TZ59&KLW7*UX9\(E71?B/& M\FEGY=PM?^[5TQU;R55Y?*

*37&&5L^YN]\E_G<2_UU_E8#F3&JQIVO.!_ MZU!*2V.<=7%;B3RWL0RV\J5K;P*CTX9?=SP=.II+;@KW)N?5,,.8QKE-VZEPN*

M_.]F6+\B1,KZ(LFM;]FB>M/Q<"B5Y)G_]<^Q<6+U]:Y1OND+ZZ_U_=H+_A.S ML6!78B1=%C[X.:A.OS;]E;M,#HL'5?R0U*1&,M+9N<>ZC9$@X<+*

<&>5H:+'M@Z_ZG:_60U_MS8T/<\S=5OG_QY]5B20$0E5\5U;_;[^9[^^UDLY_3_I>(BV- MK93RBET8WZ"JU]/._\MD:(DI&Q3LO]I_@'5_8_M[^0;-

V<%>",BI5Y@F:T"_")59.2P.I&V6E>%HY]O[EYM-J M'AWNO;BS-;_T%Z$*'L6MP$'S:/_PTP]\BEN!_7^L R_WOG@%]N-6X+"Y]T

*M'$06B;:1'"GJH\;7RX$OD^_M4)'@L])2L[A85@I7)J ?2SQ]YJB=[YGYWQ<] MM47&^%W("\MDU'Y7]OYDYIBK.Y AS57585*7A]UFPAD?*%$>?MO);&*

*[H7KYG M?;BJ$89OVM\W#PX/7G06@T9!E#"&Y!M,.*"A>.,$S5W_%7(^L\JHU*0>MCK/UGZD2/W#YO[1P\\]*"Y?[#-H?X' MNZE#/7P7;ON=-?*

*#&2]H86,&OV^771OC#'0(LI%^,$TY])3=*IK4CY6#.72^4 M;J_^O1YP7+RP]WT8<_0=H$PF7"W:DS])9SF>6*TCD^HSUE]Q';#CB\W&MFG*

*MV_G+]69^\U#C@P=VMFKE/P[LSQ=\(J>VW)4YW/"Y,/*P=;&0N^HJ?>M'4]5 M"^YPZZEKQ2,/^&WEQ]O<2I?*I.Y'7MH1U_)]&491.*

*/[TVA&HL4B$V+MB*NZR M9Q>Q D'A'^S=RLWCUWUV=GK1[;/?__<=.SOK;MG:T*P^3_<_9#B_Y)!{)W(O M.Q&@51RTZG>K&QAH/SMI/WW?*

*8QZS+K?^RC6@!6@!6MM#2UX+7D"Q:(6'12+@V)*2:X34<|CJ?"%)&R'+>E<.A?^FTXE% >[P*[M MV>4KBBXGE;/78LQGTEB?*

*@:U/A4.3PL!7?'"#8'$0S/FZDBYSK]N)NFA&.VE& MJ1QIR U]@51;4RM3WD69L/[86%^N$^.F.N,*8UX@5Z1R@UQOD.O_>%B\LFF M*

*]!J=\W'O_K>8&@>L*LMK?QM>#)F'W_/3OKH>$@J8l/;G J$DXMA]X7 UGG M7/.1F/B7D62!7I*#7I%2J^K*T N4'N2.4&N>*

*(D5Q)6^P&U0*THY0:U(&6 M3L.^"-2LP\RK7[A,3#!O:X>MZK\)9>H#F+6S MAO1.:"V<$\B\GA&X_/>P#--RJ?!$<>?"4N$CT=*

*F%?7G^8*NK"2^LF[X4(EY M(Y56E N4A&65\HGNI-)-%2_:X=6EZ+=^>,TWUAM?!+*M5GZX\L"%T^IP7(G_*.M-*

*;^^VO7Z>*YU6A*60+]=""V\C&T+A:0NUYIW&;=9.RQ)WUE_P1M7_;FL1U60 MXT-?X=MX%8\W#)S M=I5K< O;EE1]A;!+7*

K>KW!K6BXM;';;+D=I9CQE -@.VQ0E>00 M&_0"O>Y'+^N3K9%@E_P:8_3(O;X O4&O>.A5K5R$=6WQD%>T<@-7T>#]-%26 MBL4N-^ 5#[S";S/I,CR@

*MBO'YV,4&MZ+AUH6QV?A&N(SU7)&,)<^L3)![(?>*76XP+!J&F:'/M%+)-?^. MO1%:A.6->MQF_B'T9>@->|< K\W)/:HQ)@2Z@ M*WZ]@:XXT*6,|:^-*

,J/9N>"IN7$8K0^OA2]0;$X&,]S+W.D[^SF6UEG6C M/[9B)];&9LC$,&,B5KF'L'@1!FXAJXI6;X K$G 5VO<=N;48^/I7!MB']<*L MRZV (;H E<;#,*

*MJ'PRR&_SK^63/ACN KQBU1OPB@1>X='$_MA87ZC78LQGLOQ+M2$C (:.9*1R M@U]O\,NG7L(JKE.D7Z#7%R,WZ!4KO0"MW;6B/V0X/^:> EJ*

UKU"/3N>&-QN MQ(3Y+T!P0"L..)WTV'[K98O]SOH923XSO%;ZQ9B:6#U2# M6J!6E')O12W_G0^4'],Y8PEBCOWT]=3/A(-;5)1?YXO:'AY4<[W#:E3,6\W*

*M7G:&2LP;J:0B":M!M9-PWUYW4NFFBA?M\.I2]%L_O.:AU#4F_:]_Y2Z3PZ(^ M77E@0VCOF*G6F6I;7WLR.1/>W7DPQ'JB>VGT?$O/]N[AV-*

YCP:DJ26NCNGS: MO]JTW9UPOVU6N*]7GP-%6.\#&P+A:164OMS9]QF;9YGIK/^@C>N^G-9CZH(*

MQX>^PX&>YNN&%JR+=:HV]ZTAI4EE!5NK81EUYQE7B<3WY]IO6T5[G V."=&6K MW7"EQ.+WS8/#@QM2\Y%VJE.^<,/S;WE^WT-4WSJ M1-

N)J:=')A8YR4IN,^#)]-17TQY^1^WXTFM'H,;EP)_>6/:NF-[9D\%XP#,("EN.:[BP M9WEVYR279@]W7W8T+%#;X'%;3?O&?9CG-$0

D#U]D/UQ$!;WW$!8% C[C6LMP\X"FH_$Q/]M MY1E[L&MW3ZG.N8/6 !? M36XI'4KXUY=8Z<^]:H'O>LI_#XIX\D8+0O/3<0G M-T

6!\C",_:9)Y8O3\\5R5CR,)B,YRBPWF3T<@-AL2 L8[_D.N%A?_,T(I M.1FW(3$"%]7<@%<\\#KCN;_PE"ML^/2OM*7?_&?)%#U'D ODVK[17%UX2%UT M*

2GD5Q%*4K%@2GK2PS/5-YUCB12+_K3KE!K\CHA3E=8%;DBX-@;;H=2]#0\U'B-_.M?:$BGRH<(5$U M%=P"M[:W,61;K*>XU-*

A]\U^:QN6);QPVXBZ(7)$%&] M#7C% J_IF)U+I1P[]M$_D3S#0XR[;$@]H;4KU(SC$2"P"^RZAXTG3=9MKC[" MB.:SD^9SK/B 3P KP

*JPN@>L/*QJ90;'KN/67S7I&ZNS# MZ:<8V\(:$9'+#8Y%PK&9T#=%YRS@RK%TV M'V%\ 9!@ 5: U;U@54_2!]TP,SY6N8&K;'!UJE/)-7*KGY!+2O?*

*&UT_$7V$L]!"CEAO8BA%;RZ4<^L+.9(+%2D&P:.7>BF#^ M.Q\H4?Z8RAE+%'?NIZ^G?"0:VJ2B_CQ?T/#RHISO&U*G8MYNO.P,E9@W4FE%*

M$G*!MK^"?*([J713Q8MV>'4I^]T?7O-0ZAJ9_M>_0B=H6-2G*P]L".T=,TZ6 MGVQ|[X\%JJHDK8WJ\FGSOJI-V]4)7Z[5 M$N_UXFNH&.-

*ED%LH)'78ZJXX4,YC>]LSTUE_P1M7_;FL1U6TXT-?X=ME1-KM/&KCX.RW_5==U4-@V.2CLSZ>1*IDS[?ZSTAWJE(<>M-?*

*MK/JX4*$V\JXX41VY?]CH^9O9'M+ ?X#=:HW;OFG] M.+_7_")8&;(^OG R51R6WP.=!]6#K9E,K1U[4".]%E^O,VM=*DLDYE0-R[M MB&OY?FV@*

[7C2ZT=@1J7 WJZ8]F[8GIG3P9C \\@.QK:.#<_WJ[0.TYUSYI M#?LP86P =V1BU!I#FW"@JW]<37WIVO"4$>[(8'N F-4&M>*@5CX:^^+4VP @*

*MP]*S\U'*#5Q%@:M3G8JI\%]T(EAO7#B92*[12<0-Y/CE!L*B0-COHG#LC37Y*

ME)T8%2[2@5E@5IQR@UG1,"LS6K"N_Y/4>3Y!GH7GNF+5&]""UJ_IGE2#L0S MKE/VOW(E'4PX!L=BUQL*5F\@ M*RYD^0)-CL=M9ZNOY,0V.!*^*

*N'H(KJV0.E9A M,+Z;=PIT[:PE85-,0 O0>A"T_NO?=,,BW&?+A:&W$T3NO!=<>QZ FZ|6P_G MUG^ZW7]8;2[3PF*F*<:1BHW]!4'M63JV&LQYC-*

I].TJ$&;(_IOQ,5;EWF&+ M"H)#:L +\-H>7GIT8TS*>E+[8F$/%"Q<$[/6H%8LW_QGR10C]. 8 M.'8/CNF$NS#_8;D/"E8-Q%RNR 4'O"!5VZ%8I?*

\^JIQ^CH#PW]^]OQR@V, MQ08$Q,> Z;$A79V#U3 GT'O'08JQZ@UUQL$L.O! %ZQGIS_!!$1;X9 40P(6 MJ=R 6!00"TLW9Z)<**$-

*Z[.FFCVT'D$NR*4& ^R*A%W%..SX\'T]A;0+,[YB MU!K)R,I9B)M1FJH!?ZB1%J#71%@RZCV>M&9ELK+M#_BULP95.P&YP2_P;_M6HU2YF*

0F1"W&+76 %8LP+KA M^;40F_Q;[:F/Z7SOSB)=_OT KVVMO%"Y-;X7]'+9)9G(JPX>)S[7S32+]1= M46H-<,4!KG*-]/[4AA'ZCSP$A,$N/L8J=Y;4E/-*

*]0^I4S-N-EYVA$0-&*JU(PM(L;7\%^41W4NFFBA?M M\.I2]%L_O..AU#4V_:]_A8QB6-2G*P]L".T=,]7B>VTK%,_D3'AWY\$0_XGM*

MI='S+3W;NX=C>X\%JZHDK8WJ\FGSOJI-V]4)#]9JB?=Z\354C/$RT"T4DE!) M[<^=

*<9NU>9Z9SOH+WKCJSV4]JB(>'_H*W^,^)URX*O*MUJBZCI0FE15DI8YM MU)5G7"4>UY-OOVD=[74^,"9(5[:.#5=*+'[?/#@\>%$C,)0DJ.(+'@YH^#9I*

*MJ4/_S0W%N^W]GID8I&CK.0Z YY[/]?.!D*KDM M/@>Z#RL'VS(9VKIV($?Z+#_>YE:Z5);)3*@;EW;$M7R_MNX<:L>76CL"-2X'_M_O3&LG?*

*%],Z>#,8'GD%0V'Y\0%C-3K6GO^98X0BC M'KC;'->-AU(US&RAL# M*V.:K%^X3$PPM(F;,U%]#8!% .:!+?U:BGRM<'""4S$!0G=KF0T 7\C!HM4; M"*

*(L#85X"CBE]> #LBY$;X(H"7#VN)A];&Q?TVEUSPMY0@!?@]0!X"7_F:_96 M.3'ET_@8OT<&%JO<@%CL$*N'[\^.9\TN1L!VTZSZ)@]*

[1\,Q>K\ZGZ)K)E.L"C0CW(B/4&]"!%]^_MUYC;56[UK)D&<03&PS >%JO#;&Q2Z;*UU=W0=03 XI0; M (L%8-H5:L:UY*RKI"ZW8NDG8V,4UM3=98-*

*:=>)SGMA\U_[,/U_,2$*O$2^%ZO<(%GT) .^@*]8Y0;^XL!7_RT[3O[. M9;62&FX0[*X%5;N2_L*O38,)&8 6H+4]M%:V]['H*]SD+< N)5]1R@UG1,>MV*

*MJ*N^M8F9&0!8K'(#8!$##S S9'S(42V*P'K-CX]4;$(L78@ 7DJ]8Y0:WHN#6 M%9\X7K!SKOE(1.%Y/H$>(Z 5J=R 5DS0^E_Y"")?V)E,1-EC?",,+Q4>@-*

<<8#KBEV)Q'@U\%P0>HVQR@U810&K/E<9.^/7 CNP M 5Y?C-R 5V3PPB/9H-<7(S?H%0'FI)LYH+(__K[0A;'D+8H%8]R66S[&2:]8? M\U2HM752 2Z

*T:U :XXP.6)96[8>=@5DDOJ]=UN 3)T&F.4>RN2^>]\H$3Y M8RIG+%'78I^ZX?7/)2Z1J?_]:_<97)8U*MK*

M3R9GPKL[#X;X3VPOC9YOZ=G>/1S;>RQ@525I;5273YOWU>=L((&0$QZNU1+O M]>)KJ\CC9;!;"2UDMJ?.^,V:_,\,YWU%[QQU9_+>E1%/3[T%;[-*

*U0TO7!7] M5FM474=*D\H*LE+'-NK*,ZX2C^O)M]^TCO8Z'Q@3I"M;[88K)1:_;QX<'KRH M$1A*$E3Q!0\'-'R;-*

*+EO77(NTDYURA]^:.XMW^]KF.)3)]I.3#T],K'(4U;R MG0%/KD?6Q]6TL:B/P_)?=5TWE4T#H]+.3#HYD$IF1;O^W#O2G]H4A]|T%ZL^*

M+E2HC;PK3E1'[A\]VJX\>>.A!<_]@FT-WD?.0(W+@3^]L>Q=,;VS)X,Q@F<0%+8;(SCI-G[OG7S'SGKHDNV M?O&<,VCJ'

*+K_@-2SAU18SB/=:MOGU*M6OLU-BUK 3-"8]&1*0W\!4'OGHK MMUYPLP5WC>-4&[2*@U93;J\=^ZU\[\H3J%@*9&[U[^PX^3OL-Q].4?S*

M]!300D\Q4KG!K!B9!6 !6)'#6!% JRW]YW#;EEQ@"U@*U^Y@:TXL"4F(LD5 M9W]PI00F<&'WDR]!<, K%GA-U1UC\HE/ T R/*T8M]:*

6"006]S46FQ%YRG6 M3\;&"QUBUN+T>H->$4"+Q_O6;?PASK_W0IQO;H+7;.'Q N)5VQ:@UT1L0N[MF&/0_HN1&^2*B%QG/+=*L2N9C@22+B1=*

*<6L=6KO(!H-7MZ(_OX"MJK8&O MB/#5YYJ=PP2UP*T*MP:TX MN#46[-@.3&XQ/K_#UG/.G>/),'Q7MLP,'_#"TSEVEW[.;;7 M7#LD6, 5<'4_7%V4NV-*

PQ7X1?,B.$YZ"=''%%>@C51ODBH1<5@AV);T<#NMS M_9L-JMQXB76Y]5>N03%0#!1[&,56'F-\8TT^!<0 L:A%\]3B@)A1(C7U5'K6 M-*

4V0"Y/(Y4;S(J#6;D-6VJPGI%A%E?(N;!XU\[;DC"^,BV0"Z0:WMRW9BZ MPWCW7'I,E$#N%;?<(%@4!/OOZQ-FANS2BA'6> :NHI4;N(H)5[VQ$5K.V548

MI\U#J&I3^U[JRE\EA49^N/+ AM'?,5 E&V_K;D\F9\,I,@R'^_M$]M+H^=;>K9W#\?V'@M/54E:&]7ET^9]59NVJQ,>K=42[_7B;Z@8XV5H6R@D

MM9+:GSOC-FOS/#.=]1>|<=6?RWI4Q3@^]\6^S=4-+UP5ZU9K5%U'2I/"K)2 MQS;JRC.N$H_KR;??*

*M(IV.A\8$Z0K6^V&*R46OV\>'IZ\]!$82A)4\04/!S1\ MFS2Y:UUR+M)-=]\3GX

*QE#HBLA!55-$#@KF'2LEN4Y$O2_GLUZ(@;K8Y[*Y\-]T*JMRY54Y"= M@GG'RH--PYH"0L^ Z^P!Q5OD\&N>*9L07K*

MYW8D_/0^/T;T3$Y'XEUFU@37&@8B:W/7G&1]+@(0EA3!!0*YAWWNR%T ME'>D$3"(FHBGQ! NJ&N*<$'!O$6X^)6[K"S1!56":]QRINHG(@('&?*

AJBJA!P;Q%U.CE7@K#KF1B$#2(6HFQ*00-ZIHB:% P;Q$T M_A1^8O+#.Z$4W7RN>X71UU7A R$#)BWMN]:(G2Z?(#.V.EB=SXT$W0#: @+*

*MIH/L&^5Z9GBVHO ^F-C?;E.C)O*C"LLAPVN$Q(67 ?78=XJU_.!;C^ZWA|& M>HC:^B=WXVJX#M(BA%#5%"&$@GG'_\?W!E2X,':]L"3*&SE>X-*

E4X%RNIH" MY13,>RUX,F;??_.>F@8&-.A(>RK5Y!T)Y"X12\6UG:[M+._?3UE(]$0YM4U)_DBQA> M7I3P?*

*4/]5,S;C9>=H1+S1BIM]>!CVY<]G^A.*MU4\:(=7ET*>ZNYUS64MPXC M_M>_'W+'']94FO->+KZ%BC)>!?Z&0U$!J?^Z.VZS-\\QTUE_PQE5_+NM1*

*ME0'P829LFZL;7K@J$UBM474=*4TJ*\A*'=NH*\^X2CRN)]]^T5K:ZWQ@3)"N M,;+4;KI3H:S6/IE_4E L%":+XF1-KM/&HCH.RW_59=U4+@V,2CL5Z>1*

ID5[?IS M[\@_JU(OEBU<2%"[>-=H: ZK:W;M\H?!_;G"SX183NF4^=R8;=,6K8V M"H;7=L2U?'^?'4_@T-,XU!,V\3^5+2:L9QTV2[Z

MT2%+_,EYX2Z>AN9S 41*'"%X:"ZDGRB\7&@L$78L93CC&A)]&\$A>R8D"(`MJJ9@.P7S*K9;F?&18)?\VF&P'X/]-)4%V\%VF+?)]FH##ZP?*

^3028^D"P)RZ MIH Y!?,"S,LAM8G)=<8EYEHB42>J+-@.ML.\#;;?+@B\-LC>S[P#DQMC4CSY MB@2>D+"_/"

*A58A+YQ4BK,_N%*B6,G@@7;@G8RP0#O0#O,VT1Y^FTF78>4Q M3(VA*"NH#JK#O V]7QB;C6_*6:RN2,:29U8FR-N1MU,4%H0'X6'>!N'+)Q52*

*MR37_CKT16H05X7O<9OXG-Y93-!C<5B6B+/.O,.\#;SWI-8\48+UC/1_1^H. MN)-4%G 'W&'>)MRMF08EA /.@7-*R@+GP#G,V\!Y7PIK.?L#-U&!=KK**

*NU M.\S;1/MR&CO #K#35!9@!]AAWBK8E3'^M5%F_#L7/#4W#O=0P7C*RH+Q8#S, M6V6\]=_+O/TX^3N7U3KI2-V!=5+* NO .LS()ZPW^F,K9F)J;*

;"8VH[)6$! M> >YJT!OM":G7-K,>#^Q(^CAD?$6)=:?XT:CZ6"[&0U!=DIF-?E:L9MP;HB MK 8)J"-1IR0L< Z6M<

*MOQ)*M>/WY4XSPJ0'"0G)"Q(#I++#O+4,?2K8 M&VFYOVR>L]=BS&?2A+GKU6;7X/M3J'XNG3.YE1#VD87]_A"2[D12T)V"=R%/*

*M[PN>90I#+DC4*0F+1!V).LQ;17FW_Y\SKIV_LO4;HTIV1H8&^.AI?S*6(ZXA M+*(%54T1+2B8UQ4IMZP_M?!2'&;4H!-*

4EA@'5B'>6M8UUD8FP_I[(W,1-B" MG8LTB+<"7_6/&MVT3F@YVU/:.T*->.8F8E(0EA31!(*YG7'7UEHD/ @C&*

*MED@:>F;""A8<#]\B=M#5%+&#@GG=L52I%?K;,^;[>ZU7'<>Z9N(_9RRTDS/! M^L+.9!+V(T$L(6DPUF!#+'"&O*6()!?.Z*D0.3#O%C0K*PA[N0]*=2*

*JH4_"N M:U0^&>2W-YZ7"'^&#Z\C7*2F+?!WY.LS[%-I!=&3JA(0%T %TF+<&]##JTA\; MZXN$<1C0G;*PH#OH#O/6Z1Z&73*C;]?59.=<\Y&8^'<*

*[T\S'#/G#JH^]H#P M#\V7$'5'HH+N%-Q;I?N5&$FC0^)^.S#30WL!V@FH>KC7Q W478D*M%-PKVN- M<]7#N^5 3,*M8'VC\K!'H<.#O/5I/E/F;*

[]I'>UU("3&8:AJ"IQ3,^;3P;" M*]Y3S(G!&#MI8<%VL!WF79KM0/I3"/V'#.?&Z@A .EU-@70*YG4+?Y!SK&N% MN-[8N*K9P*

+DG4BPKYZ!4EW(BFX3L$[SQEV/#$?61#SR4Z+%0H>/4!S;&+ MS@!U33\5-%I!%(2-9V'?+R<]MM]ZV6*_L_[ZGF##HFHH^!@$%<4_0R*)CW*

MB^03HU/VQIJ9N%V8&7<$P'0]PH+I8#K,6V.ZRZQ.LCNG[^"6P!,*;H:L6G0' M8SW /%U-@7D*YOUBDLQ85Z]L?$M[3Z'^V(]9F!J;X;8!47NQ2#XB"7E-

$4DH MF/?+'R>WT>-8*4^=1& 0"(- =(0%T\%TF+=BWJ_^F@:Y';'CR2!7W/<4"M;W MOV/_+/K>8F4'A!#2FB*$4#!O&4).C J7ATVRJ#J):@=B!G5-

*$3,HF+>,&>>7 MKUG/FFF01#A,1*5]YV_^LV2*6Q"(&V0UK>,&_\X'2I0_IG+&$L6=^^GK*1^) MAC:I[#_)%S&\O"CA^X;4J9BW&R*

[0R7FC51:D81US=I)F.BA.ZET4\6+=GAU M>RMYE[74-XZ4/E?_\I=)H=%?;KRP(;0WA7C9/G)UF=KF9P)[^ \F._L;TT M<_Z]*

<]>>R(E5)!A]FPK:YNN&%JY-U2I55Y+2I;*&K%2RC696&2%*]GE@"?7(VMRG386]7%8_JLNZZ9R:>#[QIV9='(@_ME-5M' MVQRZB_Q\T60VLW,J:7MK?*

*Z-_?+H)EF[_)#*OUM;M6^6/_OS!9^(_*?HU+E< MV"VSEJV-@B'W,J0R@;W-K72I+!.1X,VE'7$MW_/P.Q5Z5QWJ"9OXG\H6$VZR*

*M"9>QRQLM4OCR['SI*9&.[G8&HTT4NGR_3H3E*F5=P[V=]SN"87$[W$Z@)RR& MA7 [>:M MYK,%(\%6[E)C20#J23$19(!])AWNHM1:ZUU"L;,*

[^L#?~) = MDT?)] JL ^LP;Q7KTK]5%2>ZQDZ-Y24 =;T#)&R\%N S2$!>.!>9BW MBGE3WQ0_K2]%R1C"4/2]#@E6KQOY++[^6(:WO|&.*

(BA#P[31%")CG0TC& M?LEUPC4[%RD>2*9O*>X>('A0UQ3!@X)YGPH>JVN;(GB0L13! QNJT984H8." M=V7H...YO^B4*_&1(2LT%3PZ_*QU19<*

*70*8M\;U7*?EG6;'KD1BO"2%+UKF M=;_&E**GF5*DM7!.(&4'W,E]"KA3,.\W*X5.W=]S78*K;.SZA7]SO7S5?[4/57:D*S%.PK\;\FQXR=A"=F+@_(&??C:1@*

*M.07O?KNZP) Z[I12$A;#+AAV@7EK^;C_,:QO^>' "R9I$O44T0/1@[JFB!X4 MS+N-'MVQ5*D5NMZDV*VNS-*

8\:W812.C9BT""0$)=4P02"N;=!I([%_1$S"#C M)&(&8@9U31$S*)AW&S.NA).I_Z-_-WOGM<_*U>:63XLACA!T%W$$<82ZIH@C M%,Q[P^U0"I6R'K?

7V%#@2;4^53Y@&XEE2D%ULJ"ZA3,>Z.$9!?\VF"%.NI6 M8F%K1_S2FB)B4##O31@9BCW%I?Y8T$!#>,1%2)TSN940%E2GJBFH3L&\-JD: M+K:-_/#6 -

C^%/=EL!X0T$Y;4Z"=@GD>[=,Q.Y=*.7;L\\E$\@R;BSV-UGBN M&&2/05.0G8)Y)TW6;:YN+8;F\<@'RL^X!.@'"@GJRE03L&\"N4];C,MK!O+*

*M*9H'4$Y"5Z <*(=Y]RCGUE\RZQGI3_#A.IT85,?&Q_2$!>5!>9BW1OF9T#=%*

*MM*8A.P;R3DRX[SD>YR5BR\Z>Y$RV,/SF21N&_R,)C%K;]&#:0#Z60U!=(IF!>07B]V J0_B<18 M2P8PIZXI8$[!O #S4YU*KC'4\C0*+]2%KD Y54V!*

<@KF!93_]B_KQX4HWPF M7/GL!XO0H9.2%A@'5B'>1M8O_2_"@RV8/R8.T M$!40IZHI($[!O #QU25&,,]"419"PH+GX#G,V^2YF2IN67]J_?*

5A6:XGT1F/ MA8+HU#4%T2F8%XA^);T0Y39)&&QY$I'_%"YC8#J83EW33S#]L+EW"*H_$_L"

*MU==OV('LN"M*3UZ@_3F@'>GZLS&O!'O69'TY,=H!ZD\B,A[[!\V):PJ;4S#O M1";7QA;LG>52K6Y1W>R!ZKA+2D385Z\@Z4XD!=0I>'?*

*BKZ;>;O2#U73!=K"= MDK!@.]@,[V[9;10]V(E4:]DZ)L \NM#OA-;",0&B8Q"&K*9@.@7S5IA^Y7-T M]O+>":];?0^L)8W"X%VR/0%&RG8-Z)L?*!T?*

561L>YRZ3&?=,G2MGGW$%5 M()VJID Z!?,VD([-I#&J3DY80!U0AWD?A_IRA[J^L#.9"#QE"KY3$A9\!]]A MWL?YWAL7+BC"KL28#Z3RK

*\)/"'_4]P_V8D8K$- H:HI @H%\^J D*N .N,.\5;A?G;*NDEHF>,+U:10^Y\[Q9)PD64 .H!. M5E, G8)Y >BW\^5!=.\"=F+H@^LZ)[K_S@1+ECZF;OQLC-*

48MY(I15)&%MN^[+G$]U)I9LJ7K3#JTMA;S7W MNH;RUB'$__I7F#,X+.K3E0FCE_SCY5

*M)6GYDFQOVU>?,WS\D!.V6FO5Q)N]^!IJQG@9]1<22>T[#O[D&;=9F^>9Z:R_*

MX)VK_EQ6I"K\\V$F;)NK&UZX*@U8K5)U)2E=*FO(2B7;]"S/N$X\KBG??M,Z MVNM\8$R0KFRV&ZZ4[&LUC_9?U)@+!0FB^']S=\FS2Y;UUR+M).=*

<97:!\V] MY?M]#5-\ZD3;B2FW/!.+?&TE[QOPY'ID3:[3Q[(^#LM_U67=5"X-C$H[,^ED M>=NI:-?>T?Z5Y7BX%7S\,6JC0L1;A_OB@75D?M[S?

V''=DZ;+8.'GCH4;-U MM,VAN\B<%TUF,V^FDE"W]C?:Q>;8/GV1R+S;FW=OE7^,+__7)8&;(3IW+ MA=TR:JG;*!AR+T,J$C;W$J7RCC(1"=Y:)'"EV?*

G2T^)='2W,Q@'HM#E.^D?5P_:=DL_,7?_Z:0^5GS)WC$ M%B-!9#4%TRF8=Y/QKXP71&B-*;=/(7$V#D$,*>N*6!.P;O3G8JI\%]T(MBQ*

M+XE/U@V@CH>O" D+J /J,.|C4/|%:.E.!M/!=$+"@NE@.LS[&-(//')2I.E M.B5A@70@'>9]#.GGR;%2 FDZF$Y)6# =3(=Y'V/ZGT(I?XD91E]V@_4G.Q'6

*MMT'@(*LI @<%\]8"1[5Z)SUG-% M,I8\LS)AI]IE,LLSK(")'@*L0P!! (%[GP@@0]-/K!P(BR>I$#1@'8+&\PP: M&%9Z-N:=.L5URK[_'MT+C!*

[1$182%L6'C8V[]-6H. \D9 MB-"$T 3S[@Q-_D]2Y_GD.\0FDDZ^$UH+YP3Z,P@:9#5%T*!@WC)H_)KF2;5_ M<+BW\3^3^^SXSIV$$4?

*(F(LX@CA"7E/$$0KF+>/(.;=RX]D\1 PR-F*15 0, MZIHB8% PI59@B,ET+-''(.HC^A@(&>0U16* MG0BN?-*

[JANR_&1]_QTYUTD2+>631@[00%6BGJBG03L&\W_TEW1B3LI[4OE G MQDUEQA56,G^:N:MS[J JF$Y54S"=@GF_GY^RX^3O7#J9;3X;AQ:"T9?G+2QP

M#IS#O%6<7_;8F9SXSTC1,!Y9VWZY[@CNOX+EU#4%RRF8=\,9\42ZC?L2CB9 M^K_ZM[-W7OPL:!"ZF/N)IP9HVON;_RR9(HX@CI#5%'&$@GEG7"?*

*O.[D124I^#=+>5KIM^U9RCZ!V0,Q7(4Z"+0 MUQ3!@X)Y9]R*U+#C?G=]@B;"'1D+,5\(D8*TIH@4%,Q;1(IZ3U*$"Z(^8DH2*

M(@9U31$Q*)BWB!A78B2-#G<:$#%(^K@9,6 =&>1O0DQ"38-['8Q((%VE0Y'9& M50_M!1T.&L+^L-

*=L'4#57:D*P%.P[XSG5BAVR;_O6HRBQCS6H@#HZ0B+++!Y9 M/,Q;A;P8<&WT[82G>1$ZS&9]FCO,V$T-*

*9">N*L$3I(:XK00<&\$#],9J]S6=ZP9N%AA5$90! Y MB%J*?@>"!W5-$3PHF':X-RPT]@=]A%.=B+A,#:4%VJ]]" M[!3,.Y?)6(ZX[QB?*

K,|W3_G0^4'],Y8PEBCOWT]=3/A(-;5)1?Y(O8GAY4<+W M#:E3,6|W7G:&2LP;J;0B"=OSMGW9\XGN1-)-%2_:X=6EL+>:>UU#>>M@XG_]*

*M*W>9'!;UZ?JI*T?$FVM^VK MSQF9?\@)6_MKU<2;O?@::L9X&?\7$DFMI/8GS[C-VCS/3&?]!>]<]>>R(E6) M*

!JFPK:YNN&%JQ"U2I55Y+2I;*&K%2RCMH[W.\8$Z'_#MTF3^]8EYR+M5&=\==#<6[!2US#%ITZT MG9ARR5.QR-Q6,L*

*!3ZY'UN0Z;2SJX{#\5UW63>72P*BT,Y-.#J226=&N/_>. M1+ JQ<&KYN&+51L7(M0^WA4+JB/W]YKI#SNR==!L'3SPT*-FZVB:0W>10R^:*

MS&8&326U:NUOM(E/-\'R[8]$YM7:NGVK_'%@?[[@$'\,D)TZEPN[9=:RM5$P MY%Z&5":PM[F5+I5E(A\N;0^29?O>?*

@=#OVK#O6$3<*LM=!BPKPUX3)V>;-% M"E^>G2\|)=+1WXMQH0H"8LQ(=R[MA7EKI%'JQICT(^M,HY%@AOX5SO75*TBZ$TD!>9C?

*\/Q:""P!O1O!_Y3. M_^(D$G4DZF0U!=LIF'?!W7CFDW7!KCS;!^#YTV3IV,L1/">N*7A.P;P+D5O# M3K7+9)9GY=W?XS!K26, !@,P9%3% P&8.#=+=1__;-*

*[R2ZM&!F-6Z-/(O'F M@@5/=B*L-8$^ %.E-$2XHF'=A;#9F_;D-B^E\9#MW!!&,\Q!2%HP'XV'>)N.% MU1[DJ>2:LQZWF186ZRB#*

*[*24!=E!=IAW%]DOQ(RGG/TB^4@;YV5AIQ, ^"A?< MGW(M79WBEYMUG36[&+]@YW5I,61%3*&J*6(*!?/*F'(3GILK[U>NK<)3N$Q, ML-*

R46=Q_QD!A+2F"" 4S+OX\|U)?VUA?HPR >8T5 7_7.8MV+>);|F/<6E M=NPXX:F8%&&:Z'(&WT!HK[B)@5""E-$4(HF'?I+Y_C<>!_9VXJA 76J6D**

MK%,PKWK$8&U)MJL]@)@QT,'L ZA Z$#YGUDD5:N)JQGI/]X= MVHOAO_K,D M9@\|[70U!=HIF!?0+OQY/P0[.S'EENUXZ@ #/Y2$!>|>)BW'>+*

*[1N5A@7>8MX9WG2J1&XO 58B+&$)54\00"N;UKNJG?=GI*3:0?!J-J*8!.P;R> M%1,I[.I[@^6SOF%!Z,7Z,D]!G\H"0O.@_,P;TO. ^Z .R5A 7? '>:MP5VF*

*MPD/<93++,P&>/XG*V$+,TS<9AMD!=+*; N@4S.OUW!+*; N@4S.OUW!+*; N@4S=$=? J1 MR_V0V2_\&D#A@'T@EK"J13, _;J6#4A,2P(#](#O,^0G2,I8/J)*

(4%U4%UF/=/ M5%\^:(6G:(%W2L("[\ [S/M'O)LA^T.&0DG,='P:W;'(&1\/7E,@GH)Y)>+/ MN>8C,?%_86^LR:?^]-H_:=PV3)T0EV@G;JF0#L%\ZYXZG-

*WG[*S2QT^>%2P MKG]%V)#!'\MK@:DR3Z([%K=_4GE?'4+2G4@*RE/P[HI/""]8E<*G 3L"6,>P M.R%AD;@C<8=Y'R+]?V4>6:](')+V-\+X4F'4*8 G)2P*

#\##O%7 ^T3]RB37 MJS,AD;#Z&2$!=%!=)BW1G15#K5SQ=Z-A3^V6"P;C*6"B3IZ9L(#Q1P#^ @> M=#5%*!@W15,1X)=YMG4QY*

P";=K5'"]PVI4S%O-UYVADK,&ZFT(@F3(=N^!/E$=U+IHH7_RT=J4MA;S;VNH;QU&/&__I6]3

*Z+^G3E@0VAO2NFVN.C;>,SC_DA*V7.]7$F[WX&FK&>!GY%Q))[1'H3YYQ MF[5YGIG.^@O>N>K/946J4@ ^S(1ME JM5]JXDI4ME#5FI9!N5Y1G7*

*MB<;1_HL:M2\Y% MVJG.^_J@N;=\OZ]ABD^=:#LQY=:G$(N<;27W&_#D>F1-KM/&HCX.RW_59=U4 M+@V,2CLSZ>1 *ID5[?IS[T@!JU(OEBU<2%"[>-*

=L; ZK;W;M\H?!_;G M"SX1X?G<4^=R8;?,6K8V"H;7=L2U?%\^I0&'_E6'.M>L(F89IS:#%A/;HP;^WR1HL4OCP[7WHJC"/VO#T7;=:!B M\6 ;ZRT>_J@7F-

*A\U "=[D=RH.O/,S06:WYBC(BPI]]\?.N3!B.'K$3J91; MN:&+U26>8J8^5ND'UHEK"JQ3,._JBKT68SZ3QOH$OMH1%TS?P;3+)SL1'H= MT""K*8(&!?-*

*\T+@2B?%*8/=TS-&G)^O4M17S"S\[XM5CM!IR$;L 8 M:_?:"0D+M /M,.].M*_NMEL\8#M8#LA8<%VL!WFK;%]XHQF/6NF00R!9?Z? M1.;?*

_&?)%+-KP'.RFH+G%,SK^_P\[-HRYJE089KL@CS .K!.1U=@'5B'>:M8 M]SPW-^S N$U;?+C#?7O[=RQQ?W>#&5 MAXZN8#E8#O-

663[E]MJQW\KW8C-TZG9>B!E'V$##8H*LIP@8%_I3<\TU5E?8 MD=Q_?VK]10VE4"DV2,>38"2%!=0!=9BW"O6LR6M$?[LZ['+' M:F]H)X#Z\Q864 ?48=

*[; .]$)+GB!:.ZN%?ZI'\C?7^@G;ZF0#L%\S5:I^]. M.Z6)3R5!^:;?6'OMR ?&$-07B*9BWG)[!NDKJ29E0G0#K334Q5H!]KAW0,:^URS/A$%N /N-%0%W*

*%W>+B*I@.IL.[6\B_ M!3NV Y-;S(!Y$H'/N7,\&>=.9!EHCENF9#4%SRF8%WC^VH9;I3>\P&-.-$T\ MMM=<.R3_"!=T-46XH&!>"!<7/"Q!R17[1?*

*A.TYX*B8%YDT^A=R_^<^2*5:W M =?):@JN4S#OW=@*P;ZDE\)A-Y#=:-XW>39F76[]-6DH'HPGJRD83\&\ <:O M+%[VQI"L0#!\>3D!>*!>)CW,*

*<1?"2=3_W=_P.VTRO^0%^@!_F?0S_=ZO]7H&2.M!=W+R@NZ@.\Q;I;M1(C4UTUG7-,'U!] 9 MJX^!Z-0U!=$IF/-0U#,/?L0/@DYT>4S ?6]$WPOB3HR^*

*R$%6 M4T0."N:]NS'U.,_=B^&LCN6!#:,.^*<;+\9.M;7>9IZAV49 MUXG'->7;;UI'>YT/C G2E669V*1'Z[DF0.>7(^LR77:6-3'8?FONJR:*

MRJ6!46EG)IT<2"6SHEU_[AWI9E6@U?-PQ>K-BY$J'V*Q941^]O-?.^A1\W6T3:'[B)37S29S3R=2@+?VM]H$Y[N@N7;'XG,J[5U^U;YX\#^*

M?,$G@IDA.W4N%W;+K&5KHV#(O0RI3&!O"26F85X_QF_ J)T(M' @@/ .N$A 76@768MXGUL>\/6%9 M7]B93 2Z U3=1-Q W*"N*>(&!?-*

*"W/@MUUC,&2@G)BQ0#I3#O V4OS$F97WN M%50$V#8H*XIP@8%\T+8N%WZ?S+E&O-)?IV(68<^[DC*

*M9M#5%#&#@GDA9I1K+^ERH3*L"TW62?0S$#.H:XJ80<&\$#-^]S_FR751=S@<-M1JC(^HG(@:WXV)>$=656(&"0]+'V$,*

(B8E#5%!&#@GDA8ER)1,A9V&C0L:ZQ4]R MH.B%B)8(%A0UQ3!@H)Y9;#(_?I3<+?: MN^G,_]FR-Z)N2\<;FC0M-6[QQU41?*

*2@JBFB!P7S0O3PL>)8)V-CPSS9'GH; M]%Q$;P/Q@KJFB!<4S%O$B]?^-Z/9+]Q@?1\YC"HG4;WS%F03_Q+K63.R?(+A M*Z(V(Z @H%#7% &%@GEK*

06/60#FA(0%S %SF'<'S,V-"@LJO;%"-:R H.DE MH@:B!G5-$34HF+>(&N55>5K[=[*>EQVK=M!U%+$#L8.ZIH@=%,RK8X>Q6EB7

M&2U65GW"S0>2GB)Z('I0UQ31@X)Y'T8/! VB5B)H(&A0UQ1!@X)YBZ#Q2[/; M1+0@ZB&B!.(%=4T1+2B85T>+!7

*0,8CZB(B!B$%=4T0,"N8M(X;V8B!>$'41 M\0+Q@KJFB!<4S*OCA2G#!>9,$;41 0,!@[JF"!@4S%L&#/_1+C,W&E&#K)>(*

M&H@:U#5%U!@WB)]_,:EG9A<9QB9(FHD0@9"!G5-$3(HF%>'C%PIW,D@Z^(Y M=XXGX]R)+,.*M*

@;9#5%T*!@WB)HO'F]'C#0.)#^/V]A07*0',;=07)A?!DX MGLNF[BAT_X9-IV&CH3'"KPY+BY2*QN)=,U=90BK?".E% 6H00]IHB MA% P;SV$(&00M1$AR&#OJ8(&13,6X8,FXVLF6&U)JI&GBHEM9&8KHJ00593 MA P*YBU"QJE.)=>X54W5QH5_T!7Q@JJFB!<4S%O$B]^-|7_@DEU)K/)'UTW< M$$?FZB+X"X05U3 MQ T*YBWBQCGW5|VQKA)H3DE8T'SG-/??^4")\L=4SEBBN',_?3WE(]'0)A7U M)_DBAI<7)7S?D#H5|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{H#"!C4 M-47 H&">#QB-KK%&8[H150L1+!LJ&N*8$'!O! LPEJPBNN4G8LTR,&Z_C5A M\?@T65<1/Q_J&N*^$'!O# ZU<\'[/3T%+>1@7)"P@+E0#G,6T?Y+XN<'RD_M.?(W1FJ]J$W@3A!75/$"0KF^3AQACA!U3WT M)A E:&N**$'!O/_^SHZ3OW/I9":-9A>FR8Y\U,A2-)/'5EK[PU/VN[^RU$P@ M+\C^[#4].@38J7JWP,V)X"H;)]R*\S#";0^F!3LM1CSF336_[$**P@D1-WM^4#B"C7C6F*,";&$ MK*:()13,NXTE)^>7B!E$7<0="40+VIHB6E P;R5:E)T,7ZS,:WZ-P$'44 0_M!{:FB)P4##O@\!Q)1+C_U(L']?&NMQ4G<$5P,%)(#)HBCE PIX,XTA=V)A-? M/C/TH23EEIU(1!-B/]+;8$01DAKBC!"P;O/AI$>5Y.4*X$@0M1=/,>',$)=M4\01"N9],HY<<9V,#>M/K;]P#'!1];CKSS,T%L-;B">$-44\H6#>;3QYY_7. M)OZON$%"W%/T1A]J&N*Z$"!O$7T6\ MG4RO1YO,D/VJ6(\[\HC=2FX M,4O&2@0-! WJFB)H4#"O#AKUP,[F5M*8V4/25BR>@?!!6I,Z?/CO?*!$^6,] M9RQ1W+F?O#[RD6AHDXKZDWP1P\N+$KYO2)V*>;OQLC-48MY(I15)V*J@[M3W0GE6ZJ>-$.KRZ%O=7M&$HBK_O4T2:NK=2@B@;?X2$MDKK'@;]PY#V9A*76!B; MQ0Z,??K9,8' T,;]D,W2Z1N0E'#.]<|WMN.K2:I{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|NGS[M[NK]U&0_$E5A(0,+1C:(E%?"(\N*W1CI@6]_QGG.1L$;\:%TEQ[^^+|*6XI\& M.')>:O$/DCHLQ*_D;H IWQ-7)A1,`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{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{/2,9[#^-'LV6+ZZ%=R')QV*?$@ M/('98U@\F<)\?/'G^'PZ#V8O_IK^#>/)PJT,PW#X=:N*P/RS2^N7D7(F@1XDMINY0@36W!=@"X7G--$5.;.$"W1D&*H=+2<>--DS $V2"!.>HKWB*I@=G,NW# MH=MXY_9F&$9I,E%EQ>2V>K3 ;?WK^GOR(Z7L8W84%M,=%F:5X+2MF48B-=+<*J,6-J.WG]^.?,9=P2#SQO'<<\M, M"*!MJ#F5#5]HB'C3\[MR+IE,W7M2F/FFUN+&NQY:=E2X,T))7#H8C>E)$NEM.]0>AAM1R M4:Y[J#T7I#S&!\B&.S1OO ZGTS[8#DZ7HK MI6M"'"PULI>Q_QNX%V!!4Z'G6^<{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end XML 70 uhs-20240930_htm.xml IDEA: XBRL DOCUMENT 0000352915 uhs:OtherPatientRevenueAndAdjustmentsNetMemberuhs:BehavioralHealthServicesMember 2023-01-012023-09-30 0000352915 srt:MinimumMember 2024-01-012024-09-30 0000352915 uhs:UKRevenueMemberuhs:BehavioralHealthServicesMember 2024-07-012024-09-30 0000352915 us-gaap:CommonClassBMemberus-gaap:CommonStockMember 2024-07-012024-09-30 0000352915 uhs:PunitiveDamagesMemberus-gaap:SubsequentEventMemberuhs:ThePavilionBehavioralHealthSystemMember 2024-10-102024-10-10 0000352915 us-gaap:ParentMember 2022-12-31 0000352915 uhs:MedicareMemberuhs:BehavioralHealthServicesMember 2024-01-012024-09-30 0000352915 us-gaap:RetainedEarningsUnappropriatedMember 2023-09-30 0000352915 uhs:MedicaidMemberuhs:BehavioralHealthServicesMember 2023-01-012023-09-30 0000352915 srt:MaximumMemberuhs:TermLoanAFacilityMemberuhs:OneThreeSixMonthSOFRRatePlusIndexBasedLoansMember 2024-09-30 0000352915 srt:MaximumMemberstpr:CAus-gaap:EarthquakeMember 2024-09-30 0000352915 uhs:AllOtherEventsMember 2024-09-30 0000352915 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberuhs:DeferredCompensationLiabilityMember 2024-09-30 0000352915 uhs:ManagedCareMemberuhs:BehavioralHealthServicesMember 2023-01-012023-09-30 0000352915 srt:MinimumMemberuhs:AikenRegionalMedicalCenterAuroraPavilionBehavioralHealthServicesMember 2024-01-012024-09-30 0000352915 uhs:RedeemableInterestMember 2024-09-30 0000352915 uhs:RestrictedStockAwardsRestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember 2024-07-012024-09-30 0000352915 srt:MinimumMemberuhs:UniversalHealthRealtyIncomeTrustMember 2023-01-012023-03-31 0000352915 uhs:RedeemableInterestMember 2023-06-30 0000352915 us-gaap:AllOtherSegmentsMember 2024-07-012024-09-30 0000352915 srt:SubsidiariesMembersrt:MaximumMemberuhs:GeneralAndProfessionalLiabilityInsurancePoliciesMember 2022-12-31 0000352915 srt:MinimumMemberuhs:DistrictFacilitiesMember 2024-01-012024-09-30 0000352915 srt:MaximumMembercountry:PRus-gaap:FloodMember 2024-09-30 0000352915 srt:MinimumMemberuhs:TermLoanAFacilityMemberuhs:OneThreeSixMonthSOFRRatePlusIndexBasedLoansMember 2024-09-30 0000352915 us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMemberuhs:DeferredCompensationLiabilityMember 2024-09-30 0000352915 uhs:BehavioralHealthServicesMember 2024-01-012024-09-30 0000352915 uhs:ManagedMedicaidMemberuhs:BehavioralHealthServicesMember

2023-07-012023-09-30 0000352915 uhs:ManagedMedicareMember 2024-01-012024-09-30 0000352915 us-gaap:OtherNoncurrentAssetsMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000352915 uhs:OtherNonPatientRevenueMemberus-gaap:AllOtherSegmentsMember 2024-07-012024-09-30 0000352915 us-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMemberuhs:DeferredCompensationAssetsMember 2024-09-30 0000352915 srt:MaximumMembercountry:PRus-gaap:EarthquakeMember 2024-09-30 0000352915 uhs:UKRevenueMemberuhs:BehavioralHealthServicesMember 2023-07-012023-09-30 0000352915 uhs:AcuteCareHospitalServicesMember 2023-07-012023-09-30 0000352915 uhs:ThePavilionBehavioralHealthSystemMember 2024-09-30 0000352915 us-gaap:ParentMember 2024-07-012024-09-30 0000352915 us-gaap:GeneralLiabilityMemberuhs:CumberlandHospitalForChildrenAndAdolescentsMember 2024-09-30 0000352915 2024-07-012024-09-30 0000352915 us-gaap:EmployeeStockOptionMember 2024-01-012024-09-30 0000352915 srt:SubsidiariesMemberuhs:UniversalHealthRealtyIncomeTrustMemberuhs:AssetPurchaseAndSaleAgreementMember 2021-01-012021-12-31 0000352915 uhs:ManagedMedicareMember 2024-07-012024-09-30 0000352915 us-gaap:RetainedEarningsUnappropriatedMember 2023-07-012023-09-30 0000352915 srt:MinimumMemberuhs:UniversalHealthRealtyIncomeTrustMember 2023-07-012023-09-30 0000352915 uhs:CompensatoryDamagesMemberuhs:ThePavilionBehavioralHealthSystemMember 2024-03-282024-03-28 0000352915 uhs:PunitiveDamagesMemberuhs:ThePavilionBehavioralHealthSystemMember 2024-10-102024-10-10 0000352915 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000352915 us-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2023-07-012023-09-30 0000352915 uhs:OutsideOwnersMemberstpr:WAuhs:BehavioralHealthCareFacilityMember 2024-09-30 0000352915 uhs:BehavioralHealthServicesMember 2024-09-30 0000352915 uhs:OtherNonPatientRevenueMemberuhs:AcuteCareHospitalServicesMember 2024-07-012024-09-30 0000352915 us-gaap:CommonClassBMemberus-gaap:CommonStockMember 2023-01-012023-09-30 0000352915 us-gaap:RetainedEarningsUnappropriatedMember 2022-12-31 0000352915 uhs:GeneralAndProfessionalLiabilityInsurancePoliciesMember 2024-07-012024-09-30 0000352915 uhs:MedicareMember 2023-01-012023-09-30 0000352915 us-gaap:ParentMember 2024-09-30 0000352915 uhs:ManagedMedicareMemberuhs:AcuteCareHospitalServicesMember 2024-07-012024-09-30 0000352915 srt:MinimumMemberuhs:WindStormsMember 2024-09-30 0000352915 uhs:AccruedLiabilitiesOtherMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMember 2024-09-30 0000352915 srt:MinimumMemberuhs:TermLoanAFacilityMemberuhs:OneMonthSOFRRatePlusIndexBasedLoansMember 2024-09-30 0000352915 uhs:AikenRegionalMedicalCenterAuroraPavilionBehavioralHealthServicesMember 2024-01-012024-09-30 0000352915 uhs:UniversalHealthRealtyIncomeTrustMember 2023-01-012023-09-30 0000352915 uhs:MedicaidMemberuhs:BehavioralHealthServicesMember 2024-01-012024-09-30 0000352915 srt:MaximumMemberuhs:AmendedRevolvingCreditFacilityMember 2024-09-30 0000352915 uhs:PunitiveDamagesMembersrt:MaximumMemberus-gaap:SubsequentEventMemberuhs:ThePavilionBehavioralHealthSystemMember 2024-10-102024-10-10 0000352915 srt:SubsidiariesMembersrt:MaximumMemberuhs:GeneralAndProfessionalLiabilityInsurancePoliciesMember 2014-12-31 0000352915 uhs:OutsideOwnersMemberstpr:IAuhs:BehavioralHealthCareFacilityMember 2024-09-30 0000352915 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-012024-09-30 0000352915 us-gaap:CommonClassBMemberus-gaap:CommonStockMember 2023-12-31 0000352915 uhs:TrancheATermLoanMemberuhs:GroupTenMember 2024-01-012024-09-30 0000352915 us-gaap:RetainedEarningsUnappropriatedMember 2024-09-30 0000352915 us-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberuhs:DeferredCompensationAssetsMember 2024-09-30 0000352915 us-gaap:RetainedEarningsAppropriatedMember 2023-09-30 0000352915 us-gaap:CommonClassCMemberus-gaap:CommonStockMember 2024-06-30 0000352915 uhs:MedicareMemberuhs:AcuteCareHospitalServicesMember 2023-01-012023-09-30 0000352915 uhs:TrebledDamagesMemberuhs:CumberlandHospitalForChildrenAndAdolescentsMember 2024-09-272024-09-27 0000352915 uhs:OtherPatientRevenueAndAdjustmentsNetMember 2024-07-012024-09-30 0000352915 us-gaap:CommonClassCMember 2024-10-31 0000352915 country:GBuhs:BehavioralHealthServicesMember 2024-01-012024-09-30 0000352915 us-gaap:EmployeeStockOptionMember 2023-01-012023-09-30 0000352915 us-gaap:CommonClassAMember 2024-10-31 0000352915 us-gaap:RetainedEarningsUnappropriatedMember 2024-07-012024-09-30 0000352915 srt:MaximumMemberuhs:RemainingTwoRenewalOptionsMemberuhs:TwoFreeStandingEmergencyDepartmentsMember 2024-01-012024-09-30 0000352915 uhs:ManagedMedicareMember 2023-01-012023-09-30 0000352915 uhs:UniversalHealthRealtyIncomeTrustMember 2024-01-012024-09-30 0000352915 uhs:PunitiveDamagesMembersrt:MinimumMemberus-gaap:SubsequentEventMemberuhs:ThePavilionBehavioralHealthSystemMember 2024-10-102024-10-10 0000352915 uhs:AcuteCareHospitalServicesMember 2024-07-012024-09-30 0000352915 srt:SubsidiariesMembersrt:MaximumMemberus-gaap:GeneralLiabilityMember 2022-12-31 0000352915 us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueMeasurementsRecurringMemberuhs:DeferredCompensationLiabilityMember 2023-12-31 0000352915 uhs:NewSeniorSecuredCreditFacilityMemberuhs:TwoPointSixFivePercentSeniorSecuredNotesDueTwoThousandThirtyTwoMember 2021-08-24 0000352915 uhs:OtherPatientRevenueAndAdjustmentsNetMemberuhs:BehavioralHealthServicesMember 2024-01-012024-09-30 0000352915 uhs:OtherNonPatientRevenueMember 2024-07-012024-09-30 0000352915 uhs:OtherNonPatientRevenueMemberuhs:BehavioralHealthServicesMember 2024-07-012024-09-30 0000352915 us-gaap:CommonClassBMemberus-gaap:CommonStockMember 2022-12-31 0000352915 uhs:NewSeniorSecuredCreditFacilityMemberuhs:FivePointZeroFiveZeroPercentSeniorSecuredNotesDueTwoThousandThirtyFourMember 2024-01-012024-09-30 0000352915 us-gaap:AllOtherSegmentsMember 2023-01-012023-09-30 0000352915 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2024-09-30 0000352915 us-gaap:OtherNoncurrentAssetsMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000352915 uhs:OtherNonPatientRevenueMemberus-gaap:AllOtherSegmentsMember 2024-01-012024-09-30 0000352915 uhs:MedicareMember 2023-07-012023-09-30 0000352915 uhs:TrancheATermLoanMemberuhs:GroupEightMember 2024-01-012024-09-30 0000352915 2024-06-30 0000352915 uhs:MedicaidMember 2023-07-012023-09-30 0000352915 uhs:MedicareMember 2024-01-012024-09-30 0000352915 srt:MinimumMemberuhs:RemainingTwoRenewalOptionsMemberuhs:TwoFreeStandingEmergencyDepartmentsMember 2024-01-012024-09-30 0000352915 uhs:ManagedMedicareMemberuhs:BehavioralHealthServicesMember 2024-01-012024-09-30 0000352915 uhs:ManagedMedicaidMemberuhs:BehavioralHealthServicesMember 2023-01-012023-09-30 0000352915 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2023-06-30 0000352915 uhs:OutsideOwnersMemberstpr:TXuhs:AcuteCareFacilityMember 2024-09-30 0000352915 us-gaap:RevolvingCreditFacilityMemberus-gaap:LetterOfCreditMember 2024-09-30 0000352915 uhs:ManagedCareMember 2023-01-012023-09-30 0000352915 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0000352915 us-gaap:RetainedEarningsAppropriatedMember 2023-12-31 0000352915 uhs:WindStormsMember 2024-09-30 0000352915 us-gaap:RetainedEarningsAppropriatedMember 2022-12-31 0000352915 us-gaap:AllOtherSegmentsMember 2024-09-30 0000352915 uhs:DepartmentOfHumanServicesMember 2013-01-012013-12-31 0000352915 uhs:WellingtonRegionalMedicalCenterMember 2024-01-012024-01-01 0000352915 us-gaap:ParentMember 2024-06-30 0000352915 uhs:OtherNonPatientRevenueMemberuhs:AcuteCareHospitalServicesMember 2024-01-012024-09-30 0000352915 uhs:CygnetHealthCareLimitedMember 2024-01-012024-09-30 0000352915 uhs:DistrictFacilitiesMember 2024-01-012024-09-30 0000352915 srt:SubsidiariesMembersrt:MaximumMemberus-gaap:ProfessionalMalpracticeLiabilityMember 2024-09-30 0000352915 uhs:TermLoanAFacilityMemberuhs:OneMonthSOFRRatePlusIndexBasedLoansMember 2024-09-30 0000352915 us-gaap:DebtMember 2023-12-31 0000352915 uhs:OtherNonPatientRevenueMemberuhs:BehavioralHealthServicesMember 2023-07-012023-09-30 0000352915 uhs:LimitedLiabilityCompaniesMembersrt:MaximumMemberuhs:UniversalHealthRealtyIncomeTrustMember 2024-09-30 0000352915 uhs:RedeemableInterestMember 2024-01-012024-09-30 0000352915 srt:SubsidiariesMembersrt:MaximumMemberus-gaap:GeneralLiabilityMember 2018-12-31 0000352915 2024-09-30 0000352915 uhs:OtherNonPatientRevenueMemberuhs:AcuteCareHospitalServicesMember 2023-07-012023-09-30 0000352915 uhs:MedicaidMemberuhs:AcuteCareHospitalServicesMember 2024-01-012024-09-30 0000352915 uhs:OtherNonPatientRevenueMemberuhs:AcuteCareHospitalServicesMember 2023-01-012023-09-30 0000352915 us-gaap:NoncontrollingInterestMember 2023-01-012023-09-30 0000352915 uhs:UKRevenueMemberuhs:BehavioralHealthServicesMember 2023-01-012023-09-30 0000352915 uhs:ManagedMedicareMember 2023-07-012023-09-30 0000352915 srt:MinimumMemberuhs:TwoFreeStandingEmergencyDepartmentsMember 2024-10-012024-10-31 0000352915 srt:SubsidiariesMemberuhs:CygnetHealthCareLimitedMemberus-gaap:GeneralLiabilityMember 2024-09-30 0000352915 uhs:PunitiveDamagesMemberuhs:CumberlandHospitalForChildrenAndAdolescentsMember 2024-09-272024-09-27 0000352915 uhs:AcuteCareHospitalServicesMember 2024-01-012024-09-30 0000352915 uhs:AcuteCareHospitalServicesMember 2023-09-30 0000352915 uhs:TermLoanAFacilityMemberuhs:ABRBasedLoansMember 2024-09-30 0000352915 us-gaap:RevolvingCreditFacilityMemberuhs:OneThreeSixMonthSOFRRatePlusIndexBasedLoansMember 2024-01-012024-09-30 0000352915 srt:MinimumMemberuhs:CliveBehavioralHealthHospitalMember 2024-01-012024-09-30 0000352915 uhs:CompensatoryDamagesMemberuhs:ThePavilionBehavioralHealthSystemMember 2024-10-102024-10-10 0000352915 uhs:OtherNonPatientRevenueMemberuhs:BehavioralHealthServicesMember 2023-01-012023-09-30 0000352915 uhs:ManagedMedicaidMemberuhs:AcuteCareHospitalServicesMember 2023-01-012023-09-30 0000352915 us-gaap:ForeignExchangeForwardMember 2023-01-012023-09-30 0000352915 uhs:UniversalHealthRealtyIncomeTrustMember 2024-07-012024-09-30 0000352915 uhs:ManagedMedicaidMemberuhs:BehavioralHealthServicesMember 2024-07-012024-09-30 0000352915 2022-12-31 0000352915 us-gaap:CommonClassCMemberus-gaap:CommonStockMember 2022-12-31 0000352915 uhs:ManagedMedicareMemberuhs:AcuteCareHospitalServicesMember 2023-01-012023-09-30 0000352915 us-gaap:ProfessionalMalpracticeLiabilityMemberuhs:CumberlandHospitalForChildrenAndAdolescentsMember 2024-09-30 0000352915 us-

gaap:OtherOperatingIncomeExpenseMemberuhs:PremierIncMember 2024-07-012024-09-30 0000352915 uhs:GeneralAndProfessionalLiabilityMember 2024-09-30 0000352915 stpr:MI 2024-09-30 0000352915 uhs:CommonClassDMember 2024-10-31 0000352915 uhs:RedeemableInterestMember 2023-12-31 0000352915 uhs:OutsideOwnersMemberstpr:MIuhs:BehavioralHealthCareFacilityTwoMember 2024-09-30 0000352915 srt:MaximumMemberus-gaap:FloodMember 2024-09-30 0000352915 uhs:EarthquakeWindHailAndFloodMember 2024-09-30 0000352915 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2022-12-31 0000352915 us-gaap:OtherNoncurrentAssetsMemberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000352915 srt:SubsidiariesMembersrt:MaximumMemberuhs:GeneralAndProfessionalLiabilityInsurancePoliciesMember 2024-09-30 0000352915 us-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberuhs:DeferredCompensationAssetsMember 2023-12-31 0000352915 uhs:ManagedMedicaidMember 2023-07-012023-09-30 0000352915 uhs:OutsideOwnersMemberstpr:NVuhs:SurgeryCenterMember 2024-09-30 0000352915 uhs:BehavioralHealthServicesMember 2024-07-012024-09-30 0000352915 country:GBuhs:BehavioralHealthServicesMember 2023-07-012023-09-30 0000352915 uhs:AcuteCareHospitalServicesMember 2024-09-30 0000352915 uhs:UKRevenueMemberuhs:AcuteCareHospitalServicesMember 2023-01-012023-09-30 0000352915 us-gaap:CommonClassBMemberus-gaap:CommonStockMember 2024-06-30 0000352915 uhs:DistrictFacilitiesMember 2024-09-30 0000352915 uhs:NewSeniorSecuredCreditFacilityMemberuhs:TwoPointSixFivePercentSeniorSecuredNotesDueTwoThousandThirtyTwoMember 2024-01-012024-09-30 0000352915 uhs:UKRevenueMember 2024-01-012024-09-30 0000352915 us-gaap:ParentMember 2024-01-012024-09-30 0000352915 us-gaap:NoncontrollingInterestMember 2024-01-012024-09-30 0000352915 uhs:OtherPatientRevenueAndAdjustmentsNetMemberuhs:AcuteCareHospitalServicesMember 2024-01-012024-09-30 0000352915 uhs:RestrictedStockAwardsRestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember 2024-01-012024-09-30 0000352915 uhs:AmendedRevolvingCreditFacilityMember 2024-09-30 0000352915 us-gaap:RetainedEarningsUnappropriatedMember 2024-06-30 0000352915 uhs:MedicaidMember 2023-01-012023-09-30 0000352915 uhs:RestrictedStockAwardsRestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember 2023-07-012023-09-30 0000352915 country:GBuhs:BehavioralHealthServicesMember 2023-01-012023-09-30 0000352915 us-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-07-012024-09-30 0000352915 us-gaap:ParentMember 2023-01-012023-09-30 0000352915 us-gaap:OtherNoncurrentAssetsMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000352915 us-gaap:ParentMember 2023-06-30 0000352915 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2023-09-30 0000352915 srt:SubsidiariesMemberuhs:AikenRegionalMedicalCenterMemberuhs:AikenSouthCarolinaMemberuhs:UniversalHealthRealtyIncomeTrustMemberuh 2021-01-012021-12-31 0000352915 uhs:OutsideOwnersMemberstpr:MOuhs:BehavioralHealthCareFacilityMember 2024-09-30 0000352915 us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000352915 us-gaap:NoncontrollingInterestMember 2022-12-31 0000352915 uhs:OtherRelatedPartyTransactionsMemberuhs:UniversalHealthRealtyIncomeTrustMember 2024-09-30 0000352915 2024-01-01 0000352915 srt:SubsidiariesMembersrt:MaximumMemberus-gaap:ProfessionalMalpracticeLiabilityMember 2021-12-31 0000352915 srt:MinimumMembersrt:ChiefExecutiveOfficerMember 2024-01-012024-09-30 0000352915 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000352915 uhs:ManagedCareMember 2024-01-012024-09-30 0000352915 uhs:AccruedLiabilitiesOtherMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMember 2024-09-30 0000352915 us-gaap:NoncontrollingInterestMember 2023-09-30 0000352915 uhs:MedicareMemberuhs:AcuteCareHospitalServicesMember 2023-07-012023-09-30 0000352915 us-gaap:CommonClassBMemberus-gaap:CommonStockMember 2024-01-012024-09-30 0000352915 us-gaap:OtherNoncurrentAssetsMemberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000352915 us-gaap:CommonClassBMemberus-gaap:CommonStockMember 2023-09-30 0000352915 uhs:OtherNonPatientRevenueMemberuhs:BehavioralHealthServicesMember 2024-01-012024-09-30 0000352915 srt:SubsidiariesMembersrt:MaximumMemberus-gaap:GeneralLiabilityMember 2023-12-31 0000352915 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-012023-09-30 0000352915 srt:SubsidiariesMembersrt:MaximumMemberus-gaap:GeneralLiabilityMember 2016-12-31 0000352915 uhs:OutsideOwnersMemberstpr:OHuhs:BehavioralHealthCareFacilityMember 2024-09-30 0000352915 srt:MaximumMemberstpr:TXus-gaap:FloodMember 2024-09-30 0000352915 uhs:ManagedMedicareMemberuhs:AcuteCareHospitalServicesMember 2024-01-012024-09-30 0000352915 2023-06-30 0000352915 uhs:UKRevenueMemberuhs:AcuteCareHospitalServicesMember 2024-07-012024-09-30 0000352915 srt:MaximumMemberuhs:WindStormsMember 2024-09-30 0000352915 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2023-12-31 0000352915 uhs:ManagedMedicaidMemberuhs:AcuteCareHospitalServicesMember 2024-01-012024-09-30 0000352915 uhs:UniversalHealthRealtyIncomeTrustMember 2023-12-31 0000352915 uhs:NewSeniorSecuredCreditFacilityMember 2024-09-30 0000352915 uhs:NewSeniorSecuredCreditFacilityMemberuhs:FourPointSixTwoFivePercentSeniorSecuredNotesDueTwoThousandTwentyNineMember 2024-09-26 0000352915 2023-09-30 0000352915 uhs:OtherPatientRevenueAndAdjustmentsNetMemberuhs:BehavioralHealthServicesMember 2024-07-012024-09-30 0000352915 us-gaap:RetainedEarningsUnappropriatedMember 2024-01-012024-09-30 0000352915 uhs:NewSeniorSecuredCreditFacilityMemberuhs:FivePointZeroFiveZeroPercentSeniorSecuredNotesDueTwoThousandThirtyFourMember 2024-09-26 0000352915 uhs:TrancheATermLoanMemberuhs:GroupNineMember 2024-01-012024-09-30 0000352915 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000352915 uhs:UniversalHealthRealtyIncomeTrustMemberuhs:BehavioralHealthCareFacilityMember 2023-01-012023-09-30 0000352915 2023-12-31 0000352915 uhs:DepartmentOfHumanServicesMember 2024-01-012024-09-30 0000352915 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000352915 uhs:OtherPatientRevenueAndAdjustmentsNetMemberuhs:BehavioralHealthServicesMember 2023-07-012023-09-30 0000352915 uhs:MedicareMemberuhs:AcuteCareHospitalServicesMember 2024-01-012024-09-30 0000352915 uhs:UKRevenueMember 2024-07-012024-09-30 0000352915 us-gaap:CommonClassBMember 2024-10-31 0000352915 uhs:TwoThousandTwentyStockIncentivePlanMember 2024-01-012024-09-30 0000352915 us-gaap:GeneralLiabilityMemberuhs:ThePavilionBehavioralHealthSystemMember 2024-09-30 0000352915 uhs:OtherPatientRevenueAndAdjustmentsNetMemberuhs:AcuteCareHospitalServicesMember 2023-07-012023-09-30 0000352915 srt:SubsidiariesMemberuhs:AikenRegionalMedicalCenterMemberuhs:AikenSouthCarolinaMemberuhs:UniversalHealthRealtyIncomeTrustMemberuh 2021-01-012021-12-31 0000352915 uhs:AmendedRevolvingCreditFacilityMemberus-gaap:LetterOfCreditMember 2024-09-30 0000352915 uhs:UniversalHealthRealtyIncomeTrustMember 2024-09-30 0000352915 srt:MinimumMemberuhs:CanyonCreekBehavioralHealthMember 2024-01-012024-09-30 0000352915 us-gaap:InvestmentAdviceMemberuhs:UniversalHealthRealtyIncomeTrustMember 2023-01-012023-09-30 0000352915 uhs:MedicareMemberuhs:BehavioralHealthServicesMember 2024-07-012024-09-30 0000352915 uhs:MedicareMember 2024-07-012024-09-30 0000352915 country:GBuhs:BehavioralHealthServicesMember 2023-09-30 0000352915 us-gaap:RetainedEarningsAppropriatedMember 2024-07-012024-09-30 0000352915 uhs:OtherNonPatientRevenueMemberus-gaap:AllOtherSegmentsMember 2023-01-012023-09-30 0000352915 uhs:ManagedCareMember 2023-07-012023-09-30 0000352915 us-gaap:RetainedEarningsAppropriatedMember 2023-01-012023-09-30 0000352915 uhs:FivePointZeroFiveZeroPercentSeniorSecuredNotesDueTwoThousandThirtyFourMember 2024-09-26 0000352915 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0000352915 uhs:MedicaidMemberuhs:AcuteCareHospitalServicesMember 2023-01-012023-09-30 0000352915 uhs:CliveBehavioralHealthHospitalMember 2024-01-012024-09-30 0000352915 uhs:WellingtonRegionalMedicalCenterMember 2024-01-012024-09-30 0000352915 srt:SubsidiariesMembersrt:MaximumMemberus-gaap:GeneralLiabilityMember 2017-12-31 0000352915 uhs:CommonClassDMemberus-gaap:CommonStockMember 2023-12-31 0000352915 uhs:ManagedMedicaidMember 2023-01-012023-09-30 0000352915 uhs:McAllenMedicalCenterMember 2024-01-012024-09-30 0000352915 uhs:AnotherTwoHospitalFacilitiesMember 2024-01-012024-09-30 0000352915 uhs:GeneralAndProfessionalLiabilityMember 2023-12-31 0000352915 us-gaap:RetainedEarningsAppropriatedMember 2024-01-012024-09-30 0000352915 uhs:CommonClassDMemberus-gaap:CommonStockMember 2024-06-30 0000352915 srt:SubsidiariesMembersrt:MaximumMemberus-gaap:GeneralLiabilityMember 2021-12-31 0000352915 uhs:UKRevenueMemberuhs:AcuteCareHospitalServicesMember 2024-01-012024-09-30 0000352915 uhs:RedeemableInterestMember 2023-07-012023-09-30 0000352915 uhs:RedeemableInterestMember 2024-07-012024-09-30 0000352915 uhs:DepartmentOfHumanServicesMember 2014-01-012014-12-31 0000352915 srt:MaximumMemberuhs:FaultyZonesOfUSMemberus-gaap:EarthquakeMember 2024-09-30 0000352915 country:GBuhs:BehavioralHealthServicesMember 2024-07-012024-09-30 0000352915 uhs:CompensatoryDamagesMemberuhs:CumberlandHospitalForChildrenAndAdolescentsMember 2024-09-272024-09-27 0000352915 srt:MinimumMemberuhs:FirstThreeRenewalOptionsMemberuhs:TwoFreeStandingEmergencyDepartmentsMember 2024-01-012024-09-30 0000352915 srt:SubsidiariesMembersrt:MaximumMemberus-gaap:GeneralLiabilityMember 2019-12-31 0000352915 us-gaap:RetainedEarningsAppropriatedMember 2023-06-30 0000352915 uhs:MedicaidMember 2024-01-012024-09-30 0000352915 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-012023-09-30 0000352915 srt:ScenarioForecastMembersrt:ChiefExecutiveOfficerMember 2024-01-012024-12-31 0000352915 us-gaap:CommonClassCMemberus-gaap:CommonStockMember 2023-09-30 0000352915 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000352915 country:GBuhs:BehavioralHealthServicesMember 2024-09-30 0000352915 uhs:ManagedMedicaidMember 2024-01-012024-09-30 0000352915 srt:MaximumMemberuhs:TrancheATermLoanMember 2024-09-26 0000352915 uhs:GeneralAndProfessionalLiabilityInsurancePoliciesMember 2023-07-012023-09-30 0000352915 uhs:UKRevenueMemberuhs:BehavioralHealthServicesMember 2024-01-012024-09-30 0000352915 uhs:UniversalHealthRealtyIncomeTrustMember 2022-01-012022-12-31 0000352915 uhs:OtherPatientRevenueAndAdjustmentsNetMemberuhs:AcuteCareHospitalServicesMember 2024-07-012024-09-30 0000352915 uhs:GeneralAndProfessionalLiabilityInsurancePoliciesMember 2024-01-012024-09-30 0000352915

srt:SubsidiariesMembersrt:MaximumMemberus-gaap:ProfessionalMalpracticeLiabilityMember 2018-12-31 0000352915 us-gaap:AllOtherSegmentsMember 2024-01-012024-09-30 0000352915
uhs:FirstThreeRenewalOptionsMemberuhs:TwoFreeStandingEmergencyDepartmentsMember 2024-01-012024-09-30 0000352915
uhs:ManagedCareMemberuhs:AcuteCareHospitalServicesMember 2024-01-012024-09-30 0000352915 uhs:MedicaidMember 2024-07-012024-09-30 0000352915 srt:MaximumMember 2024-01-012024-09-30 0000352915 uhs:MedicaidMemberuhs:BehavioralHealthServicesMember 2024-07-012024-09-30 0000352915 srt:SubsidiariesMemberuhs:CygnetHealthCareLimitedMemberus-gaap:ProfessionalMalpracticeLiabilityMember 2024-09-30 0000352915 us-gaap:RetainedEarningsAppropriatedMember 2024-09-30 0000352915 srt:MaximumMember 2024-09-30 0000352915 us-gaap:RestrictedStockMemberuhs:TwoThousandTwentyStockIncentivePlanMember 2024-01-012024-09-30 0000352915
uhs:OtherPatientRevenueAndAdjustmentsNetMember 2024-01-012024-09-30 0000352915 uhs:RedeemableInterestMember 2024-06-30 0000352915 srt:MaximumMemberuhs:AikenRegionalMedicalCenterAuroraPavilionBehavioralHealthServicesMember 2024-01-012024-09-30 0000352915 srt:ChiefExecutiveOfficerMemberuhs:TrustOwnedByChiefExecutiveOfficerMember 2024-01-012024-09-30 0000352915
uhs:TrancheATermLoanMember 2024-09-30 0000352915 uhs:MedicaidMemberuhs:AcuteCareHospitalServicesMember 2024-07-012024-09-30 0000352915 srt:SubsidiariesMembersrt:MaximumMemberus-gaap:ProfessionalMalpracticeLiabilityMember 2023-12-31 0000352915
uhs:PunitiveDamagesMembersrt:MaximumMemberuhs:CumberlandHospitalForChildrenAndAdolescentsMember 2024-09-272024-09-27 0000352915 us-gaap:OtherNoncurrentAssetsMemberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000352915 us-gaap:CommonClassAMemberus-gaap:CommonStockMember 2024-06-30 0000352915 srt:ChiefExecutiveOfficerMember 2024-01-012024-09-30 0000352915 2024-01-012024-09-30 0000352915 uhs:ABRBasedLoansMember 2024-09-30 0000352915
uhs:NewSeniorSecuredCreditFacilityMemberuhs:TwoPointSixFivePercentSeniorSecuredNotesDueTwoThousandThirtyMember 2024-01-012024-09-30 0000352915 uhs:UKRevenueMember 2023-07-012023-09-30 0000352915 us-gaap:RestrictedStockMemberuhs:PremierIncMemberuhs:GroupPurchasingOrganizationAgreementMember 2013-10-012013-12-31 0000352915
uhs:RestrictedStockAwardsRestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember 2023-01-012023-09-30 0000352915 us-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-01-012024-09-30 0000352915 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-012024-09-30 0000352915
uhs:NewSeniorSecuredCreditFacilityMemberuhs:TwoPointSixFivePercentSeniorSecuredNotesDueTwoThousandThirtyMember 2020-09-21 0000352915 uhs:BehavioralHealthServicesMember 2023-09-30 0000352915 uhs:CommonClassDMemberus-gaap:CommonStockMember 2023-09-30 0000352915 uhs:OtherNonPatientRevenueMember 2024-01-012024-09-30 0000352915
srt:SubsidiariesMembersrt:MaximumMemberuhs:GeneralAndProfessionalLiabilityInsurancePoliciesMember 2023-12-31 0000352915
uhs:DepartmentOfHumanServicesMember 2015-01-012015-12-31 0000352915 us-gaap:CommonClassBMemberus-gaap:CommonStockMember 2024-09-30 0000352915 us-gaap:CommonClassBMemberus-gaap:CommonStockMember 2023-06-30 0000352915
uhs:CanyonCreekBehavioralHealthMember 2024-01-012024-09-30 0000352915 us-gaap:EmployeeStockOptionMember 2023-07-012023-09-30 0000352915 srt:MaximumMemberuhs:CliveBehavioralHealthHospitalMember 2024-01-012024-09-30 0000352915 us-gaap:ForeignExchangeForwardMember 2024-01-012024-09-30 0000352915 uhs:ManagedCareMember 2024-07-012024-09-30 0000352915 us-gaap:ParentMember 2023-09-30 0000352915 uhs:ManagedMedicaidMemberuhs:AcuteCareHospitalServicesMember 2024-07-012024-09-30 0000352915 uhs:OutsideOwnersMemberstpr:PAuhs:BehavioralHealthCareFacilityMember 2024-09-30 0000352915 us-gaap:AllOtherSegmentsMember 2023-09-30 0000352915 us-gaap:NoncontrollingInterestMember 2023-12-31 0000352915
uhs:OutsideOwnersMemberstpr:NVuhs:AcuteCareFacilityMember 2024-09-30 0000352915 uhs:ManagedMedicaidMember 2024-07-012024-09-30 0000352915 uhs:NewSeniorSecuredCreditFacilityMemberuhs:OnePointSixFivePercentSeniorSecuredNotesDueTwoThousandTwentySixMember 2021-08-24 0000352915 uhs:ManagedCareMemberuhs:BehavioralHealthServicesMember 2024-07-012024-09-30 0000352915 us-gaap:RetainedEarningsAppropriatedMember 2024-06-30 0000352915 uhs:MedicareMemberuhs:BehavioralHealthServicesMember 2023-07-012023-09-30 0000352915 srt:ChiefExecutiveOfficerMember 2023-01-012023-12-31 0000352915 us-gaap:InvestmentAdviceMemberuhs:UniversalHealthRealtyIncomeTrustMember 2023-07-012023-09-30 0000352915
uhs:MedicaidMemberuhs:AcuteCareHospitalServicesMember 2023-07-012023-09-30 0000352915
uhs:CompensatoryDamagesTrebledAndPunitiveDamagesMemberuhs:CumberlandHospitalForChildrenAndAdolescentsMember 2024-09-272024-09-27 0000352915 us-gaap:OtherNoncurrentAssetsMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000352915 uhs:UKRevenueMemberuhs:AcuteCareHospitalServicesMember 2023-07-012023-09-30 0000352915
uhs:NewSeniorSecuredCreditFacilityMemberuhs:FourPointSixTwoFivePercentSeniorSecuredNotesDueTwoThousandTwentyNineMember 2024-01-012024-09-30 0000352915 uhs:OutsideOwnersMemberstpr:MIuhs:BehavioralHealthCareFacilityOneMember 2024-09-30 0000352915
uhs:RedeemableInterestMember 2023-01-012023-09-30 0000352915 us-gaap:OtherOperatingIncomeExpenseMemberuhs:PremierIncMember 2024-01-012024-09-30 0000352915 uhs:LimitedLiabilityCompaniesMembersrt:MinimumMemberuhs:UniversalHealthRealtyIncomeTrustMember 2024-09-30 0000352915 uhs:CommonClassDMemberus-gaap:CommonStockMember 2023-06-30 0000352915 us-gaap:OtherNoncurrentAssetsMemberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000352915 us-gaap:OtherNoncurrentAssetsMemberus-gaap:FairValueMeasurementsRecurringMemberuhs:DeferredCompensationAssetsMember 2023-12-31 0000352915
uhs:ManagedMedicareMemberuhs:BehavioralHealthServicesMember 2024-07-012024-09-30 0000352915
uhs:CanyonCreekBehavioralHealthMember 2024-01-012024-01-01 0000352915 uhs:OtherNonPatientRevenueMember 2023-01-012023-09-30 0000352915 srt:SubsidiariesMembersrt:MaximumMemberus-gaap:ProfessionalMalpracticeLiabilityMember 2019-12-31 0000352915
srt:MaximumMemberuhs:CanyonCreekBehavioralHealthMember 2024-01-012024-09-30 0000352915
uhs:UniversalHealthRealtyIncomeTrustMember 2021-01-012021-12-31 0000352915 us-gaap:RetainedEarningsUnappropriatedMember 2023-12-31 0000352915 uhs:PunitiveDamagesMemberuhs:ThePavilionBehavioralHealthSystemMember 2024-03-282024-03-28 0000352915 us-gaap:RestrictedStockMemberuhs:PremierIncMemberuhs:GroupPurchasingOrganizationAgreementMember 2023-01-012023-12-31 0000352915
uhs:ManagedCareMemberuhs:BehavioralHealthServicesMember 2023-07-012023-09-30 0000352915 us-gaap:CommonClassCMemberus-gaap:CommonStockMember 2023-12-31 0000352915 uhs:AmendedRevolvingCreditFacilityMember 2024-01-012024-09-30 0000352915
uhs:AccruedLiabilitiesOtherMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMember 2023-12-31 0000352915 uhs:UniversalHealthRealtyIncomeTrustMember 2023-01-012023-03-31 0000352915 uhs:CommonClassDMemberus-gaap:CommonStockMember 2022-12-31 0000352915 us-gaap:OtherNoncurrentAssetsMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000352915
uhs:OtherNonPatientRevenueMemberus-gaap:AllOtherSegmentsMember 2023-07-012023-09-30 0000352915
uhs:CaliforniaNewMadridSeismicZonePacificNorthwestSeismicZoneAlaskaAndCertainCountiesInNevadaMemberus-gaap:EarthquakeMember 2024-09-30 0000352915 uhs:OtherNonPatientRevenueMember 2023-07-012023-09-30 0000352915 uhs:RedeemableInterestMember 2022-12-31 0000352915 us-gaap:RetainedEarningsAppropriatedMember 2023-07-012023-09-30 0000352915 uhs:BehavioralHealthServicesMember 2023-01-012023-09-30 0000352915 us-gaap:NoncontrollingInterestMember 2024-07-012024-09-30 0000352915 us-gaap:NoncontrollingInterestMember 2023-07-012023-09-30 0000352915 uhs:BehavioralHealthServicesMember 2023-07-012023-09-30 0000352915
uhs:ManagedCareMemberuhs:AcuteCareHospitalServicesMember 2024-07-012024-09-30 0000352915 2023-07-012023-09-30 0000352915
uhs:OneHospitalFacilityMember 2024-01-012024-09-30 0000352915 us-gaap:AllOtherSegmentsMember 2023-07-012023-09-30 0000352915
srt:MaximumMemberuhs:WellingtonRegionalMedicalCenterMember 2024-01-012024-09-30 0000352915
uhs:OtherPatientRevenueAndAdjustmentsNetMember 2023-01-012023-09-30 0000352915 us-gaap:RestrictedStockMemberuhs:PremierIncMemberuhs:GroupPurchasingOrganizationAgreementMember 2024-01-012024-09-30 0000352915
srt:SubsidiariesMembersrt:MaximumMemberus-gaap:ProfessionalMalpracticeLiabilityMember 2022-12-31 0000352915
srt:SubsidiariesMembersrt:MaximumMemberus-gaap:ProfessionalMalpracticeLiabilityMember 2017-12-31 0000352915 us-gaap:InvestmentAdviceMemberuhs:UniversalHealthRealtyIncomeTrustMember 2024-01-012024-09-30 0000352915 us-gaap:NoncontrollingInterestMember 2024-06-30 0000352915 uhs:CommonClassDMemberus-gaap:CommonStockMember 2024-09-30 0000352915 us-gaap:DebtMember 2024-09-30 0000352915 uhs:UniversalHealthRealtyIncomeTrustMemberuhs:BehavioralHealthCareFacilityMember 2024-01-012024-09-30 0000352915 us-gaap:CommonClassCMemberus-gaap:CommonStockMember 2023-06-30 0000352915
uhs:AmendedRevolvingCreditFacilityMember 2024-09-262024-09-26 0000352915 us-gaap:RetainedEarningsUnappropriatedMember 2023-06-30 0000352915 uhs:MedicareMemberuhs:BehavioralHealthServicesMember 2023-01-012023-09-30 0000352915 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0000352915 us-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2023-01-012023-09-30 0000352915
srt:SubsidiariesMembersrt:MaximumMemberus-gaap:ProfessionalMalpracticeLiabilityMember 2020-12-31 0000352915
srt:MaximumMemberuhs:FirstThreeRenewalOptionsMemberuhs:TwoFreeStandingEmergencyDepartmentsMember 2024-01-012024-09-30 0000352915 srt:SubsidiariesMembersrt:MaximumMemberuhs:GeneralAndProfessionalLiabilityInsurancePoliciesMember 2021-12-31 0000352915
uhs:OtherPatientRevenueAndAdjustmentsNetMember 2023-07-012023-09-30 0000352915 srt:MinimumMember 2024-09-30 0000352915
srt:MaximumMemberuhs:TermLoanAFacilityMemberuhs:OneMonthSOFRRatePlusIndexBasedLoansMember 2024-09-30 0000352915
uhs:PerformanceBasedRestrictedStockUnitsMemberuhs:TwoThousandTwentyStockIncentivePlanMember 2024-01-012024-09-30 0000352915
uhs:MedicareMemberuhs:AcuteCareHospitalServicesMember 2024-07-012024-09-30 0000352915
uhs:OutsideOwnersMembercountry:AZuhs:BehavioralHealthCareFacilityMember 2024-09-30 0000352915 us-gaap:InvestmentAdviceMemberuhs:UniversalHealthRealtyIncomeTrustMember 2024-07-012024-09-30 0000352915 us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberuhs:DeferredCompensationLiabilityMember 2023-12-31 0000352915 us-gaap:NoncontrollingInterestMember 2024-09-30 0000352915 uhs:DepartmentOfHumanServicesMember 2022-01-012022-12-31 0000352915

uhs:UniversalHealthRealtyIncomeTrustMember 2023-01-012023-12-31 0000352915 srt:MaximumMemberuhs:OtherStatesMemberus-gaap:EarthquakeMember 2024-09-30 0000352915 uhs:MedicaidMemberuhs:BehavioralHealthServicesMember 2023-07-012023-09-30 0000352915 uhs:ManagedMedicaidMemberuhs:AcuteCareHospitalServicesMember 2023-07-012023-09-30 0000352915 2023-01-012023-09-30 0000352915 us-gaap:RetainedEarningsUnappropriatedMember 2023-01-012023-09-30 0000352915 uhs:OtherPatientRevenueAndAdjustmentsNetMemberuhs:AcuteCareHospitalServicesMember 2023-01-012023-09-30 0000352915 uhs:ManagedMedicaidMemberuhs:BehavioralHealthServicesMember 2024-01-012024-09-30 0000352915 us-gaap:OtherNoncurrentAssetsMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000352915 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000352915 uhs:ManagedMedicareMemberuhs:BehavioralHealthServicesMember 2023-07-012023-09-30 0000352915 uhs:ManagedCareMemberuhs:AcuteCareHospitalServicesMember 2023-01-012023-09-30 0000352915 us-gaap:ParentMember 2023-07-012023-09-30 0000352915 uhs:UKRevenueMember 2023-01-012023-09-30 0000352915 uhs:ManagedCareMemberuhs:AcuteCareHospitalServicesMember 2023-07-012023-09-30 0000352915 us-gaap:CommonClassCMemberus-gaap:CommonStockMember 2024-09-30 0000352915 us-gaap:RevolvingCreditFacilityMember 2024-01-012024-09-30 0000352915 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000352915 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000352915 uhs:ManagedMedicareMemberuhs:AcuteCareHospitalServicesMember 2023-07-012023-09-30 0000352915 uhs:NewSeniorSecuredCreditFacilityMemberuhs:OnePointSixFivePercentSeniorSecuredNotesDueTwoThousandTwentySixMember 2024-01-012024-09-30 0000352915 srt:SubsidiariesMembersrt:MaximumMemberus-gaap:GeneralLiabilityMember 2024-09-30 0000352915 srt:SubsidiariesMembersrt:MaximumMemberus-gaap:ProfessionalMalpracticeLiabilityMember 2016-12-31 0000352915 uhs:RedeemableInterestMember 2023-09-30 0000352915 srt:SubsidiariesMembersrt:MaximumMemberus-gaap:GeneralLiabilityMember 2020-12-31 0000352915 us-gaap:NoncontrollingInterestMember 2023-06-30 0000352915 uhs:UniversalHealthRealtyIncomeTrustMember 2023-07-012023-09-30 0000352915 us-gaap:RevolvingCreditFacilityMember 2024-09-30 0000352915 us-gaap:ParentMember 2023-12-31 0000352915 uhs:UnvestedStockOptionMember 2024-09-30 0000352915 us-gaap:OtherNoncurrentAssetsMemberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000352915 us-gaap:EmployeeStockOptionMember 2024-07-012024-09-30 0000352915 us-gaap:OtherOperatingIncomeExpenseMemberuhs:PremierIncMember 2023-01-012023-09-30 0000352915 us-gaap:OtherOperatingIncomeExpenseMemberuhs:PremierIncMember 2023-07-012023-09-30 0000352915 uhs:ManagedMedicareMemberuhs:BehavioralHealthServicesMember 2023-01-012023-09-30 0000352915 uhs:FourPointSixTwoFivePercentSeniorSecuredNotesDueTwoThousandTwentyNineMember 2024-09-26 0000352915 uhs:CumberlandHospitalForChildrenAndAdolescentsMember 2024-09-272024-09-27 0000352915 uhs:TrancheATermLoanMember 2024-01-012024-09-30 0000352915 us-gaap:OtherNoncurrentAssetsMemberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000352915 srt:MaximumMemberuhs:CaliforniaNewMadridSeismicZonePacificNorthwestSeismicZoneAlaskaAndCertainCountiesInNevadaMemberus-gaap:EarthquakeMember 2024-09-30 0000352915 uhs:AcuteCareHospitalServicesMember 2023-01-012023-09-30 0000352915 us-gaap:ProfessionalMalpracticeLiabilityMemberuhs:ThePavilionBehavioralHealthSystemMember 2024-09-30 0000352915 srt:MaximumMemberuhs:TwoFreeStandingEmergencyDepartmentsMember 2024-10-012024-10-31 0000352915 uhs:ManagedCareMemberuhs:BehavioralHealthServicesMember 2024-01-012024-09-30 0000352915 us-gaap:CommonClassBMemberus-gaap:CommonStockMember 2023-07-012023-09-30 0000352915 srt:MaximumMemberuhs:McAllenMedicalCenterMember 2024-01-012024-09-30 0000352915 uhs:AccruedLiabilitiesOtherMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMember 2023-12-31 0000352915 uhs:GeneralAndProfessionalLiabilityInsurancePoliciesMember 2023-01-012023-09-30 0000352915 uhs:TwoHospitalFacilitiesMember 2024-01-012024-09-30 0000352915 uhs:TwoFreeStandingEmergencyDepartmentsMember 2024-10-012024-10-31 uhs:Hospital iso4217:USD shares pure shares uhs:Plaintiffs uhs:Facility uhs:Bed iso4217:GBP uhs:SquareFoot iso4217:USD uhs:RenewalOptionfalse0000352915Q3--12-312029-09-262026-08-31http://fasb.org/us-gaap/2024#OtherAssetsMiscellaneousNoncurrenthttp://fasb.org/us-gaap/2024#OtherAssetsMiscellaneousNoncurrenthttp://fasb.org/us-gaap/2024#OtherAssetsMiscellaneousNoncurrentP5YP5Y10-Qtrue2024-09-302024false1-10765UNIVERSAL HEALTH SERVICES, INC.DE23-2077891UNIVERSAL CORPORATE CENTER367 SOUTH GULPH ROADKING OF PRUSSIAPA19406610768-3300Class B Common Stock, $0.01 par valueUHSNYSEYesYesLarge Accelerated Filerfalsefalsefalse65764755874171166168812774396302700035627740001171421300010578430000191230800017848700005611304000530847611472000-3315000-3179700034153300022050700010596250006593030007562300052499000233563000159618000265910000168008000826062000499685000719601732000258714000166989000800970000050141700003.892.4212.117.183.802.4011.887.0966537000688670006687300069825000157100075700012246310002915500-7030001700029221000-246310002917200-703000-140000-926000288000-950002936100-23705000288840000-6080002952710001443030008549460004999770007196000101900016362000-1732000288075000143284000838584000500809000106077000119439000221426800022382650002200620002169880002615490002366580002806870150007162980800088120006485372000654330006550805000300036340003637000363700080001841310001841390001841390001286700012366800020500025871400025871400069910002657050002936100029361000293610002050002587140002936100028807500069910002950660005700487000726734800038173000660569600075390000668108600051910006600059900070000-6598900006798930000928900061490010004771400061967150001100011020000110310001103100021000424056000424077000424077000307461753700017537000108100080970000080970000015281000824981000-1700017000288670002886700028867000108100080968300028884000838567000152810008538480005623000660005890007000-7004870007267348000381730006605696000753900006681086000419300660006280007000-6324730006705525000134290006087182000415770006128759000100032430003244000324400014000177320000177334000177334000613200062370500023705000-2370500050600016698900023705000143284000514000143798000471900066000615000700006462740006720777000-1027600060649150004156800061064830004695000660006370070000-6041270006533667000-9668000592058200044768000596535000070009943000995000099500002900038898200038901100038901100016395000163950001639500042143814000-3814000107400050141700050141700028060004986110006080006080006080001074000501417000-6080005008090002806000498003000471900066000615000700006462740006720777000-1027600060649150004156800061064830008260620004996850004380500004225600005124000625000031580000727270006570200011703000193108000176200060000109490003324000013290006506200001764000562100048985000257320001371700017510400001414140000121745000808610001408664000815366000697865000536665000302190002368800000372800019700000-703116000-5244280002471515000540090002210248000165000000999200030800042058800038533900040302000419640001086400098410005791000525807181170001162900026960004930001873000201980002144700002008370002045970001806390001443780001492470002369750001911890008733300010841200 (1) General This Quarterly Report on Form 10-Q is for the quarterly period ended September 30, 2024. In this Quarterly Report, “we,” “us,” “our” “UHS” and the “Company” refer to Universal Health Services, Inc. and its subsidiaries. The condensed consolidated interim financial statements include the accounts of our majority-owned subsidiaries and partnerships and limited liability companies controlled by us, or our subsidiaries, as managing general partner or managing member. The condensed consolidated interim financial statements included herein have been prepared by us, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and reflect all adjustments (consisting only of normal recurring adjustments) which, in our opinion, are necessary to fairly state results for the interim periods. Certain information and footnote disclosures normally included in audited consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations, although we believe that the accompanying disclosures are adequate to make the information presented not misleading. These condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements, significant accounting policies and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2023. (2) Relationship with Universal Health Realty Income Trust and Other Related Party Transactions Relationship with Universal Health Realty Income Trust: At September 30, 2024, we held approximately 5.7% of the outstanding shares of Universal Health Realty Income Trust (the “Trust”). We serve as Advisor to the Trust under an annually renewable advisory agreement, which is scheduled to expire on December 31

st of each year, pursuant to the terms of which we conduct the Trust's day-to-day affairs, provide administrative services and present investment opportunities. The advisory agreement was renewed by the Trust for 2024 at the same rate in place for 2023, 2022 and 2021, providing for an advisory fee computation at 0.70% of the Trust's average invested real estate assets. We earned an advisory fee from the Trust, which is included in net revenues in the accompanying consolidated statements of income, of approximately $1.4 million and $1.3 million during the three-month periods ended September 30, 2024 and 2023, respectively, and approximately $4.1 million and $4.0 million during the nine-month periods ended September 30, 2024 and 2023, respectively. In addition, certain of our officers and directors are also officers and/or directors of the Trust. Management believes that it has the ability to exercise significant influence over the Trust, therefore we account for our investment in the Trust using the equity method of accounting. Our pre-tax share of income from the Trust was approximately $300,000 and $100,000 during the three-month periods ended September 30, 2024 and 2023, respectively, and approximately $914,000 and $670,000 during the nine-month periods ended September 30, 2024 and 2023, respectively, and is included in other (income) expense, net, on the accompanying consolidated statements of income for each period. We received dividends from the Trust amounting to $575,000 and $567,000 during the three-month periods ended September 30, 2024 and 2023, respectively, and $1.7 million during each of the nine-month periods ended September 30, 2024 and 2023. The carrying value of our investment in the Trust was approximately $6.2 million and $7.0 million at September 30, 2024 and December 31, 2023, respectively, and is included in other assets in the accompanying condensed consolidated balance sheets. The market value of our investment in the Trust was $36.0 million at September 30, 2024 and $34.1 million at December 31, 2023, based on the closing price of the Trust's stock on the respective dates. The Trust commenced operations in 1986 by purchasing certain properties from us and immediately leasing the properties back to our respective subsidiaries. The base rents are paid monthly and the bonus rent, which as of January 1, 2022 is applicable only to McAllen Medical Center, is computed and paid on a quarterly basis, based upon a computation that compares current quarter revenue to a corresponding quarter in the base year. The leases with those subsidiaries are unconditionally guaranteed by us and are cross-defaulted with one another. On December 31, 2021, we entered into an asset purchase and sale agreement with the Trust, which was amended during the first quarter of 2022, pursuant to the terms of which: (i) a wholly-owned subsidiary of ours purchased from the Trust the real estate assets of the Inland Valley Campus of Southwest Healthcare System located in Wildomar, California, at its fair market value; (ii) two wholly-owned subsidiaries of ours transferred to the Trust, at their respective fair-market values, the real estate assets of Aiken Regional Medical Center ("Aiken"), located in Aiken, South Carolina (which includes a 211-bed acute care hospital and a 62-bed behavioral health facility), and Canyon Creek Behavioral Health ("Canyon Creek"), located in Temple, Texas, and; (iii) we received approximately $4.1 million in cash from the Trust. As a result of the purchase options within the lease agreements for Aiken and Canyon Creek, the asset purchase and sale transaction is accounted for as a failed sale leaseback in accordance with U.S. GAAP. We have accounted for the asset exchange and substitution transaction with the Trust as a financing arrangement and, since we did not derecognize the real property related to Aiken and Canyon Creek, we will continue to depreciate the assets. Our condensed consolidated balance sheets as of September 30, 2024 and December 31, 2023 reflects a financial liability of $74.8 million and $77.5 million, respectively, which is included in debt, for the fair value of real estate assets that we exchanged as part of the transaction. Our monthly lease payments payable to the Trust will be recorded to interest expense and as a reduction to the outstanding financial liability. The amount allocated to interest expense is determined using our incremental borrowing rate and is based on the outstanding financial liability. The aggregate rent payable to the Trust in connection with the leases on McAllen Medical Center, Wellington Regional Medical Center, Aiken Regional Medical Center and Canyon Creek Behavioral Health was approximately $5 million during each of the three months ended September 30, 2024 and 2023, and approximately $16 million and $15 million during the nine months ended September 30, 2024 and 2023,

*respectively. Pursuant to the Master Leases by certain subsidiaries of ours and the Trust as described in the table below, dated 1986 and 2021 ("the Master Leases") which govern the leases of McAllen Medical Center and Wellington Regional Medical Center (each of which is governed by the Master Lease dated 1986), and Aiken Regional Medical Center and Canyon Creek Behavioral Health (each of which is governed by the Master Lease dated 2021), we have the option to renew the leases at the lease terms described above and below by providing notice to the Trust at least 90 days prior to the termination of the then current term. We also have the right to purchase the respective leased hospitals at their appraised fair market value upon any of the following: (i) at the end of the lease terms or any renewal terms; (ii) upon one month's notice should a change of control of the Trust occur, or; (iii) within the time period as specified in the lease in the event that we provide notice to the Trust of our intent to offer a substitution property/properties in exchange for one (or more) of the hospital properties leased from the Trust should we be unable to reach an agreement with the Trust on the properties to be substituted. In addition, we have rights of first refusal to: (i) purchase the respective leased facilities during and for a specified period after the lease terms at the same price, terms and conditions of any third-party offer, or; (ii) renew the lease on the respective leased facility at the end of, and for a specified period after, the lease term at the same terms and conditions pursuant to any third-party offer. In addition, we are the managing, majority member in a joint venture with an unrelated third-party that operates Clive Behavioral Health, a 100-bed behavioral health care facility located in Clive, Iowa. The real property of this facility, which was completed and opened in late 2020, is also leased from the Trust (annual rental of approximately $2.8 million and $2.7 million during 2024 and 2023, respectively) pursuant to the lease terms as provided in the table below. In connection with the lease on this facility, the joint venture has the right to purchase the leased facility from the Trust at its appraised fair market value upon either of the following: (i) by providing notice at least 270 days prior to the end of the lease terms or any renewal terms, or; (ii) upon 30 days' notice anytime within 12 months of a change of control of the Trust (UHS also has this right should the joint venture decline to exercise its purchase right). Additionally, the joint venture has rights of first offer to purchase the facility prior to any third-party sale.</p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The table below provides certain details for each of the hospitals leased from the Trust as of September 30, 2024:</p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p><table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:46.969%;box-sizing:content-box;"></td><td style="width:1.32%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:14.023%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.32%;box-sizing:content-box;"></td><td style="width:17.423%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:10.622%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:3.321%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Hospital Name</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Annual
Minimum
Rent</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">End of Lease Term</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Renewal
Term
(years)</p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">McAllen Medical Center</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,485,000 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> December, 2026 </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (a) </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Wellington Regional Medical Center </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:nowrap;vertical-align:bottom;"> $ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,639,000 </td><td style="white-space:nowrap;vertical-align:bottom;"> <span style="min-width:fit-*

content;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> December, 2026 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (b) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Aiken Regional Medical Center/Aurora Pavilion Behavioral Health Services </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,072,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">December, 2033</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">35</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(c)</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Canyon Creek Behavioral Health</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,841,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> December, 2033 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 35 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (c) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Clive Behavioral Health Hospital </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,775,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> December, 2040 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 50 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (d) </td> </tr> </table> (a) We have one 5-year renewal option at existing lease rates (through 2031). <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New

Roman;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(b) We have one 5-year renewal option at fair market value lease rates (through 2031). On each January 1st through 2026, the annual rent will increase by 2.5% on a cumulative and compounded basis. (c) We have seven 5-year renewal options at fair market value lease rates (2034 through 2068). On each January 1st through 2033, the annual rent will increase by 2.25% on a cumulative and compounded basis. (d) This facility is operated by a joint venture in which we are the managing, majority member and an unrelated third-party holds a minority ownership interest. The joint venture has three, 10-year renewal options at computed lease rates as stipulated in the lease (2041 through 2070) and two additional, 10-year renewal options at fair market value lease rates (2071 through 2090). In each January through 2040 (and potentially through 2070 if three, 10-year renewal options are exercised), the annual rental will increase by 2.75% on a cumulative and compounded basis. In addition, certain of our subsidiaries are tenants in several medical office buildings ("MOBs") and two free-standing emergency departments ("FED") owned by the Trust or by limited liability companies in which the Trust holds 95% to 100% of the ownership interest. In connection with these two FEDs, in October, 2024, our subsidiaries exercised their 5-year renewal options on the facilities which are located in Weslaco and Mission, Texas. Each renewal option covers the period of February 1, 2025 through January 31, 2030 (the current lease terms were scheduled to expire on January 31, 2025; with aggregate annual lease rates of approximately $979,000). Pursuant to terms of the leases, and consistent with the terms of the leases currently in effect for each property, the lease rates are scheduled to increase 2% per year through the end of the renewed lease terms. Our subsidiaries have five, 5-year renewal options remaining on each of these FEDs, with the first three renewal options (covering the years 2030 through 2044) providing for 2% annual increases to the lease rates, and the remaining two, 5-year renewal options (covering the years 2045 through 2054) providing for lease rates at the then fair market value. These leases are cross-defaulted with one another and our subsidiaries have the option to purchase the leased properties upon the expiration of each five-year extended term at the fair market value at that time.<span

style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">   During the third quarter of 2023, the Trust acquired the McAllen Doctor's Center, a 79,500 rentable square feet medical office building located in McAllen, Texas. A master lease was executed between a wholly-owned subsidiary of ours and the Trust, pursuant to the terms of which our subsidiary will master lease 100% of the rentable square feet of the MOB at an initial minimum rent of $624,000 annually. The master lease commenced during August, 2023 and is scheduled to expire in twelve years. During the first quarter of 2023, the Trust substantially completed construction on a new 86,000 rentable square feet multi-tenant MOB that is located on the campus of Northern Nevada Sierra Medical Center in Reno, Nevada. Northern Nevada Sierra Medical Center, a 170-bed newly constructed acute care hospital owned and operated by a wholly-owned subsidiary of ours, was completed and opened in April, 2022. In connection with this MOB, a ground lease and a master flex lease was executed between a wholly-owned subsidiary of ours and the Trust, pursuant to the terms of which our subsidiary will master lease approximately 68% of the rentable square feet of the MOB at an initial minimum rent of $1.3 million annually plus a pro-rata share of the common area maintenance expenses. The master flex lease could be reduced during the term if certain conditions are met. The ground lease and master flex lease each commenced during the first quarter of 2023. Other Related Party Transactions: In December, 2010, our Board of Directors approved the Company's entering into supplemental life insurance plans and agreements on the lives of Alan B. Miller (our Executive Chairman of the Board) and his wife. As a result of these agreements, as amended in October, 2016, based on actuarial tables and other assumptions, during the life expectancies of the insureds, we would pay approximately $28 million in premiums, and certain trusts owned by our Executive Chairman of the Board, would pay approximately $9 million in premiums. Based on the projected premiums mentioned above, and assuming the policies remain in effect until the death of the insureds, we will be entitled to receive death benefit proceeds of no less than approximately $37 million representing the $28 million of aggregate premiums paid by us as well as the $9 million of aggregate premiums paid by the trusts. In connection with these policies, we will pay or have paid approximately $1.0 million, net, in premium payments during 2024 and 2023. In August, 2015, Marc D. Miller, our President and Chief Executive Officer and member of our Board of Directors, was appointed to the Board of Directors of Premier, Inc. ("Premier"), a healthcare performance improvement alliance. During 2013, we entered into a new group purchasing organization agreement ("GPO") with Premier. In conjunction with the GPO agreement, we acquired a minority interest in Premier for a nominal amount. During the fourth quarter of 2013, in connection with the completion of an initial public offering of the stock of Premier, we received cash proceeds for the sale of a portion of our ownership interest in the GPO. Also in connection with this GPO agreement, we received shares of restricted stock of Premier which vested ratably over a seven-year period (2014 through 2020), contingent upon our continued participation and minority ownership interest in the GPO. During the third quarter of 2020, we entered into an agreement with Premier pursuant to the terms of which, among other things, our ownership interest in Premier was converted into shares of Class A Common Stock of Premier. We have elected to retain a portion of the previously vested shares of Premier, the market value of which is included in other assets on our condensed consolidated balance sheets. Based upon the closing price of Premier's stock on each respective date, the market value of our shares of Premier was approximately $45 million and $50 million as of September 30, 2024 and December 31, 2023, respectively. Any change in market value of our Premier shares since December 31, 2023 was recorded as an unrealized gain/loss in "Other (income) expense, net" in our condensed consolidated statements of income for the three and nine-month period ended September 30, 2024. Additionally, we received cash dividends from Premier amounting to approximately $470,000 for each of the three-month periods ended September 30, 2024 and 2023, and approximately $1.4 million for each of the nine-month periods ended September 30, 2024 and 2023. The dividends are included in "Other (income) expense, net" in our condensed consolidated statements of income. A member of our Board of Directors, Executive Committee and Finance Committee is a partner in Norton Rose Fulbright US LLP, a law firm engaged by us for a variety of legal services. The Board member and his law firm also provide personal legal services to our Executive Chairman and he acts as trustee of certain trusts for the benefit of our Executive Chairman and his family. 0.0570.00700.00700.00700.00701400000130000041000004000000300000100000914000670000575000567000170000017000000620000070000
style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The table below provides certain details for each of the hospitals leased from the Trust as of September 30, 2024: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:46.969%;box-sizing:content-box;"></td> <td style="width:1.32%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:14.023%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.32%;box-sizing:content-box;"></td> <td style="width:17.423%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td

style="width:10.622%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:3.321%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Hospital Name </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Annual
Minimum
Rent </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> End of Lease Term </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Renewal
Term
(years) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> McAllen Medical Center </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,485,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">December, 2026</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(a)</p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Wellington Regional Medical Center</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,639,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> December, 2026 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (b) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Aiken Regional Medical Center/Aurora Pavilion Behavioral Health Services </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,072,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> December, 2033 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 35 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (c) </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Canyon Creek Behavioral Health </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"><p

style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,841,000</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">December, 2033</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">35</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(c)</p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Clive Behavioral Health Hospital</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,775,000 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> December,   2040 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 50 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (d) </td> </tr> </table> (a) We have one 5-year renewal option at existing lease rates (through 2031). (b) We have one 5-year renewal option at fair market value lease rates (through 2031). On each January 1st through 2026, the annual rent will increase by 2.5% on a cumulative and compounded basis. (c) We have seven 5-year renewal options at fair market value lease rates (2034 through 2068). On each January 1st through 2033, the annual rent will increase by 2.25% on a cumulative and compounded basis. (d) This facility is operated by a joint venture in which we are the managing, majority member and an unrelated third-party holds a minority ownership interest. The joint venture has three, 10-year renewal options at computed lease rates as stipulated in the lease (2041 through 2070) and two additional, 10-year renewal

options at fair market value lease rates (2071 through 2090). In each January through 2040 (and potentially through 2070 if three, 10-year renewal options are exercised), the annual rental will increase by 2.75% on a cumulative and compounded basis. 54850002026-12P5Y66390002026-12P5Y40720002033-12P35Y18410002033-12P35Y27750002040-12P50YP5Y2031P5Y20310.025P5YP5Y20342034206820680.0225P10Y20412070P10Y2071209030.027520.951P5Y2025-02-012030-01-312025-01-319790000.02203020440.022045205479500162400086000170O.681300000280000009000000370000002800000090000001000000100000P7Y201 (3) Other Noncurrent liabilities and Redeemable/Noncontrolling Interests Other noncurrent liabilities include the long-term portion of our professional and general liability, workers' compensation reserves, pension and deferred compensation liabilities, and liabilities incurred in connection with split-dollar life insurance agreements on the lives of our chief executive officer and his wife. As of September 30, 2024, outside owners held noncontrolling, minority ownership interests of: (i) approximately 7% in an acute care facility located in Texas; (ii) 49%, 20%, 30%, 20%, 25%, and 48% in six behavioral health care facilities located in Arizona, Pennsylvania, Ohio, Washington, Missouri, and Iowa, respectively, (iii) 26% and 49% in two behavioral health care facilities located in Michigan (one currently under construction with an expected opening in the second quarter of 2025) and; (iv) approximately 5% in an acute care facility and 49% in a surgery center, located in Nevada. The noncontrolling interest and redeemable noncontrolling interest balances of $75 million and $6 million, respectively, as of September 30, 2024, consist primarily of the third-party ownership interests in these hospitals. In connection with the two behavioral health care facilities located in Pennsylvania and Ohio, the minority ownership interests of which are reflected as redeemable noncontrolling interests on our consolidated balance sheets, the outside owners have "put options" to put their entire ownership interest to us at any time. If exercised, the put option requires us to purchase the minority member's interest at fair market value. Accordingly, the amounts recorded as redeemable noncontrolling interests on our consolidated balance sheets reflect the estimated fair market value of these ownership interests. 0.070.490.200.300.200.250.4860.260.4920.050.495000000060000000 (4) Treasury In September, 2024, we completed the following financing transactions: • The public offering of $500 million of aggregate principal amount of 4.625% senior secured notes due on October 15, 2029 ("2029 Notes"); • The public offering of $500 million of aggregate principal amount of 5.050% senior secured notes due on October 15, 2034 ("2034 Notes"); • Amended our credit agreement to: o Extend the maturity date to September, 2029 (from August, 2026 previously); <div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-

items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;">o Increase the revolving credit facility to $1.3 billion (from $1.2 billion previously), and; o reduce the outstanding borrowings pursuant to the tranche term loan A facility by approximately $1.0 billion, to $1.2 billion, utilizing the proceeds generated from the issuance of the above-mentioned 2029 Notes and 2034 Notes. On September 26, 2024, we entered into a tenth amendment ("Tenth Amendment") to our credit agreement ("Credit Agreement"), dated as of November 15, 2010, as amended and restated at various times from March, 2011 to June, 2022, among UHS, as borrower, the several banks and other financial institutions or entities from time to time parties thereto, as lenders, and JPMorgan Chase Bank, N.A., as administrative agent. The Tenth Amendment provided for: (i) an extension of the maturity date to September 26, 2029; (ii) a new revolving credit facility of up to $1.3 billion (which as of September 30, 2024, had $1.01 billion of aggregate available borrowing capacity, net of $288 million of outstanding borrowings and $3 million of letters of credit), and; (iii) a new replacement tranche A term loan facility ("Tranche A Term Loan") of up to $1.2 billion (which had $1.2 billion of outstanding borrowings as of September 30, 2024). Pursuant to the terms of the Tenth Amendment, the Tranche A Term Loan provides for installment payments of $7.5 million per quarter commencing on December 31, 2024 through September 30, 2026, and $15.0 million per quarter commencing on December 31, 2026 through June 30, 2029. The unpaid principal balance at June 30, 2029 (scheduled to be $975.0 million) is payable on the September 26, 2029 scheduled maturity date of the Credit Agreement. Revolving credit and Tranche A Term Loan borrowings under the Credit Agreement bear interest at our election at either (1) the ABR rate which is defined as the rate per annum equal to the greatest of (a) the lender's prime rate, (b) the weighted average of the federal funds rate, plus 0.5% and (c) one month term SOFR rate plus 1%, in each case, plus an applicable margin based upon our consolidated leverage ratio at the end of each quarter ranging from 0.25% to 0.625%, or (2) the one, three or six month term SOFR rate plus 0.1% (at our election), plus an applicable margin based upon our consolidated leverage ratio at the end of each quarter ranging from 1.25% to 1.625%. As of September 30, 2024, the applicable margins were 0.375% for ABR-based loans and 1.375% for SOFR-based loans under the revolving credit and term loan A facilities. The revolving credit facility includes a $125 million sub-limit for letters of credit. The Credit Agreement is secured by certain assets of the Company and our material subsidiaries (which generally excludes asset classes such as substantially all of the patient-related accounts receivable of our acute care hospitals, if sold to a receivables facility pursuant to the Credit Agreement, and certain real estate assets and assets held in joint-ventures with third parties) and is guaranteed by our material subsidiaries. The Credit Agreement includes a material adverse change clause that must be represented at each draw. The Credit Agreement also contains covenants that include a limitation on sales of assets, mergers, change of ownership, liens, indebtedness, transactions with affiliates, dividends and stock repurchases; and requires compliance with financial covenants including maximum leverage. We were in compliance with all required covenants as of September 30, 2024 pursuant to the terms of the Credit Agreement, as amended on September 26, 2024, and as of December 31, 2023 pursuant to the terms of the previous credit agreement. As mentioned above, on September 26, 2024, we completed the public offering of: (i) $500,000,000 aggregate principal amount of the 4.625%, 2029 Notes, and; (ii) $500,000,000 aggregate principal amount of the 5.050%, 2034 Notes (and together with the 2029 Notes, the "2029 and 2034 Notes"), each guaranteed on a senior secured basis by all of our existing and future direct and indirect subsidiaries that guarantee our senior secured credit facility or our other first lien obligations or any junior lien obligations (the "Subsidiary Guarantors"). The 2029 and 2034 Notes have been registered under the Securities Act of 1933, as amended (the "Securities Act"), pursuant to the

Issuer's and the Subsidiary Guarantors' registration statement on Form S-3 (File No. 333-282135), including the prospectus dated September 16, 2024, and a related prospectus supplement dated September 17, 2024, as filed with the Securities and Exchange Commission on September 19, 2024.</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">As of September 30, 2024, including the above-mentioned newly issued Notes, we had combined aggregate principal of $3.0 billion from the following senior secured notes:</p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;">•<div style="width:100%;display:inline;">$700 million aggregate principal amount of 1.65% senior secured notes due in September, 2026 ("2026 Notes") which were issued on August 24, 2021. Interest on the 2026 Notes is payable on March 1st and September 1st until the maturity date of September 1, 2026.</div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;">•<div style="width:100%;display:inline;">$500 million of aggregate principal amount of 4.625% senior secured notes due in October, 2029 ("2029 Notes") which were issued on September 26, 2024. Interest on the 2029 Notes is payable on April 15th and October 15th, commencing April 15, 2025 until the maturity date of October 15, 2029.</div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;">•<div style="width:100%;display:inline;">$800 million aggregate principal amount of 2.65% senior secured notes due in October, 2030 ("2030 Notes") which were issued on September 21, 2020. Interest on the 2030 Notes is payable on April 15th and October 15th, until the maturity date of October 15, 2030.</div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;">•<div style="width:100%;display:inline;">$500 million of aggregate principal amount of 2.65% senior secured notes due in January, 2032 ("2032 Notes") which were issued on August 24, 2021. Interest on the 2032 Notes is payable on January 15th and July 15th until the maturity date of January 15, 2032.</div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;">•<div style="width:100%;display:inline;">$500 million of aggregate principal amount of 5.050% senior secured notes due in October, 2034 ("2034 Notes") which were issued on September 26, 2024. Interest on the 2034 Notes is payable on April 15th and October 15th, commencing on April 15, 2025 until the maturity date of October 15, 2034.</div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The 2026 Notes, 2030 Notes and 2032 Notes (collectively the "2026, 2030 and 2032 Notes") were initially issued only to qualified institutional buyers under Rule 144A and to non-U.S. persons outside the United States in reliance on Regulation S under the Securities Act. In December, 2022, we completed a registered exchange offer in which virtually all previously outstanding 2026, 2030 and 2032 Notes were exchanged for identical 2026, 2030 and 2032 Notes that were registered under the Securities Act, and thereby became freely transferable (subject to certain restrictions applicable to affiliates and broker dealers). 2026, 2030 and 2032 Notes originally issued under Rule 144A or Regulation S that were not exchanged remain outstanding and may not be offered or sold in the United States absent registration under the Securities Act or an applicable exemption from registration requirements thereunder.</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The 2026, 2030 and 2032 Notes, and the 2029 and 2034 Notes (collectively "All the Notes") are guaranteed (the "Guarantees") on a senior secured basis by our Subsidiary Guarantors that guarantee our Credit Agreement, or other first lien obligations or any junior lien obligations. All the Notes and the Guarantees are secured by first-priority liens, subject to permitted liens, on certain of the Company's and the Subsidiary Guarantors' assets now owned or acquired in the future by the Company or the Subsidiary Guarantors (other than real property, accounts receivable sold pursuant to a Company-related receivables facility (as defined in the Indenture pursuant to which All The Notes were issued (the "Indentures"), and certain other excluded assets). The Company's obligations with respect to All the Notes, the obligations of the Subsidiary Guarantors under the Guarantees, and the performance of all of the Company's and the Subsidiary Guarantors' other obligations under the Indentures, are secured equally and ratably with the Company's and the Subsidiary Guarantors' obligations under the Credit Agreement. However, the liens on the collateral securing All the Notes and the Guarantees will be released if: (i) All the Notes have investment grade ratings; (ii) no default has occurred and is continuing, and; (iii) the liens on the collateral securing all first lien obligations (including the Credit Agreement and All the Notes) and any junior lien obligations are released or the collateral under the Credit Agreement, any other first lien obligations and any junior lien obligations is released or no longer required to be pledged. The liens on any collateral securing All the Notes and the Guarantees will also be released if the liens on that collateral securing the Credit Agreement, other first lien obligations and any junior lien obligations are released.</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">As discussed in Note 2 to the Condensed Consolidated Financial Statements-Relationship with Universal Health Realty Income Trust and Other Related Party Transactions<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, on December 31, 2021, we (through wholly-owned subsidiaries of ours) entered into an asset purchase and sale agreement with Universal Health Realty Income Trust (the "Trust"). Pursuant to the terms of the agreement, which was amended during the first quarter of 2022, we, among other things, transferred to the Trust, the real estate assets of Aiken Regional Medical Center ("Aiken") and Canyon Creek Behavioral Health ("Canyon Creek"). In connection with this transaction,

Aiken and Canyon Creek (as lessees), entered into a master lease and individual property leases, as amended, (with the Trust as lessor), for initial lease terms on each property of approximately twelve years, ending on December 31, 2033. As a result of our purchase option within the Aiken and Canyon Creek lease agreements, this asset purchase and sale transaction is accounted for as a failed sale leaseback in accordance with U.S. GAAP and we have accounted for the transaction as a financing arrangement. Our lease payments payable to the Trust are recorded to interest expense and as a reduction of the outstanding financial liability, and the amount allocated to interest expense is determined based upon our incremental borrowing rate and the outstanding financial liability. In connection with this transaction, our consolidated balance sheets at September 30, 2024 and December 31, 2023 reflect financial liabilities, which are included in debt, of approximately $75 million and $77 million, respectively. At September 30, 2024, the carrying value and fair value of our debt were approximately $4.7 billion and $4.4 billion, respectively. At December 31, 2023, the carrying value and fair value of our debt were approximately $4.9 billion and $4.6 billion, respectively. The fair value of our debt was computed based upon quotes received from financial institutions. We consider these to be “level 2” in the fair value hierarchy as outlined in the authoritative guidance for disclosures in connection with debt instruments. The aggregate scheduled maturities of our $4.7 billion total debt outstanding as of September 30, 2024 (before $21 million of unamortized financing costs), are as follows: (i) $38 million due during the next 12 months; (ii) $738 million due during months 13 to 24; (iii) $69 million due during months 25 to 36; (iv) $70 million due during months 37 to 48; (v) $1.3 billion due during months 49 to 60, and; (vi) $2.4 billion due in greater than 60 months. Foreign Currency Forward Exchange Contracts: We use forward exchange contracts to hedge our net investment in foreign operations against movements in exchange rates. The effective portion of the unrealized gains or losses on these contracts is recorded in foreign currency translation adjustment within accumulated other comprehensive income and remains there until either the sale or liquidation of the subsidiary. In connection with these forward exchange contracts, we recorded net cash outflows of $36 million during the nine-month period ended September 30, 2024 and net cash outflows of $8 million during the nine-month period ended September 30, 2023. Derivatives Hedging Relationships: The following table presents the effects of our foreign currency forward exchange contracts on our results of operations for the three and nine-month periods ended September 30, 2024 and 2023 (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:38.36%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:11.280000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:2.84%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:11.280000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:2.84%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:11.280000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:2.84%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:11.280000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td colspan="14" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"> Gain/(Loss) recognized in AOCI </td><td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"> Three months ended </td><td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"> Nine months ended </td><td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> <span

style="white-space:pre-wrap;min-width:fit-content;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> September 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> September 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> September 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> September 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Net Investment Hedge relationships </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Foreign currency forward exchange contracts </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(43,490</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 19,619 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(35,289</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (10,781 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> </table> No other gains or losses were

recognized in income related to derivatives in Subtopic 815-20. Cash, Cash Equivalents and Restricted Cash: Cash, cash equivalents, and restricted cash as reported in the condensed consolidated statements of cash flows are presented separately on our condensed consolidated balance sheets as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:47.899%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.925%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:5.162%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.925%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:5.162%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.925%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> September 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> September 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> December 31, </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Cash and cash equivalents </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">106,077</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 80,768 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 119,439 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Restricted cash (a) </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 98,520 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 99,871 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 95,031 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total cash, cash equivalents and restricted cash </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">204,597</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 180,639 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 214,470 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #fffff03;"> </td> </tr> </table> (a) Restricted cash is included in other noncurrent assets on the accompanying condensed consolidated balance sheets.
5000000000.046255000000000.050513000000001200000000-10000000001200000000002029-09-26130000000001010000000.00288000000300000012000000001200000000750000015000000975000000.0050.010.00250.006250.0010.01250.016209-01500000000000.046252029-10-158000000000.02652030-10-155000000000.02652032-01-155000000000.05052034-10-157500000007700000047000000004400000000490000000046000000004700000000210000003800000073800000069000000700000001300000000236000000-8000000 The following table presents the effects of our foreign currency forward exchange contracts on our results of operations for the three and nine-month periods ended September 30, 2024 and 2023 (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:38.36%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.280000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.84%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.280000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.84%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.280000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.84%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"> Gain/(Loss) recognized in AOCI </td> <td style="vertical-align:middle;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"> Three months ended </td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:middle;border-bottom:0.5pt solid #000000;text-align:left;"> Nine months ended </td> <td style="vertical-align:middle;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> September 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> September 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> September 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> September 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #fffff03;text-align:left;"><p style="font-

size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Net Investment Hedge relationships </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Foreign currency forward exchange contracts </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(43,490</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 19,619 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(35,289</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (10,781 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> </tr> </table>-434900001961900035289000-10781000 Cash, cash equivalents, and restricted cash as reported in the condensed consolidated statements of cash flows are presented separately on our condensed consolidated balance sheets as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:47.899%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.925%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:5.162%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.925%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:5.162%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:11.925%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> September 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> September 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> December 31, </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td

colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Cash and cash equivalents </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">106,077</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 80,768 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">119,439</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Restricted cash (a)</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">98,520</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">99,871</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 95,031 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total cash, cash equivalents and restricted cash </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">204,597</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 180,639 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 214,470 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> (a) Restricted cash is included in other noncurrent assets on the accompanying condensed consolidated balance sheets.
1060770008076800011943900098520000998710009503100020459700018063900021447000 0 (5) Fair Value Measurement Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels: • Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities. • Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These included quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. <div

class="item-list-element-wrapper" style="margin-left:3.333%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;">• Level 3: Unobservable inputs that reflect the reporting entity's own assumptions. The following tables present the assets and liabilities recorded at fair value on a recurring basis: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:27%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:12%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:28.14%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:8.36%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:8.239999999999998%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:8.26%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:left;"> Balance at </td><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> Balance Sheet </td><td colspan="8" style="vertical-align:bottom;text-align:left;"> Basis of Fair Value Measurement </td><td style="vertical-align:bottom;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> (in thousands) </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Location </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 1 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 2 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 3 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> Assets: </td><td colspan="2" style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td><td colspan="2" style="vertical-align:bottom;text-align:left;"> </td><td style="vertical-align:bottom;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Money market mutual funds </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">115,205</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Other noncurrent assets</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 115,205 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td><td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> </td></tr><tr style="height:10pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Certificates of deposit </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,201 </td><td style="white-space:nowrap;vertical-align:bottom;"> </td><td style="white-space:pre-wrap;vertical-align:bottom;"> Other noncurrent assets </td><td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,201 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Equity securities </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 44,654 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> Other noncurrent assets </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 44,654 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Deferred compensation assets </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 49,270 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> Other noncurrent assets </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 49,270 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">211,330</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 209,129 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,201 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Liabilities: </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:left;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Foreign currency forward exchange contracts </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,533</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Accounts payable and other liabilities</p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,533 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Deferred compensation liability </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 49,270 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> Other noncurrent liabilities </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 49,270 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">50,803</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 49,270 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,533 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> <span

style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Balance at </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> Balance Sheet </td> <td colspan="8" style="vertical-align:bottom;text-align:left;"> Basis of Fair Value Measurement </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> (in thousands) </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Location </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 1 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 2 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 3 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Assets: </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Money market mutual funds </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">111,129</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Other noncurrent assets</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 111,129 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Certificates of deposit </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,300 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> Other noncurrent assets </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,300 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Equity securities </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 49,923 </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> Other noncurrent assets </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 49,923 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Deferred compensation assets </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 43,060 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> Other noncurrent assets </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 43,060 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">206,412</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 204,112 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,300</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Liabilities:</p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Foreign currency forward exchange contracts</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,911 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> Accounts payable and other liabilities </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td

style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,911</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Deferred compensation liability</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">43,060</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Other noncurrent liabilities</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">43,060</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 44,971 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">43,060</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,911 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The fair value of our money market mutual funds, certificates of deposit and equity securities with a readily determinable fair value are computed based upon quoted market prices in an active market. The fair value of deferred compensation assets and the offsetting liability are computed based on market prices in an active market held in a rabbi trust. The fair value of our foreign currency exchange contracts is determined using quoted forward exchange rates and spot rates at the reporting date. The following tables present the assets and liabilities recorded at fair value on a recurring basis: <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:27%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:12%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:28.14%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.36%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.239999999999998%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.26%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Balance at </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> Balance Sheet </td> <td colspan="8" style="vertical-align:bottom;text-align:left;"> Basis of Fair Value Measurement </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> (in thousands) </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Location </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 1 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-

size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 2 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 3 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Assets: </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Money market mutual funds </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">115,205</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Other noncurrent assets</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 115,205 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Certificates of deposit </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,201 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> Other noncurrent assets </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,201 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Equity securities </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 44,654 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> Other noncurrent assets </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 44,654 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Deferred compensation assets </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New

Roman;margin-bottom:0;text-align:right;">49,270 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> Other noncurrent assets </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 49,270 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">211,330</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 209,129 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,201</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">-</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Liabilities:</p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Foreign currency forward exchange contracts</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,533 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> Accounts payable and other liabilities </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,533 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Deferred compensation liability </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 49,270 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> Other noncurrent liabilities </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 49,270 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">50,803</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 49,270 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,533 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> Balance at </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> Balance Sheet </td> <td colspan="8" style="vertical-align:bottom;text-align:left;"> Basis of Fair Value Measurement </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> (in thousands) </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> December 31, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Location </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 1 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 2 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Level 3 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Assets: </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2"

style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Money market mutual funds </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">111,129</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Other noncurrent assets</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 111,129 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Certificates of deposit </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,300 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> Other noncurrent assets </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,300 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Equity securities </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 49,923 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> Other noncurrent assets </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 49,923 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Deferred compensation assets </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 43,060 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> Other noncurrent assets </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 43,060 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">206,412</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2,300 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Liabilities: </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Foreign currency forward exchange contracts </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,911</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Accounts payable and other liabilities</p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,911 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Deferred compensation liability </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 43,060 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> Other noncurrent liabilities </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 43,060 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;">

44,971 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">43,060</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 1,911 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>1152050001152050002201000220100044654000446540004927000049270000211330000209129000220100015330001533000492700004 9
<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">(6) Commitments and Contingencies</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">Professional and General Liability, Workers' Compensation Liability </p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">The vast majority of our subsidiaries are self-insured for professional and general liability exposure up to: (i) $20 million for professional liability and $3 million for general liability per occurrence in 2024, 2023, 2022 and 2021; (ii) $10 million and $3 million per occurrence, respectively, in 2020; (iii) $5 million and $3 million per occurrence, respectively, during 2019, 2018 and 2017, and; (iv) $10 million and $3 million per occurrence, respectively, prior to 2017.</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">These subsidiaries are provided with several excess policies through commercial insurance carriers which provide for coverage in excess of the applicable per occurrence and aggregate self-insured retention or underlying policy limits up to approximately $175 million in 2024; $165 million in 2023; $162 million in 2022; $155 million in 2021 and $250 million during each of 2014 through 2020. In addition, from time to time based upon marketplace conditions, we may elect to purchase additional commercial coverage for certain of our facilities or businesses. Our behavioral health care facilities located in the U.K. have policies through a commercial insurance carrier located in the U.K. that provides for £18.5 million of professional liability coverage, and £25 million of general liability coverage. The commercial insurance limits indicated above for each policy year may have been reduced due to payment of covered claims or suits, subject to the policy terms and conditions.</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">As of September 30, 2024, the total net accrual for our self-insured professional and general liability claims was $480 million, of which $70 million was included in current liabilities. As of December 31, 2023, the total net accrual for our self-insured professional and general liability claims was $431 million, of which $70 million was included in current liabilities.</p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">As a result of unfavorable trends experienced during the past several years, included in our results of operations were increases to our reserves for self-insured professional and general liability claims amounting to approximately $30 million and $44 million during the three and nine-month periods ended September 30, 2024, respectively, and $5 million and $25 million during the three and nine-month periods ended September 30, 2023. Our estimated liability for self-insured professional and general liability claims is based on a number of factors including, among other things, the number of asserted claims and reported incidents, estimates of losses for these<span style="color:#000000;white-space:pre-wrap;font-

size:10pt;font-family:Times New Roman;min-width:fit-content;"> claims based on recent and historical settlement amounts, estimates of incurred but not reported claims based on historical experience, and estimates of amounts recoverable under our commercial insurance policies. While we continuously monitor these factors, our ultimate liability for professional and general liability claims could change materially from our current estimates due to inherent uncertainties involved in making this estimate. Given our significant self-insured exposure for professional and general liability claims, there can be no assurance that a sharp increase in the number and/or severity of claims asserted against us will not have a material adverse effect on our future results of operations. As of September 30, 2024, the total accrual for our workers' compensation liability claims was $136 million, $58 million of which was included in current liabilities. As of December 31, 2023, the total accrual for our workers' compensation liability claims was $130 million, $55 million of which was included in current liabilities. As a result of favorable trends experienced in prior years, included in our results of operations during the nine-month period ended September 30, 2023, was a pre-tax decrease to our reserves for self-insured workers' compensation liability claims of approximately $10 million (recorded during the second quarter of 2023). Although we are unable to predict whether or not our future financial statements will require updates to estimates for our prior year reserves for self-insured general and professional and workers' compensation claims, given the relatively unpredictable nature of these potential liabilities and the factors impacting these reserves, as discussed above, it is reasonably likely that our future financial results may include material adjustments to prior period reserves. As disclosed below in Legal Proceedings: • On March 28, 2024, a jury returned a verdict for compensatory damages of $60 million and punitive damages of $475 million and a related judgment was entered against The Pavilion Behavioral Health System (the "Pavilion"), an indirect subsidiary of the Company. In an order dated October 10, 2024, the trial court ordered a remittitur of punitive damages from $475 million to $120 million. The court denied the Pavilion's request for reduction of compensatory damages. The Pavilion intends to appeal the remaining judgment. • Cumberland Hospital for Children and Adolescents ("Cumberland"), an indirect subsidiary of the Company, is a defendant in multi-plaintiff lawsuits filed in the Circuit Court for Richmond, Virginia (the "Cumberland Litigation"), relating to allegations of inappropriate sexual contact during medical examinations by Dr. Daniel Davidow, an independent contractor and the former medical director for Cumberland. The Company and UHS of Delaware, Inc., our administrative services subsidiary ("UHS Delaware"), were also named as co-defendants in the Cumberland Litigation. Plaintiffs have asserted claims of negligence, assault and battery (against Dr. Davidow), false imprisonment, violations of the Virginia Consumer Protection Act ("VCPA"), and vicarious liability for Dr. Davidow's conduct against Cumberland, the Company, and UHS Delaware. The Company and UHS Delaware were dismissed from the action during the trial, which occurred in September, 2024. On September 27, 2024, a jury entered a verdict finding Dr. Davidow and Cumberland liable and awarded these three plaintiffs combined compensatory damages of $60 million for all liability theories, an additional combined $180 million in trebled damages for violation of the VCPA, and an additional combined $120 million in punitive damages. Cumberland is evaluating all legal options and intends to challenge this verdict, including the amounts awarded in the verdict, in post-trial proceedings and on appeal. Based upon Virginia law, we expect that the punitive damage amount should be reduced to a combined maximum of $1.05 million as a matter of law. There are approximately 40 additional plaintiffs making similar allegations with claims pending in the Cumberland Litigation. We are uncertain as to the ultimate financial exposure related to the above-mentioned Cumberland and Pavilion matters and we can make no assurances regarding their outcomes, or the amounts of damages that may be held recoverable after post-judgment proceedings and appeals. While Cumberland and Pavilion have professional liability insurance to cover a portion of these amounts, the resolution of these matters may have a material adverse effect on the Company. Without reduction for any potential amounts related to the above-mentioned Cumberland and Pavilion matters, the Company and its subsidiaries have aggregate insurance coverage of approximately $221 million remaining under commercial policies for matters applicable to the 2020 policy year (in excess of the applicable self-insured retention amounts of $10 million per occurrence for professional liability claims and $3 million per occurrence for general liability claims). In the event the resolution of the Cumberland and/or Pavilion matters exhausts all or a significant portion of the remaining commercial insurance coverage available to the Company and its subsidiaries for claims that occurred in 2020 (the applicable year for the Pavilion matter and substantially all of the Cumberland matters, as discussed above), or it requires the posting of large bonds or other collateral during appeal processes, our future results of operations and capital resources could be materially adversely impacted. Property Insurance We have commercial property insurance policies for our properties, covering the period of June 1, 2024 to June 1, 2025, providing property and business interruption coverage for losses in excess of $<span style="font-

size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">15 million per occurrence or per location (as applicable based upon the event) up to a $1 billion annual policy limitation for certain catastrophic events or perils. These commercial policies provide for coverage of up to $250 million of annual aggregate coverage for losses resulting from windstorm damage. Losses resulting from named windstorms are subject to deductibles between 3% and 5% of the total insurable value of the property. In addition, we have commercial property insurance policies covering catastrophic losses resulting from earthquake and flood damage, each subject to aggregated loss limits (as opposed to per occurrence losses). Commercially insured earthquake coverage for our facilities is subject to various deductibles and limitations including: (i) $100 million limitation for our facilities located in California, New Madrid Seismic Zone, Pacific Northwest Seismic Zone, Alaska and certain counties in Nevada; (ii) $100 million limitation for our facilities located in fault zones within the United States; (iii) $40 million limitation for our facilities located in Puerto Rico, and; (iv) $250 million limitation for many of our facilities located in other states. Our commercially insured flood coverage has a limit of $100 million annually. There is also a $10 million sublimit for one of our facilities located in Houston, Texas, and a $1 million sublimit for our facilities located in Puerto Rico. In addition, subject to the underlying policies' deductible provisions, our facilities located in California, New Madrid Seismic Zone, Pacific Northwest Seismic Zone, Alaska and certain counties in Nevada, have $50 million of excess commercial property insurance coverage for earthquake losses in excess of $100 million. Property insurance for our behavioral health facilities located in the U.K. are provided on an all risk basis up to a £1.5 billion policy limit, with coverage caps per location, that includes coverage for real and personal property as well as business interruption losses. These commercial policies are subject to a deductible of: (i) $5 million per location for damage resulting from earthquake, wind, hail and flood, and; (ii) $5 million per occurrence for all other events. For per location or per occurrence losses in excess of the applicable deductible, we are self-insured, through our wholly-owned captive insurance company, for up to $10 million of annual aggregate losses. Should the $10 million self-insured annual aggregate limitation be exhausted during the policy year, we have commercial insurance coverage for the next $30 million of annual aggregate losses in excess of the applicable deductible. In the event the $30 million of commercial coverage is also exhausted, we are self-insured for all per location or per occurrence losses up to $25 million, including the $5 million deductible. Commitment to Develop, Lease and Operate an Acute Care Hospital in Washington, D.C. During 2020, we entered into various agreements with the District of Columbia (the “District”) related to the development, leasing and operation of an acute care hospital and certain other facilities/structures on land owned by the District (“District Facilities”). The agreements contemplate that we will serve as manager for development and construction of the District Facilities on behalf of the District, with a projected aggregate cost of approximately $439 million, approximately $295 million of which was incurred as of September 30, 2024, which will be entirely funded by the District. Construction of the District Facilities is expected to be completed in the Spring of 2025. Upon completion of the District Facilities, we will lease the District Facilities for a nominal rental amount for a period of 75 years and are obligated to operate the District Facilities during the lease term. We have certain lease termination rights in connection with the District Facilities beginning on the tenth anniversary of the lease commencement date for various and decreasing amounts as provided for in the agreements. Additionally, any time after the 10th anniversary of the lease term, we have a right to purchase the District Facilities for a price equal to the greater of fair market value of the District Facilities or the amount necessary to defease the bonds issued by the District to fund the construction of the District Facilities. The lease agreement also entitles the District to participation rent should certain specified earnings before interest, taxes, depreciation and amortization thresholds be achieved by the acute care hospital. Additionally, we have committed to expend no less than $75

million (approximately $12 million of which has been incurred as of September 30, 2024), over a projected 12-year period, in healthcare infrastructure including expenditures related to the District Facilities as well as other healthcare related expenditures in certain specified areas of Washington, D.C. Pursuant to the agreements, the District is entitled to certain termination fees and other amounts as specified in the agreements in the event we, within certain specified periods of time, cease to operate the acute care hospital or there is a transfer of control of us or our subsidiary operating the hospital. Legal Proceedings We operate in a highly regulated and litigious industry which subjects us to various claims and lawsuits in the ordinary course of business as well as regulatory proceedings and government investigations. These claims or suits include claims for damages for personal injuries, medical malpractice, commercial/contractual disputes, wrongful restriction of, or interference with, physicians' staff privileges, and employment related claims. In addition, health care companies are subject to investigations and/or actions by various state and federal governmental agencies or those bringing claims on their behalf. Government action has increased with respect to investigations and/or allegations against healthcare providers concerning possible violations of fraud and abuse and false claims statutes as well as compliance with clinical and operational regulations. Currently, and from time to time, we and some of our facilities are subjected to inquiries in the form of subpoenas, Civil Investigative Demands, audits and other document requests from various federal and state agencies. These inquiries can lead to notices and/or actions including repayment obligations from state and federal government agencies associated with potential non-compliance with laws and regulations. Further, the federal False Claims Act allows private individuals to bring lawsuits (qui tam actions) against healthcare providers that submit claims for payments to the government. Various states have also adopted similar statutes. When such a claim is filed, the government will investigate the matter and decide if they are going to intervene in the pending case. These qui tam lawsuits are placed under seal by the court to comply with the False Claims Act's requirements. If the government chooses not to intervene, the private individual(s) can proceed independently on behalf of the government. Health care providers that are found to violate the False Claims Act may be subject to substantial monetary fines/penalties as well as face potential exclusion from participating in government health care programs or be required to comply with Corporate Integrity Agreements as a condition of a settlement of a False Claims Act matter. In September 2014, the Criminal Division of the Department of Justice ("DOJ") announced that all qui tam cases will be shared with their Division to determine if a parallel criminal investigation should be opened. The DOJ has also announced an intention to pursue civil and criminal actions against individuals within a company as well as the corporate entity or entities. In addition, health care facilities are subject to monitoring by state and federal surveyors to ensure compliance with program Conditions of Participation. In the event a facility is found to be out of compliance with a Condition of Participation and unable to remedy the alleged deficiency(s), the facility faces termination from the Medicare and Medicaid programs or compliance with a System Improvement Agreement to remedy deficiencies and ensure compliance. The laws and regulations governing the healthcare industry are complex covering, among other things, government healthcare participation requirements, licensure, certification and accreditation, privacy of patient information, reimbursement for patient services as well as fraud and abuse compliance. These laws and regulations are constantly evolving and expanding. Further, the original Patient Protection and Affordable Care Act, as amended by the Health and Education Reconciliation Act, has added additional obligations on healthcare providers to report and refund overpayments by government healthcare programs and authorizes the suspension of Medicare and Medicaid payments "pending an investigation of a credible allegation of fraud." We monitor our business and have developed an ethics and compliance program with respect to these complex laws, rules and regulations. Although we believe our policies, procedures and practices comply with government regulations, there is no assurance that we will not be faced with the sanctions referenced above which include fines, penalties and/or substantial damages, repayment obligations, payment suspensions, licensure revocation, and expulsion from government healthcare programs. Even if we were to ultimately prevail in any action brought against us or our facilities or in responding to any inquiry, such action or inquiry could have a material adverse effect on us. Certain legal matters are described below: Knight v. Miller, et. al. In July 2021, a shareholder derivative lawsuit was filed by plaintiff, Robin Knight, in the Chancery Court in Delaware against the members of the Board of Directors of the Company as well as certain officers (C.A. No.: 2021-0581-SG). The Company was named as a nominal defendant. The lawsuit alleged that in March 2020 stock options were awarded with exercise prices that did not reflect the Company's fundamentals and business prospects, and in anticipation of future market rebound resulting in excessive gains. The lawsuit made claims of breaches of fiduciary duties, waste of corporate assets, and unjust enrichment. The lawsuit sought monetary damages allegedly incurred by the Company, disgorgement of the March 2020 stock awards as well as any proceeds derived therefrom and unspecified equitable relief. Defendants denied the allegations. We filed a motion to dismiss the complaint and the court granted part and denied part of our motion. During the third quarter of 2022, we reached a preliminary settlement, which would not have had a material impact on our consolidated financial statements. The settlement required court approval which the court declined to provide. Our Board of Directors authorized the formation of a Special Litigation Committee ("SLC") to review the matter and determine whether it was in the best interests of the Company to pursue this claim. The court stayed the litigation while the SLC conducted their review. According to the SLC's status letter to the Court of Chancery, dated April 15, 2024, after a thorough examination of documentary evidence, interviews with relevant persons, and a review of the applicable law, the SLC determined that the claims asserted in the shareholder derivative lawsuit did not have merit and that pursuing them would not be in the interest of the Company. The SLC further advised the court that the SLC concluded that the claims should be dismissed. The parties jointly filed a stipulation with the court requesting dismissal of the case. After a preliminary hearing on the matter, the court requested a revised stipulation be filed which was prepared and filed with the court. During the third quarter of 2024, the court entered the stipulation dismissing the case and the matter has been concluded. Disproportionate Share Hospital Payment Matter: In late September, 2015, many hospitals in Pennsylvania, including certain of our behavioral health care hospitals located in the state, received letters from the Pennsylvania Department of Human Services (the "Department") demanding repayment of allegedly excess Medicaid Disproportionate Share Hospital payments ("DSH"), primarily consisting of managed care payments characterized as DSH payments, for the federal fiscal year ("FFY") 2011 amounting to approximately $4 million in the aggregate. Since that time, certain of our behavioral health care hospitals in Pennsylvania have received similar requests for repayment for alleged DSH overpayments for FFYs 2012 through 2015. For FFY 2012, the claimed overpayment amounts to approximately $4 million. For FY 2013, FY 2014 and FY 2015 the initial claimed overpayments and attempted recoupment by the Department were approximately $7 million, $8 million and $7 million, respectively. The Department has agreed to a change in methodology which, upon confirmation of the underlying data being accepted by the Department, could reduce the initial claimed overpayments for FY 2013, FY 2014 and FY 2015 to approximately $2 million, $2 million and $3 million, respectively. We filed administrative appeals for all of our facilities contesting the

recoupment efforts for FFYs 2011 through 2015 as we believe the Department's calculation methodology is inaccurate and conflicts with applicable federal and state laws and regulations. The Department agreed to postpone the recoupment of the state's share for FFY 2011 to 2013 until all hospital appeals are resolved but recouped the federal share. For FFY 2014 and FFY 2015, the Department initiated the recoupment of the alleged overpayments (both federal and state shares). Starting in FY 2016, the first full fiscal year after the January 1, 2015 effective date of Medicaid expansion in Pennsylvania, the Department no longer characterized managed care payments received by the hospitals as DSH payments. While the administrative appeals on the disputed DSH payments remain pending, we have been in continued settlement discussions with the Department. As a part of these discussions, we have presented certain calculation errors that we believe, if corrected, could materially reduce the alleged overpayments. We have recently reached a settlement in principle with the Department that will result in a partial repayment to us of amounts previously recouped. The parties are in the process of drafting a definitive settlement agreement codifying our agreement to conclude this matter. In the event that we are unable to complete the settlement agreement, we will continue with our administrative appeals. We can provide no assurance that we will ultimately be successful in our legal and administrative appeals related to the Department's repayment demands in the event the pending settlement is not finalized and we are unable to assess liability or damages with certainty at this time. If our legal and administrative appeals are unsuccessful, our future consolidated results of operations and financial condition could be adversely impacted by these repayments. Rachel Capriglione, as natural mother and Next Friend of A.T., a minor, Plaintiff, v. The Pavilion Foundation d/b/a The Pavilion Behavioral Health System As previously reported on Form 8-K, as filed on April 1, 2024, the Pavilion Behavioral Health System (the "Pavilion"), an indirect subsidiary of the Company, is the sole defendant in a lawsuit filed in Champaign County, Illinois, relating to the sexual assault of one minor patient by another minor patient in 2020. Plaintiff asserted claims of negligence and misrepresentation. The Pavilion denied any liability. The case went to trial in March of 2024. On March 28, 2024, a jury rejected the misrepresentation claim, returned a verdict for ordinary negligence, and awarded compensatory damages of $60 million and punitive damages of $475 million. Based on a search of verdicts in comparable cases, the magnitude of this verdict was unexpected and is unprecedented for a single-plaintiff injury case of this type in Champaign County, Illinois. The Pavilion filed post-trial motions, among other items, contesting the excessiveness of the damage awards. As previously reported on Form 8-K, as filed on October 11, 2024, in an order dated October 10, 2024, the trial court ordered a remittitur of punitive damages from $475 million to $120 million. The court denied the Pavilion's request for reduction of compensatory damages. Pursuant to Illinois law and procedure, plaintiff had 21 days from the date of the order to either accept the remittitur of the punitive damages or refuse the remittitur, which would have resulted in further legal proceedings. Plaintiff accepted the remittitur by the trial court while reserving all rights to appeal the remittitur. The Pavilion intends to appeal the remaining judgment. Although we can make no assurances regarding the ultimate outcome of this matter, or what damages will ultimately be awarded, its final resolution could have a material adverse effect on the Company K.E.E., et al., Plaintiffs v. Cumberland Hospital, LLC d/b/a Cumberland Hospital for Children and Adolescents, et al. (and related lawsuits) Cumberland Hospital for Children and Adolescents ("Cumberland"), an indirect subsidiary of the Company, is a defendant in multi-plaintiff lawsuits filed in the Circuit Court for Richmond, Virginia (the "Cumberland Litigation"), relating to allegations of inappropriate sexual contact during medical examinations by Dr. Daniel Davidow, an independent contractor and the former medical director for Cumberland. The Company and UHS of Delaware, Inc., our administrative services subsidiary ("UHS Delaware"), were also named as co-defendants in the Cumberland Litigation. Plaintiffs have asserted claims of negligence, assault and battery (against Dr. Davidow), false imprisonment, violations of the Virginia Consumer Protection Act ("VCPA"), and vicarious liability for Dr. Davidow's conduct against Cumberland, the Company, and UHS Delaware. All defendants have denied liability. The claims asserted by three of the plaintiffs in the Cumberland Litigation were consolidated for trial in September of 2024. The Company and UHS Delaware were dismissed from the action during trial. As previously reported on Form 8-K, as filed on September 30, 2024, on September 27, 2024, a jury entered a verdict finding Dr. Davidow and Cumberland liable and awarded these three plaintiffs combined compensatory damages of $60 million for all liability theories, an additional combined $180 million in trebled damages for violation of the VCPA, and an additional combined $120 million in punitive damages. Cumberland is evaluating all legal options and intends to challenge this verdict, including the amounts awarded in the verdict, in post-trial proceedings and on appeal. Based upon Virginia law, we expect that the punitive damage amount should be reduced to a combined maximum of $1.05 million as a matter of law. There are approximately 40 additional plaintiffs making similar allegations with claims pending in the Cumberland Litigation. Although we can make no assurances regarding the ultimate outcomes of the various claims made in connection with the Cumberland Litigation, or what damages will ultimately be awarded, the final resolution of these matters could have a material adverse effect on the Company Other Matters: Various other suits, claims and investigations, including government subpoenas, arising against, or issued to, us are pending and additional such matters may arise in the future. Management will consider additional disclosure from time to time to the extent it <p style="font-size:10pt;margin-top:6pt;font-family:Times New

Roman;margin-bottom:0;text-align:left;">believes such matters may be or become material. The outcome of any current or future litigation or governmental or internal investigations, including the matters described above, cannot be accurately predicted, nor can we predict any resulting penalties, fines or other sanctions that may be imposed at the discretion of federal or state regulatory authorities. We record accruals for such contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. No estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made at this time regarding the matters described above or that are otherwise pending because the inherently unpredictable nature of legal proceedings may be exacerbated by various factors, including, but not limited to: (i) the damages sought in the proceedings are unsubstantiated or indeterminate; (ii) discovery is not complete; (iii) the matter is in its early stages; (iv) the matters present legal uncertainties; (v) there are significant facts in dispute; (vi) there are a large number of parties, or; (vii) there is a wide range of potential outcomes. It is possible that the outcome of these matters could have a material adverse impact on our future results of operations, financial position, cash flows and, potentially, our reputation.
2000000020000000200000002000000030000003000000300000030000001000000030000005000000500000050000003000000300000030000000 style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">(7) Segment Reporting Our reportable operating segments consist of acute care hospital services and behavioral health care services. The “Other” segment column below includes centralized services including, but not limited to, information technology, purchasing, reimbursement, accounting and finance, taxation, legal, advertising and design and construction. The chief operating decision making group for our acute care services and behavioral health care services is comprised of our Chief Executive Officer and the Presidents of each operating segment. The Presidents for each operating segment also manage the profitability of each respective segment’s various facilities. The operating segments are managed separately because each operating segment represents a business unit that offers different types of healthcare services or operates in different healthcare environments. The accounting policies of the operating segments are the same as those described in the summary of significant accounting policies included in our Annual Report on Form 10-K for the year ended December 31, 2023. The corporate overhead allocations, as reflected below, are utilized for internal reporting purposes and are comprised of each period’s projected corporate-level operating expenses (excluding interest expense). The overhead expenses are captured and allocated directly to each segment, to the extent possible, based upon each segment’s respective percentage of total operating expenses. <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.01%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.162%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.162%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.162%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.862%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three months ended September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Acute Care
Hospital
Services </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Behavioral
Health
Services (a) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Other </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total
Consolidated </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;text-align:left;"> (Dollar amounts in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Gross inpatient revenues </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">12,277,563</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,835,301 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p

style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">15,112,864</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Gross outpatient revenues</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,573,270 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">268,182</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,841,452 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total net revenues </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,245,517</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,714,914 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,596</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,963,027 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Income/(loss) before allocation of corporate overhead and
  income taxes </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">199,316</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 318,864 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(176,647</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 341,533 </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Allocation of corporate overhead </td><td style="white-space:pre-wrap;vertical-align:bottom;">   </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(64,883</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (46,898 </td><td style="white-space:nowrap;vertical-align:bottom;">) </td><td style="white-space:pre-wrap;vertical-align:bottom;">   </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">111,781</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0 </td><td style="white-space:nowrap;vertical-align:bottom;">   </td></tr><tr style="height:8pt;background-color:#ffffff;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Income/(loss) after allocation of corporate overhead and
  before income taxes </td><td style="white-space:pre-wrap;vertical-align:bottom;">   </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">134,433</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 271,966 </td><td style="white-space:nowrap;vertical-align:bottom;">   </td><td style="white-space:pre-wrap;vertical-align:bottom;">   </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(64,866</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 341,533 </td><td style="white-space:nowrap;vertical-align:bottom;">   </td></tr><tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"><td style="white-space:pre-wrap;vertical-align:bottom;"> Total assets as of September 30, 2024 </td><td style="white-space:pre-wrap;vertical-align:bottom;">   </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,481,922</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,631,827 </td><td style="white-space:nowrap;vertical-align:bottom;">   </td><td style="white-space:pre-wrap;vertical-align:bottom;">   </td><td style="white-space:nowrap;vertical-align:bottom;"> $</p></td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">240,099</p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td><td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td><td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 14,353,848 </td><td style="white-space:nowrap;vertical-align:bottom;">   </td></tr><tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> <span style="white-space:pre-wrap;min-width:fit-

content;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine months ended September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Acute Care
Hospital
Services </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Behavioral
Health
Services (a) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Other </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total
Consolidated </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;text-align:left;"> (Dollar amounts in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Gross inpatient revenues </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">37,522,395</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,375,470 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">45,897,865</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Gross outpatient revenues</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-

width:fit-content;">25,553,451 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">833,260</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 26,386,711 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total net revenues </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,604,007</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,102,290 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7,916</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11,714,213 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Income/(loss) before allocation of corporate overhead and
  income taxes </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">616,503</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 999,282 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(556,160</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,059,625 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Allocation of corporate overhead </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(194,616</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:right;">(140,808 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">335,424</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Income/(loss) after allocation of corporate overhead and
  before income taxes </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">421,887</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 858,474 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(220,736</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,059,625 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total assets as of September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,481,922</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,631,827 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">240,099</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 14,353,848 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> <span style="white-

space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three months ended September 30, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Acute Care
Hospital
Services </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Behavioral
Health
Services (a) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Other </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total
Consolidated </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;text-align:left;"> (Dollar amounts in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Gross inpatient revenues </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10,916,060</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,703,478 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">13,619,538</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Gross outpatient revenues</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,480,353 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 259,060 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span style="white-space:pre-wrap;min-

width:fit-content;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7,739,413</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total net revenues</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,017,288 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,542,695</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,791 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,562,774</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Income/(loss) before allocation of corporate overhead and
  income taxes</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 132,406 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">262,168</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (174,067 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">220,507</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Allocation of corporate overhead</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (66,355 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(46,677</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 113,032 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td

*style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Income/(loss) after allocation of corporate overhead and
 before income taxes </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">66,051</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 215,491 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(61,035</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 220,507 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total assets as of September 30, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,252,434</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,372,995 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">248,041</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13,873,470 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine months ended September 30, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-*

top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Acute Care
Hospital
Services </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Behavioral
Health
Services (a) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Other </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total
Consolidated </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;text-align:left;"> (Dollar amounts in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Gross inpatient revenues </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">33,278,396</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,001,838 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">41,280,234</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Gross outpatient revenues</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 22,292,249 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">812,467</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 23,104,716 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total net revenues </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,993,899 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-

space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,575,378</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9,153 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10,578,430</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Income/(loss) before allocation of corporate overhead and
  income taxes</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 396,229 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">792,217</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (529,143 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">659,303</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Allocation of corporate overhead</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (199,943 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(139,998</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 339,941 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Income/(loss) after allocation of corporate overhead and
  before income taxes</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 196,286 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td

*style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 652,219 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(189,202</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 659,303 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total assets as of September 30, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,252,434</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,372,995 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">248,041</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13,873,470 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> (a) Includes net revenues generated from our behavioral health care facilities located in the U.K. amounting to approximately $230 million and $203 million for the three-month periods ended September 30, 2024 and 2023, respectively, and approximately $651 million and $561 million for the nine-month periods ended September 30, 2024 and 2023, respectively. Total assets at our U.K. behavioral health care facilities were approximately $1,442 billion and $1,260 billion as of September 30, 2024 and 2023, respectively. <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.01%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.162%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.162%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.862%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three months ended September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Acute Care
Hospital
Services </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Behavioral
Health
Services (a) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> <span*

style="white-space:pre-wrap;min-width:fit-content;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Other </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total
Consolidated </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;text-align:left;"> (Dollar amounts in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Gross inpatient revenues </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">12,277,563</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,835,301 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">15,112,864</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Gross outpatient revenues</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,573,270 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">268,182</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,841,452 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total net revenues </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,245,517</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,714,914 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-

top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,596 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,963,027</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Income/(loss) before allocation of corporate overhead and
  income taxes</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 199,316 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">318,864</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (176,647 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">341,533</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Allocation of corporate overhead</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (64,883 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(46,898</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 111,781 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">0</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Income/(loss) after allocation of corporate overhead and
  before income taxes</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 134,433 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">271,966</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (64,866 </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-

bottom:0;text-align:left;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">341,533</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total assets as of September 30, 2024</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6,481,922 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7,631,827</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 240,099 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 14,353,848 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine months ended September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Acute Care
Hospital
Services </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Behavioral
Health
Services (a) </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Other </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Total
Consolidated </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> <span style="white-space:pre-wrap;min-

*width:fit-content;"> </td> <td colspan="14" style="vertical-align:bottom;text-align:left;"> (Dollar amounts in thousands) </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Gross inpatient revenues </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">37,522,395</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,375,470 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">45,897,865</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Gross outpatient revenues</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 25,553,451 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">833,260</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 26,386,711 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total net revenues </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,604,007</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,102,290 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7,916</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11,714,213 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Income/(loss) before allocation of corporate overhead and
  income taxes </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> <span style="color:#000000;min-width:fit-*

content;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">616,503</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 999,282 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(556,160</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,059,625 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Allocation of corporate overhead </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(194,616</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (140,808 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">335,424</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Income/(loss) after allocation of corporate overhead and
  before income taxes </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">421,887</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 858,474 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(220,736</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,059,625 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total assets as of September 30, 2024 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span style="font-size:8.5pt;color:#000000;white-space:pre-wrap;min-width:fit-

content;">6,481,922 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7,631,827</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 240,099 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">14,353,848</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Three months ended September 30, 2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Acute Care
Hospital
Services</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Behavioral
Health
Services (a)</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Other</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Total
Consolidated</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="14" style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">(Dollar amounts in thousands)</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Gross inpatient revenues</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,916,060 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p

*style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,703,478</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13,619,538 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Gross outpatient revenues </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7,480,353</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 259,060 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7,739,413</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total net revenues</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,017,288 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,542,695</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,791 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,562,774</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Income/(loss) before allocation of corporate overhead and
  income taxes</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 132,406 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 262,168 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> <span style="color:#000000;min-width:fit-*

content;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(174,067</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 220,507 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Allocation of corporate overhead </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(66,355</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (46,677 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">113,032</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Income/(loss) after allocation of corporate overhead and
  before income taxes </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">66,051</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 215,491 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(61,035</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 220,507 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total assets as of September 30, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,252,434</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,372,995 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span style="font-size:9.5pt;color:#000000;white-space:pre-wrap;min-

width:fit-content;">248,041 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">13,873,470</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="14" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Nine months ended September 30, 2023</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Acute Care
Hospital
Services</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Behavioral
Health
Services (a)</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Other</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">Total
Consolidated</p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:7pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="14" style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">(Dollar amounts in thousands)</p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:7.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"> </p></td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Gross inpatient revenues</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 33,278,396 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">8,001,838</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span style="font-

size:9.5pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">41,280,234 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Gross outpatient revenues </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">22,292,249</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 812,467 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">23,104,716</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Total net revenues</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,993,899 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">4,575,378</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9,153 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">10,578,430</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Income/(loss) before allocation of corporate overhead and
  income taxes</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:8.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 396,229 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">792,217</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (529,143 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 659,303 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Allocation of corporate overhead </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times

New Roman;margin-bottom:0;text-align:left;">$</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(199,943</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> (139,998 </td> <td style="white-space:nowrap;vertical-align:bottom;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">339,941</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Income/(loss) after allocation of corporate overhead and
  before income taxes </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">196,286</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 652,219 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">(189,202</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">)</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 659,303 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total assets as of September 30, 2023 </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,252,434</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7,372,995 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">248,041</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9.5pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13,873,470 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> (a) Includes net revenues generated from our behavioral health care facilities located in the U.K. amounting to approximately $230 million and $203<span

style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> million for the three-month periods ended September 30, 2024 and 2023, respectively, and approximately $651 million and $561 million for the nine-month periods ended September 30, 2024 and 2023, respectively. Total assets at our U.K. behavioral health care facilities were approximately $1.442 billion and $1.260 billion as of September 30, 2024 and 2023, respectively.
1227756300028353010001511286400085732700002681820008841452000224551700017149140002596000396302700019931600031886406
1766470003415330006488300046898000-111781000013443300027196600-
6486600034153300064819220007631827000240099000143538480003752239500083754700004589786500025553451000833260000263867110000
5561600001059625000194616000140808000-335424000042188700085847400-
2207360001059625000648192200076318270002400990001435384800010916060000270347800013619538000748035300025906000077394130001
1740670002205070006635500046677000-113032000066051000215491000-
6103500022050700062524340007372995000248041000138734700003327839600080018380004128023400022292249000812467000231047160000
5291430006593030001999430001399980000-339941000019628600065221900-
1892020006593030006252434000737299500024804100013873470000230000000203000000651000000561000000144200000012600000000<p
style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">(8) Earnings Per Share Data and Stock Based Compensation Basic earnings per share are based on the weighted average number of common shares outstanding during the period. Diluted earnings per share are based on the weighted average number of common shares outstanding during the period adjusted to give effect to common stock equivalents. The following table sets forth the computation of basic and diluted earnings per share for the periods indicated (in thousands, except per share data): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:50.38%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1.22%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.184000000000001%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three months ended
September 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine months ended
September 30, </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> Basic and Diluted: </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;text-align:center;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;text-align:center;"> <span style="white-space:pre-wrap;min-

width:fit-content;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Net income attributable to UHS </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">258,714</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 166,989 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">809,700</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 501,417 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Less: Net income attributable to unvested restricted share
  grants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (52 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (242 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Net income attributable to UHS – basic and diluted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">258,714</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 166,937 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">809,650</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> <span style="color:#000000;white-

space:pre-wrap;min-width:fit-content;">501,175 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Weighted average number of common shares - basic </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 66,537 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 68,867 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 66,873 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 69,825 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Net effect of dilutive stock options and grants based on the
 treasury stock method </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,571 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 757 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,297 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 825 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Weighted average number of common shares and
 equivalents - diluted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 68,108 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span style="white-space:pre-wrap;min-width:fit-

content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 69,624 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 68,170 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 70,650 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Earnings per basic share attributable to UHS: </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3.89</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2.42 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">12.11</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 7.18 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Earnings per diluted share attributable to UHS: </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3.80</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2.40 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">11.88</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 7.09 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> </table> The “Net effect of dilutive stock options and grants based on the treasury stock method”, for all periods presented above, excludes certain outstanding stock options applicable to each period since the effect would have been anti-dilutive. There were no excluded weighted-average stock options for the three-months ended September 30, 2024 and 799,000 for the nine-months ended September 30, 2024. The excluded weighted-average stock options totaled 5.0<span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-

content;"> million for the three months ended September 30, 2023 and 5.1 million for the nine months ended September 30, 2023. All classes of our common stock have the same dividend rights. Stock-Based Compensation: During the three-month periods ended September 30, 2024 and 2023, pre-tax compensation costs of $13.4 million and $16.2 million, respectively, was recognized related to outstanding stock options. During the nine-month periods ended September 30, 2024 and 2023, pre-tax compensation costs of $41.0 million and $48.3 million, respectively, was recognized related to outstanding stock options. In addition, during the three-month periods ended September 30, 2024 and 2023, pre-tax compensation cost of approximately $12.9 million and $6.1 million, respectively, was recognized related to restricted stock awards, restricted stock units and performance based restricted stock units. During the nine-month periods ended September 30, 2024 and 2023, pre-tax compensation costs of approximately $30.7 million and $16.4 million, respectively, was recognized related to restricted stock awards, restricted stock units and performance based restricted stock units. As of September 30, 2024 there was approximately $177.9 million of unrecognized compensation cost related to unvested options, restricted stock awards, restricted stock units and performance based restricted stock units which is expected to be recognized over the remaining weighted average vesting period of 2.5 years. There were 3,000 stock options granted during the first nine months of 2024 under the 2020 Stock Incentive Plan with a weighted-average grant date fair value of $44.58 per option. There were an aggregate of 501,290 restricted units, net of cancellations, granted during the first nine months of 2024 under the 2020 Stock Incentive Plan, including 63,362 performance based restricted stock units, with a weighted-average grant date fair value of $181.05 per share. The expense associated with stock-based compensation arrangements is a non-cash charge. In the condensed consolidated statements of cash flows, stock-based compensation expense is an adjustment to reconcile net income to cash provided by operating activities and aggregated to $72.7 million and $65.7 million during the nine-month periods ended September 30, 2024 and 2023, respectively. The following table sets forth the computation of basic and diluted earnings per share for the periods indicated (in thousands, except per share data): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:50.38%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.184000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Three months ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> Nine months ended
September 30, </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-

align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Basic and Diluted: </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Net income attributable to UHS </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">258,714</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 166,989 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">809,700</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 501,417 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Less: Net income attributable to unvested restricted share
  grants </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> - </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (52 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (50 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">) </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> (242 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:left;">) </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Net income attributable to UHS – basic and diluted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">258,714</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 166,937 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">809,650</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 501,175 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Weighted average number of common shares – basic </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 66,537 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 68,867 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 66,873 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 69,825 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Net effect of dilutive stock options and grants based on the
 treasury stock method </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,571 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 757 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1,297 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 825 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Weighted average number of common shares and
  equivalents - diluted </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 68,108 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 69,624 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 68,170 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 70,650 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Earnings per basic share attributable to UHS: </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3.89</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 2.42 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">12.11</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 7.18 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Earnings per diluted share attributable to UHS: </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 3.80 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double

#000000;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2.40</p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 11.88 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"> 7.09 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"> </td> </tr>
</table>258714000166989000080970000050141700052000500002420002587140002587140001669370001669370008096500008096500005011750
style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;">(9) Dispositions and acquisitions Nine-month period ended September 30, 2024: Acquisitions: During the first nine months of 2024, there were no acquisitions. Divestitures: During the first nine months of 2024, we received $30 million from the sales of assets and businesses. Nine-month period ended September 30, 2023: Acquisitions: During the first nine months of 2023, we spent $4 million on the acquisition of businesses and property. Divestitures: During the first nine months of 2023, we received $24 million from the sales of assets and businesses. 3000000040000002400000000 (10) Dividends We declared and paid dividends of $13.3 million, or $.20 per share, during the third quarter of 2024 and $13.8 million, or $.20 per share, during the third quarter of 2023. We declared and paid dividends of $40.3 million, or $.60 per share, during the nine-month period ended September 30, 2024 and $42.2 million, or $.60 per share, during the nine-month period ended September 30, 2023. Included in the amounts above were dividend equivalents applicable to unvested restricted stock units which were accrued during 2024 and 2023 and will be, or were, paid upon vesting of the restricted stock unit.
133000000.2138000000.2403000000.6422000000.6 (11) Income Taxes Our effective income tax rates were 22.1% and 23.8% during the three-month periods ended September 30, 2024 and 2023, respectively, and 22.0% and 24.2% during the nine-month periods ended September 30, 2024, and 2023, respectively. The decrease in the effective tax rates during the three and nine-month period ended September 30, 2024, as compared to the comparable periods of 2023, was primarily due to favorable changes of $4 million and $16 million, respectively, in the net tax benefit recognized from employee share-based payments, net of the impact of executive compensation limitations pursuant to IRC section 162(m). <span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times

New Roman;min-width:fit-content;">As of January 1, 2024, our unrecognized tax benefits were approximately $2 million. The amount, if recognized, that would favorably affect the effective tax rate is approximately $2 million. During the nine months ended September 30, 2024, changes to the estimated liabilities for uncertain tax positions (including accrued interest) relating to tax positions taken during prior and current periods did not have a material impact on our financial statements. We recognize accrued interest and penalties associated with uncertain tax positions as part of the tax provision. As of September 30, 2024, we have less than $1 million of accrued interest and penalties. The U.S. federal statute of limitations remains open for 2020 and subsequent years. Foreign and U.S. state and local jurisdictions have statutes of limitations generally ranging from 3 to 4 years. The statute of limitations on certain jurisdictions could expire within the next twelve months. It is reasonably possible that the amount of uncertain tax benefits will change during the next 12 months, however, it is anticipated that any such change, if it were to occur, would not have a material impact on our results of operations. We operate in multiple jurisdictions with varying tax laws. We are subject to audits by any of these taxing authorities. We believe that adequate accruals have been provided for federal, foreign and state taxes. 0.2210.2380.220.2424000000160000002000000200000010000000P3YP4Yexpire within the next twelve monthsP12M (12) Revenue We recognize revenue when we transfer promised goods or services to customers in an amount that reflects the consideration to which we expect to be entitled in exchange for those goods or services. Our estimate for amounts not expected to be collected based on historical experience will continue to be recognized as a reduction to net revenue. However, subsequent changes in estimate of collectability due to a change in the financial status of a payer, for example a bankruptcy, will be recognized as bad debt expense in operating charges. The performance obligation is separately identifiable from other promises in the customer contract. As the performance obligations are met (i.e. room, board, ancillary services, level of care), revenue is recognized based upon allocated transaction price.The transaction price is allocated to separate performance obligations based upon the relative standalone selling price. In instances where we determine there are multiple performance obligations across multiple months, the transaction price will be allocated by applying an estimated implicit and explicit rate to gross charges based on the separate performance obligations. In assessing collectability, we have elected the portfolio approach. This portfolio approach is being used as we have large volume of similar contracts with similar classes of customers. We reasonably expect that the effect of applying a portfolio approach to a group of contracts would not differ materially from considering each contract separately. Management’s judgment to group the contracts by portfolio is based on the payment behavior expected in each portfolio category. As a result, aggregating all of the contracts (which are at the patient level) by the particular payer or group of payers, will result in the recognition of the same amount of revenue as applying the analysis at the individual patient level. We group our revenues into categories based on payment behaviors. Each component has its own reimbursement structure which allows us to disaggregate the revenue into categories that share the nature and timing of payments. The other patient revenue consists primarily of self-pay, government-funded non-Medicaid, and other. The following table disaggregates our revenue by major source for the three and nine-month periods ended September 30, 2024 and 2023 (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"><tr style="visibility:collapse;"><td style="width:34.86%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:7.68%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:3.94%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:2.52%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:9.16%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:4.08%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:2.52%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:6.3%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:2.52%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:8.34%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td><td style="width:4.08%;box-sizing:content-box;"></td><td style="width:1%;box-sizing:content-box;"></td></tr><tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"><td style="vertical-align:bottom;"> </td><td colspan="23" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> For the three months ended September 30, 2024 </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td></tr><tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"><td style="vertical-align:bottom;"> </td><td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Acute Care </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="vertical-align:bottom;"> </td><td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Behavioral Health </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="vertical-align:bottom;"> </td><td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Other </td><td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td><td style="vertical-align:bottom;"> </td><td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:center;">Total </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Medicare </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">322,466</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">14</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">%</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 81,148 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 403,614 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Managed Medicare </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 361,804 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 107,910 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 469,714 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Medicaid </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 296,966 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span

style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">13 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 262,393 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 559,359 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 14 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Managed Medicaid </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 154,762 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 422,563 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 25 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 577,325 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Managed Care (HMO and PPOs) </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 725,014 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 32 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 401,004 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 23 </td> <td

style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,126,018 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 28 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> UK Revenue </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 230,153 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 230,153 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Other patient revenue and adjustments, net </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 117,679 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 155,332 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 273,011 </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Other non-patient revenue </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 266,826 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 12 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 54,411 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,596 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 323,833 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 8 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> % </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total Net Revenue </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,245,517</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">100</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">%</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,714,914 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 100 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,596 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,963,027 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 100 </td> <td style="white-space:nowrap;vertical-align:bottom;"> <span

style="color:#000000;min-width:fit-content;">% </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;">

size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">11 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Managed Medicare </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,104,493 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 17 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 307,388 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,411,881 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Medicaid </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 771,298 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 804,254 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,575,552 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Managed Medicaid </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 466,881 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span style="font-size:9pt;color:#000000;white-

space:pre-wrap;min-width:fit-content;">7 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,262,108 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 25 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,728,989 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Managed Care (HMO and PPOs) </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,129,117 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 32 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,227,056 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 24 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,356,173 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 29 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> UK Revenue </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 650,655 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13 </td> <td style="white-space:nowrap;vertical-

align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 650,655 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Other patient revenue and adjustments, net </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 375,161 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 449,609 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 824,770 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Other non-patient revenue </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 747,427 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 11 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 166,925 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 7,916 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span style="white-space:pre-wrap;min-width:fit-

content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 922,268 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 8 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> % </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total Net Revenue </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,604,007</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">100</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">%</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,102,290 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 100 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7,916</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11,714,213 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 100 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="23" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> For the three months ended September 30, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> </td> <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Acute Care </td> <td style="vertical-align:bottom;border-

bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Behavioral Health </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Other </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Total </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Medicare </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">298,121</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">15</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">%</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 81,689 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 379,810 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Managed Medicare </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 324,486 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 95,094 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 419,580 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-

top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Medicaid </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 201,148 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 204,154 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 405,302 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Managed Medicaid </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 181,051 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 387,975 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 25 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 569,026 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Managed Care (HMO and PPOs) </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 651,816 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 32 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 383,146 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 25 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,034,962 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 29 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> UK Revenue </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 202,994 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 202,994 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Other patient revenue and adjustments, net </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 108,676 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 129,492 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-

space:pre-wrap;vertical-align:bottom;text-align:center;"> 8 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 238,168 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Other non-patient revenue </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 251,990 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 12 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 58,151 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 1 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,791 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 312,932 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 9 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> % </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total Net Revenue </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,017,288</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">100</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">%</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,542,695 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 100 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-

wrap;vertical-align:bottom;text-align:center;"> 2,791 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,562,774 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 100 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;">

style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,195,570 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Managed Medicare </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,013,493 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 17 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 255,782 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,269,275 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Medicaid </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 445,678 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 625,956 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 14 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,071,634 </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Managed Medicaid </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 545,173 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,184,315 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 26 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,729,488 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Managed Care (HMO and PPOs) </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,009,110 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 34 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,160,820 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 25 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,169,930 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 30 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> UK Revenue </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0 </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-

family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 560,897 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 560,897 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Other patient revenue and adjustments, net </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 303,923 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 387,327 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 691,250 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Other non-patient revenue </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 714,882 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 12 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> <span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-

width:fit-content;">166,351 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 9,153 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 890,386 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 8 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> % </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total Net Revenue </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,993,899</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">100</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">%</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,575,378 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 100 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,578,430 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 100 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> </table> The following table disaggregates our revenue by major source for the three and nine-month periods ended September 30, 2024 and 2023 (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:34.86%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:7.68%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:3.94%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.52%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:9.16%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:4.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.52%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:6.3%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.52%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:8.34%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:4.08%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="23" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> For the three months ended September 30, 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;"> <span

style="white-space:pre-wrap;min-width:fit-content;"> </td> <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Acute Care </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Behavioral Health </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Other </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Total </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Medicare </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">322,466</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">14</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">%</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 81,148 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 403,614 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Managed Medicare </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 361,804 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 107,910 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span

style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-content;">469,714 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Medicaid </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 296,966 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 262,393 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 559,359 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 14 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Managed Medicaid </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 154,762 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 422,563 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 25 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 577,325 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Managed Care (HMO and PPOs) </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span style="font-size:9pt;color:#000000;white-

space:pre-wrap;min-width:fit-content;">725,014 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 32 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 401,004 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 23 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,126,018 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 28 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> UK Revenue </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 230,153 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 230,153 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Other patient revenue and adjustments, net </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 117,679 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 155,332 </td> <td style="white-

space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 273,011 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Other non-patient revenue </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 266,826 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 12 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 54,411 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 2,596 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 323,833 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 8 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> % </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total Net Revenue </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,245,517</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">100</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">%</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,714,914 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 100 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-

size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,596 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,963,027 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 100 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2"

space:pre-wrap;vertical-align:bottom;text-align:center;"> 5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,243,925 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Managed Medicare </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,104,493 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 17 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 307,388 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,411,881 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Medicaid </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 771,298 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 804,254 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-width:fit-

content;">1,575,552 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Managed Medicaid </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 466,881 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,262,108 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 25 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,728,989 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 15 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Managed Care (HMO and PPOs) </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,129,117 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 32 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,227,056 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 24 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,356,173 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 29 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> UK Revenue </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span style="font-size:9pt;color:#000000;white-space:pre-wrap;min-

width:fit-content;">0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 650,655 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 650,655 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Other patient revenue and adjustments, net </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 375,161 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 449,609 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 824,770 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Other non-patient revenue </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 747,427 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 11 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-

top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">166,925 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 3 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 7,916 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 922,268 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 8 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> % </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total Net Revenue </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">6,604,007</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">100</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">%</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5,102,290 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 100 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">7,916</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11,714,213 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 100 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2"

style="vertical-align:bottom;">   </td> <td style="vertical-align:bottom;">   </td> <td colspan="2" style="vertical-align:bottom;">   </td> <td style="vertical-align:bottom;">   </td> </tr> <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;">   </td> <td colspan="23" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> For the three months ended September 30, 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;">   </td> </tr> <tr style="height:9pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;text-align:left;"> <td style="vertical-align:bottom;">   </td> <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Acute Care </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">   </td> <td style="vertical-align:bottom;">   </td> <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Behavioral Health </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">   </td> <td style="vertical-align:bottom;">   </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Other </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">   </td> <td style="vertical-align:bottom;">   </td> <td colspan="5" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"> Total </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;">   </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Medicare </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">298,121</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">15</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">%</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 81,689 </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;">   </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;">   </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 379,810 </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Managed Medicare </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 324,486 </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;">   </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 95,094 </td> <td style="white-space:nowrap;vertical-align:bottom;">   </td>

<td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 419,580 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Medicaid </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 201,148 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 204,154 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 405,302 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Managed Medicaid </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 181,051 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 387,975 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 25 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td>

<td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 569,026 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Managed Care (HMO and PPOs) </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 651,816 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 32 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 383,146 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 25 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,034,962 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 29 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> UK Revenue </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 202,994 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 13 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 202,994 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Other patient revenue and adjustments, net </td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-

align:left;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 108,676 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 129,492 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 238,168 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Other non-patient revenue </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 251,990 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 12 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 58,151 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,791 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 312,932 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 9 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> % </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total Net Revenue </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,017,288 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> <span style="font-size:9pt;color:#000000;white-

space:pre-wrap;min-width:fit-content;">100 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">1,542,695</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">100</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">%</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,791 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,562,774 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 100 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td>

Roman;margin-bottom:0;text-align:right;">961,640 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">233,930</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">%</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,195,570 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 11 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Managed Medicare </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,013,493 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 17 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 255,782 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 6 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,269,275 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Medicaid </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 445,678 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 625,956 </td> <td style="white-

space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 14 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,071,634 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Managed Medicaid </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 545,173 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 9 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,184,315 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 26 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,729,488 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 16 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Managed Care (HMO and PPOs) </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,009,110 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 34 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 1,160,820 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 25 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span

style="white-space:pre-wrap;min-width:fit-content;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,169,930 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 30 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> UK Revenue </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 0 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 560,897 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 12 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 560,897 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Other patient revenue and adjustments, net </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 303,923 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 5 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 387,327 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td colspan="2" style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 691,250 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 7 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> <tr style="height:9pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> <span

style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other non-patient revenue </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 714,882 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 12 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 166,351 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 4 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 9,153 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 890,386 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"> 8 </td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"> % </td> </tr> <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:bottom;"> Total Net Revenue </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">5,993,899</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">100</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">%</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 4,575,378 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 100 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">9,153</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 10,578,430 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 100 </td> <td style="white-space:nowrap;vertical-align:bottom;"> % </td> </tr> </table>
3224660000.14811480000.054036140000.103618040000.161079100000.064697140000.122969660000.132623930000.155593590000.141547(
style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;">(13) Lease Accounting Our operating leases are primarily for real estate, including

certain acute care facilities, off-campus outpatient facilities, medical office buildings, and corporate and other administrative offices. Our real estate lease agreements typically have initial terms of five to ten years. These real estate leases may include one or more options to renew, with renewals that can extend the lease term from five to ten years. The exercise of lease renewal options is at our sole discretion. When determining the lease term, we included options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Five of our hospital facilities are held under operating leases with Universal Health Realty Income Trust with two leases expiring in 2026, two expiring in 2033 and one expiring in 2040 (for additional disclosure, see Note 2 to the Consolidated Financial Statements-Relationship with Universal Health Realty Income Trust and Other Related Party Transactions). We are also the lessee of the real property of certain facilities from unrelated third parties. Supplemental cash flow information related to leases for the nine-month period ended September 30, 2024 and 2023 are as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.520000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.74%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.520000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> Nine months ended
September 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Cash paid for amounts included in the measurement of lease liabilities: </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Operating cash flows from operating leases </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">99,526</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 96,922 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Operating cash flows from finance leases </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td>

<td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,756 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,890</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Financing cash flows from finance leases</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 3,167 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,910</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Right-of-use assets obtained in exchange for lease obligations:</p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Operating leases</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 50,696 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">50,940</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Finance leases</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,441 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 452 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table> P10YP10Ytrue5202620332040 Supplemental cash flow information related to leases for the nine-month period ended September 30, 2024 and 2023 are as follows (in thousands): <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.22%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.520000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:2.74%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> <td style="width:13.520000000000001%;box-sizing:content-box;"></td> <td style="width:1%;box-sizing:content-box;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="6" style="vertical-align:bottom;text-align:left;"> Nine months ended
September 30, </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"> 2024 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p

style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">2023 </td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"> </td> </tr> <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:left;"> </td> <td style="vertical-align:bottom;text-align:left;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Cash paid for amounts included in the measurement of lease liabilities: </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;text-align:center;"> </td> <td style="vertical-align:bottom;text-align:center;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Operating cash flows from operating leases </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">99,526</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 96,922 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Operating cash flows from finance leases </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">2,756</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,890 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Financing cash flows from finance leases </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">3,167</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 2,910 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> <tr style="background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;"> <td style="vertical-align:bottom;"> Right-of-use assets obtained in exchange for lease obligations: </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> <td colspan="2" style="vertical-align:bottom;"> </td> <td style="vertical-align:bottom;"> </td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"> Operating leases </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 50,696 </td> <td style="white-space:nowrap;vertical-align:bottom;"> <span style="min-width:fit-

***content;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $</p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;">50,940</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"> </p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;">Finance leases</p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 8,441 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> <td style="white-space:pre-wrap;vertical-align:bottom;"> </td> <td style="white-space:nowrap;vertical-align:bottom;"> $ </td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"> 452 </td> <td style="white-space:nowrap;vertical-align:bottom;"> </td> </tr> </table>99526000969220002756000289000031670002910000506960005094000084410004520002000-06-30 false --12-31 false 0001628280 us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001628280 2024-07-31 0001628280 2024-06-30 0001628280 2023-01-01 2023-06-30 0001628280 2024-04-01 2024-06-30 0001628280 2023-04-01 2023-06-30 0001628280 2023-12-31 0001628280 2024-06-30 0001628280 2023-06-30 0001628280 2022-12-31 0001628280 2023-12-31 0001628280 us-gaap:RetainedEarningsMember 2024-01-01 2024-06-30 0001628280 us-gaap:RetainedEarningsMember 2023-01-01 2023-06-30 0001628280 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001628280 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001628280 us-gaap:RetainedEarningsMember 2023-12-31 0001628280 us-gaap:RetainedEarningsMember 2024-06-30 0001628280 us-gaap:RetainedEarningsMember 2023-06-30 0001628280 us-gaap:RetainedEarningsMember 2022-12-31 0001628280 us-gaap:RetainedEarningsMember 2023-12-31 0001628280 us-gaap:CommonStockMember 2024-06-30 0001628280 us-gaap:CommonStockMember 2023-06-30 0001628280 us-gaap:CommonStockMember 2022-12-31 0001628280 us-gaap:CommonStock

size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color; #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 65 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html 462 297 1 true 129 0 false 11 false false R1.htm 100000 - Document - Document and Entity Information Sheet
http://www.universalhealthservices/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Consolidated Statements of Income Sheet http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome Condensed Consolidated Statements of Income Statements 2 false false R3.htm 100020 - Statement - Condensed Consolidated Statements of Comprehensive Income Sheet
http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveIncome Condensed Consolidated Statements of Comprehensive Income Statements 3 false false R4.htm 100030 - Statement - Condensed Consolidated Balance Sheets Sheet
http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 4 false false R5.htm 100040 - Statement - Condensed Consolidated Statements of Changes in Equity Sheet
http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity Condensed Consolidated Statements of Changes in Equity Statements 5 false false R6.htm 100050 - Statement - Condensed Consolidated Statements of Cash Flows Sheet
http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 7 false false R8.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 8 false false R9.htm 995455 - Disclosure - General Sheet http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureGeneral General Notes 9 false false R10.htm 995465 - Disclosure - Relationship with Universal Health Realty Income Trust and Other Related Party Transactions Sheet
http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactions Relationship with Universal Health Realty Income Trust and Other Related Party Transactions Notes 10 false false R11.htm 995475 - Disclosure - Other Noncurrent liabilities and Redeemable/Noncontrolling Interests Sheet http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureOtherNoncurrentLiabilitiesAndRedeemableNoncontrollingInterests Other Noncurrent liabilities and Redeemable/Noncontrolling Interests Notes 11 false false R12.htm 995485 - Disclosure - Treasury Sheet http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasury Treasury Notes 12 false false R13.htm 995495 - Disclosure - Fair Value Measurement Sheet http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureFairValueMeasurement Fair Value Measurement Notes 13 false false R14.htm 995505 - Disclosure - Commitments and Contingencies Sheet
http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 995515 - Disclosure - Segment Reporting Sheet http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSegmentReporting Segment Reporting Notes 15 false false R16.htm 995525 - Disclosure - Earnings Per Share Data and Stock Based Compensation Sheet http://www.universalhealthservices/20240930/taxonomy/role/DisclosureEarningsPerShareDataAndStockBasedCompensation Earnings Per Share Data and Stock Based Compensation Notes 16 false false R17.htm 995535 - Disclosure - Dispositions and acquisitions Sheet
http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureDispositionsAndAcquisitions Dispositions and acquisitions Notes 17 false false R18.htm 995545 - Disclosure - Dividends Sheet http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureDividends Dividends Notes 18 false false R19.htm 995555 - Disclosure - Income Taxes Sheet
http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureIncomeTaxes Income Taxes Notes 19 false false R20.htm 995565 - Disclosure - Revenue Sheet
http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRevenue Revenue Notes 20 false false R21.htm 995575 - Disclosure - Lease Accounting Sheet
http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureLeaseAccounting Lease Accounting Notes 21 false false R22.htm 995585 - Disclosure - Recent Accounting Standards Sheet http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRecentAccountingStandards Recent Accounting Standards Notes 22 false false R23.htm 995595 - Disclosure - Relationship with Universal Health Realty Income Trust and Other Related Party Transactions (Tables) Sheet
http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsTables Relationship with Universal Health Realty Income Trust and Other Related Party Transactions (Tables) Tables
http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactions 23 false false R24.htm 995605 - Disclosure - Treasury (Tables) Sheet http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryTables Treasury (Tables) Tables
http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasury 24 false false R25.htm 995615 - Disclosure - Fair Value Measurement (Tables) Sheet
http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementTables Fair Value Measurement (Tables) Tables
http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureFairValueMeasurement 25 false false R26.htm 995625 - Disclosure - Segment Reporting (Tables) Sheet
http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSegmentReportingTables Segment Reporting (Tables) Tables
http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSegmentReporting 26 false false R27.htm 995635 - Disclosure - Earnings Per Share Data and Stock Based Compensation (Tables) Sheet http://www.universalhealthservices/20240930/taxonomy/role/DisclosureEarningsPerShareDataAndStockBasedCompensationTables Earnings Per Share Data and Stock Based Compensation (Tables) Tables http://www.universalhealthservices/20240930/taxonomy/role/DisclosureEarningsPerShareDataAndStockBasedCompensation 27 false false R28.htm 995645 - Disclosure - Revenue (Tables) Sheet http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRevenueTables Revenue (Tables) Tables
http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRevenue 28 false false R29.htm 995655 - Disclosure - Lease Accounting (Tables) Sheet
http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureLeaseAccountingTables Lease Accounting (Tables) Tables
http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureLeaseAccounting 29 false false R30.htm 995675 - Disclosure - Relationship with Universal Health Realty Income Trust and Other Related Party Transactions - Additional Information (Detail) Sheet
http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail Relationship with Universal Health Realty Income Trust and Other Related Party Transactions - Additional Information (Detail) Details 30 false false R31.htm 995685 - Disclosure - Relationship with Universal Health Realty Income Trust and Other Related Party Transactions - Additional Information 1 (Detail) Sheet
http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation1Detail Relationship with Universal Health Realty Income Trust and Other Related Party Transactions - Additional Information 1 (Detail) Details 31 false false R32.htm 995695 - Disclosure - Relationship with Universal Health Realty Income Trust and Other Related Party Transactions - Additional Information 2 (Detail) Sheet
http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation2Detail Relationship with Universal Health Realty Income Trust and Other Related Party Transactions - Additional Information 2 (Detail) Details 32 false false R33.htm 995705 - Disclosure - Relationship with Universal Health Realty Income Trust and Other Related Party Transactions - Additional Information 3 (Detail) Sheet
http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation3Detail Relationship with Universal Health Realty Income Trust and Other Related Party Transactions - Additional Information 3 (Detail) Details 33 false false R34.htm 995715 - Disclosure - Relationship with Universal Health Realty Income Trust and Other Related Party Transactions - Additional Information 4 (Detail) Sheet
http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation4Detail Relationship with Universal Health Realty Income Trust and Other Related Party Transactions - Additional Information 4 (Detail) Details 34 false false R35.htm 995725 - Disclosure - Summary of Details of Hospitals Leased from Trust (Detail) Sheet http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustDetail Summary of Details of Hospitals Leased from Trust (Detail) Details 35 false false R36.htm 995735 - Disclosure - Summary of Details of Hospitals Leased from Trust (Parenthetical) (Detail) Sheet
http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustParentheticalDetail Summary of Details of Hospitals Leased from Trust (Parenthetical) (Detail) Details 36 false false R37.htm 995745 - Disclosure - Other Noncurrent Liabilities and Redeemable/Noncontrolling Interests - Additional Information (Detail) Sheet
http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureOtherNoncurrentLiabilitiesAndRedeemableNoncontrollingInterestsAdditionalInformationDetail Other Noncurrent Liabilities and Redeemable/Noncontrolling Interests - Additional Information (Detail) Details 37 false false R38.htm 995755 - Disclosure - Treasury - Additional Information (Detail) Sheet
http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail Treasury - Additional Information (Detail) Details 38 false false R39.htm 995765 - Disclosure - Summary of Effects of Foreign Currency Forward Exchange Contracts on Result of Operations (Detail) Sheet
http://www.universalhealthservices/20240930/taxonomy/role/DisclosureSummaryOfEffectsOfForeignCurrencyForwardExchangeContractsOnResultOfOperationsDetail Summary of Effects of Foreign Currency Forward Exchange Contracts on Result of Operations (Detail) Details 39 false false R40.htm 995775 - Disclosure - Summary of Cash, Cash Equivalents and Restricted Cash Reported In Condensed Consolidated Statements of Cash Flows (Detail) Sheet
http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfCashCashEquivalentsAndRestrictedCashReportedInCondensedConsolidatedStatementsOfCashFlowsDeta Summary of Cash, Cash Equivalents and Restricted Cash Reported In Condensed Consolidated Statements of Cash Flows (Detail) Details 40 false false R41.htm 995785 - Disclosure - Summary of Assets and Liabilities Recorded at Fair Value on Recurring Basis (Detail) Sheet
http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfAssetsAndLiabilitiesRecordedAtFairValueOnRecurringBasisDetail Summary of Assets and Liabilities Recorded at Fair Value on Recurring Basis (Detail) Details 41 false false R42.htm 995795 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet
http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 42 false false R43.htm 995805 - Disclosure - Segment Reporting (Detail) Sheet
http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSegmentReportingDetail Segment Reporting (Detail) Details
http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSegmentReportingTables 43 false false R44.htm 995815 - Disclosure - Segment Reporting (Parenthetical) (Detail) Sheet http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSegmentReportingParentheticalDetail Segment Reporting (Parenthetical) (Detail) Details
http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSegmentReportingTables 44 false false R45.htm 995825 - Disclosure - Computation of Basic and Diluted Earnings Per Share (Detail) Sheet http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureComputationOfBasicAndDilutedEarningsPerShareDetail Computation of Basic and Diluted Earnings Per Share (Detail) Details 45 false false R46.htm 995835 - Disclosure - Earnings Per Share Data and Stock Based Compensation - Additional Information (Detail) Sheet
http://www.universalhealthservices/20240930/taxonomy/role/DisclosureEarningsPerShareDataAndStockBasedCompensationAdditionalInformationDetail Earnings Per Share Data and Stock Based Compensation - Additional Information (Detail) Details 46 false false R47.htm 995845 - Disclosure - Dispositions and Acquisitions - Additional Information (Detail) Sheet
http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureDispositionsAndAcquisitionsAdditionalInformationDetail Dispositions and Acquisitions - Additional Information (Detail) Details 47 false false R48.htm 995855 - Disclosure - Dividends - Additional Information (Detail) Sheet
http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureDividendsAdditionalInformationDetail Dividends - Additional Information (Detail) Details 48 false false R49.htm 995865 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail Income Taxes - Additional Information (Detail) Details 49 false false R50.htm 995875 - Disclosure - Schedule of Disaggregates Revenue by Major Source (Detail) Sheet
http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureScheduleOfDisaggregatesRevenueByMajorSourceDetail Schedule of Disaggregates Revenue by Major Source (Detail) Details 50 false false R51.htm 995885 - Disclosure - Lease Accounting - Additional Information (Detail) Sheet
http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail Lease Accounting - Additional Information (Detail) Details 51 false false R52.htm 995895 - Disclosure - Supplemental Cash Flow Information Related to Leases (Detail) Sheet
http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSupplementalCashFlowInformationRelatedToLeasesDetail Supplemental Cash Flow Information Related to Leases (Detail) Details 52 false false All Reports Book All Reports uhs-20240930.htm uhs-20240930.xsd http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 false false JSON 68 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "uhs-20240930.htm": { "nsprefix": "uhs", "nsuri": "http://www.universalhealthservices/20240930", "dts": { "inline": { "local": ["uhs-20240930.htm"] }, "schema": { "local": ["uhs-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] } }, "keyStandard": 216, "keyCustom": 81, "axisStandard": 38, "axisCustom": 0, "memberStandard": 51, "memberCustom": 77, "hidden": { "total": 11, "http://fasb.org/us-gaap/2024": 7, "http://xbrl.sec.gov/dei/2024": 4 }, "contextCount": 462, "entityCount": 1, "segmentCount": 129, "elementCount": 724, "unitCount": 11, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 881, "http://xbrl.sec.gov/dei/2024": 33,

```
"http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ] }, "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome", "longName": "100010 - Statement - Condensed Consolidated Statements of Income", "shortName": "Condensed Consolidated Statements of Income", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_98815176-29b9-4ef4-b5d9-809be23c94a1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_98815176-29b9-4ef4-b5d9-809be23c94a1", "name": "us-gaap:LaborAndRelatedExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "uhs-20240930.htm", "unique": true } }, "R3": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveIncome", "longName": "100020 - Statement - Condensed Consolidated Statements of Comprehensive Income", "shortName": "Condensed Consolidated Statements of Comprehensive Income", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_98815176-29b9-4ef4-b5d9-809be23c94a1", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_98815176-29b9-4ef4-b5d9-809be23c94a1", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "uhs-20240930.htm", "unique": true } }, "R4": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets", "longName": "100030 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_c6fbeca0-9832-4e57-ae58-8bd0c27634ca", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_c6fbeca0-9832-4e57-ae58-8bd0c27634ca", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "uhs-20240930.htm", "unique": true } }, "R5": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity", "longName": "100040 - Statement - Condensed Consolidated Statements of Changes in Equity", "shortName": "Condensed Consolidated Statements of Changes in Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_d078ac00-1c71-4ab3-8234-8344dc5ea8d3", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_d078ac00-1c71-4ab3-8234-8344dc5ea8d3", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows", "longName": "100050 - Statement - Condensed Consolidated Statements of Cash Flows", "shortName": "Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "uhs:DepreciationForDiscontinuedOperationsAndAmortization", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "uhs-20240930.htm", "unique": true } }, "R7": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "C_98815176-29b9-4ef4-b5d9-809be23c94a1", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "body", "html" ], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true }, "uniqueAnchor": null }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "C_98815176-29b9-4ef4-b5d9-809be23c94a1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_98815176-29b9-4ef4-b5d9-809be23c94a1", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureGeneral", "longName": "995455 - Disclosure - General", "shortName": "General", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactions", "longName": "995465 - Disclosure - Relationship with Universal Health Realty Income Trust and Other Related Party Transactions", "shortName": "Relationship with Universal Health Realty Income Trust and Other Related Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureOtherNoncurrentLiabilitiesAndRedeemableNoncontrollingInterests", "longName": "995475 - Disclosure - Other Noncurrent liabilities and Redeemable/Noncontrolling Interests", "shortName": "Other Noncurrent liabilities and Redeemable/Noncontrolling Interests", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "uhs:OtherNoncurrentLiabilitiesAndRedeemableNoncontrollingInterestsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "uhs:OtherNoncurrentLiabilitiesAndRedeemableNoncontrollingInterestsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasury", "longName": "995485 - Disclosure - Treasury", "shortName": "Treasury", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "us-gaap:TreasuryStockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "us-gaap:TreasuryStockTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureFairValueMeasurement", "longName": "995495 - Disclosure - Fair Value Measurement", "shortName": "Fair Value Measurement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies", "longName": "995505 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSegmentReporting", "longName": "995515 - Disclosure - Segment Reporting", "shortName": "Segment Reporting", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/DisclosureEarningsPerShareDataAndStockBasedCompensation", "longName": "995525 - Disclosure - Earnings Per Share Data and Stock Based Compensation", "shortName": "Earnings Per Share Data and Stock Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureDispositionsAndAcquisitions", "longName": "995535 - Disclosure - Dispositions and acquisitions", "shortName": "Dispositions and acquisitions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureDividends", "longName": "995545 - Disclosure - Dividends", "shortName": "Dividends", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "uhs:DividendsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "uhs:DividendsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureIncomeTaxes", "longName": "995555 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRevenue", "longName": "995565 - Disclosure - Revenue", "shortName": "Revenue", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureLeaseAccounting", "longName": "995575 - Disclosure - Lease Accounting", "shortName": "Lease Accounting", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "uhs:LesseeOperatingAndFinancingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "uhs:LesseeOperatingAndFinancingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRecentAccountingStandards", "longName": "995585 - Disclosure - Recent Accounting Standards", "shortName": "Recent Accounting Standards", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true },
```

"uniqueAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsTables", "longName": "995595 - Disclosure - Relationship with Universal Health Realty Income Trust and Other Related Party Transactions (Tables)", "shortName": "Relationship with Universal Health Realty Income Trust and Other Related Party Transactions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "us-gaap:ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "us-gaap:ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryTables", "longName": "995605 - Disclosure - Treasury (Tables)", "shortName": "Treasury (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementTables", "longName": "995615 - Disclosure - Fair Value Measurement (Tables)", "shortName": "Fair Value Measurement (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSegmentReportingTables", "longName": "995625 - Disclosure - Segment Reporting (Tables)", "shortName": "Segment Reporting (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/DisclosureEarningsPerShareDataAndStockBasedCompensationTables", "longName": "995635 - Disclosure - Earnings Per Share Data and Stock Based Compensation (Tables)", "shortName": "Earnings Per Share Data and Stock Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRevenueTables", "longName": "995645 - Disclosure - Revenue (Tables)", "shortName": "Revenue (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureLeaseAccountingTables", "longName": "995655 - Disclosure - Lease Accounting (Tables)", "shortName": "Lease Accounting (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "uhs:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "uhs:LesseeOperatingAndFinancingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "uhs:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "uhs:LesseeOperatingAndFinancingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true } }, "R30": { "role":
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail", "longName": "995675 - Disclosure - Relationship with Universal Health Realty Income Trust and Other Related Party Transactions - Additional Information (Detail)", "shortName": "Relationship with Universal Health Realty Income Trust and Other Related Party Transactions - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "C_98815176-29b9-4ef4-b5d9-809be23c94a1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_b0fcbf2e-d2f4-406e-b3f6-fc9e67f7b919", "name": "uhs:PercentageOfAdvisoryFeeOnAverageInvestedRealEstateAssets", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": ["span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "unique": true } }, "R31": { "role":
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation1Detail", "longName": "995685 - Disclosure - Relationship with Universal Health Realty Income Trust and Other Related Party Transactions - Additional Information 1 (Detail)", "shortName": "Relationship with Universal Health Realty Income Trust and Other Related Party Transactions - Additional Information 1 (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "C_4e68353d-645d-4c4c-95d5-0ba321ce4ff7", "name": "uhs:NumberOfBedsAvailableInAcuteCareHospital", "unitRef": "U_Bed", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_98e66e8a-6c35-4721-a41c-0d9dba35422d", "name": "us-gaap:ProceedsFromSaleOfRealEstate", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "unique": true } }, "R32": { "role":
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation2Detail", "longName": "995695 - Disclosure - Relationship with Universal Health Realty Income Trust and Other Related Party Transactions - Additional Information 2 (Detail)", "shortName": "Relationship with Universal Health Realty Income Trust and Other Related Party Transactions - Additional Information 2 (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "C_98815176-29b9-4ef4-b5d9-809be23c94a1", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_f4dc63d4-65ce-41e1-8b6c-2536a97cc1c3", "name": "uhs:FinancialLiabilityFromFairValueOfRealEstateAssetsExchanged", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "unique": true } }, "R33": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation3Detail", "longName": "995705 - Disclosure - Relationship with Universal Health Realty Income Trust and Other Related Party Transactions - Additional Information 3 (Detail)", "shortName": "Relationship with Universal Health Realty Income Trust and Other Related Party Transactions - Additional Information 3 (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "C_98815176-29b9-4ef4-b5d9-809be23c94a1", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_71f6a477-4d93-4952-a825-19f03a9bea44", "name": "uhs:NumberOfSquareFeetToBeAcquiredInMedicalOfficeBuilding", "unitRef": "U_SquareFoot", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "unique": true } }, "R34": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation4Detail", "longName": "995715 - Disclosure - Relationship with Universal Health Realty Income Trust and Other Related Party Transactions - Additional Information 4 (Detail)", "shortName": "Relationship with Universal Health Realty Income Trust and Other Related Party Transactions - Additional Information 4 (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "C_2bfb17a9-6953-48a1-abc6-489a60ff4c41", "name": "uhs:EstimatedPaymentsToAcquireLifeInsurancePolicies", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2bfb17a9-6953-48a1-abc6-489a60ff4c41", "name": "uhs:EstimatedPaymentsToAcquireLifeInsurancePolicies", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true } }, "R35": { "role":
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustDetail", "longName": "995725 - Disclosure - Summary of Details of Hospitals Leased from Trust (Detail)", "shortName": "Summary of Details of Hospitals Leased from Trust (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "C_98815176-29b9-4ef4-b5d9-809be23c94a1", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_0ed067d8-ee93-44db-b444-17dcb9a56965", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "unique": true } }, "R36": { "role":
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustParentheticalDetail", "longName": "995735 - Disclosure - Summary of Details of Hospitals Leased from Trust (Parenthetical) (Detail)", "shortName": "Summary of Details of Hospitals Leased from Trust (Parenthetical) (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "C_25ec9856-914b-4a57-94e2-8647caf9366a", "name": "us-gaap:LesseeOperatingLeaseRenewalTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "uhs:LesseeOperatingAndFinancingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_0ed067d8-ee93-44db-b444-17dcb9a56965", "name": "uhs:OperatingLeasesRenewalOptionsTermAtExistingLeaseRates", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "link:footnote", "div", "div", "us-gaap:ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "unique": true } }, "R37": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureOtherNoncurrentLiabilitiesAndRedeemableNoncontrollingInterestsAdditionalInformationDetail", "longName": "995745 - Disclosure - Other Noncurrent Liabilities and Redeemable/Noncontrolling Interests - Additional Information (Detail)", "shortName": "Other Noncurrent Liabilities and Redeemable/Noncontrolling Interests - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "C_c6fbeca0-9832-4e57-ae58-8bd0c27634ca", "name": "uhs:BehavioralHealthCareFacilitiesOutsideOwnersHoldingNoncontrollingMinorityInterest", "unitRef": "U_Facility", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_c6fbeca0-9832-4e57-ae58-8bd0c27634ca", "name": "uhs:BehavioralHealthCareFacilitiesOutsideOwnersHoldingNoncontrollingMinorityInterest", "unitRef": "U_Facility", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true } }, "R38": { "role":
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail", "longName": "995755 - Disclosure - Treasury - Additional Information (Detail)", "shortName": "Treasury - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "uhs:RateAdjustmentToOneMonthEurodollarRateOnCreditFacilityBorrowings", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["span", "p", "us-gaap:TreasuryStockTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "uhs:RateAdjustmentToOneMonthEurodollarRateOnCreditFacilityBorrowings", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": ["span", "p", "us-gaap:TreasuryStockTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true } }, "R39": { "role":
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureSummaryOfEffectsOfForeignCurrencyForwardExchangeContractsOnResultOfOperationsDetail", "longName": "995765 - Disclosure - Summary of Effects of Foreign Currency Forward Exchange Contracts on Result of Operations (Detail)", "shortName": "Summary of Effects of Foreign Currency Forward Exchange Contracts on Result of Operations (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "C_e604bcca-cf53-4097-8cb3-84ae86af68a5", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e604bcca-cf53-4097-8cb3-

84ae86af68a5", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3" "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfCashCashEquivalentsAndRestrictedCashReportedInCondensedConsolidatedStatementsOfCashFlowsDeta "longName": "995775 - Disclosure - Summary of Cash, Cash Equivalents and Restricted Cash Reported In Condensed Consolidated Statements of Cash Flows (Detail)", "shortName": "Summary of Cash, Cash Equivalents and Restricted Cash Reported In Condensed Consolidated Statements of Cash Flows (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "C_c6fbeca0-9832-4c57-ae58-8bd0c27634ea", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_f5ba79e7-76c1-45ac-b426-3935b1e5d159", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "uhs:ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "unique": true } }, "R41": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfAssetsAndLiabilitiesRecordedAtFairValueOnRecurringBasisDetail", "longName": "995785 - Disclosure - Summary of Assets and Liabilities Recorded at Fair Value on Recurring Basis (Detail)", "shortName": "Summary of Assets and Liabilities Recorded at Fair Value on Recurring Basis (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "C_e892ccf8-7fc3-4482-883a-910d14972255", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_e892ccf8-7fc3-4482-883a-910d14972255", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "longName": "995795 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "C_c6fbeca0-9832-4c57-ae58-8bd0c27634ea", "name": "uhs:SelfInsuredAmountPerOccurrenceExcessClaims", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["span", "p", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_f86e75a9-419e-41b0-87ba-12116fb88b4d", "name": "us-gaap:SelfInsuranceReserveCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "unique": true } }, "R43": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSegmentReportingDetail", "longName": "995805 - Disclosure - Segment Reporting (Detail)", "shortName": "Segment Reporting (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "C_98815176-29b9-4ef4-b5d9-809be23c94a1", "name": "uhs:GrossInpatientRevenues", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_98815176-29b9-4ef4-b5d9-809be23c94a1", "name": "uhs:GrossInpatientRevenues", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSegmentReportingParentheticalDetail", "longName": "995815 - Disclosure - Segment Reporting (Parenthetical) (Detail)", "shortName": "Segment Reporting (Parenthetical) (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "parenthetical", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "C_98815176-29b9-4ef4-b5d9-809be23c94a1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_161b8301-184e-4eff-aac3-ccedb478b486", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["span", "link:footnote", "div", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "unique": true } }, "R45": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureComputationOfBasicAndDilutedEarningsPerShareDetail", "longName": "995825 - Disclosure - Computation of Basic and Diluted Earnings Per Share (Detail)", "shortName": "Computation of Basic and Diluted Earnings Per Share (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "C_98815176-29b9-4ef4-b5d9-809be23c94a1", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_539a9ff5-c2b0-4af0-81e7-a9a5c07c8cfd", "name": "uhs:NetIncomeAllocatedToUnvestedRestrictedShares", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "div", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "unique": true } }, "R46": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/DisclosureEarningsPerShareDataAndStockBasedCompensationAdditionalInformationDetail", "longName": "995835 - Disclosure - Earnings Per Share Data and Stock Based Compensation - Additional Information (Detail)", "shortName": "Earnings Per Share Data and Stock Based Compensation - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "C_98815176-29b9-4ef4-b5d9-809be23c94a1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_98815176-29b9-4ef4-b5d9-809be23c94a1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureDispositionsAndAcquisitionsAdditionalInformationDetail", "longName": "995845 - Disclosure - Dispositions and Acquisitions - Additional Information (Detail)", "shortName": "Dispositions and Acquisitions - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "C_6950a8a5-f150-4cec-8762-aa18438f3dd0", "name": "us-gaap:PaymentsToAcquireBusinessesGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["span", "p", "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_6950a8a5-f150-4cec-8762-aa18438f3dd0", "name": "us-gaap:PaymentsToAcquireBusinessesGross", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": ["span", "p", "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureDividendsAdditionalInformationDetail", "longName": "995855 - Disclosure - Dividends - Additional Information (Detail)", "shortName": "Dividends - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "C_98815176-29b9-4ef4-b5d9-809be23c94a1", "name": "us-gaap:DividendsCommonStockCash", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "uhs:DividendsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_98815176-29b9-4ef4-b5d9-809be23c94a1", "name": "us-gaap:DividendsCommonStockCash", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["span", "p", "uhs:DividendsTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail", "longName": "995865 - Disclosure - Income Taxes - Additional Information (Detail)", "shortName": "Income Taxes - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "C_98815176-29b9-4ef4-b5d9-809be23c94a1", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_98815176-29b9-4ef4-b5d9-809be23c94a1", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": ["span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureScheduleOfDisaggregatesRevenueByMajorSourceDetail", "longName": "995875 - Disclosure - Schedule of Disaggregates Revenue by Major Source (Detail)", "shortName": "Schedule of Disaggregates Revenue by Major Source (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "C_98815176-29b9-4ef4-b5d9-809be23c94a1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_98815176-29b9-4ef4-b5d9-809be23c94a1", "name": "uhs:RevenueFromContractWithCustomerExcludingAssessedTaxPercentage", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "unique": true } }, "R51": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail", "longName": "995885 - Disclosure - Lease Accounting - Additional Information (Detail)", "shortName": "Lease Accounting - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "uhs:LesseeOperatingAndFinancingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "p", "uhs:LesseeOperatingAndFinancingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSupplementalCashFlowInformationRelatedToLeasesDetail", "longName": "995895 - Disclosure - Supplemental Cash Flow Information Related to Leases (Detail)", "shortName": "Supplemental Cash Flow Information Related to Leases (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "us-gaap:OperatingLeasePayments", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "uhs:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "div", "uhs:LesseeOperatingAndFinancingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2d0f19bc-3b74-402e-994d-033b89470aac", "name": "us-gaap:OperatingLeasePayments", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["span", "p", "td", "tr", "table", "uhs:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "div", "uhs:LesseeOperatingAndFinancingLeasesTextBlock", "div", "body", "html"], "reportCount": 1, "baseRef": "uhs-20240930.htm", "first": true, "unique": true } } }, "tag": { "uhs_ABRBasedLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "ABRBasedLoansMember", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "ABR based loans.", "label": "A B R Based Loans [Member]", "terseLabel": "ABR based loans" } } }, "auth_ref": [] }, "country_AZ": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "AZ", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureOtherNoncurrentLiabilitiesAndRedeemableNoncontrollingInterestsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "AZERBAIJAN", "terseLabel": "Arizona" } } }, "auth_ref": [] }, "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingChangesAndErrorCorrectionsAbstract", "lang": { "en-us": { "role": { "label": "Accounting Changes and Error Corrections [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts Payable and Other Accrued Liabilities, Current", "terseLabel": "Accounts payable and other liabilities", "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable, net", "totalLabel": "Accounts Receivable, after Allowance for Credit Loss, Current, Total", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r1018"] }, "us-gaap_AccruedIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedIncomeTaxesCurrent", "crdr": "credit", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accrued Income Taxes, Current", "terseLabel": "Federal and state taxes", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations." } } }, "auth_ref": ["r72", "r119"] }, "uhs_AccruedLiabilitiesOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "AccruedLiabilitiesOtherMember", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfAssetsAndLiabilitiesRecordedAtFairValueOnRecurringBasisDetail"], "lang": { "en-us": { "role": { "terseLabel": "Accrued Liabilities Other", "label": "Accrued Liabilities Other [Member]", "documentation": "Accrued liabilities other." } } }, "auth_ref": [] }, "us-

gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: accumulated depreciation", "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total", "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance", "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": ["r38", "r149", "r637"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity"], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r1", "r14", "r20", "r483", "r486", "r546", "r674", "r675", "r995", "r996", "r997", "r1005", "r1006", "r1007", "r1009"] }, "uhs_AcquisitionOfNonControllingInterestIncreaseDecreaseFromBusinessCombination": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "AcquisitionOfNonControllingInterestIncreaseDecreaseFromBusinessCombination", "crdr": "debit", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity"], "lang": { "en-us": { "role": { "documentation": "Acquisition of non controlling interest increase decrease from business combination.", "label": "Acquisition Of Non controlling Interest Increase Decrease From Business Combination", "terseLabel": "Acquisition of noncontrolling interest in majority owned business" } } }, "auth_ref": [] }, "uhs_AcuteCareFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "AcuteCareFacilityMember", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureOtherNoncurrentLiabilitiesAndRedeemableNoncontrollingInterestsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Acute care facility.", "label": "Acute Care Facility [Member]", "terseLabel": "Acute Care Facility" } } }, "auth_ref": [] }, "uhs_AcuteCareHospitalServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "AcuteCareHospitalServicesMember", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation1Detail", "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail", "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureScheduleOfDisaggregatesRevenueByMajorSourceDetail", "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSegmentReportingDetail"], "lang": { "en-us": { "role": { "documentation": "Acute care hospital services.", "label": "Acute Care Hospital Services [Member]", "terseLabel": "Acute Care Hospital Services" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r928"] }, "uhs_AdditionalFundsReceivedFromGovernmentByCARESAct": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "AdditionalFundsReceivedFromGovernmentByCARESAct", "crdr": "debit", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureGeneralAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Additional funds received from government by C A R E S Act.", "label": "Additional Funds Received From Government By C A R E S Act", "terseLabel": "Additional funds received from government by CARES Act" } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation, Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": ["r941"] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": ["r941"] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": ["r941"] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": ["r941"] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "auth_ref": [] }, "uhs_AggregateInsuranceCoverage": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "AggregateInsuranceCoverage", "crdr": "debit", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Aggregate insurance coverage", "documentation": "Aggregate insurance coverage." } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForApplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForApplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": ["r974"] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": ["r900", "r910", "r920", "r952"] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": ["r903", "r913", "r923", "r955"] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": ["r975"] }, "uhs_AikenRegionalMedicalCenterAndCanyonCreekBehavioralHealthMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "AikenRegionalMedicalCenterAndCanyonCreekBehavioralHealthMember", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail", "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Aiken Regional Medical Center and Canyon Creek Behavioral Health.", "label": "Aiken Regional Medical Center And Canyon Creek Behavioral Health [Member]", "terseLabel": "Aiken Regional Medical Center and Canyon Creek Behavioral Health" } } }, "auth_ref": [] }, "uhs_AikenRegionalMedicalCenterAuroraPavilionBehavioralHealthServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "AikenRegionalMedicalCenterAuroraPavilionBehavioralHealthServicesMember", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustDetail", "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustParentheticalDetail"], "lang": { "en-us": { "role": { "documentation": "Aiken Regional Medical Center/Aurora Pavilion Behavioral Health Services.", "label": "Aiken Regional Medical Center Aurora Pavilion Behavioral Health Services [Member]", "terseLabel": "Aiken Regional Medical Center/Aurora Pavilion Behavioral Health Services" } } }, "auth_ref": [] }, "uhs_AikenRegionalMedicalCenterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "AikenRegionalMedicalCenterMember", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation1Detail", "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Aiken Regional Medical Center.", "label": "Aiken Regional Medical Center [Member]", "terseLabel": "Aiken Regional Medical Center" } } }, "auth_ref": [] }, "uhs_AikenSouthCarolinaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "AikenSouthCarolinaMember", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation1Detail", "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Aiken, South Carolina.", "label": "Aiken South Carolina [Member]", "terseLabel": "Aiken South Carolina" } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": ["r941"] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": ["r948"] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": ["r904", "r914", "r924", "r948", "r956", "r960", "r968"] }, "uhs_AllOtherEventsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "AllOtherEventsMember", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "All Other Events", "label": "All Other Events [Member]", "documentation": "All other events." } } }, "auth_ref": [] }, "us-gaap_AllOtherSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllOtherSegmentsMember", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureScheduleOfDisaggregatesRevenueByMajorSourceDetail", "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSegmentReportingDetail"], "lang": { "en-us": { "role": { "label": "Other Operating Segment [Member]", "terseLabel": "Other", "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items." } } }, "auth_ref": ["r227", "r247", "r248", "r249", "r250", "r251", "r254", "r813", "r814"] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": ["r966"] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/DisclosureEarningsPerShareDataAndStockBasedCompensationAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Compensation cost recognized, pre-tax charge", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": ["r427", "r432"] }, "uhs_AmendedRevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "AmendedRevolvingCreditFacilityMember", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Amended Revolving Credit Facility", "label": "Amended Revolving Credit Facility [Member]", "documentation": "Amended revolving credit facility." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Amendment Flag", "verboseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "uhs_AmountClaimedFromOverPaymentsOfLegalSettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "AmountClaimedFromOverPaymentsOfLegalSettlements", "crdr": "debit", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Amount claimed from over payments of legal settlements.", "label": "Amount Claimed From Over Payments Of Legal Settlements", "terseLabel": "Amount claimed from over payments of legal settlements" } } }, "auth_ref": [] }, "uhs_AmountClaimedFromOverPaymentsOfLegalSettlementsDueToChangeInCalculations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "AmountClaimedFromOverPaymentsOfLegalSettlementsDueToChangeInCalculations", "crdr": "debit", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Amount claimed from over payments of legal settlements due to change in calculations.", "label": "Amount Claimed From Over Payments Of Legal Settlements Due To Change In Calculations", "terseLabel": "Amount claimed from over payments of legal settlements due to change in calculations" } } }, "auth_ref": [] }, "uhs_AnotherTwoHospitalFacilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "AnotherTwoHospitalFacilitiesMember", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Another two hospital facilities.", "label": "Another Two Hospital Facilities [Member]", "terseLabel": "Another Two Hospital Facilities" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [

```
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureEarningsPerShareDataAndStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Anti-dilutive weighted average stock options excluded from computation of earnings per share", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r220" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation1Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation4Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"
], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r470" ] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetImpairmentCharges", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Asset Impairment Charges", "terseLabel": "Provision for asset impairment", "totalLabel": "Asset Impairment Charges, Total", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": [ "r10", "r36" ] }, "uhs_AssetPurchaseAndSaleAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "AssetPurchaseAndSaleAgreementMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation1Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"
], "lang": { "en-us": { "role": { "documentation": "Asset purchase and sale agreement.", "label": "Asset Purchase And Sale Agreement [Member]", "terseLabel": "Asset Purchase and Sale Agreement" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSegmentReportingDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSegmentReportingParentheticalDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets", "terseLabel": "Total assets", "totalLabel": "Total Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r117", "r132", "r151", "r183", "r222", "r230", "r249", "r253", "r297", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r472", "r476", "r517", "r632", "r729", "r813", "r814", "r860", "r891", "r1043", "r1044", "r1112" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r145", "r159", "r183", "r297", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r472", "r476", "r517", "r860", "r1043", "r1044", "r1112" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfAssetsAndLiabilitiesRecordedAtFairValueOnRecurringBasisDetail" ], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure", "terseLabel": "Assets, fair value", "totalLabel": "Assets, Fair Value Disclosure, Total", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r495", "r496", "r847" ] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfAssetsAndLiabilitiesRecordedAtFairValueOnRecurringBasisDetail" ], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "auth_ref": [] }, "ecd_AwardExcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r963" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r964" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r959" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r959" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r959" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r959" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r959" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r959" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureEarningsPerShareDataAndStockBasedCompensationAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation4Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r962" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r961" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r960" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r960" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfAssetsAndLiabilitiesRecordedAtFairValueOnRecurringBasisDetail" ], "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location, Balance [Axis]", "terseLabel": "Balance Sheet Location", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r330", "r1125", "r1126" ] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfAssetsAndLiabilitiesRecordedAtFairValueOnRecurringBasisDetail" ], "lang": { "en-us": { "role": { "label": "Statement of Financial Position Location, Balance [Domain]", "terseLabel": "Balance Sheet Location", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r57", "r59", "r330", "r1125", "r1126" ] },
"uhs_BehavioralHealthCareFacilitiesOutsideOwnersHoldingNoncontrollingMinorityInterest": { "xbrltype": "integerItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "BehavioralHealthCareFacilitiesOutsideOwnersHoldingNoncontrollingMinorityInterest", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureOtherNoncurrentLiabilitiesAndRedeemableNoncontrollingInterestsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Behavioral health care facilities outside owners holding noncontrolling minority interest.", "label": "Behavioral Health Care Facilities Outside Owners Holding Noncontrolling Minority Interest", "terseLabel": "Behavioral health care facilities with outside owners holding non-controlling minority interest" } } }, "auth_ref": [] },
"uhs_BehavioralHealthCareFacilitiesOutsideOwnersHoldingNoncontrollingMinorityInterestOne": { "xbrltype": "integerItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "BehavioralHealthCareFacilitiesOutsideOwnersHoldingNoncontrollingMinorityInterestOne", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureOtherNoncurrentLiabilitiesAndRedeemableNoncontrollingInterestsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Behavioral health care facilities outside owners holding noncontrolling minority interest one.", "label": "Behavioral Health Care Facilities Outside Owners Holding Noncontrolling Minority Interest One", "terseLabel": "Behavioral health care facilities with outside owners holding non-controlling minority interest" } } }, "auth_ref": [] },
"uhs_BehavioralHealthCareFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "BehavioralHealthCareFacilityMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation1Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation2Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureOtherNoncurrentLiabilitiesAndRedeemableNoncontrollingInterestsAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"
], "lang": { "en-us": { "role": { "documentation": "Behavioral health care facility.", "label": "Behavioral Health Care Facility [Member]", "terseLabel": "Behavioral Health Care Facility" } } }, "auth_ref": [] }, "uhs_BehavioralHealthCareFacilityOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "BehavioralHealthCareFacilityOneMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureOtherNoncurrentLiabilitiesAndRedeemableNoncontrollingInterestsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Behavioral health care facility one.", "label": "Behavioral Health Care Facility One [Member]", "terseLabel": "Behavioral Health Care Facility One" } } }, "auth_ref": [] }, "uhs_BehavioralHealthCareFacilityTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "BehavioralHealthCareFacilityTwoMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureOtherNoncurrentLiabilitiesAndRedeemableNoncontrollingInterestsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Behavioral health care facility two.", "label": "Behavioral Health Care Facility Two [Member]", "terseLabel": "Behavioral Health Care Facility Two" } } }, "auth_ref": [] }, "uhs_BehavioralHealthServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "BehavioralHealthServicesMember", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureScheduleOfDisaggregatesRevenueByMajorSourceDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSegmentReportingDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSegmentReportingParentheticalDetail" ], "lang": { "en-us": { "role": { "documentation": "Behavioral health services.", "label": "Behavioral Health Services [Member]", "terseLabel": "Behavioral Health Services" } } }, "auth_ref": [] }, "uhs_BonusRentalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "BonusRentalMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Bonus rental.", "label": "Bonus Rental [Member]", "terseLabel": "Bonus Rental" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r320", "r321", "r322", "r323", "r324", "r466", "r838", "r839" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r47", "r48", "r320", "r321", "r322", "r323", "r324", "r466", "r838", "r839" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
```

```
"localname": "BusinessAcquisitionLineItems", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureDispositionsAndAcquisitionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r466" ] }, "us-gaap_BusinessCombinationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationsAbstract", "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]" } } },
"auth_ref": [] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureGeneral" ], "lang": { "en-us": { "role": {
"label": "Business Description and Basis of Presentation [Text Block]", "terseLabel": "General", "documentation": "The entire disclosure for the business description and basis of presentation
concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and
subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the
underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } } }, "auth_ref": [
"r67", "r102", "r103" ] }, "stpr_CA": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "CA", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label":
"CALIFORNIA", "terseLabel": "CALIFORNIA" } } }, "auth_ref": [] }, "uhs_CaliforniaNewMadridSeismicZonePacificNorthwestSeismicZoneAlaskaAndCertainCountiesInNevadaMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname":
"CaliforniaNewMadridSeismicZonePacificNorthwestSeismicZoneAlaskaAndCertainCountiesInNevadaMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation":
"California New Madrid Seismic Zone Pacific Northwest Seismic Zone Alaska And certain counties in Nevada.", "label": "California New Madrid Seismic Zone Pacific Northwest Seismic Zone
Alaska And Certain Counties In Nevada [Member]", "terseLabel": "California, New Madrid Seismic Zone, Pacific Northwest Seismic Zone, Alaska and certain counties in Nevada" } } },
"auth_ref": [] }, "uhs_CanyonCreekBehavioralHealthMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname":
"CanyonCreekBehavioralHealthMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustParentheticalDetail" ], "lang": { "en-us": { "role": {
"documentation": "Canyon Creek Behavioral Health.", "label": "Canyon Creek Behavioral Health [Member]", "terseLabel": "Canyon Creek Behavioral Health" } } }, "auth_ref": [] }, "us-
gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr":
"debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfCashCashEquivalentsAndRestrictedCashReportedInCondensedConsolidatedStatementsOfCashFlowsDeta
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at
Carrying Value", "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total", "documentation": "Amount of currency on hand as well as
demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid
investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r26", "r147", "r804" ] }, "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfCashCashEquivalentsAndRestrictedCashReportedInCondensedConsolidatedStatementsOfCashFlowsDeta
], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "totalLabel": "Total cash, cash equivalents and restricted cash",
"periodStartLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Beginning Balance", "periodEndLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted
Cash Equivalents, Ending Balance", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal
group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics
of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity
that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r26", "r99", "r182" ] }, "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents,
Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
"periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period", "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including
Disposal Group and Discontinued Operations, Total", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but
not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with
general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and
so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r26", "r99", "r182" ] }, "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Decrease in cash,
cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
"documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash
includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents
include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of
changes in value because of changes in interest rates." } } }, "auth_ref": [ "r0", "r99" ] }, "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffectAbstract", "lang": { "en-
us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect [Abstract]" } } }, "auth_ref": [] },
"uhs_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname":
"CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSupplementalCashFlowInformationRelatedToLeasesDetail" ], "lang": { "en-us": { "role": { "documentation": "Cash
paid for amounts included in measurement of lease liabilities.", "label": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]", "terseLabel": "Cash paid for amounts
included in the measurement of lease liabilities." } } }, "auth_ref": [] }, "us-gaap_CatastrophicEventDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CatastrophicEventDomain", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Catastrophic
Event [Domain]", "terseLabel": "Catastrophic Event", "documentation": "Catastrophic event, for example, but not limited to, earthquake, windstorm, fire or explosion." } } }, "auth_ref": [ "r872"
] }, "us-gaap_CertificatesOfDepositMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CertificatesOfDepositMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfAssetsAndLiabilitiesRecordedAtFairValueOnRecurringBasisDetail" ], "lang": { "en-us": { "role": {
"label": "Certificates of Deposit [Member]", "terseLabel": "Certificates of Deposit", "documentation": "Short to medium-term investment available at banks and savings and loan institutions
where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit
Insurance Corporation (FDIC) insured." } } }, "auth_ref": [ "r13", "r882", "r883", "r884", "r885" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed
Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r939" ] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "ChiefExecutiveOfficerMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation4Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"
], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]", "terseLabel": "Chief Executive Officer" } } }, "auth_ref": [ "r1017" ] },
"ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Change in Fair Value as
of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } }
}, "auth_ref": [ "r936" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-over-Year
Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in
Prior Years That are Outstanding and Unvested" } } }, "auth_ref": [ "r934" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "CityAreaCode", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": {
"label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Class of Stock
[Domain]", "terseLabel": "Class of Stock", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock,
redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r139", "r155", "r156", "r157", "r183", "r209", "r210", "r217", "r219", "r224", "r225",
"r297", "r341", "r343", "r344", "r345", "r348", "r349", "r369", "r370", "r371", "r372", "r374", "r517", "r684", "r685", "r686", "r687", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701",
"r702", "r703", "r704", "r705", "r718", "r738", "r760", "r781", "r782", "r783", "r784", "r785", "r978", "r1002", "r1010" ] }, "us-gaap_ClassOfTreasuryStockTable": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfTreasuryStockTable", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Class of Treasury Stock [Table]",
"terseLabel": "Class Of Treasury Stock [Table]", "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share
repurchase program, shares repurchased, shares held for each class of treasury stock." } } }, "auth_ref": [ "r42", "r43", "r44", "r45" ] }, "uhs_CliveBehavioralHealthHospitalMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "CliveBehavioralHealthHospitalMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustParentheticalDetail" ], "lang": { "en-us": { "role": {
"documentation": "Clive Behavioral Health Hospital.", "label": "Clive Behavioral Health Hospital [Member]", "terseLabel": "Clive Behavioral Health Hospital" } } }, "auth_ref": [] },
"uhs_CliveIowaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "CliveIowaMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"
], "lang": { "en-us": { "role": { "documentation": "Clive, Iowa.", "label": "Clive Iowa [Member]", "terseLabel": "Aiken, South Carolina" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": {
"xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": {
"role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r940" ] }, "ecd_CoSelectedMeasureName": { "xbrltype":
"normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": {
"role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r940" ] }, "us-
gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } } }, "auth_ref": [] },
"uhs_CommitmentsAndContingenciesDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname":
"CommitmentsAndContingenciesDisclosureLineItems", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation":
"Commitments and contingencies disclosure.", "label": "Commitments And Contingencies Disclosure [Line Items]", "terseLabel": "Commitments and Contingencies Disclosure [Line Items]" } }
}, "auth_ref": [] }, "uhs_CommitmentsAndContingenciesDisclosureTable": { "xbrltype": "stringItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname":
"CommitmentsAndContingenciesDisclosureTable", "presentation": [
```

```
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Commitments and contingencies disclosure.", "label": "Commitments And Contingencies Disclosure [Table]", "terseLabel": "Commitments And Contingencies Disclosure [Table]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r106", "r334", "r335", "r788", "r1029", "r1034" ] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonClassAMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Common Class A [Member]", "terseLabel": "Class A", "documentation": "Classification of common stock representing ownership interest in a corporation." } } }, "auth_ref": [ "r1159" ] }, "us-gaap_CommonClassBMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonClassBMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Common Class B [Member]", "terseLabel": "Class B", "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation." } } }, "auth_ref": [ "r1159" ] }, "us-gaap_CommonClassCMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonClassCMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Common Class C [Member]", "terseLabel": "Class C", "documentation": "Classification of common stock that has different rights than provided to Class A or B shares, representing ownership interest in a corporation." } } }, "auth_ref": [] }, "uhs_CommonClassDMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "CommonClassDMember", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "Common class D.", "label": "Common Class D [Member]", "terseLabel": "Class D" } } }, "auth_ref": [] }, "uhs_CommonStockAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "CommonStockAbstract", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "Common stock." , "label": "Common Stock [Abstract]", "terseLabel": "Common Stock" } } }, "auth_ref": [] }, "us-gaap_CommonStockDividendsPerShareCashPaid": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockDividendsPerShareCashPaid", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureDividendsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Common Stock, Dividends, Per Share, Cash Paid", "terseLabel": "Dividends declared and paid, per share", "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding." } } }, "auth_ref": [ "r109" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r878", "r879", "r880", "r882", "r883", "r884", "r885", "r1005", "r1006", "r1009", "r1084", "r1158", "r1159" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r945" ] },
"ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r944" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r946" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r943" ] }, "uhs_CompensatoryDamagesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "CompensatoryDamagesMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureGeneralAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Compensatory Damages", "label": "Compensatory Damages [member]", "documentation": "Compensatory damages." } } }, "auth_ref": [] }, "uhs_CompensatoryDamagesTrebledAndPunitiveDamagesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "CompensatoryDamagesTrebledAndPunitiveDamagesMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Compensatory Damages, Trebled Damages And Punitive Damages", "label": "Compensatory Damages, Trebled And Punitive Damages [Member]", "documentation": "Compensatory damages, trebled and punitive damages." } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income attributable to UHS", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r21", "r164", "r166", "r173", "r628", "r645", "r647" ] }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxAbstract", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "Comprehensive income:" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "terseLabel": "Less: Comprehensive income (loss) attributable to noncontrolling interests", "totalLabel": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest, Total", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r6", "r51", "r55", "r164", "r166", "r172", "r627", "r645", "r646" ] },
"uhs_ComprehensiveIncomeNetOfTaxAttributableToRedeemableNonControllingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "ComprehensiveIncomeNetOfTaxAttributableToRedeemableNonControllingInterest", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "Comprehensive income net of tax attributable to redeemable non-controlling interest.", "label": "Comprehensive Income Net Of Tax Attributable To Redeemable Non Controlling Interest", "verboseLabel": "Subtotal attributable to redeemable noncontrolling interest" } } }, "auth_ref": [] },
"uhs_ComprehensiveIncomeNetOfTaxExcludingPortionAttributableToRedeemableNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "ComprehensiveIncomeNetOfTaxExcludingPortionAttributableToRedeemableNoncontrollingInterest", "crdr": "credit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "Comprehensive income net of tax excluding portion attributable to redeemable noncontrolling interest.", "label": "Comprehensive Income Net Of Tax Excluding Portion Attributable To Redeemable Noncontrolling Interest", "totalLabel": "Subtotal - comprehensive income" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Comprehensive income", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r55", "r113", "r164", "r166", "r171", "r626", "r645" ] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesAxis", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation1Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]", "terseLabel": "Consolidated Entities" } } }, "auth_ref": [ "r185", "r472", "r473", "r476", "r477", "r555", "r793", "r1042", "r1045", "r1046" ] }, "srt_ConsolidatedEntitiesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidatedEntitiesDomain", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation1Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]", "terseLabel": "Consolidated Entities" } } }, "auth_ref": [ "r185", "r472", "r473", "r476", "r477", "r555", "r793", "r1042", "r1045", "r1046" ] }, "uhs_ConsolidatedLeverageRatio": { "xbrltype": "percentItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "ConsolidatedLeverageRatio", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Consolidated leverage ratio.", "label": "Consolidated Leverage Ratio", "terseLabel": "Consolidated Leverage Ratio" } } }, "auth_ref": [] }, "uhs_CostsRelatedToExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "CostsRelatedToExtinguishmentOfDebt", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Costs related to extinguishment of debt.", "label": "Costs Related To Extinguishment Of Debt", "terseLabel": "Costs related to extinguishment of debt" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r340", "r1040" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r340", "r1040", "r1041" ] }, "uhs_CumberlandHospitalForChildrenAndAdolescentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "CumberlandHospitalForChildrenAndAdolescentsMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Cumberland Hospital for Children and Adolescents", "label": "Cumberland Hospital for Children and Adolescents [Member]", "documentation": "Cumberland hospital for children and adolescents." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "uhs_CygnetHealthCareLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "CygnetHealthCareLimitedMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Cygnet health care limited.", "label": "Cygnet Health Care Limited [Member]", "terseLabel": "Cygnet Health Care Limited" } } }, "auth_ref": [] }, "stpr_DC": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "DC", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureDispositionsAndAcquisitionsAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureOtherNoncurrentLiabilitiesAndRedeemableNoncontrollingInterestsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "DISTRICT OF COLUMBIA", "terseLabel": "Washington, District of Columbia" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]",
```

```
"terseLabel": "Debt Instrument", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r19", "r71", "r72", "r118", "r121", "r185", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r822", "r823", "r824", "r825", "r826", "r858", "r1003", "r1030", "r1031", "r1032", "r1103", "r1104" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Face Amount", "terseLabel": "Senior notes, issued", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r350", "r528", "r529", "r823", "r824", "r858" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Senior notes, interest rate", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r74", "r351" ] }, "us-gaap_DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentMaturityDate", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Maturity Date", "terseLabel": "Line of credit facility, maturity date", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth_ref": [ "r153", "r822", "r1089", "r1090" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation", [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role", { "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r19", "r185", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r822", "r823", "r824", "r825", "r826", "r858", "r1003", "r1030", "r1031", "r1032", "r1103", "r1104" ] }, "us-gaap_DebtInstrumentPaymentTerms": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPaymentTerms", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Payment Terms", "terseLabel": "Debt instrument payment, description", "documentation": "Description of the payment terms of the debt instrument (for example, whether periodic payments include principal and frequency of payments) and discussion about any contingencies associated with the payment." } } }, "auth_ref": [ "r66", "r75" ] }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPeriodicPaymentPrincipal", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Periodic Payment, Principal", "terseLabel": "Scheduled principal payments per quarter", "documentation": "Amount of the required periodic payments applied to principal." } } }, "auth_ref": [ "r19" ] },
"uhs_DebtInstrumentPrincipalAmountIssuancePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "DebtInstrumentPrincipalAmountIssuancePercentage", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Debt instrument principal amount issuance percentage.", "label": "Debt Instrument Principal Amount Issuance Percentage", "terseLabel": "Senior notes issued percentage" } } }, "auth_ref": [] }, "uhs_DebtInstrumentRedemptionPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "DebtInstrumentRedemptionPrice", "crdr": "debit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Debt instrument redemption price.", "label": "Debt Instrument Redemption Price", "terseLabel": "Senior notes, redemption price" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPricePercentage", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Redemption Price, Percentage", "terseLabel": "Redemption price, percentage", "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer." } } }, "auth_ref": [ "r127" ] }, "us-gaap_DebtInstrumentRepurchaseAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRepurchaseAmount", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Repurchase Amount", "terseLabel": "Senior notes, redeemed", "documentation": "Fair value amount of debt instrument that was repurchased." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Unamortized financing costs", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "totalLabel": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total", "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r356", "r367", "r527", "r528", "r529", "r823", "r824", "r858" ] },
"uhs_DebtInstrumentYieldPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "DebtInstrumentYieldPercentage", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Debt instrument yield percentage.", "label": "Debt Instrument Yield Percentage", "terseLabel": "Senior notes yield percentage" } } }, "auth_ref": [] }, "us-gaap_DebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Debt [Member]", "terseLabel": "Debt", "documentation": "Contractual obligation to pay money on demand or on fixed or determinable dates." } } }, "auth_ref": [] }, "uhs_DecreaseInProvisionForIncomeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "DecreaseInProvisionForIncomeTax", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease in provision for income taxes", "label": "Decrease In Provision For Income Tax", "documentation": "Decrease in provision for income tax." } } }, "auth_ref": [] }, "uhs_DeferredCompensationAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "DeferredCompensationAssetsMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfAssetsAndLiabilitiesRecordedAtFairValueOnRecurringBasisDetail" ], "lang": { "en-us": { "role": { "documentation": "Deferred compensation assets.", "label": "Deferred Compensation Assets [Member]", "terseLabel": "Deferred Compensation Assets" } } }, "auth_ref": [] }, "us-gaap_DeferredCompensationLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCompensationLiabilityCurrent", "crdr": "credit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Deferred Compensation Liability, Current", "terseLabel": "Compensation and related benefits", "totalLabel": "Deferred Compensation Liability, Current, Total", "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable within one year (or the operating cycle, if longer). Represents currently earned compensation under compensation arrangements that is not actually paid until a later date." } } }, "auth_ref": [ "r46", "r111" ] }, "uhs_DeferredCompensationLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "DeferredCompensationLiabilityMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfAssetsAndLiabilitiesRecordedAtFairValueOnRecurringBasisDetail" ], "lang": { "en-us": { "role": { "documentation": "Deferred compensation liability.", "label": "Deferred Compensation Liability [Member]", "terseLabel": "Deferred Compensation Liability" } } }, "auth_ref": [] }, "us-gaap_DeferredCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCosts", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deferred Costs, Noncurrent", "terseLabel": "Deferred charges", "totalLabel": "Deferred Costs, Noncurrent, Total", "documentation": "Amount of deferred cost, excluding capitalized cost related to contract with customer, classified as noncurrent." } } }, "auth_ref": [ "r116", "r994" ] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Assets, Net", "terseLabel": "Deferred income taxes", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [ "r436", "r437" ] }, "us-gaap_DeferredRevenueArrangementTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueArrangementTypeAxis", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureGeneralAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Deferred Revenue Arrangement Type [Axis]", "terseLabel": "Deferred Revenue Arrangement Type", "documentation": "Information by type of deferred revenue arrangement." } } }, "auth_ref": [] }, "us-gaap_DeferredRevenueArrangementTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredRevenueArrangementTypeDomain", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureGeneralAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Deferred Revenue [Domain]", "terseLabel": "Deferred Revenue", "documentation": "Category of obligation arising when an entity receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized." } } }, "auth_ref": [] }, "uhs_DepartmentOfHumanServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "DepartmentOfHumanServicesMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Department of human services.", "label": "Department Of Human Services [Member]", "terseLabel": "Department of Human Services" } } }, "auth_ref": [] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization", "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": [ "r10", "r37" ] }, "uhs_DepreciationForDiscontinuedOperationsAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "DepreciationForDiscontinuedOperationsAndAmortization", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Depreciation for discontinued operations and amortization.", "label": "Depreciation For Discontinued Operations And Amortization", "terseLabel": "Depreciation & amortization" } } }, "auth_ref": [] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureSummaryOfEffectsOfForeignCurrencyForwardExchangeContractsOnResultOfOperationsDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r709", "r711", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r730", "r731", "r732", "r733", "r748", "r749", "r750", "r751", "r754", "r755", "r756", "r757", "r773", "r778", "r806", "r1092", "r1093", "r1094", "r1095", "r1096", "r1098", "r1099" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureSummaryOfEffectsOfForeignCurrencyForwardExchangeContractsOnResultOfOperationsDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r58", "r60", "r61", "r115", "r709", "r711", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r730", "r731", "r732", "r733", "r748", "r749", "r750", "r751", "r754", "r755", "r756", "r757", "r773", "r774", "r777", "r778", "r806", "r878", "r880", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1098", "r1099" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureSummaryOfEffectsOfForeignCurrencyForwardExchangeContractsOnResultOfOperationsDetail" ], "lang": { "en-us": { "role": { "label": "Hedging Relationship [Axis]", "terseLabel": "Hedging Relationship", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": [ "r16", "r58", "r60" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureSummaryOfEffectsOfForeignCurrencyForwardExchangeContractsOnResultOfOperationsDetail" ], "lang": { "en-us": { "role": { "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments Gain Loss By Hedging Relationship By Income Statement Location By Derivative Instrument Risk [Table]", "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r16", "r58", "r60", "r61", "r62", "r63", "r480" ] }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossLineItems", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureSummaryOfEffectsOfForeignCurrencyForwardExchangeContractsOnResultOfOperationsDetail" ], "lang": { "en-us": { "role": { "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments Gain Loss [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r480" ] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/DisclosureSummaryOfEffectsOfForeignCurrencyForwardExchangeContractsOnResultOfOperationsDetail" ], "lang": { "en-us": { "role": { "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Designated As Hedging Instrument", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r16" ] }, "uhs_DevelopmentAndConstructionCostIncurred": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "DevelopmentAndConstructionCostIncurred", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation":
```

```
"Development and construction cost incurred.", "label": "Development and construction cost incurred", "terseLabel": "Development and construction cost incurred" } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureScheduleOfDisaggregatesRevenueByMajorSourceDetail" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation Of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r385", "r828", "r829", "r830", "r831", "r832", "r833", "r834" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureScheduleOfDisaggregatesRevenueByMajorSourceDetail" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation Of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r385", "r828", "r829", "r830", "r831", "r832", "r833", "r834" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRevenueTables" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Schedule of Disaggregates Revenue by Major Source", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r1049" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureEarningsPerShareDataAndStockBasedCompensation" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share Data and Stock Based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r397", "r400", "r428", "r429", "r431", "r841" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "uhs_DisclosureOfGeneralInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "DisclosureOfGeneralInformationLineItems", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureGeneralAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of general information.", "label": "Disclosure Of General Information [Line Items]", "terseLabel": "Disclosure of General Information [Line Items]" } } }, "auth_ref": [] }, "uhs_DisclosureOfGeneralInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "DisclosureOfGeneralInformationTable", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureGeneralAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of general information.", "label": "Disclosure Of General Information [Table]", "terseLabel": "Disclosure Of General Information [Table]" } } }, "auth_ref": [] }, "uhs_DistrictFacilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "DistrictFacilitiesMember", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "District Facilities.", "label": "District Facilities [Member]", "terseLabel": "District Facilities" } } }, "auth_ref": [] }, "us-gaap_Dividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Dividends", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Dividends", "negatedLabel": "Dividends paid and accrued", "totalLabel": "Dividends, Total", "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock." } } }, "auth_ref": [ "r5", "r109" ] }, "us-gaap_DividendsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsAbstract", "lang": { "en-us": { "role": { "label": "Dividends [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DividendsCommonStockCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsCommonStockCash", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureDividendsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Dividends, Common Stock, Cash", "terseLabel": "Dividends declared and paid", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash." } } }, "auth_ref": [ "r109" ] }, "uhs_DividendsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "DividendsTextBlock", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureDividends" ], "lang": { "en-us": { "role": { "documentation": "Dividends.", "label": "Dividends [Text Block]", "terseLabel": "Dividends" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "verboseLabel": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "verboseLabel": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "terseLabel": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Information [Table]", "terseLabel": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "verboseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r895" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "terseLabel": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r927" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "verboseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r938" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureComputationOfBasicAndDilutedEarningsPerShareDetail" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Basic and Diluted:" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureComputationOfBasicAndDilutedEarningsPerShareDetail", "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "Basic earnings per share attributable to UHS", "verboseLabel": "Earnings per basic share attributable to UHS:", "totalLabel": "Earnings Per Share, Basic, Total", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r174", "r195", "r196", "r197", "r198", "r199", "r200", "r206", "r209", "r217", "r218", "r219", "r221", "r464", "r469", "r492", "r493", "r629", "r648", "r807" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureComputationOfBasicAndDilutedEarningsPerShareDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted earnings per share attributable to UHS", "verboseLabel": "Earnings per diluted share attributable to UHS:", "totalLabel": "Earnings Per Share, Diluted, Total", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r174", "r195", "r196", "r197", "r198", "r199", "r200", "r209", "r217", "r218", "r219", "r221", "r464", "r469", "r492", "r493", "r629", "r648", "r807" ] }, "us-gaap_EarthquakeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarthquakeMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Earthquake [Member]", "terseLabel": "Earthquake", "documentation": "Sudden movement of the earth's crust." } } }, "auth_ref": [] }, "uhs_EarthquakeWindHailAndFloodMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "EarthquakeWindHailAndFloodMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Earthquake Wind Hail and Flood", "label": "Earthquake Wind hail and Flood [Member]", "documentation": "Earthquake wind hail and flood." } } }, "auth_ref": [] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash", "totalLabel": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1102" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective income tax rate", "totalLabel": "Effective Income Tax Rate Reconciliation, Percent, Total", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r439", "r843" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureEarningsPerShareDataAndStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation cost related to unvested options and restricted stock", "totalLabel": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r430" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureEarningsPerShareDataAndStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Unrecognized compensation cost vesting period", "documentation": "Weighted average period over which cost not yet recognized is expected to be recognized for award under share based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r430" ] }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Share-Based
```

```
Payment Arrangement, Exercise of Option, Tax Benefit", "terseLabel": "Issued/(converted)", "documentation": "Amount of tax benefit from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r135" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureEarningsPerShareDataAndStockBasedCompensationAdditionalInformationDetail",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] },
"dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } },
"auth_ref": [ "r893" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityCommonStockSharesOutstanding", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityCurrentReportingStatus", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } },
"auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation4Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureGeneralAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"
], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "terseLabel": "Entity", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype":
"booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r893" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "verboseLabel":
"Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [
"r893" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode",
"presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } },
"auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r977" ] },
"dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel":
"Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r893" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "terseLabel":
"Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r893" ] },
"dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "terseLabel":
"Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r893" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype":
"employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number",
"terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r893" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]",
"terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r932" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": {
"role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in
Compensation Table" } } }, "auth_ref": [ "r973" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity
Awards Adjustments" } } }, "auth_ref": [ "r973" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date
Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary
Compensation Table" } } }, "auth_ref": [ "r973" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": {
"en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityClassOfTreasuryStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "EquityClassOfTreasuryStockLineItems", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ],
"lang": { "en-us": { "role": { "label": "Equity, Class of Treasury Stock [Line Items]", "terseLabel": "Equity Class Of Treasury Stock [Line Items]", "documentation": "Line items represent financial
concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-
gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Equity Component
[Domain]", "terseLabel": "Equity Component", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury
stock, retained earnings, etc." } } }, "auth_ref": [ "r15", "r140", "r167", "r168", "r169", "r186", "r187", "r188", "r192", "r199", "r201", "r203", "r223", "r298", "r301", "r326", "r375", "r449",
"r450", "r459", "r460", "r461", "r465", "r468", "r469", "r482", "r483", "r484", "r485", "r486", "r488", "r491", "r518", "r520", "r521", "r522", "r523", "r524", "r530", "r532", "r546", "r643", "r674",
"r675", "r676", "r694", "r760" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"EquityMethodInvesteeNameDomain", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"
], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name" } } }, "auth_ref": [ "r294", "r295", "r296", "r458", "r980", "r981", "r982", "r1080",
"r1081", "r1082", "r1083" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EquityMethodInvestmentOwnershipPercentage", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"
], "lang": { "en-us": { "role": { "label": "Equity Method Investment, Ownership Percentage", "terseLabel": "Trust outstanding shares held, percentage", "documentation": "The percentage of
ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r294" ] }, "us-
gaap_EquityMethodInvestmentQuotedMarketValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentQuotedMarketValue",
"crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"
], "lang": { "en-us": { "role": { "label": "Equity Method Investment, Quoted Market Value", "terseLabel": "Market value of investment in Trust", "documentation": "This item represents the
aggregate value of each identified investment accounted for under the equity method of accounting based on the quoted market price for those investments in common stock for which a quoted
market price is available." } } }, "auth_ref": [ "r296" ] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EquityMethodInvestments", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"
], "lang": { "en-us": { "role": { "label": "Equity Method Investments", "terseLabel": "Carrying value of investment in Trust", "documentation": "This item represents the carrying amount on the
entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the
entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r222",
"r241", "r253", "r293", "r993", "r1023" ] }, "us-gaap_EquitySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesMember",
"presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfAssetsAndLiabilitiesRecordedAtFairValueOnRecurringBasisDetail" ], "lang": { "en-us":
{ "role": { "label": "Equity Securities [Member]", "terseLabel": "Equity Securities", "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and
other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants." } } }, "auth_ref": [ "r35", "r861",
"r886", "r887", "r888", "r1160" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption
Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r942" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": {
```

```
"role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r900", "r910", "r920", "r952" ] },
"ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded
Compensation Recovery" } } }, "auth_ref": [ "r897", "r907", "r917", "r949" ] }, "uhs_EstimatedPaymentsToAcquireLifeInsurancePolicies": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.universalhealthservices/20240930", "localname": "EstimatedPaymentsToAcquireLifeInsurancePolicies", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation4Detail" ],
"lang": { "en-us": { "role": { "documentation": "Estimated payments to acquire life insurance policies.", "label": "Estimated Payments To Acquire Life Insurance Policies", "terseLabel":
"Estimated payments to acquire life insurance policies" } } }, "auth_ref": [ ] }, "uhs_EstimatedProceedsFromLifeInsurancePolicies": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.universalhealthservices/20240930", "localname": "EstimatedProceedsFromLifeInsurancePolicies", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation4Detail" ],
"lang": { "en-us": { "role": { "documentation": "Estimated proceeds from life insurance policies.", "label": "Estimated Proceeds From Life Insurance Policies", "terseLabel": "Estimated death
benefit proceeds" } } }, "auth_ref": [ ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r948" ]
}, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfAssetsAndLiabilitiesRecordedAtFairValueOnRecurringBasisDetail" ], "lang": { "en-us": { "role": {
"label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And
Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with
domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r495", "r496", "r509", "r847" ] }, "us-
gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfAssetsAndLiabilitiesRecordedAtFairValueOnRecurringBasisDetail" ], "lang": { "en-us": { "role": {
"label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "documentation":
"Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r495", "r496", "r509", "r847" ] }, "us-
gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfAssetsAndLiabilitiesRecordedAtFairValueOnRecurringBasisDetail" ], "lang": { "en-us": { "role": {
"label": "Asset Class [Domain]", "terseLabel": "Asset Class", "documentation": "Class of asset." } } }, "auth_ref": [ "r500", "r501", "r502", "r503", "r504", "r505", "r510", "r849" ] }, "us-
gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByAssetClassAxis", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfAssetsAndLiabilitiesRecordedAtFairValueOnRecurringBasisDetail" ], "lang": { "en-us": { "role": {
"label": "Asset Class [Axis]", "terseLabel": "Asset Class", "documentation": "Information by class of asset." } } }, "auth_ref": [ "r500", "r501", "r502", "r503", "r504", "r505", "r510", "r849" ] },
"us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis",
"presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfAssetsAndLiabilitiesRecordedAtFairValueOnRecurringBasisDetail" ], "lang": { "en-us":
{ "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV", "documentation": "Information by level within fair value hierarchy and fair value
measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r358", "r388", "r389", "r390", "r391", "r392", "r393", "r494", "r496", "r497", "r498", "r499", "r508", "r509",
"r511", "r560", "r561", "r562", "r823", "r824", "r835", "r836", "r837", "r847", "r851" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfAssetsAndLiabilitiesRecordedAtFairValueOnRecurringBasisDetail" ], "lang": { "en-us": { "role": {
"label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r495", "r496", "r497",
"r499", "r847", "r1089", "r1100" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [ ] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureFairValueMeasurement" ], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "terseLabel":
"Fair Value Measurement", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as
defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments,
assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair
value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable
to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum
amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or
security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a
recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value
measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups]
items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all
other required (as defined) and desired information." } } }, "auth_ref": [ "r504", "r506", "r507", "r508", "r511", "r512", "r513", "r514", "r515", "r623", "r847", "r852" ] }, "us-
gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfAssetsAndLiabilitiesRecordedAtFairValueOnRecurringBasisDetail" ], "lang": { "en-us": { "role": {
"label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Basis of Fair Value Measurement, Level 1", "documentation": "Quoted prices in active markets for identical assets or liabilities that
the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r358", "r388", "r393", "r496", "r509", "r560", "r835", "r836", "r837", "r847" ] }, "us-
gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfAssetsAndLiabilitiesRecordedAtFairValueOnRecurringBasisDetail" ], "lang": { "en-us": { "role": {
"label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Basis of Fair Value Measurement, Level 2", "documentation": "Inputs other than quoted prices included within level 1 that are
observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or
similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r358", "r388", "r393", "r496", "r497", "r509", "r561", "r823", "r824", "r835", "r836", "r837", "r847" ] }, "us-
gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfAssetsAndLiabilitiesRecordedAtFairValueOnRecurringBasisDetail" ], "lang": { "en-us": { "role": {
"label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Basis of Fair Value Measurement, Level 3", "documentation": "Unobservable inputs that reflect the entity's own assumption about
the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r358", "r388", "r389", "r390", "r391", "r392", "r393", "r496", "r497", "r498", "r499", "r509", "r562", "r823",
"r824", "r835", "r836", "r837", "r847", "r851" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueMeasurementFrequencyDomain", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfAssetsAndLiabilitiesRecordedAtFairValueOnRecurringBasisDetail" ], "lang": { "en-us": { "role": {
"label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency", "documentation": "Measurement frequency." } } }, "auth_ref": [ "r495", "r496", "r497", "r499", "r847",
"r1089", "r1100" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueMeasurementsFairValueHierarchyDomain", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfAssetsAndLiabilitiesRecordedAtFairValueOnRecurringBasisDetail" ], "lang": { "en-us": { "role": {
"label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure
fair value." } } }, "auth_ref": [ "r358", "r388", "r389", "r390", "r391", "r392", "r393", "r494", "r496", "r497", "r498", "r499", "r508", "r509", "r511", "r560", "r561", "r562", "r823", "r824", "r835",
"r836", "r837", "r847", "r851" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"FairValueMeasurementsRecurringMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfAssetsAndLiabilitiesRecordedAtFairValueOnRecurringBasisDetail" ], "lang": { "en-us": { "role": {
"label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of
asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r847", "r1086", "r1087", "r1088", "r1089", "r1090", "r1100" ] }, "uhs_FaultyZonesOfUSMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "FaultyZonesOfUSMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation":
"Faulty Zones of US.", "label": "Faulty Zones Of U S [Member]", "terseLabel": "Faulty Zones of UNITED STATES" } } }, "auth_ref": [ ] }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeaseInterestPaymentOnLiability", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSupplementalCashFlowInformationRelatedToLeasesDetail" ], "lang": { "en-us": { "role": { "label": "Finance Lease,
Interest Payment on Liability", "terseLabel": "Operating cash flows from finance leases", "documentation": "Amount of interest paid on finance lease liability." } } }, "auth_ref": [ "r536", "r540" ]
}, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit",
"presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSupplementalCashFlowInformationRelatedToLeasesDetail" ], "lang": { "en-us": { "role": { "label":
"Finance Lease, Principal Payments", "terseLabel": "Financing cash flows from finance leases", "documentation": "Amount of cash outflow for principal payment on finance lease." } } },
"auth_ref": [ "r535", "r540" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis",
"presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfAssetsAndLiabilitiesRecordedAtFairValueOnRecurringBasisDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]",
"terseLabel": "Financial Instrument", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271",
"r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r302", "r303", "r304", "r305",
"r306", "r307", "r308", "r309", "r366", "r373", "r489", "r516", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r573", "r574",
"r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r644", "r819", "r847", "r849", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r861",
"r985", "r986", "r987", "r988", "r989", "r990", "r991", "r1019", "r1020", "r1021", "r1022", "r1085", "r1088", "r1089", "r1090", "r1097", "r1100" ] },
"uhs_FinancialLiabilityFromFairValueOfRealEstateAssetsExchanged": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname":
"FinancialLiabilityFromFairValueOfRealEstateAssetsExchanged", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation2Detail" ],
"lang": { "en-us": { "role": { "documentation": "Financial liability from fair value of real estate assets exchanged.", "label": "Financial Liability From Fair Value Of Real Estate Assets Exchanged",
"terseLabel": "Financial liability included in debt" } } }, "auth_ref": [ ] }, "us-gaap_FinancialServicesLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "FinancialServicesLiabilities", "crdr": "credit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail"
], "lang": { "en-us": { "role": { "label": "Financial Services Liabilities", "terseLabel": "Financial liabilities", "documentation": "For entities that provide full or partial financing and servicing for
customers supplementary to its major operations (such as a manufacturer or a homebuilder providing and servicing loans to buyers), represents the liabilities associated with such activities,
including accounts payable and accrued liabilities." } } }, "auth_ref": [ "r120" ] }, "uhs_FirstThreeRenewalOptionsMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.universalhealthservices/20240930", "localname": "FirstThreeRenewalOptionsMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation3Detail" ],
"lang": { "en-us": { "role": { "terseLabel": "First Three Renewal Options", "label": "First Three Renewal Options [Member]", "documentation": "First three renewal options." } } }, "auth_ref": [ ]
}, "uhs_FivePointZeroFiveZeroPercentSeniorSecuredNotesDueTwoThousandThirtyFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930",
"localname": "FivePointZeroFiveZeroPercentSeniorSecuredNotesDueTwoThousandThirtyFourMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "5.050% Senior Secured Notes
due 2034", "label": "Five Point Zero Five Zero Percent Senior Secured Notes Due Two Thousand Thirty Four [Member]", "documentation": "Five point zero five zero percent senior secured notes
due two thousand thirty four." } } }, "auth_ref": [ ] }, "uhs_FivePointZeroZeroPercentSeniorSecuredNotesDueJuneTwoThousandTwentySixMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.universalhealthservices/20240930", "localname": "FivePointZeroZeroPercentSeniorSecuredNotesDueJuneTwoThousandTwentySixMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Five point zero zero
percent senior secured notes due June two thousand twenty six.", "label": "Five Point Zero Zero Percent Senior Secured Notes Due June Two Thousand Twenty Six [Member]", "terseLabel":
"5.00% Senior Secured Notes due 2026" } } }, "auth_ref": [ ] }, "uhs_FivePointZeroZeroPercentSeniorSecuredNotesDueTwoThousandTwentySixMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.universalhealthservices/20240930", "localname": "FivePointZeroZeroPercentSeniorSecuredNotesDueTwoThousandTwentySixMember", "presentation": [
```

"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Five point zero zero percent senior secured notes due two thousand twenty six.", "label": "Five Point Zero Zero Percent Senior Secured Notes Due Two Thousand Twenty Six [Member]", "terseLabel": "5.00% Senior Secured Notes due 2026" } } }, "auth_ref": [] }, "us-gaap_FloodMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FloodMember", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Flood [Member]", "terseLabel": "Flood", "documentation": "Overflowing of a body of water." } } }, "auth_ref": [] }, "uhs_ForeignAndUnitedStatesAndLocalJurisdictionsStatutesOfLimitations": { "xbrltype": "durationItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "ForeignAndUnitedStatesAndLocalJurisdictionsStatutesOfLimitations", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Foreign and U.S. state and local jurisdictions statutes of limitations.", "label": "Foreign And United States And Local Jurisdictions Statutes Of Limitations", "terseLabel": "Foreign and U.S. state and local jurisdictions have statutes of limitations, in years" } } }, "auth_ref": [] }, "us-gaap_ForeignExchangeContractMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignExchangeContractMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureSummaryOfEffectsOfForeignCurrencyForwardExchangeContractsOnResultOfOperationsDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfAssetsAndLiabilitiesRecordedAtFairValueOnRecurringBasisDetail"], "lang": { "en-us": { "role": { "verboseLabel": "Foreign Currency Foreign Exchange Contracts", "terseLabel": "Foreign Currency Forward Exchange Contracts", "label": "Foreign Exchange Contract [Member]", "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates." } } }, "auth_ref": ["r806", "r935", "r846", "r947"] }, "us-gaap_ForeignExchangeForwardMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignExchangeForwardMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Foreign Exchange Forward [Member]", "terseLabel": "Foreign Currency Forward Exchange Contracts", "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate." } } }, "auth_ref": ["r723", "r727", "r732", "r750", "r756", "r775", "r776", "r777", "r880"] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r904", "r914", "r924", "r956"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r904", "r914", "r924", "r956"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r904", "r914", "r924", "r956"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r904", "r914", "r924", "r956"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r904", "r914", "r924", "r956"] }, "uhs_FourPointSixTwoFivePercentSeniorSecuredNotesDueTwoThousandTwentyNineMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "FourPointSixTwoFivePercentSeniorSecuredNotesDueTwoThousandTwentyNineMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "4.625% Senior Secured Notes due 2029", "label": "Four Point Six Two Five Percent Senior Secured Notes Due Two Thousand Twenty Nine [Member]", "documentation": "Four point six two five percent senior secured notes due two thousand twenty nine." } } }, "auth_ref": [] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": ["r937"] }, "country_GB": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "GB", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSegmentReportingParentheticalDetail"], "lang": { "en-us": { "role": { "label": "UNITED KINGDOM", "terseLabel": "Located in U.K." } } }, "auth_ref": [] }, "uhs_GWHospitalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "GWHospitalMember", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "GW Hospital.", "label": "G W Hospital [Member]", "terseLabel": "GW Hospital" } } }, "auth_ref": [] }, "uhs_GainLossOnSaleOfAssetsAndBusiness": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "GainLossOnSaleOfAssetsAndBusiness", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "negatedLabel": "Gain on sale of assets and businesses", "documentation": "Gain loss on sale of assets and business.", "label": "Gain Loss On Sale Of Assets And Business" } } }, "auth_ref": [] },
"uhs_GeneralAndProfessionalLiabilityInsurancePoliciesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "GeneralAndProfessionalLiabilityInsurancePoliciesMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "General and professional liability insurance policies.", "label": "General And Professional Liability Insurance Policies [Member]", "terseLabel": "General And Professional Liability Insurance Policies" } } }, "auth_ref": [] }, "uhs_GeneralAndProfessionalLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "GeneralAndProfessionalLiabilityMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "General and professional liability.", "label": "General And Professional Liability [Member]", "terseLabel": "General and Professional Liability" } } }, "auth_ref": [] }, "us-gaap_GeneralLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralLiabilityMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "General Liability [Member]", "terseLabel": "General Liability", "documentation": "Type of business insurance which provides insurance coverage for a wide variety of liability exposures including, but not limited to, contractual liability, product liability and personal injury liability." } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Goodwill", "terseLabel": "Goodwill", "totalLabel": "Goodwill, Total", "periodStartLabel": "Goodwill, Beginning Balance", "periodEndLabel": "Goodwill, Ending Balance", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r150", "r310", "r624", "r814", "r821", "r848", "r860", "r1026", "r1027"] },
"uhs_GrossInpatientRevenues": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "GrossInpatientRevenues", "crdr": "credit", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSegmentReportingDetail"], "lang": { "en-us": { "role": { "documentation": "Gross inpatient revenues.", "label": "Gross Inpatient Revenues", "terseLabel": "Gross inpatient revenues" } } }, "auth_ref": [] }, "uhs_GrossOutpatientRevenues": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "GrossOutpatientRevenues", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSegmentReportingDetail"], "lang": { "en-us": { "role": { "documentation": "Gross outpatient revenues.", "label": "Gross Outpatient Revenues", "terseLabel": "Gross outpatient revenues" } } }, "auth_ref": [] }, "uhs_GroupEightMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "GroupEightMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Quarterly Payment Beginning on December 31,204 Through September 30, 2026", "documentation": "Group eight.", "label": "Group Eight [Member]" } } }, "auth_ref": [] }, "uhs_GroupNineMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "GroupNineMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Quarterly Payment Beginning on December 31, 2026 Through June 30, 2029", "label": "Group Nine [Member]", "documentation": "Group nine." } } }, "auth_ref": [] }, "uhs_GroupPurchasingOrganizationAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "GroupPurchasingOrganizationAgreementMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation4Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Group purchasing organization agreement.", "label": "Group Purchasing Organization Agreement [Member]", "terseLabel": "Group Purchasing Organization Agreement" } } }, "auth_ref": [] }, "uhs_GroupTenMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "GroupTenMember", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Payment on September 26, 2029", "label": "Group Ten [Member]", "documentation": "Group ten." } } }, "auth_ref": [] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationAxis", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureSummaryOfEffectsOfForeignCurrencyForwardExchangeContractsOnResultOfOperationsDetail"], "lang": { "en-us": { "role": { "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": ["r16", "r480"] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationDomain", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureSummaryOfEffectsOfForeignCurrencyForwardExchangeContractsOnResultOfOperationsDetail"], "lang": { "en-us": { "role": { "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": ["r16"] }, "us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingRelationshipDomain", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureSummaryOfEffectsOfForeignCurrencyForwardExchangeContractsOnResultOfOperationsDetail"], "lang": { "en-us": { "role": { "label": "Hedging Relationship [Domain]", "terseLabel": "Hedging Relationship", "documentation": "Nature or intent of a hedge." } } }, "auth_ref": ["r16"] }, "uhs_HospitalMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "HospitalMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureDispositionsAndAcquisitionsAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureOtherNoncurrentLiabilitiesAndRedeemableNoncontrollingInterestsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Hospital.", "label": "Hospital [Member]", "terseLabel": "Hospital" } } }, "auth_ref": [] }, "stpr_IA": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "IA", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureOtherNoncurrentLiabilitiesAndRedeemableNoncontrollingInterestsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "IOWA", "terseLabel": "Iowa" } } }, "auth_ref": [] },
"uhs_IncomeLossFromContinuingOperationsBeforeAllocationOfCorporateOverheadAndIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "IncomeLossFromContinuingOperationsBeforeAllocationOfCorporateOverheadAndIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSegmentReportingDetail"], "lang": { "en-us": { "role": { "documentation": "Income (loss) from continuing operations before allocation of corporate overhead and income taxes extraordinary items noncontrolling interest.", "label": "Income Loss From Continuing Operations Before Allocation Of Corporate Overhead And Income Taxes Extraordinary Items Noncontrolling Interest", "verboseLabel": "Income/(loss) before allocation of corporate overhead and income taxes" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSegmentReportingDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome"], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Income before income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r88", "r125", "r131", "r630", "r639", "r808", "r813", "r1012", "r1013", "r1014", "r1015", "r1016"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation4Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "terseLabel": "Income Statement Location", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": ["r328", "r330", "r331", "r501", "r505", "r510", "r671", "r673", "r745", "r801", "r850", "r1127"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation4Detail",

```
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "terseLabel": "Income Statement Location", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r330", "r331", "r501", "r505", "r510", "r671", "r673", "r745", "r801", "r850", "r1127" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureIncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r184", "r434", "r439", "r440", "r441", "r442", "r445", "r446", "r451", "r453", "r456", "r457", "r688", "r843" ] }, "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Income Tax Examination, Penalties and Interest Accrued", "terseLabel": "Accrued interest and penalties", "totalLabel": "Income Tax Examination, Penalties and Interest Accrued, Total", "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations." } } }, "auth_ref": [ "r1079" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit)", "terseLabel": "Provision for income taxes", "totalLabel": "Income Tax Expense (Benefit), Total", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r134", "r136", "r202", "r203", "r222", "r238", "r253", "r438", "r439", "r452", "r650", "r843" ] }, "uhs_IncomeTaxesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "IncomeTaxesLineItems", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Income taxes.", "label": "Income Taxes [Line Items]", "terseLabel": "Income Taxes [Line Items]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Income Taxes Paid, Net", "terseLabel": "Income taxes paid, net of refunds", "totalLabel": "Income Taxes Paid, Net, Total", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r27", "r181", "r447", "r448" ] }, "uhs_IncomeTaxesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "IncomeTaxesTable", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Income taxes.", "label": "Income Taxes [Table]", "terseLabel": "Income Taxes [Table]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedInterestReceivableNet", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accrued Interest Receivable, Net", "negatedLabel": "Accrued interest", "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments." } } }, "auth_ref": [ "r9" ] }, "uhs_IncreaseDecreaseInCapitalReservesOfCommercialInsuranceSubsidiary": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "IncreaseDecreaseInCapitalReservesOfCommercialInsuranceSubsidiary", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease in capital reserves of commercial insurance subsidiary", "documentation": "Increase (decrease) in capital reserves of commercial insurance subsidiary.", "label": "Increase Decrease In Capital Reserves Of Commercial Insurance Subsidiary", "negatedLabel": "Decrease in capital reserves of commercial insurance subsidiary" } } }, "auth_ref": [] },
"uhs_IncreaseDecreaseInDeferredIncomeTaxesAndAccruedIncomeTaxesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "IncreaseDecreaseInDeferredIncomeTaxesAndAccruedIncomeTaxesPayable", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Deferred Income Taxes And Accrued Income Taxes Payable", "label": "Increase Decrease In Deferred Income Taxes And Accrued Income Taxes Payable", "negatedLabel": "Accrued and deferred income taxes" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInInsuranceSettlementsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInsuranceSettlementsReceivable", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Insurance Settlements Receivable", "negatedLabel": "Payments made in settlement of self-insurance claims", "documentation": "The increase (decrease) during the reporting period in insurance settlements receivable, which are amounts due in settlement of a claim for reimbursement from an insurance company when the Company has suffered a loss covered under an insurance policy. The expectation is that such reimbursement will be received within one year of the balance sheet date." } } }, "auth_ref": [ "r9" ] },
"uhs_IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredCARESActAndOtherGrants": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "IncreaseDecreaseInMedicareAcceleratedPaymentsAndDeferredCARESActAndOtherGrants", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Increase decrease in Medicare accelerated payments and deferred CARES Act and other grants.", "label": "Increase Decrease In Medicare Accelerated Payments And Deferred C A R E S Act And Other Grants", "negatedLabel": "Medicare accelerated payments and deferred CARES Act and other grants" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapital", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Net cash outflows", "label": "Increase (Decrease) in Operating Capital", "totalLabel": "Increase (Decrease) in Operating Capital, Total", "documentation": "The increase (decrease) during the reporting period of all assets and liabilities used in operating activities." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in assets & liabilities, net of effects from acquisitions and dispositions." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingCapitalNet", "crdr": "credit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net", "negatedLabel": "Other working capital accounts", "totalLabel": "Increase (Decrease) in Other Operating Assets and Liabilities, Net, Total", "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Other", "totalLabel": "Increase (Decrease) in Other Operating Liabilities, Total", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Other assets and deferred charges", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInSelfInsuranceReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInSelfInsuranceReserve", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Self Insurance Reserve", "terseLabel": "Accrued insurance expense, net of commercial premiums paid", "documentation": "The increase (decrease) during the period in the carrying amount of accrued known and estimated losses incurred for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's' compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property." } } }, "auth_ref": [ "r1000" ] }, "uhs_IncreaseDecreaseOfRevenues": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "IncreaseDecreaseOfRevenues", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Increase decrease of revenues.", "label": "Increase Decrease Of Revenues", "terseLabel": "Self-insured for professional and general liability" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r904", "r914", "r924", "r948", "r956", "r960", "r968" ] }, "uhs_InlandValleyCampusOfSouthwestHealthcareSystemMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "InlandValleyCampusOfSouthwestHealthcareSystemMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Inland Valley Campus of Southwest Healthcare System.", "label": "Inland Valley Campus Of Southwest Healthcare System [Member]", "terseLabel": "Inland Valley Campus of Southwest Healthcare System" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r966" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r896", "r972" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r896", "r972" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r896", "r972" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "label": "Interest Expense, Operating and Nonoperating", "terseLabel": "Interest expense, net", "totalLabel": "Interest Expense, Total", "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense." } } }, "auth_ref": [ "r222", "r230", "r234", "r240", "r253", "r526", "r813", "r814" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Interest paid", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r176", "r179", "r180" ] }, "uhs_InterestRateMarginAdjustmentPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "InterestRateMarginAdjustmentPercentage", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Interest rate margin adjustment percentage.", "label": "Interest Rate Margin Adjustment Percentage", "terseLabel": "Current applicable margins" } } }, "auth_ref": [] }, "us-gaap_InvestmentAdviceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentAdviceMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Investment Advice [Member]", "terseLabel": "Advisory Fee", "documentation": "Investment recommendation and research provided to customer." } } }, "auth_ref": [ "r1050" ] }, "us-gaap_InvestmentIncomeDividend": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeDividend", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation4Detail" ], "lang": { "en-us": { "role": { "label": "Investment Income, Dividend", "terseLabel": "Dividend", "documentation": "Amount of dividend income on nonoperating securities." } } }, "auth_ref": [ "r92" ] }, "uhs_JurisdictionsStatutesOfLimitationsExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "JurisdictionsStatutesOfLimitationsExpirationPeriod", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Jurisdictions statutes of limitations expiration period.", "label": "Jurisdictions Statutes Of Limitations Expiration Period", "terseLabel": "Jurisdictions statutes of limitations expiration period" } } }, "auth_ref": [] }, "us-gaap_LaborAndRelatedExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LaborAndRelatedExpense", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "label": "Labor and Related Expense",
```

```
"terseLabel": "Salaries, wages and benefits", "documentation": "Amount of expense for salary, wage, profit sharing, incentive and equity-based compensation, and other employee benefit." } } },
"auth_ref": [ "r998" ] }, "us-gaap_LeaseContractualTermAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermAxis", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation3Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"
], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Axis]", "terseLabel": "Lease Contractual Term", "documentation": "Information by contractual term of lease arrangement." } } },
"auth_ref": [ "r543", "r984" ] }, "us-gaap_LeaseContractualTermDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseContractualTermDomain",
"presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation3Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"
], "lang": { "en-us": { "role": { "label": "Lease Contractual Term [Domain]", "terseLabel": "Lease Contractual Term", "documentation": "Contractual term of lease arrangement." } } }, "auth_ref":
[ "r543", "r984" ] }, "us-gaap_LeaseExpirationDate1": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseExpirationDate1", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation3Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Lease
Expiration Date", "terseLabel": "Lease expiration date", "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format." } } }, "auth_ref": [] },
"uhs_LeaseExpirationMonthAndYear": { "xbrltype": "gYearMonthItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "LeaseExpirationMonthAndYear",
"presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustDetail" ], "lang": { "en-us": { "role": {
"documentation": "Lease expiration, month and year.", "label": "Lease Expiration Month And Year", "terseLabel": "End of Lease Term" } } }, "auth_ref": [] }, "uhs_LeaseExpirationPeriod": {
"xbrltype": "durationItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "LeaseExpirationPeriod", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustDetail" ], "lang": { "en-us": { "role": { "documentation": "Lease
expiration period.", "label": "Lease Expiration Period", "terseLabel": "Renewal Term (years)" } } }, "auth_ref": [] }, "uhs_LeaseExpirationTerm": { "xbrltype": "gYearItemType", "nsuri":
"http://www.universalhealthservices/20240930", "localname": "LeaseExpirationTerm", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Lease expiration
term.", "label": "Lease Expiration Term", "terseLabel": "Lease expiration term" } } }, "auth_ref": [] }, "uhs_LeaseRentReceivable": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.universalhealthservices/20240930", "localname": "LeaseRentReceivable", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustParentheticalDetail" ], "lang": { "en-us": { "role": {
"documentation": "Lease rent receivable.", "label": "Lease Rent Receivable", "terseLabel": "Lease rent receivable" } } }, "auth_ref": [] }, "us-gaap_LeasesAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": {
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation4Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureGeneralAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"
], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-
gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description
[Line Items]", "terseLabel": "Lessee Lease Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose
reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r538", "r543" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description
[Table]", "terseLabel": "Lessee Lease Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r538", "r543" ] },
"uhs_LesseeOperatingAndFinancingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname":
"LesseeOperatingAndFinancingLeasesTextBlock", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureLeaseAccounting" ], "lang": { "en-us": { "role":
{ "documentation": "Lessee operating and financing leases.", "label": "Lessee Operating And Financing Leases [Text Block]", "terseLabel": "Lease Accounting" } } }, "auth_ref": [] }, "us-
gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LesseeOperatingLeaseExistenceOfOptionToExtend", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease,
Existence of Option to Extend [true false]", "terseLabel": "Lessee, operating lease, existence of option to extend [true false]", "documentation": "Indicates (true false) whether lessee has option
to extend operating lease." } } }, "auth_ref": [ "r539" ] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustParentheticalDetail" ], "lang": { "en-us": { "role": { "label":
"Lessee, Operating Lease, Renewal Term", "terseLabel": "Real estate leases option to extend lease term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS'
format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1106" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": {
"xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease,
Term of Contract", "verboseLabel": "Initial term of real estate lease", "terseLabel": "Lease initial terms", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for
example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1106" ] }, "us-gaap_LetterOfCreditMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LetterOfCreditMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Letter of Credit [Member]",
"terseLabel": "Letter of Credit", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a
specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)." } } }, "auth_ref": [] }, "us-
gaap_LettersOfCreditOutstandingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LettersOfCreditOutstandingAmount", "crdr": "credit",
"presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Letters of Credit
Outstanding, Amount", "terseLabel": "Letters of credit, outstanding", "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting
date." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilitiesAndStockholdersEquity", "crdr": "credit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ],
"lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Stockholders\u2019 Equity", "documentation": "Amount of liabilities and equity items, including
the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r85", "r123", "r635", "r860", "r1004", "r1024", "r1101" ] }, "us-
gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract",
"presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and
Equity [Abstract]", "terseLabel": "Liabilities and Stockholders\u2019 Equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel":
"Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business
cycle, if longer." } } }, "auth_ref": [ "r73", "r146", "r183", "r297", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r473", "r476", "r477", "r517", "r860", "r1043", "r1112",
"r1113" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]",
"terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfAssetsAndLiabilitiesRecordedAtFairValueOnRecurringBasisDetail" ], "lang": { "en-us": { "role": {
"label": "Liabilities, Fair Value Disclosure", "terseLabel": "Liabilities, fair value", "totalLabel": "Liabilities, Fair Value Disclosure, Total", "documentation": "Fair value of financial and nonfinancial
obligations." } } }, "auth_ref": [ "r496", "r1086" ] }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilitiesFairValueDisclosureAbstract", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfAssetsAndLiabilitiesRecordedAtFairValueOnRecurringBasisDetail" ], "lang": { "en-us": { "role": {
"label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilityForCatastropheClaimsByCatastrophicEventAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilityForCatastropheClaimsByCatastrophicEventAxis", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Catastrophic
Event [Axis]", "terseLabel": "Catastrophic Event", "documentation": "Information by type of catastrophic event, for example, but not limited to, earthquake, windstorm, fire or explosion." } } },
"auth_ref": [ "r872", "r1155" ] }, "us-gaap_LiabilityForCatastropheClaimsCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilityForCatastropheClaimsCarryingAmount", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "verboseLabel":
"Commercial property insurance policies covering catastrophic losses", "terseLabel": "Commercial property insurance policies", "label": "Liability for Catastrophe Claims, Carrying Amount",
"documentation": "The amount of estimated liability as of the balance sheet date for the specific conflagration, earthquake, windstorm, explosion, or similar event." } } }, "auth_ref": [ "r1155" ]
}, "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilityForClaimsAndClaimsAdjustmentExpense", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Liability for
Claims and Claims Adjustment Expense", "terseLabel": "Compensation liability claims", "totalLabel": "Liability for Claims and Claims Adjustment Expense, Total", "periodStartLabel": "Liability
for Claims and Claims Adjustment Expense, Beginning Balance", "periodEndLabel": "Liability for Claims and Claims Adjustment Expense, Ending Balance", "documentation": "The amount
needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that
date." } } }, "auth_ref": [ "r872", "r876", "r1121", "r1128" ] }, "uhs_LimitedLiabilityCompaniesMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.universalhealthservices/20240930", "localname": "LimitedLiabilityCompaniesMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation3Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"
], "lang": { "en-us": { "role": { "documentation": "Limited Liability Companies.", "label": "Limited Liability Companies [Member]", "terseLabel": "Limited Liability Companies" } } }, "auth_ref": []
}, "us-gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCredit", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Long-Term Line of Credit",
"terseLabel": "Line of credit facility amount outstanding", "totalLabel": "Long-Term Line of Credit, Total", "documentation": "The carrying value as of the balance sheet date of the current and
noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the
application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any
point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current
liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing
agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year
and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing
agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref": [ "r19", "r121", "r1122" ] }, "us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityIncreaseDecreaseForPeriodNet", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Decrease in outstanding
borrowings", "label": "Line of Credit Facility, Increase (Decrease), Net", "terseLabel": "Line of credit facility increased (decreased) amount", "totalLabel": "Line of Credit Facility, Increase
(Decrease), Net, Total", "documentation": "Amount of increase (decrease) of the credit facility." } } }, "auth_ref": [ "r1003" ] }, "us-gaap_LineOfCreditFacilityInitiationDate1": { "xbrltype":
"dateItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityInitiationDate1", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Initiation
```

Date", "terseLabel": "Line of credit facility, starting date", "documentation": "Date the credit facility first became available, in YYYY-MM-DD format." } } }, "auth_ref": ["r70", "r76"] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Line of credit facility, borrowing capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": ["r70", "r76"] }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Remaining Borrowing Capacity", "terseLabel": "Line of credit facility, available borrowing capacity", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)." } } }, "auth_ref": ["r70", "r76", "r340"] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseAxis", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureGeneralAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]" } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseTypeDomain", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureGeneralAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Long-Term Debt", "terseLabel": "Debt instrument carrying amount", "totalLabel": "Long-Term Debt, Total", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": ["r19", "r121", "r357", "r368", "r823", "r824", "r858", "r1122"] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Current Maturities", "terseLabel": "Current maturities of long-term debt", "totalLabel": "Long-Term Debt, Current Maturities, Total", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": ["r152"] }, "us-gaap_LongTermDebtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtFairValue", "crdr": "credit", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Fair Value", "terseLabel": "Fair value of debt", "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission." } } }, "auth_ref": ["r1086", "r1088", "r1089", "r1090"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive", "crdr": "credit", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Debt, due in greater than 60 months", "label": "Long-Term Debt, Maturity, after Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r12", "r185", "r1048"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Debt, due during the next 12 month", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r12", "r185", "r361"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "crdr": "credit", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Debt, due during months 49 to 60", "label": "Long-Term Debt, Maturity, Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r12", "r185", "r361"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Debt, due during months 37 to 48", "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r12", "r185", "r361"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Debt, due during months 25 to 36", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r12", "r185", "r361"] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Debt, due during months 13 to 24", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r12", "r185", "r361"] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Excluding Current Maturities", "terseLabel": "Long-term debt", "totalLabel": "Long-Term Debt, Excluding Current Maturities, Total", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": ["r154"] }, "us-gaap_LongTermPurchaseCommitmentAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermPurchaseCommitmentAmount", "crdr": "credit", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Long-Term Purchase Commitment, Amount", "terseLabel": "Committment to expend", "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment." } } }, "auth_ref": [] }, "us-gaap_LongtermPurchaseCommitmentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermPurchaseCommitmentPeriod", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Long-Term Purchase Commitment, Period", "terseLabel": "Projected commitment expend period", "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format. for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_LossContingencyDamagesAwardedValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyDamagesAwardedValue", "crdr": "debit", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Damages awarded", "label": "Loss Contingency, Damages Awarded, Value", "documentation": "Amount of damages awarded to the plaintiff in the legal matter." } } }, "auth_ref": ["r1035", "r1036", "r1037"] }, "us-gaap_LossContingencyDamagesSoughtValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyDamagesSoughtValue", "crdr": "debit", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Loss Contingency, Damages Sought, Value", "terseLabel": "Plaintiff's counsel's fee demand", "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter." } } }, "auth_ref": ["r1035", "r1036", "r1037"] }, "us-gaap_LossContingencyNumberOfPlaintiffs": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyNumberOfPlaintiffs", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Number of plaintiffs", "label": "Loss Contingency, Number of Plaintiffs", "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency." } } }, "auth_ref": ["r1036", "r1037"] }, "uhs_LossContingencyTimelineOfRemittitur": { "xbrltype": "durationItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "LossContingencyTimelineOfRemittitur", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Timeline of remittitur", "label": "Loss Contingency, Timeline Of Remittitur", "documentation": "Loss contingency, timeline to either accept the remittitur or refuse the remittitur." } } }, "auth_ref": [] }, "uhs_LossOnBusinessInterruptionInsuranceRecovery": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "LossOnBusinessInterruptionInsuranceRecovery", "crdr": "credit", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "terseLabel": "Loss on business interruption insurance recovery", "label": "Loss On Business Interruption Insurance Recovery", "documentation": "Loss on business interruption insurance recovery." } } }, "auth_ref": [] }, "stpr_MI": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "MI", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureOtherNoncurrentLiabilitiesAndRedeemableNoncontrollingInterestsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "MICHIGAN", "terseLabel": "Michigan" } } }, "auth_ref": [] }, "stpr_MO": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "MO", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureOtherNoncurrentLiabilitiesAndRedeemableNoncontrollingInterestsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "MISSOURI", "terseLabel": "Missouri" } } }, "auth_ref": [] }, "us-gaap_MajorPropertyClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MajorPropertyClassAxis", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustDetail", "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustParentheticalDetail"], "lang": { "en-us": { "role": { "label": "Major Property Class [Axis]", "terseLabel": "Major Property Class", "documentation": "Amount of property owned but leased or available for lease to third parties, by major property class." } } }, "auth_ref": ["r133"] }, "us-gaap_MajorPropertyClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MajorPropertyClassDomain", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustDetail", "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustParentheticalDetail"], "lang": { "en-us": { "role": { "label": "Major Property Class [Domain]", "terseLabel": "Major Property Class", "documentation": "The major classes of assets leased or available for lease to third parties under operating lease agreements as of the balance sheet date." } } }, "auth_ref": ["r133"] }, "uhs_ManagedCareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "ManagedCareMember", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureScheduleOfDisaggregatesRevenueByMajorSourceDetail"], "lang": { "en-us": { "role": { "documentation": "Managed care.", "label": "Managed Care [Member]", "terseLabel": "Managed Care (HMO and PPOs)" } } }, "auth_ref": [] }, "uhs_ManagedMedicaidMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "ManagedMedicaidMember", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureScheduleOfDisaggregatesRevenueByMajorSourceDetail"], "lang": { "en-us": { "role": { "documentation": "Managed medicaid.", "label": "Managed Medicaid [Member]", "terseLabel": "Managed Medicaid" } } }, "auth_ref": [] }, "uhs_ManagedMedicareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "ManagedMedicareMember", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureScheduleOfDisaggregatesRevenueByMajorSourceDetail"], "lang": { "en-us": { "role": { "documentation": "Managed medicare.", "label": "Managed Medicare [Member]", "terseLabel": "Managed Medicare" } } }, "auth_ref": [] }, "uhs_MaximumInsuranceDeductible": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "MaximumInsuranceDeductible", "crdr": "debit", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Maximum insurance deductible.", "label": "Maximum Insurance Deductible", "terseLabel": "Maximum insurance deductible" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation3Detail",

"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustParentheticalDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "auth_ref": ["r336", "r337", "r338", "r339", "r395", "r433", "r499", "r588", "r670", "r672", "r682", "r710", "r711", "r766", "r768", "r770", "r771", "r779", "r799", "r800", "r818", "r827", "r840", "r851", "r852", "r856", "r857", "r871", "r1047", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119"] }, "uhs_McAllenMedicalCenterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "McAllenMedicalCenterMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustParentheticalDetail"], "lang": { "en-us": { "role": { "documentation": "McAllen medical center.", "label": "Mc Allen Medical Center [Member]", "terseLabel": "McAllen Medical Center" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": ["r940"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r940"] }, "uhs_MedicaidMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "MedicaidMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureScheduleOfDisaggregatesRevenueByMajorSourceDetail"], "lang": { "en-us": { "role": { "documentation": "Medicaid.", "label": "Medicaid [Member]", "terseLabel": "Medicaid" } } }, "auth_ref": [] }, "uhs_MedicareAcceleratedAndAdvancePaymentProgramMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "MedicareAcceleratedAndAdvancePaymentProgramMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureGeneralAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Medicare accelerated and advance payment program.", "label": "Medicare Accelerated And Advance Payment Program [Member]", "terseLabel": "Medicare Accelerated and Advance Payment Program" } } }, "auth_ref": [] }, "uhs_MedicareAcceleratedPaymentsReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "MedicareAcceleratedPaymentsReceived", "crdr": "credit", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureGeneralAdditionalInformationDetail"], "lang": { "en-us": { "role": { "documentation": "Medicare accelerated payments received.", "label": "Medicare Accelerated Payments Received", "terseLabel": "Medicare accelerated payments received" } } }, "auth_ref": [] }, "uhs_MedicareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "MedicareMember", "presentation": ["http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureScheduleOfDisaggregatesRevenueByMajorSourceDetail"], "lang": { "en-us": { "role": { "documentation": "Medicare.", "label": "Medicare [Member]", "terseLabel": "Medicare" } } }, "auth_ref": [] }, "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureDispositionsAndAcquisitions"], "lang": { "en-us": { "role": { "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]", "terseLabel": "Dispositions and acquisitions", "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings." } } }, "auth_ref": ["r68", "r112"] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation3Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation4Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustParentheticalDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "auth_ref": ["r336", "r337", "r338", "r339", "r395", "r433", "r499", "r588", "r670", "r672", "r682", "r710", "r711", "r766", "r768", "r770", "r771", "r779", "r799", "r800", "r818", "r827", "r840", "r851", "r852", "r856", "r871", "r1047", "r1114", "r1115", "r1116", "r1117", "r1118", "r1119"] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterest", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling interest", "totalLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Total", "periodStartLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Beginning Balance", "periodEndLabel": "Stockholders' Equity Attributable to Noncontrolling Interest, Ending Balance", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": ["r84", "r122", "r183", "r297", "r341", "r343", "r344", "r345", "r348", "r349", "r517", "r634", "r719"] }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity"], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "negatedLabel": "Distributions to noncontrolling interests", "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders." } } }, "auth_ref": ["r109"] }, "us-gaap_MinorityInterestInJointVentures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestInJointVentures", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureOtherNoncurrentLiabilitiesAndRedeemableNoncontrollingInterestsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest in Joint Ventures", "terseLabel": "Non-controlling interest balances", "documentation": "Carrying amount of the equity interests owned by noncontrolling shareholders, partners, or other equity holders in joint ventures included in the entity's consolidated financial statements." } } }, "auth_ref": ["r50"] }, "us-gaap_MinorityInterestLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestLineItems", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureOtherNoncurrentLiabilitiesAndRedeemableNoncontrollingInterestsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Line Items]", "terseLabel": "Minority Interest [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureOtherNoncurrentLiabilitiesAndRedeemableNoncontrollingInterestsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Subsidiary, Ownership Percentage, Noncontrolling Owner", "terseLabel": "Percentage of non-controlling, minority ownership interests held by outside owners", "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestOwnershipPercentageByParent", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation3Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureDispositionsAndAcquisitionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "verboseLabel": "Non-controlling ownership interests", "label": "Subsidiary, Ownership Percentage, Parent", "terseLabel": "Non-controlling ownership interests by subsidiaries", "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestTable", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureOtherNoncurrentLiabilitiesAndRedeemableNoncontrollingInterestsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Table]", "terseLabel": "Minority Interest [Table]", "documentation": "Disclosure of information about noncontrolling interest, including, but not limited to, name of subsidiary, ownership percentage held by parent, ownership percentage held by noncontrolling owner, amount of noncontrolling interest and its location in statement of financial position, explanation of increase (decrease) in noncontrolling interest, noncontrolling interest share of net income (loss) of subsidiary and its location in statement of income, amount of noncontrolling interest represented by preferred stock, description and dividend requirement of preferred stock, and nature of noncontrolling interest." } } }, "auth_ref": ["r50", "r52", "r84", "r89"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": ["r959"] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfAssetsAndLiabilitiesRecordedAtFairValueOnRecurringBasisDetail"], "lang": { "en-us": { "role": { "label": "Money Market Funds [Member]", "terseLabel": "Money Market Mutual Funds", "documentation": "Fund that invests in short term money market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": ["r1051"] }, "srt_MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MortgageLoansOnRealEstateDescriptionTypeOfPropertyAxis", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation1Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Real Estate, Type of Property [Axis]", "terseLabel": "Real Estate, Type of Property" } } }, "auth_ref": ["r787", "r789", "r790", "r791", "r792", "r794", "r795", "r796", "r797", "r798"] }, "srt_MortgageLoansOnRealEstateNamePropertyTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MortgageLoansOnRealEstateNamePropertyTypeDomain", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation1Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "Real Estate [Domain]", "terseLabel": "Real Estate" } } }, "auth_ref": ["r789", "r790", "r791", "r792", "r794", "r795", "r796", "r797", "r798"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": ["r967"] }, "stpr_NV": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "NV", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureDispositionsAndAcquisitionsAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureOtherNoncurrentLiabilitiesAndRedeemableNoncontrollingInterestsAdditionalInformationDetail"], "lang": { "en-us": { "role": { "label": "NEVADA", "terseLabel": "Nevada" } } }, "auth_ref": [] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r941"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash used in financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r178"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash Flows from Financing Activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r178"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by

```
(Used in) Investing Activities [Abstract]", "terseLabel": "Cash Flows from Investing Activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash provided by operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r99", "r100", "r101" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash Flows from Operating Activities:" } } }, "auth_ref": [] }, "uhs_NetIncomeAllocatedToUnvestedRestrictedShares": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "NetIncomeAllocatedToUnvestedRestrictedShares", "crdr": "debit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureComputationOfBasicAndDilutedEarningsPerShareDetail" ], "lang": { "en-us": { "role": { "documentation": "Net income allocated to unvested restricted shares.", "label": "Net Income Allocated To Unvested Restricted Shares", "negatedLabel": "Less: Net income attributable to unvested restricted share grants" } } }, "auth_ref": [] }, "uhs_NetIncomeExcludingRedeemableNoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "NetIncomeExcludingRedeemableNoncontrollingInterests", "crdr": "credit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Net income (loss) to UHS / noncontrolling interests", "documentation": "Net income excluding redeemable noncontrolling interests.", "label": "Net Income Excluding Redeemable Noncontrolling Interests" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureComputationOfBasicAndDilutedEarningsPerShareDetail", "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "totalLabel": "Net income attributable to UHS", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r90", "r101", "r126", "r144", "r162", "r165", "r169", "r183", "r191", "r195", "r196", "r197", "r198", "r199", "r202", "r203", "r215", "r297", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r464", "r469", "r493", "r517", "r642", "r737", "r758", "r759", "r889", "r1043" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "terseLabel": "Less: Net income (loss) attributable to noncontrolling interests", "totalLabel": "Net Income (Loss) Attributable to Noncontrolling Interest, Total", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r54", "r114", "r162", "r165", "r199", "r202", "r203", "r641", "r997" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureComputationOfBasicAndDilutedEarningsPerShareDetail" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic", "totalLabel": "Net income attributable to UHS - basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, of income (loss) available to common shareholders." } } }, "auth_ref": [ "r175", "r195", "r196", "r197", "r198", "r206", "r207", "r216", "r219", "r469" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureComputationOfBasicAndDilutedEarningsPerShareDetail" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "totalLabel": "Net income attributable to UHS - diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares, of income (loss) available to common shareholders." } } }, "auth_ref": [ "r175", "r208", "r211", "r212", "r213", "r214", "r216", "r219" ] }, "us-gaap_NetInvestmentHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetInvestmentHedgingMember", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/DisclosureSummaryOfEffectsOfForeignCurrencyForwardExchangeContractsOnResultOfOperationsDetail" ], "lang": { "en-us": { "role": { "label": "Net Investment Hedging [Member]", "terseLabel": "Net Investment Hedge", "documentation": "Hedges of a net investment in a foreign operation." } } }, "auth_ref": [ "r56" ] }, "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRecentAccountingStandards" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]", "terseLabel": "Recent Accounting Standards", "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle." } } } }, "auth_ref": [ "r137", "r142", "r189", "r190", "r193", "r194", "r204", "r205", "r261", "r299", "r300", "r462", "r463", "r465", "r469", "r487", "r490", "r545", "r547", "r548", "r590", "r591", "r592", "r677", "r678", "r679", "r680", "r681" ] }, "uhs_NewSeniorSecuredCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "NewSeniorSecuredCreditFacilityMember", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "New senior secured credit facility.", "label": "New Senior Secured Credit Facility [Member]", "terseLabel": "New Senior Secured Notes" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r940" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r904", "r914", "r924", "r948", "r956" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r931" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r930" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r948" ] }, "uhs_NonRule10B51ArrModifiedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "NonRule10B51ArrModifiedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "documentation": "Non rule 10b51 arr modified flag", "label": "Non Rule 10b51 Arr Modified Flag", "terseLabel": "Non-Rule 10b5-1 Arrangement Modified" } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r967" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r967" ] }, "us-gaap_NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1", "crdr": "debit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Noncash or Part Noncash Acquisition, Fixed Assets Acquired", "terseLabel": "Noncash purchases of property and equipment", "documentation": "The amount of fixed assets that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r28", "r29", "r30" ] }, "us-gaap_NoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestAbstract", "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestMember", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interest", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r49", "r375", "r1005", "r1006", "r1007", "r1009", "r1159" ] }, "uhs_NoticePeriodOnRenewalOfLease": { "xbrltype": "durationItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "NoticePeriodOnRenewalOfLease", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation2Detail" ], "lang": { "en-us": { "role": { "documentation": "Notice period on renewal of lease.", "label": "Notice Period On Renewal Of Lease", "terseLabel": "Notice period on renewal of lease" } } }, "auth_ref": [] }, "uhs_NumberOfBedsAvailableInAcuteCareHospital": { "xbrltype": "integerItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "NumberOfBedsAvailableInAcuteCareHospital", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation1Detail", "http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation3Detail" ], "lang": { "en-us": { "role": { "documentation": "Number of beds available in acute care hospital.", "label": "Number Of Beds Available In Acute Care Hospital", "terseLabel": "Number of beds available in acute care hospital" } } }, "auth_ref": [] }, "uhs_NumberOfBedsAvailableInBehavioralHealthCareFacility": { "xbrltype": "integerItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "NumberOfBedsAvailableInBehavioralHealthCareFacility", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation1Detail", "http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation2Detail" ], "lang": { "en-us": { "role": { "documentation": "Number of beds available in behavioral health care facility.", "label": "Number Of Beds Available In Behavioral Health Care Facility", "terseLabel": "Number of bed available in behavioral health care facility" } } }, "auth_ref": [] }, "uhs_NumberOfBedsAvailableInMicroHospital": { "xbrltype": "integerItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "NumberOfBedsAvailableInMicroHospital", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureDispositionsAndAcquisitionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Number of beds available in micro-hospital.", "label": "Number Of Beds Available In Micro Hospital", "terseLabel": "Number of beds available in micro-hospital" } } }, "auth_ref": [] }, "uhs_NumberOfBehavioralHealthCareHospitals": { "xbrltype": "integerItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "NumberOfBehavioralHealthCareHospitals", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Number of behavioral health care hospitals.", "label": "Number Of Behavioral Health Care Hospitals", "terseLabel": "Number of behavioral health care hospitals" } } }, "auth_ref": [] }, "uhs_NumberOfDaysToCompleteExchangeOffer": { "xbrltype": "durationItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "NumberOfDaysToCompleteExchangeOffer", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Number of days to complete exchange offer.", "label": "Number Of Days To Complete Exchange Offer", "terseLabel": "Number of days to complete exchange offer" } } }, "auth_ref": [] }, "uhs_NumberOfFreestandingEmergencyDepartmentsToBeAcquiredInBusinessAcquisition": { "xbrltype": "integerItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "NumberOfFreestandingEmergencyDepartmentsToBeAcquiredInBusinessAcquisition", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation3Detail" ], "lang": { "en-us": { "role": { "documentation": "Number of freestanding emergency departments to be acquired in business acquisition.", "label": "Number Of Freestanding Emergency Departments To Be Acquired In Business Acquisition", "terseLabel": "Number of free-standing emergency departments to be acquired" } } }, "auth_ref": [] }, "uhs_NumberOfHospitalFacilities": { "xbrltype": "integerItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "NumberOfHospitalFacilities", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Number of hospital facilities.", "label": "Number Of Hospital Facilities", "terseLabel": "Number of hospital facilities", "verboseLabel": "Number of hospital facilities" } } }, "auth_ref": [] }, "uhs_NumberOfLeaseRenewalOptionExercised": { "xbrltype": "integerItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "NumberOfLeaseRenewalOptionExercised", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustParentheticalDetail" ], "lang": { "en-us": { "role": { "documentation": "Number of lease renewal option exercised.", "label": "Number Of Lease Renewal Option Exercised", "terseLabel": "Number of lease renewal option exercised" } } }, "auth_ref": [] }, "uhs_NumberOfSquareFeetToBeAcquiredInMedicalOfficeBuilding": { "xbrltype": "integerItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "NumberOfSquareFeetToBeAcquiredInMedicalOfficeBuilding", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation3Detail" ], "lang": { "en-us": { "role": { "documentation": "Number of square feet to be acquired in edical office building.", "label": "Number Of Square Feet To Be Acquired In Medical Office Building",
```

```
"terseLabel": "Number of square feet to be acquired" } } }, "auth_ref": [] }, "uhs_NumberOfSquareFeetToBeConstructedInMedicalOfficeBuilding": { "xbrltype": "integerItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "NumberOfSquareFeetToBeConstructedInMedicalOfficeBuilding", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation3Detail" ], "lang": { "en-us": { "role": { "documentation": "Number of square feet to be constructed in medical office building.", "label": "Number Of Square Feet To Be Constructed In Medical Office Building", "terseLabel": "Number of square feet to be constructed" } } }, "auth_ref": [] }, "stpr_OH": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "OH", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureOtherNoncurrentLiabilitiesAndRedeemableNoncontrollingInterestsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "OHIO", "terseLabel": "Ohio" } } }, "auth_ref": [] }, "uhs_OneHospitalFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "OneHospitalFacilityMember", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "One hospital facility.", "label": "One Hospital Facility [Member]", "terseLabel": "One Hospital Facility" } } }, "auth_ref": [] }, "uhs_OneMonthLIBORRatePlusIndexBasedLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "OneMonthLIBORRatePlusIndexBasedLoansMember", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "One month libor rate plus index based loans.", "label": "One Month L I B O R Rate Plus Index Based Loans [Member]", "terseLabel": "One Month LIBOR Rate Plus Index Based Loans" } } }, "auth_ref": [] }, "uhs_OneMonthSOFRRatePlusIndexBasedLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "OneMonthSOFRRatePlusIndexBasedLoansMember", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "One month SOFR rate plus index based loans.", "label": "One Month S O F R Rate Plus Index Based Loans [Member]", "terseLabel": "One Month SOFR Rate Plus Index Based Loans" } } }, "auth_ref": [] }, "uhs_OnePointSixFivePercentSeniorSecuredNotesDueTwoThousandTwentySixMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "OnePointSixFivePercentSeniorSecuredNotesDueTwoThousandTwentySixMember", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "One point six five percent senior secured notes due two thousand twenty six.", "label": "One Point Six Five Percent Senior Secured Notes Due Two Thousand Twenty Six [Member]", "terseLabel": "1.65% Senior Secured Notes due 2026" } } }, "auth_ref": [] }, "uhs_OneThreeSixMonthLIBORRatePlusIndexBasedLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "OneThreeSixMonthLIBORRatePlusIndexBasedLoansMember", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "One three six month LIBOR rate plus index based loans.", "label": "One Three Six Month L I B O R Rate Plus Index Based Loans [Member]", "terseLabel": "One Three Six Month LIBOR Rate Plus Index Based Loans" } } }, "auth_ref": [] }, "uhs_OneThreeSixMonthSOFRRatePlusIndexBasedLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "OneThreeSixMonthSOFRRatePlusIndexBasedLoansMember", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "One three six month SOFR rate plus index based loans.", "label": "One Three Six Month S O F R Rate Plus Index Based Loans [Member]", "terseLabel": "One Three Six Month SOFR Rate Plus Index Based Loans" } } }, "auth_ref": [] }, "uhs_OneTwoThreeSixMonthLIBORRatePlusIndexBasedLoansMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "OneTwoThreeSixMonthLIBORRatePlusIndexBasedLoansMember", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "One two three six month libor rate plus index based loans.", "label": "One Two Three Six Month L I B O R Rate Plus Index Based Loans [Member]", "terseLabel": "One Two Three Six Month LIBOR Rate Plus Index Based Loans" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Operating Expenses, Total", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating charges:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Income from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r131", "r808", "r1012", "r1013", "r1014", "r1015", "r1016" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation2Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation3Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "verboseLabel": "Lease and rental expense", "terseLabel": "Annual Minimum Rent", "label": "Operating Lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r1105" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r534" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r534" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSupplementalCashFlowInformationRelatedToLeasesDetail" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r537", "r540" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right of use assets-operating leases", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r533" ] },
"uhs_OperatingLeasesAdditionalNumberOfRenewalOptionsAtFairMarketValueLeaseRates": { "xbrltype": "positiveIntegerItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "OperatingLeasesAdditionalNumberOfRenewalOptionsAtFairMarketValueLeaseRates", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustParentheticalDetail" ], "lang": { "en-us": { "role": {
"documentation": "Operating leases additional number of renewal options at fair market value lease rates.", "label": "Operating Leases Additional Number Of Renewal Options At Fair Market Value Lease Rates", "terseLabel": "Operating leases additional number of renewal options at fair market value lease rates" } } }, "auth_ref": [] },
"uhs_OperatingLeasesAdditionalRenewalOptionsAtFairMarketValueLeaseRatesExpirationDate": { "xbrltype": "dateItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "OperatingLeasesAdditionalRenewalOptionsAtFairMarketValueLeaseRatesExpirationDate", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation3Detail" ], "lang": { "en-us": { "role": { "terseLabel": "Operating leases additional renewal options at fair market value lease rates expiration date", "label": "Operating Leases Additional Renewal Options At Fair Market Value Lease Rates Expiration Date", "documentation": "Operating leases additional renewal options at fair market value lease rates expiration date." } } }, "auth_ref": [] },
"uhs_OperatingLeasesAdditionalRenewalOptionsAtFairMarketValueLeaseRatesExpirationYear": { "xbrltype": "gYearItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "OperatingLeasesAdditionalRenewalOptionsAtFairMarketValueLeaseRatesExpirationYear", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation3Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustParentheticalDetail" ], "lang": { "en-us": { "role": {
"documentation": "Operating leases additional renewal options at fair market value lease rates expiration year.", "label": "Operating Leases Additional Renewal Options At Fair Market Value Lease Rates Expiration Year", "terseLabel": "Operating leases additional renewal options at fair market value lease rates expiration year" } } }, "auth_ref": [] },
"uhs_OperatingLeasesAdditionalRenewalOptionsTermAtFairMarketValueLeaseRates": { "xbrltype": "durationItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "OperatingLeasesAdditionalRenewalOptionsTermAtFairMarketValueLeaseRates", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustParentheticalDetail" ], "lang": { "en-us": { "role": {
"documentation": "Operating leases additional renewal options term at fair market value lease rates.", "label": "Operating Leases Additional Renewal Options Term At Fair Market Value Lease Rates", "terseLabel": "Operating leases additional renewal options term at fair market value lease rates" } } }, "auth_ref": [] },
"uhs_OperatingLeasesNumberOfRenewalOptionsAtExistingLeaseRates": { "xbrltype": "positiveIntegerItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "OperatingLeasesNumberOfRenewalOptionsAtExistingLeaseRates", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustParentheticalDetail" ], "lang": { "en-us": { "role": {
"documentation": "Operating leases, number of renewal options at existing lease rates.", "label": "Operating Leases Number Of Renewal Options At Existing Lease Rates", "terseLabel": "Number of renewal options at existing lease rates" } } }, "auth_ref": [] }, "uhs_OperatingLeasesNumberOfRenewalOptionsAtFairMarketValueLeaseRates": { "xbrltype": "positiveIntegerItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "OperatingLeasesNumberOfRenewalOptionsAtFairMarketValueLeaseRates", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustParentheticalDetail" ], "lang": { "en-us": { "role": {
"documentation": "Operating leases, number of renewal options at fair market value lease rates.", "label": "Operating Leases Number Of Renewal Options At Fair Market Value Lease Rates", "terseLabel": "Number of renewal options at fair market lease rates" } } }, "auth_ref": [] }, "uhs_OperatingLeasesRenewalOptionsAtExistingLeaseRatesExpirationYear": { "xbrltype": "gYearItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "OperatingLeasesRenewalOptionsAtExistingLeaseRatesExpirationYear", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustParentheticalDetail" ], "lang": { "en-us": { "role": {
"documentation": "Operating leases, renewal options at existing lease rates, expiration year.", "label": "Operating Leases Renewal Options At Existing Lease Rates Expiration Year", "terseLabel": "Renewal options at existing lease rates expiration year" } } }, "auth_ref": [] }, "uhs_OperatingLeasesRenewalOptionsAtFairMarketValueLeaseRatesExpirationYear": { "xbrltype": "gYearItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "OperatingLeasesRenewalOptionsAtFairMarketValueLeaseRatesExpirationYear", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustParentheticalDetail" ], "lang": { "en-us": { "role": {
"documentation": "Operating leases, renewal options at fair market value lease rates, expiration year.", "label": "Operating Leases Renewal Options At Fair Market Value Lease Rates Expiration Year", "terseLabel": "Renewal options at fair market value lease rates expiration year" } } }, "auth_ref": [] }, "uhs_OperatingLeasesRenewalOptionsTermAtExistingLeaseRates": { "xbrltype": "durationItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "OperatingLeasesRenewalOptionsTermAtExistingLeaseRates", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustParentheticalDetail" ], "lang": { "en-us": { "role": {
"documentation": "Operating leases, renewal options term at existing lease rates.", "label": "Operating Leases Renewal Options Term At Existing Lease Rates", "terseLabel": "Renewal options term at existing lease rates" } } }, "auth_ref": [] }, "uhs_OperatingLeasesRenewalOptionsTermAtFairMarketValueLeaseRates": { "xbrltype": "durationItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "OperatingLeasesRenewalOptionsTermAtFairMarketValueLeaseRates", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation3Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustParentheticalDetail" ], "lang": { "en-us": { "role": {
"documentation": "Operating leases, renewal options term at fair market value lease rates.", "label": "Operating Leases Renewal Options Term At Fair Market Value Lease Rates", "terseLabel": "Renewal options term at fair market lease rates" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Assets, Current", "terseLabel": "Other current assets", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r158", "r860" ] }, "us-gaap_OtherAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfAssetsAndLiabilitiesRecordedAtFairValueOnRecurringBasisDetail" ], "lang": { "en-us": { "role": { "label": "Other Assets [Member]", "terseLabel": "Other Assets", "documentation": "Primary financial statement caption encompassing other assets." } } }, "auth_ref": [ "r57", "r62" ] }, "us-gaap_OtherAssetsMiscellaneousNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsMiscellaneousNoncurrent", "crdr": "debit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Assets, Miscellaneous, Noncurrent", "terseLabel": "Other", "documentation": "Amount of other miscellaneous assets expected to be realized or consumed after one year or normal operating cycle, if
```

```
longer." } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherAssetsNoncurrentAbstract", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": {
"role": { "label": "Other Assets, Noncurrent [Abstract]", "terseLabel": "Other assets:" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossBeforeTax": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossBeforeTax", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Other
Comprehensive Income (Loss), before Tax", "totalLabel": "Other comprehensive income (loss) before tax", "documentation": "Amount before tax, after reclassification adjustments of other
comprehensive income (loss)." } } }, "auth_ref": [ "r170", "r518", "r519", "r524", "r625", "r643", "r995", "r996" ] }, "us-
gaap_OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherComprehensiveIncomeLossBeforeTaxPeriodIncreaseDecreaseAbstract", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Other
Comprehensive Income (Loss), before Tax [Abstract]", "terseLabel": "Other comprehensive income (loss):" } } }, "auth_ref": [] }, "us-
gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureSummaryOfEffectsOfForeignCurrencyForwardExchangeContractsOnResultOfOperationsDetail" ], "lang": { "en-us": {
"role": { "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Gain/(Loss) recognized in AOCI", "documentation":
"Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [
"r160", "r161", "r478", "r479", "r481" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Other
Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax", "terseLabel": "Foreign currency translation adjustment", "totalLabel": "Other
Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Total", "documentation": "Amount before tax, after reclassification adjustments of gain
(loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign
currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r2", "r86", "r643" ] }, "us-
gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Other
Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Foreign currency translation adjustments, net of income tax", "totalLabel":
"Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total", "documentation": "Amount after tax and reclassification adjustments of gain
(loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign
currency transactions that are of a long-term investment nature." } } }, "auth_ref": [ "r2", "r643" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "label": "Other
Comprehensive Income (Loss), Net of Tax", "totalLabel": "Total other comprehensive (loss) income, net of tax", "documentation": "Amount after tax and reclassification adjustments of other
comprehensive income (loss)." } } }, "auth_ref": [ "r15", "r18", "r163", "r166", "r170", "r199", "r518", "r519", "r524", "r625", "r643", "r995", "r996" ] }, "us-
gaap_OtherComprehensiveIncomeLossTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossTax", "crdr": "debit",
"presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": {
"label": "Other Comprehensive Income (Loss), Tax", "terseLabel": "Income tax expense (benefit) related to items of other comprehensive income (loss)", "totalLabel": "Other Comprehensive
Income (Loss), Tax, Total", "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss)." } } }, "auth_ref": [ "r3", "r167", "r170", "r438", "r454", "r455",
"r518", "r522", "r524", "r625", "r643" ] }, "uhs_OtherComprehensiveIncomeOther": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname":
"OtherComprehensiveIncomeOther", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Other",
"label": "Other Comprehensive Income Other", "documentation": "Other comprehensive income other." } } }, "auth_ref": [] }, "uhs_OtherComprehensiveIncomeOtherBeforeTax": { "xbrltype":
"monetaryItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "OtherComprehensiveIncomeOtherBeforeTax", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Other",
"label": "Other Comprehensive Income Other Before Tax", "documentation": "Other comprehensive income other before tax." } } }, "auth_ref": [] }, "us-gaap_OtherCostAndExpenseOperating": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCostAndExpenseOperating", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "label": "Other Cost and Expense,
Operating", "terseLabel": "Other operating expenses", "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue
producing operation." } } }, "auth_ref": [ "r91", "r649", "r813" ] }, "us-gaap_OtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherCurrentAssetsMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfAssetsAndLiabilitiesRecordedAtFairValueOnRecurringBasisDetail" ], "lang": { "en-us": { "role": {
"label": "Other Current Assets [Member]", "terseLabel": "Other Current Assets", "documentation": "Primary financial statement caption encompassing other current assets." } } }, "auth_ref": [
"r57", "r62" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit",
"presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Liabilities,
Noncurrent", "terseLabel": "Other noncurrent liabilities", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } },
"auth_ref": [ "r77" ] }, "uhs_OtherNonPatientRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname":
"OtherNonPatientRevenueMember", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureScheduleOfDisaggregatesRevenueByMajorSourceDetail" ],
"lang": { "en-us": { "role": { "documentation": "Other non-patient revenue.", "label": "Other Non Patient Revenue [Member]", "terseLabel": "Other Non-patient Revenue" } } }, "auth_ref": [] },
"us-gaap_OtherNoncurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncurrentAssetsMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfAssetsAndLiabilitiesRecordedAtFairValueOnRecurringBasisDetail" ], "lang": { "en-us": { "role": {
"terseLabel": "Other Noncurrent Assets", "label": "Other Noncurrent Assets [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent assets." } } },
"auth_ref": [] }, "uhs_OtherNoncurrentLiabilitiesAndRedeemableNoncontrollingInterestsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.universalhealthservices/20240930",
"localname": "OtherNoncurrentLiabilitiesAndRedeemableNoncontrollingInterestsTextBlock", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureOtherNoncurrentLiabilitiesAndRedeemableNoncontrollingInterests" ], "lang": { "en-us": { "role": {
"documentation": "Other noncurrent liabilities and redeemable noncontrolling interests.", "label": "Other Noncurrent Liabilities And Redeemable Noncontrolling Interests [Text Block]",
"terseLabel": "Other Noncurrent liabilities and Redeemable/Noncontrolling Interests" } } }, "auth_ref": [] }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncurrentLiabilitiesMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfAssetsAndLiabilitiesRecordedAtFairValueOnRecurringBasisDetail" ], "lang": { "en-us": { "role": {
"label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other Noncurrent Liabilities", "documentation": "Primary financial statement caption encompassing other noncurrent liabilities."
} } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherNonoperatingIncomeExpense", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income
(Expense)", "negatedLabel": "Other (income) expense, net", "totalLabel": "Other Nonoperating Income (Expense), Total", "documentation": "Amount of income (expense) related to nonoperating
activities, classified as other." } } }, "auth_ref": [ "r93" ] }, "us-gaap_OtherOperatingIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherOperatingIncome", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"
], "lang": { "en-us": { "role": { "terseLabel": "Pre-tax share of income from the Trust", "label": "Other Operating Income", "documentation": "The total amount of other operating income, the
components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operation." } } }, "auth_ref": [ "r87" ] },
"us-gaap_OtherOperatingIncomeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingIncomeExpenseMember",
"presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation4Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"
], "lang": { "en-us": { "role": { "label": "Other Operating Income (Expense) [Member]", "terseLabel": "Other (Income) Expense, Net", "documentation": "Primary financial statement caption
encompassing other operating income (expense)." } } }, "auth_ref": [] }, "uhs_OtherPatientRevenueAndAdjustmentsNetMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.universalhealthservices/20240930", "localname": "OtherPatientRevenueAndAdjustmentsNetMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureScheduleOfDisaggregatesRevenueByMajorSourceDetail" ], "lang": { "en-us": { "role": { "documentation": "Other
patient revenue and adjustments net.", "label": "Other Patient Revenue And Adjustments Net [Member]", "terseLabel": "Other Patient Revenue and Adjustments, Net" } } }, "auth_ref": [] },
"ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref":
[ "r940" ] }, "uhs_OtherRelatedPartyTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname":
"OtherRelatedPartyTransactionsMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"
], "lang": { "en-us": { "role": { "documentation": "Other related party transactions.", "label": "Other Related Party Transactions [Member]", "terseLabel": "Other Related Party Transactions" } }
}, "auth_ref": [] }, "uhs_OtherStatesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "OtherStatesMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation":
"Other states.", "label": "Other States [Member]", "terseLabel": "OTHER STATES" } } }, "auth_ref": [] }, "uhs_OutsideOwnersMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.universalhealthservices/20240930", "localname": "OutsideOwnersMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureOtherNoncurrentLiabilitiesAndRedeemableNoncontrollingInterestsAdditionalInformationDetail" ], "lang": { "en-
us": { "role": { "documentation": "Outside owners.", "label": "Outside Owners [Member]", "terseLabel": "Outside Owners" } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": {
"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ],
"lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [
"r902", "r912", "r922", "r954" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount",
"terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r905", "r915", "r925", "r957" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label":
"Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r905", "r915", "r925", "r957" ] }, "uhs_OverheadAllocationsAdjustment": { "xbrltype": "monetaryItemType",
"nsuri": "http://www.universalhealthservices/20240930", "localname": "OverheadAllocationsAdjustment", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSegmentReportingDetail" ], "lang": { "en-us": { "role": { "documentation": "Costs and expenses incurred associated
with centralized services and general corporate overhead allocated to divisions.", "label": "Overhead Allocations Adjustment", "negatedLabel": "Allocation of corporate overhead" } } },
"auth_ref": [] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipAxis", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation3Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureDispositionsAndAcquisitionsAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureOtherNoncurrentLiabilitiesAndRedeemableNoncontrollingInterestsAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"
], "lang": { "en-us": { "role": { "label": "Ownership [Axis]", "terseLabel": "Ownership" } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "OwnershipDomain", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation3Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureDispositionsAndAcquisitionsAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureOtherNoncurrentLiabilitiesAndRedeemableNoncontrollingInterestsAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"
```

```
], "lang": { "en-us": { "role": { "label": "Ownership [Domain]", "terseLabel": "Ownership" } } }, "auth_ref": [] }, "stpr_PA": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "PA", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail", "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureOtherNoncurrentLiabilitiesAndRedeemableNoncontrollingInterestsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "PENNSYLVANIA", "terseLabel": "Pennsylvania" } } }, "auth_ref": [] }, "country_PR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "PR", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "PUERTO RICO", "terseLabel": "PUERTO RICO" } } }, "auth_ref": [] }, "us-gaap_ParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ParentMember", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Parent [Member]", "terseLabel": "UHS Common Stockholders' Equity", "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests." } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r929" ] }, "uhs_PaymentForProceedsFromPurchaseOfInformationTechnologyApplications": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "PaymentForProceedsFromPurchaseOfInformationTechnologyApplications", "crdr": "credit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Payment for proceeds from purchase of information technology applications.", "label": "Payment For Proceeds From Purchase Of Information Technology Applications", "negatedLabel": "Costs incurred for purchase of information technology applications, net of refunds" } } }, "auth_ref": [] }, "us-gaap_PaymentsForLegalSettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForLegalSettlements", "crdr": "credit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Payments for Legal Settlements", "terseLabel": "Repayment of legal settlement amount on demand", "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period." } } }, "auth_ref": [ "r8" ] }, "us-gaap_PaymentsForProceedsFromHedgeInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromHedgeInvestingActivities", "crdr": "credit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Outflows from foreign exchange contracts that hedge our net U.K. investment", "label": "Payments for (Proceeds from) Hedge, Investing Activities", "totalLabel": "Payments for (Proceeds from) Hedge, Investing Activities, Total", "documentation": "The cash outflow or inflow for a financial contract that meets the hedge criteria as either a cash flow hedge, fair value hedge, or hedge of a net investment in a foreign operation." } } }, "auth_ref": [] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Repurchase of common shares", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r97" ] }, "us-gaap_PaymentsOfDividendsCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDividendsCommonStock", "crdr": "credit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Dividends paid", "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity." } } }, "auth_ref": [ "r97" ] }, "us-gaap_PaymentsOfDividendsMinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDividendsMinorityInterest", "crdr": "credit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments of Ordinary Dividends, Noncontrolling Interest", "negatedLabel": "Profit distributions to noncontrolling interests", "documentation": "Amount of cash outflow in the form of ordinary dividends provided by the non-wholly owned subsidiary to noncontrolling interests." } } }, "auth_ref": [ "r97" ] }, "us-gaap_PaymentsOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfFinancingCosts", "crdr": "credit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments of Financing Costs", "negatedLabel": "Financing costs", "totalLabel": "Payments of Financing Costs, Total", "documentation": "The cash outflow for loan and debt issuance costs." } } }, "auth_ref": [ "r25" ] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureDispositionsAndAcquisitionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Acquisition, cash paid", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r23", "r467" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedLabel": "Acquisition of businesses and property", "totalLabel": "Payments to Acquire Businesses, Net of Cash Acquired, Total", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r23" ] }, "us-gaap_PaymentsToAcquireLifeInsurancePolicies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireLifeInsurancePolicies", "crdr": "credit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation4Detail" ], "lang": { "en-us": { "role": { "label": "Payment to Acquire Life Insurance Policy, Investing Activities", "terseLabel": "Payments to acquire life insurance policies, net", "documentation": "Amount of cash outflow for payment of premium on corporate-owned life insurance policy, classified as investing activities. Includes, but is not limited to, bank-owned life insurance policy." } } }, "auth_ref": [ "r7", "r95" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Property and equipment additions", "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r96" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r939" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r939" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r931" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r948" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r941" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r930" ] }, "uhs_PercentageOfAdvisoryFeeOnAverageInvestedRealEstateAssets": { "xbrltype": "percentItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "PercentageOfAdvisoryFeeOnAverageInvestedRealEstateAssets", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Percentage of advisory fee on average invested real estate assets.", "label": "Percentage Of Advisory Fee On Average Invested Real Estate Assets", "terseLabel": "Percentage of advisory fee on average invested real estate assets" } } }, "auth_ref": [] }, "uhs_PercentageOfAnnualRentalIncreaseOnCumulativeAndCompoundBasis": { "xbrltype": "percentItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "PercentageOfAnnualRentalIncreaseOnCumulativeAndCompoundBasis", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation3Detail", "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustParentheticalDetail" ], "lang": { "en-us": { "role": { "documentation": "Percentage of annual rental increase on cumulative and compound basis.", "label": "Percentage Of Annual Rental Increase On Cumulative And Compound Basis", "terseLabel": "Percentage of annual rental increase on cumulative and compound basis" } } }, "auth_ref": [] }, "uhs_PercentageOfInsuranceDeductible": { "xbrltype": "percentItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "PercentageOfInsuranceDeductible", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Percentage of insurance deductible.", "label": "Percentage Of Insurance Deductible", "terseLabel": "Percentage of insurance deductible" } } }, "auth_ref": [] }, "uhs_PercentageOfMasterLeaseRentableSquareFeetOfMedicalOfficeBuilding": { "xbrltype": "percentItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "PercentageOfMasterLeaseRentableSquareFeetOfMedicalOfficeBuilding", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation3Detail" ], "lang": { "en-us": { "role": { "documentation": "Percentage of master lease rentable square feet of medical office building.", "label": "Percentage Of Master Lease Rentable Square Feet Of Medical Office Building", "terseLabel": "Percentage of master lease rentable square feet" } } }, "auth_ref": [] }, "uhs_PerformanceBasedRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "PerformanceBasedRestrictedStockUnitsMember", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/DisclosureEarningsPerShareDataAndStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Performance based restricted stock units.", "label": "Performance Based Restricted Stock Units [Member]", "terseLabel": "Performance Based Restricted Stock Units" } } }, "auth_ref": [] }, "uhs_PeriodOfRightsOfRefusalToLeasedFacilities": { "xbrltype": "durationItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "PeriodOfRightsOfRefusalToLeasedFacilities", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation2Detail" ], "lang": { "en-us": { "role": { "documentation": "Period of rights of refusal to leased facilities.", "label": "Period Of Rights Of Refusal To Leased Facilities", "terseLabel": "Period of rights of refusal to leased facilities" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/DisclosureEarningsPerShareDataAndStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/DisclosureEarningsPerShareDataAndStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": [ "r932" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": [ "r976" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r931" ] }, "uhs_PreTaxDecreaseToReservesForSelfInsuredWorkersCompensationLiabilityClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "PreTaxDecreaseToReservesForSelfInsuredWorkersCompensationLiabilityClaims", "crdr": "debit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-tax decrease to reserves for self-insured workers' compensation liability claims", "label": "Pre-tax Decrease To Reserves For Self-insured Workers' Compensation Liability Claims", "documentation": "Pre-tax decrease to reserves for self-insured workers' compensation liability claims." } } }, "auth_ref": [] }, "uhs_PremierIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "PremierIncMember", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation4Detail", "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Premier, Inc.", "label": "Premier Inc [Member]", "terseLabel": "Premier, Inc." } } }, "auth_ref": [] }, "us-gaap_PrincipalAmountOutstandingOnLoansSecuritized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrincipalAmountOutstandingOnLoansSecuritized", "crdr": "credit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Loan, Securitized or Asset-Backed Financing Arrangement, Principal Outstanding", "terseLabel": "Accounts receivable securitization program credit facility, amount outstanding", "documentation": "This is the principal amount outstanding for securitized loans only (across all types of loans)." } } }, "auth_ref": [ "r17" ] }, "us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested": { "xbrltype":
```

```
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromDivestitureOfBusinessesNetOfCashDivested", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureDispositionsAndAcquisitionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Proceeds from Divestiture of Businesses, Net of Cash Divested", "terseLabel": "Aggregate cash proceeds from divestiture of businesses", "totalLabel": "Proceeds from Divestiture of Businesses, Net of Cash Divested, Total", "documentation": "This element represents the cash inflow during the period from the sale of a component of the entity." } } }, "auth_ref": [ "r22" ] }, "us-gaap_ProceedsFromDividendsReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromDividendsReceived", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Proceeds from Dividends Received", "terseLabel": "Dividends received from the Trust", "documentation": "Dividends received on equity and other investments during the current period." } } }, "auth_ref": [ "r999" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Issuance of common stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r4" ] }, "us-gaap_ProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromLinesOfCredit", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Lines of Credit", "terseLabel": "Additional borrowings, net", "totalLabel": "Proceeds from Lines of Credit, Total", "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r24", "r1003" ] }, "us-gaap_ProceedsFromPaymentsToMinorityShareholders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromPaymentsToMinorityShareholders", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from (Payments to) Noncontrolling Interests", "totalLabel": "Proceeds from (Payments to) Noncontrolling Interests, Total", "terseLabel": "Sale of ownership interests to minority members", "documentation": "Amount of cash inflow (outflow) from (to) a noncontrolling interest. Excludes dividends paid to the noncontrolling interest." } } }, "auth_ref": [] }, "uhs_ProceedsFromSaleOfAssetsAndBusiness": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "ProceedsFromSaleOfAssetsAndBusiness", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Proceeds from sale of assets and business.", "label": "Proceeds From Sale Of Assets And Business", "terseLabel": "Proceeds received from sales of assets and businesses" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfRealEstate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfRealEstate", "crdr": "debit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation1Detail" ], "lang": { "en-us": { "role": { "label": "Proceeds from Sale of Real Estate", "terseLabel": "Cash received for sale of real estate asset", "documentation": "Cash received for the sale of real estate that is not part of an investing activity during the current period." } } }, "auth_ref": [ "r94" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureScheduleOfDisaggregatesRevenueByMajorSourceDetail" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service" } } }, "auth_ref": [ "r256", "r589", "r662", "r663", "r664", "r665", "r666", "r667", "r669", "r802", "r828", "r870", "r871", "r873", "r876", "r877", "r1038", "r1039", "r1049", "r1124", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150", "r1151", "r1152", "r1153", "r1154", "r1156", "r1157" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureScheduleOfDisaggregatesRevenueByMajorSourceDetail" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service" } } }, "auth_ref": [ "r256", "r589", "r662", "r663", "r664", "r665", "r666", "r667", "r669", "r802", "r828", "r870", "r871", "r873", "r876", "r877", "r1038", "r1039", "r1049", "r1124", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150", "r1151", "r1152", "r1153", "r1154", "r1156", "r1157" ] }, "us-gaap_ProfessionalMalpracticeLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfessionalMalpracticeLiabilityMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Professional Malpractice Liability Insurance [Member]", "terseLabel": "Professional Liability", "documentation": "Business insurance coverage for professionals, such as doctors, lawyers, insurance agents, accountants, real estate agents, veterinarians, and others. This liability coverage insures losses for claims arising from mistakes and errors or omissions in the course of professional activities." } } }, "auth_ref": [] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfComprehensiveIncome",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income", "totalLabel": "Net income", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r144", "r162", "r165", "r177", "r183", "r191", "r199", "r202", "r203", "r297", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r464", "r469", "r471", "r474", "r475", "r493", "r517", "r630", "r640", "r693", "r737", "r758", "r759", "r844", "r845", "r890", "r997", "r1043" ] }, "uhs_ProjectedAggregateDevelopmentAndConstructionCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "ProjectedAggregateDevelopmentAndConstructionCost", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Projected aggregate development and construction cost.", "label": "Projected aggregate development and construction cost", "terseLabel": "Projected aggregate development and construction cost" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r11", "r542" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment", "totalLabel": "Property, Plant and Equipment, Gross, Total", "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance", "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r105", "r148", "r638" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "totalLabel": "Property, plant and equipment, net, Total", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r11", "r542", "r631", "r638", "r860" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r105", "r542" ] }, "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseByMajorPropertyClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertySubjectToOrAvailableForOperatingLeaseByMajorPropertyClassTable", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Property, Plant, and Equipment, Lessor Asset under Operating Lease [Table]", "terseLabel": "Property Subject To Or Available For Operating Lease By Major Property Class [Table]", "documentation": "Disclosure of information about lessor's underlying asset for which right to use has been conveyed to lessee under operating lease." } } }, "auth_ref": [ "r133", "r327", "r544" ] }, "us-gaap_PropertySubjectToOrAvailableForOperatingLeaseLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertySubjectToOrAvailableForOperatingLeaseLineItems", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Property, Plant, and Equipment, Lessor Asset under Operating Lease [Line Items]", "terseLabel": "Property Subject to or Available for Operating Lease [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r133", "r327", "r544" ] }, "uhs_PunitiveDamagesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "PunitiveDamagesMember", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureGeneralAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Punitive Damages", "label": "punitive damages [Member]", "documentation": "Punitive damages." } } }, "auth_ref": [] }, "uhs_PurchaseOfMinorityOwnershipInterestPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "PurchaseOfMinorityOwnershipInterestPercentage", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Purchase of minority ownership interest percentage.", "label": "Purchase Of Minority Ownership Interest Percentage", "terseLabel": "Purchase of minority ownership interest percentage" } } }, "auth_ref": [] }, "uhs_PurchaseSaleOfOwnershipInterestsByFromMinorityMembers": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "PurchaseSaleOfOwnershipInterestsByFromMinorityMembers", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "Purchase (sale) of ownership interests by (from) minority members.", "label": "Purchase Sale Of Ownership Interests By From Minority Members", "negatedLabel": "Purchase (sale) of ownership interests by (from) minority members" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r929" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r929" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation3Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation4Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustParentheticalDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement" } } }, "auth_ref": [ "r336", "r337", "r338", "r339", "r387", "r395", "r423", "r424", "r425", "r433", "r499", "r563", "r572", "r588", "r670", "r672", "r682", "r710", "r711", "r766", "r768", "r770", "r771", "r779", "r799", "r800", "r818", "r827", "r840", "r851", "r852", "r856", "r857", "r871", "r880", "r1033", "r1047", "r1089", "r1115", "r1116", "r1117", "r1118", "r1119" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation3Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation4Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail",
```

```
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustParentheticalDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]",
"terseLabel": "Statistical Measurement" } } }, "auth_ref": [ "r336", "r337", "r338", "r339", "r387", "r395", "r423", "r424", "r425", "r433", "r499", "r563", "r572", "r588", "r670", "r672", "r682",
"r710", "r711", "r766", "r768", "r770", "r771", "r779", "r799", "r800", "r818", "r827", "r840", "r851", "r852", "r856", "r857", "r871", "r880", "r1033", "r1047", "r1089", "r1115", "r1116", "r1117",
"r1118", "r1119" ] }, "uhs_RateAdjustmentToFederalFundsRateWeightedAverage": { "xbrltype": "percentItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname":
"RateAdjustmentToFederalFundsRateWeightedAverage", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ],
"lang": { "en-us": { "role": { "documentation": "Rate adjustment to federal funds rate weighted average.", "label": "Rate Adjustment To Federal Funds Rate Weighted Average", "terseLabel":
"Rate adjustment to weighted average federal funds rate for credit facility borrowings" } } }, "auth_ref": [] }, "uhs_RateAdjustmentToOneMonthEurodollarRateOnCreditFacilityBorrowings": {
"xbrltype": "percentItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "RateAdjustmentToOneMonthEurodollarRateOnCreditFacilityBorrowings", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Rate adjustment to one
month Eurodollar rate on credit facility borrowings.", "label": "Rate Adjustment To One Month Eurodollar Rate On Credit Facility Borrowings", "terseLabel": "Rate adjustment to one month
Eurodollar rate on credit facility borrowings" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery
of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r897", "r907", "r917", "r949" ] }, "uhs_RedeemableInterestMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.universalhealthservices/20240930", "localname": "RedeemableInterestMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation":
"Redeemable interest.", "label": "Redeemable Interest [Member]", "terseLabel": "Redeemable Noncontrolling Interest" } } }, "auth_ref": [] },
"uhs_RedeemableNonControllingInterestDistributions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname":
"RedeemableNonControllingInterestDistributions", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "negatedLabel":
"Distributions to noncontrolling interests", "label": "Redeemable Non controlling Interest, Distributions", "documentation": "Redeemable non-controlling interest, distributions." } } },
"auth_ref": [] }, "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RedeemableNoncontrollingInterestEquityCarryingAmount", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureOtherNoncurrentLiabilitiesAndRedeemableNoncontrollingInterestsAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Redeemable
Noncontrolling Interest, Equity, Carrying Amount", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "terseLabel": "Redeemable non-controlling interest balances", "totalLabel":
"Redeemable Noncontrolling Interest, Equity, Carrying Amount, Total", "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are
redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an
event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest
(common, preferred, other) including all potential organizational (legal) forms of the investee entity." } } }, "auth_ref": [ "r30", "r40", "r107", "r108" ] }, "us-gaap_RelatedPartyDomain": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation1Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation2Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation3Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation4Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"
], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Domain]", "terseLabel": "Related Party", "documentation": "Related and nonrelated parties. Related party includes, but is
not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family,
and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r262", "r394", "r552", "r553",
"r633", "r636", "r713", "r714", "r715", "r716", "r717", "r734", "r736", "r765" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation1Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation2Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation3Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation4Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"
], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial
concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r262",
"r741", "r742", "r745" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract",
"lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation1Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation2Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation3Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation4Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"
], "lang": { "en-us": { "role": { "label": "Related and Nonrelated Parties [Axis]", "terseLabel": "Related Party", "documentation": "Information by related and nonrelated parties. Related party
includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of
immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r262", "r394",
"r552", "r553", "r633", "r636", "r713", "r714", "r715", "r716", "r717", "r734", "r736", "r765", "r1111" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactions" ], "lang": { "en-us": {
"role": { "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Relationship with Universal Health Realty Income Trust and Other Related Party Transactions",
"documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary, (b)
subsidiaries of a common parent, (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r549", "r550", "r551", "r553", "r554", "r689", "r690", "r691", "r743", "r744",
"r745", "r763", "r764" ] }, "uhs_RemainingTwoRenewalOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname":
"RemainingTwoRenewalOptionsMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation3Detail" ],
"lang": { "en-us": { "role": { "terseLabel": "Remaining Two Renewal Options", "label": "Remaining Two Renewal Options [Member]", "documentation": "Remaining two renewal options." } } },
"auth_ref": [] }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermDebt", "crdr":
"credit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label":
"Repayments of Long-Term Debt", "negatedLabel": "Repayments of long-term debt", "totalLabel": "Repayments of Long-Term Debt, Total", "documentation": "The cash outflow for debt initially
having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r98", "r687" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement
Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r898", "r908", "r918", "r950" ] }, "ecd_RestatementDeterminationDate": { "xbrltype":
"dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": {
"role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r899", "r909", "r919", "r951" ] },
"ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require
Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r906", "r916", "r926", "r958" ] }, "us-gaap_RestrictedCash": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCash", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfCashCashEquivalentsAndRestrictedCashReportedInCondensedConsolidatedStatementsOfCashFlowsDeta
], "lang": { "en-us": { "role": { "label": "Restricted Cash", "terseLabel": "Restricted cash", "totalLabel": "Restricted Cash, Total", "documentation": "Amount of cash restricted as to withdrawal or
usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } },
"auth_ref": [ "r992", "r1001", "r1120", "r1123" ] }, "us-gaap_RestrictedCashAssetStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAssetStatementOfFinancialPositionExtensibleList", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfCashCashEquivalentsAndRestrictedCashReportedInCondensedConsolidatedStatementsOfCashFlowsDeta
], "lang": { "en-us": { "role": { "label": "Restricted Cash, Statement of Financial Position [Extensible Enumeration]", "terseLabel": "Restricted Cash, Statement of Financial Position [Extensible
Enumeration]", "documentation": "Indicates line item in statement of financial position that includes cash restricted to withdrawal or usage." } } }, "auth_ref": [ "r1001" ] },
"uhs_RestrictedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname":
"RestrictedShareBasedCompensationExpense", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation":
"Restricted share based compensation expense.", "label": "Restricted Share Based Compensation Expense", "terseLabel": "Restricted share-based compensation expense" } } }, "auth_ref": [] },
"uhs_RestrictedStockAwardsRestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.universalhealthservices/20240930", "localname": "RestrictedStockAwardsRestrictedStockUnitsAndPerformanceBasedRestrictedStockUnitsMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureEarningsPerShareDataAndStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"documentation": "Restricted stock awards, restricted stock units and performance based restricted stock units.", "label": "Restricted Stock Awards Restricted Stock Units And Performance
Based Restricted Stock Units [Member]", "terseLabel": "Restricted Stock Awards, Restricted Stock Units and Performance Based Restricted Stock Units" } } }, "auth_ref": [] }, "us-
gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureEarningsPerShareDataAndStockBasedCompensationAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation4Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"
], "lang": { "en-us": { "role": { "label": "Restricted Stock [Member]", "terseLabel": "Restricted Stock", "documentation": "Stock including a provision that prohibits sale or substantive sale of an
equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r31" ] }, "us-gaap_RetainedEarningsAppropriatedMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAppropriatedMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings,
Appropriated [Member]", "terseLabel": "Retained Earnings", "documentation": "Accumulated undistributed earnings (deficit) not available for dividend distribution. Includes, but is not limited
to, retained earnings appropriated for specific business purpose." } } }, "auth_ref": [ "r41", "r81" ] }, "us-gaap_RetainedEarningsUnappropriatedMember": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsUnappropriatedMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Retained Earnings,
Unappropriated [Member]", "terseLabel": "Cumulative Dividends", "documentation": "Accumulated undistributed earnings available for dividend distribution. Includes, but is not limited
to, retained earnings not appropriated for specific business purpose." } } }, "auth_ref": [ "r92" ] }, "uhs_ReturnOfFundsByCARESActToGovernment": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.universalhealthservices/20240930", "localname": "ReturnOfFundsByCARESActToGovernment", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureGeneralAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Return of funds by CARES
Act to government.", "label": "Return Of Funds By C A R E S Act To Government", "terseLabel": "Return of funds by CARES Act to government" } } }, "auth_ref": [] }, "us-
gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang":
{ "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": [
```

```
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureScheduleOfDisaggregatesRevenueByMajorSourceDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSegmentReportingDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSegmentReportingParentheticalDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "verboseLabel": "Total net revenues",
"label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Net revenues", "documentation": "Amount, excluding tax collected from customer, of revenue from
satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and
concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r129", "r130", "r222", "r231", "r232", "r247",
"r253", "r256", "r258", "r260", "r384", "r385", "r589" ] }, "uhs_RevenueFromContractWithCustomerExcludingAssessedTaxPercentage": { "xbrltype": "percentItemType", "nsuri":
"http://www.universalhealthservices/20240930", "localname": "RevenueFromContractWithCustomerExcludingAssessedTaxPercentage", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureScheduleOfDisaggregatesRevenueByMajorSourceDetail" ], "lang": { "en-us": { "role": { "documentation": "Revenue
from contract with customer excluding assessed tax percentage.", "label": "Revenue From Contract With Customer Excluding Assessed Tax Percentage", "terseLabel": "Percentage of Net
Revenue" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRevenue" ], "lang": { "en-us": { "role": { "label":
"Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and
to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to
contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r138", "r376", "r377",
"r378", "r379", "r380", "r381", "r382", "r383", "r386" ] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"RevolvingCreditFacilityMember", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": {
"role": { "label": "Revolving Credit Facility [Member]", "terseLabel": "Revolving Credit Facility", "documentation": "Arrangement in which loan proceeds can continuously be obtained following
repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSupplementalCashFlowInformationRelatedToLeasesDetail" ], "lang": { "en-us": { "role": { "label": "Right-of-Use
Asset Obtained in Exchange for Finance Lease Liability", "terseLabel": "Finance leases", "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease
liability." } } }, "auth_ref": [ "r541", "r859" ] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSupplementalCashFlowInformationRelatedToLeasesDetail" ], "lang": { "en-us": { "role": { "label": "Right-of-Use
Asset Obtained in Exchange for Operating Lease Liability", "verboseLabel": "Operating leases", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating
lease liability." } } }, "auth_ref": [ "r541", "r859" ] }, "uhs_RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://www.universalhealthservices/20240930", "localname": "RightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSupplementalCashFlowInformationRelatedToLeasesDetail" ], "lang": { "en-us": { "role": { "documentation": "Right
of use assets obtained in exchange for lease obligations.", "label": "Right Of Use Assets Obtained In Exchange For Lease Obligations [Abstract]", "terseLabel": "Right-of-use assets obtained in
exchange for lease obligations:" } } }, "auth_ref": [] }, "uhs_Rule10B51ArrModifiedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname":
"Rule10B51ArrModifiedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "documentation": "Rule 10b51 arr modified flag.",
"label": "Rule 10b51 Arr Modified Flag", "terseLabel": "Rule 10b5-1 Arrangement Modified" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": {
"label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r967" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": {
"label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r967" ] }, "srt_ScenarioForecastMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioForecastMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation4Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"
], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Scenario Forecast" } } }, "auth_ref": [ "r396", "r1008" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScenarioUnspecifiedDomain", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation4Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"
], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario" } } }, "auth_ref": [ "r204", "r396", "r979", "r1008" ] }, "us-
gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureDispositionsAndAcquisitionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Schedule of
Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule Of Business Acquisitions By Acquisition [Table]", "documentation": "Disclosure of information about business combination.
Includes, but is not limited to, recognized asset and liability." } } }, "auth_ref": [ "r47", "r48", "r466" ] }, "uhs_ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "ScheduleOfCashCashEquivalentsAndRestrictedCashTableTextBlock", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryTables" ], "lang": { "en-us": { "role": { "documentation": "Schedule of cash cash equivalents and restricted
cash.", "label": "Schedule Of Cash Cash Equivalents And Restricted Cash Table [Text Block]", "terseLabel": "Summary of Cash, Cash Equivalents and Restricted Cash Reported In Condensed
Consolidated Statements of Cash Flows" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Effects of Foreign Currency Forward
Exchange Contracts on Result of Operations", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the location and amount of derivative
instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative
instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r58", "r60", "r480" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureEarningsPerShareDataAndStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of
Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Computation of Basic and Diluted Earnings per Share", "documentation": "Tabular disclosure of an entity's basic and
diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } }
}, "auth_ref": [ "r1011" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname":
"ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"
], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name" } } }, "auth_ref": [ "r294", "r295", "r296", "r458", "r980", "r981", "r982", "r1080", "r1081",
"r1082", "r1083" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureFairValueMeasurementTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value, Assets and
Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary of Assets and Liabilities Recorded at Fair Value on Recurring Basis", "documentation": "Tabular disclosure
of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The
disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall,
segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level
3)." } } }, "auth_ref": [ "r1086", "r1087" ] }, "us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Insurance
Type and Tier Identifier [Axis]", "terseLabel": "Insurance Type and Tier Identifier", "documentation": "Information by type of insurance coverage or layer of insurance that covers malpractice
claims." } } }, "auth_ref": [ "r128" ] }, "us-gaap_ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "ScheduleOfPropertySubjectToOrAvailableForOperatingLeaseTextBlock", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsTables" ], "lang": { "en-us":
{ "role": { "label": "Property, Plant, and Equipment, Lesser Asset under Operating Lease [Table Text Block]", "terseLabel": "Remaining Renewal Options and Terms for Each of Three Hospital
Facilities Leased from Trust", "documentation": "Tabular disclosure of lessor's underlying asset for which right to use has been conveyed to lessee under operating lease." } } }, "auth_ref": [
"r133", "r1028", "r1107" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation1Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation2Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation3Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation4Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"
], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Table]", "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]", "documentation": "Disclosure of
information about related party transaction." } } }, "auth_ref": [ "r64", "r65", "r741", "r742", "r745" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSegmentReportingDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSegmentReportingParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting
Information, by Segment [Table]", "terseLabel": "Schedule Of Segment Reporting Information By Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total
assets by reportable segment." } } }, "auth_ref": [ "r32", "r33", "r34" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSegmentReportingTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by
Segment [Table Text Block]", "terseLabel": "Segment Reporting", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses
certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise
regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r32", "r33", "r34" ] }, "us-
gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureEarningsPerShareDataAndStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label":
"Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment
Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r398", "r399", "r401", "r402", "r403", "r404", "r405", "r406", "r407",
"r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426" ] },
"uhs_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname":
"ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTextBlock", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureLeaseAccountingTables" ], "lang": { "en-us": { "role": { "documentation": "Schedule of supplemental cash flow
information related to leases.", "label": "Schedule Of Supplemental Cash Flow Information Related To Leases Table [Text Block]", "terseLabel": "Supplemental Cash Flow Information Related to
Leases" } } }, "auth_ref": [] }, "uhs_SecuritizedBorrowingsCreditFacilityBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthservices/20240930",
"localname": "SecuritizedBorrowingsCreditFacilityBorrowingCapacity", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Securitized borrowings
credit facility borrowing capacity.", "label": "Securitized Borrowings Credit Facility Borrowing Capacity", "terseLabel": "Accounts receivable securitization program credit facility, borrowing
capacity" } } }, "auth_ref": [] }, "uhs_SecuritizedBorrowingsCreditFacilityRemainingBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.universalhealthservices/20240930", "localname": "SecuritizedBorrowingsCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": [
```

```
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Securitized borrowings credit facility remaining borrowing capacity.", "label": "Securitized Borrowings Credit Facility Remaining Borrowing Capacity", "terseLabel": "Accounts receivable securitization program credit facility, available borrowing capacity" } } }, "auth_ref": [] }, "uhs_SecuritizedExtendedMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "SecuritizedExtendedMaturityDate", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Securitized extended maturity date.", "label": "Securitized Extended Maturity Date", "terseLabel": "Securitized extended maturity date" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r892" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r894" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation1Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation2Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureOtherNoncurrentLiabilitiesAndRedeemableNoncontrollingInterestsAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureScheduleOfDisaggregatesRevenueByMajorSourceDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSegmentReportingDetail"
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSegmentReportingParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Segments [Domain]", "terseLabel": "Segments", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r129" "r130", "r131", "r132", "r222", "r227", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r241", "r242", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r253", "r254", "r255", "r260", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r325", "r332", "r333", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r810", "r813", "r814", "r821", "r875", "r1124", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150", "r1151", "r1152", "r1153", "r1154", "r1156", "r1157" ] },
"srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation1Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureDispositionsAndAcquisitionsAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureOtherNoncurrentLiabilitiesAndRedeemableNoncontrollingInterestsAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSegmentReportingParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical" } } }, "auth_ref": [ "r258", "r259", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r706", "r707", "r708", "r767", "r769", "r772", "r780", "r787", "r789", "r790", "r791", "r792", "r794", "r795", "r796", "r797", "r798", "r803", "r829", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r874", "r880", "r1049", "r1124", "r1129", "r1130", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150", "r1151", "r1152", "r1153", "r1154", "r1156", "r1157" ] },
"us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSegmentReporting" ], "lang": { "en-us": { "role": { "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Reporting", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r132", "r222", "r226", "r227", "r228", "r229", "r230", "r243", "r245", "r246", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r260", "r809", "r811", "r812", "r813", "r815", "r816", "r817" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSegmentReportingDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSegmentReportingParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SelfInsuranceReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SelfInsuranceReserve", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Self Insurance Reserve", "terseLabel": "Self-insured for professional and general liability", "documentation": "Carrying amount (including both current and noncurrent portions) of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property." } } }, "auth_ref": [ "r77" ] },
"uhs_SelfInsuranceReserveAmountExhausted": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname":
"SelfInsuranceReserveAmountExhausted", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Self insurance reserve amount exhausted", "label": "Self Insurance Reserve Amount Exhausted", "documentation": "Self insurance reserve amount exhausted." } } }, "auth_ref": [] }, "us-gaap_SelfInsuranceReserveCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SelfInsuranceReserveCurrent", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Self Insurance Reserve, Current", "terseLabel": "Self-insured for professional and general liability, current", "documentation": "Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid within one year (or the normal operating cycle, if longer)." } } }, "auth_ref": [] },
"uhs_SelfInsuredAmountPerOccurrence": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "SelfInsuredAmountPerOccurrence",
"presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"documentation": "Self insured amount per occurrence.", "label": "Self Insured Amount Per Occurrence", "terseLabel": "Purchased several excess policies through commercial insurance carriers per occurrence" } } }, "auth_ref": [] }, "uhs_SelfInsuredAmountPerOccurrenceExcessClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthservices/20240930",
"localname": "SelfInsuredAmountPerOccurrenceExcessClaims", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Self insured amount per occurrence excess claims.", "label": "Self Insured Amount Per Occurrence Excess Claims", "terseLabel": "Purchased several excess policies through commercial insurance carriers per occurrence excess claim amount" } } }, "auth_ref": [] }, "uhs_SelfInsuredAmountPerOccurrenceExhausted": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.universalhealthservices/20240930", "localname": "SelfInsuredAmountPerOccurrenceExhausted", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel":
"Purchased several excess policies through commercial insurance amount exhausted", "label": "Self Insured Amount Per Occurrence Exhausted", "documentation": "Self insured amount per occurrence exhausted." } } }, "auth_ref": [] }, "uhs_SelfInsuredRetentionAmounts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname":
"SelfInsuredRetentionAmounts", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Self-insured retention amounts", "documentation": "Self-insured retention amounts." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureEarningsPerShareDataAndStockBasedCompensationAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense", "verboseLabel": "Compensation cost recognized", "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r9" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation4Detail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Shares vesting period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r841" ] }, "uhs_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodEndYear": { "xbrltype": "gYearItemType",
"nsuri": "http://www.universalhealthservices/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodEndYear", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation4Detail" ], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, award vesting period end year.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period End Year", "terseLabel": "Shares vesting period end year" } } }, "auth_ref": [] },
"uhs_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodStartYear": { "xbrltype": "gYearItemType", "nsuri":
"http://www.universalhealthservices/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriodStartYear", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation4Detail" ], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, award vesting period start year.", "label": "Share Based Compensation Arrangement By Share-Based Payment Award Award Vesting Period Start Year", "terseLabel": "Shares vesting period start year" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureEarningsPerShareDataAndStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label":
"Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Restricted shares and restricted units, net of cancellations, granted during period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r415" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureEarningsPerShareDataAndStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label":
"Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel":
"Weighted-average grant date fair value, per share", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r415" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crdr":
"debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation4Detail" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
"terseLabel": "Market value of retained vested shares", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash." } } }, "auth_ref": [ "r419" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
```

```
"ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureEarningsPerShareDataAndStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label":
"Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or
many axes to the table." } } } }, "auth_ref": [ "r398", "r399", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417",
"r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureEarningsPerShareDataAndStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label":
"Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures", "terseLabel": "Stock options granted during period", "totalLabel":
"Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures, Total", "documentation": "Net number of share options (or share units)
granted during the period." } } } }, "auth_ref": [ "r1060" ] }, "us-
gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation":
[ "http://www.universalhealthservices/20240930/taxonomy/role/DisclosureEarningsPerShareDataAndStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average grant
date fair value, per option", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing
methodology." } } } }, "auth_ref": [ "r418" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureEarningsPerShareDataAndStockBasedCompensationAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation4Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail",
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based
payment arrangement." } } } }, "auth_ref": [ "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419",
"r420", "r421", "r422", "r423", "r424", "r425", "r426" ] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ShortTermDebtTypeAxis", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": {
"label": "Short Term Debt, Type [Axis]", "terseLabel": "Short-Term Debt, Type", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": [ "r71", "r1030",
"r1031", "r1032" ] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermDebtTypeDomain", "presentation":
[ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt, Type [Domain]",
"terseLabel": "Short-Term Debt, Type", "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter
of credit financing." } } }, "auth_ref": [ "r69", "r1030", "r1031", "r1032" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StatementBusinessSegmentsAxis", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation1Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation2Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureOtherNoncurrentLiabilitiesAndRedeemableNoncontrollingInterestsAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureScheduleOfDisaggregatesRevenueByMajorSourceDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSegmentReportingDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSegmentReportingParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Segments [Axis]", "terseLabel":
"Segments", "documentation": "Information by business segments." } } }, "auth_ref": [ "r129", "r130", "r131", "r132", "r143", "r222", "r227", "r230", "r231", "r232", "r233", "r234", "r235",
"r236", "r237", "r238", "r239", "r241", "r242", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r253", "r254", "r255", "r260", "r311", "r312", "r313", "r314", "r315", "r316", "r317",
"r318", "r319", "r325", "r329", "r332", "r333", "r651", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r810", "r813", "r814", "r821", "r875", "r1124", "r1129",
"r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150",
"r1151", "r1152", "r1153", "r1154", "r1156", "r1157" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StatementClassOfStockAxis", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Class of Stock
[Axis]", "terseLabel": "Class of Stock", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r139", "r155", "r156", "r157", "r183", "r209", "r210",
"r217", "r219", "r224", "r225", "r297", "r341", "r343", "r344", "r345", "r348", "r349", "r369", "r370", "r371", "r372", "r374", "r517", "r684", "r685", "r686", "r687", "r694", "r695", "r696", "r697",
"r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r718", "r738", "r760", "r781", "r782", "r783", "r784", "r785", "r978", "r1002", "r1010" ] }, "us-
gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Equity Components
[Axis]", "terseLabel": "Equity Components", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r15", "r80", "r83", "r84", "r140", "r167", "r168", "r169", "r186", "r187",
"r188", "r192", "r199", "r201", "r203", "r223", "r298", "r301", "r326", "r375", "r449", "r450", "r459", "r460", "r461", "r465", "r468", "r469", "r482", "r483", "r484", "r485", "r486", "r488", "r491",
"r518", "r520", "r521", "r522", "r523", "r524", "r530", "r532", "r546", "r643", "r674", "r675", "r676", "r694", "r760" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation1Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureDispositionsAndAcquisitionsAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureOtherNoncurrentLiabilitiesAndRedeemableNoncontrollingInterestsAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSegmentReportingParentheticalDetail" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel":
"Geographical" } } }, "auth_ref": [ "r258", "r259", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610",
"r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r706", "r707", "r708", "r767", "r769", "r772", "r780", "r787", "r789", "r790", "r791", "r702", "r794",
"r795", "r796", "r797", "r798", "r803", "r829", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r874", "r880", "r1049", "r1124", "r1129", "r1130", "r1132", "r1133", "r1134",
"r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148", "r1149", "r1150", "r1151", "r1152", "r1153", "r1154", "r1156",
"r1157" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Line
Items]", "terseLabel": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information
associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r186", "r187", "r188", "r223", "r532", "r589", "r683", "r705", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r720", "r721", "r722",
"r723", "r724", "r725", "r726", "r727", "r728", "r730", "r731", "r732", "r733", "r734", "r736", "r739", "r740", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756",
"r757", "r760", "r881" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": {
"role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } }
}, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementScenarioAxis", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation4Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"
], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario" } } }, "auth_ref": [ "r204", "r396", "r979", "r983", "r1008" ] }, "us-gaap_StatementTable": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Table]",
"terseLabel": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows,
and shareholders' equity." } } }, "auth_ref": [ "r186", "r187", "r188", "r223", "r262", "r532", "r589", "r683", "r705", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r720", "r721", "r722",
"r723", "r724", "r725", "r726", "r727", "r728", "r730", "r731", "r732", "r733", "r734", "r736", "r739", "r740", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756",
"r757", "r760", "r881" ] }, "uhs_StatuteOfLimitationsOnCertainJurisdictions": { "xbrltype": "stringItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname":
"StatuteOfLimitationsOnCertainJurisdictions", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "lang":
{ "en-us": { "role": { "documentation": "Statute of limitations for certain jurisdictions.", "label": "Statute Of Limitations On Certain Jurisdictions", "terseLabel": "Period of expiration of the
statute of limitations for certain jurisdictions" } } }, "auth_ref": [] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation
Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r901", "r911", "r921", "r953" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ],
"lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to
appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "uhs_StockOptionExpense": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.universalhealthservices/20240930", "localname": "StockOptionExpense", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "documentation": "Stock
option expense.", "label": "Stock Option Expense", "terseLabel": "Stock option expense" } } }, "auth_ref": [] }, "us-gaap_StockRepurchasedDuringPeriodValue": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "negatedLabel":
"Repurchased, including excise tax", "label": "Stock Repurchased During Period, Value", "documentation": "Equity impact of the value of stock that has been repurchased during the period and
has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment
therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r15", "r79", "r80", "r109", "r694", "r760", "r784", "r890" ] }, "us-
gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent",
"terseLabel": "UHS common stockholders\u2019 equity", "totalLabel": "Stockholders' Equity Attributable to Parent, Total", "periodStartLabel": "Stockholders' Equity Attributable to Parent,
Beginning Balance", "periodEndLabel": "Stockholders' Equity Attributable to Parent, Ending Balance", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary
equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r80", "r83", "r84", "r104", "r719", "r735", "r761", "r762", "r860", "r891", "r1004", "r1024", "r1101", "r1159" ] }, "us-
gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfChangesInEquity" ], "lang": { "en-us": { "role": { "label": "Equity, Including
Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total equity", "documentation": "Amount of equity (deficit)
attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r49", "r50", "r53", "r140", "r141", "r168", "r186", "r187", "r188", "r192", "r199", "r201",
"r298", "r301", "r326", "r375", "r449", "r450", "r459", "r460", "r461", "r465", "r468", "r469", "r482", "r483", "r484", "r485", "r486", "r488", "r491", "r518", "r520", "r524", "r531", "r546", "r675",
"r676", "r692", "r719", "r735", "r761", "r762", "r786", "r890", "r1004", "r1024", "r1101", "r1159" ] }, "us-
gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Equity, Including Portion
Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Equity:" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [
```

```
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r525", "r556" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r525", "r556" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r525", "r556" ] }, "srt_SubsidiariesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SubsidiariesMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation1Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"
], "lang": { "en-us": { "role": { "label": "Subsidiaries [Member]", "terseLabel": "Subsidiaries" } } }, "auth_ref": [ "r1052", "r1108", "r1109", "r1111" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental Disclosures of Cash Flow Information:" } } }, "auth_ref": [] }, "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersEarnedPremiums": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersEarnedPremiums", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters, Earned Premium", "terseLabel": "Property insurance", "documentation": "Amount of premium revenue earned by property-casualty insurance underwriter." } } }, "auth_ref": [ "r668" ] }, "us-gaap_Supplies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Supplies", "crdr": "debit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid Supplies", "terseLabel": "Supplies", "documentation": "Amount of consideration paid in advance for supplies that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r805", "r820", "r1025" ] }, "us-gaap_SuppliesExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SuppliesExpense", "crdr": "debit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "label": "Supplies Expense", "terseLabel": "Supplies expense", "documentation": "Amount of expense associated with supplies that were used during the current accounting period." } } }, "auth_ref": [ "r124" ] }, "uhs_SurgeryCenterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "SurgeryCenterMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureOtherNoncurrentLiabilitiesAndRedeemableNoncontrollingInterestsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Surgery center.", "label": "Surgery center [Member]", "terseLabel": "Surgery center" } } }, "auth_ref": [] }, "stpr_TX": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "TX", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureOtherNoncurrentLiabilitiesAndRedeemableNoncontrollingInterestsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "TEXAS", "terseLabel": "Texas" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r947" ] }, "uhs_TempleTexasMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "TempleTexasMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"
], "lang": { "en-us": { "role": { "documentation": "Temple, Texas.", "label": "Temple Texas [Member]", "terseLabel": "Temple, Texas" } } }, "auth_ref": [] }, "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests", "crdr": "credit", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests", "terseLabel": "Redeemable noncontrolling interests", "totalLabel": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests, Total", "periodStartLabel": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests, Beginning Balance", "periodEndLabel": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests, Ending Balance", "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer." } } }, "auth_ref": [ "r78", "r183", "r297", "r517" ] }, "uhs_TermLoanAFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "TermLoanAFacilityMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Term loan A facility.", "label": "Term Loan A Facility [Member]", "terseLabel": "Term Loan A" } } }, "auth_ref": [] }, "uhs_ThePavilionBehavioralHealthSystemMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "ThePavilionBehavioralHealthSystemMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureGeneralAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "The Pavilion Behavioral Health System", "label": "The Pavilion Behavioral Health System [Member]", "documentation": "The pavilion behavioral health system." } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation4Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"
], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]", "terseLabel": "Title of Individual" } } }, "auth_ref": [ "r1017", "r1110" ] },
"srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation4Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"
], "lang": { "en-us": { "role": { "label": "Title and Position [Domain]", "terseLabel": "Title of Individual" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r939" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r946" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r966" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r968" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "verboseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "uhs_TrancheATermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "TrancheATermLoanMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Tranche A term loan.", "label": "Tranche A Term Loan [Member]", "terseLabel": "Tranche A Term Loan" } } }, "auth_ref": [] }, "uhs_TrancheBTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "TrancheBTermLoanMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Tranche B term loan.", "label": "Tranche B Term Loan [Member]", "terseLabel": "Tranche B Term Loan" } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfAssetsAndLiabilitiesRecordedAtFairValueOnRecurringBasisDetail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r263", "r264", "r265", "r266", "r267", "r268", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r366", "r373", "r489", "r516", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r644", "r847", "r849", "r851", "r852", "r853", "r854", "r855", "r856", "r857", "r861", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r1019", "r1020", "r1021", "r1022", "r1085", "r1088", "r1089", "r1090", "r1097", "r1100" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r969" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [
"r970" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [
"r970" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r968" ] },
"ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r968" ] },
"ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r971" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r969" ] }, "us-gaap_TreasuryStockTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockTextBlock", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasury" ], "lang": { "en-us": { "role": { "label": "Treasury Stock [Text Block]", "terseLabel": "Treasury", "documentation": "The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock." } } }, "auth_ref": [ "r110" ] }, "uhs_TrebledDamagesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "TrebledDamagesMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Trebled Damages", "label": "Trebled Damages [Member]", "documentation": "Trebled damages." } } }, "auth_ref": [] }, "uhs_TrustOwnedByChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "TrustOwnedByChiefExecutiveOfficerMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation4Detail",
"http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail"
], "lang": { "en-us": { "role": { "documentation": "Trust owned by chief executive officer." , "label": "Trust Owned By Chief Executive Officer [Member]", "terseLabel": "Trust Owned by CEO" } } }, "auth_ref": [] }, "uhs_TwoFreeStandingEmergencyDepartmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "TwoFreeStandingEmergencyDepartmentsMember", "presentation": [
"http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation3Detail" ],
```

```
"lang": { "en-us": { "role": { "terseLabel": "Two Free-standing Emergency Departments", "label": "Two Free-standing Emergency Departments [Member]", "documentation": "Two free-standing emergency departments." } } }, "auth_ref": [] }, "uhs_TwoHospitalFacilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "TwoHospitalFacilitiesMember", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureLeaseAccountingAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Two hospital facilities.", "label": "Two Hospital Facilities [Member]", "terseLabel": "Two Hospital Facilities" } } }, "auth_ref": [] }, "uhs_TwoPointSixFivePercentSeniorSecuredNotesDueTwoThousandThirtyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "TwoPointSixFivePercentSeniorSecuredNotesDueTwoThousandThirtyMember", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Two point six five percent senior secured notes due two thousand thirty.", "label": "Two Point Six Five Percent Senior Secured Notes Due Two Thousand Thirty [Member]", "terseLabel": "2.65% Senior Secured Notes due 2030" } } }, "auth_ref": [] }, "uhs_TwoPointSixFivePercentSeniorSecuredNotesDueTwoThousandThirtyTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "TwoPointSixFivePercentSeniorSecuredNotesDueTwoThousandThirtyTwoMember", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Two point six five percent senior secured notes due two thousand thirty two.", "label": "Two Point Six Five Percent Senior Secured Notes Due Two Thousand Thirty Two [Member]", "terseLabel": "2.65% Senior Secured Notes due 2032" } } }, "auth_ref": [] }, "uhs_TwoThousandTwentyStockIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "TwoThousandTwentyStockIncentivePlanMember", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/DisclosureEarningsPerShareDataAndStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Two thousand twenty stock incentive plan.", "label": "Two Thousand Twenty Stock Incentive Plan [Member]", "terseLabel": "2020 Stock Incentive Plan" } } }, "auth_ref": [] }, "us-gaap_TypeAndTierIdentifierDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeAndTierIdentifierDomain", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Type and Tier Identifier [Domain]", "terseLabel": "Type and Tier Identifier", "documentation": "Name of the type of insurance coverage or layer of insurance that covers malpractice claims." } } }, "auth_ref": [ "r128" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation1Detail", "http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation4Detail", "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r470" ] }, "uhs_UKRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "UKRevenueMember", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureScheduleOfDisaggregatesRevenueByMajorSourceDetail" ], "lang": { "en-us": { "role": { "documentation": "UK Revenue.", "label": "U.K Revenue [Member]", "terseLabel": "UK Revenue" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r965" ] }, "uhs_UniversalHealthRealtyIncomeTrustMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "UniversalHealthRealtyIncomeTrustMember", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation1Detail", "http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation2Detail", "http://www.universalhealthservices/20240930/taxonomy/role/DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformation3Detail", "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Universal Health Realty Income Trust.", "label": "Universal Health Realty Income Trust [Member]", "terseLabel": "Relationship with Universal Health Realty Income Trust", "verboseLabel": "Universal Health Realty Income Trust" } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits", "terseLabel": "Unrecognized tax benefits", "periodStartLabel": "Unrecognized Tax Benefits, Beginning Balance", "periodEndLabel": "Unrecognized Tax Benefits, Ending Balance", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r435", "r443", "r842" ] }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "crdr": "credit", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "terseLabel": "Impact of unrecognized tax benefits if recognized", "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate." } } }, "auth_ref": [ "r444", "r842" ] }, "uhs_UnvestedStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "UnvestedStockOptionMember", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/DisclosureEarningsPerShareDataAndStockBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Unvested stock option.", "label": "Unvested Stock Option [Member]", "terseLabel": "Unvested Stock option" } } }, "auth_ref": [] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateAxis", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateDomain", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureTreasuryAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r935" ] }, "stpr_WA": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "WA", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureOtherNoncurrentLiabilitiesAndRedeemableNoncontrollingInterestsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "label": "WASHINGTON", "terseLabel": "Washington" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureComputationOfBasicAndDilutedEarningsPerShareDetail", "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "terseLabel": "Add: Other share equivalents", "verboseLabel": "Net effect of dilutive stock options and grants based on the treasury stock method", "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment, Total", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per share or per unit computation." } } }, "auth_ref": [ "r1011" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureComputationOfBasicAndDilutedEarningsPerShareDetail", "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Weighted average number of common shares and equivalents - diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r208", "r219" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureComputationOfBasicAndDilutedEarningsPerShareDetail", "http://www.universalhealthservices/20240930/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfIncome" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average number of common shares - basic", "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r206", "r219" ] }, "uhs_WellingtonRegionalMedicalCenterMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "WellingtonRegionalMedicalCenterMember", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustDetail", "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureSummaryOfDetailsOfHospitalsLeasedFromTrustParentheticalDetail" ], "lang": { "en-us": { "role": { "documentation": "Wellington regional medical center.", "label": "Wellington Regional Medical Center [Member]", "terseLabel": "Wellington Regional Medical Center" } } }, "auth_ref": [] }, "uhs_WildomarCaliforniaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "WildomarCaliforniaMember", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureRelationshipWithUniversalHealthRealtyIncomeTrustAndOtherRelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Wildomar, California.", "label": "Wildomar California [Member]", "terseLabel": "Wildomar, California" } } }, "auth_ref": [] }, "uhs_WindStormsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.universalhealthservices/20240930", "localname": "WindStormsMember", "presentation": [ "http://www.universalhealthservices/20240930/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "documentation": "Wind storms.", "label": "Wind Storms [Member]", "terseLabel": "Wind Storms" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r933" ] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21C", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21C" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478353/942-405-50-1" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(e)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(a)", "Paragraph": "4", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99",
```

```
"Paragraph", "1", "Subparagraph", "(SX 210.5-02(22))", "SubTopic", "10", "Topic", "210", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "220", "SubTopic", "10", "Section", "45", "Paragraph", "14A", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "220", "SubTopic", "10", "Section", "45", "Paragraph", "5", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "230", "SubTopic", "10", "Section", "45", "Paragraph", "12", "Subparagraph", "(b)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "230", "SubTopic", "10", "Section", "45", "Paragraph", "13", "Subparagraph", "(b)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "230", "SubTopic", "10", "Section", "45", "Paragraph", "14", "Subparagraph", "(b)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "230", "SubTopic", "10", "Section", "45", "Paragraph", "15", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "230", "SubTopic", "10", "Section", "45", "Paragraph", "4", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "230", "SubTopic", "10", "Section", "50", "Paragraph", "2", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "230", "SubTopic", "10", "Section", "50", "Paragraph", "3", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "230", "SubTopic", "10", "Section", "50", "Paragraph", "4", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "230", "SubTopic", "10", "Section", "50", "Paragraph", "5", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "260", "SubTopic", "10", "Section", "50", "Paragraph", "1", "Subparagraph", "(c)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "280", "SubTopic", "10", "Section", "50", "Paragraph", "22", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "280", "SubTopic", "10", "Section", "50", "Paragraph", "25", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "280", "SubTopic", "10", "Section", "50", "Paragraph", "30", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "320", "Publisher", "FASB", "URI", "https://asc.fasb.org/320/tableOfContent" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "360", "SubTopic", "10", "Section", "45", "Paragraph", "4", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147482130/360-10-45-4" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "360", "SubTopic", "10", "Section", "50", "Paragraph", "1", "Subparagraph", "(a)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "360", "SubTopic", "10", "Section", "50", "Paragraph", "1", "Subparagraph", "(c)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "480", "SubTopic", "10", "Subparagraph", "(12)(c)", "Section", "S99", "Paragraph", "3A", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "480", "SubTopic", "10", "Subparagraph", "(16)(c)", "Paragraph", "3A", "Section", "S99", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "505", "SubTopic", "10", "Section", "45", "Paragraph", "3", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147481142/505-10-45-3" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "505", "SubTopic", "30", "Section", "45", "Paragraph", "1", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "505", "SubTopic", "30", "Section", "50", "Paragraph", "2", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147481520/505-30-50-2" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "505", "SubTopic", "30", "Section", "50", "Paragraph", "3", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147481520/505-30-50-3" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "505", "SubTopic", "30", "Section", "50", "Paragraph", "4", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "710", "SubTopic", "10", "Section", "30", "Paragraph", "2", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147483043/710-10-30-2" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "805", "SubTopic", "10", "Section", "50", "Paragraph", "2", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "805", "SubTopic", "10", "Section", "50", "Paragraph", "3", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "810", "SubTopic", "10", "Section", "45", "Paragraph", "15", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "810", "SubTopic", "10", "Section", "45", "Paragraph", "16", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "810", "SubTopic", "10", "Section", "45", "Paragraph", "21", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147481231/810-10-45-21" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "810", "SubTopic", "10", "Section", "50", "Paragraph", "1A", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "810", "SubTopic", "10", "Section", "55", "Paragraph", "4I", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "810", "SubTopic", "10", "Section", "55", "Paragraph", "4J", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "810", "SubTopic", "10", "Section", "55", "Paragraph", "4K", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "815", "SubTopic", "10", "Section", "50", "Paragraph", "2", "Subparagraph", "(a)(1)(iii)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "815", "SubTopic", "10", "Section", "50", "Paragraph", "4A", "Subparagraph", "(a)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "815", "SubTopic", "10", "Section", "50", "Paragraph", "4A", "Subparagraph", "(b)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "815", "SubTopic", "10", "Section", "50", "Paragraph", "4B", "Subparagraph", "(d)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "815", "SubTopic", "10", "Section", "50", "Paragraph", "4C", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "815", "SubTopic", "10", "Section", "50", "Paragraph", "4D", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "815", "SubTopic", "10", "Section", "55", "Paragraph", "182", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480401/815-10-55-182" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "815", "SubTopic", "25", "Section", "50", "Paragraph", "1", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "850", "SubTopic", "10", "Section", "50", "Paragraph", "1", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "850", "SubTopic", "10", "Section", "50", "Paragraph", "3", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name", "Accounting Standards Codification", "Topic", "942", "SubTopic", "470", "Section", "50", "Paragraph", "3", "Subparagraph", "(c)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic", "205", "Name", "Accounting Standards Codification", "Publisher", "FASB", "URI", "https://asc.fasb.org/205/tableOfContent" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic", "205", "SubTopic", "20", "Name", "Accounting Standards Codification", "Publisher", "FASB", "URI", "https://asc.fasb.org/205-20/tableOfContent" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic", "210", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "1", "Subparagraph", "(SX 210.5-02(19)(a))", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic", "210", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "1", "Subparagraph", "(SX 210.5-02(19)(b))", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic", "210", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "1", "Subparagraph", "(SX 210.5-02(19))", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic", "210", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "1", "Subparagraph", "(SX 210.5-02(20))", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic", "210", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "1", "Subparagraph", "(SX 210.5-02(21))", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic", "210", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "1", "Subparagraph", "(SX 210.5-02(22)(a)(1))", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic", "210", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "1", "Subparagraph", "(SX 210.5-02(22)(a)(3))", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic", "210", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "1", "Subparagraph", "(SX 210.5-02(22)(b))", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic", "210", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "1", "Subparagraph", "(SX 210.5-02(24))", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic", "210", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "1", "Subparagraph", "(SX 210.5-02(27)(b))", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic", "210", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "1", "Subparagraph", "(SX 210.5-02(28))", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic", "210", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "1", "Subparagraph", "(SX 210.5-02(29))", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic", "210", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "1", "Subparagraph", "(SX 210.5-02(30)(a)(3)(i))", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic", "210", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "1", "Subparagraph", "(SX 210.5-02(30)(a)(3)(ii))", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic", "210", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "1", "Subparagraph", "(SX 210.5-02(30))", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic", "210", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "1", "Subparagraph", "(SX 210.5-02(31))", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic", "210", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "1", "Subparagraph", "(SX 210.5-02(32))", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic", "220", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "45", "Paragraph", "11", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic", "220", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "2", "Subparagraph", "(SX 210.5-03(1))", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic", "220", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "2", "Subparagraph", "(SX 210.5-03(10))", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic", "220", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "2", "Subparagraph", "(SX 210.5-03(19))", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic", "220", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "2", "Subparagraph", "(SX 210.5-03(20))", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic", "220", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "2", "Subparagraph", "(SX 210.5-03(3))", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic", "220", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "2", "Subparagraph", "(SX 210.5-03(7)(a))", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic", "220", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "S99", "Paragraph", "2", "Subparagraph", "(SX 210.5-03(9))", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic", "230", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "45", "Paragraph", "12", "Subparagraph", "(e)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic", "230", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "45", "Paragraph", "13", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic", "230", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "45", "Paragraph", "13", "Subparagraph", "(e)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic", "230", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "45", "Paragraph", "15", "Subparagraph", "(a)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic", "230", "SubTopic", "10", "Name", "Accounting Standards Codification", "Section", "45", "Paragraph", "15", "Subparagraph", "(b)", "Publisher", "FASB", "URI", "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic", "230", "SubTopic", "10", "Name",
```

"Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Subparagraph": "(14)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Subparagraph": "(15)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505-30/tableOfContent" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "710", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483070/710-10-25-9" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/805/tableOfContent" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "915", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "470", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "954", "SubTopic": "450", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481501/840-20-50-4" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "250", "Publisher": "FASB", "URI": "https://asc.fasb.org/250/tableOfContent" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10",

```
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r178": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r180": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r182": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r184": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX
210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r187": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r189": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r191":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)
(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" },
"r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r196": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r198": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting
Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r200": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r202": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r204": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic
11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-6" }, "r206": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r208": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r210": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r212": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40"
}, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40",
"Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r217": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r219": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r221": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r223": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r225": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting
Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r228": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" },
"r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r232":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "
(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" },
"r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r237": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" },
"r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22",
"Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24" },
"r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r244": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r246": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r248": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" },
"r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" },
"r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r255": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI":
```

```
"https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
```

"https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-11" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480627/815-20-45-3" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r488": { "role":

```
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r490": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(1)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r492":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)
(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40",
"Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" },
"r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r496": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" },
"r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r501": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r503":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)
(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" },
"r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r508": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r510": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r512":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "
(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" },
"r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r517": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r519": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r521": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" },
"r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830",
"SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r525":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1" }, "r527": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r529": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI",
"https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r531": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" },
"r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r536": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r538": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r540": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r542":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "
(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" },
"r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-13" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1" }, "r546":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)
(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
}, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850",
"Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r552": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r554": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481435/852-10-45-14" }, "r556": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r558": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r560":
{ "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)
(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
}, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r565": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name",
```

"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147470941/924-10-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic",

"220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-18(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-3" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r717": {

"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))" "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))" "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))" "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))" "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))" "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))" "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))" "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))" "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))" "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))" "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))" "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))" "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))" "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))" "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))" "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))" "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))" "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))" "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))" "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))" "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI",

"https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r803": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r804": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r805": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r806": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r807": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r808": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r809": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r810": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r811": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r812": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r813": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r814": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r815": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r816": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r817": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r818": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r819": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r820": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r821": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r822": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r823": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r824": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r825": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r826": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r827": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r828": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r829": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r830": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r831": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r832": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r833": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r834": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r835": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r836": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r837": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r838": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r839": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r840": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r841": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r842": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217" }, "r843": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r844": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r845": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r846": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r847": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r848": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r849": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r850": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r851": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r852": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r853": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r854": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r855": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r856": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r857": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r858": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r859": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r860": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r861": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r862": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r863": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r864": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r865": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r866": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI":

```
"https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r867": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r868": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r869": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r870": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r871": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r872": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480046/944-40-55-7" }, "r873": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r874": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r875": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r876":
{ "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r877": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting
Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r878": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r879": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r880":
{ "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r881": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r882": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-
12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r883": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic":
"946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r884": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r885": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-
6" }, "r886": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7",
"Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r887": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-
15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r888": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946",
"SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-7" }, "r889": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r890": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r891": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r892": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r893": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r894": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r895": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r896": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "f", "Paragraph": "a" }, "r897": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r898": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r899": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r900": {
"role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" },
"r901": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence":
"C" }, "r902": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i",
"Sentence": "D" }, "r903": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1",
"Subparagraph": "i", "Sentence": "E" }, "r904": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F",
"Paragraph": "1", "Subparagraph": "ii" }, "r905": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F",
"Paragraph": "1", "Subparagraph": "iii" }, "r906": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F",
"Paragraph": "2" }, "r907": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r908": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r909": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r910": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r911": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r912": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r913": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r914": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r915": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r916": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r917": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r918": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR",
"Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r919": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
"Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r920": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
"Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r921": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
"Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r922": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
"Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r923": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
"Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r924": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
"Paragraph": "a", "Subparagraph": "2" }, "r925": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a",
"Subparagraph": "3" }, "r926": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r927": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r928": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x" }, "r929": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r930": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii" },
"r931": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2",
"Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r932": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r934": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "iii",
"Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r935": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section":
"402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r936": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" },
"r937": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2",
"Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r938": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r939": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" },
"r940": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2",
"Subparagraph": "vi" }, "r941": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v",
"Paragraph": "3" }, "r942": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v",
"Paragraph": "4" }, "r943": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v",
"Paragraph": "5", "Subparagraph": "i" }, "r944": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r945": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r946": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r947": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r948": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "6", "Subparagraph": "i" }, "r949": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r950": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r951": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i",
"Sentence": "A" }, "r952": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w",
"Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r953": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii", "Sentence": "C" }, "r954": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii", "Sentence": "D" }, "r955": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i",
"Sentence": "E" }, "r956": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w",
"Paragraph": "1", "Subparagraph": "ii" }, "r957": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r958": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "w", "Paragraph": "2" }, "r959": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "x", "Paragraph": "1" }, "r960": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "x", "Paragraph": "2" }, "r961": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r962": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r963": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii",
"Sentence": "D" }, "r964": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x",
"Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r965": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r966": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
```

```
"Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r967": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r968": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r969": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r970": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r971": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" },
"r972": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" },
"r973": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2",
"Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r974": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402",
"Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r975": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r976": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B",
"Clause": "1", "Subclause": "i", "Number": "229" }, "r977": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section":
"405" }, "r978": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r979": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic":
"450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
}, "r980": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r981": { "role":
"http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph":
"(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r982": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740",
"SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r983": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r984": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "20", "Topic": "842", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229",
"Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section":
"1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229",
"Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)",
"Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-
K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name":
"Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r991": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" },
"r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r993": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX
210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r996": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r998": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX
210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482740/230-10-45-16" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1001": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" },
"r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1004": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX
210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r1007": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r1009": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r1011": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" },
"r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" },
"r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32",
"Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r1018": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r1020": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" },
"r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1025": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1027": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r1029": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-
30/tableOfContent" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1031": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" },
"r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1035": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r1037": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" },
"r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SAB Topic 5.Y.O2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1040": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" },
"r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1043": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX
210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
}, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B",
"Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r1047": { "role":
```

```
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" },
"r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" },
"r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1054": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" },
"r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1059": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)
(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1062": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "
(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)(iv)(04)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1065": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)
(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-
10-50-2" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"2", "Subparagraph": "(e)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1068": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)
(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1071": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" },
"r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1076": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)
(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-
10-50-2" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1081": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic":
"323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-
50-1A" }, "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1085": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r1086": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1087": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" },
"r1088": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1089": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1090": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1091": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "
(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1092": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic":
"10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-
50-2" }, "r1093": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1094": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1095": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1096": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1097": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1098": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1099": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" },
"r1100": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1101": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1102": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1103": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1104": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1105": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r1106": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" },
"r1107": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479773/842-30-50-13" }, "r1108": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" },
"r1109": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r1110": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" },
"r1111": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r1112": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" },
"r1113": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1114": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1115": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1116": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1117": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" },
"r1118": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1119": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1120": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" },
"r1121": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(13)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1122": { "role":
```

"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1123": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1124": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1125": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1126": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1127": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1128": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(cc)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-3" }, "r1129": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1130": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1131": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1132": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1133": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1134": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1135": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1136": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1137": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1138": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1139": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1140": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1141": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1142": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1143": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1144": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1145": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1146": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1147": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1148": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1149": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1150": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1151": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1152": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1153": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1154": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1155": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r1156": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1157": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1158": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1159": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1160": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" } } } ZIP 69 0000950170-24-124103-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-24-124103-xbrl.zip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j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l.IO2P_X,3%U*)S#CV_HP]9;&O:R.],:T_Y$O???NS=UOL;S8@QL-CDQ;RS M$*OQ\]L R-O3/K+76RGANRKHI8;G?GN7'IG)\))$T=.E*W$'{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|>>$4WSEC]N5V>.;)91!TEME. M76B/U3K72UB-HT9]6.S^T0+9.X6Q1\O.M/R#EO;+E!|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

Z([_:]$_T#@VLV18V79CQ>27K0*&[]@PE):.Y04H>Y@4)L M*E8AP1NVA6 'A26;FZ@1XU-C1)&V&DA!ZVQBQS>A#)8P64:0,B8-MA=G;K=-1 M#=-3;5O0;#TD8#ZE9=U UVPD#:/,XV)A,'%C M9_C=H5=3;ZFS]O+B G=P6K,]]#$#IB3UZ4H1#5LOMT-C^$ C&U6%T]N![A%E M_C(I#,N.?%6X]2BEZ MU,/E]01D%})]&UK8IVN{)6SU:!/3T6 M-V#R^HK58%<3P"MQ#ARHD[<4"W4& "$X%B:706(.0,DXZZ,QH0PK3)_]/{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zBU[GM* M=;,B*S6"@D(D)B10A72'6+,.JH<4 ^]&#ENK\9+9:G.[YVX]#B13?:',J1LJB MXEW4D.(+BE MID@5ZM5#HT.#@=a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{[7&]OZ7^2^]+Y? =G M,ZZ[ICN7%O1WY3'G/CRM[L]>TIF_]>;H7=[.9[G'[DI$ >LU^'U[],N0.4X4 MJP=5I(BZ;0W%I"STVJW&'%+RXI:.@#Q32VY>RBC;:'(0DFU?/1 >8"B,,:AY] M0)W+L%[[.)7&'VO8^(VEZ? 0W7/Q,JWLGL[.+2P_=J[%.AS84KRKLKH(4T*+ MI_HZ,:'[SAY2TXR^QYT6O5\U\T>S(_M63,>S*>3&6[CHK_%ZMG^(S60S0>SN3!?E[*C,#G4Q>3%)6S@3FO(.GO3MZ M3,_.B.K64:#1O7R&!W9/KO<+:@%5O3:E0U9.<>ZX&5)/W+531*^Q0.VP)$6\I M1^=#PIH)AXN3:HG%8OO2,P0ARL,#@)DIFUI[@MBKE2XC TE(*;k63:L0_9FF+1?5S/>\)DP!MM_AM/5:&WJ> ,A2PCD',F<#*D(F%B-M56^.9N<_YUZ'*P':W7QW.=73R4KD^_ZL35Y.VLE;""S+?SRA_O-K1EF207K8 M.TON#IJI1Z@,*ZR$765!2TZZ=5. HE,&DW-KE%L/8=BLT#8H1,SW4/_7JY2] MDY99O3TT5BDV6T@2K4Q>D<\NHTM#J[3/*[F\UOZ*%O1=5=. M[$K5N,7VTQL\,IDUPWH%F2 5]O" MS6^@ZY)5,.GZ.&RJ[YA.,M"KI^";=N.+ MS.")\1VP%(P H[K%W(3].DH+E>- _BLFL<7HSF%RVK0\7+!VO<&* ^XIF>^F M=GI!8:A.M6@:(6F4*:F\)[$$!*<[48DVUGKH0.HF*MT=@;,:>32/?(!3A"6HM PV2^TD6MK%B[J34.EQ7?EON)KK$#:]7@%OZ7^2^

MR{M]TN],'__AXW2+>0'$U72/;6_TEQ<'AV]OEM2#/1"%P1C-+GGO5]D12G:X M$G/&-_FHZUV3ZZ@M0B)T[+];L 75.6F1\$B@K95&*B#&__M!<,T"><2(']:&ZDHL;,L&(4(;2C%'\4B-QY0+>R! >D M3G 0!A-HPD)BWX 9]6H7S8/Q*:+~(,3Y/=*N_/6L6?^NT>_K;+F*O M4B]^1:$[G)Z;90;Y;+$_*G1'%SU[N9N__3YU!-[) 4)RRV8 /OW@'Y/1N)LN MYR^L;T6Q'UY=#*:?[O#F$'-\?'K.KH? WZP$7Y#9R76C-C& 7/TYU]A"F9_ MY_DZN[H)9VWN\GO=/C1E,(I'#6L_U4/5@_O'8]8>E+'X M-A:/R!27'W)'E!;Z?M;!O;_M5X=`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~@/A9E'PJZ"N1SFMN3R-O=0+E1LB<9PL=,;25D#9;.F$)' M"ATI=*30D2U8TLNS=]_8G7^D''$V^ZG>AS^& [LA/1B/8Z#_"A[W+47<$W&$5 MK*&,JZ4[U1]7C;DIG_3F]E&U^6)OUK!L /G&)3+9F);MR]<9FH%7]A_*]%BN51@^7!1",!&BW$A (4 ,.R27K)A@'SLQ4^V-[4(-MQ-R0U9DR[U+K]\.@N8OKPP@%;"17N-.6N3UZIP@<(%VKFX"O=8DR6],"Y@-M/PZ[HW]^3-,/!\,5\H"]G=I!H'H[27'A *V$B<(!U@XPMG/?*QR@<("_7=)+ MCVF8)(?Q4W<$HI(3.-C>5)4Q#1^N-.8ZR8W)@0FS1%$GT_9T MX]2CX, ,HYB|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c2\$ISU.%T2:HVZ[M<,Z^9*#/B_2^Q*#[@WQZ MOVK

ZAWY?KTZ?;?NZMG] M\3M55Y=Q^&%UDLMZ7QU4+4/[5&CHB!&%AAZ1AD;'LS&9]C66%&>!HC6>O%"Z MQFBEX'$?;;2AH2/54+2@OF8+ZI9ULU6=K?ZY,&GY?/B38GU4'Y}^CK?9Z?E M-!87X/%U-&0:W>_!P_8C@AIEUYT #4YW#C4X.Q$@P=ENH 9G)P(D_L-U.#L M1($9[N!&IR=")#@:#=0@[.3 1<[09[<'8B0(*SW4 SDX$2'"V&ZC!V8D M.8Z2P0.7!0EFJC+*47 VD"K!D*O.$ LYM_]+S_G"J.?;^[^_6R=GH=-&>]@ MGM0GEU50E^5ZF^]>#;5]EV5_?[NH@OKXZKU-NW?MJS\IXY S8]R4"OD@:! T M" J.H(5D.&,U$FEIO%,V6V6*,5:,.G[9YDSEKCW^7!H!W#XS;=WO)TIASG] MT'HLI47R(K31AH;D1&BC#0W)B=!&&QJ2$Z&--C0D)Tt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a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t(;.6A(SB,.[=*.BLZC M6"QSNXZ+CF#7+"QY? 72.5[?/.'2M#V97>WV:.[WY<<=F^7F6>?7&RVF*>Z.K#B^2M_?F'IL/@<4=ZK.P4W

*MPP9,;KPU"8C*R)61A4CJ'9&96N)$CB0++Q*GC&6U<5!EH9'IFOHC8SW7CGQ;YD7],MD-EME3[Q8)4^\K[D3-MRX<\&J?*

W%YD41^>)%&_S_%UY[S]O.P=24[N[A%N(C=F22*$(X3O,X3SX%-T M61$M L"Q4(H$SB*A.67&B[.U ?3^Y4HWZ8K)1C;H:?!XYTTV]A;1-B M[/YB++$8K>H8=B V(#8@-B V(#8@-B V(#8@-B V(#8@-B V(#8@-B V(#8@-B V(#8@-M'<6&O=[OT-8D?L> MQM0!C/I*+Z8#2]VAP2OR8D350T75O>,%A9FDA;#$FL* XPI&O &,2ZDWG$F; M1PW>,LE)QI5RV)$1GB*

*O!DU#Y+1=69)TH-M%UH\]F"]#J#L5X^OMEO<&KQV]KBX3B/UCTOQ$_RXY@'S7$*F^?3D*>-H(.& M@W6A\[J*3?%GO!15FBP ++ZA^[H.9?FWG?FQF^?*

*A(#R9I]+3HC+AK!ZQ&%P MAT0-T9F[QO1E3/GKGLQ0'XVF\)E8Z^.\9<1FKXEP65M96#9\HW;[:T[IU;\6 MP_F7%WXZ_0*O'IT""F[-40T,>[(SC55VBM'A<5MB+"(L-M&6%NHLXX78K6' MM4*1E(3B)0FL),5IBC)OK\4 09GE4A#%/",2VD(\7$;8*58ED5C@^CK'"L\G M\9\GDQ', ^FR)IK!H^)-EPDX7! K)PBX(N BX"+@(N)\,E]6%=([6DQ*

*7JB(0&V.AD,FGC> RK!756",B< >5F MGA,O=*9"T!~MFF;PIG=RO>]7K GZ[W9 2?9>>)>HCRB/+]0 E=XW!+PL=2 M2'1)$:.#$B;@"C-D9V0U2D)NMLKN.P[U%6VPC87;@ [Z9."DSDR;9$+H= MQM #P^G & QG(+M&W$7<{1V[5D%8ZFO^!2N!2.I2S7#+ /)*Y,@U /C&=B#U MCD6E*6&1PV=L MQKD[3:ZIE@.'N1E808ZXBKBZ$URE/(F2<@U5&"(S]*

<0:$8G-23DCO'6;N)]C M-#FR6L!A 8N+-B0(%4@,TFO#@.*6;F>[2390^LEZ'O4.5)',(N@BZ-XW .,4 MQ&L>ABY*PV(L5%!6|<-L3H6+N,^DA[USDB'$ ORRHQ MY3H-NGK

J!Y(^V0EW_N,N^NB;_BWBJ;]0Y6H.'//S[WA;4]. 37/LV??OTM M_#^)#<^UH-(_;C6;S;CR1P^Z?P,M@,7/9AZD?-F9 .FTEIYB=YE[MY1#R> MY51_;YV.G\,?*

93CVXSB$RV=S>*$>U3M[=FF^ZTRFX<M2SX'AOWE"_4$X6'Y[UO["]J,DC],/9Y/9L+WW--?3AC|F4.C/ M=6KAGL_/=?OS'1&4)G%'D 6JY15<*=*c5G79QNS\\?;- MWU[]?GST2_/SJZ-?WO_<'+_Z_6]O7KPZ'C1OWKYXUAR]?=D<__'3\9N7;XY^ M?_/J^!HT/<4,MBSD'#[_?AD^_WX!FG^/?G;R]]+U^7[Q[NW+5V^/?[ULX+?C M=[^\>7GT'OXXOFFKJ',/_QZ>]==?;]\?-^]>-R^.CG]3H'_Z3_MWK=]&F;@X<&G3Q0B%_T2CE%28CFSQ#]1&;.N4>L>>>[CUMT0O$='SIZ/3P*A<3X?D;VGWXX MGC5@73-0UEK]*

[&>S/)\U?IR:L)@-QQG^GJ&'Z;6Y'J'N;'AY_9[(-F0M 7-M)73=$$EO #Q7G@@E.1$GE8_EV-<.Z%_)N? QV_*X,[,(:?V8V_A[7BL,P@$0$1 ;\A F8E++!S3K0.P+]3+"0X(XC-C@:KC3&;#RM@M,3G47&+Y1,/ZP&,Y.ZH9Q M9>X!ASFZ]3TR/'13CW,K0C.?LK"$AAB(5,"4+=.%&,DD55:ZDC="0?35U>,[EU'"2;W),\B!DSML&=HG]4;D.HWHNPI4C$6=1$"'+"I9-8E M1ZSCBD1:%0X30X5\- %_]3]%_O%X'1W26_;8)8$O^S">7]6Q[-E!D^O7'_'M$]'^&QKZD,1^Q/CB=`&"%.L%B58[XF72!'!K]/4F4{G1U?DAE3_']/-OOX*

*M]^*2R6W)=Q@^,'R'A_GU6:\1HGHCRIY"E,>24Y$8":DVD9?)$RL|)3E85;B& M2:PG(CV^]F>G$*75P-!#KU-\>& 7RX >6P;TXL2//^2V;>T]&6.9L#P:.^K8Q MZS#/!FT1T*0TN90#1?*

*#2D\55CJ"<=D8?HC'GZLS=1QF=9K.HO+M"OG@P4>0DR9.*WKF>,E MD!!A\1:D$H52FWG;2B3IS3@"'LWRRIS\|\UX;7F_GQO>UD\49|\ZV^$98'U6*

*M=T2NWHAR[Y'K:1{3G4_>1%&(#+D>^RUK\$ED(@IGS EN(?XW;"%AM%PG_'"= M&##;KTP2S%#<#U8]7>34GJ=8S_5$Q[1'%H:.J5N.2<4H@Hf%>,,\D2{JXK.A MA-(88V&6K^QD{(UBE[->'TZ[X5_>INWE4 $%+UGC2^QB @AA}7-A\18(TR7.M&V1O&0B-?4$2+8D*4B6M$E%[$S;KT%"+M;O %+!3%LL,O&*BU*W9S25/RW;*

*M7K:%!)^Q2K_GEG:H[N6):E0+*X8]2S2EC$CK'+&6<\)L\"KS(`\=%>L35?U-MU1_;&[NN1F[,L M&N'Y09POED:X@^ 1&PC>+QI.N2H(7P<'7T_#0BW7PA@5B8[>$;EU(EXD3U34*

MPHEDDN,[RE5Y//Q^K>"J;P?#/2G5QGCZP\SLUYQ@A--5>W.J3GS7Y8'M,%V)LK\X^OW5<3V0NWUYTG+T#U./C'R_S!)=VN-<4 1.!$\S\//DP06%0(!F

*M*Z(X53(KEE.AVX^1K+WTZ,),?UM9Z=$XK<-#K8F"A<)+K,ZSJ8\M\W8^Q41 M0K..T(.0MF370H?L@!KK6 21W FR.F.7""66%XD%MQ0U/QVGKXX MGC5@73-0UEK]*

[&>S/)\U?IR:L)@-QQG^GJ&'Z;6Y'J'N;'AY_9[(-F0M 7-M)73=$$EO #Q7G@@E.1$GE8_EV-<.Z%_)N? QV_*X,[,(:?V8V_A[7BL,P@$0$1 ;\A F8E++!S3K0.P+]3+"0X(XC-C@:KC3&;#RM@M,3G47&+Y1,/ZP&,Y.ZH9Q M9>X!ASFZ]3TR/'13CW,K0C.?LK"$AAB(5,"4+=.%&,DD55:ZDC="0?35U>,[EU'"2;W),\B!DSML&=HG]4;D.HWHNPI4C$6=1$"'+"I9-8E M1ZSCBD1:%0X30X5\- %_]3]%_O%X'1W26_;8)8$O^S">7]6Q[-E!D^O7'_'M$]'^&QKZD,1^Q/CB=`&"%.L%B58[XF72!'!K]/4F4{G1U?DAE3_']/-OOX*

*MJ

*\|O[E:JAC"0AY:S3P[*XU|&QZ6S,V(_M1&/-M-@OF39Z?'=7P40U_H2QU\<>]>ZLHX2]/D>FK>7;4P]^@HCK@D'P&G5=GNP_/-M(TA'B3=."XM?I$_])8WBG,8=;,0M3^B\|C@@.>TCN:-UM7W8Z&]8K{TK!5>_Z-M+P>>V|W+_2Y?O4:@#K@"KF-R9B)[3BEQ!OL:P2?MCU^TTJK4&O-MYOT:.LH9&B.GA#HDC3-Z$!IC@C]-\9DG$6BO(<>-EN*[YOE]J8U;5N!?<$_-NMY33]/T"INZL-2P+;MA1X,D$82_+T<-JH1?-QO,KQR;YIR_9F!V.-"/>K>QZ,&W6K>CW8Y6',C-R=!{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|[=7[?Z+]1*R;!W4-I?UBE+N1[%H-.MM1THGR[>S6?+M^_NJBF5*;#\M",E.%.1C%IB:6+$*2S2-R;Y"X+D8E9:^8H-M229)W-F-!!M&D\2\SMZ&S(V^MA#M$Z-(/I_#R4UG-HV.,%Y=KK]2"OE"^:!-M2EW]/!JR.S9DX2"&3/LH-XV>",O!N?!@R#SX#'1BL];HJ&6.?2N&+-LGC>,,M6$?!*,4(OT4DVLJ7@N.5%*I=.*,5OJ>P\N/Y+]6+X\E$\&C/:NM/>OW-M9;Q'PV9C2.I32:@3'(V4!Z2D"U$ERYP$#[*D?J\Z925V9"L"PA5H>"]1Y=(-MD3RQ4*PR@M_L%TI4$?[=I5]&[V>MGW_LM/EWV^.6)?^#27'/9F"5,U!8CZ-MU'SA,S:+AQN?T6K)(-E'VZIQ|\OSZ.X-AF-IW%>5UFX&%R+\LBDR9QGHJB'-M!;6E)E;P2$S1(5!8?>#<75Z345H>,ZQ>AAFPM8VE]=F1;!-/*;JLBKO4O!)C-M.?YM?EW:-C#8]<5/?N[&Y?7TA^79=T6F/#M+3F!G7_5@#K_?H===_THKM^LMOV-H;MATW)\O:\%/=YG/\.#0L=XM$.BHA+?.44H$,YI(&I$]34F-CDQZR3HLZ-CD]_FN&N(-RUF@18$FP?Z=-M&HW))S3(${'PKP"..S@A\|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{^UM#1N.I5#MU$HG#BZUHF#0[""_F"7)(92,D6['>ID6-S6",&W@+N+XNK7AMB^=/"_\CIN<.M=H)0.X=\JL*YFL+I\@QC% W66E8?=D_1J,1HU?8)O"Z\^KMG_7"FO#/X .; M)E=N08GWC#PZ97+)%@G2(E,F>R"%'/6HG-O@4WS"..GX]K]O1F,?0:Q5GZ.M -Z,&A!&P*PIBOT;>)(0K[=Y&B]^S!B'Q+!\YV:V?7X9_ID?K]LAE/M<|/43YIQ]FWUN>K+E9Z,W7_83:@53LJ,")D-22CO!H3>*/UH(R>/GGUTX]/-MGM6X; T&H^)_.U\VB]%LCG]/QF?C&DX;^]!&CW"=^RG*[3I0O#FI#?@.30XC ME5E[P*J4.P6F ?P.JYDA(6CPN8LU@O<\(*EY!A9- \N.R @@UR&'F4_94\S# MDCI=YDCY!0MS_]S%ME^OHMT;N_'!Q6\>++>IUK<'G653/*28F-&2\V!T'L3T MLT_0YSS$_#_*.Z=LU'CI5MX_9A..X"3]L\6Z1YFEZ>Q%F'W%(X)K/ UB|/(=2!PF:0#C M7P[>-%P*#QI7/-^!3AS[!OG>RK{^-D6TOUG4(M54:6HT3$0.&"X$X>1LE$84NE!9Y[_QZPWMH_1E-KOU#ZC@P;&"/Z:MXAM]M&"\]\FQRW: !'-N<("1]'1VUF$./'D\QZ.X:BPT*.$4)K0C M_[9+Q'-EB!/@]- 0@O*]W1Q3 O-":R(8[A:!FZTG((1&]4BP .IX=U7T_F?%1[M.(^C-K3!.A"C"Z3\]6I=8#0@Y_.XBJ!X'IR_.%Q5GWR7\9-4R. ,_)'W\#Z M^0FCM9>*3N.,7/ZF?ON\4BEAG.",.A,.9D5)282UELBB//%6((^MQ+*%,%[MJ2_1Y:18L20P" X35]T$HSBQB6J6DLTY?2H1_58!_Q_AST\RVR5_|>7L=@>0 ME%@<=$M>F'[$W(413< M9HH9"Y99(@[D$BOGC4TJJ"S3-RM0JYT<405*#&_"74O@\R@NYS7Cn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`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{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|]D"K9BTP0*>CEY-FMO^YQ\V>(5P_18VIM5QG"2\|'U<6\ .#=!N![. *^Q5A\ ..(Y2BWWS>_HLR@"&%S88(H'K$6%W%5 MC)Y(E;#\4:<|&W:"4Z"!8#.YLF$Z*CFBJAV&7M_P>^?_6T.7B: MTT5W)=S4/YOZW!]?[$YI#,5+S_&]P__AM&:,P;R]fT94]+9=4> MS34]?G"%"'"LNGSOJZY"UT6#^.5&U%YpI0*@#0!*6[.6FJI*R;T&\K<$'I*.KP'K%1APZM4N>LR]LZ+,!3I2R4@18FD4F@.10E'84]&,O#?,!!>2G M:7I\>##]D&---R$;Y%=%%+A-I*=OR$&";UV&!U?-X!$41<5S?:VS&EGZG;.MH'N@T#;2V48UG\FJ.4%0@GBA[ES!S:9OFY-/6/NU:.[I15/L(;MZA(T=_P%)M4T^,_^8^ M:U#3]D# ^>P03$<. 4^,^WXU< V7W__(-^]N|Z(Y\OVNB"H">;2,TJ MHV1%>P:.[D8QUB**E]..+$?CO,/RHKO:.MTM$VP?43>,TT>@NVYD^@P6N7A"XNT*;]/(7KS<[RLU465XU#=2&"-D&NMAC-.M OI%[&;*J+W.VJMN^7[P$*9(.%VIZ%8>2)MLTA\S'(UX?GD8H_SGL;O,=:#MWOM\=K8>FS;04"'$;.BV(_D@/1+'<&-@W9HB"%.I$>8-LSK.5'0OC21QK7F$ M%.XSI406|_HA:TI :11I=.;#4](C*L/T\1/^#T_%QGYL=NZ&Y3D'2%]DK9:FHUM45B,*@OVID!>'6//M)6<=')]XB\%'F&)D02O#9$*SO9(G*B9%MY(9[8S?>_P MC;2A5Q1O#$?5K%GB.HA8E],.BF]N7%+K@'&7]S#PM<$4MZYP4BJE2XT^HNME!TC-N?)2$TP@0-_2$ABN_U)>F NRLY>K#I M /N<1(H?K312XQ7"M0B2ITAY?{?;2.MS*9KDY)!3SR=B,S4DTUOBD,&6H._Y MY=BI'/1]6IGFRZNF9X:NL6C:;O ,H^-KL>+&O;1+2_]05!G?PN;2RVOL!VUE M%8)K/UXL.DCS:MQFOF\^'=>T>3]?3-N*.*R! R'\?8;\B,M)F&,.]^BO?XS^ M\I??<%=HXC]@4OH9R.!;_S:O$C#:_9/WR-NRJ'5#D_S63T9-GK\'MWN58=|^ M:O?X]VS?I14]IDNTG#-URZE!-'7I0HB3KDB,K-?#*9]%S0>I_RYHM%+^9O&\;1+PB.V.S04P?YT)Y$]4P *@'Y3+%Y"!Q_$9 K$EO//BN*\48(MW]MEY8D6YD(D<+0$ \4S<4XF0H4(U@$\7ZW>3%]DU|GTXXP]B]=[J-Q;EY. MT^\YY7R&&=AX!-QG/@-U-WV!;O+4O(S;?S^9O7'|\6720[=*P49BQ_&03WNY MN.Z,_(T-NH?(%Q9&7"4<3)6S4:O)-X._;C0W[C+>-^/_I]T)&*UGX%M0GNTX M3?>/4V!5S +|;-!EF%B$GZTB.RF7/)_GM'OLUL.U,/C2TR[G,5RYMY7;G,-! M 'I#$S^_,7+_QB;J-.NEK(D)=*Y/95B+"NCCCLCKJ=2,]MN4>-ELNMC.'Q[9<MWW!;KJ_1-X24E\1"\4-M@4F;76;,(O)ZE:CXW]//G49B%>]SDX6,\&7O/. M#'79LD22+HQ(BZT]BXB$*N4IS1;+=WHTKLE1DP0G226,_2N#O883,2&P(+V. M4?5<_&NU]MS%)^TAARIX'U+!PW=HN='+V-!)=!VQ+K;YV"H-VPL0(I"BH!.@P057CBV4;.]C>4'%P0^I,V\ 01"*'9E2A.)+B7,IHM(`M'P\(D=GL"HC#'K'+ MC#)#BH^SX0V/|@?.*%]MYHH*0Z/[ZCAED4V>DXA,\M0: MR-*?=0[.H0'Q);EZ"0HF :80NRQ)&%U6PFKVX)5<#ESW1.$;)5*.@:0'0X$ MP2<0A.P541X$*?E8LB_#$X0AY0U!UP:,AB8,@JE8M+S(#!A") !TN1[$!*V MG"F#!J+7$L!&:A0H!%^K(96/Q%E*B2\N^>(5X,_AX00Y1$+;ZFD,310HURK M;))H%:954T=LRA*62"@Z<@U3W-LSC[J$'#T% 0#'$]N<@E%!*Q$2C=QH(;/?MWI+X/K_S[\>SN9_\N58S(5'AJW77X=>M<]|. _)[GE5EM5R8NB|&.=`07NO@4 MPV$M[0#A6)=V-../ Q*,45@/4%?OM>.'8IAYRQ-]_1__[VSJ3T;_Y>FTN9B\ M]|,Q_/7ZW7AV,OH?WV!2|@(K K%9\YPVY!%),U^8Z;4X8;/4A*X.*XA9--(%*AG@A_!)";$:]0Y. M.W$}(""\;I"62@,T*4IBC1> 'Q(3H$;.F*9*DS4%@$@/MB2IBXC6(ODV0!T: M(@D!3@0#1H6-G-+0*Y[^<%D85FACB)8J.19#1 2L#6WRI8XRK!#;>01I&8X MZUF]+Q-TH+WFI)^/[A@MPMP;#-3.453DE/#ME2+#!,!"<;-+-4OX_AN_!:>M\2DV&=ITL%U.4Y[OTH^WW9.G'=|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|CYW-XJLEZ++HDX#HDGQ@#8Q@Z#7,.U;...SM MC1FEWUVZZL/(W9Mj:7L,8.#SZ_$6>;8F$X6\.$3%]BB#MSX0#FE6K/D>OP+ M1DO&2X1S5'\%K&A3CE.2HHZF41MU+V.[!]S6&Q(%%[!$Q\4(@^L<^X5-++C M*7($K=@:|=NAB4,LG#&PSD049XD,%+>AD*[<&]D]$UJJ.Q"'E0_U.PS3'XO* M0+R.YEPW;O.XVEUYJH>57C%]\A2P/(:'D08?D. B(^-I1NC7]2(9(?4G&"TW M>OJD_O,K'O3DV2:I?U-V<31,1\/T\1DF5Z0$?\""9X#]K94OQ.JBL'J92!}) MI5-O]V1Z%;A0@H!&%DV"\Q:F6A?]>XGA1\/T* R3C&1-H9QH[YE**]1'5\N"%X3X.DSJE@<?)WNHEA$K(;)OCG;)B.ANF6)71=]8: M]0*Y&R^V>"X7L^<'E2QW2K7Z5B3+6<-I4HG9)1EU!Q*%V!%Z]>A\Q*0#@=7 MRQK.Q4@J!GMOS_2[?2;FOI#Q1_)NG%*>/G_U-UC#'TE&=B&)1*$W9PPS*;CC,K9?5SC\/ $\>5EZ[.YX6*ICQ2@5"HZ/8$@>]5N%(5-JI M$(756CV0^ENW>\#4RH',R8:2|\"6_;A_OP7]^_:TSO-J0PU$;39YC^YF9]W7_M^4R@C8?G?@I>R@I3_MBIB2P6XJ3+",EG&O M.TT6(S9H><)}37]9@G(;=4U31A-9O# +S<6*@R^=S(S-!5M!*'<(R<&P^;@ M.1,=4K"F4++!-O30XHXW)-D0B#3(1@WTB(=E,&(V6,N:"5;VRR'Uj:F7F?\SM-MOZ]F\Y8,_==\=1BUIZH:6![PVQ?UM'MHG74R2 R3)+,^RDBXPR:SAE+BBO $ MYK9H:Y++*?0S#G18H2'"0]VPL*92"Z*Q9LF5F(3J149NR\17;9I.1LL%2/S_MKEM>KQ]JM0Q^-?L*04SM;MV@>HFK]*NV;3;9M-'>;,=UG+NK(.KI/G/W8.DYM6*K"W=VQ*6ZEYXRXWLK0]:GLF_9_>/R]D<<88=OB[\F;^LG+U2=/G]V8770! MPZ=/6MD^ZKKSU5__4:_96]!5)QOLF8;9G,%/_]'* M0=NVIDM#@F_&4S#$BV5-0\+FL2@_-=.S%31X@FK\-_:A"C7_L7SO)C5VTWP M#>8=]^-__?9+;9B(]+3@E'T/-ST9_7KZ\K1]VP23!"AJ7MGQ8/@R-C#$[<)+ M([UBV$VXA#MN,JQ^6G1LE)W WT'$;5_^8>" <5PH)":9)\SP#>)@[>&-`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|9-4 MV5LWIKA9@:085E7##JD!RS9^UZ(<; M,\P.-X^KO4V++N9@P:C0C.$)]B@%9X8X!08E4..DZ=%WW%ZEAFE#N&Y?#YQ3P|I ME_P3W6W&EUN%ZK;KFEYY*EW!5KM-UF(9F,"6N^:$(@.9]>CU:BNJO(VE[A4 MLE=)T>L:=V5+4@GX"/1N+[M7\.AYD:5+U"#C!T@@9O:X+ H)&%D% MU|FR/HF9+EXFX0P1.AHB8_3$F8A]%9C.2@9?]&=\]\/QZ-VQW&S-SJ4>#=>F MT;OC)|S+&W]$1D=H]BA4EK3IP5%_]WDO/G)!=%+D,W)B"E.00* M&D]MN'AWLLVYL3]NWD#=/W1BPC4(%&IG*0@%X2NZ(#5&IG*0626LG2V_4BIE'0!X MPPC4+"EXP8WL1+P#U<:D%*5/D_5(H=/E7L9'Y1$3D?D=&<]'Z2":&$6AG!M[&$@02J_3\B$"S-$4[]/KH"Y$X8'PJ51!,Z7Q!;C2,PV%JK!TC)^S\C)#A,YM2[8%!RG*F#7*FT8P*8"SGWT,,V\!"IL5-KV@T]WEH7[""\KQQQ14VD)-@K;]MDNFU45,;::#]4-/]*GOE[GY>_ 9X[=Y1F_(B%H;K2@6=!#@(1FM)U[,1#)WM.F@&F%_W.I@RM80)&HE!,G?P*P$9^>R(\U$X1<:,T%[GB$>*C#93U4K&$1D= MD=$1&=V1*=0L!J9I{2:CEP9N&G%%41)D)907XW+NI>P7G6E@%BA&ED-?59DZ"MM0$W"W00LL0\,9?41& T5&*7GI,M@8 #B882NQH ?[&I1"J0S2)M^K[[N] M. RR@F,P,2O90B-YB)V^=37#E^WT,1WZ4)MD(HGD:#'$1L' E6.2>!.1!@G< MN&"R+;G'IA; >-N^JBE,?R%|ZH\F6^Q_,VJVHMW9VR>S"[@)8J9-R1]JS5)X[M0UK,R.B.:_?F=?MB[&VQO$ JHK9HZ?U MJ$JY:.8IUZ?Y*]P!+.WA0.R.1"5;\M!0EH!-^SV^7D[;L MD(/1WW <@I-PCSV3_@_BF#-9PWSTX_|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|$\'@)NG[#/5&7?73'9ZRH^OW<&\(C 2>OG-$3#,UBG^N#2&@A M3M8^6Z?!VNZW\@G'9%TCY06KOAR_(\<'>/6_X%]-MZF#_4<1L!|=ZN'K6& MS3AH/X!>@0D"A93_,?

H^@^T"#;,9KM6)VX=MC<[/2!XZG7:M[U;,M\TVT>E) M]VB]FR%@ P37@$I%3IB=^07_#GW>455I:W*7]^.TW,*/[;?--N7)R>CI&EET MBZ.]R6P.]VB[!-<81G?E;C:[?E;K"R-
0.H>_/HZ1A1:]Z]Y D8= VT-/FO: MW_I3"!B3AUMJ+Q\R-1"#*0WBF8ZL9[TT9^=KX1A/"W"/Y#(#[#85Y9$#]I%P MP(HC!^QCYH#]XFV9+^6-?5
"V#M>#%AZ\>#C/Q#SX['SM&$MKUL)__GRY6_UZI5M"DSV M[A4K@MNZ97N"%HNCZSS'QEY=\.#UCVTU^NJMFIPWKS+M8'"8A^%/#Y# MG^M]G@O&B/<\S;@RBE7,[>O.5!>!
[E POV3/H0;7":,UTI$51AA5&++0*^(M3SJ1DGQ.)D66K+J\L:R,C@&[(G/JX)P4*+8.%407+:FW(0;5R\I;NYI_Y/G[M<"A*H"'E@&Z*MT"F!C?KU$1:A),D)UZ0Z4 0KYTFW"!D!'(NZ%YI
M.TA)44(&,&W:P#DA$2LI(YGKD!V<'G2OM/T^9MT,<-9/5F'UNK'T;03#]FG4 M-E80P:)=H#Y_[R?+5M.#/9UW?W:>&BK,=@=DX!K3)ANIC9P4[0QVM,.>R2D1
MW%_T@/B$93T"M:@+;HBCGA2< &(TQ&^1I65F#&6>T>X]IY(*1WQS%(2K0.YIJHD MVD]WMCJ;6O3#7(8?
/*L"9XPSAB(N;5!]EC6[D1EN0&*\#!5%E,VBT+J6X0T_SX566'N!\7\)S=0OW*GW@VZYHR\6N^_O/9=W) M;;-&,!" .5P;EW(K9;&I;='0>QVWV]8/]_ZYR=WN=;<#@YW;)B/>;;ZL\W$V
M0_%NG.=(,'E16Z%%$U\E],2HU!=SOEF9W)XJLBK(+T-!ELX6R(=:!3/#"5: MTQA-!*"D>A;G")(_97$6,PR:U76PDX9Z53O$IR'#:^;AB09,H_0J9<*L!M%(M+A&75" %4(K,TEK?
+V7X$M'8+67X*WPYFR_@E=./H&HPD/G;/)^-EV MVN .>\P_S)I%\VL^5(D69T,2IJT*K>5F0+9BSQ'?_EF;.8==*BH=?G/0MFR' MDZ1"P205*X@5(A$IO"5.6
LNFG;%:Q\#8X=6,K^L=>_O>161?UU^6Q6Y_3S] M%>[UIF[4_P(W?G>H,)>P0Y0CK-O:RC"9PKN/&!_5PJ#FL$V[#B75D1&3""^Y'*5 M6SHX8=%9Z51*)+G@_J[-@7ALOL*\M]
(;:USJ<0+?C["\F^>KG:Z;B8L>E(]] MM;1PA=(B-$K+^P$*"_A$2E*=2(S>8,,=3RR7A8 $266Y\W 0L,'N6>Q8BAX.\]82='6D6G:"= CB49]:+,"PVR2[J;H MX-5L#K>8CG[,J)IO,#.BQ_\?
>?X72!L[K;2FVX0W8[Z?F?/%HV-;Y91V%= MW!U7HX!JYQV6!=4HWC0OMBNV0-Q-Z"8$;ZJLGGK,0X*DO>^*_>%X]97QE2J MIHU/YU+:@/7H'/W\3;[7ZJ
MESN&C3SN2A)RFWI7RX[^B7'C[1=:UVI"D>O!HE>GP@/V/"GF_RC[G]]^?IZU84IV]_\.>H#JX/*QN0&_CMW_ M;/#E)LB!2=M5[V-9ZWB61FVES17YA(]#GD0JW/-42.0Z8CLXP
A9!R)$XIQ* M96P_#3 690UX/*0H$XC40A%GM* 02,-W*)< MQ<8D76$R4$>*EAI3(36Q5$M23(HJM]+G_RCV_)[739OO-G2:/X3[.5?P'#_/%V7;[XNZY3+WS8U]V_@,;Z? MS.
(_GHPRK*9SN 5<(]]%5<(!Q>CVFZ>;;KZ+FC$/UV]6#"D=/EIOH?: S2=0 M6Y?-WI.:M5?8 +1UAC\&Z%H3<'F)-Y\V&37K_&G=,Y\M01I3\VQ;H/_/J/[W M;^T[]>'6K-5$76$/#BS6^0
BQL/)Q%^ (8*Q^IC3BS5-Y"G];G5"+18_;_+S M!CP^A).K"9[715VO_63U#/ 0ZW*G]^-FW.;H/U]=8^M .#+MLE,*>RKT=]NU M2-WDM<5(?_K$J>P+3V.GW-
M_[[T.E]V&C^U\OB^Q_=]G._[;W]:S/L??O[DL'[I2+;R2L4@QO MLG9Z>/5Q[?;0-X+?;GNE@MWC>KVI>'W)\F$/4JS_*1?ZN+[N8GW]"B[E
M<7D=S>$@S2&_:KEV[SH$:3KD8MP)XWRY2A_"L-RK#?L:7_BX"(Z+X CDCHOB MN"B.EN&X"(Z+X.B##-,'^?9"!KB]_.6K[QN,$GQS*NFX@CZ[@L1Q!1V]G^.*
M.MJDP:ZHK_&%CROH:)/NR>^JWLXWX'A=0P;K%1+6Q=3,UN>UBU+;:?VJ79Q[,B-ZBD/?5]0O6KB-DV_>>SH8\2E<-R+_<]#4_ M(PY[O=*[?/5:87= "7GZA97.-RL=-
SI3GK@E6L9$I"V4>.DXH3H9;T(Q1=++ MQ;!94QEB]"06)8BDSA ;@R!6^FRU+]IZ=;D8MC87_6&;/:)MGXD%(C_XYMVK MR>Q#]3A79;'?5P+4WW/MHS&65N=BI,A?
7K3*7XD2ZJYFQ MONZ%]^S "^]Q6[:O:VZ/2O5:2C!;KD))@=@<)9$N9>)-+ 24&2VV&&M*CX_% M16FE]9HH@TJ09TJ"16X 4X*1107A>FVT'D@)?IKFS9UH=C6#Y&-='X==_8]B
M61RUX%$+#@E:B@1J50?4D!QY5B@'K5HD$4X8E3@34?2@I6 I*$\#T3E;(E5) MQ$FF2=:,"DQ!+G7#[]:G7(]0*M6C4GT I1I9XCFK3))$^GOC
M)7'!&.*#2T4Y'J,,O8ZOP3COC2<4''HB!87#34A$!TN1--\%+1Z54F7TQ-BK M6W-\W0OO2J6Z'92%WY$PZC]68]0QH/U'U^_^:Z5L_776\91>ID:M??YV:4@Z M\M*:X-!VPTY;Q'1PP!_+
,QCB/+%.'TI@1^C'^E/,&X_$]&^'/TTS^7,&*3 MRLJ&W&>_YV8!8H;CB=]?@\COEU0;)N7Q>_>X'K[%JGZ6G&H)*EY,SXG'2OP6A[J M 1[IB)'0>-
-5#BZ4L/5\VNWXWJPX$2M!7SVYY5_%WD8=$R >UM'<32Y6M'Y7 M7.]R!_EU=Z2OGZI/FE/KW'USFSFN[O66ZI1I?GS)1_>2QTJZ!\VS&$)^\+%< M]>$+#^[V!8\B?Q3YH\@?1?
Y0(O]CCIW$LZ/$'Y'4(-;8-UF]=JS_/-JDXWHY M5GL>U\MQO1S7RT.OEV-9QFTWW>NN%NY<7-[/^#;VEH])'=?K%*ZU\T$GXJ,. M1#J6B&-1$9\2%Z)0:YTX1#-?
E,:7TW1YZW'Q@Y_/+\;3M__M)\NK._?>, ^8 MZA-JS%>75'&OB< /OK!O)-RCQSZW1Z5VR*:T@EDI02T5GAB1I63B#"\D6:N* M$BPKU5-J105O7#;$Z CG*!])D%QCBJ*
<$9BJE<$<9]*S=(3HZ_N(?I8Y?ZH MTXXZ[:C3KJ'3),O1>&&)DAJS96D G>8=$3%KIK03(LF>3K,Z&P4'2>8R_B4 M6!,\89PQP'#6!ID>%*@Q=R+%UU=2\!"$8(_>Y=T=0M+D2,8?
R;MQ2GGZ'!P5 MJW0*5H*CDC3(L@#[+#0GIBCEP!N!Q6$NST/O(BQ2D[VC)-?T\1PSL1JKOT-T MK(AD0DR?O8@06AJ7*$G*PI,X(T@PUL.3%!Z-#D9F>T!U\/MNXN%:>C[QSX'N
MW(KK4W_CVI=/KL?/!_\>S8K]PD5UH_#GUV3#N'1!:1E(HA[L43".^,(9B5P$ M[8)E2L1#!!MVTYD/9*R&0N^7RK$A1")]:#S$J4 'WLESA9_4 M:$&_FG%?,>,=RB(_Y2B,:;;$PL,'U-
0/$XR^SF!\I4H[ )B5%-SU9"DX[J"P MB#!C7DO"JJ<&OSH=(:'EJC,DM/ M]%UO#1XUZE&C'C7J-ZQ1>1&%1>N7%3JV0A' M=%2'=/1+]CB@R
9V0PZ^1ZE2ZIN_KV\.:S#E,I["XO%-76?G(-L9?O.+T8?9 M<@*+JO(:YO'[EL.PR9/)")ZXKDXD0#SWX_K%8NZG38$E[$>3L6_YPT9/XWKOIPO_-L^6S0A&[1]P<3"<[=)?W6IS
M7;@.7+F:M^L.0H2\^)#S='6-7QW,5KQCN9VG,;3\R5<$EX<#ZSZ8K3(\=UT_,\E'+)LVN'J M[K5]R?$4/I]-,_+.+=[-1X\S'7MYWE)B#=RU=WL@:1:G$I09LPQJ1@%M]1\M[W1\
(^PX\M7LDUS=YWEZ[Z, OY+R@W(_9\]->I3_A*('/_7,[P MG[K>*LLHKHOWN5L/35U48S">%2:N;>QF;8%\;PQG:Q;KSZ- '@7RF@+)GX]^ M;K5CB^G F$POR66U+\BT.0M-
GK^O_)=7J_N341[7*Z4QF*(%!^7/\JFX5SG4NNKK5^60"@W7V.2^RXQ&ZS MQ 3J_*VULT(C*&GS#&\6%W4MM62XB&E0[VDSAM:">HY0#8RG:6\>L0G.X/WOP26:?
[XG(@7=;C;)8OMPF&TEF?379D] M]RG!LVYE3(S;@>B2#-H/]LYCGJ87Y[-F7*_=]A1_G[?90=00F@EN#?%6)B*%IR24R B+3B=;)-7;_?_LO7MS&T>6+_A5 M$+VW=^P()#M?
E95IS]X(66IW>\;=5K1[IF/WGQOY%-$& 38*D,3Y]'M.9E6A M@(+>% F2)8]_F=VW!R['1>W?'LRQI2I*S5!'P7X%&]270&H,#%0@.8O?E:6= M.5S;1PA;SNN[!;J^6UQMKB^8O-
,WZ@NA[G9%/W><7)C!'_U !OTU%W>"]OP: M ? G"Y_[0QN(L=N/B6.>[YK<*=3@.4SX:Q#!KQB-^[ASHI_<.0'5"N, 'PY& M/3Q:NG?>!!$Z(),/06.B',)GCJ6Y>!3X^D?EZ71I;3D?S,]2LQ
MT.D<3KC0MTQ3?**IB:9NF:8FN/%)[?\::G]^0D!W?E8FOH/EB)L2R'_'RI? MRG=WZ;^ZM44Z T5UFO&CF/%$X4]KQM-^/ZT93_O]9&8\ =1\J8_X+^M5O.D*
M)ZYVVYU=SA*LU=2;9H(\W^>AI6!=725)=*PLD:*6Q!GFB8%SY&I5*6%&> =1 MU:(61A%EX"_)X1ZK'24RALI6P;+D1@@RQ4 Y4?=V:S#GU9S3:H(Y?SH,[I?3 M):8/?<KN
)#E\4]ZVO4G-NDGWK'E%B3C MM)3Y.]+.23BFFYO9@W6?.?2\"?, M/B8!V0I(D9(38*@1(UPD4M*:V-IZ(CA+POM@E1@%^FK!=;21$BNJFL M8!Y6
MQA%FN>,*I*VMV5T+2"GGJI*3A'PZ[.R1QODFIO;E3$U6-(J@&&%&@]9/M27 MKARQM(XNF&A=&/FO@/]5*H6*L)! ZZ]J372-N0^)16^KZ"MUY_ZKB:E-:O]#
MY.I3=&_:]2FZ=Z_:T8N8(JA%>':NKN.J*2!S7T%%FGK#/MG>L";4+@90E$RM M#':E$$0KQTC%$JV33[[B3Y9YDFED2(Y2@QS@4A/@7D*P8BM33!,2!DJ>\P\
MK=6J!IY)'%BQ1,KHB7$:?DTNQLH[9YV>F.=#."A?9M&<)=NX?YOG3,GDO*SA MB7:>*.U, =2S2"2:^I]^XF(\4OV/IH_3?IZXY<0MSX%; M4AN,5XP2'[@CLE:.Z#H:PBS5M5/:)L-
'!9O15]PEAKDL<(\1%.QF&HE/M0.3 MU2D5XIUS2VKFC)N)6TZ,8V(<=Y(SD/MM&&$LB!!S5+ !'1D\%.247KA<^?L M(S7+B6 EMC[2V)I>:44WA,OZCI5A]](T\7V-![\6R-VT
_?,3!1^T3M$S5,U#!1PT0- M4PCSJR6U_;C>P%JM9B6GS=^@T^&-W819?.LO[>I5S*X0="\|^$*J"3#Q%MUH MVF'G\501I:PB4IE$3!T\X9:+(*DT+(YP%"P/R6CO2&V=
(=)7FKA@'0F<"X^MZ/Q23FODC,2>NTY-83ZD4@LD+$<^LD$58 M)#Q%@;C @5CM(XG&Q,K0NC9FE)0]B;F'EW3].-G9HY[T5$;ZI6SR=!EIIS3= M3,507S'R^H2*H42J*E&+2
2U%*M"'7&QEH3YH&MK@W9J7$G*&=-,,.(3FJ0B M&&)IE8B57EGK*/?Q?LS+J2+JTK:G M92H.G(H#)]J9:.?LK>Q'%Y6];]_SF:8N3Q4/=^[#KCE-%2/8R8[(9!BQ%9C)
ME93*5]);YL5M%);>B1)8T;FF7]F)_..7',B6-^"L<,7EH9N20I2$TD M]6 "7R0>5C!ZXJF@-6AH#JQ2A$= MO2+15-();U3%PVT4F#Z6E(&)=YPM[YBJ3*]A MSV^BU<*/M%@R>][
M4TC"K9?AG6OS@UW:E8\SN_W\ W4.:W*G'.0<)OPUB.#7RQC?3P?].=%/[IPT MBV:V3C-TSLVR=V[VEVC1-W<%5SQL6KKW9)%')Y^^P*?TS6(UVUZN=XU=A>;;
MVY%:GY0Q^RC.ZXOHXY6+FYE@\QFG7'S^"?V8#*]S6+X[%8%/CZ)^7OM<'36= MR,]*+PIS7C:;^?UHRG_7XR,YY0>[[41?R7]2K>S.!]O\7M[&JW
MW=GE+,%:39BN$]C=/G/=\V!.D\@K8&PT,&^Q2DE1T*IFHI!BQM[H.UDD&3$U33J02DNBD'*ET M<%)K8WQE)_9V[^QM O)\BI.>=OV)37H"EOE2R?
@D"@J4]':*FWJ8_4HU$SE!MR6>5"/ M1.W!#J2.T!"D=K)F(M*[;XPKZ%>&.WCL%/ZP>-KGV'Z3ZC!->CKGCU22*5Z; M8 4CB=.*2_^6N]%&$)]$325(,ROU"
($C"6N"KXFL0R)2PE^.&T],"MQJ:41(M]23))C/_[!C8HY[T%/G[4@[YQW_M%MN;61-!.;I]:/F'Q3XF =DU;T3+#$0D M6&Q&$JE%3;0-V-J*@96GE'"'S,U
MIY*N$*^36@E,37!)3(R1Z"#JX$6*4=UY>&]B:I/:_Q"Y^A3=FW9]BNZ=87/& MKZ BG65KEW/IXC(N0TXSQ68M2941IK M:AXM$135+$=KXF2()'%E:QLHIW&$C?
[5U2PQIVKJ)O889=*9VY<3\WRRS+-2 MM=5>2")8)8$1 @^TE4G E4*MO:W2J1P+(QBKA25<4V">7FGLPL,(%=I3[ROO M:S8QSX=P4*9V>E,
[O8EV)MHY>YOZT050[SN1Z$S[>TR]@>Y8_ZL-UXI3.&@Z M56 \.S"$A1&DAJ"=$G?/+>6<3=QR8AP3X[@C(L3L#*;DABQ M:IM%18S6H'5Y%;FA2OMHCQD'0??
%CTN_F"!9WP?).NC5>TNXK.]8&7;79N'P^?_V M'&YVF\6_S1N[:D@3-XMTUTVYGOP"/"3'P$3M$[5/U#!1PT0-$S5,(S\6DYC[(C%G;92O?7*,DZ22)#*8BFA642)L
MLHH%:ERE[D7N3A51CU8VW68YZ<=:GA,;G=CHQYHO.OG$)"74C!% MA*N]UT:(5(]K"GA2/L)%7#@';!1L&,>E(DD&7UO)-:]&:*<3&SW;TS(5!T[% M@1/M3+1S]E;VHXO*WK?
O^4Q3EZ>*A[NVI:F+-0^6,"QAD)(I8J/B)-11)^H% M:'7^-@I+[T8)E'-3?V4G]B-+WIXXYL0Q)X[Y*1Q32F^UKP6I&-:(N2H21Z4C MVFH6K9
L8>NJ+R\N?:1F\Z/EF!/SF)C'AS/C9&U8T($(KH$1U)$3XQ,G=>6E M%MH*'D98XY]38/I84@8FWG&VO&.J,IVJ3.^IRA1^QL3,_]WQGK_NKN)FX>'W ML'C]41-2\.O=1OJ.QO+>E[]C@?
Y^&6<)N/GL-;)S[,*[WFUF5^M5O)G!@'^+ MV]G5;KNSRUG:K4(SG_G337MS0FL\[N\T>[/87L[L;!-M@%'!Q7"$8"@Y!7;P M6KN).;]CMXUAYFP#?^^N0<#]:[?&3]J!7,-
^P#,7*WC9#"7#Z]A^=3$;SR.\ M!W\\CW9[B=R:DT/#)4[' M=1#C^H?9HNE7#%>DP6&V2S*JFMCD#<%Y-=?K;??K-L]R WNTR9,,\/'%P7$ M:L<7+E8[VXI:I'Z?
[@,'2(%DI5AH+>H)V4!-LWH>6A2*BTYDIB*OXH M5X('FIAQ'B.!<_ED1@C X''.&UD32WZA X5CN?KJZO%]@H(M7FV"L_S*%_! M6@%A[?6.O\,[?EBN_6^_FT70.*[A?ECWMA0
9A7#L^W'#OK_L(]C7?=TTM\4 M=[9;+\-M'/UOU+>SP1)GVCE8Y"&=/+I5*9?BJ[Y;;&$4_IWK]'*S3K%IX' M%\1%^E-QA[/:7 M2[O7M@&99O^YWB"O;[EQLW/-(BSL!H46\O\F+A-
9K)##9&8+?/^("EZU5+"7 M&_'M=69)(+MFV_5WLV\6W\[^UZE-_X29W'Z[/OG(I*5ZAETD1J23P3DQY2ZY*M;14U'248/XK+.!/N'YVY>/? M8A,WK]]M(ZJAC?
C37W_\@)'XCF80A@F5*DMB[9'#!PZ\OLY-M&J;*AFJ,,H] MX58P:Z0CC!I8#<4#B*5:DYCJQ)67S%A]_S.KC<:@24U<@*%**Q*Q#-9?!"$TBHRZH$?JI$>>O?'PG.84I2>
<&^1X7I'7*TE809T MY>2-T=5H9HGF>I] @"=@'U5FB0TJHI;+!5.5"Y[?_\SJI!+C01-N\,!C:W.M M4TU4@&U(VC&I1S":CE>!:5_!GF&>-;>(H.=JX-D1MC.IBM&1L_+N9T8%Y<$+
M1SA#MI1_1?Z;9SX'/[#O07D[1^V-^5H* M!E:LR=J;L1[S:QD1T4AM':6:C7S]E=-!1!=176-P?$ OLLDR4IM0,^ 9T=M1 M:L77)#+V[MC@/9+,64HX$;B,RG-
4CX#SF:HB3E0U\!0G$E7"A,!&H ,T!CP2E 40(;"W=93 MGJBIX//[%Z*&A2@C4*O7&OA;91@Q8+!BBP+0S:S5<=R3@%,!%AQ#3BC@'@=V MD@X>?O5UDHX"PU-GH/A$V)DH147
8(9C"88J*#XJD535%6,R.E6/]DQ:4/2< MC:162N#,0#VPFI&@:MABZHW0=WJ4JX>I#9PE:V>6@6X/JJQ6%EB[,A:8/&C\ MWCHMHK:"F5'*#^B'8+9PD-\5&CP*[>9:>Q*
>*H8N..ANG]*!WT$[#'@+S1& MX"]:6C#G@=QK':5-8)@$.X(P*K6%%@:X58*3/^,Q$1FX"#7MO))P*3OE-+? M8;S J0-%JB+ 4F3Q@YG*&1)X74?'N--I9)8Q+13C7!%:PW8!/X)
[;+!$@;I6 M)1,3#^:^Q?$#.,/O%]AAM\'H%J?,H"+/=*O(LWJ./Z$@?WV&HS5]O%NO-;+O._.#BB82YFCB..:5UOUJ\7(8:2E='$U]D_$M_Z MV#2SZ_5R@4'?V?9RL]Z]NL0,B*NX\0NX9-
$1T\S;#3QNT\Q@Z/ZR>V+VM_@U M/N]5]JNTSURGG'Y@KZ_AV3GGX\@%@\?4OGJUB:_L]BCFMHDX&=Q=>'8!-;]! M'I_'>3-;+JX6VZ9$VO %F_5;(- M;/CYG?NH7,4CP]H6A3[G",H-
51X4HE 9 M6M=@G8_8?- "+#:I0>&O%-RC)=Q3!1)!70PT2,WM/LAQV>S/? S/KA!J[F7< M_-(O]*TQ^_J4"7#OY[_UY'W_GJ&D]'6'#2@\=H*-5Y7 M$G:>IHU)OF)@UA!OT9OE*2@N
M%&R5RH$MZU45/!L=?*MYY!;L'YD"YGY$X/XI!F*C#(I6W')W#[O/J[,T:%L/ M1[2@=8-:#::,[#5UC%5$!0YX/DN;]=5L"R]!]3C_.\BJ+NG*UTOK M<[)QN:>9S]Y@)O/-+"[!=L+[KG<;?
PFW]<\%4V!@%?0*?];^XV9K@42[[&;K MVU(A5-\=IBZ#01";B]GL%_C:Q4O[&JPR>,IEM$NP1CP:*(.[EFO,,,_IU&A" M_-?%?U[,X)XXME/L>RV5DP_:7MIM9[LT>?
A8)R!.ZH_W>ZJX1&QSL!04'A-C M0#0R2JB7UDMC!-.C:"^O:A^$1C2E"CBI"@EQT@5)22EK%.'GZ M/)'J0\Q47YPE-P4Z?4>J4T?6V7-XIH01&#2,=10#S
MP@3BD^RF]45K[;"P4*5G\>Z;^)-Q=S[*G MZ==XO8U7#EB^H/,VLP=79[O>PDZMXG9FO=_D2B98R9ST/?0W?41^=[L/;VQS M?@H8,TK02&L2M$UPNI,BCC-&7*55$LH)8 \C'Q-
WHG;!$%%A:*JVAF@1&*$F M>E]S6P=YBX'S#W($J<]1\YHC;15OY]EMN@I5,* B@(2O8 .CBL3%6A-&A02C MFEO#QV(#+7H+25&"] I/-A<-L+=V@7J>:V$]!\E!IX7$-%;VOOZ'+
<^G_3% MRB]WH2B0)X!3+V:%^[R(OF4^K$LH?#K,QP97>= HB$E,@)Y*/;&@LA+//:V5 MMHR.4U]IX@I4CYH8)1$I%/14A^47T40-FJJP4=PI\Q'O1AV8F,_)- \=*6QW M
..D]D2RVA*G.>B@(KDD PTNC=R\2:M8YR9.S(#>RAPE&AT^#$05\"6MG?RH M)+2)^13F\T2T.RP@;W;+K!3O5LF^7F]R-'$+"Q(:K+N+8.NOBA:=_219+<9"
MOR[*B8IW,S]84.3"Y;F9@Z_A(;E@$Y@LJ-UXZ2;:!CT-Z^Y:I+WB,/A,]FVS MXRJ/\.S#EJ)2%?..$>\=9IH$35SP-9Q867OJ3)WX*/G8)<V)G$AYJA))#$
M5)Z2D"P')=1&)>JA3^^G=I%!?.9_?TE_@PU;[6)S2V=;G.79/DL?KI81L1DC MJ9._<;D5)NP-$>D2EG/9>*C#%66(N8JU20E3$MGF*BBDB'6"U%5W$C%Z)WN MMY3GN-
\#KK2]W,22^+!:K"*Y@HLO,2UBL49.MD+>=,J2/4QI.4OZ\:JF4M6* M"(_%3 ZT A-1N%-C652VCM4HHY5%HWC%O@%%KI5544TK01:I+SF#'6(NZ6? ML_1*G>5V"QE%] F4?
A$K,"0YF)0^>N)%9:D2G#(WTO_J$"HPE!0)UCLP6!,C M6M? /5@=A/(5&*[F3K?[/+V0]S>$+V14HHWOQ&:;U9HPT("^0&M:-'L8'CN# M3<17@LJ68,O6FTY-
AH'/4<&"\9?.FMM+^*@IAOC^)D0 VFSW;E5\U^CXLFNNEO?D.O_W^&D.! MJU<#,/E%&6H+M5X^^.<.UB[=="_,MQ(@F>\S5!0^>Q.7%H79]V[]%A<$GOE=
M#R[V]B,1Q!C_?'MFC^9V]UO(JH,]S#A+_@7JR6>OV9K-]OO[&Z[M_O[P"UC7\G'>Z)A;Q-,[CN[?&-OFN]_]X>>)-HG=[N88=CRC@VH8+2;M[MI M=]3Z_Q([3UKEG>(*;?8MO)
MKTYTSO/S=LORZB-I_?$"VJ]W2YAL0:+#)VU@;/#.G(:21]PZK_:3;,.=BQ5(M:OQFMVI32'+ZQV+U>KU\7?PT5_:WHI. &M#=?S'[$S"BXL-I@'HS(N%J>ZA@ M]'A,GS29K"\@
B!0H0/%88T:0[O&.7'$SII+N[GN'41=:DFK8L"S_Y!5'=BW M%F&JTS0ZS<.^@GDV,&<$2%PN,\GD@+#M%V]F]P/#X\I8:AW7>::=ENE+Y1'EE6.2NN@T:Z!KN#C$,>[JXW9ED(G$<)!
M;.;E)O[=ONU<]7]?M[D:#;#N0>E&BY1\^C#GY;PM/GZ.;'SV#5KTFW"8J=!$ MS-B=_6MGP3SE#8 N](< #.A@5H68/J^N8S9G;_> M9$-Y8 :GQ0K,3:]X%S8A'W M/0OZJ,?5-
=)UH:$F]G.8SX#;A47C=TW3):(#?]UB& 6/YAI7&"OH?\.19)?& MR37M.#"FJ[?<>>B>Z+2OINP5+F7+A[N!/ WZ+6N]7.-:N[A;M8^1G3[-]\-]V40*8(!79'EHMF26-R=>5"PJ;\
["DG@:G_' M+Y2J?W\8'CK:S)-QH!S(^#YO&\$W-M^A=Q1#&:,-WL^H?=D][3B_J"6E=0WB MS]2&"JI^/VP;_%N,US"J9;\6;60F+\E[U@#C#)ISU0<:!B&:\F)&Z>^/GGH_
M5/[+:O87NP$5E.O.WV9G_]QM;A"G8[?!]B1V]CIN,L,N:" M*US#-<%>V5?% ML7UVFA$+GC-3(]1R$D3&H(GF,9%@$_>^0C3"$5J9<90)X241500K)BA'M#": M.*R\,TY5/HQ I']>-
\V^N\;-B[(DS[")2PRYE]HMZ3WO:;UXSRDLUS@_[)=S MSO2@7.#4I4 439K(!$JRM5P2; 8@4DT-MZ-"&NFYB$P*=*Z!=FVP Y]FB;B* M&V5ELK8:=].[*WJ0YXG9DJ%_BDH$S..?N_
J!]C04LNA^4&8!(ON7MK7BWS? M#_O2X3^7TN%?;QH0([-O4#?*#)5^WUV=?V7??XL1MER;A[D->V"DFPZA"*T1 MN[JYF/UT?
RN3&TKE:'KNTA1FOX":AV8L.PQQ;$KM]6ZS+5?'LHY7B^UV :PX M5[8>'[0A-JR\%B'91ALIANV*/P,5(!=8AHG%EO:MK M-G8@@V2MM00.*SA6G(A*$$3)
(DS:Y**2B&%\;WO/3K8!N>^]OV@KEI%;A+A: MQ&)"#ODC&*Y-MI?!0,ZJ6RY(WK:.QU-ZW,4A1U[@2T/35C0 3VZ-W2O@WFB= M=KQ];P[N,YXF\V,R/SZ"G)_GU(HEZ@Q_7C?
7:/!F4GU^N5B&32S:Q+.P7L;& M9Y?$-ZTBL+_Q$U6!.7I+;&XBN0J868*)*)@G0V Q,$DEI=G2OLD%^;.T6.X1 M1IXO-AX^A0?AH<-1_FWA+Z_6JS"?_?
<"*6QA#Y25P>1^!K']*KN/]L,M7J.V M8FBYC*]:5WC..\INYVM0"3)\XMM=5@U66^_G7_Q"MU,.=W(8N/-6. (2_CG]2*LWW0K$Z_1D0Y3QB=MLK-I[WL"%@@J2??0LHKK3=F,?AZ%
M0;0KF>_]KS__6J*DL&9V$^>SGU;^HB0?V0#C@E._R;ZQ&;J.IU9?T#OEU^3?N>:?F-.K?/%[&6WGTV;@W.4'PS#7L57<.C; M5*VFL1C?P,-4>)6X-A]!P>/K\:\T.Z[[:K6^C3F]E]6U8?
>,35(GL;"_0@GZ6"0P3RE%SG;>AK!8$ M-)^:/F)3]-R+V2^#SV:\/O(X].;!WN& YQG>,IAWZ6:YWW%6*U-8ASJ;TQ'KLG:>Y\UH9+_@(@MH&SJ.*FE"*G2L2MABCGA/!G [!
M\^CC")O_[M3NLP0-R2)G$QVJ!;T-#N33<_^>^0-/+RSWH5 0EFH8^,3-]QR M?L21&^=B*- P&1H;BA?=,/.E'.=97Q?M(E^SM\S\)>J.F)Z=\ZA;R3G?ETX5
MH=VFG7S'[8HPWV^@TH#!EC$+- M$+SJLNU.?C3-=A"SYC(GE;O8(V2A KP_&5?V[>)J=W66$KFVG*FD<*$)[*B ME+B*&>)X"-
&RR)4;E5)S:VAE9"),8)=#&0(QS*OI6LKY_5<934\E^G9-UE=W91<@L.DG',CDBA9JK'DIY+:(5>,H()A_TA5 M&6XK4[,3S=U4)9,3GG
G+3:,5,0J;TAP,:;:NZ3HAV3Q7S,/^27M[9X#&AE^ M_"FXJ?*LN.A E Y4^[:2I%G P^SFP)K.+1%:BP_M7[SNO7;C*6?6U\UQ:%TY M]^.!^4>7G=,!O=JF@Q_LJX?VJ2-
]Y4T7WVDOS;DHY*HT=H@'!AK^W[L4RXDN M4N5-*<6!O3LLQD&GY2M@=*WL6F!.SQ:D ZKCIDCH5[@XOZ!:IAY-\;_7009CK'PM,NMH.7+W9N '[?I]ZM"]!^Y(M/' N
M%*5DVQRV)BEC[[N #"!\.X#A\|^O5)1%Q6U-1-()A+<"6>\3)3X9#QJNCS2. MP!# WN9!BIK4F@O4I,&N"MCP$)M[JHHF:@[$)YU2]2C83UO%^BVP!#X.6*@
M#2()I0)R4/W8@T$C^?9,8]]NIJ59!,@^0&#]YGT]:M[1AF; 3,Z._+17(54\ M$B6QY09S-4;&**DKL/=-7<4ZH$JH6UM'*M)L-AW0<$]3H*B&J*4-7.4LMJ\ M W[];]VB%!SVV\K8?
0<(MJRMK$--#*<&RZ,9T50;8F4R+@2C=#TZ6@%[<*/" MG:+"3ELN$JV4(L:9.MC:.1_N>&XGLY'/[ZP=]6<:%8L8W1D?J6D>%"U),&@C\(8">:79B1I,-^4%+ZF[AR.
M@V+6ZHS8@2<=^G0:M"A(L(9+A23/(V[:R(D&Z]]35B%?2MKJXDV5A$>*D=# MK)1PZ6[G]E%=*,_Q-+RK:OPND_7OU1#XJ:B2",.T/:V:'JF$6 P_4NSCVTL+ MLVBRXPI5SX,J_D-
=>* G.[TT*F)]K4%NVX@]]^K=N8LU<+$2@[\("*5%89O MCO2"K#FT"$#',\JOP,=O;=:>04?-,QLM2*\6CW/TO\UVRV+;%2\T+;A[DSU\ MV;NQ@5FZ-;KTL(0A5T7 KJ-^CC39QMK:)
(QLN"!JT?R#R $%--Z6N#KNYVZ# M]I7O'' #1(?6L("?2OE!# \DR_]-@;1QZV7X.FGV+S>XH, 0>O7\82S,%_L% MLOTV5,J[A1ACDPQ*;_(U.7:6SV\/VEI*2(_V.WBK-23"WQ0
]^K^9M]Y;< M$+)[78[(MYUFLNM[L]E=EU*<8:>:%LKKP (X.PU&U+K"_O7$UYIBJILD.HF* M)%\SSXROZG&]GA;&"(JM7@S"^:L8,,JBB,6FU=HIQMB!THM^P5]6/[0K]M-@

*MP09PRWGI;FY+\"3Y+\'_*1E"]U3*5O4*{8LPP=;Y M3GV_0 M?**AIR6ZQ+-F533SIYCC9;Q=!L:_/,LG7>^>M\I$D,-.1BQGB+!"? ML=0:K{%E^1BRA-,$=IHES!L&]DU*1/NZ(AX;6'EO9&+C6/M-_C:!.'GM)"M@7N'ZBGI5)1 %)\Y8>O- G3*+5U)L.NO+FVE!]V(0O$G Y]L M0&_#"V. E?QEWIO@1;\X!T1X#6IY3X6$/|QVI+_/M&MBY,:;?EQD>N!%$1LYYS{T]^?X] (ZU=7="5BIF!NAGFPW1E|+U=<#$[;(WYIE@L M9X3@.X02G3\'PB&KYHP?)\LAB__/ Q?\9@O?/?6ROUQUO=YGGHOTX'Q=5H=MCG!,+_^UPXP35G2V0G|9U D6WP?KZ.L."W11M^NV;(>-P+7[|Q\H[T>=E1?-*%A\Z&W0 E/_=[0\ OB_,+,49N, IV%,)?L(6M=O>EAVZT!(D2?%OJ!$M.N_',%MVW9^5,>-34EZ17R(BDAI@0-1$4@"_J.=2\K2VZ.Z& JQO8R;7WKA\,9^ 61%F0!&3VM1$UZ!>*1Z-2RYY&D8X M"K=-3I?+RD_LXM>U;-2@+!9!%MJ{CG#D@-.!9Q M 3@9KS D7-65&<+/TF#^B"IW5[&PAF2V#'0Y]GMO_2B%K0"O9D[W$OFB<4R M*V=!:DDN QMC6\[JWFBAM] YCP,A]I7AVK I.M%;EZ)O/ %2.#E^GH^^SDW M!49'R2\9&@-_GCWS. CA.7+ OO4$2/A.V.82#E,.H+ ^X>/Y 5O;+*.I%49T1 M"%4 ^,9 (O5(/W<@C;4=V!=?F9N\P+;.R!0/PBZYUB1Y(Y;8'07=.T-CD$'-M0[FBTD)A"=N4<4XO"X=CAV@K MZ'?.S\R_"'=S./1OCH8Z^[% 2#?]BUENE3!8@;QV5]!CY^LUNI%S3[5]67"S M?0#(BEQ24#:KBEBN(B@&%&"1"K2W1K*(F5'50U2CN'!GP3!E&O @U6-]"$9TD M2(<@E/-8U"GB0?UFMSPIQ.*+_58\6X7G@XUX#LMV6^W"A#D[>7&/-9W 2<^< M%@,SE0:=DU"&.&H1E52E/-C7W*,*&>?8%|/B^RGOU4!J;HMQ$]SEAH+<*72 M)0:[02I:*2.WA"_VC6%$WQ>QO1@9]MB:,%!^DF8>S3BY!>$YQ>5Q%B/V/5 MQI-EI7>S*B "?7ZTT+"X; 2$]"__BOZXSEE!?B_5LW!P7M,NMT M{]KA;#K/5FOLC(7(9ZMM#W$%{]O-6DZCIB0ECE_# M,2'4 / 55[G$T9 =.XH_B:5T&3@(!1>+7@MTDU7=O\)?-U2\))H>`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|&U#.WH&-L_1BR6|QA> MSV\I"2(!MPGSH\>70,3^#!9U9- W!FTR8*]+|/RZR13Z:IU5BW7A=J_"Q8XZMN^;D'DYZ1R_=^O0KEA=D:,%I,)^LOU&G,+@4(/QCQO@7B/-_D;V$*D[%8>X3<1YY7/]3Z=88+H MG2!ZO\0JK2>(WB<+T2L^#Z)7/F*(WO4QW[Z8_7F@Z!X)4/PHK7.49MUJ>_&DME.BZ*0$I4XT$CM-G5>A6W.*4DM8$ ^_&P>7GGDP@+#U\ Z4C'2@6-)HF>PY0=QF$ M<4I3|HI'DN3R:9KRRXI;2+2OEZ<[W.5AJV/]UP1Y^S_9NAXRX!HM6 M;(&<(.?2<[LM^ 'E]Q-+@.(\6Q%{!R6G3+;MCS>+DF'P8E&P;OI 5\3)=0_^ M#^3GL!)]]N$Q_]$G1-K5:HW.M.[.[!PG=1'3;#ILU^;2[OI]+=B-?0OS2&ZMXIC)VH;%I44K8#GSW0@/3(4N7.:R9;N*H43A8%P%F2YK2/W [\"I+_M(MM\0F MFQVH&UEWSOF,W4LZU;53XX;]7^OEL5W=YY!.BO;2,5]V.]W@;N>?LO[\3C/N MM 6PP0"78!UC+0%"M)864YVH,O79*GHYC#\|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|&U#.WH&-L_1BR6|QA> MSV\I"2(!MPGSH\>70,3^#!9U9- W!FTR8*]+|/RZR13Z:IU5BW7A=J_"Q8XZMN^;D'DYZ1R_=^O0KEA=D:,%I,)^LOU&G,+@4(/QCQO@7B/-_D;V$*D[%8>X3<1YY7/]3Z=88+H MG2!ZO\0JK2>(WB<+T2L^#Z)7/F*(WO4QW[Z8_7F@Z!X)4/PHK7.49MUJ>_&DME.BZ*0$I4XT$CM-G5>A6W.*4DM8$ ^_&P>7GGDP@+#U\ Z4C'2@6-)HF>PY0=QF$ M<4I3|HI'DN3R:9KRRXI;2+2OEZ<[W.5AJV/]UP1Y^S_9NAXRX!HM6 M;(&<(.?2<[LM^ 'E]Q-+@.(\6Q%{!R6G3+;MCS>+DF'P8E&P;OI 5\3)=0_^ M#^3GL!)]]N$Q_]$G1-K5:HW.M.[.[!PG=1'3;#ILU^;2[OI]+=B-?0OS2&ZMXIC)VH;%I44K8#GSW0@/3(4N7.:R9;N*H43A8%P%F2YK2/W [\"I+_M(MM\0F MFQVH&UEWSOF,W4LZU;53XX;]7^OEL5W=YY!.BO;2,5]V.]W@;N>?LO[\3C/N MM 6PP0"78!UC+0%"M)864YVH,O79*GHYC#\|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|&U#.WH&-L_1BR6|QA> MSV\I"2(!MPGSH\>70,3^#!9U9- W!FTR8*]+|/RZR13Z:IU5BW7A=J_"Q8XZMN^;D'DYZ1R_=^O0KEA=D:,%I,)^LOU&G,+@4(/QCQO@7B/-_D;V$*D[%8>X3<1YY7/]3Z=88+H MG2!ZO\0JK2>(WB<+T2L^#Z)7/F*(WO4QW[Z8_7F@Z!X)4/PHK7.49MUJ>_&DME.BZ*0$I4XT$CM-G5>A6W.*4DM8$ ^_&P>7GGDP@+#U\ Z4C'2@6-)HF>PY0=QF$ M<4I3|HI'DN3R:9KRRXI;2+2OEZ<[W.5AJV/]UP1Y^S_9NAXRX!HM6 M;(&<(.?2<[LM^ 'E]Q-+@.(\6Q%{!R6G3+;MCS>+DF'P8E&P;OI 5\3)=0_^ M#^3GL!)]]N$Q_]$G1-K5:HW.M.[.[!PG=1'3;#ILU^;2[OI]+=B-?0OS2&ZMXIC)VH;%I44K8#GSW0@/3(4N7.:R9;N*H43A8%P%F2YK2/W [\"I+_M(MM\0F MFQVH&UEWSOF,W4LZU;53XX;]7^OEL5W=YY!.BO;2,5]V.]W@;N>?LO[\3C/N MM 6PP0"78!UC+0%"M)864YVH,O79*GHYC#\|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|&U#.WH&-L_1BR6|QA> MSV\I"2(!MPGSH\>70,3^#!9U9- W!FTR8*]+|/RZR13Z:IU5BW7A=J_"Q8XZMN^;D'DYZ1R_=^O0KEA=D:,%I,)^LOU&G,+@4(/QCQO@7B/-_D;V$*D[%8>X3<1YY7/]3Z=88+H MG2!ZO\0JK2>(WB<+T2L^#Z)7/F*(WO4QW[Z8_7F@Z!X)4/PHK7.49MUJ>_&D ME.BZ*0$I4XT$CM-G5>A6W.*4DM8$ ^_&P>7GGDP@+#U\ Z4C'2@6-)HF>PY0=QF$ M<4I3|HI'DN3R:9KRRXI;2+2OEZ<[W.5AJV/]UP1Y^S_9NAXRX!HM6 M;(&<(.?2<[LM^ 'E]Q-+@.(\6Q%{!R6G3+;MCS>+DF'P8E&P;OI 5\3)=0_^ M#^3GL!)]]N$Q_]$G1-K5:HW.M.[.[!PG=1'3;#ILU^;2[OI]+=B-?0OS2&ZMXIC)VH;%I44K8#GSW0@/3(4N7.:R9;N*H43A8%P%F2YK2/W [\"I+_M(MM\0F MFQVH&UEWSOF,W4LZU;53XX;]7^OEL5W=YY!.BO;2,5]V.]W@;N>?LO[\3C/N MM 6PP0"78!UC+0%"M)864YVH,O79*GHYC#\|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|&U#.WH&-L_1BR6|QA> MSV\I"2(!MPGSH\>70,3^#!9U9- W!FTR8*]+|/RZR13Z:IU5BW7A=J_"Q8XZMN^;D'DYZ1R_=^O0KEA=D:,%I,)^LOU&G,+@4(/QCQO@7B/-_D;V$*D[%8>X3<1YY7/]3Z=88+H MG2!ZO\0JK2>(WB<+T2L^#Z)7/F*(WO4QW[Z8_7F@Z!X)4/PHK7.49MUJ>_&D

*MWU*G03@?/@P4N\8=PUH-7:#H< MYRD$/BC1@U99=PIUK2HEKNS%N@%,>8B_CA>GKY{V!^ZR%I$H*L$R6CK\>?3OI27@ MHU2!({V3A_@3A@G/1{[8AA"I% <)X0{)GO3>VJ1R,BKO#!RQ1EM:H:Y"W0$L M:H6Z71Y3BC'P;)";!850YW/IWXPL+4B);JFA/HDK\OKO$ -]X!,=*:%7AA?ON.NWIZ,9FU!3:V:XOZL-3%PP=,AGX!576#JP+F M(2S]YP0O?L*-(Q0DXP^JC1% M.-0.C$9^2]A(1+$LZDZ>&\BDV2,0AI28NA-6$_!E];M0?%$$_,&!/K0>/C&FFWTOWT5_[YL M%^_PR;9DK)1JN#$"C+O^\BMT5NC<2^B4*CI/$RVA|(0P]!182P*R6- 9G M'I;) $C0*52CI\'2 _]=%3J/$IW7Z_$*YMYU. %XR HS>#++#\UM#I0&%W-X M:(QY2|!VRR@PY0WA|/A KN|/56RKV':G###*74S&@Q,R@HB:@DN6@0E)*J^(MH&[@\=XU^+L=;/NNEEMZ2.RUYAE?FV?L,JKW0]*,5XG*-=OXX!6RVIH=VAIG M!#,I"PA:!Q#!9[L,>2ETJ !B9&Y 8^^3VV'VVXV/MUFHE(-D?688.7?A[*H M%1-WB(E!.JHMYV -\2"2Y."M158=I-7E?R0,8POW* "Q_YC{J&Q$/3M=0?$@ M%O4Y@^+!|U4Q;DW.TD R08!06H"SRD$*EM&<*--F<.SM/F4H]@)T;Q<25K0A MO&8,5!0^PM4I3A3>.4JJH+.S1(%1"A&/R8"(%Q$O;4:>]O$?M4*%GN/CH!3PDX_YI.4(YIFH\X:4:,,,%Y#R >I4I4F[9*YJ%s M)0)BL!KM2_)@+!=+H:J0,0<5LR8"M*J4SX%!J;0)0HL 5OL .=6>3.4F"O>Y M37K5]>;.ViHKT-DZP1O!9*JJSZ$!.U(M@NZ\)1(72)UBKA+8B,_-I[ET!&ZK)1 M5ODTR)/EW IGA #7U9*S]6R<25>B$-1H)KBG U:\5033#=>LL;6(;T6P@UC4 MBF"[[&>=HO:6"B!(GT H2<$!2H#Z%)RR(:8\B MP'WB6UH'**H*@2-X]=MPFM4H'B-"^4P@-)NN?0T(7F3=]?X17EC-&^$KEFP-T0A-MKT]]O4IT[A*/O-.,'1XB'NOPKFC1>]Q@K<,[Y.%50:W#.XCA54&MPSN(X55! M/8+AW9!NH+]XW.TO.;|^Q#C(\0YPH_Q4W'*#]'M<_S33<1RMPPY7 M//I,Y^<\|_G+'C)/N^S[fTN%GDWCM#/XZGJ;1,_SUM\VE:4SQGADH=YI17C,) MWY,YK4"U[WH] ,:-4MYCCCU*PB7:?3;S5-W'-/WGLCK+,WS4|HOO:?Y^<&YW MV+KB5-6JJE7K^? L^G;KWX|E\!4@_)S=9G%[2]=$+=ZM3$56OJEY5O5K/WYO% M:9I7M:E[4]7F+FK3G8?HS,_KV:0;K%ND6U5 KWI4W<^^3(4)!L/E7E 0M"+ M'V;3B9N/W#O4@44[&D]'B]/9LG73V#Z }>['O#P>E-0*T3O LYJ?GF%LT."LZ2RD=P!=UR!B)&!#PHYD59&RD2X"L-.&,PCS&D'MFMC M6G+2#2$*'#$Y()XP2<.CP9EI"*&-X;6!"Y0R(\08X40>G"4H2B!D*DMY MUQ3Z+KO.42.XR3QO&\F@67M"&&=*P6I*DUK3;,L1KME54D%>U(-6"W' &PB@ MA"HY64&0J.M\4KD8DND)-0E(P8U%.X5\G]ST<)94HA87@A@WG$0SN6", $$YTS$;*2R<2LQKYWAF:&L$:K6>*U@5D-> M->15=>+P@*X;^)T;>#37+&D(0O+2)]2#C4P#-T%+D:A*+FtEY+4[AX4WE(A& MT[I}_Y"85\WR&M1QGZ8:[#IP!.JV8Y>VPV?/K2P-ZK1!V\$-.,HL4$^9,B2) MY!X6[%H5W%L9C'47D?(0?QTO3E\O6YR(-/_O8Y@LXWCZMA3FPW_C^:\CEFR+ M;*SEC,$U%E:hB$L.H6[`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|@9$@0E;"6,*5X&%2PO?S^=BKT W=L%C*FQ#2/L^-"W]HI5&#Y. M&-XY3!KG%??TQG*L4_S$2?-"&TQKT'D@]2I:I-VF87F46-9H)[&G>*8+KAFC76RHH@%<$.8%$K@NV2@TDC#",6&.=E M_TGQLO\4\-<0R]D 2LA@SXK[P+,T#E16$02U&ASA&BD9M\DJ(D.)N>X0P9@P M#.D9L16_#F)1*W!M.JZ9#'}'H*X*+!;^R4N L.H4J^4@L%\&809GR+++W3-FG0 M*E#$/!? "Z8 .9ST-,E(I=TI? E'>&,T;H6L>[!512'SM_"1]]^]Q_'X4)[f% M*<4!OX/)N%U-FJ22B-S)REF:;WIYKAZS/-)++?L(Y__K:.&[/)N[3RSQ)'R^. M5^'P2T+S.'|:/V#W&6@7:K[XMAL;E&|L7WK7ILEXF@:S<#],U9<]/++YX887P M ;^X|)+>7 AMJ:5"4]*XU5]?#,K^(Z4S?*,)9B;&TS(8Z",D"S/PU7L?]:-9V\4:EN2@'H3A C5-!K R M>, ^3MSI?]\E:,/P E\?9^8&6<239<2/7FSZ-GJ;IF77(L51 MGL >C6;+^@TN#'&B[K48[OD/!TM3M/H M+R? _^V3DWLV692?D[6@Q&Z'\$7YZ4F;?3>/>R0*3AEHO%.1R0ECP),!ZGX!SSS0S7N&] M/Y>%&+W$94_@G>F2X'3X1#,B@*6:9&54EGLD"U_8"'PZ64-\47'FSH:=#-Y^I!*$XF] M1BL2=%26>G!"(EJ5O$$G:(! K-.$,^2\@_/E-!!N24*"Y*U +Q6OL8%I"$F9 MTD-52#\PBC=XG/9.0D?13(@^(?#QQ<[O,01)+G"!M8!@,<>*)E!RLY%CPV M 8(+]B3^AD]HYF<QE^7"/C;N=70R_O 8S2Z&8$X#/M^M4E_,_P1BQI%+X-IVWG XG9)4Z MU;IQI9N-D/KMV:P=+=_>>IXDKH_ 6SSZ66<=[OO3HO*' M<<[C@_>6D^YQ[B.HC%X*9YO3R>Q#)R|E&D:=GXOL/W9(D H'F?+ MQ:,\B_^TI6! (O%Z*U^[WVN=&!C+NMQ%>=/L(LV6+=VB;4?H8D$M?N#(B0GWS M\K+MZO<+ ^V<;[HYU!&G%5]"2%, ^#DAN42UPS!\]3_+8?OR4GY.OUYW&2 M)^ZL32_:=.;*ULAZG;K=W_]67UUUG.#]N$?(0B__T\OU/:X[*-\]JR0GW'Q] MD5VMU]"G5W_ZP]7H"K%[7GF_R^P)-8*<-W/SWLCK<.MS#'.X-9X_%\|> M707P=SF0=*>#-8>7$G6LPT.I*_MHNY?'.K&&U']9!LMK).(I6'.&*)]_A MY#PLRG+1W;F>F\Q3&G7!^U74OBMR=BGX=G_1^<)\]BD)^%[.-6GJD_;T:=? MQ].J3EN4MVKN^SS=&YY8A.?/MTX(&Q5_JKY4?;FUOMRJ#$/5EZHO55^J?:GZ M4O6EVI>G\P>[/;K]< AWFM7R@ 3&[S=[BZM]V9?;QJ;'S^=Y#'#:C\.QCVIZ MGN&0JT0?]? (^PR%7B3[HY7V&0X@J9?

MFT);4CMZ?",!U?U_*>_<6.C5LJ!9"R! M$ &IB2,,;L^$R1"TEH.3|'?2|WVA,^SH$C0JG:G;MG4+LX|YDCF/ M6K'1AC+5$&J.S9Q73:^;?I<$#9D=]9*
H9VF6PZ&.0G!4H8H0!47@S.V=]+T M1|RX94>GS/6,[9-NW/lE?X|6LGO@19X;_[PY!J7[?G.[BJX>@#44]- M#@D(JC0(IAFX)#4P$Q-ARD=)!EL7=]+P?0Ef'IVBUXAF1;F*LL62D5CQ0
MH#1I$$8BRI4NM9YGE]W20@?[.W;9-U?,JYW?0% MS=2.#I7.U W:Y[KF=?7S\XJ 19))IH@F2QF%;XNPD"A7SLM7)EYGX0T@E\3C@!8;4'QVB$
M1!T/R9O.PHC*U%,9_MH[5W^'}GT(0<.D!>144MOXR9M"V&UIP'A.7ED4_<,0X M"N=CD>V3[A88VZ?]>KVW>8LK9H+MYGAS\V]_$N[M;%?Z-EG^/+ZI99L,T+ MM[/*N:?
F7!.8YTH9,"$@?U(46%:($;Q%'1U+-N!2PS-WJ?L&3"6(HBL+9@4 MN[!=0B*/1 LY'FU%J6Z5KN4E7F_G*LJ?OH_!^1!*03AI*6+6&M16.H)UVGF2 M)9%TX,)Q%,/'HJUJ/I-
Z4O1"9K:RW,E/BCS/N/'SD&E EC,T@]/* ^,A*.N, MSW[HJ*9H3MI+L"G@KE,D"B9F_"|SV7#C4AB3HOJ5LN732S-0<5YQ?@3,"?#&,8@Q4FTY<06!9, M:D,]]^-1[4SSEE
ZM<6\XKSB,)ATGRI(YE&U1VL-B)@B6.X%,!:I(-K)* >] M_2B[:$]XBVI#W!&;E<6+#3:M^?-_)BTZR?\UEL=HV>.,E_ M?@!>!4UKS;1*&4:@U!9"^<7&!FGMH(?_&
JGQ2^>@3"*!T4|Z%8ZK73Z=`0JK::$P.1,H*!.-P, M.QV1*8DR00F3DA_0J9>:K=`A7"^(CZRN)&3Q!NP&K#@ EE@TXT.39PF3F*3L.BSAXYNF]<
MA%+%6673RJ9/QZ:&L\RYRJ6B>P 1" 7K709EDXE"-A4,YXBZ1>,,3R M2>63Q\ Y3]R--')(0C 07!3G,L9!$Y]2)(8E.G N.XI/QK*_?>1\|.,DE)IX MX%D=4WY:,MP(D 8,(&8Y2'E'V.*0K)
M%!WP,*/9,2%!LU)0DWI?BN9)<$$|(JG)8DRUOEF+36TEG9SW7W7SK4@_NE) M1LH=\|U0*3K+,&0J,!PI[T(5-%AJH&CD/Y4BNN[?[S]G,<]?GDZWG7I&:V
MBILOH#PKM98O4.G4.P8D<&E'"'!*3;SS@H4X\,F((5*#M,2-J2LE-TI"RQA* W<'HB.+,SB<4-,345K:,W]OE]MF++,7F?R)\QO.S+0)PU,:"[$O8E@^&)DBA?-?@?!,N-
ZGY-MUJWN%3$UUHB\|[&2"H()PN!/ZE.1] MLE0I*N[NEH(QFDMK58G^&=06]=K23#UX:C0([AP8%B-$(A3UDN8P)J=0VA)B M6\4GYR=6G4(KTH])?9QUY!8!:Q*Q(@S,X$OZ
2,SY9XKKV-\$-+'DAJ*RJDA MO0:R397FJK)YO' 7K[SSP8"4A>]D4F"3C.",=$GXX*0=9"DPBD6E" >,,WXF
ME'2(UGAK]$NTA,B,1=DP+EIF)|=VDP9\U34GW\9%PGPG&72BJ%%,RN"D-MCI+\<0*Q'F\IX'<4SL>B:R8'1"IK3G9G*KZ7_O\:OO\
(AFLRO1_O:I)=IZ3STP8Q'I1%*PTCOP,BMF4RK^&@|"^E@..]=74Z*>=%:: MJS1WS^1EU$G!26$K4XIC1*2Y%##PRDJU61.1M8;,P1QD!:J4%;@=%$B-SA-/
M1#.B(FX66;+C$325UK%4=2*"@@@YE>IO EC.6C 6?3*# BE'(7TLNIVR MJ2&|U@\?033N++YP*Z]4>O*:4Q%9;,'K74)PE497'86=")6.16TI^HFI08C M;22TC,D&)1!N#KW@#)
(FADJKB=!N//'+&$-$R6:N# MOJI.59R_?<^-"HDI#H"{((C7(V.%)Q-*EMO-0T/P_EHY$R]PJURIE|AOM(Y MKWT>(X/5Y?SDIY"1>%7N=%+2'D1BN)SC6((})
HMA=)I$"%+G5.1!PH^>E4N M@S)X+1D$)@0EV3I93C3&(MMI*[5LI9SD7Z,>>0VJ9$"8.L- KWX&Q!
MNH6HI3642'STP,7Z**2/1KA/+F.LAN..*\RW7N56:KU!K4%DBK1(@>>2ML0E MA(PF$8@A7%I:5Y8HF4"8C,*+N0369P$S(9S.1X1)92J7G"O MNG,5YV_?*Y\"2J(V1(*@I
SB8"JD3@&\2H'@ _#"O-XA?X3V57FH] MC,8|"NECT3/32[=8!4V]RZWWFK7/+Y?!ZG)^\EQA.@3K50(G/,&E.0CPM/R! M@IXKZI/S]%G5$[@L_-@C69,."7#F(XA::N9::VQ4UO.*](K
MTH] .N["&9%,@.VD.%121"V*>6!62V9),H3G!R%]+,.*]EG6KX,B/&'=^L_O'##JBQ[\BS+GLKVP HHDJ$KM5@E;?.N'$$V3)X M.ICN8<0G4.$XV.&48I7.$H]$.0@"]
{10L=43*ZES+9T>KE7]YZJ2#\"Z8)+ MY9,(H*E1(+1UX!5"-V6741VA;.+A04@?BY[BD_."K0>AE>8JS=U3T-!L4DH$ MB"_7NS*0(FB0O+20R3A+.:D(&AUX-"&@"&(I(LTY!2.8!
(IP1K*5@KI1.?L5-MIELB)Q>[5Y%>D7Y,6(1GR46+.H1'@:B-%IS, 4Q$,#/BI70K4 M4!(C9!43"&XY&,+P#TF2M,(Z8<94'}7E4K543RYVKR*](OVHNK@L9Q85,*D0 MM]V?
W7WYJM8;]P.Z]D>FI2 MU8$RH5 T4:<9"|<=..DMA$R=T(!& =U*!!0G>,R@8S%Q<9(CY^AB+)$?>2& M!03C>.03F1J95ME4$7Y,!#ZG(DIJP/%RG^%) ,2G
9DR8T9F!/)@@W04PLB+2 M4%Q;%#C"*1BJI779!1M'5#)")"2=(J.3FGWXKSBO,C<&Z8-S%0"226NGH\1G > M$1^#$DGG'$4<1. ?A?.Q]!F:JJW*F7!["UKGO/9YC
Q6E`.3RW;EK0^N7.UD M!8]F#VZZ#%Y1*P*NVD$.TFPD*OBF6D%(V>)R3DJLGW*08E)$4J%%RE6OV@R M3+IS%>>(\^RTDYE"C@:HEN*46C),FX>U;SSF@\JO1V%\
{'(]LEY5]>@W&>]MNGVW.4NKYL)M9OASL^I-O O,=?'?;-GG^/*Z;19I\\+MK'+NR8I*(A&!\P!$ M%7\95V)TC3?XAR#2:(M,+ ; \RQ%I*ZYE M2U5-O?QZ.U=QCC@7CK'(":?!-/8@<-3B?
<5Y\?@7 9*?;:@?60@E"9@J=(0@PO4 M,A>E&3AR'(7SL:B9R0&]IEZOUOO.FN?7RZ#U=7\Y,]G,I.8#8$HD@=!E0-K M) 5M0B!2H-R-@[S+3!'*96; 3-(@6]++1"0,W"".6UM&%'!%,-
$J_7D?,\K MSBO.CXG"ITI&2S/@GP)O[BRXDD99,2,O-LUZ.9 %9M?HB9/PYP?@5=!TB)X1,WFY&TH@ M H]@3!80!
LZ6NE<'LBQ4L&7Y7+2RB(%H3T%DY@#]I6+C/G.XHBB?;70K6"/ MS-*_8DT!M1''X@%5^:3RR6?YA#AEQ1) N(=$B.Q1L1A M-
$3)B95$!.7+C5<4O&3%BB!2U+&DVP^:C$>>4.5.^]@E1\=)H5/*!\,9]8 MSI@E+)H#DSJ'4*JFNM9#@C%?A5'56V;2RZ1/& ML&EA#!,4*'$$^1!WO"8B1[H@5"92.T*''HA:9N10
SE!CPPL%=@BZPS?/*NL M5799Q/.I,MY8^LI/U.*FT>G)4!JT, ^N@,>*PE ",DI=O$&0"'' .+0(C%;._V M/M)\Z17.IH.T8$*:1,FT (U& ^*@U)>\H4359F/QX&M8RU)G*H05/*I\\?BDG
M@O]%E2!1CXHL(*F8S"WPJ&+,D205!QGAC^*3L>QO7R6AU,P#S^J9\M-RX^;X MS9N)Y(Z_GSG]MGK_?4$$LH\RR.@+!9=TT8Z7*UT/GE@;AR#D]" ME2FC%J0,C-
06R=AXHKM\C2.J!JY:141+R.3<_ZJ?;T7Z,3<*QG*>HX0HJ -1 M3L.\T@&1[@QAVEHNV(.0_E2*ZM_O/W<5269G%-_O3&8*M-5 G"$E=H$O_%@]/!49N<&(^X
MD2TEK&5Y8Z(A'K(Q*UV>H1E{JQ;U@B@N>>>[5I*;+A9IR MMES=:-%W0L4"4]\ <5%DJGU:;@O588(0UJT(@+AW\N+'W-CJG!*:.NI:-GT-M2@9-&O-U W=R_R+-
I8L&H9X=;L$2PM9HP4$&YI7G)2IQ$(YX%-3K!N[9U\"C M[_OO3C|QF\$=<-_S,"=#%?WUDN'S_]F-7/S$^>H>T6]?WT!KO-=>SSM'E<+ M?:UT]KO-
=>SSM'E<+KSV>=H^KA;^N'C|POE_@%<4$N_>@#*%/>43SY./Y2%CA MGP'+4<%CN\%XGA=G4???1IX]_A]!,W(+^?QSN%[NUPUF].$_U^EU)SCZV?K
M)BUBBLV/Z6*3SGU:-9RT#2.,?SE,[Q-&-8:A?7G@'H[:6,#^Z"\'\=SRP=@> M*9;O&IQOPN4F-=^ZU;W"S\8:WO@T5E)A,%D8_"F=N9]GRY6;-W]-;KXYJVBH M:++CO|FAR:.B2YE<$5
2\VO6@"\ZO"#CUSJ2F?]B/IO#+/+!B.MR QH5/@9%PH1*8J1'U%OB MF0E2CR@?(K.FI>R14_^_=,?327>NXOSM^\BH(\08X+(4##AI@2?$ V/>,.HS
M5T0]"_=CR;)%'SDO_5A7OQH3.=69K,KFB[+F.Z>R))")#Z6&O$-=PS00&8,A M*C#)\WF>>98L9F6 !A=|("^"9UE"<(Q$Q[44>439K QME9E<_?E)X[W*FE/# MG%F,",46?) *
(9L86*L)*)^5HI$*&8?)B(^!^5AD354U5=7<=6'PJOI?^_OJ M^_PB&:RJ]R\YE21$&T(=&"XL".8\6!XE<"IU8IX(3P<9*KT.Q-!$()KD0 2= MP%!24ENFY$SB1 LY'O7.M6VQ>5-;U2<-
^"K?3UZ-R0K);.[4\@0N+-@ F>0 M4E2*."N#&,3Z'X7SL9,M,+4M'"QMW,5YV-?XTXI2H6|)UB27WD_CH/61]5&Q<'A#AQ'X7PT$FIR2*!'H)7F*LW=C^:4U99[P$E8-?
MZD;@2K0X"<*1#,QZ)F]HBI8[>Y|[2.:|!'B.#U=7\Y*$=X+(< M7 "|(L?5/"NP+D1(E+N<8TI:Z4&A09N,L$Y!2%F <#; $=Y#-%QZYJ6T=$2E MX@6UK33U&O?
U=J[B"'$>9#8A4,@F4A 1M^DNE(-(AR_FK!V7 V?KHW ^%M5. MV=207NNSCR! =Q9?N!552CUYP5)ELW .!1/3"83Q!'RT$EBIT1R|BDX-'-1% M)5,L_%()T9H2X69&J%6Z51Q?
HQT$CE8D0T8 MPS.(!%)#,I#X#(KZZW6<2"=CL+Y;*3Y*89%P81*1U%OB MF0E2CR@?(K.FI>R14_^_=,?327>NXOSM^\BH(\08X+(4##AI@2?$ V/>,.HS
MZ_WMZ^U5 M,_4"MUYFUCZ_7 ;KR_G)EW/AC'%'0.2X(`L,-1AE$U\|E?,2;^<&R[DW.84H M) 2% E|P*\|(ET%G3P@++N1@QB/;!9$M)Y.[UJDXKS@_QNW21V$U5T 519QG M'G%
[']A)*<&F9UHIQ/8RW/P;GHY'M-0ZWQN$^7AQNO;&0YF\|\3 MYT%,1HC0R)3E[G<5Y\?L6G16D7$!5)?(^682&*;+KH4+ MZQ71(@W<3X_"^5C4#)LX|4ZS]OGE,EA=SD[>#
<6B:F(WH9,<'L9Y%20KP85'D|"N=CD>TU&6 -Q'V4 M>]QOW2HUO__K]^\:MXC-#S^\6_AA1M69+O=F3IUQUGGC+$C@N58EH(27YO$9Q M91R^,*V1PY2K,4LO2).!"D>~@G%EY!
M;V=JSA_^UXG9IB7&9'9=FV:'",/#.*"T]YT$.#H>.POE8 MY$RI?ZURIM[IOM8$YKWT>(X/5Y?STIV"!9"D24"DT"$U+@;?05<2DW! JG1S(
M=F(B8SYH2"2?Y=QP\$DRD)8E3VP..8TH0YM"1>M59,[G:A(KT@_ NG&V2@C MHZ"94R"XR&"XRL %,\XEF]3(#T+Z;(1[C2VIT;FGO-7[U]^;K6&_<#NJ!'IJ M4F6&1E10'I1R"83-
#DS)>Y"RD8X$I|DUKG?/:Y$R6%W.3W|MXTUP M+&%S,_=QI3NZLXS M)@B*IDA+D'[N9*8IE5ZD\X4ETF:I S)'N% MN\%DP?&2F8DSW&[0G'\$J4DBR6GA1J1FF&V%K;
[ZK[=S%>=OWTL2%&6< A4% MLUH+L"YED)$9J963RCQP,YV-1,V9J0*IJIE[AUNO,VN>7RV!U-3_Y:FZ$)1I5 M.Q'!@XA9E4Q_"1++,1(6DI&#HDXR!4FYY1
2P\|H2\$SED#)Y+U)ECH|)L|+ M,E[J)K>85YQ7G!|3UBAKQ[WA8%/D)!LL*M3@3*-V)MIQ$QEU1X__^5A4NYX-.MT&N I0CN=]&>X,8=[TG-RN/ IM6^/V_DQ:99+^>SV.P:/7$2_OP O
J:YCP[M:@6'2(@"X,1':9894,X$HZ7BN!A<"0?-)'?%T\;QB-2>/1CC&13W>/POI2S8 MB.28I*VUCQSM|RO6U%,;X2\>4)5/*I\|V N F:9\9.H(2Y>J9. 4N6PW>.N\= M:CO!E?/1_')6&0??
>1KF7$R2CW1K71:Z?0)/7FRDRD51VA.<4?,=00K!8&< M!>ZAC0K5 M3IZ83CRA1D0K(&17DKL0 2Y!|DK1H/.VOCA;N\|8.AF+.GOD *IQ$DH59Y5- M*YL^9NB$M.6B0C2XV95.$7
*"F R,!"]? (W: $K,B::,<#2$TH[G6=!:-] MA$B0F*D(.G@Q'G'&6FVK-JN.')5!*X, ^RB6QIX&3+T"I(§'$2,"ZH(!,8P6A M0B0_2,,I*3-
(F0R82"5UET$&39J!BM099HEB.8Z'03EEK7WL8G"O@4,KGU0^ MN<=Q&@$=.W#Y.SJBY!9[5 M]^2GY<;-|9LW$\GQ?C]S^FWU[_L"Z6:($EX8(#0@;89(P5#:*MLB059U_'&-
(S$_AV205H.@!!*T3BF%(QM83[%A>']3GX54_>BO1CCKE8 MB@I^%$BBI-6[2BDN"HZ]B=I(E%-IF!''^^0_E,C:ZA]IO/XL^I&.%KT=:DYK9 M*FZ^)YZTRP"?&
(A$(@C["'BN1:EOH1*QU&LZ.-F77)A$]"OI"$K^.6O 2,5* MA3%/-.,,VS8>=4-;*5BK[.0RJ$P:\E7?0FLXF;J.UO%S1=0'D!N\EI$T.686RA)P7%/(#-K+0V"
M2C_P*97"..EQ*T<,RR"\2DAYN+V3WEN;5$Y&Y?&(FR=P6YCXVE\IKE+<'Z8X MXU)('(DMI\[+2FIP)\A0DDC*"9/4JJ&JI\|F+*$P7XH89@*&()OR@=3(0'4P8
ME5]!BXJSU;I6"GB[G;M(?_M>4>4=2PJ8#@Z$$1[,)AE2 M]V./O@0>?=U_=WZ)VPSNF(O_L0SOI_*OK<)WMVN$) M=[B;!VO[<)WMVN$)=
[B;=^WPA#M4|$9*'HS869#_Z"%_'MGPPM$<* MY;L$YYMPN4G-MVYUK_"SL88W/HY55!A,%@9_2F?NYIERY>;-7Y,;;\X]&BX: M[KM=FAP;NK3X%0$5 :lV/>B"\RL"3KTSJ>D?!J/!?
8K8@_O)A?O550=:[_ MW2Y(4E.4 8(JG8I.K#$25#4,FI4S":+F^YV+@AN60[@55U[S>SE632V#T'+G]=VZG[7+WC]^[!9IG;"9RR5NI]>34:@C+LM2O(]F6 MN\IT$GG
"5$:'9,N2E_(FM48<;,?Y@4X>.*:HC4I=<|SB)9%5_)'I7Z)1MH(`M@A,.+G$)5CNEI";2\QE=^C$I6VT>N;KD2X?"1#M7A%$]DQ<\3GBB!2,QEKL@?7,T3B^"R]Z-2$CA"GUXU'M
MM&7*MDQ/SD>K(KTB_1BG:V&8]3I##A21SDL*=F%:(Y"^EAT M.YW<#KW6:1]!H.XLOG KJH1Z\OAC,>|22$;)6N-=E?;^VV<"@ED M\HA.:C3X'-/DJ T++*241!VD"CT+Z:
(3[Y.+N:S3NB*)QZTUNI=8;U"H\IUXF M"\0|%%*HXAB3 /?GK#,HG=[<"82,HF$)PXA6@(B4 N."0>1**>RI#58$8DH M*61+=8W%?;V=]SA_^UZ6BUQK+&1I$."1@G#X
M+T.Y!9V%5UR00"D9C\IA+36BY;0Z[;_>SE6DOWWO2^2LL(@$\)QH$5Q:,B:AO ML<1D)ZSC>7#X>Q32QZ)GV.2\-JJ@]7>Y]5ZSIOGE,EA=SD[^/(#$KL%>7) 4. M"81*%(PB'H@R1
F:J-*#PB@D68$Z7T-R0>)RGE#G1Y\ GT"#IS3[[,8DW#6S MK3 UI.3U=]XB_>U[$T(.+B](HHAPB_MT:UVIX<.3Y2;9H/V#D#X6X5Y+OM5H MW$>YR_W6K5+S^[]^_ZYQBIC\\,.
/]1]>N&%5ECTURZ80I.<\0_"2@6!&@"\I M$+0STB@6M+7Q)LNJX(+3]1>+8>G*E.PQ>E=-%YP'RB'(C-3H8@=/> !& MJ-#X#V[-B)(LTQ9MHS6L"IK7V[F*[%)DSUB1,P?-
BN.^C<5Q/\L"?*.=8S'S M06+4HV ^%D'#)N?#405-O=FMMYRUSR^?P>IR?G)'+>,MU]2"LDD +M,,/&$, M3(/.5V &\)/(MK+R4MC n0(C2+1ZGO5!S\|:3@*&=
%+62&6E]M',B88)/B%A4/#!%!R50"EN+6DB8I%=/<93NB^UM9;F_MY!+)5YQ7G!^3]BTI MRUB(142$ 2&4!L^CQ.T+YXPG:94=N*,=A?.QJ)E:,*O*F7[I^UKGO/9YC Q6
ME_,3.V,Q$R)-%E3.!+6[TRC,I8*@O3/>!2K,0+,K*(,PV0 SRA2]3\#)[")"G MQ*SF7G,RHN/'*MM?>^,1L")[I"D*X4T<4_F+5"N&"<&Z8J M/ KG55N-4UNI&/U33XHJRSV4Y.*,
(F;K(13:$I*AFLG<@Y;!,":XB[<4U^1, M9^,2)&N1&8GFX+QCD"UGROOH@S,C4C-&M]C@]9%[]:ZS]OGE,EA=S4_N?"ZD=)H3 M(#:4E=FXDHU50L@R$ZT2(6)P!BF%%ZCG-4@3&
ACRET1L<5YP?@?,H:-6MNC00=<8LNF.5@LN! HZ2:(HHM&029(7SL:CV MR6W/:VCN".YWT9[@QAWO21-TM+31(;>\|)Y5ZOX7X]CF^(]+Y,!RRC)02N? M=!R/,/%IC7FD7WG'
\6:>FHC ,4#]O))Y9//7\]P[TG% A+'(02 GS.N,>+ M+&;ELC!4)6 I)@)R8]%(!_$)V.19X]2KH*!9S2 M2XXR22RUU"-'U@[&DY>:1* ,.^!@ZM M?%+YY/,*3'"F#>Y0+27(#=&7-,:)
0O>!9/5-^6F[<'+]Y,Y<\?8BX1T;% M)QW3 UVGC:%;9 *)%A[6BH*AE@'2MK&!>JL,'8^NDZVUO#763LW]K_KY5J0? M+Z[A]O/W=522;GU%]O M#*,*=%7"(R1D9ADD:QB-
N1"NU,+F>?$3RI"%?Q@LG6*$6V'04S'(+V*FV=?]NXF>K,5G'S)907C/=4<:,>2A0W/(-/N$1S M.N).SW%MR;!Z7Y$696>P*=AXFM,I.A*
M<2^8XI@BD3)"2MGH#,)%#59&!CDS+SR34=\"\$ZRRDCCC)&1;ZA^&A'L^K1eO M1XW@)O,XI@+QE. &SK1B>G6C)XWYNH$[>7BSH\E$8R!&44@*X<4.P MMW /?L;>*_[?
ORW_/TN!9^,^5RX[M_]>ONSPDX^>?WL\6EV]Y^_MG/U\Y^LX,/\; V["W*W1P"[0&&&QC&GW'=B/\NMM-_X'9HN8?OD*^-=YGGZ! M.%NESL;PT?/+\\77<;:^F+M/7Y???GWA8K'X
_^16=^3K:M% T*15C#+GW9? MV'T4TB)^?;% MA\5E]-Q7;O[1?5I _9O_VIO$]LF[6>PPT7:05FB@NR8OX=K9PBX#_ M_GMRN#[_A, ^TWP9_O.,)N@%"?(&?
VZPNT_V.5GTYT6RY\$NG]6./1+^7JV:YLXYFWIE$XU:IN5BAREKA-MHXH(;Y]YV@?&[=);3-;.5>$U WN=FB<>%RDYI0/I===F.V1%]Z;99HS,&= M7'URNF^7E9I?=Z?
=YRD6W57>.0NI\9>S>7DP_J;4]PG+U<42FI97^UEV>;)< MQ*[.UIM51IG;#Z[?-$WIR4$S^[XTIL,JI:Y"4+/Y=%&^"WMTYO^3^)3-#-^. M*\(YMB_OH7Z[6K\/R_\"6N4I;-?
X&P68U\]?9I(BF$4JPWQNT^)9# #_:CXEMUKOI_ ;#ZC.2"N?SI+B..!LM?-N?NT MI2*D@07^?)6<+Y&!EA=E:V+):W2(GULFX^.X_^W_6C0+9G/F-LA5BP;G&44B
M_KPCBT(%3<9M[6-S032!:Z$SF*B+704&WEF%5IEX*G5IH+25"QZ/"[@0TFG! M@!HD!,&3!,NS!V>2D9E&D9U]+"[X9V^A1(J$1Q!!,,@#B-BT"K-U6?:WD-VB M>@_Z&:J7#:J-58G>2
UNTL,JE5^\:?[!#'L74P$YKOVH7JX#'VDBI?@/IK=_M!:.YLL!Y[^\@NJIK0(Z5U^UPW63\N_ M= 1X_9@MSWY)$;9;@*>?YP/R[NEY=)98UIG>ALL:=&5#'XMYS3;% G&QGB\7
MSJ/4W"GD;M%'_ LXF\^OS+A[M>_RF^?=:1PQ,"<_L^8N9DBMV1*%!.&I 8Z#7EG\X>3*?UVN+V8;-W^[WX1<.Y#>_:K73(([HEYOW/S<:<.GI9/KE8K8[3T)C?QSR-$[CA"\CH%1 M-),
<<;V6]RB8\|:J(T8AMADEDBTLKB}{N$&87'3120NVB';9"51[,9Q2<>4 MV)7NY+A;I)_E*)0P-3KF.[OY?OR)IEHRMT]_AOI*E4K9&7P("<5:4+A ,L.I M&609P5UU"):!Y,$412T
NT\A:9>R]B9[X<8YT9R/;]+|XY9%>@I09YPX$E",))SX((^DXYU]0 M|>N\G[9I_5O+D#[\JZ]4LW-G8?RQ1 MP ^_0>WPC?]M'*+=;^^KY]OQOZ 6YG4K>0H3Y9,!5KT?EGXRT_=6%R/
@D.5;I_1C.4KR/X@K@<)B:@./49!PHI/S]2#5[,JG+O4(:Q=86 MY:KU')]UU]"YS9:QP3T;OO/"=($@1,G=<-(V*&=$ARK\!^]-MSQBCM^S;G!? M;8^6EVM]P_H/7UV_<>MJ-
|K4W+C^+>/5W^]NKUK+P)2,5]SJE+?#W'U;7F!W MLU_W_::$O^&_VWT 1W?N+M,]W5'P\?^2.H|OIGWV5[^ @?<+/I_7,%R!] M^FKWC+L2(W1'?]H0;QGYW>#N\'?S^>OB_?
N6C]-L_QMI(1@[^]Z7/^;*/L3=: M3+>_G\FJ87ZUWLMMU<8QGDI/[V)PBA*0ZC>_WM=;VG5+W\V)NOXP?YC# M6^H[-0TR:-
,QZ+KGSO_M5__UQVO\>1^OMO$.U@DMI4+O4:"\(@.]HW)N30*< M1;A\.?KNDU1J#"/V2,$FQP#F5!VL>'ENO/"*EQ.L:'49>SQ8WL^$3M;W$7#N M2^MQM>OR9?
4W7D;LS=4YF17B 9T$YWVTN'$]%[CKCO+APKZ_<>;HC M1MQP)U|A@G-JZ\1+DH[\RK:[7MS>M-QZLGB%M^ MPD%Z79D5QQBKLE'&Z:1/X25\W3_X[_>IHDP9?
PU^5X8OK3=;^GVW^/OV*.W3B8B8 MM5I6#5DUY.BGM%+9*?C>>WECC#71@+?$EXPY&1RW$D0N V6YY0? M%]US"P__L)IAG5ZX^8FW]+RE2E?ZK4IR[%:&>R4-RG,""NH_-
A#E>1C,1AK+:T"\M<%Y"OPD7HV%Y)]+7V[V7WK|KJ)/KW ML.W_9)C\ 6KGGV6@8)GALJ2X7;_39MTL?RNA@\GXM!/?>MIR8W3DVB=(FS8(Z6?+O
M,0K.L0#$<:JBE{%8;,T+SCW]53_N_RO=2[5HC;OM@+7N5IO+E[7)UW<_K M\)=RDK3*5(@>#!X'@92\]+V5**&=DN 48!M]""D ME390_"^<),CI/AQ\>'UW:@8VK1"T$G!5F&.?
TLIN)V2WK RSN&E7:E1+?I$ MP.#&&2)GBE/\C>2#%/;/3 ?D!V$K&%20W&YK[T\R/*^KT\\>/41:JC>(\/T MDQ6*?8X2I4 :N5/G20^6.0$2=4V11!0,L@.4ZA<4B8!)1T\ACK A5^5.?
U@M-M% C/T.?._V81O^T89/W=XO]G7/3_/GJQCXD3_K)B\:*/S3_3&7=.J@:6^H/ M+*),Q6O[G:K 3W>"7]83[|;-/]8_MQG82Z)8-LNA]3;,W[\45-;KR]3 M,+
[Y\5_=:Q!D:?._B_#&/EZ6TEB7X4"_IDNEJO,.KY=GF/[SM)B74K7]F^$ MQ_QR@2^DYL^SM?OP897Z2_KRX]8.Q[KY_?K2XR@B/>_7(+3_\)LWAU_=K-+_ MN9R5-
U[5JEBWNYQ7B^4F=?74|KY"QGI?(:/4Z&W6%[B5F M7SHB+->;=9?"/_7M77>E.6?KKB'X5\IHYA:XD;_$YR+,B)_I:@HU/.+==Q:VN M_GKS9X1,-ZA4=J4!U+9")
[YY_JEQL2^(5NH}G,\VFQ3QF[8%+|\+E:H7-QG>E MG|W\LK_!*IV/L;TH9BW6SP(E=;S'8UUOKZOTN%)OB&'TI@X.AVHU4.*PG MQ>GZGU7,@^LKJT;++IU)7:7G9]$;?
U6WX,7WH$JY=L^B?>G,V MY _=^C7;PX?\YYPO8!{4DIQ_YSU|CE7,[Q+X;1 M$;$YFZ7<7%VHHG7/UL5^OW?_P2\'_;_?O_OS\!X@<VO=%=0HIQ85X$?OQVC83 M[1#A,3N_NX5\
M4];L?9^W:?"ZJM?8'9S_TD5\{[[N]{#?5]Q^X[6]!4Y+RY7%\QUOO3,0:=F M?1"13=WL\7/:,U9KKK7?-H4&NA*T'5 O6IX,0:]O\:6X7; (71Q6#M**L/3
MO1.W,>MU<[$LUEK0F2\WI65784UO?H66W&)QZ>,,2B6?)R;>#\=N6G8?*V15 MBIX?]S#Q698.!\FUC4=XQ&59,+|:3\UGZN2MSN=H6K_38R@;7".PV?]YOTVLA MQOV?
>TQ"-2/*2T*=% Y+SHP1/SU&C?]Q8Z+ MM?>B("8T)?S$5D]$/9L>E I:)?SF4H[!WY)_7ZYFZS@+Y\IC^*7-JBNJNCS M[>[57\/U47)#;$D.[:?8\L7%O$B?
HG@*&98>=,_U;CU;CP64KP)@;T\\ZF9V MWAE ^,;OM1M1=;.T^7.(8=2OE>HTZ=F5>94[PP9V<7A=HA+Y0:D>(-[@H/;=G3?]UTG"C]_2IN#IQ:SWC+VNM?^.'S[MSW4&63[4&>6
PXN9EK*Q:).H%[J1N*'[C!NN /<)53DE0 MQ*S7_=O+MR'\(ME3#L+^.VU8G/_T]US_O(5*_S//T'$=FO(XI2<^OR?)$U MPNAB[CY]57{[]4715HL/!Z4#9KV=;>]V^Q?^?
8G,E3_MOK#I**!@^7K7B:\Z MC.)0'I:VEIY&4?3GZ'E;BX8'U*=6U:>S/*GXDL)NQ-RL8S.9I M)^UEGCP>=7;\X$6A.YW$GIV_9^_Q SBO97%Z7Q:TRW79\[S'%^>?<-U\GVV-T
M!+!9Z)L7T8^MK9:5[JH2[+?+1,!+[SKRSZO%\-U^,3S^6F,$Y!V/,1+O<+'^M\ROJ?#$C\[#N?M,9Q+/#$*>[P4>M|+%#:#$:5>1H9S3X,U<?+5>1H9S3X,U<?+5>GCTY@#DH MQ%NL3%A47!O=+
[OBVYV,O7I;NRUEL-MU]+53\;>VF2]#]PTH-[GMMPSX|O]&-MN8;_W133IC^_^?9-OUG]WWNX[IO^S%RKC&^*,E+BA&":MG-CN:.W-'<96)<@4M8_NG=.9^GN&7X?@E-

*}^<#>3{{SD7=\O-ZW-S|[|>W^\ULW;+/S!.JNZ7>#NML4=P(M55L?N=17/Y?Z=YWW%G[%-NTLX)<_[J37/[V'W6QC%,<&? M?,2Z>L?/?VR2<8K1=S1/9 ?X-]6<#@4O9O:YH/:,&]D:\VMSB?N(ZMEK_.MBE?D_%/S6\9)@VV:[SQ\?LL(W[]P8.)?: *'L]8;Q&^5I->_42IZVS>> E0_M+9%L=IECW:.S_&Y\/C^J'XOCZXW!HF^$8(W?-?X.]XB^5_0-9_K&>_OQ9!_+'XS)89G'U7D/W63L5\0MHX?:6N\'\VX0.S=[G)U/W4U^6GUJ^R"5 MXD5_GN(LH{G@2N+7F[19S0*N*E?W?*LE4FB95+0)%V?8S0_X\>4B;A59^[# M8MFY^=/? O0C6Z7+C5I^v/%_A\5Y!:K+)-Q}2.W.KML,5+L?/?Y8FCS8]*-:WYV]UQ"SI*E7+D=?GT?ZM8R9+=[RY2KI_+U M%_C<.[?N7&8.ROTN.K&KA+2+@%HMVJWZT[H(TD0 "IBUNO""TNU/:QQK-)I5 M"JO+V>9:NTH !LX[JN55YYX:T+I+A9I?M"+%O^]^D_JG-3+%U]<>E3L?:Q M\35[.4!X]/N?M\O51X>2^N_+Y7^V<=:;Z(C>56^V_D_SUH429?9B!NUA[/-_M+2^;]=GRO.BQ^T\?&;1^, M7X^3=]Y0 G ;AP.58)WMPC6@__976KB/2^Q#0[MPA+@,E]L{JVV+\FR>>K5X M&%#21^"5; \Q!5Q1]T)QERZEA&.XF*^_MQ<55U-"VR? V@H'W,4^B7^F7T4U.BN!D-F# M\F^#1-K#]K;I*EM%R!*ZX_NV=S 7W<4B8*&L^>W&7)(-M7>A9UZ"+)*!=X,V,D=?B-M:\+.'I$G=;D_.+W"UZ- >3;0!$UZ>K^*)U''2W?=|NW'@]G6G?^^T69K:(ES@0 MGZZBB(L/:.^^VVNZ?|%%\(/?TP[?^A$KDPRQM@WFO*@_I=V?EV^=IT_O!=K2Q MG1T7_L_EK&_U-M;XP RVF/BP+++*GLR#_]UZR;M^[#>Z:(4D6[O@%N;2#ZOK0 M*:ST,U9T:[=#,Q*]"G M)&^^&FY[\>-M+V*[2]3C>O#Z+JIV^.@N9#/=?+TWTL%S'+Z[E*.JP+[OJWX> M;KY:Q.,B#MO30>'&B[L LT%;]EQRLS47%R4NB(]>]G:;]#W4-]LRVEMP=2W8KY\EK'!6HGD?% !R:NG5 MQG@/.4P.=1R=74H4=;*_>9[@>>)BO>[S@I5\ M+R%<=DEFT 91V_? [^]UU?M=\MVG+T_RG?C_<]IO$VI_K*B52."N[HC@1\$W\ MNT!-4%9B2*PYR#7WI\.]SWE%-M]BW90YI\'%U-M%_C<.[?N7ZDZSMI47*>?<(E;]I=.,WJCY7ZDZSMI47*>?<(E;]I=.,WJCY7ZDZSMI47*>?<(E;]I=.,WJCY

*M;4*QM{!NR7AC83=?6MY-@4D_|\^W/TMX9F%O@UX/R:\%C30P6N\K)K)SOUJ9(-M9?V^WEOJOO!R[A3GB70D@%]^U6!J)OST^W[N@]_RKGIE/!$/K:1^&G]=X7!Q.1*_)9&OC V<'G^,^E)HA2M?<{1/ENLXR",+2_B MP.Y<_X/>,T<7W:FAWJ!QU)XFGO^%D/=R'D?.K?ZH!$+E*!>NLZ*3I?:9%P?\ MZ?>O(11S!8PYZGUJ(VAG7=SJ=?:.;[MA[2YKU3JfV,R98-*

%,I.XTJS61KH M(`YM)PF!Q87CA3$3GSAI(4-F)3]MK$0D!8$"#!0!TW MW-@FW'(R":HWR<$R6G(LRM#0RU!BF%S 4TL&YR\' M%3?!B== HY$D25[.ID50Y K 5#T8'(J3'N=0!0^3QB-'I>_ %6\&A_@\ M/\IGLOV!PI@<%PA*109+!I$ MK'UB?Z=PY#%XI?K6Z>/O-E3N7\1/\MKR_O.A?*25CE]b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|_!U A&X'8$1 +O)Y]M4 L=`P0"T(V$['0L4#L M^5<+O$+' \WAAUUIB\1 *[&-(60#$ L=":\2>]?[3:GM%N%V!<'\2>?[M17^[5 K'01 4 L"-E(Q Y|!4(L MK@"_CE-^LR*;.B1ZP+<FKB&-H51.^);2L^6 MMP2Q@=K&$+((]!6N!6]KL5]@MCQIOSUCVK{!_+@1_+8;P;9%\Q!<%CI&7+@% M4E) >GW<066>2N(9FAV8W8E9DS#;+KT.S+;;D/7'+/0L,%N)U0*ST+/ + C9 M4,SVQZ/.%*0&9L^]6F#V!;9QOS,"]8'9!69!R(9BMC<==7_&/>#_MG^>57^?SF$::/UR@27#+Q,1HT*ES?N;FRO6MY3IG4@*Y0&Y;D0N= M*^16:,5 ;GF=6^?N#6] +]X4OS6$<#;#K9,6HTZWQG2&GhN>>;RMR$8@"65/^K<9>F4,61<0[9]>V5$X.:]R%]W +Y,#&-<;_.5CE]BD"E MMPRR7:,/$KS2Bv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{6EC0BO57(@7E*KBT#U*-5SZL30T MSS?9 A8S-(4@>]Z.DTU\[?T__H7'>$,DYX8?0X43+DLTVN@WR.OL=BBOX4 M^JYC*ZMCIQ+B,4@1:XLFD*2';$2FK)5^/U]2//Y_L170I-P'$BYK/U!4_(&V-M0)C=B_]W=&7%3U='73&;+WR7>)#Y0HN+4$E9&E8;A9G5N1"93:0-0R:TI? [M9_P6[$!EH>Y2@\HD"44/? MO%M;-_+"\VV9;A.1AG^=2.5CE]D"X<-^?7]YT;\B1-]?vc$GF^2^2*!:OO"M:S]U!M%EU=KRV;$949*9^AH8B39OOH'_XK+R%@\!!]4KU[0"J_6? NBHL95514;= MU'U)) Q' +ZTX\]\V?T'[JG^L"*W3]*T%+>[2>,)9*14RHJ M?X*B6($+'E'SL$0[OE/N !3:X?](Z9/(E T2\=0T#9+MX!GO[M "^/$+PH]? M$PZ<>VE? Z0^;W6ZG^R%]8<{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f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`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|OT<6(_G4ROI]4?X/[RXO^U<*5]Q?ZT,- FO//V;LB>V!M M6@^7_-NK-9MZWDTA].KH225WY?4/6)$[BX?T@^K5"Z+_57K2NE0G*CI$7UXZ'WVSJ.]GN#M-D;,WNM!DL203T^L_N9M'2)&Q\N656?B"9O>.Q,"/A M1++ZTHHC_VKS%[2Q^L>*T+]H(@;6@Q5U;[WU%$Z]^4TQOI#)R2D45 E<4*W#! M(VH>EFC'SUD]&F]|'YCY+1GCC9#[_U"H=-1;[P5.GTZQKEP@C\2 MBD0H11+N#Y\.S.[&T"]T\L301?6BM=-]0[A/+&E'&4TQXBC(HY:5XGR2FOP MI6'4X:O#[.KER;.1U&T) <2HK]VUAU'YG_%08=>M9\U&,=&_TLT3T=*)#>+T. M*X%B"&Y#&!YQ\]X<)YWNC9, ^FO69PJ3)'H\VO3ZOF1VBI$7E?B0.W9 AKPJ1 M3GL;)@[C^X@ATO+&US,K? 464M/*QT4)^VS&V#&'14F%1\7INW\1&NWN\Y1O MJ?]VB.2*+A^N75^&WPH>[IYF85UA@AI?W!$2"-(OO@Z<%@?QHG'38@3MK= ME!<3=4K;&(^'YH? [PUF=$'8],86CZ$#@D4[R+5:^FZU!?O MI.OR?_EKCZ72'Q_*$\96":U8.F *J<)=P6-!U"%+X@9;IW2Z"LF.H.^,$#T M>/KTP?!%P>-QT[CDX`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

M>^@N81K"KAC56_6U$M_Z89N@K-=^->]9O4QR(2\#([CL&N>]*A[W!KTAWS4G#OQV]MEGEWSI(>#]FF#SYF3%IES]Y1S3P>]UO$I

MU\4SS[!Z:IEGUY6VPW:3RVE9VC+G[BGG@JP]&;5&_28KRRQOF6OWBVN'_?:H MP>?,\I8Y=T\YMT>5>?#)M?UL+QEKMTOK@7[MLGAG]O75,L^N>=+=4_;P,^?6:+7.*

MN>MZ'+#SSRG[]YEG7WVUS+/K2MO1OOH;F'-K>;+,N6N>]@_:4[35:56=HR*

*MS^X5ZN0)MVV3UF*4M<^Z>7U^7P>!0!Q%4G\'3'IGN(M1=,V3'IZT23GI<),>*SZNOEEEVS9/NLT^?&;=& MJV7&75?6#EM=OK2.6?;U5\LLN[:L/6[P,:.L9<;=4\;MGG1;IEQJW3:IEQUQ6VQ]U6G\/GS+.OOUKF6;9L-QP]YTKT)Q'8!P&/>(&; M!7%$K=W=60QK_HM^P:'TQK :(^]Z[OU>]W/29 N&E2!FV?UBV7Z[R48+>QR8*

*M4<0W2^>W5O+E@O17R;4_D_AIH)BZ G\ MP@VY(/V97#8&>A.)F6I[,, ^<- X#W]'GL\-P^_#BFP{W6[KM+.Y]*9[-DP" M6]>_R_2R7WH60\.0T-G@^WGZXD+[#QA@&"*

>+KNT&F=;0#<3"VWCTMOW3/I"GGXP;7CA6Z;_O>,:,2SA#(IH7<9SA7_MK(IU+VH/?'MVU#^?A.+VR \2U'KCZ.0#<A(S. 1?GH7MWAG\|G[N^#[.)2! M/$M57B9_@3P;3.IT!^G5(U

*2S^=Q&M#8B0A=5*W/Q_$M4@R,>69/^&F;#NS!2=6!??PH!W:O+"[[4ZGYXR+CV".SKW.YDF0I!GMJ$,[FJ[V8Y^,CBM^{)-[A[;W61[3GBEA M3R39QJ]R@9"ZS_%EGSSHRZXX-*

*D6X*8)[FPNZ=#6SYAF'6UDVO]N?? M1$MN;,".%W5C=YKCQGZ2R[K?'KU;Z]26N*V':]VY-\K(F]]KXT%)QT0F:FV! M,UZ,,;*

*<2AM$*RMH.S=.GD7%WA(%V)N.U')MONYWfPRX;lH]VGD.KC')OK3_4> MY^:SK:IG> 9KY8)0914T7($[_%9?E26R[_>$KQ".)W$8QC=$2$0_*

*M.3Z#N<*P*5%64H3.8A,Z@Y= >8%MO,?VTJZ2A?0'4@&>HI&3^ >DMX/DF%A M]HLSYR XO&\F9@DK738N#N8'GIOI".8Y# JCXJ0#0"TOPPV8)_%U-(2{CAIX M!R*

*_E=$U.]!@^@*42KB TU\L9YYDQ=>",VWXFT.VB)@33-=VK@XQ2ZE>_-=`DD!!>7;QIF@JO^FCH\?A>Y= MG&N_%T4N+@U.'O_RWV^.W]R*

*MS8>55.I9;W%CGI=#8]O*I];&:4<"&5?_-4Y^_G^+!M;3Z&:=HLLZ;"DS$<C/2 MRS!2GQF)&8D9:34C_69YMED@,1\QVV5CU@>&K4-L;&4R%JV-13W&HFHPE4)#*

MC#3,)%:1ZCI+C">P MV1EI(M]4Z)M1@5&!48%E)W,)&N'AY]]\SHQ>ZU>-2._F;5Q6W]9IQM M[L%KWHQ3UYM,-GDY5N.OMVF== >M47=S=^[N\&U'S=:@^"!WAVNQ$K?!!\T7*

*M5^X;Z[+D?;SD'0YZK>/1L,&GSDW1]B7)2]+7I:\.WRB+'F+O1BVNIU>JS=] M.A^SY-T1[F7)RY*7)>\.GRA+WF(O!]WAR;#5/SEM*FSY-T1[F7)RY+W((LW]G+17F/"^I-?G(A']<$*

*M/*YP+YN*Q(E-^9ZXG8LHY2:X#>(R1M.U3[H_'(&Q/%TUH!>?;7,L^O:+1WV M.##GUFBUS+GK2MM>K]7KL+^!>?;55]\L\N[ZT'37XG%G:,N?N*>=V6QVP;CN=*

*M)BO+++&^9;_>+:]FZ9GC2.NTWN3TX*S[,LOO%LOUVD\M: MVJT.9X[_7&@S9O<[*T*NOEEEV;26H MR1Y"]C@PX^XIXPY.6K+]3EMCEGWUU3++!J@E6=O $V7&7=>*

[/^RT1H,F=Y)@ M8,VQW@/2H<2F>>?775,L^R9;OA4#H7HC^)P/XI MW%10##V!7[@A%Z0_D\O&0&\B,5-M#^>9D\9AX#OZ?'88;A]>?-,!N=MMC8;_M]RY9\-*

D;E"GO\OTLE]Z%D/#3D/#)EOTU1,7V'G" ,$ \73=H=,;=3=GS]43 M(UAW88A@;&#=@74'!@@&B U>2=?]]3=75E5/C&#=@:&!H8%U!]8=&" 8(#9X MP5[KM+^Y_B?UQ

C6'1@:&!]8=WO-')1'MG,M=0[%LRXW&&=O!DN(YQ)QLR"GZ MTEDE>,5, XS#B^]E;$_&K9.3S;76EI/-&8MC=&!'>&QZ'#;W6#fRGH^[MX M&*$0[9ZA/_1.,ZW^D"-$C Z,#HP.%?*

UADS6[00&UA\8(1@AGMI[TJM7M]%K]MP:[#!.L/C Z,#H_6'SKL?V#]@1&"$6)EBDGKY+37.AWL.DRP_L#HP.CP:/VA MQVDFKJ?JI-8Y%<^@JL^1%\^$,TGBF:,R3>(,TR>RE<[C+!-*

Q\]^=!3J;%"W MVN&CWB^].8:+9[HAM6^;<&JV6.7?-DSX9]5K# M#?:"V.&C9I[=D8-L.L^";=MO\#G7N $#7P*B(^G %2+-=)N&EA.)C /IC6$Q MAM)UH;35&33Y0B56?

IAC]KMC. MZ 1HS;BU/E!EW;5';&_;XH)EC7WNUS+$L M:6EA4-O!$F7'7/;E^]W/2Y'@B<,DBP&L5#B1BQ4HU@0X%?!LC!@E6(Q@^C

M&/8&_$$-6+;W1YJG6WQ_'L0QF(2)*1>2A.YMX*O@MAEX!X/=9ZRXC\F'3>M[FGKI)@OK6)M:4= @K6U>E[@4$]@X$*>_4.(5B.VI#)#*Q&*

[!]"L;]QG:LP>J>;,YI53]1@-6)O0(+5B'I>N5%/8&_U8O\0 M@M6([=SQT>N>[#A:L;]Q-R#!:D0]Q)DS!LH&4*_*\[#@?]<\GLJ4N)-?UC*

M^/%E4'T!H.SG+A9$$=G>00G$P:1.!,^]YYRD=Q$#=!!O/S M5N!)%VDH-]0,?IXZIW>P'$C'__1/L.V MO-X[N!]YVK=[<#WD21%=..A7P_!5]6KE-+<=-'2^>S=T$_I[%]+*

[\&6G1F=L]Z3FPQA!(1^7 9[K===N]=V_D^%>9!YP;F M!Y. +8?-<-PL2X)Q3GRB9^N.XVM8+>P"C ,CO^T.3]O# D:|:Q5#!E%Y"6ZV M8MH3UPO"(M$"N-

$CNMP+_3C0)_Y9S>|OZGIT>W;4/Y^$XO;(#Q+A$3O#$/-9 M=.X'Z3QT[\[PK^=SU_>!SBSX#>2D5,Z<_,6?>9H%DSO]07KU^&CP?!ZG_8V=_MB! PXUH G-_BTF',,X/LMRL O,JHW=

*[3.;40\]'T:5G:00]*1A^Y[\.]QD^]CQF"]=<\$ M&T,*K^C&^@V--0PB/23.H^HV;<*))+4?;H]KV+N!^K"&K,:]A#4X6%C'+^3# M@H]WV!"L'VNL;0CV.A5+!%A9@]-*

1V1(-+#=+4U>#]6H/]M)PV]58MP_?54 43B3\DH1)U-6X!+=IQ-P(;+C,J1/\$ [)9YXJ1]\G0+L'LZ M9!/P)4S ;F=0E><5&W!#*/)D4CC>EC/@F6K OA#2 V9@MU.BGV.*/6Z6?/ /*

*M6S$'UY],'Y:UPB2LD/F>4,77D/@C%<+9?A!X?5OSFTCSD+1KYXN$OCA*G2/G M/9BWF%KC7&;N9 *GV'*^3N_2P M@SM\4FOQ-0R0*N[]-)L*3(WV.)B&-](KA M;H))%!_0I!T.9.!E8#*I*

89SF"2+BE9OXAK#(]HF35-DF^%N$R4(8>'') #; NM/)B=);!-J'-'X?^36)*(_=Hs^K#-=K_XN;L%6G^ #R1K3P1 ^/W3MK>R 'K M-9&@MIMH/P;H$M? QR"?D".2E-P'84Y,

*=\|>>$[\@"Z,P_="/Y*C")@ .'D M*^^N),)/.$10],=2A1_(%Y+X*G%G(%KR_$#Q<%H\'20PG72.]237^M7 UZ[* M3)&I)]#KR/D" >^3(O$I3N<(WY:!+ !P??>?*

*D\JE!L./)2^'R7EW3@@/ANJD M9K2C(>TC_!%4#C>Y*T@!?XT:KSN_*_:<4C6DGC+7;"\?54H=R79]#O((UY@$ M1)I%G&=Z2O"X)T#\%Q]RO"GL,4)%*

BK(59P%)$(4G3HHXBIBS;W"F=9VW]O7 M<)A>!+-QGJ2B\DJQ%0G,;43L\QK7+3<-D+1+2+]UF^8T8_.86=Z\:,%^,&N&] .6#<0]4/TFAYQ6QHO#0'D(

*M'%&01#4>ILBK9GIRI3FP>I*Y8/M(!7$2I*BU:ZTZ130".T\:I*NVIF0%M)!3 MT1^C: MP=W2%?@?%2'&DL,!8)O!1$X@iU$WB5_S>^R___OSAJ#N"Y0$XSP(/*

MD!%Y.X9_X4)Q%G@FP2P'6(.'O!\8G&MIR)761800:V#;]J1(T0;7ID;6P6C47\]/P M#7W8<1B -0D2+B*3.[++=F;#NYL#03 !U-M?-I60]$+:+R-*

*CTIW)T/#XCWY60$6>;[*+4DQ0V+#$)G\$5YU#I0@ !8+[^2' M_ ^__>WU:N?_+,0;_:9!?DA1/1$![0MIBB)%93>Q.J+0@&90?MV@?6E1B_1Y M.%L09 M**?Bf%NWT@+3R#'18-*

*JWYPY$."VH6DSJ!-5%DQ _4G:]+ ''YE>#) M.)3@JV(V!\4!CE&3^O -CN$#G1-]EL]-[ME.0=8<_0=D-;,**&0[/$; \]2/**3@?`M(U^@^@!O*FL<=B^>D/*

*X5IU24O@^JB#*R\2^TH8O+5#LKW4F)5'O08X'WS:(^ M7'X]4+1PO:3>%)X/I6ML#&.B ,'0UG!?N.P"F:SG_-Z^,#N7.8P,RO!| !Q0 MSO.0X9H$G/!72*

ADAN{).9RGPDHDFEL$=.VI*-1.0^C5.1#\NF!D(*CRH(L M5PB:"G5ZRN5F'S0IE6F<@VZ#WT$OBY^X-V9:2K!/9P /XHQ'6<./&[<,DHH M%J1AH6(_^1!(F2|V_D*#).*

*142:#M2[2O>D1KHN$98H0E#K)(}&GE'Z'1=WH M3>,X%*1W\LJB\7LPER:'Q8R!+[""EPY[_4+,7"5^VFO8K!QDB#]H0-M895Z>BU+T[BHM_76K9. M94_7I*%,T?XB_,4M"D8*

*MT(:5L3E=+O=(9SG#$E/2E4 80$+]{K(!;IQ+8(`MAAY?H"V R2LR#2V+II@AZ7P XU(47.6!3V0*9Z-,$/W6L)M9X;[%00PO5+9 XY@:',>#[EL9R90E0C2F43.7P]454$0 B*U1,K*

*5CH%5B,%X"Z>,_> MX4(Q(0O&4RA.&HQE)&"EO+?10S8Y]*J05^,<;V/V%LI'MQBQ>6STS1+C!:Z M@"F ZLX_F!G& ,Q#Q)?.7\A7&1MQ6M2$>V MW/SEI$W^%\D) ^R+=OD3.!^*

:TC^Z Z2%[BDHB!#G(\^:&+@6?+ ^ P M_4710Z&,!8&%*@-*E^<*9)R*[DTPF!T+!}HG(-V1 'A6) \ZO<-B$_^@K C@# M;9|2V&>[C$4HJG\)'1^9Y_-\0%9I_'-\@3Y3 -?N*

*[>^N\SZ59^X]XG))F M2PD[W9.2/+% ";$:)V-_A%)_.\Y!T!9MP,,,GF42HS:::E-/F[(ZG4.3!9W M-S%9.K#(QX-#'K94%%O/P-[?ZLX"SQ9;25 Y%:'.RK'PW#P5*U:!\U!ZNYF+*

*MTMUZI7]8=+=D@'A6I8+]'I&1=2EXN*6)Z!F\>.+6K\A MT25TKST?&HR6*=$P*1%.*JI.]:&2NU8A'Y&_Y?:C?^,P:>=2^]P/WGSZ=/GF MT%C#5HX(2+<(]8'%H44Y,!*

*[:1\5"+82%2C>KHW;><30-XU-JF)(ROI^X1$ M?&]O$1-R;^$\9G&;=^UV7*4F-%#LN!/|!BU- EYF 4(>UHG_OLE 87H)HYI M%"A:>P), 66FR2OV+2FA="G99]K:TW*(E*]HK(3*38B-*

:$BB)5?TSA<[*I-M2XP*BFFH#"OA7,SG,7">5,;>AR05%-633?O>8BG%'PHAC-(%C^NY?/K\;U)] M94*VRG2@?Y8^^HWT>DSK^)@(X8.L^ 9R0B7IH;R56H"V& G\%Q!?S@Z)#"9P*

*M07^55@3^]6,P0<]ZD'AY8'0 C/2//!).KZL+""'>3(-&Z2IER#4PH^5.D3.KU M70L[MPS56^,S*TNCK\4+AM,_N^D/YR/Q[5@L,^0M;EU8CX,[#XI!&8>T;[= MH'A0\E%-*

#/N3]K>6K;Cl2 M"96;4;C4GE2:H\%,EEP9;7>2N+ETTKKC?9M&; /418\BN8]3I^J#8>%U 2E4 MCD"7(Q9RYT?@ [M G[=49>5I7T),A+/L-XFZOP6*

.0C6Z_-1AHZR"RYOS[^^0H\C$K4Z04 M.'*Q* I3YML\3C*5[X829\[:]JG9ALH<83*.A+IHUN@2WD$A F4I;(X(F:R

*M>!1>Y):!G+>W3MY>C /V.&^O9OH62]?!W+:,M559=4:RL#S6(KL%ZE]=*7Z&,1/*$9VB& M]NB/U$'FVA=/7C=3U8@^K:-$3-#E$4IOT8(21 .FA39?O&W/($"?D,DSS>+"*

*M5Z6G4$IMQ5"%W$Q%THH)[T/P1217!A+I%RR*0PAW2"1*BWHQQ%@GY9.#* M!$Z,FMEE/))$I%X,*ULK%0W^MS5%);I5BT MQ3!OEB$,6CZ4HJ;A MK 4(S"4YH*2W-*

;SKN_.LB,HH]TZ0&A.@,<#R/";^_9X3,"FIK@7)3/*!]$EHMX:B M8YU9<6,+&F- +=@A=E^;U4B2R6I;5]4)E:BI91\S&I]4B#>Y4^T4M*\ZSC:_M:&L_ =3GT?>Q.E4^)*

*[NE)18,).D*RQ"4S5#8*PO(_Y<'T!#&@2MN@!!)@*"'SU M:NMI+SE],N9AMRF#51TK$92I{)&%R^ACT9EP5*I*M;%?X'E*VM(M5WUQZ^0] MFT! ^P]ZV1%8C83@_0E4D*TH\K6U,?*

@AJ]8/_0R.V]_+4?&B9D#7#D8$NG&B MU0G(E[5N&GZ1#Z7/"QGO*D83B*]33<>LOQ?NA*F=/V>Y]$N%(8L48<=00]H1

*M,*0#&/"G]&S9+5]E+J1,R+Z+_<^1>_1N@FT^TEAN4L3,^DO5NUH9I4S)RK:9 M-[Y(P"L02+(1^9G)B5[0/YV?&3U(I>%QJRLUNNW3=YBZD!TA]EQP%OXQ!fF7*

*M.APJ':#VEMX4"HJL^:,_.UI2E2$HK*(]HI8#;4Y)>>X?5QW)6?P&*6GOUK)&2Q1 M,V_A)N'R"W M2P>HY1&1*0QF.E4>H.FHIB!I:8\PN;*TOQV\D4W^2$/H,I"%Q*Z"1%.^6-.W*

*MP:12?7=OJ6LEE9F*B=6_H4?-S0PU*;KL==/,>0_]G2=WSGMJ[4<59IA"2CU! M?56V]M.T5 (4#"_,\IK5D,1*"*#A.lVN'/"7@:)4ZPAD-D0Q93&TH^>^^1*I[W*

*M"&*Q3I?:C8PDFY9;:^D"Y5*9K4H==(NR8=VLE/C0\B*:>TZLNR^7(\M!G9(H M+/OZ">5Y39!E82K<1T"7%KUFH_EO<=KHG1]W!Z< YH I=.+^VTY[B(I8/J MU75#*

[N%KHF=0YY6&UF4J-&6J2@1E_CU%,@M[8V!A XZB@E&/.0Z9G4I:F(MFQ2A2NKY7ID?E2 M',I&H=@--4^+Q/5K5X:U>IV.U)E5I3'&0TH[KI.*S|&GNN=P"[Y!S,C:K5. MDU/*

(HHQ^_P(=N1(M@O(K/&51#6GHS+M=34F:IDR%<|LG:$>W3(%-V:IOJ92 MP5HX/CIC)>)\&8O'#F @FK-[[SEHF[RM>2A%##=D."4%=_N2.ZM2.UN9H/8 M!!SH7!XYRJ(+

(E=U4U4IDV:/IK"U/<#B6#7ON(.P\+'H+H.2L6;/H6%]7PWZ".TXGG!M&]D:J@NQ5[,#[U1V2!63R(=GK32!*G7;5F+,]RM2A M|8H IV-6^TC,M3<[Y8RT,ERZ0B&6I$. ^2-*

T$_FW77)L,G:EZ[|8%AN4"F'W1 M,[Y;VIF&0E[K>KIPA')_R41]44ZU-)38C%UQC&-DLLM! 1=3@O=%*IME/%F MQ%'WQ!FK\]!'1IU%U27GH*FI.GU90I&JS3;[#Y4VIYL22*

}42N07[#PK-N+ M>B:DRM8HFCY(@12Z-TBIKK9F79B344C+(\M. ID0E6CP/("=##QK_BKY[L9- M%WK]^]CH.Y(++)A^]@8KNB+C8@]*U&^Z, G71[\DGE7+-DWPS)(X M38_@/:!]+*

*sE$P,&QTP@ #B<,W+7*I)68$%'I%6714AC3?#3E43-DJUTBPL.0 M;@(S)4L.I(U+4UD15M#I1AI0!=*W.<2>|=2BL;PK'!RIC,&[IBI[#.$3>1 M$$3R"78P*!E!!>CW>*

[KAU\6WOUU6^TH#L8%_ICXOF$B8T_H$UTKZN;[']@6ZWD -^P^17[Y(L$B#\KY@XN>% M#!K8IR22<(!7HZ5WWC1PL?#04E\?2![JE3"==_OG5&N&KE9KW5>W^93DUCQYW

*M2OEYU0.3F;Q+)\U:DB5$R4BD54&"F&7R)DK$DA5B;-G7/|DP>GQ;"$WTK,&&\ MVBK,Z V5RZ+S3R')U%;W08@"TWU2"Q8@F9X/VL'?ZKARX M+T5@E\;G^\6CG&;1/A@#[I\>#4:|_*

M,CCI#=^=WXE{-(A9S^$F,/$0K,9*FA.>W+/-F (&'3LL8D:6[]#%S^>%NI_.N M,NKKD.,WH26H)D8!=KLO[!*4EH5,?S:1CU+R=*&M%-J.K95\U#++^X,WGKQ_? M'$IY@)U5ENL8J E8?

Y$;FD=]H.A0CA@%%>%[K!65-73RXM3U!>J,/1E.PVR M'XH;&$SO]=/3XX/T\&!X>'!QJ$>_C&7]G/R@PPFK?OEVS$HNCNPM0)T8X6 MQ>=]6/_IBPOITYM#V7G?*

N$MDGSO[&&"W-'0?5:%,1QS5W:PKGDJ-2](H>9>Z MQN&#]7'0=[#_'6L<4N=_^?JZYQ^^_3T]M//Q=;UD)3$;EAMAA_FPJ#7 AI/]

M"$!VOLDX!*E$IZ7+8X;=;'7O+#+R7EFQ%NTGH98UZ%%+D4YVV5;&(>RA5%NAU#N ML[;SD>]28,$;]=B1'I C%=/';'L$+@;U_6Q.?FBKH<"BTN[06HS]OS)6 M30/!0IG]HD% QI.R*

*Mf%9:!2I-@:)!MN(>P<1U(V.R.6A$19!?8*0_[<<_XW5-N:SHK.9W63;.1GS2 M@HI+Y%2X1,_X7^HRQF]:W*!?6MW]!B)F;"4D4J2(XG"X*]_0!_*_RKVV7^E:*

*MRJFZM.CG*4[5P3;Z3$T205G')L3Q/H*5FTU[+=N0=D)L1Y=3<739MXR:L@\R MNC6*R|N)HB,Z9'G!B-V9X5P*@.*.#@78F >$%W;(W:8X[!)(RL')=-%EH_%?=*

M8O(M#.F$WH!$CX:5ZS.!$/3=+OKIXNM?ZS]:'?7SY3NB"V0K?P_40FEI'72 FZ\VDU6+DC-!G[XYH6

M0#IC9G"Uf;35S2P2+YTLDN^:'C+6H"ZDUX93R4JL(F@V/NQ'DB#&_(Y!K;Q M?EIU91]R*K:/#*(E,%W\AXH$Z?*:[UC<]L|O*"O;>X>VXERE?14&K-(D5)M*

MSV@HF7Q&.",9;]TEO=;6 ZNU IY[NB|KQN5 W|-P3);U0@?RR1(F5N27?K4!-M536"L,7]N"=D:,KM#OKV/1!ROK#1572+L_"?BLJ4T.FC=HUAH8#[" >W5^O MYUQ)*

*(,SOUU(R+",*0':/I4:^A4-9@9-O4+5X!32U)Z+'+YBP6,;>FF9[CQ9H;4)55-F!/M;WIBFMI?M>EU<$C:+7_:%KBV-]YF[3Z9%9H;K$5K*

MH_:):\LNE:5K#F%R$6N+VDI"749F<@N(ZHDME] .]5&++3:#DU>@ZTQ'>2]Z M2W:,!HEI752,6_:,N'9]MZ5%,45O] >=[*Z]$]@"79Z[K^S36Y=]^FNS#UG_ MCV*?([+YU^,?;-*

*>DNE..*98OP+O73E{!^!E%@4H%QY#@G=:Q?#%QL1$5V%T7LGMK0W8/A/JC(?MD7?6\LVY5 M9UVJICV2JGMHM"Q0=1\6U$BJ[K;[W6Y-R+JBAV CA;(K#NG:B,*O)#Z^)VZ4*

*M8I0"JT.*HESC?EEQ^UKA=Y37JP_D!_'B\U1>/-M?^)N%TND+W21L8?G&>D7 M%&<-U 5I.@9;FA)\N)#BQ34G,,37/--AX=3Y&"1!MC+*(YTY.)%_N%&.';JI M-*

M?;641G96\6.9S(^>N=.0?=0^6L-1?M:J7[@%!KK#RSS2\E^5"=RY,K1WK#M8] 3&E(A7:(SUYMB_@=PB. ^J3)K]S0-P/IF^&!R2LI[^3G\'4D"%?9'T?V*

*MH>$#$[SC6]V80^VDU95!4F7*2C1OD35 *KHHPP"TE, +.*Y>6T0U6\AJ"4K*6 M5;U(IZ/B?7;REK/"SBX8=*

*(;&W5QKWZI*MZ!>E_QL91H>8!&_EZO,;\ZT#*%5I)JS7BAQPQ)C)++>?):E+*D=6J5*ZG9IBY@$+tC5%O586@-M18MMQ00T:Z%1[D"TK]I%WW\G509U/-5I)6VBKIK!A0<7]U>6TRI-M)*

*(BC,"J^ND^4M-U.4J9_?H.)\TP6>;>FF9[CQ9H;4)55-F!/M;WIBFMI?M>EU<$C:+7_:%KBV-]YF[3Z9%9H;K$5K*1 M67D\Q<6\HZ#6HK@M;X &]*

<8C<\4<)"%>B&-BO;T-Z-ZGO?T*D">_\#:Q/) M5:1N=+-='}K@-'!=VPN2.XLF1>K6X0TZ5-%(NA:<+=O*_(:V-AX*X5,S+KO"3K M_$VWE,(08^7^;3#=E1F#;?*

+$4HI&\I46$M53%:N@)^A#YG(FIFVF|>?T(I %AU:NG!$,2YQ.O4[GU/E5DJ929KZZ MB6XH=_!#^&XPJR_=7E?GMJD(H;X!3)<^DLY%+5G6<#,A77%P@6,C.HH*;9_K',A 4%\/=R#XZ1<\W*ZNCN-:YN"N[?$OWTERWYBCM6[DJ.//!?_ZI@-M3'[%(-?U-Y/>5ZJY$7MZAITNYA#IZN4;A3& 7QL'P*&FU5()C-B**]5]06U-MKQ)6-P?*1$N,3_DY73Q_*U8NR^^;&1;-OA(A&YJ;IFA?+X^0U)752)>RR[^9 MA|(T11,\,$H>E=;I6XF+"5A7SCU\UV_@E]JV;?>NWTI/(2L90.UNGB=I[A;9 MZ(N7Q\J,!-ET5=W&N^JV8!&0 B'IA-BYMK@I,K":=6)I9?P+$!I="'>VYJA3; MG;"Q)_T;3UB_N>8|S^IZP.??\QSX3{OGN3&X|$S941"$,7DZ3VS7$N>IXD,9 M\0!>N#N2;7KT^=O65@$GLD&9A0#F;E0@0'6'-$6+##*'*AK%F!#.7Q4P9T&-T M;@SQ^A5JI>@)H6E3$U)XZ;NX=6%R.N>N2,5K.9\QMA!CPX^O(HK2N_#:I=__MX:936$:&XWYHOV^WG/^|/ M(A%(A>QB;-(J@-#B6>#!OZ+K((D-HZD FLCD3$K7?6-,4JZ7EG)_5VEKVC8D M"C>)%@$Q%1;=EC;%5\ '!P5>4LZH]-,/X!AN8Q#,Z0.K&2.GLP.Z\,IV8"'^%BU8KT.MU! MV_ED7Z-;SO3$=L!8=N_]<'P.SRH0,(W9I0TKW.36PF[GRFL;)$MD.1;>W*H; M%67/;G+?E$_FU/1#PAAW1H;<0/.|>X>I)943UM WI>/Q?;764H<-J+N|OOO M3"&=^OX<'_NI.K5UGWC OE=-0^4#S/5-MNM>3%#Q:JF+UK>"/UV+8M0Y7\ M0"9;+1D#YFX|{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|\-VO)CXV;7%[BW1E\)93 M,"TP+>Z>#,YWO/9TS+3 M MW&|%$:SMN!FU!F&MTQ?FB:RU?ZZ.C]B(2E\^-6 _!YMFS#^/X1_F&B:D31%2MGPF)C4)F$D9;)B1&VYH0$INC&ZRR6IFB@37+ZQ=#<6H6KZTY:V/Z;/[:^ QY M;75>&]-G\]?&9]CHM3W>4/# 5IIX:]L$2^=9FUU\1MSJFRKC?XAB[$&CN,[+ M7[72MX]9X@-GO-0WN:RJ?YW@\?>'_::?.+/0!JZ,_,6X+[.1\G,^VCF[3[L MAZ[SB3,M,RV;S3@],?*!LQOBWMU?WNT-'@QCU?G$F9.9E@N=ZF38Y!-_R=CJ MOKM,R@W^-D8U#^=:-(*NGD@"C\H";2;$"'3]HR|+283Y-79:M5,/-A]-[8 M\9],,:/$KJ/$8',6\?Z !//,7O-,O\,\PX*508)!XAZ0&!TS2+!@99YY#,|< M;RY-8/=XAK..GDI7OQ6W=^PV&++V\)WX/4*G7W5S^0TU1B0/++Z3E,TAL 21. M=MZ-QBS#+++-1EADRR[!898Q@C+@O3V;WPU/,,\PSF^69[N;R)'>&9Y8YSW:|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{@&=7]K4'=^;4R?S5\;GR&O MK76F# MU\82@,]PM];):VOFVI@^F[\V/L-&KXWS9;GK'O>9>'Q&3FMPRAV/:LK4W/&(MV?>!V_9.1TT^<:9EIF6S&;W><9-/G 41,^_^,F^WU1D.FWSF3,U,S68SCKM[MUDF2V^]Q^[W:*3I[D+E],.SU=CUW>SWY<\@:,J,$H\1RE.CV=[YP<@LHP4RS MUTQSLCEWTOIP#$M6!HE] HG^\0FC!$M69H'J,.CG;_1?P,3<",24PGKXNHJ M$5=N)IRHZ-fG3))XYKAAI4)!%9LB1![f1Y2HA_GXU#L<\.$Y1O1> P,'6_+ M,JAL6+.Z)C0'9NIC%C!4[#94](,TG9V$BJ8ZNX?XM9-*IXU|P[_M,3Y1[WW<;W-6;45[X$IW"!RXHD3 MYXGC>GDF,]-A#.-TSGN8^]$L>=FPG?@L6LW">(\=;PXC|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| MN)^Y>1:?E_|^RI_30Z#H*$5,6/00H6O_.P@6]\O+C_QY*H+215:KS MLSB3&J3K7[N1)T6;5,ZE!@\ZWE5,ID.$3@8SYH]E>1H&'5 M4,U1OIY'"F@IR'.C@P(5&MD?E5)4M<03+,17;2SZO$UP5DM4^.#L* 3;X$A(M8XH^"E3XI@+=./NS07O8.WU7%],EK5DJ+0GNSVD3CO!Z=D8-#;9"K6R7<4* MX%/JDW>OM7^#]LD0K)?3X\&HUS\9G/2&[^RTL!]"S&%6H=D)):|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{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|/^EX^MV?9ISE8S_XH>88EFJ4<4BD55"S'>ZP?\QOM".)]- M\CC5'$C*4/$4Y5@HMI1<6GDYGG(>A #W>M.>@-CCJ=[]$2OF"UQ'GD*>/+'!-(1&F)#Y1.DHM4>=:@ODDI*?6K@!JJ1)) MF45F5X*